<SEC-DOCUMENT>0001104659-25-110824.txt : 20251113
<SEC-HEADER>0001104659-25-110824.hdr.sgml : 20251113
<ACCEPTANCE-DATETIME>20251113065856
ACCESSION NUMBER:		0001104659-25-110824
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		60
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251113
DATE AS OF CHANGE:		20251113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Protalix BioTherapeutics, Inc.
		CENTRAL INDEX KEY:			0001006281
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				650643773
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33357
		FILM NUMBER:		251475310

	BUSINESS ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601
		BUSINESS PHONE:		201-696-9345

	MAIL ADDRESS:	
		STREET 1:		2 UNIVERSITY PLAZA
		STREET 2:		SUITE 100
		CITY:			HACKENSACK
		STATE:			NJ
		ZIP:			07601

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ORTHODONTIX INC
		DATE OF NAME CHANGE:	19980422

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EMBASSY ACQUISITION CORP
		DATE OF NAME CHANGE:	19960124
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>plx-20250930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 11.1.0.0 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 11/13/2025 10:02:15 AM -->
<!-- iXBRL Library version: 1.0.9397.4506 -->
<!-- iXBRL Service Job ID: 1eaca830-8850-4955-8770-78eeb5ec2f49 -->
<html xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:plx="http://www.protalix.com/20250930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title>PROTALIX BIOTHERAPEUTICS,&#160;INC._September&#160;30, 2025</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" xs:nil="true" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" name="us-gaap:CommitmentsAndContingencies" id="Hidden_3kGEIIf6dEuB3tV0byXRYQ"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" xs:nil="true" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" name="us-gaap:CommitmentsAndContingencies" id="Hidden_xRc61GuW2kicfqhaqXlXMA"></ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityCentralIndexKey" id="Tc_fQw286d6a0mXbwhGk_299w_2_1">0001006281</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:CurrentFiscalYearEndDate" id="Tc_A5M2oPkatUi8HJvvM72mag_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:DocumentFiscalYearFocus" id="Tc_TwVbeFNsgUCc0lWhBsJNDg_4_1">2025</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:DocumentFiscalPeriodFocus" id="Tc_0zSE23xB30SAZ-wxzYjCXw_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:AmendmentFlag" id="Tc_IGAZlHGoyE-_PSBu136iWg_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_segment_m0Z75cdS8U2pVonlKC3GPQ" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="INF" name="us-gaap:NumberOfReportableSegments" id="Hidden_QJxRIWVBeUCE75e_V0YVVg">1</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_segment_m0Z75cdS8U2pVonlKC3GPQ" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="INF" name="us-gaap:NumberOfOperatingSegments" id="Hidden_bTovpeYB_EG_cx9KDkApfQ">1</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="plx-20250930.xsd"/></ix:references><ix:resources><xbrli:context id="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gx6X1c0dg0-aboMNBFKFGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_x2V2OwuyRkGovAC9kMzO1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gQDsVSQOBESn2aton7MkCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kp0yapnm40GB10yQ_ydGnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_82uuoTEUkkeqvb5YouDXFQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_USxfrXz1rkCYTcNzIVQZ0A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JLAmLejgKEWYC493nuhe1Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1Uwm5-nSiEe1UtufcBH-0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ci3mkA8inEugSxpG-FuQrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yU7hKhH3lEmO2pb_PDOgwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h9xaPufFAUWhI__zK0WDdQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_hFoy38nssE-_Imrl9korwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rwMgEGPVD0SY1Y-KA3qD6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3QCYXsKzjkqrL_Tqx7sWEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_upHYMK9ggEy3QQ-m5XNdoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UNTa3I5u9kqeTv9FgW1_Ag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7BvwDWTQK0ShOuP9uKsL_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_JrP2MNklRUaZCBhVdKEU3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Ji-guYoHVUu8eVJ9spIzyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_tGVlUvMwNESS1QuVEsIxCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_LjReUd2e3ECAW3t58uSqwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_U3vsnozyEUyKSmL6qLgZuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_EM-2D042mUKZtARE4xNQQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__wSFk5nFpUKVmADVapX-hA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_J35jXCLpZEemlLCh3xmZDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_TC6cWr1PVEmqOYnE9WVTEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_gQv-s1-zbEiYrnnAYvRtQQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_B_RDBf3UakmFxKgLCE1u4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__u5aEet9ik6m5qJP9wbdkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_zd9vtIegUUmVwTycldKD6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_-58If4GE2UOATvhmgfPXFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_8K2eAUmCmkWnafp6nTCcww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_-nchaslNr0uweGPjWu-YUQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_QMoe7jUDBUORp5O-RNIp8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_xIDPNJ0kwU6c6DEVa4EIhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_82eWapBWXEC0gB4NcExxIA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_aZcDMzIGjE-AMBlyb0cM3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_DfUDjS8huEe8YHRZP_FF_g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_5TVhAsNFQE213aFWrjtG8g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zYmBSshLM0q2nl3i43mcsA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_71PZO8VDYEeOr9oCkh_Hog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CrvjSyzu0kePIviFTWVKvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_V8A_9r0xvk696ZxvjJRa8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_9plBbFjl-0GfbTD6J4eCZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_f2rN9XEbVUelOX_cn66r4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-11-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TcJrtT61UU-RVxesnAWVRg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TAwwe5x3akmfidt8z-84Zw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WUrqKarnvUy3SRJfTqmqnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wFcKmiOLbke6KQ0TZk5Zsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_r-Ghqyl9T0iF4Ti21qRoSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_GGLx0RMJkEWOCKabwh15XA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MoWXQGG3_ka4yi-5e8DRWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gT-aDshKVkGrJq9_mtpt4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1BJ44ASqyEukCpWkJ6dVGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6l0NaCT1sEOnj3WEXVnpEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YfnvTfvAE0KtNUtZkwS5AA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_761cvv_HXU2xI_U7AsL1AA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_dH_SIULHC0imY02WiFQo7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_12_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_1UAWM1totEqWlXUe3rPvGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ikcM5x4J7Ua7ndrvsMT4WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember_-2H5wzF6b02WyHEkdfnNXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndUnvestedRestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_xH2ut0yotUKC0HIos63e3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_gq56zarwQUuh08Mxtq1EHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_xVbKyWax_0uHtrglZoisTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SwvQijHg2UmvkpniQH3hSQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_evPySq6pWUGtY591BlkL7g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OnEzSTerJUmlL5WGD4HZ3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uHaruiJLYEGlS_yAuGkvlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-x0_bEphIU2K4orXSd874w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T9xFatVQiU6cxnwo_7JjZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5Le7HqH0wEynn7U0eLUwpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-_wFays9-UWPOynoqeE24A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_D4u9NxlfVEGwyeTxPj6T4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_tPyaORiFkkOM-rUgWSubEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_srt_RangeAxis_srt_MinimumMember_C7QvDhrMDUq4S3iRN9FCdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2025_srt_RangeAxis_srt_MaximumMember_lTg-LzfNR0mwdU1OEzj4aQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_srt_RangeAxis_srt_MaximumMember_3zb9vtsmPUO-q5fMEz9RUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_O5qbhcAkvUyU14-GI5Itpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_OgxzvfhlIUigqCIom_Fjpw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_17_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_CFDzr7g43kS7D8I0mFf4kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_crdEnIEuZ0uz2yhEN1tslA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-10-01</xbrli:startDate><xbrli:endDate>2015-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2025_iz7XutoutEWL2Qag_QvcBw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001006281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_D0AldO7cf0SCjEYMUWnWVg"><xbrli:measure>plx:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_facility_0Iv5bNDqPUmCp-a8ET1QPQ"><xbrli:measure>plx:facility</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_agreement_FXubWDLurk-D3rwvgsKCMg"><xbrli:measure>plx:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_La8zkqC6pUaqrn9vr4M5jA"><xbrli:measure>plx:installment</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_m0Z75cdS8U2pVonlKC3GPQ"><xbrli:measure>plx:segment</xbrli:measure></xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_vhpegQ9XAU-O7ZTk8mEm5A_10_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_oUNW5FB3IUaHwHEkz3jDQg_24_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_ScyVFUPI80q6wHfbEkNl1w_17_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_rxQDkKYEFEiJ2WmgJtETYw_30_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_eGd5M6r8mEq-ic6FBd_Iuw_18_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_XLZq7il8QE2LEjRtLdk9Jw_31_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_9UAB6ZalEka19hY4YhOg5A_6_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_e3m2lejV3E6_xHTX2KUqPA_21_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Le8enGNn-U2_sRTg_vxE8A_26_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_HhK-UvHh-ECa7iCf80nPyA_12_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_o-soIjnwX0mno9iveiTtnQ_13_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_Eto7e-Xr2Em4IMXw0lGBpQ_27_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_DIQSy69MjE6Hx7Lvt9M1dA_33_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_d1wvEIx0gEO3V9yDgYRFbg_20_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Tc_l6ZF-GSBfk-JXLKuKWOyaQ_15_2" toRefs="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" order="1"/></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="border-bottom-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;padding-top:1pt;text-align:center;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-bottom-style:none;border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:0pt;text-align:center;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="border-top-style:none;font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_f4b911a2_9311_4ad1_a505_d65f5117b66a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:DocumentType" id="Narr_rl93tMkoYUq7d3IewQAQdA"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:DocumentQuarterlyReport" id="Narr_knY32YhavUS71z9Wj-Rz5w"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9746;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><b style="font-size:8pt;font-weight:bold;">For</b><span style="font-size:8pt;"> </span><b style="font-size:8pt;font-weight:bold;">the quarterly period ended </b><ix:nonNumeric format="ixt:date-monthname-day-year-en" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:DocumentPeriodEndDate" id="Narr_UgtC-gnHRUK09_lt_-kePA"><b style="font-size:8pt;font-weight:bold;">September&#160;30, 2025</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OR</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:DocumentTransitionReport" id="Narr_rhYds3_hMEOLIFQh5tnx1g"><b style="font-family:'Segoe UI Symbol';font-weight:bold;">&#9744;</b></ix:nonNumeric><b style="font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">For the transition period from </b><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</b><b style="font-weight:bold;">&#160; to</b><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityFileNumber" id="Narr_dd5JJosc40aqVs4Ty1nGIQ"><b style="font-size:8pt;font-weight:bold;">001-33357</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission file number)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:16pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityRegistrantName" id="Narr_jwHrsgorE0m3ELnGsV5Cng"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a1bb36ca_e2bf_4dc9_949a_f711226b91ef"></a><a id="Tc_A7_yCfA7xkKlxIo8cgNCew_1_1"></a><a id="Tc_b-13Dg2wDEmI1FgBkk5B_A_2_0"></a><a id="Tc_dtlwYjEVU0ycCofcapOt3g_2_1"></a><a id="Tc_gwnymZlmNUWJLe4P72YCsA_4_0"></a><a id="Tc_szrjNPAl9Eu8uqCM9nQ-HQ_5_0"></a><a id="Tc_xFZbD-5a5kyGORFFaH2_3g_5_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityIncorporationStateCountryCode" id="Tc_II1KWFRGikO7iyQGbFl2hA_1_0"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;">&#160;</span><b style="font-size:8pt;font-weight:bold;">__</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityTaxIdentificationNumber" id="Narr_noOnhfkAVka7mU0np48waQ"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">65-0643773</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;">__</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of incorporation or organization)&#160;</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(I.R.S. Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)&#160;</b></p></td></tr><tr><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:middle;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityAddressAddressLine1" id="Narr_mDOklUVrx0u2amqe7QZbbA"><b style="font-size:8pt;font-weight:bold;">2 University Plaza</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityAddressAddressLine2" id="Narr_kou38x8q1keUTPjtFN4d-g"><b style="font-size:8pt;font-weight:bold;">Suite 100</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityAddressCityOrTown" id="Narr_EFm6y7JLqk6Ka_X-I0pgMg"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hackensack</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">, </b><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityAddressStateOrProvince" id="Narr_I4tVl-qKD0y-NkBYe86YYA"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NJ</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityAddressPostalZipCode" id="Tc_9CA4qp62ZkmWdiFwapBNvQ_4_1"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">07601</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive offices)</b></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:CityAreaCode" id="Narr_Uj3GTWVGJEOBOquQpLpPBA"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">201</b></ix:nonNumeric><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">)-</b><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:LocalPhoneNumber" id="Narr_Gq9uPc9V6UOcaZiGraeD2A"><b style="font-size:8pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">696-9345</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Registrant&#8217;s telephone number, including area code)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Former name, former address and former fiscal&#160;year, if changed since last report)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_45e8230e_f727_4422_812c_a1e35f80e47e"></a><a id="Tc_EXZkvX3kpEKKEps-XmLthA_1_0"></a><a id="Tc_xBRM5HAvx0Wglb9TXM_6xQ_1_2"></a><a id="Tc_3WtcYbZ0qEGf1poX1YMnjw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"/></tr><tr><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:Security12bTitle" id="Tc_912yUTkvAUaGRJGlqhaw_A_2_0"><span style="font-size:8pt;">Common stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:TradingSymbol" id="Tc_1xraoRV4c0y8QUE7l7rRFw_2_2"><span style="font-size:8pt;">PLX</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:3.12%;border-bottom:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:30.93%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:SecurityExchangeName" id="Tc_YRHZE-UjKk2UZvp8hugAAw_2_4"><span style="font-size:8pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:5pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityCurrentReportingStatus" id="Narr_Azh_qlwgTEa907mMVLgqVA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;">&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160;&#160;No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;&#160;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityInteractiveDataCurrent" id="Narr_gncDjS3ZaUWV8FJgXu4-vA"><span style="font-size:8pt;">Yes</span></ix:nonNumeric><span style="font-size:8pt;"> </span><span style="font-family:'Times New Roman';font-size:8pt;">&#8999;</span><span style="font-size:8pt;">&#160; No&#160;&#160;</span><span style="font-family:'Times New Roman';font-size:8pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a975f266_f6c7_407d_aa80_42ce67244ae1"></a><a id="Tc_Z-xLFoOqVUGZvLDXo0pE1g_1_0"></a><a id="Tc_Jjdx36iRvEmE-eYMbdyX8w_1_1"></a><a id="Tc_ixulTgRF4EOTNmsapDLFaQ_1_2"></a><a id="Tc_BlLmLqn0FEetZ2bur0sQmw_1_3"></a><a id="Tc_SsrsjWrbiEqK1vSJlpd4jQ_2_1"></a><a id="Tc_0E_8AnN9-kitTKVgOISR2g_2_2"></a><a id="Tc_OWRgVTpMWkqnCh2xRvCO6g_3_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:90.1%;"><tr style="height:1pt;"><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Large accelerated filer</p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Accelerated filer</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityFilerCategory" id="Tc_7rupBYvUDkSnOpi5nKXUMw_2_0"><span style="font-size:8pt;">Non-accelerated filer</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Times New Roman';">&#8999;</span></p></td><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Smaller reporting company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntitySmallBusiness" id="Tc_8lgawC9eoU28U0gCFdpd6g_2_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:25.99%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:38.02%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Emerging growth company</p></td><td style="vertical-align:top;width:10.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityEmergingGrowthCompany" id="Tc_revsfCkg3USnHwnY-8pO7g_3_3"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="dei:EntityShellCompany" id="Narr_FXmbatbmlUmXhHnKVMJ38w"><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9744;</span></ix:nonNumeric><span style="font-size:8pt;"> &#160;&#160;No&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:8pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">On November&#160;1, 2025, approximately <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" format="ixt:num-dot-decimal" scale="0" contextRef="As_Of_11_1_2025_iz7XutoutEWL2Qag_QvcBw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_I-ez9iU_e0GCfD1HSOhelA">80,421,181</ix:nonFraction> shares of the Registrant&#8217;s common stock, $0.001 par value, were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_40bada46_bd9f_4c80_8e35_4c6f1c96a847"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM 10-Q</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"></div></div></td></tr><tr><td style="vertical-align:middle;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:5.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIFINANCIALINFORMATION_363674"><b style="font-style:normal;font-weight:bold;">PART I &#8211; FINANCIAL INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_969154"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Balance Sheets (Unaudited) &#8211; As of September&#160;30, 2025 and December&#160;31, 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Operations (Unaudited) &#8211; For the Nine and Three Months Ended September&#160;30, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Changes in </span><span style="font-style:normal;font-weight:normal;">Stockholders&#8217; Equity </span><span style="font-style:normal;font-weight:normal;">(Unaudited) &#8211; For the Nine and Three Months Ended September&#160;30, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"><span style="font-style:normal;font-weight:normal;">Condensed Consolidated Statements of Cash Flows (Unaudited) &#8211; For the Nine Months Ended September&#160;30, 2025 and 2024</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;background:#ffffff;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"><span style="font-style:normal;font-weight:normal;">Notes to Condensed Consolidated Financial Statements</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_865226"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><a href="#PARTIIOTHERINFORMATION_770480"><b style="font-style:normal;font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></a></p></td><td style="vertical-align:top;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_676392"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_983377"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2UnregisteredSalesofEquitySecurities"><span style="font-style:normal;font-weight:normal;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Item&#160;3.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3DefaultsUponSeniorSecurities_505234"><span style="font-style:normal;font-weight:normal;">Defaults Upon Senior Securities</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosure_204781"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_679200"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td style="vertical-align:top;width:7.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:bottom;width:86.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_829552"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_574709"><span style="font-style:normal;font-weight:normal;">Signatures</span></a></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.9%;margin:0pt;padding:0pt 0pt 0pt 7.19pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b90f68b4_1992_4159_915f_84780616bc30"></a><a id="PARTIFINANCIALINFORMATION_363674"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PART&#160;I&#160;&#8211; FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_969154"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;1. Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDBALANCESHEETS_49495"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_26ebb788_9b3d_4dbb_85f8_adaa92a7253b"></a><a id="Tc_JcdnShLQoEqRZB3gSUVIKw_1_2"></a><a id="Tc_lb7oWZNY30yqq47ENsfU8w_1_5"></a><a id="Tc_4GQJR7sW_Em1dB4NUSs8pA_3_0"></a><a id="Tc_5L-aJkuZh0qQ3RvWrgQTFw_5_0"></a><a id="Tc_nADYdzUMV0aGG1u0-omeag_6_0"></a><a id="Tc_0CF9Fj_apE-Q_HtbUUNyHA_6_2"></a><a id="Tc_1gMf5lP1p0apDSkNbEVqUQ_6_5"></a><a id="Tc_WeP93gw1-UirPv5F5pzCcA_7_0"></a><a id="Tc_cS96w0ieqUer7j0__2jhAw_8_0"></a><a id="Tc_NbZzPcNJH0KPW2X3jLqtvA_9_0"></a><a id="Tc_IZP_K7l1fUWdsXSXe_2ggg_10_0"></a><a id="Tc_k_eNyt22Ck6D4bXaFoWvew_11_0"></a><a id="Tc_UbtH0gg3gkiykox-QLtahA_11_2"></a><a id="Tc_VTbmWuuC3k6fGAR1TeAPpA_11_5"></a><a id="Tc_f8GeKnd-4UW4R-saRFu_Nw_13_0"></a><a id="Tc_ZVPwpxQYyUWc41L4MV3ylg_14_0"></a><a id="Tc_BAEz4ryWsUCPar9gddn5KQ_14_2"></a><a id="Tc_AFXi4aukuUWaoWP0BtqUUg_14_5"></a><a id="Tc_ZIGCHeuMqke-vkotPX5g5g_15_0"></a><a id="Tc_3CQHy7RlT0qnFmkssUJoOw_16_0"></a><a id="Tc_izdXltqtfEurXHKTwNKaUg_17_0"></a><a id="Tc_JP0fEJW8IEO_E7zGy_wRIA_18_0"></a><a id="Tc_I5LTW1A4tUa84-BrE-br4Q_18_2"></a><a id="Tc_Ie8RB5MX1kWyDRlXqI2cpQ_18_5"></a><a id="Tc_A17oCULxvkWKryEIBo2u_Q_20_0"></a><a id="Tc_ICy-WowzhEOd00Um4XFHTQ_22_0"></a><a id="Tc_WDyvp6sVSk2ZgojftHybWw_23_0"></a><a id="Tc_cd69ZASTJkqtZTJykcuNUg_24_0"></a><a id="Tc_2OXvxrXklUavODgtYwlPig_24_2"></a><a id="Tc_SHikmz6tjk2tLU6u_EcKeg_24_5"></a><a id="Tc_HOh8haVPq0uESHFRI3GRPQ_25_0"></a><a id="Tc_s0OaYPnJ3EOYx8r7N6PEGA_26_0"></a><a id="Tc_U0WZFp9w4Eehjz3GLtNWJg_27_0"></a><a id="Tc_MekMN1rhHEySgnyLw914-Q_27_2"></a><a id="Tc_32Lej-Oki0Kfpgz6s7hLnw_27_5"></a><a id="Tc_Ovrn5rg4G0uZpL_ZlkwlXg_29_0"></a><a id="Tc_Ctt-NyuwpEOKWXoRlqctUA_30_0"></a><a id="Tc_-E9RTZd6ZE6NlbsJ7xlxDw_30_2"></a><a id="Tc_EHJu4j9tQEKz92uc842DVQ_30_5"></a><a id="Tc_PItjXpUGgk-7rZNbW2AOOA_31_0"></a><a id="Tc_wNLmzhHE60mIkgJPvNE75A_32_0"></a><a id="Tc_DncmA9GrzUWnfP8RJ8HJ9g_32_2"></a><a id="Tc_DcRlpHod9EadzTX86akkUQ_32_5"></a><a id="Tc_Cndh-ch_q0C8wgrzMNKa8A_33_0"></a><a id="Tc_CfSjPEil00qRFjBFLcaVDA_33_2"></a><a id="Tc_Pbsfl2k3y0Wkn9kGDZWp1w_33_5"></a><a id="Tc_FTCtPscpcUiRbq3H9vYfZw_35_0"></a><a id="Tc_npiynbpyhE6yf3nkXnsv9w_37_0"></a><a id="Tc_cdDR9LRD80Gd9bgA1j0CkA_38_0"></a><a id="Tc_QNvmSYxW6keqztbBPNmsXw_38_2"></a><a id="Tc_u8469loTD0etaT1WNXC-Hw_38_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_0hIhu2HthkO-XAl8iCwC0w_6_3">13,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_t_0PWsYDX0aOZffcGQ7yYQ_6_6">19,760</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Short-term bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_EI525-bg40yGKRSARouvOg_7_3">15,723</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShortTermBankDeposits" scale="3" id="Tc_8guaM1ozfUaRtFlyXr9jDg_7_6">15,070</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_4DWbJdkbA0yCaoDfivlqnA_8_3">14,425</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="Tc_JD3vM8lbC0i-PhupNySTlw_8_6">2,909</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_Hog3m0yYn02xkltpRZYvpw_9_3">1,452</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="Tc_-v4qGg9YUEy5Oog9ACy7Yw_9_6">1,096</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_Nw_a1uujUEmy0PVBiD288g_10_3">21,255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_CqkN3tXvpEO65KTzsgANmw_10_6">21,243</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_0e75j5J17E6JKFOPqXFR6g_11_3">66,502</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_uwRzT6qgpE-9z9a-v3g8Gg_11_6">60,078</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Funds in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_DUWzUHZEWUOc0wc5-V6qEQ_14_3">549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" scale="3" id="Tc_sEPtgUJtWEyNHts-xQEtcw_14_6">462</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_JrhylNUjzkCufiSy_hNlAg_15_3">4,724</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_qUV9-TH7a0mwqOluVsR2JQ_15_6">4,591</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Deferred income tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_PkMlwuosqkeekWuU0y1qlw_16_3">2,679</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="Tc_rxUn-H9QAUeE8BOTQgNstA_16_6">2,856</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_LZgJlpG-9U-3hvJvJouC8g_17_3">7,810</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_2SDeYSoadEmHXVaNkthzig_17_6">5,430</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_XQgSpRvT80KGf6adxu1gAA_18_3">82,264</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="Tc_CS8deAAOhEahkuHvUC_ewQ_18_6">73,417</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LIABILITIES AND STOCKHOLDERS' EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable and accruals:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_eISZ_rJX30qgLKOMCptTUw_24_3">5,375</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" id="Tc_LZ7-25jqa0yorRbk6QnMVw_24_6">4,533</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_c-OiO0BQGEi5K5IOUe4xYA_25_3">15,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_p9gmRkJFa0CLtcaUNryIUQ_25_6">19,588</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_NMkF5rXJ3U2frS-FbhArzg_26_3">1,397</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_eBF9QJ_ReEOw86kijLEUlg_26_6">1,500</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_nwpEKZHG50OJr2RLCYFjVw_27_3">21,945</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_BX3BoOiYQUOG5nicjXNctg_27_6">25,621</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">LONG TERM LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_jYNnxzMqSkqXUIh_FT7hQA_30_3">631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" scale="3" id="Tc_4AkCVdXJ60-cK5mQZ8ruaA_30_6">559</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_YGsHenF1jkiQRcPdQKG7iw_31_3">6,780</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_awzQzOkztkmVEv9nTf8L9w_31_6">4,026</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total long term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_aRqrENFzVk2JxjjHkN4tDg_32_3">7,411</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="Tc_M8-lMyievEezxmvV8jyNLw_32_6">4,585</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_2w4GIYnLg0eqWAyljHlLNQ_33_3">29,356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="Tc_sTgjVpD_BkOYC5c6vwvvIA_33_6">30,206</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COMMITMENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">STOCKHOLDERS' EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Q4D5tf9rv0mFvpB93lznzw_37_3">52,908</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_mVtFTkij8UiABFmvbw2Wxw_37_6">43,211</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total liabilities and stockholders' equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_ZOCLFEt9r0eh7D2pj-FxRA_38_3">82,264</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_EKO7lXv6T0G2UL_CbmZNCw_38_6">73,417</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c8d2178f_b4b5_4137_bff6_0bc83f73c635"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATI"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0pt -13.5pt;">(U.S. dollars in thousands, except share and per share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_245770eb_1795_4abb_94f5_de46e607fba1"></a><a id="Tc_VhKyqYTOrEmt5atJaFp-GQ_1_2"></a><a id="Tc_u96p0eOwKEyFpvUK_gaYYQ_1_8"></a><a id="Tc_75nxGgX2CUKX_tFe5c3JkQ_2_2"></a><a id="Tc_cchyKUFlXk6QDsBElJufzg_2_5"></a><a id="Tc_q_yThB8eEU27W_kML-06zA_2_8"></a><a id="Tc_Zw_4d-ERhku5Z8i06OHuHg_2_11"></a><a id="Tc_jc7hICTBlEeGAKlZpX-LEg_3_0"></a><a id="Tc_LdCbhGZe3EWNCmq19L9D9w_3_2"></a><a id="Tc_nMtEjYN3WEyHzu2j1oYa8Q_3_5"></a><a id="Tc_d1goqC7y50Kd_VmrN7Aaaw_3_8"></a><a id="Tc_zFDhzwShn0CTeLIlhXuNZg_3_11"></a><a id="Tc_ybBFEc9vkUG3xCmG5NRQNg_4_0"></a><a id="Tc_7W0gQ31qv06JGolFJ5wGzA_5_0"></a><a id="Tc_l575v3lCPEiBbuFV3CEg1A_6_0"></a><a id="Tc_QSFWD8mOrEWfPY3pvJwEbQ_7_0"></a><a id="Tc_zc1wDAoRUUO8puvPeiboIg_8_0"></a><a id="Tc_AJuMMAuBV0S0ZmPUpIv1QQ_9_0"></a><a id="Tc_WyLpWERyAUeY3Q1w7cDMlw_10_0"></a><a id="Tc_4YhVK_oNlU6C2r384DyVig_11_0"></a><a id="Tc_mOEG_aO7PUuiZAxIsARrJA_12_0"></a><a id="Tc_RxvNfCPDMEK6KpDzvhFIbA_13_0"></a><a id="Tc_rKnTlMmZQ0Kj6qI0EsVbvw_14_0"></a><a id="Tc_JHRGkYhh0EmJ-flhhBLjTQ_15_0"></a><a id="Tc_PiaOKBrgvUK4jr5bXdnnVw_15_2"></a><a id="Tc_hqhbbD3prUWbVi5mAo85ww_15_5"></a><a id="Tc_k89Mw5SXtkWWiIdCdUyazw_15_8"></a><a id="Tc_AVypAcm3gUab3B24IXxaOw_15_11"></a><a id="Tc_GSe5igmh7kuyYsxLXNLC-g_16_0"></a><a id="Tc_kCaJXws4IEWIlV3aDuuCiw_17_0"></a><a id="Tc_59pkp2TA8Ualq-HIdNTEYw_17_2"></a><a id="Tc_l5khc9T3d0yB-8ytbfdccw_17_5"></a><a id="Tc_YXZM-JV3XkizDPEcRYV1gQ_17_8"></a><a id="Tc_06_IPbddo0iPIGvjJZvZhw_17_11"></a><a id="Tc_G1JmiIiqP0GaqTv4kbaBeg_18_0"></a><a id="Tc__ks5zPAjD0KhQOuJU-HLdg_18_2"></a><a id="Tc_QEyGep7xdUO2q8mM2t3-Fg_18_5"></a><a id="Tc_WsohUMP__U6mcRMEcdljzg_18_8"></a><a id="Tc_fBvwTwZMJUm48jP2DPLQ-w_18_11"></a><a id="Tc_mINF7HWo4UKyDYH_rdKr8Q_19_0"></a><a id="Tc_DN5EWsdKmkODo6lR7v590A_20_0"></a><a id="Tc_tkG9-NQfoEC7QvVB_k00tA_21_0"></a><a id="Tc_vrknalT9lUqvKRkn_-utaw_22_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-1.4814796%;padding-left:0pt;padding-right:0pt;width:102.96%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-size:7.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM SELLING GOODS</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_B_RDBf3UakmFxKgLCE1u4Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_iQNpBLv0kU61v-WhQy-1yA_3_3">43,108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_DfUDjS8huEe8YHRZP_FF_g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_36jeKvEkJkC4DHsEcFJa5g_3_6">34,820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_EM-2D042mUKZtARE4xNQQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_iRT3eaI3xkuk8mXg6lghxw_3_9">17,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_-nchaslNr0uweGPjWu-YUQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_3AOYD2-q80Cc91Kc12nuQQ_3_12">17,839</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">REVENUES FROM LICENSE AND R&amp;D SERVICES</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__u5aEet9ik6m5qJP9wbdkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_yH9vEGl1d0W9B-Ap1qFJuA_4_3">514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_5TVhAsNFQE213aFWrjtG8g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_7YijXZcs70SMwnnj8eSHiw_4_6">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__wSFk5nFpUKVmADVapX-hA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_jDJVEgctGEWOyw5NpHpwWQ_4_9">178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_QMoe7jUDBUORp5O-RNIp8Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_JHXcktNkSkCR99KEp3aKuQ_4_12">120</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TOTAL REVENUE</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_pyA350x_LUGySuP84A5rxw_5_3">43,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_3TlWARxkKUyFk9v0MoYdXw_5_6">35,181</ix:nonFraction></p></td><td style="vertical-align:middle;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_SpshFGR7lk62iT50p5NMEg_5_9">17,851</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_PD1vrY0gLUiJ-Fbx4XKBFw_5_12">17,959</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">COST OF GOODS SOLD</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_hy3966HrfUmjT7WnTMBmEQ_6_3">22,374</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_C1LG_avzMU2ERLL69jhulQ_6_6">20,433</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_jOEQctBb8UqUYz-vGHQPvg_6_9">8,324</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="Tc_x7imsZn2u06xCjkg87r56Q_6_12">8,375</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_7ezfJfQNWECeTFjz3x2lSQ_7_3">13,934</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_X-d6T5pI1kmyZmdhUhV4MQ_7_6">8,846</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_B_8ccGI5aU-xJfwQ_EA6Mw_7_9">4,467</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_8gY0xRx290KBfYsr63buGw_7_12">2,998</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_sIE2unldXESDIOoFZM1C3w_8_3">8,156</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_SZkV_uSSnkCVQ1MSOdeYOQ_8_6">9,194</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_WYI3fxHyD0ic89eC-2AzcA_8_9">2,929</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_xmS6Yi4XHkKlxx5loXDHcw_8_12">2,595</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">OPERATING INCOME (LOSS)</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_cvy_XbpD6U2h3P8tRDsJ-A_9_3">842</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_7vtegeVrj0aTqiqG96rIVA_9_6">3,292</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_Vj7Yj0SgMUGc3MAdgU3kFw_9_9">2,131</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="Tc_fMW-p8HONEieRswA52OVBw_9_12">3,991</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" scale="3" id="Tc_1mg3Zuo8d0moanV8oukP3A_10_3">808</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" scale="3" id="Tc_SabyQaMCFkiAV5OrCFkp3g_10_6">1,056</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" scale="3" id="Tc_hZCV2cbHfkWGZYHF2-HaEg_10_9">180</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" scale="3" id="Tc_ZIaFkU4rTUGLOHC83pfEFg_10_12">299</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc__QE9bKlha0qt15MX55jQtg_11_3">818</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_EpPJfe39DkOWUd9GTcQXsg_11_6">1,186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_QpvNzryal0CDUqGAZiJLDQ_11_9">288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNonoperatingIncome" scale="3" id="Tc_CLF567JEtEegxFd_APrB4w_11_12">151</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">FINANCIAL INCOME (EXPENSES), NET</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_NQm7X_bVn0Wnu8Ntwzl_AA_12_3">10</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_Gj9g5wQNeUiranCHm88Qbg_12_6">130</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_tzzC8N27o0qnMpdbpMunEQ_12_9">108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" sign="-" scale="3" id="Tc_r9rxSD-Fb0mz2kK3YUo_CA_12_12">148</ix:nonFraction>)</p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">INCOME (LOSS) BEFORE TAXES ON INCOME</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_w5Yb65vmTUqaef85SIr11Q_13_3">832</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_ERXc2yi_f0-ow400pSltRA_13_6">3,162</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_seJrCUZzWUyj2iqWms0KTQ_13_9">2,239</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_-45Sn-CbSkW_xhTQSltvhw_13_12">3,843</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">TAXES ON INCOME (TAX BENEFIT)</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_wBjn4eCB6UGrd67harpmOg_14_3">268</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_nX3VDjDuu068KMNrtA6pFA_14_6">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_lAUhp-L0wUqFiIrfx0rRjA_14_9">116</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_CCDHfQZeMUCXLzvpwvofvw_14_12">607</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCOME (LOSS)</b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Tup6S6nEi0SBTOvTFtctEA_15_3">1,100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_wT0w-xl_TkioOe1P1oPlwA_15_6">3,562</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_N73aFzg1ikWdl0ZLarSR2w_15_9">2,355</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_JO7eW8OKlUyhpMHXNXiXfQ_15_12">3,236</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EARNINGS (LOSS) PER SHARE OF COMMON STOCK:</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">     BASIC </b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_vY7Zz8V2JE6pma9q8qXowQ_17_3">0.01</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_76A4yhud8EmT_1KVRC-pXA_17_6">0.05</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc_qa57J30H7EOeCmH1vWjooA_17_9">0.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" id="Tc__2jE-YNCtkq0MHti7WxYwA_17_12">0.04</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">     DILUTED</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_kdu9UUep7ESz3Q7HSiy_-g_18_3">0.01</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_LgnDWwxmeE66ouLtJXalfg_18_6">0.05</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_soN1DngY4UCaBVDFCcCS6Q_18_9">0.03</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_HEYGItwv4EKjA41yFgw7pA_18_12">0.03</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">USED IN COMPUTING EARNINGS (LOSS) PER SHARE:</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">     BASIC </b></p></td><td style="vertical-align:bottom;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_WMsV2aBnN0iLZLK02QJt4Q_21_3">78,225,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_noORtC1jaE2gBJ20c2e_Jw_21_6">73,301,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_5GAsIUm3v0S45x97ylroeQ_21_9">79,281,685</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_4iDWed2OYUqKSmcF-ANvMw_21_12">73,549,745</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">     DILUTED</b></p></td><td style="vertical-align:bottom;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_U8QfkxLAi0qRfeyOcOWX8w_22_3">78,225,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_9UrxHKzcdUelLy3uHarROQ_22_6">73,301,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_GGMzZdDCZ0SB2dUb2qGtBg_22_9">80,814,564</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_vwa-7G9HXU-DpzuBqCQ8OA_22_12">81,217,068</ix:nonFraction></p></td><td style="vertical-align:bottom;width:0.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_fac46261_6b3d_48cf_92d5_e6dcc678f2dc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands, except share data)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_51b0fa27_d06a_4470_84d5_013b9f213bd8"></a><a id="Tc_RSrdwbTtkUK6K_7wyLB-_A_1_7"></a><a id="Tc_UtcX1JPi6UGShDBCC0OF8A_2_2"></a><a id="Tc_bu14GPUGLUClf-hXUPLEFA_2_4"></a><a id="Tc_IMshuVE3uE6sLFH0qgcrKg_2_7"></a><a id="Tc_VzS0KUF_B02j8BGrmckcWQ_2_10"></a><a id="Tc_5iFNnpsrIEmoId7EL74DvA_3_2"></a><a id="Tc_1Re4QcFhRkOjAdtbjBYcdQ_3_4"></a><a id="Tc_Q7MNI1ObR0K4nx-ufDdbsQ_3_7"></a><a id="Tc__uGSfpdezUuKg0-AZl0m6Q_3_10"></a><a id="Tc_LSEFVVlYuUeau8EroF-FxQ_3_13"></a><a id="Tc_eGrJb8YHbkKOOIsjDkNHnA_4_2"></a><a id="Tc_xKw_CxtiYEW2m2l5mvX2Ig_5_2"></a><a id="Tc_krPeHmF8WkOwGi2lrEuD4A_5_4"></a><a id="Tc_gb8IA1nPS02K_5PagpwW9Q_6_0"></a><a id="Tc_butwbFUM70KoLzSf9P8eEQ_6_4"></a><a id="Tc_1zkq8-LiUEi7vdQKZfwgGg_6_7"></a><a id="Tc_HyyAedz08kGQAANGuDHLpQ_6_10"></a><a id="Tc_g16eRY0hZUihyaU5o0Fq2w_6_13"></a><a id="Tc_bCDdtXkBFk2Ge63bdsuIPw_7_0"></a><a id="Tc_HWNtXAZ0Bk-ru49oe6SxKA_8_0"></a><a id="Tc_lC4YHIJTBESGzCcqocGE3w_9_0"></a><a id="Tc_GYuO6HMxU0661aLG6YyMfw_10_0"></a><a id="Tc_weRoVur6KEudnm9YOLFV_A_11_0"></a><a id="Tc_C5AuSATKeUOe771t7-Ns4A_12_0"></a><a id="Tc_oLK-_Rcf90GEQxqQq-f6sw_12_4"></a><a id="Tc_yAvUy-qOuEOvB88gSofz4A_12_7"></a><a id="Tc_OmWX1qdm8UOquXAcCdV2fg_12_10"></a><a id="Tc_VwhQbj05dkikX--YTD2xeQ_12_13"></a><a id="Tc_vy6q_f953kCq1QK_-ujEig_13_0"></a><a id="Tc_bfViyGZvI0uiC9j2iEWxRw_13_4"></a><a id="Tc_zEQ1J-2yBUGP5YEaEs5oQQ_13_7"></a><a id="Tc_YYMLXSX0mka456_ElXoBxA_13_10"></a><a id="Tc_MmNheYFseEuUzkRNb2rLNQ_13_13"></a><a id="Tc_N2JW5HCLQk-UresGFQWUZw_14_0"></a><a id="Tc_eFQfRj2SBkuwJZ6GmzZTzQ_15_0"></a><a id="Tc_sXpV8l6t_0qAch0lXLF31Q_16_0"></a><a id="Tc_xQjpUF328kW8eQVvL7w9EQ_17_0"></a><a id="Tc_R-IV1sjJQkWdQan3P_ENzw_17_5"></a><a id="Tc_bcKaxW_pW0WpmMsvzSDBtw_18_0"></a><a id="Tc_ill-W-eGDk6CbXBscbDISA_19_0"></a><a id="Tc_Rh4gbyS4R0y_cqCY9ZVxKw_20_0"></a><a id="Tc_hbNVzECsCUyEeQ5Z4a9ODQ_20_4"></a><a id="Tc_3zfrQK70sESSxTNqAXhk4g_20_7"></a><a id="Tc_d_jtzyU1wEaXMS2JuONfhw_20_10"></a><a id="Tc_2eNUyYCxtUu8WjhxV9NGJQ_20_13"></a><a id="Tc_vfEYhjnctESipA3b9NdP3g_21_0"></a><a id="Tc_fFP39feuqUCf3nWBB4E-uA_21_4"></a><a id="Tc_hcPiOFi_FE60iq6euQcH8g_21_7"></a><a id="Tc_LmrP0BkooUKuHxoTq4-VtA_21_10"></a><a id="Tc_7RYTXDN-zUyDwenWq6qusg_21_13"></a><a id="Tc_zjClkSYCi0K1aa7P6QJUXg_22_0"></a><a id="Tc_NKPHDxqGKE2vDZU9tqebxA_23_0"></a><a id="Tc_HcfaPH6Qg0WQivQZagXKjw_24_0"></a><a id="Tc_N_XtZxHnQkilAg11Yx4CLw_25_0"></a><a id="Tc_dy88NItrfk2Ib33JDOyNhA_26_0"></a><a id="Tc_qKidmjKggkmf3BpWVaN3pw_26_4"></a><a id="Tc_0QeDH2eZ7kCMVnrRIF4SLA_26_7"></a><a id="Tc_FDym8UZtSU-2rQGuU229dA_26_10"></a><a id="Tc_0yEhQA5hsEKivbiD8AjdHg_26_13"></a><a id="Tc_fFklDk_0fESftRMT1C5T-A_27_0"></a><a id="Tc_-h4A6PeUS0-g_-zub0mudg_27_4"></a><a id="Tc_6vNtlUTMB0uQlvr9XQ0j7A_27_7"></a><a id="Tc_o-7maxCrRU6kmdZB-QQXcw_27_10"></a><a id="Tc_XSBR6natxEm0SLr_Lq00Lw_27_13"></a><a id="Tc_WJXVowVu90GfqZ8tqhgifQ_28_0"></a><a id="Tc_-0hJBNbg00-b3Dk0O2qJeQ_29_0"></a><a id="Tc_M25ANnDS6kKA26YbMpRvEw_30_0"></a><a id="Tc_CzyBJnc6SEqeRPOyJUVQwA_31_0"></a><a id="Tc_dtef8KafeUq-TH2riCblXg_31_5"></a><a id="Tc_xu0IOgnUfkCA-dGpfoKBEA_32_0"></a><a id="Tc_htSIx41C5U6SdA0Eo-h1Ig_33_0"></a><a id="Tc_4Wb30RDXq0OzS_rDCbKHXg_33_4"></a><a id="Tc_Drzz7vWQnUSSdRr8ERhejg_33_7"></a><a id="Tc_G5JHIPomHUGa4329YBTJEQ_33_10"></a><a id="Tc_9fX9UFLIkkCxAz-cPR2hfQ_33_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock (1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:40.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_761cvv_HXU2xI_U7AsL1AA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_9UAB6ZalEka19hY4YhOg5A_6_2">72,952,124</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_761cvv_HXU2xI_U7AsL1AA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qFLKm1oDkUO3ysbHZ2tqwQ_6_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7BvwDWTQK0ShOuP9uKsL_w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_UrjVywT_w0uf55LtJeQfZg_6_8">415,045</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UNTa3I5u9kqeTv9FgW1_Ag" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_MD7h0mHadUuvLqhOYUH6Fw_6_11">381,549</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2023_ikcM5x4J7Ua7ndrvsMT4WQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_O1sdQozggU--sz8MJFDsGg_6_14">33,569</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the nine-month period ended September&#160;30,&#160;2024:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Initial adoption of ASU 2020-06</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3QCYXsKzjkqrL_Tqx7sWEg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_rsVV4AYt40ekY27Zn2ov-A_8_8">393</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rwMgEGPVD0SY1Y-KA3qD6Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_k-IAnEWvwUGv92jnDVFljw_8_11">224</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_upHYMK9ggEy3QQ-m5XNdoQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_xcbqDkbPnU-1FH0PInO9LA_8_14">169</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-_wFays9-UWPOynoqeE24A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Dw58Fz0DRUyRr4yoK6nDOA_9_8">1,191</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_blh0E11oy0qWoa7QlepKuw_9_14">1,191</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5Le7HqH0wEynn7U0eLUwpw" decimals="INF" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_vhpegQ9XAU-O7ZTk8mEm5A_10_2">681,459</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5Le7HqH0wEynn7U0eLUwpw" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_2IvoTeJgzk2u9pbUxgDYUg_10_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-_wFays9-UWPOynoqeE24A" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_qGQs6P8KYkeUJ5kkuVzuWQ_10_8">1,407</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_K0uEfz_RJUelY0ZE9ye3Sg_10_14">1,408</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wFcKmiOLbke6KQ0TZk5Zsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_ySl0Ha4tWU-rl4q9Ib_1TA_11_11">3,562</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_YeAGhN0jNEKDwrARqJQ1vQ_11_14">3,562</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6l0NaCT1sEOnj3WEXVnpEA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_HhK-UvHh-ECa7iCf80nPyA_12_2">73,633,583</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6l0NaCT1sEOnj3WEXVnpEA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_f4vIXjnutEmP-Vfh9wbHew_12_5">74</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ci3mkA8inEugSxpG-FuQrQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_2CHGE2frnU-LYYdAgeM0HA_12_8">417,250</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1Uwm5-nSiEe1UtufcBH-0Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ulP1wIBizkyd1kb1zOANHw_12_11">384,887</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_1vNk_DVvWEexBHGhB0VnHQ_12_14">32,437</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at January 1, 2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1BJ44ASqyEukCpWkJ6dVGA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_o-soIjnwX0mno9iveiTtnQ_13_2">75,850,275</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1BJ44ASqyEukCpWkJ6dVGA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_E5H3xW4MvUmri7DDp7SFHA_13_5">76</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JLAmLejgKEWYC493nuhe1Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_MJBe5UmF3kK0qulZ-zTocA_13_8">421,528</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_USxfrXz1rkCYTcNzIVQZ0A" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_zSapq1JMnkqZmiNarkaXcQ_13_11">378,393</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ZzR-QtJYgU6slpvQlNO7dA_13_14">43,211</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the nine-month period ended September&#160;30,&#160;2025:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_evPySq6pWUGtY591BlkL7g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Tc_l6ZF-GSBfk-JXLKuKWOyaQ_15_2">2,775,215</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_evPySq6pWUGtY591BlkL7g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_aUJLH1s_AkSqR_TWkKM9Xg_15_5">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uHaruiJLYEGlS_yAuGkvlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_9hMeFSUU8UGZb5nlZyglYw_15_8">6,809</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="Tc_ZtnESanZg0GS8nrX2afqPw_15_14">6,812</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uHaruiJLYEGlS_yAuGkvlw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Wjg0TXeSj0WZ6H56EJIDGQ_16_8">1,004</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_BH_RyJm3AEC088OY_nOA6Q_16_14">1,004</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_evPySq6pWUGtY591BlkL7g" decimals="INF" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_ScyVFUPI80q6wHfbEkNl1w_17_2">559,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uHaruiJLYEGlS_yAuGkvlw" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_Ot5i5j0vBk2dtzXFcNl-uQ_17_8">561</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_VbBR7Rzwa06toW6kEwMeVA_17_14">561</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of warrants and options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_evPySq6pWUGtY591BlkL7g" decimals="INF" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" scale="0" id="Tc_eGd5M6r8mEq-ic6FBd_Iuw_18_2">1,156,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_evPySq6pWUGtY591BlkL7g" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" scale="3" id="Tc_5B7GF19NLEioHWoahxic5Q_18_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uHaruiJLYEGlS_yAuGkvlw" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" scale="3" id="Tc_JAif2Tmk7UysPKEtp6D1hA_18_8">2,419</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" scale="3" id="Tc_bgIWY-wskEqcI4IknLqxYQ_18_14">2,420</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TAwwe5x3akmfidt8z-84Zw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_2GnCXj9Mikqtqox3tW42wA_19_11">1,100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_5DLxOpSj_UKPArJCtTAEOQ_19_14">1,100</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MoWXQGG3_ka4yi-5e8DRWQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_d1wvEIx0gEO3V9yDgYRFbg_20_2">80,341,325</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MoWXQGG3_ka4yi-5e8DRWQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Aimk5I0s2UOxD4Pxmo7Vkg_20_5">80</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_x2V2OwuyRkGovAC9kMzO1w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_qkqhcATeD0So8Iew1vc9kA_20_8">432,321</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gx6X1c0dg0-aboMNBFKFGg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_tLmwbzS1D0aFqp1uhHXXnA_20_11">379,493</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_gt9OFz-50E6p3OUiPhhnTQ_20_14">52,908</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YfnvTfvAE0KtNUtZkwS5AA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_e3m2lejV3E6_xHTX2KUqPA_21_2">73,292,674</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YfnvTfvAE0KtNUtZkwS5AA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_00WLczCPwUmdXayC2QsyPg_21_5">73</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h9xaPufFAUWhI__zK0WDdQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_OFrx7KOgkUCv9sqlrUIX7g_21_8">416,631</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yU7hKhH3lEmO2pb_PDOgwA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_ZDt3cYP_VUWMfQygpEyNKA_21_11">388,123</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_6_30_2024_hFoy38nssE-_Imrl9korwA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_vuvGTmjto0yeu1TVngD8Bw_21_14">28,581</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended September&#160;30,&#160;2024:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T9xFatVQiU6cxnwo_7JjZA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_viqePOY8zkWba2fYuwOivg_23_8">358</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_9KRZg0GZpE6l3hsFOSWDDA_23_14">358</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-x0_bEphIU2K4orXSd874w" decimals="INF" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_oUNW5FB3IUaHwHEkz3jDQg_24_2">340,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-x0_bEphIU2K4orXSd874w" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_-PUNZgHMQkyTkTWCcJj9_w_24_5">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T9xFatVQiU6cxnwo_7JjZA" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_pOzZ1l6pCkO6LMwZNUedvA_24_8">261</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_QGZh_j8pJkyTbtcAtL_l2Q_24_14">262</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net income for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WUrqKarnvUy3SRJfTqmqnA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_8GQ2wD8MOU-31bqN9n4xrA_25_11">3,236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_JFLGBJFvrkS4YzZzxG8-Lw_25_14">3,236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6l0NaCT1sEOnj3WEXVnpEA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_Le8enGNn-U2_sRTg_vxE8A_26_2">73,633,583</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6l0NaCT1sEOnj3WEXVnpEA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_bdJtiJ58nEOjhGpCtMB9Og_26_5">74</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ci3mkA8inEugSxpG-FuQrQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_h1eSdIfHXESjQPBjNBFpGw_26_8">417,250</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1Uwm5-nSiEe1UtufcBH-0Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_MVZcAPRX3EOvBE58Mf97Nw_26_11">384,887</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_5M9xxZwU3UmF_cblZhhGZQ_26_14">32,437</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at June&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gT-aDshKVkGrJq9_mtpt4w" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_Eto7e-Xr2Em4IMXw0lGBpQ_27_2">79,732,115</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gT-aDshKVkGrJq9_mtpt4w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_9QcC-lAKFECnxia1z9k-dQ_27_5">80</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kp0yapnm40GB10yQ_ydGnA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_0W4geiAqpkaspCfcc4_F_A_27_8">431,671</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gQDsVSQOBESn2aton7MkCQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_VgwMD-k0gUyvUkmvJb8Dew_27_11">381,848</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_6_30_2025_82uuoTEUkkeqvb5YouDXFQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_k1IeEsFAj0ecvTkAX0hXIA_27_14">49,903</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Changes during the three-month period ended September&#160;30,&#160;2025:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OnEzSTerJUmlL5WGD4HZ3Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_4brF_PJvBUG7Q75r0y-IZA_29_8">405</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_eS6E1dCzw0-H4zM_NcDNcA_29_14">405</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation related to restricted stock awards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SwvQijHg2UmvkpniQH3hSQ" decimals="INF" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" scale="0" id="Tc_rxQDkKYEFEiJ2WmgJtETYw_30_2">559,210</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OnEzSTerJUmlL5WGD4HZ3Q" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_WipQVR98XkK9EfOJmc-sUA_30_8">193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" scale="3" id="Tc_FTn3EpyUwUC6kizPPRvgsA_30_14">193</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SwvQijHg2UmvkpniQH3hSQ" decimals="INF" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" scale="0" id="Tc_XLZq7il8QE2LEjRtLdk9Jw_31_2">50,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OnEzSTerJUmlL5WGD4HZ3Q" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" scale="3" id="Tc_jf7IfLxhb0O2W9k3FZkcMw_31_8">52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" scale="3" id="Tc_C4QHKDtlt0yWjusF7kQlPQ_31_14">52</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:46.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net income for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TcJrtT61UU-RVxesnAWVRg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_lTHmg6ELbE-NNIZDR4WIMQ_32_11">2,355</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_ObIzKEgO7UacufW59txhuw_32_14">2,355</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:46.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at September&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MoWXQGG3_ka4yi-5e8DRWQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Tc_DIQSy69MjE6Hx7Lvt9M1dA_33_2">80,341,325</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#ff0000;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MoWXQGG3_ka4yi-5e8DRWQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_bFmcmbsqUEiTiw2HcVzy5g_33_5">80</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_x2V2OwuyRkGovAC9kMzO1w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_7KM4LKxbEEO3dwEZjdauYw_33_8">432,321</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.56%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gx6X1c0dg0-aboMNBFKFGg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_BtsjFvxv0EmoN_e2CkNW1A_33_11">379,493</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_YHNHZn5JY0mkMVwE3b3Myg_33_14">52,908</ix:nonFraction></b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="background:#ffffff;">*Represents an amount equal to less than $1.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a2e03645_2643_4168_926d_13e04faf108a"></a><a id="_c3493724_079a_487d_a703_63d3836f1c6f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(1)&#160;<ix:footnote xml:lang="en-US" id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr__gpeNqqRWEySSfwcmaaObA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_5Sr6M1ia2UuLn9aa0knvNQ">0.001</ix:nonFraction></ix:nonFraction> par value; Authorized &#8211; as of September&#160;30, 2025 and December&#160;31, 2024 &#8211; <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_bERza9spgUmuCuM1wJBTjQ"><ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_Y84_Je8qFU2a0vMn869iKg">185,000,000</ix:nonFraction></ix:nonFraction> shares.</ix:footnote></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cd1507ab_3c46_45ac_bad2_d1f9a1c8f861"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><a id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited) </p><a id="_036b0258_18a7_4ba6_9dee_ce3a7dd27b55"></a><a id="Tc_7YCS9Zf2SESjPgYnBxj_Rw_1_2"></a><a id="Tc_WRGuTAAnv0Ogy3OD8ETqzg_2_2"></a><a id="Tc_419PyIfk7E-ypeD7cXfO2Q_2_5"></a><a id="Tc_mQah39EaXU6TeNvHrJSsmw_3_0"></a><a id="Tc_7TXMH1rkeUqnuRju13uu2w_4_0"></a><a id="Tc_gY205HgzrEmAjSF8MGKYHQ_4_2"></a><a id="Tc_6dh28iwTYUWLZfOfn4FrWA_4_5"></a><a id="Tc_RBqZjYEAkUKRMhaa0WqSbg_5_0"></a><a id="Tc_TzPwnlAdkku2yqG_3S2K7Q_6_0"></a><a id="Tc_2E8LXgktHkisE51tTIfBlw_7_0"></a><a id="Tc_eevdnDT_70GNkp9VwjuzGQ_8_0"></a><a id="Tc_OER_V_Z7HE6u2yY2sGpmHg_9_0"></a><a id="Tc_MDJAkkKXr06gKduqKYzJmA_10_0"></a><a id="Tc_5T1jZxZVjEGY6mZoLknfsg_11_0"></a><a id="Tc_h5C2uzv9Dkqk3AdNIekm5w_12_0"></a><a id="Tc_1f7XSrA7aEGTFaag0Ilbjw_13_0"></a><a id="Tc_Q9KPOTx5OUGi_9NHbxWSKA_14_0"></a><a id="Tc_Rt9C_79WaUqYqPabkl1JJA_15_0"></a><a id="Tc_deZlslNcREqZuEAnNOn1PQ_16_0"></a><a id="Tc_SRB1PpvJpUabdb_-LuSs1Q_17_0"></a><a id="Tc_zexLqTvK3Um9jj6CU9JREg_18_0"></a><a id="Tc_8xlxjmvFj0yzzU-2Dfoz8g_18_2"></a><a id="Tc_t9eUyloiL0q02uKHWyVpVA_18_5"></a><a id="Tc_IKdVB_IJRUyng_aD0DRtMA_20_0"></a><a id="Tc_M72-QerPzEeRL0W-yKdyTA_21_0"></a><a id="Tc_6sgqP__X-EGjgR0lW5yZuw_21_5"></a><a id="Tc_8kZ2S7J2OECNM9MimPCRig_22_0"></a><a id="Tc_DeBJEBj3HU2cgRQptjds4w_22_2"></a><a id="Tc_oP3L0K0dHU2NbtvDkUKyWQ_23_0"></a><a id="Tc_zXXEoUYGVkOELzKwUUUEDw_24_0"></a><a id="Tc_7O2NhtNxWkC1fk4kSILpoQ_25_0"></a><a id="Tc_iNBQyPnVak6PTM5LYLvNNg_25_2"></a><a id="Tc_shhSm4i80keNeYRU9Ipvqg_25_5"></a><a id="Tc_j2T0leEYjEaXHA6heEz2UQ_27_0"></a><a id="Tc_ALR1S7wPoECBMlemT1oT1Q_28_0"></a><a id="Tc_VIhC7VvX7kmadg3QME3K6g_28_5"></a><a id="Tc_FqPbae8NMUuAu4FU0o--Hw_29_0"></a><a id="Tc_d6476BUwGEa3tPo8M6Jrcg_29_2"></a><a id="Tc_jn6a_iV2B0-IbJQ6GYml8A_29_6"></a><a id="Tc_UZOol_4EXUenv1APUmzmUw_30_0"></a><a id="Tc__V69qVufY0uFAqZ72plKDA_30_6"></a><a id="Tc_LGhhj0m7lECAQ8y1suToYQ_31_0"></a><a id="Tc_4e9dT9_6z0mGgFvFa3MePg_31_2"></a><a id="Tc_xDP5mda0p0q9gwrvxJ1x7w_31_5"></a><a id="Tc_EeK-qpH0FEClIpVINfJS0w_32_0"></a><a id="Tc_NShzCq7rwkKPuXomVxZzrg_32_2"></a><a id="Tc_cS1rkzIPr0-FdtxcgSn0OQ_32_5"></a><a id="Tc_Rq7lD2okVUaz9W_HLNhUBQ_33_0"></a><a id="Tc_6algBfxVw0-X24Lm2VWRCw_34_0"></a><a id="Tc_4SRG-lCjQk-6Z1Iy7A_MQw_35_0"></a><a id="Tc_sb18IoR5a0-_2jZODDmkXg_35_2"></a><a id="Tc_PduSF1CE5UaISkt7EbrbMQ_35_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_SiqsywtSBUiYOqibDdKb-g_4_3">1,100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_doZeP18yKkiurKeN1-PdHA_4_6">3,562</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_Qob-UEAF9EmExlPxBFFMJg_6_3">1,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_YHW07GBjtkikgiFyNJGnRw_6_6">2,599</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_tlOKQwU-yEewFmB_pNaPeQ_7_3">1,078</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_z3RHjoqcK0SzNApUCiecGg_7_6">970</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Financial expenses, net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="3" id="Tc_1sTJysWqRk2T47Wdt3_c2g_8_3">136</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ForeignCurrencyTransactionGainLossUnrealized" sign="-" scale="3" id="Tc_EPaS4WdCykW4HV19tK9qTQ_8_6">173</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in accrued liability for employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_-JrUSDkMVEehpp2Mllbmog_9_3">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PensionAndOtherPostretirementBenefitExpense" scale="3" id="Tc_QGaQh44OAEeUGTou_hYuKg_9_6">32</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in deferred income tax asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_kKC16ba09E6i3GxgxGgY1w_10_3">177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_IadXkWq-jU2JZ5z47BKT9A_10_6">236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on amounts funded in respect of employee rights upon retirement</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_5o_rcLXpdE6exHB3cTUxfA_11_3">18</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" scale="3" id="Tc_FI4qYg6Fsk6uafli2RCYlQ_11_6">20</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Gain on sale of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="Tc_p3-fuz4xOEuH2Pa99618gg_12_6">3</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (Increase) in accounts receivable-trade and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_jUgk4hGsf0airUQq2C3a2Q_14_3">11,768</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" sign="-" scale="3" id="Tc_T5eXMifMH0atEdQLNMAg3A_14_6">3,069</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating lease right of use assets, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" scale="3" id="Tc_83s5f-GC0EeV0d1EGv35Aw_15_3">62</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ChangeInOperatingLeaseRightOfUseAssets" sign="-" scale="3" id="Tc_VvBgo0Gk7EaehGsBo-Ffjg_15_6">13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease (increase) in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="Tc_uY6huhE6DE-BLIB28NazbQ_16_3">12</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" sign="-" scale="3" id="Tc_qr0Xn5XT1UmhNkfKZ42fKg_16_6">1,846</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Decrease in accounts payable and accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_yC4El8sftkGrlBt4EsaxHQ_17_3">4,033</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" sign="-" scale="3" id="Tc_E9pp2EZ_aEaHf7UeZSueTg_17_6">670</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net cash provided by (used in) operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_EddYIByaA06fdkPP5aJMrg_18_3">14,023</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="Tc_OHS4m6kLk0SzjIoVeQf0kw_18_6">4,683</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Short-term deposit withdrawal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:ProceedsFromWithdrawalOfShortTermDeposits" scale="3" id="Tc_1bzvrZ1H-UO9nhyEO02FLA_21_6">20,420</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_wbIzxtNScESnqVhl2cOKYQ_22_3">1,235</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_0CLl_Cahi0ulqVLXTn2ayA_22_6">857</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from sale of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_bAJNTrjeX0e3mgniYITTuQ_23_6">3</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amounts funded in respect of employee rights upon retirement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_QQ-8aVzoQkeqsCB136wL2A_24_3">19</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="Tc_Sh391ma6_Eu6dLIETD6Jpg_24_6">25</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by (used in) investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" sign="-" scale="3" id="Tc_Zkv3G4cMfUWQLGgRK8YQpQ_25_3">1,254</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_4s7nxJY9RE-vQtk-w_qj1w_25_6">19,541</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">CASH FLOWS FROM FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Payment for convertible notes redemption</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConvertibleDebt" scale="3" id="Tc_-V2Td1reckKHuoGGCLhipQ_28_6">20,420</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Proceeds from issuance of common stock under the Sales Agreement, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="Tc_LW5l86ntVEySJnz31Snk6A_29_3">6,812</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of warrants and options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="plx:ProceedsFromWarrantsAndStockOptionExercises" scale="3" id="Tc_KErlkJoeoEOdE7j7bPDgzQ_30_3">2,368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Net cash provided by (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_PjGg5_F6dUaotW5waJhc2Q_31_3">9,180</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_FUBVQ2ZL0UChgAmQT7kd1A_31_6">20,420</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_k8g5Ma70oE61_ehhYdXTnA_32_3">16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" sign="-" scale="3" id="Tc_JsLhKMNkiUChX8rIfNH7Qw_32_6">29</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_zVGZZTW3zkqO6eUvHqs9zw_33_3">6,113</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_9B8BYJvsA0yAqfXWjt81YA_33_6">3,775</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_tmFNX1BKZECIv_LmXQyfIQ_34_3">19,760</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2023_ikcM5x4J7Ua7ndrvsMT4WQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_Hu2rDi_HX0WScH0BeoWSEA_34_6">23,634</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.24%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_exnBfk_OJU-Go0IEcFzLWA_35_3">13,647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_ZX5TME-l0EmZk_7ut3lgeQ_35_6">27,409</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(U.S. dollars in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_46a503f9_bdde_4384_ae1e_7932ccc325a6"></a><a id="Tc_MM1FlbtlNk2rf6gT9-fuXw_1_2"></a><a id="Tc_ZjfZ8uy1KkiBaTqa7Y69uQ_2_2"></a><a id="Tc_CONXWpPJw0KuaKpiyQLj3g_2_5"></a><a id="Tc_zu7Eac1TVkeqPWHcTNwcWA_3_0"></a><a id="Tc_FNyNZARKEU6wjJDnbyGaPg_4_0"></a><a id="Tc_rNbJr3nkhUupbDj6v_UZVQ_4_2"></a><a id="Tc_5qG1cNQ_JUiQMO4qoqHUYA_4_5"></a><a id="Tc_n8XQH_ZtAkmM1LUR5mBwXw_5_0"></a><a id="Tc_S99pTm--3kWdXTobKA0V8w_5_2"></a><a id="Tc_w_NV5NHkXk2cm3GxEajr5Q_5_5"></a><a id="Tc_5Ma0wWAM0Ua5pqNlQHwopg_5_6"></a><a id="Tc_Fsjc01xhwUWzme452XjQdA_6_0"></a><a id="Tc_JVEglMIRbkuoLFVz2I1-oQ_6_2"></a><a id="Tc_qyt1FOGwi0-Ftfrac1GwkA_6_5"></a><a id="Tc_pfcuWwNqGkuzKyy9kxrkzA_8_0"></a><a id="Tc_e0B1cE60BU25qH9WF62A-A_9_0"></a><a id="Tc_FxmCpD2CekeBmHa9f1AY3A_9_2"></a><a id="Tc_MdfYVd4GnUGbkduhOInsYQ_10_0"></a><a id="Tc_VJTD_HvwkEe98nYf0CSiDA_10_2"></a><a id="Tc_xVm3TXKMz0yAfAqrn9cBDw_10_3"></a><a id="Tc_YGvIsEYAW0KnOTIZ4PXAmg_10_5"></a><a id="Tc_XLEYk1y7r0O9TQUJNUIXpQ_11_0"></a><a id="Tc_ggXTYVLtDUO9U0XUMRjL5Q_11_2"></a><a id="Tc_E6UgaaREVEev0xeYtiFwyg_11_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Purchase of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_AihvGYzZw0m4B0XYCBzhXw_4_3">230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="Tc_i3U-7R1XJUyVfSs5eq-cJQ_4_6">402</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Exercise of options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="plx:OptionsExercised" scale="3" id="Tc_Q1lBu59WMk-7vanrC7A2SA_5_3">52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Operating lease right of use assets obtained in exchange for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_6aAPLUtkl0Ov9EV3w80GMA_6_3">3,104</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_q3gcZFqXskaO8wFaLxbFVg_6_6">376</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Tax paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="Tc_UhC6Qy_QPkyXYwF8pTQFWQ_9_3">1,182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest paid</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_3yIdIarT20y9X544JCltPg_10_6">1,532</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Interest received</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="plx:InterestReceivedNet" scale="3" id="Tc_sEjtkiM2-0q_3cmDtT0W1A_11_3">258</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:InterestReceivedNet" scale="3" id="Tc_L8boP15fgEWIea96KWGGBA_11_6">1,481</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of the condensed consolidated financial statements.</b></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTE1SIGNIFICANTACCOUNTINGPOLICIES_79340"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="Tb_F5exF5Y-8E6faVSC5m3EVw" continuedAt="Tb_F5exF5Y-8E6faVSC5m3EVw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="plx:NatureOfOperationsPolicyTextBlock" id="Tb_UBrlwoupxUCubhwOjK9Szw" continuedAt="Tb_UBrlwoupxUCubhwOjK9Szw_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#8220;Company&#8221;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients and children four years of age and greater with Gaucher disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Elelyso was first approved by the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others. In May 2023, both the European Commission (&#8220;EC&#8221;) and the FDA announced the approval of Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia, Singapore, Australia and Taiwan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases (neutrophil extracellular traps).</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company, through its wholly-owned subsidiary, Protalix Ltd., has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio through <ix:nonFraction unitRef="Unit_Standard_agreement_FXubWDLurk-D3rwvgsKCMg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="INF" format="ixt-sec:numwordsen" name="plx:NumberOfGlobalLicensingAndSupplyAgreements" scale="0" id="Narr_KwlsgX3n80-nUy7hnzTMgw">two</ix:nonFraction> exclusive global licensing and supply agreements. On October&#160;19, 2017, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">7</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_F5exF5Y-8E6faVSC5m3EVw_cont1" continuedAt="Tb_F5exF5Y-8E6faVSC5m3EVw_cont2"><ix:continuation id="Tb_UBrlwoupxUCubhwOjK9Szw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">2015, Protalix Ltd. and Pfizer entered into an amended and restated exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for <ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_crdEnIEuZ0uz2yhEN1tslA" decimals="2" format="ixt:num-dot-decimal" name="plx:CollaborativeArrangementRevenuesExpensesSharingPercentage" scale="-2" id="Narr_54Hu-sDFaEWkOKIMGvP0lA">100</ix:nonFraction>% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;">On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). After giving effect to the sales under the Sales Agreement in January 2025, <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_dH_SIULHC0imY02WiFQo7g" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_NHAj3FXx70ehD5JRn-D_eQ">no</ix:nonFraction> shares of common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_dH_SIULHC0imY02WiFQo7g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_UIgfiFbNxkuqSzOaOwCksA">0.001</ix:nonFraction> per share (the &#8220;Common Stock&#8221;), remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_3_17_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_CFDzr7g43kS7D8I0mFf4kw" decimals="-5" format="ixt:num-dot-decimal" name="plx:CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" scale="6" id="Narr_gc_jPC8l0UygaieXDny7MQ">20.0</ix:nonFraction>&#160;million. As of September&#160;30, 2025, approximately $<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_OgxzvfhlIUigqCIom_Fjpw" decimals="-5" format="ixt:num-dot-decimal" name="plx:CommonStockValueOfCapitalSharesReservedForFutureIssuance" scale="6" id="Narr_yxXFxYwiXkmF29TMX3PQhg">15.7</ix:nonFraction>&#160;million in shares of Common Stock remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel. Since October 2023, following an infiltration by Hamas terrorists of Israel&#8217;s southern border from the Gaza Strip and attacks on civilian and military targets, Israel has been engaged in military activity on a number of fronts, including with the Hamas in the Gaza Strip, Hezbollah in Lebanon, Iran, the Houthis terrorist group that controls parts of Yemen, and others. Such clashes may escalate in the future into a greater regional conflict. On October&#160;9, 2025, Israel and Hamas entered into a ceasefire agreement intended to permanently end the war between Israel and Hamas. However, there are no assurances regarding continued compliance with such agreement. While the conflict created and continues to create heightened security concerns, disruptions to business operations, and economic instability within Israel, the ceasefire may contribute to improved regional stability. However, the security situation remains fluid and any renewed military actions, restrictions, or government-imposed measures could adversely affect the Company&#8217;s business, operations and financial condition. The Company&#8217;s facilities are deemed an &#8220;essential enterprise&#8221; which means it operates or can be operated for the purposes of state defense or public security or for the maintenance of essential supplies or services, allowing the Company to maintain operations during emergencies. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss. As of the issuance of these financial statements, the impact of the military action has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of September&#160;30, 2025, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_8Ie7WZ0F00qNeo5XvfHyyA" continuedAt="Tb_8Ie7WZ0F00qNeo5XvfHyyA_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">8</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_F5exF5Y-8E6faVSC5m3EVw_cont2" continuedAt="Tb_F5exF5Y-8E6faVSC5m3EVw_cont3"><ix:continuation id="Tb_8Ie7WZ0F00qNeo5XvfHyyA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;) on March&#160;17, 2025. The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_4ouvBEQjqU24YXMG4MA9gA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Net earnings (loss) per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of Common Stock outstanding for each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:DebtPolicyTextBlock" id="Tb_7UA5GvRh9E2E4DGvXvGm0w" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its <ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_GGLx0RMJkEWOCKabwh15XA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_pDK1kORZckioC-XL-WvHmg">7.50</ix:nonFraction>%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the Company had the option to settle such notes may be settled wholly or partly in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_qRgd_aNCkkq_AZ6_qHYX_Q" continuedAt="Tb_qRgd_aNCkkq_AZ6_qHYX_Q_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"/><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">e.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;">Recently issued accounting pronouncements, not yet adopted</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company expects the adoption of this standard to result in expanded disclosures in its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2024, the FASB issued ASU&#160;2024-03 &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures<span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">In July 2025, the FASB issued ASU 2025-05,&#160;Financial Instruments - Credit Losses&#160;(Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This amendment introduces a practical expedient for the application of the current expected credit loss (CECL) model to current accounts receivable and contract assets.&#160;The </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">9</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_F5exF5Y-8E6faVSC5m3EVw_cont3"><ix:continuation id="Tb_qRgd_aNCkkq_AZ6_qHYX_Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">amendments will be effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods, on a prospective basis, with early adoption permitted. Based on the Company&#8217;s evaluation of this guidance, no material impact is expected on its consolidated financial statement disclosures.</p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="Tc_5n4KKlq0yEuBpaMlkexpaA_1_2"></a><a id="Tc_SHu6KLKVUkC2tLtjCY8xow_1_5"></a><a id="Tc_4pIqFFP55EmLCrZPOmRv0Q_2_0"></a><a id="Tc_53saiAlY1U2gVvPLja_kig_2_2"></a><a id="Tc_tTsv7fkiVkSWfUBZTJwS2w_2_5"></a><a id="Tc_NC6s-wwKDki5-6-TXOXL9g_3_0"></a><a id="Tc_vA-RCFechkerAzgDvbyMVg_3_2"></a><a id="Tc_8GC5k7B0FEqA0QP7fxJ7ew_3_5"></a><a id="Tc_drYsu8_CB0GvsnooVcQaEw_4_0"></a><a id="Tc_DpKHzkgDAEuedzarzNHurw_5_0"></a><a id="Tc_n2kDk5BEhUGH2Qz9Shuwbw_6_0"></a><a id="Tc_l_9RDCzTAUuy45yp94ZbWQ_6_2"></a><a id="Tc_7hofoNZor0e0w-lE5nIYPA_6_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:InventoryDisclosureTextBlock" id="Tb_jzZmTInS7Ey9HzkNJaELGg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Group_bI6GT31Xv0C34MZjDKrp2Q" continuedAt="Group_bI6GT31Xv0C34MZjDKrp2Q_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at September&#160;30, 2025 and December&#160;31, 2024 consisted of the following:</p></ix:nonNumeric><ix:continuation id="Group_bI6GT31Xv0C34MZjDKrp2Q_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_o4cVtA746U6-b3qD0SGAKw_3_3">4,983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" id="Tc_fKuXWC6sg0aEdNdw7wIPYw_3_6">4,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_5-oVeSGVb0eWmLLA4oWwgQ_4_3">5,355</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" id="Tc_5Wqsfz0jCkGN-R56SWKCeg_4_6">11,245</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_YA71NgIUdECEQTnLfzAGaQ_5_3">10,917</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" id="Tc_wmqjUOkvykalNe2Uoyz9qQ_5_6">5,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_3-8tZMd64Eyz1jQZvknVxg_6_3">21,255</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="Tc_obJ2UUni3UWl62-jdk87Sw_6_6">21,243</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_z5o9Aq5gIUKurNhDSxXhSA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is identical or close to their carrying value.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_YrnblJbP5UG0a-yds5pW3Q" continuedAt="Tb_YrnblJbP5UG0a-yds5pW3Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 4 &#8211; OPERATING LEASES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company is a party to several lease agreements for its facilities that included varying lease periods and <ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" format="ixt:fixed-true" name="us-gaap:LesseeOperatingLeaseOptionToExtend" id="Narr_ANkVj9Dl3UG6vp8ROgt80w">options for extensions</ix:nonNumeric>. The Company is currently in the second option period for each of the <ix:nonFraction unitRef="Unit_Standard_facility_0Iv5bNDqPUmCp-a8ET1QPQ" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="INF" format="ixt-sec:numwordsen" name="plx:NumberOfFacilitiesLeased" scale="0" id="Narr_lDK2m7hx8k2IC7udZKUm4w">three</ix:nonFraction> leases, which periods are not uniform. In the three months ended September&#160;30, 2025, the Company amended all of the facility leases, collectively, to provide that the third option period for each lease will end on December&#160;31, 2031 and will be associated with a unform rent increase equal to <ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="INF" format="ixt:num-dot-decimal" name="plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" scale="-2" id="Narr_yYvJc90w0UK5ej__0ZWnLQ">7.5</ix:nonFraction>%. Thereafter, each lease will extend automatically, on an individual basis, for up to <ix:nonFraction unitRef="Unit_Standard_item_D0AldO7cf0SCjEYMUWnWVg" contextRef="Duration_1_1_2025_To_9_30_2025_srt_RangeAxis_srt_MaximumMember_3zb9vtsmPUO-q5fMEz9RUA" decimals="INF" format="ixt-sec:numwordsen" name="plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions" scale="0" id="Narr_vt9bB3u7s0iSlrV3E4ja1Q">four</ix:nonFraction> additional <ix:nonNumeric contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_qzJLiSFhmESlZ7vfxuABgg">five-year</ix:nonNumeric> periods unless the Company provides the lessor with <ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" format="ixt-sec:durwordsen" name="plx:LesseeOperatingLeaseTerminationAdvancedNoticeTerm" id="Narr_Z8XIdSugnk2qgIAzpx5urQ">six months</ix:nonNumeric>&#8217; advance notice that it does not intend that any individual option extension become effective. Each option to renew a lease in each of the <ix:nonFraction unitRef="Unit_Standard_item_D0AldO7cf0SCjEYMUWnWVg" contextRef="Duration_1_1_2025_To_9_30_2025_srt_RangeAxis_srt_MaximumMember_3zb9vtsmPUO-q5fMEz9RUA" decimals="INF" format="ixt-sec:numwordsen" name="plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions" scale="0" id="Narr_Q1HIUEeqCUufOjOqVJB2nw">four</ix:nonFraction> option periods shall include a rent increase equal to <ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="INF" format="ixt:num-dot-decimal" name="plx:LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod" scale="-2" id="Narr_r1a2g49H00SkR5KcxZdZmg">5</ix:nonFraction>% of the rent payable for the applicable previous option period. Prior to the amendment, the options to extend the leases were associated with increases of either <ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="As_Of_6_30_2025_srt_RangeAxis_srt_MinimumMember_C7QvDhrMDUq4S3iRN9FCdA" decimals="INF" format="ixt:num-dot-decimal" name="plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" scale="-2" id="Narr_QBlTOJJaE0CdAXs40eNolg">7.5</ix:nonFraction>% or <ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="As_Of_6_30_2025_srt_RangeAxis_srt_MaximumMember_lTg-LzfNR0mwdU1OEzj4aQ" decimals="INF" format="ixt:num-dot-decimal" name="plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" scale="-2" id="Narr_FcpTR_s7-0mpL-3fl6jEeQ">10</ix:nonFraction>%. The Company expects to exercise the options in future periods. As of September&#160;30, 2025, the Company provided bank guarantees of approximately $<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-5" format="ixt:num-dot-decimal" name="plx:BankGuarantee" scale="6" id="Narr_BON_kzVir0CmMizOKl9ZAA">0.6</ix:nonFraction>&#160;million, in the aggregate, to secure the fulfillment of its obligations under the lease agreements.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">10</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_0672ce4d_1340_4703_8fa9_799bb3843257"></a><a id="Tc_jmB6qED9fE6E_kOfUraxow_1_2"></a><a id="Tc_QyY0cK1xoECkiodMR6hNAA_1_8"></a><a id="Tc_XcrfPMtSQEOrWr5eiIGYwQ_2_0"></a><a id="Tc_msw2aGnDLkuhOlCZ8-9GQw_2_2"></a><a id="Tc_KLtw52CpmESuL80LsZ7A6w_2_5"></a><a id="Tc_BDNgThMHYka6f4WPwtqwQQ_2_8"></a><a id="Tc_jiRWLoiPZEmDlqBvRX5Hdg_2_11"></a><a id="Tc_u42ID7ZhV0qdaWkN_Z1fKA_3_0"></a><a id="Tc_ySoQJwm48kuBBT3hlkN7Vg_3_2"></a><a id="Tc_oofLLOuFik-MzCrCEfqTTA_3_5"></a><a id="Tc_zZExZlNthkmRsfApJ-i31Q_3_8"></a><a id="Tc_0EYOr2CifkKjWQc-lSyAIQ_3_11"></a><a id="Tc_QErannmhzU2llo8HZEMd_g_4_0"></a><a id="Tc_iJ1gtEqA40y5zEWWjePIdw_5_0"></a><a id="Tc_efA8XHxNmUmjQHe5ApOd0g_6_0"></a><a id="Tc_cKGhYcDXPUeD-2d-22HmDQ_6_4"></a><a id="Tc_H3wDE_d6B0CmywmfkzeAOw_6_7"></a><a id="Tc_Vuil63oYIkWe1X2H4Rc3_w_6_10"></a><a id="Tc_-mrMQ_OdEUyyKm2BZo7jBg_6_13"></a><a id="_7c0e42cd_37f7_4464_95d1_739728d945e2"></a><a id="Tc_5bhSm1zqV0Kgwjs_b4pmxQ_1_0"></a><a id="Tc_tcJshyO2Sku0CQ2fYVyOkg_1_2"></a><a id="Tc_E3Qy9Z_TrUG1CKrn4l6p0A_2_0"></a><a id="Tc_NBEjiwGJUkebFQRTakDeSA_2_2"></a><a id="Tc_GxXlnvurtEK6IDDYkIBOTA_3_0"></a><a id="Tc_6bGLM4Ja1katZUIeontLSA_3_2"></a><a id="Tc_3HplBPkdQUGfiExjVG5Pjg_4_0"></a><a id="Tc_1E6Ns805ukuZMSyoJMXIDw_4_2"></a><a id="Tc_tpSnvRSoBEy0HGquBeSZHw_5_0"></a><a id="Tc_Iidp4o6xcUqYgkWgDVxq4Q_5_2"></a><a id="Tc_dbvzF7gJfkiOk2gVcuGCGg_6_0"></a><a id="Tc_Ed5aP4jh306dIKv8Q-MOlw_6_2"></a><a id="Tc_M8kIoY2XIkSAzqFK1KG4Jg_7_0"></a><a id="Tc_AKhpBxmN4kSwFjtwaUU8nA_7_2"></a><a id="Tc_euc_v6cFTk2HOCgDzisEdw_8_0"></a><a id="Tc_7K-bNpzzn0aBP4-RirpDiw_8_2"></a><a id="Tc_27mWs0OtpEaRG41_ywdokQ_9_0"></a><a id="Tc_6QDIE3PUFUil1JAzeu5qGw_9_2"></a><ix:continuation id="Tb_YrnblJbP5UG0a-yds5pW3Q_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company adjusted the operating lease right of use assets by $<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-5" format="ixt:num-dot-decimal" name="plx:LesseeOperatingLeaseLiabilityAdjustment" scale="6" id="Narr_CuohFdnnNUib4OWuofkaLA"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-5" format="ixt:num-dot-decimal" name="plx:LesseeOperatingLeaseRightOfUseAssetAdjustment" scale="6" id="Narr_LlkIgIVQxE2l6A-t46WFew">3.1</ix:nonFraction></ix:nonFraction>&#160;million reflecting the amount of remeasurement of the lease liability using a new discount rate at the amendment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company is a party to several <ix:nonNumeric contextRef="As_Of_9_30_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_r-Ghqyl9T0iF4Ti21qRoSQ" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_U34mrtHUFESyu2ldj3vBow">three-year</ix:nonNumeric> leases for vehicles which are regularly amended as new vehicles are leased.</p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:LeaseCostTableTextBlock" id="Tb_q9fl2KnODEG8iGWPwAiPdw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The following table sets forth data regarding the Company&#8217;s operating leases for the three and nine months ended September&#160;30, 2024 and 2025:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:28.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:29.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc__69OLY4QXEWGUquUnED3Xg_3_3">1,395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_ohLrsAujokq_0V6xAxIW9w_3_6">1,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_kAlBcwjyfEChG0zcNfOVnA_3_9">476</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_LoVtPuXaNUqnGG5VzX-8aA_3_12">420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_3BFv4FrBF0uVB3DiMtxKfg_4_3">1,338</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_2AEOc2y3wE-_QAW4wu_Mnw_4_6">1,207</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_sP8AoU-LY0mqKUDqxJSHTw_4_9">457</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_SFkrJFjuX0SD4nxR71x-VA_4_12">413</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_UG57LpEyb0-8W5C7dGWq7w_5_3"> 22.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_hmU3upGtLE6vBOHOnfZjnA_5_6"> 6.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_dYjs26OI60iQQglavRFJXA_5_9"> 22.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_FfdgD_37vkuOqHLuplMM3g_5_12"> 6.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_mlmd-wk0O02VFQB3E7fNLw_6_3">13.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_nxaUS1X8Ckikow4du94sWQ_6_6">12.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_sFhcDwTuZ0aMJ4u-0JK3vw_6_9">13.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_eKCev_z4i0iTavTggB39Yg_6_12">12.8</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">%</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_6lzWnNoFwEiWB-Bx9-bGog" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The following table sets forth a maturity analysis of the Company&#8217;s operating lease liabilities as of September&#160;30, 2025:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#009999;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2025</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">First year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_Df5DLAF8qkK4-Siuoin80A_2_3">1,397</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Second year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_Oms0vPSbS0y9Zg_6yXRgIA_3_3">1,141</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Third year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_yBrsLGklGE6brQJD0sw7dw_4_3">1,074</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fourth year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_syXvLDfAAke7A0dx9ssPng_5_3">1,040</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fifth year and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="plx:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" scale="3" id="Tc_xOqkO2Egx0-B_XDJjPCP1w_6_3">22,273</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_-Cn7peqQokCOsRvC6YAiFw_7_3">26,925</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_aTO29UQNukyQKF4s__Ltmw_8_3">18,748</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_3mRarL_tOkSlr9Y_FA-XpA_9_3">8,177</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_hMiNjYWkKUC2b_PVsYnWyg" continuedAt="Tb_hMiNjYWkKUC2b_PVsYnWyg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the nine months ended September&#160;30, 2025, the Company issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zYmBSshLM0q2nl3i43mcsA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_HwwwFz8mMUKDmLq-En6_Xw">908,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zYmBSshLM0q2nl3i43mcsA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="6" id="Narr_QWsY8j-JT0-smMydl5nphA">2.1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from such exercises. All such exercises were effected during the first quarter of 2025 and all unexercised warrants expired on March&#160;11, 2025. Accordingly, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as of March&#160;12, 2025, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="As_Of_3_12_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_1UAWM1totEqWlXUe3rPvGw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="Narr_Q-KASU-VR0qBI18zWVC5WA">no</ix:nonFraction></span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants remained outstanding</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the nine months ended September&#160;30, 2025, the Company sold, in the aggregate, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_O5qbhcAkvUyU14-GI5Itpw" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_cpQytt07TUqVoG9cCzEJ8Q">2,775,215</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock under the Sales Agreement. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company generated </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">gross proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_O5qbhcAkvUyU14-GI5Itpw" decimals="-5" format="ixt:num-dot-decimal" name="plx:GrossProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_agIEseXqmk2uEjsry0Y1Aw">7.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in connection with such sales (issuance costs were </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_O5qbhcAkvUyU14-GI5Itpw" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_J5DTofHxaUeCtSjOPx3jfw">0.2</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million). All such sales were effected during the first and second quarters of 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the nine months ended September&#160;30, 2025, the Company issued, in the aggregate, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CrvjSyzu0kePIviFTWVKvA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_ISQUd6JPI0Cg0T6rN5gHvA">248,625</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock in connection with the exercise of options to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CrvjSyzu0kePIviFTWVKvA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_ct3LS5W_0Uu4ktp2tDdTjA">248,625</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock by certain current and former employees of the Company. The Company received cash proceeds equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CrvjSyzu0kePIviFTWVKvA" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="6" id="Narr_3ux5FgwliUuoc67ZDJgKpQ">0.2</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in connection with such exercises. All such exercises were effected during the third quarter of 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the three months ended September&#160;30, 2025, the Company granted, with the approval of the Company&#8217;s compensation committee, </span><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Narr_dPfL0rGwAUWXe05U59zdOw"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10-year</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> options to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_c7LKr6edEEi86W4WsgDXlA">1,448,990</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock, in the aggregate, to certain of the Company&#8217;s officers, directors, other employees and a consultant under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The options generally vest over a </span><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ZcGVkO-1-E6VMspZq6CnSA"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three-year</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> period in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_installment_La8zkqC6pUaqrn9vr4M5jA" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="INF" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" scale="0" id="Narr_YFPkQ9iD2060zc4eZD9u1g">12</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;equal quarterly increments. Vesting of the options granted to executive officers is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the applicable dates of grant </span></td></tr></table></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">11</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_hMiNjYWkKUC2b_PVsYnWyg_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"/><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">using the Black-Scholes option-pricing model to be approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-5" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" scale="6" id="Narr_zzaekX2XykG-KJp2GnwWkw">1.5</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million using the following assumptions (weighted average): stock price equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Narr_IBG1TvYEYU2NjwyuqT6FeA">1.56</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, exercise price equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="Narr_l7ZQmEiZREaHJBNXeeW04Q">1.56</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, dividend yield of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_iNKE7M0t7E6liOXhcWP8Sg">0</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, expected volatility of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Narr_m4WoUBuz-0et0c973EH-Sg">73.64</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, risk-free interest rate of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_7YfPa9NnNkqbCZtW0qNBHQ">3.9</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and expected life in years, </span><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_xmM8BEYZ80OvJlYa0T90eA"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.75</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">e.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the three months ended September&#160;30, 2025, the Company granted, with the approval of the Company&#8217;s compensation committee, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_tPyaORiFkkOM-rUgWSubEA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_3KI3MphbbUSZiLFIQcDorw">559,210</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock, in the aggregate, to certain of the Company&#8217;s officers, directors, other employees and a consultant under the Plan. The shares of restricted Common Stock generally vest over a </span><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_tPyaORiFkkOM-rUgWSubEA" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_muPYxeY0KkeNDUgiom_gIQ"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three-year</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> period in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_installment_La8zkqC6pUaqrn9vr4M5jA" contextRef="As_Of_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_D4u9NxlfVEGwyeTxPj6T4w" decimals="INF" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" scale="0" id="Narr_yd6gTAUk4kWfb0BjWRS8Aw">12</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;equal quarterly increments, with </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_tPyaORiFkkOM-rUgWSubEA" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_zbp-GgD5G0WwBC-Tp9O5Tg">52,910</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of such shares of restricted Common Stock fully vested upon grant (September&#160;22, 2025). Vesting of restricted Common Stock granted to executive officers is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the restricted stock on the applicable dates of grant to be approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_tPyaORiFkkOM-rUgWSubEA" decimals="-5" format="ixt:num-dot-decimal" name="plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" scale="6" id="Narr_1Bo3JRkVzkiKtyXLIS-tBQ">0.9</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million using stock prices equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="As_Of_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Ji-guYoHVUu8eVJ9spIzyQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Narr_6lIw1dJBbEGepX8_XjHNIg">1.64</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ" contextRef="As_Of_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_JrP2MNklRUaZCBhVdKEU3Q" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" id="Narr_hX2b4Ec6TUKCfTC73zKqvg">1.89</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:10pt;"></div></ix:continuation><a id="_6decb5fe_5bf4_42a7_8c51_83efe763b9f1"></a><a id="Tc_f5CM6Gx4lkyP4Hd4lyxamA_1_2"></a><a id="Tc_9vxACLZeAUy35sbwPGhoOw_1_9"></a><a id="Tc_ziY0jgxpGkasR7PeiiDXeA_2_0"></a><a id="Tc_fKJpurp3FUOHZ736kVMdBg_2_2"></a><a id="Tc_KJP4SlnWQEO6Qe8kSEnAZg_2_5"></a><a id="Tc_QncwdumbPU2z62LwXkpfbA_2_8"></a><a id="Tc_QW90PyKDfUWcm1moqtCRlA_2_11"></a><a id="Tc_1_va3Hy1B0-9Sdrb317-oA_3_0"></a><a id="Tc_5MauaowUM0GXbruoApNcGg_4_0"></a><a id="Tc_g8_SRAyKFkOlkOqE5hiBGg_4_2"></a><a id="Tc_2ca_kuJaHUKoeoMwiVjHvQ_4_5"></a><a id="Tc_Nd4m8vxvzUSg5iY9erojog_4_8"></a><a id="Tc_aVX-87ZuZEKzCA_z307qcw_4_11"></a><a id="Tc_95IEObkhmk25-iYwtExwiw_5_0"></a><a id="Tc_CNhqAL86RU6_2pNpvGwqeA_6_0"></a><a id="Tc_PXHPqkJW0ku0XXj95xwfLg_7_0"></a><a id="Tc_TafCIuKjV0ad3rBetdnk0A_7_2"></a><a id="Tc_z6wzgfBy1US0zwC8dLaRGQ_7_5"></a><a id="Tc_ryxhjw5XUEKFEN3tHFrL0A_7_8"></a><a id="Tc_WsxXP_ieEkqLXRJQrbze2w_7_11"></a><a id="Tc_944s68Wuskyj89sybrRgdg_8_0"></a><a id="Tc_AZ3N3rm2lk-upj8117yAQw_9_0"></a><a id="Tc_DDeuqWyGkk6BeJjAZ4MUOw_10_0"></a><a id="Tc_XfOvGt4swkScuL7EdcjQeA_11_0"></a><a id="Tc_E0uJW9ABfk6HwObyzMecvQ_12_0"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:EarningsPerShareTextBlock" id="Tb_1CtZPikh1EedwbITHotbbg" continuedAt="Tb_1CtZPikh1EedwbITHotbbg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; EARNINGS (LOSS) PER SHARE</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_2_vJLHtgZkCxHpBblF9tWg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted earnings (loss) per share attributable to common stockholders were calculated as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#160;&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_wEtrT2b2b066qBOcA66d1A_4_3">1,100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_VAZv86JHOk6utTrZFCmXTQ_4_6">3,562</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_WBX8Q-NI70W1A8idDfXkUw_4_9">2,355</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_THx7AiuUmESQyphVXQdKJw_4_12">3,236</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DilutiveSecurities" sign="-" scale="3" id="Tc_Snv6ssdxF02YdxlKntDHfQ_6_12">503</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc__3wquKP_pEeCu6Zo1ygVgQ_7_3">1,100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" sign="-" scale="3" id="Tc_6sEXbnfzU0WdBGF4PYfoqA_7_6">3,562</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_F3ssW5Nt3kOBfFj6AdzQZA_7_9">2,355</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" id="Tc_NWWyd7bsu0iEikkKbyaWIQ_7_12">2,733</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_2YzGkjYE0UKf11cPy7_kLQ_9_3">78,225,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_LnOUfT9ec0q8TuI3v1ePMQ_9_6">73,301,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_RcWyLmI4SEmPN0Vd6n2tyw_9_9">79,281,685</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_FdMvpT0rBEadP0pAB9X_bw_9_12">73,549,745</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities" scale="0" id="Tc_S8PqYG3sIUWFEIuDq0eQeQ_10_12">7,667,323</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of stock options and restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="0" id="Tc_664q6GYyc0OXpcMpeCFATA_11_9">1,532,879</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_B6sqqr4QyUGtYAkmr_O-TQ_12_3">78,225,112</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_EunwWHD8cEW21BP4bRSFGQ_12_6">73,301,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_VrErwCaAdkqT4StOXLTY_w_12_9">80,814,564</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_IeppVqtH1k-G4rT9912Dwg_12_12">81,217,068</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3pt 0pt 10pt 36pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_xH2ut0yotUKC0HIos63e3g" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_p8xtW39IgkW8FbzTU-HADQ">11,288,007</ix:nonFraction> shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock and warrants for the nine months ended September&#160;30, 2025 because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember_-2H5wzF6b02WyHEkdfnNXQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_l5jgI6vybUe_zd2lO-AnMw">3,745,682</ix:nonFraction> shares of Common Stock underlying outstanding stock options and unvested shares of restricted stock for the three months ended September&#160;30, 2025 because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_xVbKyWax_0uHtrglZoisTQ" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_ewHjhJWpt0iBl5XByV7ywA">30,515,287</ix:nonFraction> shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock, warrants and the 2024 Notes for the nine months ended September&#160;30, 2024, and <ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_gq56zarwQUuh08Mxtq1EHg" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_2JW_ecEDlEqtRaTTi6v3Uw">20,173,438</ix:nonFraction> shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock and warrants for the three months ended September&#160;30, 2024, because the effect would be anti-dilutive.</p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">12</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_1CtZPikh1EedwbITHotbbg_cont1"></ix:continuation><a id="Tc_Lo0yIv1stkS91pu9lAPyEg_1_3"></a><a id="Tc_w7XbG0RyU0GHr9PJ_C0-2w_1_8"></a><a id="Tc_xVOtL3s1rUGMXH87L_PyEQ_2_0"></a><a id="Tc_cyTAH8okA02IWL5VYc5SYA_2_2"></a><a id="Tc_5MFoWb2pCEW-1Vi5WiNlQw_2_5"></a><a id="Tc_vRZO-Bht10aTF_0GxBcR0g_2_8"></a><a id="Tc_kPRe73qutEOFkME5N7N-Nw_2_11"></a><a id="Tc_TlRSuOHkIUCik-erf0z-KA_3_0"></a><a id="Tc_Csjd381M0E-yYIMur5S3Fg_3_2"></a><a id="Tc_6h-X2HZZAUKyRXjZjBCgow_3_5"></a><a id="Tc_FUsghukykUq_FpqnpF8ETQ_3_8"></a><a id="Tc_G5ge7c5Bq0K0MmUQDL0quw_3_11"></a><a id="Tc_sT6DWhDaXE68t-78ke1_Ag_4_0"></a><a id="Tc_jApJqwTVxUiJ8LKYj7-CzA_4_8"></a><a id="Tc_anOP8JnuZ0q3p0mT82gxDw_4_11"></a><a id="Tc_9ZEY4Ufew0CCvsusHotmKA_5_0"></a><a id="Tc_a9M90fYARUaOzVFmXd3WFg_5_2"></a><a id="Tc_x3KsJWxbm0q5q08C3Bmexg_5_5"></a><a id="Tc_tHJD1swUEEaGKs9r2cKz3Q_5_8"></a><a id="Tc_Iy8HX_arikySVJs_V5ZbDA_5_11"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_I5qno-5Y3kuXLbt4DcOeNw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; TAXES ON INCOME (TAX BENEFIT)</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Group_t5JAA8mmWUKnrW9W8ZSK2g" continuedAt="Group_t5JAA8mmWUKnrW9W8ZSK2g_2" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p></ix:nonNumeric><ix:continuation id="Group_t5JAA8mmWUKnrW9W8ZSK2g_2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_iu0qiUW_7kyJnOwlh_38wg_3_3">91</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_dVJ3VdtoX0uGtx0ZB6ZdkA_3_6">164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_ja5PXXhq80-C9jRHkuNHkg_3_9">175</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="Tc_lLroaUihSEm4P1vpYbQwHg_3_12">164</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_jD5QpM8W_kOpxJ9OfMBeDA_4_3">177</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_bLD6VXwD20-rlnUiTEBFLQ_4_6">236</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_4CAu52z-pkCXIaXpBcNEwQ_4_9">59</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="Tc_SZhQIT_HXEmwARVQ9LCi_g_4_12">443</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income (tax benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_pcSD99HvpE-1rWmaOVg61A_5_3">268</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_LLOj48pw2kKr27cnRCdniA_5_6">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_vlcyRNXOME2hH0oSoUPkeQ_5_9">116</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_9KY41QfH3k-vIXQKMRm_rw_5_12">607</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company had an effective tax rate of (<ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Narr_YKGvomTET0iKMDdaof8Ugg">32</ix:nonFraction>)% for the nine months ended September&#160;30, 2025 compared to an effective tax rate of (<ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" sign="-" scale="-2" id="Narr_tcOm_mxWN0yeJ2wZ4EWiTA">13</ix:nonFraction>)% for the nine months ended September&#160;30, 2024. For the nine months ended September&#160;30, 2025, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of <ix:nonFraction unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A" contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_Fcaq6NdS6UyIbyo3md9Pkg">21</ix:nonFraction>% was the result of forecasted profits derived primarily from U.S.&#160;taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;), which was enacted in December 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On July&#160;4, 2025, tax reform legislation was enacted in the United States through the passage of H.R.1, One Big Beautiful Bill Act (&#8220;HR1&#8221;), which includes significant corporate tax changes, including a restoration of the current deductibility for domestic research expenditures beginning in 2025, with transition options for previously capitalized amounts.</p></ix:nonNumeric><a id="NOTE_7"></a><a id="_f10d0571_9307_4863_b1ac_d02a1bb9aefb"></a><a id="Tc_UVuppdD7mEOw2281idMZRg_1_2"></a><a id="Tc_BhsKOTHZWkuVQeFy6o_Ipg_1_8"></a><a id="Tc_CIoMh4VECUSXm2oF_YXvog_2_0"></a><a id="Tc_blYCOrzjdkqOM-MoFHIshg_2_2"></a><a id="Tc_aR48BcZh8U2khKK3jtJ9rg_2_5"></a><a id="Tc_NyrExQRm8Ue8teisPFEYfA_2_8"></a><a id="Tc_fTh2M9edgkSNOti-jdUxsg_2_11"></a><a id="Tc_hztZTMYsYEKi7pxmhH48mg_3_0"></a><a id="Tc_UZxPrsoldEmHuAUV13KA1w_3_2"></a><a id="Tc_ER9nW8DYO0u0wHXhb-JWOw_3_5"></a><a id="Tc_7W1x6iwtTkKSatKLnbjsKA_3_8"></a><a id="Tc_R32OW9R3YUunQ3Bk29Dfgw_3_11"></a><a id="Tc_j4qmPx4iJkOQ916Fa6CyQg_4_0"></a><a id="Tc_t2yQJirjH0qW0165yqjTzA_5_0"></a><a id="Tc_n5T4O1VArkK_X05A0apiqg_6_0"></a><a id="Tc_QFCYq3VQZEewlBzMIKmOWw_7_0"></a><a id="Tc_XJ90ZCs6S0qNWTFmFvuMnw_7_3"></a><a id="Tc_kz7w_9HZLUOLtQFTkEJxDA_7_9"></a><a id="Tc_0_syuQWTbEmaLC7ySbJtUQ_8_0"></a><a id="Tc_tDNWVAlEmEeRfBOAcdFygQ_9_0"></a><a id="Tc_-1LJ9t5Lk0eAZAIaj3Ef_w_10_0"></a><a id="Tc_MMw_9e07zE2IY-3Xu-XA9w_11_0"></a><a id="Tc_nXt3fuCDAEGJEgtenGyi6w_12_0"></a><a id="Tc_DcOsvgcyhEWO8Avg58Ez9A_13_0"></a><a id="Tc_5XENQkGZnEOEe-yCiSIOuw_13_2"></a><a id="Tc_Ykw3Jytw4E2EraCKZUdwCA_13_5"></a><a id="Tc_83t-gTJ9kUi3PUlJD3RCOg_13_8"></a><a id="Tc_uAjQMBhMykGFAMoEakI4Pg_13_11"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:SegmentReportingDisclosureTextBlock" id="Tb_5MDvr-2ePkm2tTxJ_fCzUw" continuedAt="Tb_5MDvr-2ePkm2tTxJ_fCzUw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 8 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SEGMENT INFORMATION</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company operates in Israel as a </span><span style="-sec-ix-hidden:Hidden_QJxRIWVBeUCE75e_V0YVVg;"><span style="-sec-ix-hidden:Hidden_bTovpeYB_EG_cx9KDkApfQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> operating segment. The Company&#8217;s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.</span></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="Group_LFc4KfJtWUuGJakM82E22Q" escape="true"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Segment information:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from customers</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_L2Zbk4Vnk0-8ysvFzjIeEg_3_3">43,622</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_ilx_lxTgSU-c55vVaIbaTg_3_6">35,181</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_Y2XUml5_dk6AmX2WeVL8rg_3_9">17,851</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_kMgE_zmQq0CsAchnzGYhew_3_12">17,959</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee salaries and related expenses</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_93yvnpHx70eEiAuG48zI9w_5_3">16,502</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_kZ4kzV3jL0qEYWy2t8yjxQ_5_6">15,091</ix:nonFraction></p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_JjUxxQg88U2XuMGXU4imqw_5_9">5,853</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LaborAndRelatedExpense" scale="3" id="Tc_hlVslgHha0W7W5tJFvLO1w_5_12">4,734</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-contractors expense</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="Tc_rOnA0fKaY0iAcLrX8csmQA_6_3">9,348</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="Tc_ASEYtI-DxkKG-GQJCpcOgQ_6_6">6,413</ix:nonFraction></p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="Tc_AR2ll7EiuEqJMt1nV1NUEw_6_9">1,886</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfessionalAndContractServicesExpense" scale="3" id="Tc_DFAv0yT7OUy_cKhq9n8M3A_6_12">1,649</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_3NRDE9nc5k202hAViWlBvA_7_6">1,021</ix:nonFraction></p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpenseNonoperating" scale="3" id="Tc_d_5rjolQcESf-cpKyVlX7w_7_12">260</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_sx1CbWkWDUePXBinjlhEUA_8_3">817</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_zsLjCkB1aUekcPSB0UyUow_8_6">970</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_UK_We3TaskSYZkeSmPdaNQ_8_9">289</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_u4RvjnkkOUWl05VwZMJYEQ_8_12">212</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_lUPZ90wYHkKrJvagmhjOgQ_9_3">1,078</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_-DUqfoI9d0aJKNhQU9Z3aQ_9_6">970</ix:nonFraction></p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_m5On53T_Lku2CS4Ztb4vUw_9_9">372</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" id="Tc_fqLtCRylwkODtNY2x6fQ_Q_9_12">329</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment expenses*</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_an9HFOvlSkWAln62f8W58A_10_3">18,343</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_QaQoUrN97Eew80TM_B5mXQ_10_6">15,818</ix:nonFraction></p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_SVPA_2L8nEOVffQtAtglSA_10_9">7,790</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SegmentReportingOtherItemAmount" scale="3" id="Tc_X_jpynl-JUeZwsMopA9pEA_10_12">7,356</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income (loss) before taxes on income</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_QsxeoMcTWkqZq18Z_3csfg_11_3">832</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="3" id="Tc_bAQXHHOKlkyU_wYHsWQUmA_11_6">3,162</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_o9GXV6I6aEO1zVuR4LVKJA_11_9">2,239</ix:nonFraction></p></td><td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="Tc_wYSWXHePzUiiUliBuhVO0g_11_12">3,843</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxes on income (tax benefit)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_59oBr9yMS0q66Da29jeIHQ_12_3">268</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_VO7VZaKCS0Ce3aQC6PsWOg_12_6">400</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" sign="-" scale="3" id="Tc_kJt0eIxatEaqyNia7AE4ZQ_12_9">116</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="Tc_ImA2bnB1ZEaUX57UhlnhaQ_12_12">607</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net income (loss)</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_iiEU-6gG5kefQW0gdgOTww_13_3">1,100</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_Vv6C2zLeXkKc_sGXOoEs9w_13_6">3,562</ix:nonFraction>)</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_F__DsLllNEa4EyF1_awpfQ_13_9">2,355</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="Tc_-DGDSoqzSEa_B7As01iwCg_13_12">3,236</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;">* <ix:nonNumeric contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_vvl5T-0_rkKGHFeoIxIo8w"><ix:nonNumeric contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_mvOR0EI-x0Oz6WUDG46PJw"><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_gYf1pCgN8kq8n8_Ip6cuWw"><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" name="us-gaap:SegmentReportingOtherItemCompositionDescription" id="Narr_2jeQHPH_FUuPhqQVS0q4HQ">Other expenses included in net income includes raw materials, rent and utilities and others.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="Tb_Yx6WLEpnaUiBszqtkFGilA" continuedAt="Tb_Yx6WLEpnaUiBszqtkFGilA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">13</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">PROTALIX BIOTHERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_efea1927_263e_4853_975e_490fff50e12e"></a><a id="Tc_NcZtuhEEEkmiqgRR9N4EEg_1_1"></a><a id="Tc_o9gBaOXU90G2heG6itcE-Q_1_7"></a><a id="Tc_DtqhMADGVEKSItK8ABECKQ_2_0"></a><a id="Tc_bfBCNzIgskmPOPLuyYPNGA_2_1"></a><a id="Tc_Y7gcOmhpwkCFH-2Xxlb5Fw_2_4"></a><a id="Tc_8nNIfsJd8USdShgYajh2aA_2_7"></a><a id="Tc_tRRHRcNizUek1ZU0OlsREw_2_10"></a><a id="Tc_ypZ15yBklE-tx8FCYHe6aA_3_0"></a><a id="Tc_jALn0czjt0C7ILM_csAldw_4_0"></a><a id="Tc_FzXWJU4AWEGHO1AmeQLZPg_4_1"></a><a id="Tc_wRtaYfVM6UqyWnMYSxjHfw_4_4"></a><a id="Tc_bgH-yVOJJkGWHsqqQVFFtw_4_7"></a><a id="Tc__ncvmB2VUUuwXWoV9qyfJw_4_10"></a><a id="Tc_Nullhzx89kWQMyhZQbNO1w_5_0"></a><a id="Tc_sFxxuVl-tU6vBBwBFzGjzw_5_1"></a><a id="Tc_s00PmAr-wEKqqGxtSzVDew_5_4"></a><a id="Tc_jJShg1IrXEyGx3cz03BGsA_5_7"></a><a id="Tc_nhbVVD02Bk6iYyHCPh9Wxw_5_10"></a><a id="Tc_beoDNKS7XkS4sVgPBd8GXQ_6_0"></a><a id="Tc_1TyS588C1UCzSuVZA2NfzA_7_0"></a><a id="Tc_wtKaS8UlKEe-ktkgOuDGsg_7_1"></a><a id="Tc_L2sMfTef6EGhf84blP23yw_7_4"></a><a id="Tc_5sxI6hscH0G3h9Rb8SXz1w_7_7"></a><a id="Tc_7Y46AHdTuUKLyU1UmvcUkg_7_10"></a><a id="Tc_nLkSVjcoXky-ZL8mw8Nezw_8_0"></a><a id="Tc_HzauZb06mUWpzds_uyWHBw_8_1"></a><a id="Tc_Q7cHYPiys0yeqeIq1AVf4Q_8_4"></a><a id="Tc_S4RR6uczZkKMwRdxIMaNaA_8_7"></a><a id="Tc_oKMWRvZxn02Drs1-QtZ_2Q_8_10"></a><a id="Tc_9paoZIrWOkSGH1BL3zUfpg_9_0"></a><a id="Tc_Phor3-clxUmhPNH6wYNJwQ_9_1"></a><a id="Tc__wkIJaSIHU2DHNcnI6cjYQ_9_4"></a><a id="Tc_3VJNy1xG-Ua9RLklI24vRw_9_7"></a><a id="Tc_zMMjO6RU6EqHpbMvgyZuEg_9_10"></a><ix:continuation id="Tb_5MDvr-2ePkm2tTxJ_fCzUw_cont1"><ix:continuation id="Tb_Yx6WLEpnaUiBszqtkFGilA_cont1"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Gaucher disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer (Ireland)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_J35jXCLpZEemlLCh3xmZDw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_KxKYJHQL2UC1IpjVrhR_TQ_4_2">15,431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_xIDPNJ0kwU6c6DEVa4EIhA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_NNp69tEQ20mXoXY5o6SpyA_4_5">11,431</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_tGVlUvMwNESS1QuVEsIxCg" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_j8hzN3IjbUOMzwX8Uj96iQ_4_8">2,805</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_zd9vtIegUUmVwTycldKD6w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_yxJtmisw4EqOvKTMKFJCpQ_4_11">3,430</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiocruz (Brazil)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_TC6cWr1PVEmqOYnE9WVTEw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_C-9JKZPv_k2ILkvfKNGOcA_5_2">9,121</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_82eWapBWXEC0gB4NcExxIA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_kYsBtJiPz0S0iiBhr5vKGg_5_5">9,314</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_LjReUd2e3ECAW3t58uSqwQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_5O2SCcrNX0KxAbinX1DoeA_5_8">6,105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_-58If4GE2UOATvhmgfPXFw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_vigUpx6DtUaEGqZCQ5VFxA_5_11">2,048</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Fabry disease:</i></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi (Italy)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_gQv-s1-zbEiYrnnAYvRtQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_E46hscydGEWfbKqTBCc5sg_7_2">18,556</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_aZcDMzIGjE-AMBlyb0cM3w" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_NuS42PjD2EaiKVuNE5n9pg_7_5">14,075</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_U3vsnozyEUyKSmL6qLgZuw" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_ci_mMM0QuEKrbz2zK2C6Vw_7_8">8,763</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_8K2eAUmCmkWnafp6nTCcww" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_-LbKKqrGHU6PUFVqEkxyKw_7_11">12,361</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_B_RDBf3UakmFxKgLCE1u4Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_0M681MZ84kCVG2iyh0dK8w_8_2">43,108</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_DfUDjS8huEe8YHRZP_FF_g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_G7P6NK1X10C1vlPiGymK0A_8_5">34,820</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_EM-2D042mUKZtARE4xNQQQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_YslMopAImEW_8GbrpXIx6w_8_8">17,673</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_-nchaslNr0uweGPjWu-YUQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_-ND6Nd5AjEOikh1Vxm3u5w_8_11">17,839</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__u5aEet9ik6m5qJP9wbdkQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_K3dbX9F7X0eI0-f3JV4swQ_9_2">514</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_5TVhAsNFQE213aFWrjtG8g" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_8KSaprCqY06JKW01TTVokA_9_5">361</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__wSFk5nFpUKVmADVapX-hA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_99jMlGgXU0CXwcm9Io1DFQ_9_8">178</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_QMoe7jUDBUORp5O-RNIp8Q" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" id="Tc_-a1qZfsYa0asNn0ewPq3VQ_9_11">120</ix:nonFraction></p></td></tr></table></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Long lived assets are located in Israel.</span></td></tr></table><div style="margin-top:10pt;"></div></ix:continuation><a id="Tc_4tXIzT4VZUKIt7Ro342DbA_1_2"></a><a id="Tc_zPT4dpLPdk6gCXhiKjPSyQ_1_5"></a><a id="Tc_bzTA7rcheEW6y5WgeJForQ_2_0"></a><a id="Tc_HsuYudfE8E-CeqZkYMMuXw_2_2"></a><a id="Tc_pKM7tzr7YkOBXaK1DcdPbQ_2_5"></a><a id="Tc_VL6CfpvrF0mCmM4GJmqCVg_3_0"></a><a id="Tc_rRcui-l-00yTWZnbjHq87Q_4_0"></a><a id="Tc_k9TWy2kyW0mXlj26evmZlw_4_2"></a><a id="Tc_9xi17KtCb0OpA9i_urZehw_4_5"></a><a id="Tc_dCmL8uhgl0ebJ9ul4iX3IA_5_0"></a><a id="Tc_V5zrQVMiI0C_wuweKm7QIA_6_0"></a><a id="Tc_7n4bgKl230anrCK9mNcdSQ_7_0"></a><a id="Tc_6C7ti5FJiEme_Bxan3OGng_8_0"></a><a id="Tc_R4j7s6UB0kKqjeti8eQ3Ww_9_0"></a><a id="Tc_jgCu_PnD6E2b_3-K5Bk3rQ_10_0"></a><a id="Tc_97tcddqueUqD1AWfBqRKAQ_11_2"></a><a id="Tc_Hw6GDFUr6EeiKCybVE-FVw_11_5"></a><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="Tb_TACYuMaUoEScf365cFKxsA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 9 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Balance sheets:</b></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="plx:SupplementaryBalanceSheetsInformationTableTextBlock" id="Tb_k6xHrvZZn0m4b8oMNtitVw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_-FEXbTpUSkGxCcmTsTIBSg_4_3">745</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_ZF6QFY62nEuxCvjyzCCSiQ_4_6">1,343</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_d43XXnP1v0W0SmvrbVXk6w_5_3">2,209</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedVacationCurrent" scale="3" id="Tc_9K53Ha-HWkG5v5thno5sug_5_6">1,811</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_aWFk_nj22Eym5wFQpHxfkg_6_3">8,126</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_qmr1js1vp0OnsJGo3Ohk-A_6_6">9,568</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_BPYPdCC-_EKEHsyMLrtvlw_7_3">558</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedRoyaltiesCurrent" scale="3" id="Tc_c5Hsh19fFE2QMalgs6Rzkw_7_6">1,080</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_R4KxftU3VkKUUCCYEaejUA_8_3">2,385</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="Tc_J_ps75kYPUmbRhvpK8iEmg_8_6">3,476</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable to customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="plx:PayableToCustomerCurrent" scale="3" id="Tc_s3zG2-INYESuPWGjbM3YVQ_9_3">920</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:PayableToCustomerCurrent" scale="3" id="Tc_CPCBVwXmj0yowPNgD0meVA_9_6">2,056</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_DfzMScZwkU2TesTYfTelmQ_10_3">230</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent" scale="3" id="Tc_Gcpij7Ee0E6H09udVNRx_A_10_6">254</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_fH_qMpt-pke00mLdGHvJxw_11_3">15,173</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ" decimals="-3" format="ixt:num-dot-decimal" name="plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent" scale="3" id="Tc_QvEVHtQyXkaAyR9eRRUegA_11_6">19,588</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw" name="us-gaap:SubsequentEventsTextBlock" id="Tb_R6-AOICe3E6O1ozt9YR7_Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 10 &#8211; SUBSEQUENT EVENTS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since the end of the quarter ended September&#160;30, 2025 and through the issuance of these financial statements, the Company collected approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_V8A_9r0xvk696ZxvjJRa8A" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCustomers" scale="6" id="Narr_mBbwb7j8l0OLPGwaHUOrBg">3.0</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from sales to Fiocruz (Brazil), approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_f2rN9XEbVUelOX_cn66r4w" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCustomers" scale="6" id="Narr_xQxetgUS70eyf3jT0rDSsg">9.9</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from sales to Chiesi and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_9plBbFjl-0GfbTD6J4eCZQ" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromCustomers" scale="6" id="Narr_P0nn3Xk0CE2BaSdT43LFeA">1.4</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from sales to Pfizer.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since the end of the quarter ended September&#160;30, 2025, the Company issued, in the aggregate, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_71PZO8VDYEeOr9oCkh_Hog" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_C9y7FJN4BECUWZ_dvasqiA">79,856</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock in connection with the exercise of options to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ" contextRef="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_71PZO8VDYEeOr9oCkh_Hog" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_RYLWg1_1N0W1h1b6K36GVg">79,856</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock by a former employee and a current employee of the Company. The Company received cash proceeds equal to approximately $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg" contextRef="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_71PZO8VDYEeOr9oCkh_Hog" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="0" id="Narr_GG8pP4Tan0yoYmEjsXTM8Q">94,200</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in connection with such exercise.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">14</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c4d7c62a_9ed6_4497_98e7_8453d0a13c7a"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</b><b style="font-weight:bold;"><br/></b><b style="font-weight:bold;">AND RISK FACTORS SUMMARY</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the consolidated financial statements and the related notes included elsewhere in this Form</i>&#160;<i style="font-style:italic;">10-Q and in our Annual Report on Form</i>&#160;<i style="font-style:italic;">10-K for the year ended December</i>&#160;<i style="font-style:italic;">31, 2024. Some of the information contained in this discussion and analysis, particularly with respect to our plans and strategy for our business and related financing, includes forward-looking statements within the meanings of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, including statements regarding expectations, beliefs, intentions or strategies for the future. When used in this report, the terms &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and words or phrases of similar import, as they relate to our company, our subsidiary or our management, are intended to identify forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are only predictions and reflect our views as of the date they are made with respect to future events and financial performance, and we undertake no obligation to update or revise, nor do we have a policy of updating or revising, any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, except as may be required under applicable law. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements as a result of several factors, including those set forth in this Quarterly Report on Form 10-Q.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Examples of the risks and uncertainties include, but are not limited to, the following:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the commercialization of Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa-iwxj), our approved product for the treatment of adult patients with Fabry disease;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to Elfabrio&#8217;s market acceptance, competition, reimbursement and regulatory actions, including as a result of the boxed warning contained in the FDA approval received for the product;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possible disruption of our operations due to military actions conducted by Israel with the Hamas terrorist organization located in the Gaza Strip, Hezbollah and others, including as a result of the disruption of the operations of certain regulatory authorities and of certain of our suppliers, collaborative partners, licensees, clinical trial sites, distributors and customers, and the risk that the current hostilities will result in a greater regional conflict;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the regulatory approval and commercial success of our other product and product candidates, if approved;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our expectations with respect to the projected market of our products and product candidates;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>failure or delay in the commencement or completion of our preclinical studies and clinical trials, which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; inability to monitor patients adequately during or after treatment; and/or lack of sufficient funding to finance our clinical trials;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>delays in the approval or potential rejection of any applications we file with the FDA, European Medicines Agency, or EMA, or other health regulatory authorities for our other product candidates, including the requested a re-examination of the negative opinion issued by the CHMP regarding the proposed dosing regimen of 2&#160;mg/kg body weight infused E4W for Elfabrio, and other risks relating to the review process;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks associated with global conditions and developments such as <span style="background:#ffffff;">new or increased tariffs, new trade restrictions, </span>supply chain challenges, the inflationary environment and tight labor market, and instability in the banking industry, which may adversely impact our business, operations and ability to raise additional financing if and as required and on terms acceptable to us;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to any transactions we may effect in the public or private equity or debt markets to raise capital to finance future research and development activities, general and administrative expenses and working capital;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our evaluation and pursuit of strategic partnerships;</div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">15</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the risk that the results of our clinical trials will not support the applicable claims of safety or efficacy and that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to our ability to manage our relationship with our collaborators, distributors or partners, including, but not limited to, Pfizer and Chiesi;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to the amount and sufficiency of our cash and cash equivalents and short-term bank deposits;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes to interim, top-line or preliminary data from clinical trials that we announce or publish;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to the compliance by Fiocruz with its purchase obligations under the Brazil Agreement, which may have a material adverse effect on us and may result in the termination of such agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risk of significant lawsuits, including stockholder litigation, which is common in the life sciences sector;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>our dependence on performance by third-party providers of services and supplies, including without limitation, clinical trial services;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the inherent risks and uncertainties in developing drug platforms and products of the type we are developing;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the impact of development of competing therapies and/or technologies by other companies;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks related to our supply of drug products to Pfizer;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>potential product liability risks, and risks of securing adequate levels of related insurance coverage;</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>the possibility of infringing a third-party&#8217;s patents or other intellectual property rights and the uncertainty of obtaining patents covering our products and processes and successfully enforcing our intellectual property rights against third-parties; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>risks relating to changes in healthcare laws, rules and regulations in the United States or elsewhere.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Given these uncertainties, you should not place undue reliance on these forward-looking statements. Companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced or late-stage clinical trials, even after obtaining promising earlier trial results or preliminary findings for such clinical trials. Even if favorable testing data is generated from clinical trials of a drug product, the FDA or foreign regulatory authorities may not accept or approve a marketing application filed by a pharmaceutical or biotechnology company for the drug product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recent Company Developments</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On August&#160;24, 2025, Gilad Mamlok succeeded Eyal Rubin as our Senior Vice President and Chief Financial Officer.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span><span style="background:#ffffff;">On October 6, 2025, we submitted an Investigational New Drug (IND) application to the FDA in connection with our planned phase&#160;2 clinical trial of PRX-115. The IND has become effective following the FDA&#8217;s standard 30-day review period.</span></div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On October&#160;17, 2025, we announced, together with Chiesi, that the EMA&#8217;s Committee for Medicinal Products for Human Use (CHMP) had issued a negative opinion on the request to approve the dosing regimen of 2&#160;mg/kg body weight infused every 4 weeks (E4W) for Elfabrio.</div><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>On November&#160;3, 2025, we announced, together with Chiesi, that we have requested a re-examination of the negative opinion issued by the CHMP regarding the proposed dosing regimen of 2&#160;mg/kg body weight infused E4W for Elfabrio.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Business</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are a commercial stage biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced via our proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> plant cell-based protein expression system. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension. Our unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, we have successfully developed two commercial products, both of which are enzyme replacement therapies (ERTs): Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients and children four years of age and greater with Gaucher disease. Elelyso was first approved by the FDA in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others. Elfabrio, which we referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia, Singapore, Australia and Taiwan. We have licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer, and in Brazil to Fiocruz. Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil. We have partnered with Chiesi for the development and commercialization of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our partnership with Chiesi is governed by two exclusive global licensing and supply agreements for Elfabrio for the treatment of Fabry disease with Chiesi; the Chiesi Ex-US Agreement and the Chiesi US Agreement, or collectively, the Chiesi Agreements. Under the agreements, we have received certain upfront payments and development cost reimbursements, and remain entitled to potential milestone payments and tiered payments for drug product purchased by Chiesi from Protalix Ltd. See Commercialization of Approved Products--Elfabrio (pegunigalsidase alfa/PRX-102) &#8211; Chiesi Farmaceutici.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the terms of our agreements with Chiesi, Chiesi is solely responsible for the global commercialization and medical programs of Elfabrio, including patient acquisition and retention, and distribution of Elfabrio to patients. We are responsible for manufacturing of Elfabrio drug substance and product delivery to Chiesi. Operationally, Chiesi conducts its own internal commercial forecasting to guide inventory needs. To date, since approval in 2023, Chiesi has placed bulk orders for Elfabrio. As a result, the orders we receive from Chiesi may not be timed in relation to Chiesi&#8217;s pace of patient acquisition and retention. Our sales of Elfabrio to Chiesi may not reflect patient demand for Elfabrio. In addition, on a period-to-period basis, there may be variations in the orders placed by Chiesi resulting in variability in our period-to-period results as we, in turn, recognize revenues from sales of Elfabrio upon delivery of the drug product to Chiesi. There may be periods during which no orders are placed by Chiesi, whether as a result of inventory de-stocking or other factors. We do not anticipate that these Chiesi ordering patterns will change until the demand characteristics for Elfabrio stabilize, the launch of Elfabrio matures and Elfabrio&#8217;s share of the market for Fabry disease treatment grows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Under the Amended Pfizer Agreement, we have licensed to Pfizer the global rights to market and sell Elelyso in all markets, excluding Brazil. We sell drug substance to Pfizer for the production of Elelyso, subject to certain terms and conditions and Pfizer retains the revenues generated from such sales. See Commercialization of Approved Products--Elelyso &#8211; Pfizer and --Alfataliglicerase &#8211; Funda&#231;&#227;o Oswaldo Cruz (Fiocruz).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our sales of Elelyso to Pfizer and Fiocruz are structured in a manner similar to Chiesi. We sell the products at a fixed price directly to Pfizer and Fiocruz who maintain product in inventory, and we recognize revenue from those sales upon delivery. The timing of such sales does not directly reflect patient demand and, on a period-to-period basis, there may be variations in the orders placed by each of Pfizer and Fiocruz resulting in variability in our period-to-period results. There may be periods during which no orders are placed by either Pfizer or Fiocruz, whether as a result of inventory de-stocking or other factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition to Elelyso and Elfabrio, we are developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase&#160;I, or PRX-119, for the treatment of NETs-related diseases, and a number of other technologies and preclinical assets. We have completed a phase&#160;1 First-in-Human clinical trial of PRX-115 and we are currently in the advance stages of preparations for a phase&#160;2 clinical trial of PRX-115. We <span style="background:#ffffff;">submitted an IND to the FDA in connection with the trial and it has become effective following the FDA&#8217;s standard 30-day review period. W</span>e expect to initiate the trial in the fourth quarter of 2025.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:189.6pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Product Pipeline</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20250930x10q005.jpg" alt="Graphic" style="display:inline-block;height:189.6pt;width:540pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our proprietary ProCellEx platform is being used to manufacture both of our approved and marketed products as well as PRX-115 and PRX-119.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are committed to leveraging our track record of success as we progress with the development of treatments for rare and orphan diseases. In addition, we continuously work on the further development and enhancement of our ProCellEx technology. Accordingly, we are turning our focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. We are also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">ProCellEx: Our Proprietary Protein Expression System</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx is our proprietary platform used to produce and manufacture recombinant proteins through plant cell-based expression in suspension. We are the first and only company to receive FDA approval of a protein produced through plant cell-based expression, and with the approval of Elfabrio, we now produce two commercial proteins through our platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">ProCellEx consists of a comprehensive set of proprietary technologies and capabilities, including the use of advanced genetic engineering and plant cell culture technology, enabling us to produce complex, proprietary, and biologically equivalent proteins for a variety of human diseases. Our protein expression system facilitates the creation and selection of high-expressing, genetically-stable cell lines capable of expressing recombinant proteins. The system plays an important role in the execution of our corporate strategy as it allows us to develop and produce tailored complex recombinant therapeutic proteins and to genetically engineer and/or chemically modify such proteins pre- and/or post-production. The engineering and modification of the therapeutic proteins have the potential to provide added clinical benefits by improving the biological characteristics (e.g., glycosylation, half-life, immunogenicity).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our ProCellEx technology allows for many unique advantages, including: biologic optimization; an ability to handle complex protein expressions; flexible manufacturing with improvements through efficiencies, enhancements and/or rapid horizontal scale-ups; a simplified production process; elimination of the risk of viral contaminations from mammalian components; and intellectual property advantages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We developed ProCellEx based on our plant cell culture technology for the development, expression and manufacture of recombinant proteins that are the essential foundation of modern biotechnology. We develop new, recombinant therapeutic proteins by using the natural capability of agrobacterium to transfer a DNA fragment into the plant chromosome, allowing the genome of the plant cell to code for specific proteins of interest. The agrobacterium-mediated transformed cells are then able to produce specific proteins, which are extracted and purified and can be used as therapies to treat a variety of diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our ProCellEx technology can be utilized to express complex therapeutic proteins belonging to different drug classes, such as enzymes, hormones, monoclonal antibodies, cytokines and vaccines. The entire protein expression process, from initial nucleotide cloning to large-scale production of the protein product, occurs under Current Good Manufacturing Practice-, or cGMP-, compliant, controlled processes. Our plant cell culture technology uses cells, such as carrot and tobacco (BY-2) cells, which undergo advanced </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">18</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">genetic engineering and/or chemical modifications, and are grown on an industrial scale in a disposable, flexible bioreactor system. Our system does not involve mammalian or animal-derived components or transgenic field-grown or whole plants at any point in the production process.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cell growth, from initiating scale-up steps from a cell-bank through large-scale production takes place in a clean-room environment in flexible, sterile, custom-designed polyethylene bioreactors, and does not require the use of large stainless-steel bioreactors commonly used in mammalian-based systems for recombinant protein production. The ProCellEx reactors are easy to use and maintain, allow for rapid horizontal scale-up and do not involve the risk of mammalian viral contamination. Our bioreactors are well-suited for plant cell growth using a simple, inexpensive, chemically defined growth medium. The reactors, which are custom-designed and optimized for plant cell cultures, require low initial capital investment and are rapidly scalable at a low cost.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In addition, we continuously work on the further development and enhancement of our ProCellEx technology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Our Marketed Products</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have two commercial products, each of which is an ERT; Elelyso and Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Elelyso for the Treatment of Gaucher Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso (taliglucerase alfa), our first commercial product, was approved by the FDA in 2012 for injection as an ERT for the long-term treatment of adult patients with a confirmed diagnosis of type&#160;1 Gaucher disease. In August 2014, the FDA approved Elelyso for injection for children four years of age and greater. Elelyso is the first plant cell derived recombinant protein to be approved by the FDA for the treatment of Gaucher disease and is now approved in 23&#160;markets including the United States, Brazil, Israel and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gaucher disease, also known as glucocerebrosidase, or GCD, deficiency, is a rare genetic autosomal recessive disorder and one of the most common Lysosomal Storage Disorders, or LSDs, in the world. It is one of a group of disorders that affect specific enzymes that normally break down fatty substances for reuse in the cells. If the enzymes are missing or do not work properly, the substances can build up and become toxic. Gaucher disease occurs when a lipid called glucosylceramide accumulates in the cells of the bone marrow, lungs, spleen, liver, and sometimes the brain. Gaucher disease symptoms can include fatigue, anemia, easy bruising and bleeding, severe bone pain and easily broken bones, and distended stomach due to an enlarged spleen and thrombocytopenia. Epidemiology of Gaucher disease varies; recent literature provides that prevalence of Gaucher disease ranges from 0.70 to 1.75 per 100,000 in the general population. In people of Ashkenazi Jewish heritage, estimates of occurrence vary from approximately 1&#160;in 400 to 1&#160;in 850 people.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The global market for Gaucher disease, that includes Sanofi&#8217;s Cerezyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, Shire&#8217;s (acquired by Takeda Pharmaceutical Company Limited) Vpriv<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Sanofi&#8217;s Cerdelga<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, was $1.7&#160;billion in 2024, is forecasted to be approximately $1.7&#160;billion in 2025 and is forecasted to grow at a compound annual growth rate (CAGR) of approximately -1.82% from 2024-2030. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The current standard of care for Gaucher disease is ERT, which is a medical treatment where recombinant enzymes are injected into patients to replace the lacking or dysfunctional enzyme. In Gaucher disease, recombinant GCD is infused to replace the mutated or deficient natural GCD enzyme. Elelyso is the only alternative ERT treatment of Gaucher disease to Cerezyme and Vpriv.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Elfabrio for the Treatment of Fabry Disease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Elfabrio, our second commercial product, was approved by the EC for marketing in the EU and by the FDA for marketing in the United States in May 2023 for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. According to the EMA, overall, the benefit/risk balance of Elfabrio is positive in the claimed indication (Fabry disease). Similarly, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease. The FDA noted its determination that substantial evidence of effectiveness for Elfabrio in Fabry patients was established with one adequate and well-controlled study, our phase 1/2 clinical trial of Fabry disease, with confirmatory evidence provided by the <i style="font-style:italic;">BALANCE</i> study. The FDA review team also concluded that the <i style="font-style:italic;">BALANCE</i> study met its primary efficacy endpoint, which assessed the annualized rate of change in eGFR (estimated glomerular filtration rate) over 104 weeks. However, the FDA also determined that the results from the <i style="font-style:italic;">BALANCE</i> study did not support a non-inferiority claim to the comparator product due to the lack of data to support the non-inferiority margin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">Since the approvals by the FDA and the EMA, Elfabrio has been approved for marketing in Great Britain, Switzerland, Peru, Israel, Russia, Singapore, Australia and Taiwan for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">19</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-bottom:10pt;background:#ffffff;margin:0pt;"><span style="font-size:10pt;">Fabry disease is a serious life-threatening rare genetic disorder. Fabry patients lack or have low levels of &#945;-galactosidase-A resulting in the progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide, or Gb</span><sub style="font-size:5.62pt;vertical-align:sub;">3</sub><span style="font-size:10pt;">, in blood vessel walls throughout their body. The ultimate consequences of Gb</span><sub style="font-size:5.62pt;vertical-align:sub;">3</sub><span style="font-size:10pt;">&#160;deposition range from episodes of pain and impaired peripheral sensation to end-organ failure, particularly of the kidneys, but also of the heart and the cerebrovascular system. Fabry disease occurs in one person per 40,000 to 60,000 males.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The standard of care for Fabry disease is ERT. Currently, the marketed ERTs for Fabry disease are agalsidase alfa and agalsidase beta, and now Elfabrio. Through an ERT, the missing &#945;-galactosidase-A is replaced with a recombinant form of the protein via intravenous, or IV, infusion once every two weeks. Fabry disease, if left untreated, will progress from a less severe condition to a more serious one. It can have a significant impact on quality of life due to presence of serious, chronic and debilitating complications, including cardiovascular and renal complications, and comorbid conditions such as pain can have a significant impact on the psychological well-being of Fabry patients and their social functioning. Fabry disease involves substantial reduction in life expectancy. Causes of death are most often cardiovascular disease and, to a lesser extent, cerebrovascular disease and renal disease. The life expectancy of Fabry patients is significantly shorter compared to the general population. Untreated male Fabry patients may experience shortened lifespans to approximately 50&#160;years, and 70&#160;years for untreated female patients with Fabry disease. This represents a 20- and 10-year reduction of their respective lifespans. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The global market for Fabry disease, that includes agalsidase beta, Sanofi&#8217;s Fabrazyme<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, agalsidase alfa, Shire&#8217;s Replagal<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> and Amicus Therapeutics&#8217; Galafold<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, among others, is forecasted to be approximately $2.2&#160;billion in 2025 and is forecasted to grow at a CAGR of 8.19% from 2024-2030 reaching approximately $3.4&#160;billion in annual sales in 2030.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Regulatory Background of Elfabrio</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">On November&#160;9, 2022, we, together with Chiesi, resubmitted to the FDA a BLA for PRX-102, the name we assigned to Elfabrio internally prior to its approvals, for the potential treatment of adult patients with Fabry disease. The initial BLA for PRX-102 was submitted to the FDA in May 2020. However, in April 2021, the FDA issued a CRL in response thereto. No concerns relating to the potential safety or efficacy of PRX-102 in the submitted data package were raised in the CRL. The FDA noted in the CRL that an inspection of our manufacturing facility in Carmiel, Israel, including the FDA&#8217;s subsequent assessment of any related FDA findings, was required before the FDA can approve a new drug. Due to travel restrictions during the COVID-19 pandemic, the FDA was unable to conduct the required pre-approval inspection during the review cycle. In addition to the foregoing, the FDA noted that agalsidase beta had recently been converted to full approval, a change in regulatory circumstances which had to be addressed in the resubmitted BLA for PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt;">The PRX-102 MAA was submitted to the EMA in February 2022 after a meeting we held, together with Chiesi, with the Rapporteur and Co-Rapporteur of the EMA regarding PRX-102. In February 2023, we, together with Chiesi, announced that the CHMP had adopted a positive opinion, recommending marketing authorization for PRX-102. As disclosed above, Elfabrio was subsequently approved by the EC for marketing in the EU and in the United States in May 2023 for adult patients with Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio was approved by the FDA with a boxed warning for hypersensitivity reactions/anaphylaxis, consistent with ERT class labeling, and warnings/precautions providing guidance on the signs and symptoms of hypersensitivity and infusion-associated reactions seen in the clinical studies as well as treatments to manage such events should they occur. The warnings/precautions for membranoproliferative glomerulonephritis (MPGN) alert prescribers to the possibility of MPGN and provide guidance for appropriate patient management. Overall, the FDA review team concluded that in the context of Fabry disease as a rare, serious disease with limited therapeutic options that may not be suitable to all individual patients, the benefit-risk of Elfabrio is favorable for the treatment of adults with confirmed Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">In December 2024, the EMA validated Chiesi&#8217;s Variation Submission for PRX-102. The Variation Submission sought to add an additional dose and dosing regimen, 2&#160;mg/kg body weight administered every four weeks in adult patients with Fabry disease, to the current Elfabrio label. In October 2025, the CHMP issued a negative opinion regarding the submission. In November 2025, Chiesi requested a re-examination of the negative opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><span style="font-style:italic;font-weight:bold;">Key Trials and Design</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our PRX-102 clinical development program was designed to show that PRX-102 has a potential clinical benefit in all adult Fabry patient populations when compared to the then marketed Fabry disease enzymes, agalsidase beta and agalsidase alfa. In preclinical studies, PRX-102 showed significantly longer half-life due to higher enzyme stability, enhanced activity in Fabry disease affected organs leading to reduction of the accumulated substrate and reduced immunogenicity, which together can potentially lead to improved efficacy through increased substrate clearance and significantly lower formation of anti-drug antibodies, or ADAs.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">20</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The phase&#160;3 clinical program included three individual studies; the <i style="font-style:italic;">BALANCE</i> study, the <i style="font-style:italic;">BRIDGE</i> study and the <i style="font-style:italic;">BRIGHT</i> study. In the phase&#160;3 clinical program overall, two potential dosing regimens for PRX-102 were analyzed; 1&#160;mg/kg every two weeks, with the potential for improved efficacy and safety offering a potential alternative to existing enzyme replacement therapies, and 2&#160;mg/kg every four weeks. The phase&#160;3 program was preceded by the phase&#160;1/2 clinical trial, a dose range finding study in ERT-na&#239;ve adult patients with Fabry disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Phase&#160;3 BALANCE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BALANCE</i> study (PB-102-F20, NCT02795676) was a pivotal 24-month, randomized, double blind, active control study of PRX-102 in adult Fabry patients with deteriorating renal function designed to evaluate the safety and efficacy of 1&#160;mg/kg of PRX-102 administered every two weeks compared to agalsidase beta. The Clinical Study Report for the <i style="font-style:italic;">BALANCE</i> study, completed in July 2022, demonstrated a favorable tolerability profile. A total of 78 patients who were previously treated with agalsidase beta for at least one year with an eGFR slope at screening worse than -2&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year were enrolled in the study. Patients were randomized on a 2:1 ratio for switching to PRX-102 or continuing on agalsidase beta. A total of 77&#160;patients were treated; 52 with PRX-102 and 25 with agalsidase beta. Approximately 40% of the enrolled patients were female.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Forty-seven (90.4%) patients in the PRX-102 arm experienced at least one treatment-emergent adverse event (TEAE) compared to 24 (96.0%) in the agalsidase beta arm. The number of events adjusted to 100&#160;years of exposure was 572.36 events for the PRX-102 arm and 816.85 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">TEAEs were reported for 21 (40.4%) patients in the PRX-102 arm compared to 11 (44.0%) in the agalsidase beta arm. The number of treatment-related events adjusted to 100 years of exposure is 42.85 events for the PRX-102 arm and 152.91 events for the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Usage of infusion pre-medication was tapered down during the study, if possible, for all patients. At baseline, 21&#160;(40.4%) patients in the PRX-102 arm used infusion premedication compared to 16 (64.0%) in the agalsidase beta arm. At the end of the study, only three out of 47 (6.4%) patients in the PRX-102 arm used infusion premedication compared to three out of 24 (12.5%) in the agalsidase beta arm. Even with this reduction in use of premedication, there were fewer reported infusion-related reactions with PRX-102: 11&#160;(21.2%)&#160;patients in the PRX-102 arm experienced a total of 13&#160;events compared to six (24.0%) patients experiencing a total of 51&#160;events in the agalsidase beta arm. The number of infusion-related reactions adjusted to 100 infusions is 0.5 for the PRX-102 arm and 3.9 for agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Assessment of immunogenicity, that is, the existence and development of anti PRX-102 antibodies or anti-agalsidase beta antibodies, in the study indicated that for the PRX-102 arm, 18 (34.6%) patients were ADA positive at baseline, of which 17 (94.4%) had neutralizing antibody activity. For the agalsidase beta arm, eight (32.0%) patients were ADA positive at baseline, of which seven (87.5%) had neutralizing antibody activity. Only a small number of patients showed treatment-emergent ADA. At the end of the two-year study, 11 (23.4%) patients that received PRX-102 were ADA positive, of which seven (63.6%) had neutralizing antibody activity, while in the agalsidase beta arm six (26.1%) were ADA-positive and all six (100%) had neutralizing antibody activity. There was little change in the percentage of patients who were ADA positive, with a trend of reduction observed in the PRX-102 arm and stability in the agalsidase beta arm. The proportion of patients with neutralizing ADA decreased in the PRX-102 arm while it remained stable in the agalsidase beta arm.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Out of the 78 randomized patients, six patients discontinued the study: out of the five (9.4%) from the PRX-102 arm, one patient withdrew consent prior to the first infusion, two discontinued due to personal reasons, and two due to adverse events (one due to an unrelated adverse event and one due to a treatment related adverse event); one (4%) patient from the agalsidase beta arm discontinued for personal reasons. There were no deaths in this study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Considering that in the trial patients in the PRX-102 arm were exposed for the first time to the novel enzyme, tolerability data appear favorable for PRX-102 and in-line with what was observed in the previous clinical studies of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The results of the direct, blinded comparison of PRX-102 to agalsidase beta, for the primary efficacy renal endpoints (i.e., eGFR change, eGFR slope) and for the main secondary endpoints (e.g., urine protein to creatinine ratio [UPCR] LVMI, MSSI, BPI) strongly suggest comparability in treatment effects between the two treatments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">At the same time, a potentially favorable safety profile was identified based on lower rates of IRR, lower ADA positivity, and less premedication use in the PRX-102 arm compared to agalsidase beta. Overall, a positive benefit-risk balance was confirmed.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Phase&#160;3 BRIDGE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIDGE</i> study (PB-102-F30, NCT03018730) was a 12-month open-label, single arm switch-over study evaluating the safety and efficacy of PRX-102, 1&#160;mg/kg infused every two weeks, in up to 22 Fabry patients previously treated with agalsidase alfa for at least two years and on a stable dose for at least six months. In the study, patients were screened and evaluated over three months while continuing agalsidase alfa treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Final results of the data generated in the <i style="font-style:italic;">BRIDGE</i> study showed substantial improvement in renal function as measured by mean annualized eGFR slope in both male and female patients. Twenty of 22&#160;patients completed the 12-month treatment duration. In the study, the mean annualized eGFR slope of the study participants improved from -5.90&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year while on agalsidase alfa to -1.19&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year on PRX-102 in all patients. Male patients improved from -6.36&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -1.73mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year and female patients improved from -5.03&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year to -0.21&#160;mL/min/1.73m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year. Following the switch to PRX-102, there was a decrease in patients with progressing or fast progressing kidney disease which is consistent with the therapeutic goals for Fabry disease, as identified by Christoph Wanner, et. al., in 2019, and most patients achieved a stable status post-switch.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-102 was well-tolerated in the <i style="font-style:italic;">BRIDGE</i> study, with all adverse events being transient in nature without sequelae. The majority of TEAEs were mild or moderate in severity, with two patients (9.1%) withdrawing from the therapy due to hypersensitivity reaction that was resolved. The most common moderate TEAEs were nasopharyngitis, headache and dyspnea. An immunogenicity assessment indicated that four out of 20 patients (20%) developed persistent ADAs over the course of the study, of which two had neutralizing activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Phase&#160;3 BRIGHT Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">The <i style="font-style:italic;">BRIGHT</i> study (PB-102-F50, NCT03180840) was a multicenter, multinational open-label, switch-over study designed to evaluate the safety, efficacy and pharmacokinetics of treatment with 2&#160;mg/kg of PRX-102 administered every four weeks for 52 weeks (a total of 14&#160;infusions). The 2&#160;mg/kg every four weeks dosage has not been approved by the EMA, FDA or any other jurisdiction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Enrollment in the study included 30 adult patients (24 males and 6 females) with mean (SD) age of 40.5 (11.3) years, ranging from 19 to 58 years previously treated with a commercially available ERT (agalsidase beta or agalsidase alfa) for at least three years and on a stable dose administered every two weeks. To determine eligibility for participation in the study, candidates were screened to identify and select Fabry patients with clinically stable kidney disease. The most common Fabry disease symptoms at baseline were acroparesthesia, heat intolerance, angiokeratomas and hypohydrosis. Patients who matched the criteria were enrolled in the study and switched from their current treatment of IV infusions every two weeks to 2&#160;mg/kg of PRX-102 every four weeks for 12 months. Patients participating in the study were evaluated, among other disease parameters, to determine if their kidney disease had not further deteriorated while being treated with the four-week dosing regimen as measured by eGFR and for lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>levels as a Fabry biomarker, as well as other parameters. In addition, participating patients were evaluated to assess the safety and tolerability of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The final results from the <i style="font-style:italic;">BRIGHT</i> study indicate that 2&#160;mg/kg of PRX-102 administered by intravenous infusion every four weeks was well tolerated, and Fabry disease assessed by eGFR slope and plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> was stable throughout PRX-102 treatment in adult Fabry patients. None of the patients without ADAs at screening developed treatment-induced ADAs following the switch to PRX-102 treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">All 30 patients received at least one dose of PRX-102, and 29 patients completed the one-year study. Of these 29 patients, 28 received the intended regimen of 2&#160;mg/kg every four weeks throughout the entire study, while one patient was switched to 1&#160;mg/kg PRX-102 every two weeks per protocol at the 11th infusion. One patient withdrew from the study after the first infusion due to a traffic accident.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Overall, 33 of 183 total TEAEs reported in nine (30.0%) of the patients were considered treatment related; all were mild or moderate in severity and the majority were resolved at the end of the study. There were no serious or severe treatment-related TEAEs and no TEAEs led to death or study withdrawal. Of the treatment-related TEAEs, 27 were infusion-related reactions (IRRs) and the remainder were single events of diarrhea, erythema, fatigue, influenza-like illness, increases urine protein/creatinine ratio, and urine positive for white blood cells. The 27 IRRs were reported in five (16.7%) patients, all male. All IRRs occurred during the infusion or within two hours post-infusion; no events were recorded between two and 24 hours post-infusion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Study outcome measures show that plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> concentrations remained stable during the study with a mean change (&#177;SE) of 3.01&#160;nM (0.94) from baseline (19.36 nM &#177;3.35) to Week&#160;52 (22.23 &#177;3.60&#160;nM). Mean absolute eGFR values were stable during the 52-week treatment period, with a mean change from baseline of -1.27&#160;mL/min/1.73&#160;m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>&#160;(1.39). Mean (SE) eGFR slope, at the end of the study, for the overall population, was -2.92&#160;(1.05) mL/min/1.73 m<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">2</sup>/year indicating stability.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">22</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The study suggests that Fabry patients who are currently receiving ERT every two weeks may be successfully transitioned to PRX-102 2&#160;mg/kg every four weeks as an effective and tolerable alternative treatment option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Following a survey of participants using the Quality of Life EQ-5D-5L questionnaire, responses indicate that patient perception of their own health remained high and stable throughout the 52-week study duration, with overall health mean (SE) scores of 78.3 (3.1) and 82.1 (2.9) at baseline and Week 52, respectively, in a 0 to 100 scale. Using the short-form Brief Pain Inventory, or, questionnaire, approximately 75% of study participants had an improvement or no change in average pain severity at Week 52 (compared to baseline). The short-form BPI interference items also remained stable during the study. Pain-related results indicate that there was no increase and/or relapse in pain. No Fabry clinical events were reported during the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Phase 1/2 Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The phase&#160;1/2 clinical trial of PRX-102 (NCT01678898) was a worldwide, multi-center, open-label, dose ranging study designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity and efficacy parameters of PRX-102 in adult patients with Fabry disease. It was completed in 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Sixteen adult, na&#239;ve Fabry patients (9 male and 7 female) completed the phase&#160;I/II study, each in one of three dosing groups, 0.2&#160;mg/kg, 1&#160;mg/kg and 2&#160;mg/kg. Each patient received IV&#160;infusions of PRX-102 every two weeks for 12 weeks, with efficacy follow-up after six-month and twelve-month periods. The overall results demonstrate that PRX-102 reaches the affected tissue and reduces kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> inclusions burden and lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>in the circulation. A high correlation was found between the two Fabry disease biomarkers, reduction of kidney Gb<sub style="font-size:7.5pt;vertical-align:sub;">3 </sub>inclusions and the reduction of plasma lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> over six months of treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Data was recorded at 24&#160;months from 11 patients who completed 12&#160;months of the long-term open-label extension trial that succeeded the phase&#160;I/II study. Patients who did not continue in the extension trial included female patients who became or planned to become pregnant and therefore were unable to continue in accordance with the study protocol and patients who relocated to a location where treatment was not available under the clinical study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Results show that lyso-Gb<sub style="font-size:7.5pt;vertical-align:sub;">3</sub> levels decreased approximately 90% from baseline. Renal function remained stable with mean eGFR levels of 108.02 and 107.20 at baseline and 24&#160;months, respectively, with a modest annual eGFR slope of -2.1. An improvement across all the gastrointestinal symptoms evaluated, including severity and frequency of abdominal pain and frequency of diarrhea, was noted. Cardiac parameters, including LVM, LVMI and EF, remained stable with no cardiac fibrosis development detected. In conclusion, an improvement of over 40% in disease severity was shown as measured by the Mainz Severity Score Index, or MSSI, a score compiling the different elements of the disease severity including neurological, renal and cardiovascular parameters. In addition, an improvement was noted in each of the individual parameters of the MSSI.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The majority of adverse events were mild-to-moderate in severity, and transient in nature. During the first 12 months of treatment, only three of 16 patients (less than 19%) formed ADAs of which two of these patients (less than 13%) had neutralizing antibodies. Importantly, however, the ADAs turned negative for all three of these patients following 12&#160;months of treatment. The ADA positivity effect had no observed impact on the safety, efficacy or continuous biomarker reduction of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Extension Studies</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Two long-term open-label extension studies were available for patients who completed the <i style="font-style:italic;">BALANCE</i>, <i style="font-style:italic;">BRIDGE</i> and <i style="font-style:italic;">BRIGHT</i> studies, and the extension of the phase&#160;1/2 study. Overall, 126 patients who participated in our PRX-102 clinical program initially opted, with the advice of the treating physician, to enroll in one of the extension studies: 97 patients in the 1&#160;mg/kg every two weeks extension study (PB-102-F60, NCT03566017) (10 patients who completed an extension study from the phase&#160;1/2 study, 18 patients who completed the <i style="font-style:italic;">BRIDGE</i> study; 69 patients who completed the <i style="font-style:italic;">BALANCE</i> study), and 29 patients who completed the <i style="font-style:italic;">BRIGHT</i> study in the 2&#160;mg/kg every four weeks extension study (PB-102-F51, NCT03614234). Two of the patients in the 2&#160;mg/kg every four weeks extension study were treated with 1&#160;mg/kg every two weeks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">After the approval of Elfabrio in the US and the EU, sponsorship and administration of the extension studies was transferred to Chiesi. Over time, and as Elfabrio is approved for marketing in different jurisdictions, patients switch-out of the open-label extension studies. Most of them have transferred to a commercial setting; others withdraw for other reasons. Accordingly, the 1&#160;mg/kg every two weeks dosage extension study is now closed as most patients have transferred to commercial or expanded access programs. In addition, the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">23</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">US-based patients that enrolled in the 2&#160;mg/kg every four weeks dosage extension study are now being treated with Elfabrio on a commercial basis; EU-based patients remain on the extension study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Pediatric FLY Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi is sponsoring, with our collaborative efforts, a clinical trial entitled &#8220;Multi-Centre, Open-label Trial to Assess the Safety, Pharmacodynamics, Efficacy and Pharmacokinetics of pegunigalsidase alfa in Patients From 2 Years to Less Than 18 Years of Age With Confirmed Fabry Disease&#8221; (NCT06328608). Recruitment has commenced. The design of the study is based on the Initial Pediatric Study Plan (iPSP) agreed to with the FDA and the paediatric investigation plan (PIP) for Elfabrio, which has been accepted, as amended, by the Paediatric Committee (PDCO) of the EMA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Japanese RISE Study</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Chiesi is currently recruiting patients for its clinical trial entitled &#8220;A Multicenter Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Pegunigalsidase Alfa (PRX-102) in Japanese Patients With Fabry Disease,&#8221; or the <i style="font-style:italic;">RISE</i> study (NCT05710692). The aim of the <i style="font-style:italic;">RISE</i> study is to evaluate the safety and efficacy of pegunigalsidase alfa in Japanese patients (adults and adolescents) affected by Fabry disease. It is planned that a total of approximately 18-20 male and female Fabry disease patients between the ages of 13 and 60 years will be enrolled in the study which is being conducted in Japan. The study involves both the 1&#160;mg/kg every two weeks and the 2&#160;mg/kg every four weeks dosage regimens.</p><a id="_DV_M79"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Commercialization of Approved Products</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Elelyso &#8211; Pfizer</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have licensed to Pfizer the global rights to market and sell Elelyso in all markets, excluding Brazil, pursuant to the Amended Pfizer Agreement. For the first 10-year period after the execution of the Amended Pfizer Agreement, we have agreed to sell drug substance to Pfizer for the production of Elelyso for a fixed cost, subject to certain terms and conditions, and Pfizer maintains the right to extend the supply period for up to two additional 30-month periods, subject to certain terms and conditions. In a subsequent amendment, we agreed that after the completion of the first 10-year supply period, the supply term would automatically extend for a five-year period. Any failure to comply with our supply commitments may subject us to substantial financial penalties. The Amended Pfizer Agreement includes customary provisions regarding cooperation for regulatory matters, patent enforcement, termination, indemnification and insurance requirements. We retain distribution rights to taliglucerase alfa in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Alfataliglicerase &#8211; Funda&#231;&#227;o Oswaldo Cruz (Fiocruz)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Elelyso, marketed as BioManguinhos alfataliglicerase in Brazil, is commercialized in Brazil through the Brazil Agreement with Fiocruz, which became effective in January&#160;2014. Gaucher patients in Brazil are entitled to receive ERT paid for by the Brazilian MoH. The Brazilian MoH clinical treatment guidelines (PCDT) state that BioManguinhos alfataliglicerase is the therapy of choice for newly diagnosed patients. BioManguinhos alfataliglicerase is currently estimated to be used by approximately 25% of Gaucher patients in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The Brazil Agreement provides for a staged technology transfer which is intended to transfer to Fiocruz the capacity and skills required for the Brazilian government to construct its own manufacturing facility, at its sole expense, and to produce a sustainable, high-quality, and cost-effective supply of BioManguinhos alfataliglicerase. Fiocruz has not satisfied certain purchase commitments under the Brazil Agreement. We have continued to sell BioManguinhos alfataliglicerase for a fixed price through purchase orders. We, on a continuous basis, discuss with Fiocruz potential steps to maximize sales of BioManguinhos alfataliglicerase sales to the Brazilian MoH.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Elfabrio (pegunigalsidase alfa/PRX-102) &#8211; Chiesi Farmaceutici</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Under the Chiesi Agreements, Protalix&#160;Ltd. has received $50.0&#160;million in upfront payments and development cost reimbursements of $45&#160;million, and is entitled to more than $1.0&#160;billion in potential milestone payments and tiered payments for drug product purchased from Protalix Ltd. equal to 15%&#160;- 35% (ex-US) and 15%&#160;- 40% (US), depending on the amount of annual net sales in the applicable territories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Under the Chiesi Ex-US Agreement, we granted to Chiesi an exclusive license for all markets outside of the United States to commercialize PRX-102. Chiesi made an upfront payment to Protalix&#160;Ltd. of $25.0&#160;million in connection with the execution of the agreement, and Protalix&#160;Ltd. was entitled to additional payments of up to $25.0&#160;million in development costs in the aggregate, capped at $10.0&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $320.0&#160;million, in the </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">24</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">aggregate, in regulatory and commercial milestone payments. Protalix&#160;Ltd. agreed to manufacture all of the PRX-102 needed for all purposes under the agreement, subject to certain exceptions, and Chiesi will purchase PRX-102 from Protalix&#160;Ltd., subject to certain terms and conditions. Chiesi is required to make tiered payments of 15% to 35% of the net sales of the drug product in each applicable territory as consideration for the supply of PRX-102.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The exclusive license to develop and commercialize PRX-102 in the United States was granted to Chiesi under the Chiesi US Agreement. Protalix&#160;Ltd. received an upfront, non-refundable, non-creditable payment of $25.0&#160;million from Chiesi and was entitled to additional payments of up to a maximum of $20.0&#160;million to cover development costs for PRX-102, capped at $7.5&#160;million per&#160;year. Protalix&#160;Ltd. is also eligible to receive additional payments of up to a maximum of $760.0&#160;million, in the aggregate, in regulatory and commercial milestone payments. Chiesi agreed to make tiered payments of 15% to 40% of the net sales of the drug product in as consideration for product supply.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On May&#160;13, 2021, we signed a binding term sheet with Chiesi amending the Chiesi Agreements in order to provide our company with near-term capital. Chiesi agreed to make a $10.0&#160;million payment to us before the end of the second quarter of 2021 in exchange for a $25.0&#160;million reduction in a longer term regulatory milestone payment provided in the Chiesi EX-US Agreement. All other regulatory and commercial milestone payments remain unchanged. We received the payment in June&#160;2021. We also agreed to negotiate certain manufacturing related matters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">On August&#160;29, 2022, we entered into a Fill/Finish Agreement, or the F/F Agreement, and a Letter Agreement, or the Letter Agreement, in each case with Chiesi. Under the F/F Agreement, we agreed to supply Chiesi with drug substance for PRX-102 and, following relevant technology and technical information transfer activities, Chiesi has agreed, among other things, to provide us with commercial fill/finish services for PRX-102, including to support the anticipated global launch of PRX-102. The Letter Agreement changed the obligations of both us and Chiesi under the Chiesi Agreements with respect to, among other things, the evaluation, selection and establishment of an initial alternate source of commercial fill/finish services for PRX-102. In addition, the Letter Agreement amended certain provisions of the Chiesi Agreements to reflect the appointment of Chiesi as a supplier to our company of commercial fill/finish services and the potential establishment of an initial alternate source of commercial fill/finish services. Subsequently, in November 2024, we amended the agreement to provide that a different Chiesi facility may act as a secondary supplier of such services and that the F/F&#160;Agreement shall have an initial term of 10&#160;years, unless terminated earlier in accordance with the terms of the F/F&#160;Agreement. Prior to expiration of the initial term, the term may be extended by mutual agreement for an additional period of seven years upon mutual written agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Product Development Pipeline </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our corporate strategy includes development of treatments for rare and orphan diseases. To execute on the strategy, we are turning our focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. Our current pipeline of product candidates includes PEGylated uricase for the treatment of uncontrolled gout, Long Acting (LA) DNase&#160;I for the treatment of NETs and other technologies and preclinical assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">PEGylated Uricase (PRX-115)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">PRX-115 is our recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme under development for the potential treatment of patients with uncontrolled gout. The uricase enzyme, which does not exist naturally in humans, converts urate to allantoin, which is easily eliminated through urine. This recombinant enzyme, expressed via our ProCellEx system, is designed to lower urate levels and improve clinical manifestation of the disease while having low immunogenicity and increased half-life of the drug in the blood. Pre-clinical data demonstrates long half-life, reduced immunogenic risk and high specific activity supports the potential of PRX-115 to be a safe and effective treatment for patients with gout. One-month multiple dosing toxicity studies in two animal species and a six-month multiple dosing toxicity study in one animal species were conducted to support single- and multiple-dose studies in humans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have completed a phase&#160;1 clinical trial of PRX-115 for the potential treatment of uncontrolled gout entitled &#8220;A Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Properties of PRX-115 in Adult Volunteers With Elevated Uric Acid Levels&#8221; (NCT05745727), or the <i style="font-style:italic;">FIH</i> study. The study was conducted at New Zealand Clinical Research (NZCR) under the New Zealand Medicines and Medical Devices Safety Authority (MedSafe) and the Health and Disability Ethics Committee (HDEC) guidelines. The completed study included eight sequential dosing cohorts, each composed of eight subjects (six active and two placebo), a 3:1 ratio. Subjects in each cohort, males and females aged 18 through 65, received a single dose of PRX-115 and were analyzed for safety, pharmacokinetics (PK), pharmacodynamics (PD) </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">25</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:226.6pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">(concentrations of plasma urate) and immunogenicity for 85 days. Overall, 64 randomized subjects were enrolled across the eight cohorts; 48 subjects were treated with PRX&#8211;115 and 16 subjects were treated with placebo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Key results from the full <i style="font-style:italic;">FIH</i> study are as follows:</p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>Exposure to PRX-115 increased in a dose-dependent manner. Detectable PRX-115 levels were observed in plasma for up to 12&#160;weeks from subjects in cohorts 6, 7, and 8. See Figure&#160;1.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Figure&#160;1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;"><img src="plx-20250930x10q006.jpg" alt="Graphic" style="display:inline-block;height:226.6pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:389.37pt;"/></b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>In all tested doses, a single dose of PRX-115 rapidly reduced plasma urate levels. The effect and duration of response were found to be dose dependent. Following a single dose, mean plasma urate levels remained below 6.0&#160;mg/dL for up to 12&#160;weeks at the highest doses. See Figure&#160;2.</div><div style="margin-top:10pt;"></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">26</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:249.03pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Figure&#160;2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="plx-20250930x10q007.jpg" alt="Graphic" style="display:inline-block;height:248.68pt;left:0%;padding-bottom:0.35pt;position:relative;top:0pt;width:387.85pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-indent:36pt;"><span style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">&#9679;</span>All randomized participants completed the study. PRX-115 was found to be well-tolerated. See Figure&#160;3.</div><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Figure&#160;3. Overall Summary of Adverse Events*</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><img src="plx-20250930x10q008.jpg" alt="Graphic" style="display:inline-block;height:135.15pt;width:415.7pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 10pt 0pt;">*Number of subjects reporting at least one adverse event.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Only 25% of the subjects treated with PRX-115 in the study (12/48) having reported study drug-related adverse events. The majority of such adverse events were mild to moderate and transient in nature. One subject experienced an anaphylactic reaction in cohort&#160;2 immediately following the commencement of the infusion (6 minutes) and, accordingly, was exposed to approximately 5% of the applicable PRX-115 dose. The reaction resolved completely and the subject continued in the study for follow-up safety assessments. Premedication with anti-histamines and steroids were administered to all subjects following the anaphylaxis event. No other subjects experienced a similar reaction and no other serious adverse events were reported in the study. No related adverse events were reported for subjects treated in cohorts 6 and 7, and only for one patient per cohort in cohorts 4, 5 and 8. Approximately 50% of the subjects developed ADAs. The incidence of ADAs showed a negative relationship with the applicable PRX-115 dose, with the highest incidence observed in Cohort 1 and lower incidences in the higher PRX-115 dose cohorts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">These results suggest that PRX-115 has the potential to be a promising treatment option for patients with gout. The results demonstrate that PRX-115 may offer an effective urate-lowering treatment with an added benefit of a potentially wide dosing interval, which may enhance patient compliance and treatment flexibility. Further studies are needed to confirm the long-term safety and efficacy of PRX-115 in the gout patient population.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">27</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have initiated preparations for a phase&#160;2 clinical trial of PRX-115, and the <span style="background:#ffffff;">IND we submitted in connection with the phase&#160;2 trial has become effective following the FDA&#8217;s standard 30-day review period. W</span>e expect to commence the study in the fourth quarter of 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Gout is the most common inflammatory arthritis, affecting an estimated 14.9&#160;million adults in the United States alone. Based on market research we have commissioned, we estimate that approximately 25% of the gout population in the US and Western Europe do not have their gout controlled. Some of those patients cannot be treated with existing therapies; others stop treatment with existing therapies due to adverse events. In addition, such research shows that there are gout patients treated with existing therapies that continue to suffer from tophi despite having reached urate target levels. The risk of gout increases with age, and is more common in males. Gout results from sustained elevation of serum urate levels (hyperuricaemia). Urate levels may increase due to diet, genetic predisposition and environmental factors leading to the deposition of monosodium urate crystals and/or tophi in joints, tendons and other tissues, which triggers recurrent episodes of pronounced acute inflammation, known as gout flares. Gout leads to substantial morbidity, severe pain, reduced quality of life, decreased physical function, increased healthcare costs, and lost economic productivity. Furthermore, gout is strongly associated with a number of comorbidities, including hypertension, cardiovascular disease, renal impairment, diabetes, obesity, hyperlipidaemia and frequently occurs in a combination known as the metabolic syndrome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Uncontrolled gout is when serum urate (sUA) levels are above the maximum medically appropriate level (6.8 mg/dL), as well as tophi formation and/or flares that cannot be treated with available urate lowering therapies. Currently available ULTs can be effective in treating gout. However, factors such as low adherence, under dosing, disease progression that causes high patient burden or patients that are not suitable for available therapy, require new, effective and safe therapies to treat these underserved uncontrolled gout patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">To date, two variants of recombinant uricases are approved for marketing: (i)&#160;Krystexxa<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegloticase) for treatment of chronic gout refractory to conventional therapy (gout patients who have contraindication/failure of other lowering urate treatments) and (ii)&#160;Elitek<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup>, indicated for the treatment of tumor lysis syndrome but not gout. Both have a black box warning for anaphylaxis and other major side-effects. The FDA label of Krystexxa was amended in 2022 to include co-treatment of methotrexate to prolong efficacy and increases tolerability in patients with refractory gout. Krystexxa is no longer marketed in the European Union. The EC withdrew the marketing authorization for Krystexxa in 2016 at the request of the marketing authorization holder which notified the EC of its decision not to market the product in the European Union for commercial reasons. We believe that new effective, safe therapies are needed to treat severe gout, chronic refractory and uncontrolled<b style="font-weight:bold;"> </b>gout, regardless of treatment history.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">PRX-119</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">PRX-119 is our plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate which we are designing to have an elongated half-life in the circulation for the potential treatment of NETs-related diseases. NETs, or Neutrophil extracellular traps, are web-like structures released by activated neutrophils that trap and kill a variety of microorganisms. NETs are composed of DNA, histones, antimicrobial and pro-inflammatory proteins. Excessive formation or ineffective clearance of NETs can cause different pathological effects. NETs formation has been observed in various autoimmune, inflammatory and fibrotic conditions, diverse forms of thrombosis, cancer and metastasis. According to scientific literature, animal studies have demonstrated that DNase treatment reduce NETs toxicity. Our proprietary modified DNase&#160;I, which we have designed for long and customized systemic circulation in the bloodstream, may potentially enable effective treatment for these conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The administration of PRX-119 resulted in a decrease in circulating of DNA levels and significantly enhanced the survival of mice in both a CLP-induced sepsis model and an ARDS model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Intellectual Property</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">A key element of our overall strategy is to establish a broad portfolio of patents to protect our proprietary technology, proprietary product and product candidates and their methods of use. As of September&#160;30, 2025, we hold a broad portfolio of 16 patent families consisting of approximately 67 patents in Europe, the United States, Israel and additional countries worldwide, as well as approximately 43 pending patent applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Research &amp; Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We continuously work on the further development of our ProCellEx plant cell expression technology and bioreactor system.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consistent with our corporate strategy, we are focusing on new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. We intend to use our ProCellEx platform and PEGylation capabilities, as well as other modalities such as small </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">28</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">molecules and oligonucleotides, to take advantage of highly innovative opportunities. We are also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Critical Accounting Policies</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our significant accounting policies are more fully described in Note&#160;1 to our consolidated financial statements appearing in this Quarterly Report. There have been no material changes to our critical accounting policies since we filed our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">The discussion and analysis of our financial condition and results of operations is based on our financial statements, which we prepared in accordance with U.S.&#160;generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate such estimates and judgments, including those described in greater detail below. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Three months ended September&#160;30, 2025 compared to the three months ended September&#160;30, 2024</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $17.7&#160;million during the three months ended September&#160;30, 2025, a decrease of $0.1&#160;million, or 1%, compared to revenues of $17.8&#160;million for the three months ended September&#160;30, 2024. The decrease resulted primarily from a decrease of $3.6&#160;million in sales to Chiesi and of $0.6 million in sales to Pfizer, partially offset by an increase of $4.1&#160;million in sales to Fiocruz (Brazil).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $0.2&#160;million for the three months ended September&#160;30, 2025, an increase of $0.1&#160;million, or 100%, compared to license and R&amp;D services of $0.1&#160;million for the three months ended September&#160;30, 2024. <span style="color:#212529;background:#ffffff;">Revenues </span>from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. Other than potential regulatory milestone payments that may become payable, we expect to generate minimal revenues from license and R&amp;D services now that we have completed the clinical development of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $8.3&#160;million for the three months ended September&#160;30, 2025, a decrease of $0.1&#160;million, or 1%, from cost of goods sold of $8.4&#160;million for the three months ended September&#160;30, 2024. The decrease in cost of goods sold was primarily the result of the decrease in sales to Chiesi and Pfizer partially offset by the increase in sales to Fiocruz (Brazil).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;">For the three months ended September&#160;30, 2025, our total research and development expenses were approximately $4.5&#160;million comprised of approximately $2.6&#160;million of salary and related expenses, approximately $0.5&#160;million in subcontractor-related expenses, approximately $0.5&#160;million of materials-related expenses and approximately $0.9&#160;million of other expenses. For the three months ended September&#160;30, 2024, our total research and development expenses were approximately $3.0&#160;million comprised of approximately $1.6&#160;million of salary and related expenses, approximately $0.6&#160;million in subcontractor-related expenses, approximately $0.2&#160;million of materials-related expenses and approximately $0.6&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total increase in research and developments expenses for the three months ended September&#160;30, 2025 was $1.5&#160;million, or 50%, compared to research and developments expenses of $3.0&#160;million for the three months ended September 30, 2024. The increase in research and development expenses resulted primarily from <span style="color:#212529;background:#ffffff;">preparations for the planned phase&#160;2 clinical trial of PRX-115.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;"><span style="color:#212529;background:#ffffff;">We expect to continue to incur significant, increasing research and development expenses as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">29</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $2.9&#160;million for the three months ended September&#160;30, 2025, an increase of $0.3&#160;million, or 12%, compared to $2.6&#160;million for the three months ended September&#160;30, 2024. The increase resulted primarily from an increase of $0.1&#160;million in salary and related expenses and an increase of $0.2&#160;million in selling expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Financial Income (Expenses), Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial income, net was $0.1&#160;million for the three months ended September&#160;30, 2025, compared to financial expenses, net of $0.1&#160;million for the three months ended September&#160;30, 2024. The decrease in financial expenses, net resulted primarily from lower notes interest expenses due to the September 2024 repayment in full of all the outstanding principal and interest payable under the 2024 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Taxes on Income (Tax Benefit)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded tax benefit of approximately $0.1&#160;million for the three months ended September&#160;30, 2025, compared to tax expenses of approximately $0.6&#160;million for the three months ended September&#160;30, 2024. The tax expenses or benefit resulted primarily from taxes on income mainly derived from GILTI income mainly in respect of Section&#160;174 of the TCJA. Effective in 2022, Section&#160;174 of the TCJA requires all U.S. companies, for tax purposes, to capitalize and subsequently amortize R&amp;D expenses that fall within the scope of Section 174 over five years for research activities conducted in the United States and over 15 years for research activities conducted outside of the United States, rather than deducting such costs in the current year. On July 4, 2025, tax reform legislation was enacted in the United States through the passage of HR1 which includes significant corporate tax changes, including a restoration of the current deductibility for domestic research expenditures beginning in 2025, with transition options for previously capitalized amounts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="font-style:italic;font-weight:bold;">Nine months ended September&#160;30, 2025 compared to the nine months ended September&#160;30, 2024</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from Selling Goods</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from selling goods of $43.1&#160;million during the nine months ended September&#160;30, 2025, an increase of $8.3&#160;million, or 24%, compared to revenues of $34.8&#160;million for the nine months ended September 30, 2024. The increase resulted primarily from an increase of $4.5&#160;million in sales to Chiesi and of $4.0&#160;million in sales to Pfizer, partially offset by a decrease of $0.2&#160;million in sales to Fiocruz (Brazil).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Revenues from License and R&amp;D Services</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded revenues from license and R&amp;D services of $0.5&#160;million for the nine months ended September&#160;30, 2025, an increase of $0.1&#160;million, or 25%, compared to revenues from license and R&amp;D services of $0.4&#160;million for the nine months ended September&#160;30, 2024. <span style="color:#212529;background:#ffffff;">Revenues from license and R&amp;D services are comprised primarily of revenues we recognized in connection with the Chiesi Agreements. </span>Other than potential regulatory milestone payments that may become payable, we expect to generate minimal revenues from license and R&amp;D services now that we have completed the clinical development of Elfabrio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Cost of Goods Sold</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Cost of goods sold was $22.4&#160;million for the nine months ended September&#160;30, 2025, an increase of $2.0&#160;million, or 10%, from cost of goods sold of $20.4&#160;million for the nine months ended September&#160;30, 2024. The increase in cost of goods sold was primarily the result of an increase in sales to Chiesi and Pfizer partially offset by a decrease in sales to Fiocruz (Brazil).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Research and Development Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;">For the nine months ended September&#160;30, 2025, our total research and development expenses were approximately $13.9&#160;million comprised of approximately $6.5&#160;million of salary and related expenses, approximately $4.3&#160;million in subcontractor-related expenses, approximately $0.9&#160;million of materials-related expenses and approximately $2.2&#160;million of other expenses. For the nine months ended September&#160;30, 2024, our total research and development expenses were approximately $8.8&#160;million comprised of approximately $4.8&#160;million of salary and related expenses, approximately $1.6&#160;million of subcontractor-related expenses, approximately $0.5&#160;million of materials-related expenses and approximately $1.9&#160;million of other expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 12pt 0pt;">Total increase in research and developments expenses for the nine months ended September&#160;30, 2025 was $5.1&#160;million, or 58%, compared to research and developments expenses of $8.8&#160;million for the nine months ended September 30, 2024. The increase in research and development expenses resulted primarily from <span style="color:#212529;background:#ffffff;">preparations for the planned phase&#160;2 clinical trial of PRX-115.</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 21.6pt 10pt 0pt;"><span style="color:#212529;background:#ffffff;">We expect to continue to incur significant, increasing research and development expenses as we enter into a more advanced stage of preclinical and clinical trials for certain of our product candidates.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Selling, General and Administrative Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Selling, general and administrative expenses were $8.2&#160;million for the nine months ended September&#160;30, 2025, a decrease of $1.0&#160;million, or 11%, compared to $9.2&#160;million for the nine months ended September&#160;30, 2024. The decrease resulted primarily from a decrease of $0.7&#160;million in salary and related expenses and a decrease of $0.3&#160;million in selling expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Financial Income (Expenses), Net</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Financial income, net was $0.01&#160;million for the nine months ended September&#160;30, 2025, compared to financial income, net of $0.1&#160;million for the nine months ended September&#160;30, 2024. The decrease resulted primarily from exchange rate costs and lower interest income on bank deposits partially offset by lower notes interest expenses due to the September 2024 repayment in full of all the outstanding principal and interest payable under the 2024 Notes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 72pt;"><i style="font-style:italic;">Taxes on Income (Tax Benefit)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We recorded tax expenses of approximately $0.3&#160;million for the nine months ended September&#160;30, 2025, compared to tax expenses of approximately $0.4&#160;million for the nine months ended September&#160;30, 2024. The tax expenses or benefit resulted primarily from taxes on income mainly derived from GILTI income mainly in respect of Section&#160;174 of the TCJA. Effective in 2022, Section&#160;174 of the TCJA requires all U.S. companies, for tax purposes, to capitalize and subsequently amortize R&amp;D expenses that fall within the scope of Section 174 over five years for research activities conducted in the United States and over 15&#160;years for research activities conducted outside of the United States, rather than deducting such costs in the current year. On July 4, 2025, tax reform legislation was enacted in the United States through the passage of HR1 which includes significant corporate tax changes, including a restoration of the current deductibility for domestic research expenditures beginning in 2025, with transition options for previously capitalized amounts. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 10pt 0pt;"><span style="font-size:10pt;">Our sources of liquidity include our cash balances and short-term bank deposits. At September&#160;30, 2025, we had $</span>29.4<span style="font-size:10pt;">&#160;million in cash and cash equivalents and short-term bank deposits. </span><span style="color:#212529;font-size:10pt;background:#ffffff;">In September 2024, we satisfied the outstanding principal and accrued interest under the 2024 Notes with a cash payment of approximately $21.2&#160;million which was available primarily from the withdrawal of short-term deposits. </span><span style="font-size:10pt;">We have primarily financed our operations through sales proceeds, equity and debt financings, business collaborations, and grants funding.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">During the nine-month period ended September&#160;30, 2025, we sold, in the aggregate, 2,775,215 shares of Common Stock under the Sales Agreement generating gross proceeds equal to approximately $7.0&#160;million. In March 2025, we amended the Sales Agreement to provide for the offer and sale of up to an additional $20.0&#160;million in shares of Common Stock. As of September&#160;30, 2025, approximately $15.7&#160;million in shares of Common Stock remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We believe that our cash and cash equivalents and short-term bank deposits are sufficient to satisfy our capital needs for at least 12&#160;months from the date this report is issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;"><span style="background:#ffffff;">Net cash used in operations was $14.0&#160;million for the </span>nine months ended September&#160;30, 2025<span style="background:#ffffff;">. The net loss for the nine</span> months ended September&#160;30, 2025<span style="background:#ffffff;"> of $1.1&#160;million was increased by a $11.8&#160;million increase in accounts receivable-trade and other assets, a $4.0</span>&#160;<span style="background:#ffffff;">million decrease in accounts payable and accruals, and was offset by a $1.6&#160;million in share-based compensation and $1.1&#160;million in depreciation. </span>Net cash used in investing activities for the nine months ended September&#160;30, 2025 was $1.3&#160;million and consisted primarily of the purchase of property and equipment. <span style="background:#ffffff;">Net cash provided by financing activities for the nine</span> months ended September&#160;30, 2025<span style="background:#ffffff;"> was $9.2&#160;million and consisted of $6.8&#160;million proceeds from issuance of Common Stock under the Sales Agreement, net and $2.4&#160;million from the exercise of warrants and options.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt;">Net cash provided by operations was $4.7&#160;million for the nine months ended September&#160;30, 2024. The net loss for the nine months ended September&#160;30, 2024 of $3.6&#160;million was increased by a $0.7&#160;million decrease in accounts payable and accruals and was offset by a $3.1&#160;million decrease in accounts receivable-trade and other assets, $2.6&#160;million in share-based compensation, a $1.8&#160;million decrease in inventories and $1.0&#160;million in depreciation. Net cash provided by investing activities for the nine months ended September&#160;30, 2024 was $19.5&#160;million and consisted primarily of $20.4&#160;million in proceeds from the sale of deposits partially offset by a $0.9&#160;million purchase of property and equipment. Net cash used in financing activities for the nine months ended September&#160;30, </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;">2024 was $20.4&#160;million representing the payment of the outstanding principal and accrued interest under our 2024 Notes which matured in September 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Future Funding Requirements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;margin:0pt;">Since our inception, we have incurred significant research and development expenditures which have not been offset by revenues. We have not generated significant revenues from sales of Elelyso or Elfabrio. W<span style="background:#ffffff;">e have generated operating losses from our continuing operations since our inception although the revenues generated in the years ended December&#160;31, 2023</span><span style="font-family:'28mugxoulnobhnx';"> and 2024 exceeded our expenditures for the same periods.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="color:#212529;">As the 2024 Notes were paid in full during the </span>year ended December&#160;31, <span style="color:#212529;">2024, we are no longer subject to the financial limitations related to such notes.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As we increase our research and developments efforts with respect to our current and future product candidates, we expect to continue to incur significant expenditures. We cannot anticipate the costs or the timing of the occurrence of such costs. Although we expect the revenues generated from the sales of Elfabrio and Elelyso will increase, such revenues may not be sufficient to fund the expenditures. To the extent we need to obtain additional financing in excess of such anticipated revenues, it may be difficult for us to do so given the volatility of the price of our Common Stock. Our material cash needs for the next 24&#160;months will include, among other expenses, (i)&#160;costs of preclinical and clinical trials, (ii)&#160;employee salaries, (iii)&#160;payments for rent and operation of our manufacturing facilities, (iv)&#160;fees to our consultants and legal advisors, patent advisors and fees for service providers in connection with our research and development efforts and (v) tax payments. We believe that the funds currently available to us are sufficient to satisfy our capital needs for at least 12&#160;months <span style="color:#212529;">from the date this report is issued</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">As discussed above, we may be required to raise additional capital to develop our product candidates and continue research and development activities. Our ability to raise capital, and the amounts of necessary capital, will depend on many other factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the duration and cost of discovery and preclinical development and laboratory testing and clinical trials for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Chiesi&#8217;s progress in commercializing Elfabrio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our progress in commercializing BioManguinhos alfataliglicerase in Brazil;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and outcome of regulatory review of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs associated with any litigation claims.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We expect to finance our future cash needs through sales of Elfabrio and Elelyso, corporate collaborations, licensing or similar arrangements, public or private equity offerings and/or debt financings. We currently do not have any commitments for future external funding, except with respect to the milestone payments that may become payable under the Chiesi Agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Effects of Currency Fluctuations </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Currency fluctuations could affect us through increased or decreased acquisition costs for certain goods and services and salaries expenses. For the three and nine months ended September 30, 2025 the currency fluctuations were $0.2 million and $0.8 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Off-Balance Sheet Arrangements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We have no off-balance sheet arrangements as of each of September&#160;30, 2025 and December&#160;31, 2024.</p><a id="_525852bb_8d3c_44ce_8e3f_213b4d2e211a"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Quantitative and Qualitative Disclosures about Market Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Currency Exchange Risk</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The currency of the primary economic environment in which our operations are conducted is the U.S.&#160;dollar. Most of our revenues and more than 50% of our expenses and capital expenditures are and were incurred in dollars, and a significant source of our financing has </p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">been provided in U.S.&#160;dollars. Since the dollar is the functional currency, monetary items maintained in currencies other than the dollar are remeasured using the rate of exchange in effect at the balance sheet dates and non-monetary items are remeasured at historical exchange rates. Revenue and expense items are remeasured at the average rate of exchange in effect during the period in which they occur. Foreign currency translation gains or losses are recognized in the statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Approximately 44% of our costs, including salaries, expenses and office expenses, are incurred in NIS. Inflation in Israel may have the effect of increasing the U.S.&#160;dollar cost of our operations in Israel. If the U.S.&#160;dollar declines in value in relation to the NIS, it will become more expensive for us to fund our operations in Israel. A revaluation of 1% of the NIS will affect our loss before tax by less than 1%. The exchange rate of the U.S.&#160;dollar to the NIS, based on exchange rates published by the Bank of Israel, was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:17.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:17.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="color:#009999;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Average rate for period</p></td><td style="vertical-align:bottom;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.364</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.715</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.519</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.701</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.700</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Rate at period-end</p></td><td style="vertical-align:bottom;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.306</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.710</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.306</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.710</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> 3.647</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 0pt;">To date, we have not engaged in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rate of the U.S.&#160;dollar against the NIS. These measures, however, may not adequately protect us from material adverse effects due to the impact of inflation in Israel.</p><a id="_7a9cd39f_c4fa_4451_9a02_1b9fea39a97c"></a><a id="Item4ControlsandProcedures_865226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Evaluation of Disclosure Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form&#160;10-Q. The evaluation was conducted under the supervision and with the participation of management, including our Chief Executive Officer and Chief Financial Officer. Disclosure controls and procedures are controls and procedures designed to reasonably assure that information required to be disclosed in our reports filed under the Exchange Act, such as this Quarterly Report on Form&#160;10-Q, is recorded, processed, summarized and reported within the time periods specified in the Commission&#8217;s rules and forms. Disclosure controls and procedures are also designed to reasonably assure that such information is accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Based on the evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form&#160;10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified by the Commission, and that material information relating to our company and our consolidated subsidiary is made known to management, including the Chief Executive Officer and Chief Financial Officer, particularly during the period when our periodic reports are being prepared.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Inherent Limitations on Effectiveness of Controls</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all error and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. The design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Further, because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud, if any, within a company have been detected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Changes in Internal Control over Financial Reporting</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">There were no changes in our internal control over financial reporting (as defined in Rules 13a-15f and 15d-15f under the Exchange Act) that occurred during the quarter ended September&#160;30, 2025 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">33</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c12e0933_77a7_4262_8f63_1e94a7b4efda"></a><a id="PARTIIOTHERINFORMATION_770480"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PART II &#8211; OTHER INFORMATION</b></p><a id="Item1LegalProceedings_676392"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1.  Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">We are not involved in any material legal proceedings.</p><a id="_02227ae9_6465_45e7_b5d6_2e0b8a8490ba"></a><a id="Item1ARiskFactors_983377"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">1A.  Risk Factors</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 18pt 10pt 0pt;">There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2024<span style="background:#ffffff;">.</span></p><a id="_53390533_2092_49a3_a168_cbf221100d93"></a><a id="Item2UnregisteredSalesofEquitySecurities"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">2.  Unregistered Sales of Equity Securities and Use of Proceeds</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_3ad4db62_6e8e_4223_a379_9dc164099b58"></a><a id="Item3DefaultsUponSeniorSecurities_505234"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">3.  Defaults Upon Senior Securities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">None.</p><a id="_bc847556_8bfa_4af5_80c6_92657fc4945a"></a><a id="Item4MineSafetyDisclosure_204781"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">4.  Mine Safety Disclosure</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">Not applicable.</p><a id="_cc94c6d0_eb48_44a0_9a0f_cc97cfc975db"></a><a id="Item5OtherInformation_679200"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">5.  Other Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="background:#ffffff;">During the quarter ended September&#160;30, 2025, none of our directors or officers </span><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" format="ixt:fixed-false" name="ecd:NonRule10b51ArrAdoptedFlag" id="Narr_AyYZIyWzhU2sV1Iuoh_iSg"><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" format="ixt:fixed-false" name="ecd:Rule10b51ArrAdoptedFlag" id="Narr_wMrRpYHaHESprHskGDFT5g"><span style="background:#ffffff;">adopted</span></ix:nonNumeric></ix:nonNumeric><span style="background:#ffffff;"> or </span><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" format="ixt:fixed-false" name="ecd:NonRule10b51ArrTrmntdFlag" id="Narr_FLgggVPY7Em1GFvLA8wadw"><ix:nonNumeric contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg" format="ixt:fixed-false" name="ecd:Rule10b51ArrTrmntdFlag" id="Narr_Cvipb9xXekSyxS9qmfmHXg"><span style="background:#ffffff;">terminated</span></ix:nonNumeric></ix:nonNumeric><span style="background:#ffffff;"> a Rule&#160;</span>10b5-1 <span style="background:#ffffff;">trading arrangement or&#160;</span>non-Rule<span style="background:#ffffff;">&#160;</span>10b5-1<span style="background:#ffffff;">&#160;trading arrangement (as such terms are defined in Item 408 of Regulation&#160;</span>S-K)<span style="background:#ffffff;">.</span></p><a id="_824f8650_e477_498b_8566_ab2557f9c337"></a><a id="Item6Exhibits_829552"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Item&#160;</b><b style="font-weight:bold;white-space:pre-wrap;">6.  Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:13.5pt;"><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;width:41.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Incorporated by Reference</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Exhibit Number</b></p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Exhibit Description</b></p></td><td style="vertical-align:bottom;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Form</b></p></td><td style="vertical-align:bottom;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">File Number</b></p></td><td style="vertical-align:bottom;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:bottom;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Date</b></p></td><td style="vertical-align:bottom;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><b style="font-weight:bold;">Filed or Furnished Herewith</b></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416092335/v435826_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">April&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:22.5pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420416111273/v443094_def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">July&#160;1, 2016</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.3</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420418054229/tv504383-def14a.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Def 14A</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">Appen. A</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">October&#160;17, 2018</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465919074602/tm1926620d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">December&#160;19, 2019</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837022013560/plx-20220630xex3d5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.5</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;15, 2022</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837023013483/plx-20230630xex3d6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Certificate of Incorporation of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.6</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">August&#160;7, 2023</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">3.7</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837025007063/plx-20250331xex3d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated </span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Bylaws of the Company</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">3.7</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">May&#160;9, 2025</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.1&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000114420412040015/v318898_ex4-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement/Notice</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">8-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.1</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">July&#160;18, 2012</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13pt;"><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000155837024003161/plx-20231231xex4d7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Capital Stock</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-K</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.7</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">March&#160;14, 2024</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.3&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Executives)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.8</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">4.4</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1006281/000110465920092375/plx-20200630xex4d9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement (Standard)</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">10-Q</p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">001-33357</p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">4.9</p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;">August&#160;10, 2020</p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"/></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">10.1&#8224;&#8224;</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20250930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Amended and Restated Exclusive License and Supply Agreement by and between Pfizer&#160;Inc. and Protalix&#160;Ltd., dated October&#160;12, 2015</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 1.75pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">34</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.00925827%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20250930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">31.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20250930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Chief Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.1</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20250930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Executive Officer</span></a></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">32.2</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="plx-20250930xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Certification of Chief Financial Officer</span></a> </p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.INS</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">XBRL Instance Document - <span style="color:#333333;background:#ffffff;">the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Schema Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;">X</p></td></tr><tr><td style="vertical-align:top;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">104</p></td><td style="vertical-align:top;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:36.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 3pt 0pt;">COVER PAGE INTERACTIVE DATA FILE (formatted as Inline XBRL and contained in Exhibit 101).</p></td><td style="vertical-align:top;width:7.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:8.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:15.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:13.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 3pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td colspan="8" style="vertical-align:top;width:100%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 3pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 3pt 0pt;">&#8224;&#160;&#160;&#160;&#160;&#160;Management contracts or compensation plans or arrangements in which directors or executive officers are eligible to participate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 3pt 0pt;"><span style="background:#ffffff;">&#8224;&#8224;&#160;&#160;&#160;Portions of this exhibit were omitted and have been filed separately with the Secretary of the Securities and Exchange Commission pursuant to the Registrant&#8217;s application requesting confidential treatment under Rule&#160;24b-2 of the Exchange Act.</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">35</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cd8593c1_4ea1_47ad_9d39_425644e024ca"></a><a id="SIGNATURES_574709"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.9pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:12pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PROTALIX BIOTHERAPEUTICS, INC.</p></td></tr><tr style="height:10.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Registrant)</p></td></tr><tr style="height:15.75pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:10.8pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;13, 2025</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Dror Bashan</p></td></tr><tr style="height:20.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr style="height:17.25pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;13, 2025</p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Gilad Mamlok</p></td></tr><tr style="height:13.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gilad Mamlok</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer, Treasurer and Secretary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial and Accounting Officer)</p></td></tr><tr style="height:16.5pt;"><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:47.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;width:458.2pt;"></span><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">36</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>plx-20250930xex10d1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.1.0.82--><!--Created on: 11/13/2025 10:02:15 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.1</b></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><a name="_cp_text_1_1"></a><b style="font-weight:bold;">Portions of this exhibit have been omitted pursuant to Item 601(b)(10) of Regulation S-K on the basis that they are not material and are the type of information that the Registrant treats as confidential and private. The omitted portions, marked by [***], have been separately filed with the Securities and Exchange Commission.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:210pt 0pt 12pt 0pt;"><b style="font-weight:bold;">AMENDED AND RESTATED</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">EXCLUSIVE LICENSE AND SUPPLY AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">by and between</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PFIZER INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">and</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">PROTALIX LTD. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 108pt 0pt;"><a name="_cp_text_1_3"></a><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 108pt 0pt;"><b style="font-weight:bold;">October 12, 2015</b></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b><a name="_cp_text_1_4"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Page</b></p><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628840">Section 1.</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628840"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628840">DEFINITIONS</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628840"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628840">1</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628841">Section 2.</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628841"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628841">[INTENTIONALLY OMITTED]</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628841"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628841">12</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628842">Section 3.</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628842"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628842">LICENSE</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628842"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628842">12</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628843">3.1</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628843"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628843">Exclusive License</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628843"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628843">12</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628844">3.2</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628844"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628844">Other License Provisions</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628844"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628844">13</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628845">3.4</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628845"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628845">Sublicensing and Subcontracting</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628845"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628845">13</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628846">3.5</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628846"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628846">Improvements</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628846"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628846">14</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628847">3.6.</a></font><font style="display:inline-block;width:2.94%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628847"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628847">No Implied License; Brazil Activities</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628847"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628847">14</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628848">Section 4.</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628848"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628848">REGULATORY APPROVALS AND MARKETING</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628848"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628848">16</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628849">4.1</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628849"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628849">Regulatory Affairs</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628849"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628849">16</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628850">4.2</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628850"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628850">Commercialization and Pricing</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628850"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628850">22</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628851">4.3</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628851"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628851">Protalix Trademarks</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628851"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628851">23</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628852">4.4</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628852"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628852">Pfizer Trademarks</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628852"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628852">23</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628853">4.5</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628853"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628853">Use of Names</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628853"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628853">25</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628854">4.6</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628854"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628854">Access to Information</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628854"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628854">25</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628855">4.7</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628855"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628855">Transition Assistance</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628855"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628855">26</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628856">4.8</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628856"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628856">Records</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628856"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628856">26</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628857">Section 5.</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628857"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628857">MANUFACTURE AND SUPPLY.</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628857"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628857">27</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628858">5.1</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628858"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628858">Supply Chain Committee</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628858"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628858">27</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628859">5.2</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628859"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628859">Capacity</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628859"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628859">28</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628860">5.3</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628860"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628860">Development Supply of Drug Substance</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628860"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628860">29</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628861">5.4</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628861"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628861">Commercial Supply of Drug Substance</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628861"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628861">29</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628862">5.5</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628862"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628862">Supply Term</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628862"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628862">29</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628863">5.6</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628863"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628863">Forecasting and Ordering</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628863"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628863">30</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628864">5.7</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628864"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628864">Pricing and Invoicing</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628864"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628864">31</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628865">5.8</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628865"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628865">Shipping and Delivery</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628865"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628865">31</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628866">5.9</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628866"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628866">Compliance; Quality Control Obligations</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628866"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628866">32</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628867">5.10</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628867"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628867">Certificate of Analysis; Acceptance and Returns</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628867"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628867">32</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628868">5.11</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628868"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628868">Product Specification and Manufacturing Changes</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628868"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628868">34</a></font></font></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">iii</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-bottom:0pt;margin-left:27pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628869">5.12</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628869"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628869">Change Control</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628869"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628869">34</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628870">5.13</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628870"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628870">Practices</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628870"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628870">34</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628871">5.14</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628871"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628871">Pest Control</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628871"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628871">34</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628872">5.15</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628872"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628872">Records and Audits</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628872"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628872">34</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628873">5.16</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628873"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628873">Quality Assurance</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628873"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628873">35</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628874">5.17</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628874"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628874">Technical Support</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628874"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628874">35</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628875">5.18</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628875"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628875">Technical Assistance; Facility Access</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628875"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628875">35</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628876">5.19</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628876"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628876">Other Assistance by Pfizer</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628876"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628876">35</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628877">5.20</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628877"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628877">Master Cell Bank</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628877"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628877">36</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628878">5.23</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628878"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628878">Manufacturing Transition Assistance</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628878"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628878">36</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628879">Section 6.</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628879"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628879">FINANCIAL PROVISIONS</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628879"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628879">37</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628880">6.1</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628880"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628880">Second Amendment Effective Date Payment</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628880"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628880">37</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628881">6.2</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628881"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628881">Deferred Payment</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628881"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628881">37</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628882">6.3</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628882"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628882">Payments With Respect to Commercialization in Israel</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628882"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628882">37</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628883">6.4</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628883"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628883">Payments With Respect to Commercialization in Brazil</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628883"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628883">37</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628884">6.5</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628884"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628884">Release of Payment Obligations</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628884"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628884">37</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628885">Section 7.</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628885"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628885">ACCOUNTING AND PROCEDURES FOR PAYMENT</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628885"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628885">38</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628886">7.1</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628886"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628886">Currency</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628886"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628886">38</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628887">7.2</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628887"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628887">Method of Payments</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628887"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628887">38</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628888">7.3</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628888"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628888">Tax Matters</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628888"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628888">38</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628889">Section 8.</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628889"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628889">PATENTS AND INFRINGEMENT</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628889"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628889">39</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628890">8.1</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628890"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628890">Filing and Prosecution</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628890"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628890">39</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628891">8.2</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628891"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628891">Correspondence</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628891"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628891">39</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628892">8.3</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628892"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628892">Maintenance</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628892"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628892">40</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628893">8.4</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628893"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628893">Notices and Encumbrances</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628893"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628893">41</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628894">8.5</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628894"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628894">Patent Term Extensions</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628894"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628894">41</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628895">8.6</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628895"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628895">Third Party Infringement</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628895"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628895">41</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628896">8.7</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628896"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628896">Paragraph IV Notices</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628896"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628896">42</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628897">8.8</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628897"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628897">Other Actions by a Third Party</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628897"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628897">43</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628898">8.9</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628898"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628898">Compensation to Inventors</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628898"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628898">43</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628899">8.10</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628899"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628899">Patent Marking</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628899"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628899">43</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628900">8.11</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628900"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628900">In-Licensed Patents</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628900"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628900">43</a></font></font></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">iv</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-bottom:0pt;margin-left:0pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628901">Section 9.</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628901"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628901">CONFIDENTIALITY; PUBLICATION</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628901"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628901">43</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628902">9.1</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628902"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628902">Confidential Information</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628902"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628902">43</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628903">9.2</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628903"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628903">Permitted Disclosure of Confidential Information</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628903"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628903">44</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628904">9.3</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628904"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628904">Publication</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628904"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628904">45</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628905">9.4</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628905"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628905">Publicity</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628905"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628905">46</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628906">9.5</a></font><font style="display:inline-block;width:3.43%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628906"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628906">Filing, Registration or Notification of the Agreement</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628906"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628906">47</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628907">Section 10.</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628907"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628907">REPRESENTATIONS, WARRANTIES AND COVENANTS</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628907"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628907">47</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628908">10.1</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628908"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628908">Protalix Representations, Warranties and Covenants</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628908"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628908">47</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628909">10.2</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628909"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628909">Manufacturing Representations, Warranties and Covenants</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628909"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628909">52</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628910">10.3</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628910"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628910">Environmental Representations, Warranties and Covenants</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628910"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628910">54</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628911">10.4</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628911"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628911">Pfizer Representations, Warranties and Covenants</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628911"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628911">55</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628912">10.5</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628912"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628912">Disclaimer of Warranty</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628912"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628912">56</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628913">Section 11.</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628913"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628913">ADDITIONAL COVENANTS</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628913"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628913">56</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628914">11.1</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628914"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628914">Restrictions on Transfers and Liens</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628914"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628914">56</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628915">11.2</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628915"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628915">Third Party Licenses and Agreements</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628915"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628915">56</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628916">11.3</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628916"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628916">Compliance with Laws</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628916"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628916">57</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628917">11.4</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628917"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628917">Coordination outside the Territory</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628917"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628917">57</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628918">11.5</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628918"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628918">Protalix Non-Compete</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628918"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628918">57</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628919">11.6</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628919"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628919">Limitation on Non-Compete Restrictions</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628919"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628919">57</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628920">Section 12.</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628920"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628920">[Reserved.]</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628920"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628920">57</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628921">Section 13.</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628921"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628921">TERM</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628921"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628921">57</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628922">Section 14.</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628922"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628922">TERMINATION</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628922"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628922">58</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628923">14.1</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628923"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628923">Pfizer Termination Right for Convenience</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628923"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628923">58</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628924">14.2</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628924"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628924">Pfizer Termination Right for Breach</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628924"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628924">58</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628925">14.3</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628925"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628925">Protalix Right of Termination</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628925"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628925">58</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628926">14.4</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628926"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628926">Continuing and Accrued Obligations and Surviving Provisions</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628926"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628926">58</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628927">14.5</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628927"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628927">Effects of Termination or Expiration</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628927"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628927">59</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628928">14.6</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628928"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628928">Bankruptcy</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628928"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628928">59</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628929">Section 15.</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628929"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628929">INDEMNIFICATION AND INSURANCE</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628929"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628929">60</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628930">15.1</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628930"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628930">Indemnification</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628930"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628930">60</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628931">15.2</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628931"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628931">Losses</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628931"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628931">61</a></font></font></p></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">v</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="margin-bottom:0pt;margin-left:27pt;margin-top:0pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628932">15.3</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628932"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628932">Defense Procedures; Procedures for Third Party Claims</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628932"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628932">61</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628933">15.4</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628933"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628933">Disclaimer of Liability for Consequential Damages</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628933"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628933">62</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628934">15.5</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628934"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628934">Sole Remedy</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628934"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628934">63</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628935">15.6</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628935"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628935">Insurance Requirements</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628935"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628935">63</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628936">Section 16.</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628936"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628936">[RESERVED.]</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628936"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628936">65</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628937">Section 17.</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628937"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"><a href="#_Toc434628937">GOVERNING  LAW AND JURISDICTION</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628937"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628937">65</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628938">17.1</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628938"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628938">Governing Law</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628938"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628938">65</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628939">17.2</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628939"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628939">Jurisdiction</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628939"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628939">65</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:0pt;margin-top:12pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:28.8pt;text-indent:-28.8pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628940">Section 18.</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628940"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628940">MISCELLANEOUS</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628940"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628940">66</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628941">18.1</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628941"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628941">Force Majeure</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628941"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628941">66</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628942">18.2</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628942"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628942">Severability</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628942"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628942">66</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628943">18.3</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628943"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628943">Waivers</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628943"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628943">66</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628944">18.4</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628944"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628944">Entire Agreements; Amendments</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628944"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628944">66</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628945">18.5</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628945"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628945">Survival</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628945"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628945">67</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628946">18.6</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628946"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628946">Assignment; Binding Effect</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628946"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628946">67</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628947">18.7</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628947"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628947">Divestiture</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628947"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628947">68</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628948">18.8</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628948"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628948">Independent Contractor</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628948"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628948">68</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628949">18.9</a></font><font style="display:inline-block;width:2.45%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628949"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628949">Notices</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628949"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628949">68</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628950">18.10</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628950"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628950">Third Party Beneficiaries</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628950"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628950">69</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628951">18.11</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628951"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628951">Binding Effect</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628951"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628951">69</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628952">18.12</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628952"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628952">Performance by Affiliates</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628952"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628952">69</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628953">18.13</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628953"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628953">Corporate Integrity Agreement</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628953"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628953">70</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628954">18.14</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628954"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628954">Counterparts</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628954"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628954">70</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628955">18.15</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628955"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628955">Headings</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628955"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628955">70</a></font></font></p></div><div style="margin-bottom:0pt;margin-left:27pt;margin-top:6pt;overflow:hidden;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;padding-left:36pt;text-indent:-36pt;"><font style="padding-bottom:2.0pt;padding-right:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628956">18.16</a></font><font style="display:inline-block;width:1.47%;">&#9;</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;"><a style="font-family:'Times New Roman','Times','serif';font-size:12pt;" href="#_Toc434628956"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628956">Equitable Remedies</a></font></font><font style="bottom:3.0957031pt;display:block;height:1em;position:absolute;width:100%;z-index:0;border-bottom:1.0px dotted #000000;">&#8204;</font><font style="float:right;padding-left:2.0pt;position:relative;text-indent:0pt;z-index:1;background:white;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628956"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a href="#_Toc434628956">70</a></font></font></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EXHIBITS</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">EXHIBIT A &#8211; AMINO ACID SEQUENCE FOR DRUG SUBSTANCE</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">EXHIBIT B &#8211; PROTALIX PATENT RIGHTS</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">EXHIBIT C &#8211; THIRD PARTY LICENSES</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_2_140"></a><a name="_cp_blt_2_142"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">EXHIBIT D &#8211; BRAZIL </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;">Uplyso Trademarks</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;">EXHIBIT E </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8211;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"> IMPORTATION AUTHORIZATION</font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">vi</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;">EXHIBIT F </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8211; </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;">TRANSITION PLAN </font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;">Exhibit g </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">&#8211;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;"> PERSISTENT FAILURE TO SUPPLY promissory note</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">EXHIBIT H &#8211; PROTALIX PAYMENT PROMISSORY NOTE</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">EXHIBIT I &#8211;  PRESS RELEASE</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="_cp_blt_2_144"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">EXHIBIT J &#8211;  [***] LETTER AGREEMENT </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-variant:small-caps;font-weight:normal;">COMPLIANCE CERTIFICATE</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;">EXHIBIT K &#8211; cOMPLIANCE CERTIFICATE</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-line:none;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-transform:uppercase;">exhibit l &#8211; Audit Completion CertificatION</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">APPENDICES</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Appendix 4.1(g) &#8211; Regulatory Approvals for the Licensed Product in the Field in the Territory</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a name="OLE_LINK85"></a><a name="OLE_LINK86"></a>Appendix 7.2(a) &#8211; Protalix Account Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Appendix 7.2(b) &#8211; Pfizer Account Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Appendix 10.1(t) &#8211; Pfizer&#8217;s Anti-Bribery and Anti-Corruption Principles</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">[***] Redacted pursuant to confidential treatment request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">vii</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><a name="_cp_text_1_146"></a>AMENDED AND RESTATED EXCLUSIVE LICENSE AND SUPPLY AGREEMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><a name="_cp_text_1_147"></a>This Amended and Restated Exclusive License and Supply Agreement (this &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Agreement</u>&#8221;) dated as of <a name="_cp_text_1_149"></a>October 12, 2015 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Amendment Effective Date</u>&#8221;) between Protalix Ltd., a limited liability company incorporated under the laws of Israel with offices located at 2 Snunit Street, Science Park, P.O.B. 455, Carmiel 20100, Israel (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix</u>&#8221;), and Pfizer Inc., a Delaware corporation with offices located at 235 East 42nd Street, New York, New York, 10017, U.S.A. (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pfizer</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Protalix and Pfizer are parties to that certain Exclusive License and Supply Agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Original Agreement</u>&#8221;) dated November 30, 2009, pursuant to which Protalix provided Pfizer with an exclusi<a name="_cp_text_2_150"></a>ve license in all countries of the world other than Israel to certain patents, patent applications, technology, know how and scientific and technical information relating to an enzyme replacement therapy for the treatment of Gaucher Disease;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">WHEREAS, Protalix and Pfizer amended the Original Agreement pursuant to the Amendment to the Exclusive License and Supply Agreement (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Amendment</u>&#8221; and, the Original Agreement as amended by the First Amendment, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amended Agreement</u>&#8221;) dated June 18, 2013 (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment Effective Date</u>&#8221;) pursuant to which the parties amended the territory and other terms with respect to Brazil; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;">WHEREAS, Protalix and Pfizer<a name="_cp_text_1_156"></a> wish to further amend and also restate in its entirety the Amended Agreement (including, for the avoidance of doubt, the First Amendment) to modify the territory and make such other changes as set forth herein, with the effect that the Original Agreement and First Amendment shall be superseded hereby.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NOW, THEREFORE, in consideration of the mutual covenants and agreements provided<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u>herein, Protalix and Pfizer hereby agree that the Amended Agreement is hereby amended and restated in its entirety to read as follows:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_Ref246830910"></a><a name="_Toc428350781"></a><a name="_Toc428351573"></a><a name="_Toc428409540"></a><a name="_Toc428410098"></a><a name="_Toc428410152"></a><a name="_Toc428410236"></a><a name="_Toc428736348"></a><a name="_Toc428736646"></a><a name="_Toc428736991"></a><a name="_Toc428737339"></a><a name="_Toc428738032"></a><a name="_Toc428739892"></a><a name="_Toc431831926"></a><a name="_Toc434628840"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">DEFINITIONS</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For purposes of this Agreement, the following definitions shall be applicable:</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.1</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Affiliate</u><font style="white-space:pre-wrap;">&#8221; means any entity directly or indirectly controlled by, controlling, or under common control with, a party to this Agreement, but only for so long as such control shall continue.  For purposes of this definition, &#8220;control&#8221; (including, with correlative meanings, &#8220;controlled by&#8221;, &#8220;controlling&#8221; and &#8220;under common control with&#8221;) means (a) possession, direct or indirect, of the power to direct or cause direction of the management or policies of an entity (whether through ownership of securities or other ownership interests, by contract or otherwise), or (b) beneficial ownership of at least 50% of the voting securities or other ownership interest (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable </font><a name="OLE_LINK40"></a><a name="OLE_LINK59"></a>equity interests of an entity, it being understood and agreed that for purposes of clause (a), neither ownership of voting securities or other ownership interests of an entity nor membership or representation on (if less than half of the members of) an entity&#8217;s board of directors shall, by themselves, be presumed to constitute the power to direct or cause direction of the management or policies of such entity<font style="white-space:pre-wrap;">.  With respect to the grant of license rights by Protalix </font></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="white-space:pre-wrap;">to Pfizer under </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</u>, &#8220;Affiliate&#8221; shall exclude any Third Party that becomes an Affiliate due to such Third Party&#8217;s acquisition of Protalix. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.2</font>&#8220;<a name="_cp_text_1_158"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation Percentage</u>&#8221; shall have the meaning assigned to it in <a name="_cp_text_1_161"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><a name="_cp_field_47_162"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.2(c)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.3</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amended Agreement</u>&#8221; shall have the meaning assigned to it in the Recitals. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.4</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment Effective Date</u>&#8221; shall have the meaning assigned to it in the Recitals. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.5</font>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.6</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brazil Activities</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.6(b)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.7</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brazil Uplyso Trademark</u>&#8221; means the trademark &#8220;UPLYSO&#8482;&#8221; registered in Brazil, as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit D</u>, as such <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit D</u> may be updated by mutual agreement of the parties within thirty (30) days following the Second Amendment Effective Date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.8</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business </u><a name="_cp_text_1_164"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Associates</u>&#8221; shall have the meaning assigned to it in <a name="_cp_text_1_167"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix </u><a name="_cp_field_47_168"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(t)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.9</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Business Day</u>&#8221; means a day other than a Saturday, Sunday, or bank or other public holiday in New York, New York.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.10</font><a name="_cp_text_1_169"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capacity Cap</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section</u><a name="_cp_field_47_170"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.2(c)</u><a name="_cp_text_1_172"></a>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.11</font><a name="_cp_blt_1_174"></a><a name="_cp_blt_2_173"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capacity Expansion Project</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.2(b)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.12</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change of Control</u>&#8221; means any transaction or series of related transactions that would occasion: <a name="DocXTextRef6"></a>(a) any share exchange, re-capitalization, business combination, consolidation, merger, or other transaction or series of transactions resulting in the exchange of the outstanding shares of a party, unless the stockholders of a party that exist immediately prior to the closing date of such transaction (or series of related transactions) hold, after the closing date, more than fifty percent (50%) of the voting securities or other similar interest of the surviving entity in such transaction computed on a fully diluted basis; <a name="DocXTextRef7"></a>(b) a sale, lease, or other transfer of all or substantially all of the stock or assets of a party; <a name="DocXTextRef8"></a>(c) any tender offer or exchange offer for fifty percent (50%) or more of the outstanding voting securities or other similar interest of a party or the filing of a registration statement under the United States Securities Act of 1933, as amended, in connection therewith; or <a name="DocXTextRef9"></a>(d) any Person or group acting in concert having acquired beneficial ownership or the right to acquire beneficial ownership of fifty percent (50%) or more of the outstanding voting securities or similar interest of a party.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.13</font><a name="_Ref429822918"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialization</u>&#8221; means, with respect to a product or compound (including any Compound, Licensed Product, Drug Substance or Competing Product), any activities directed to and including marketing, promoting, distributing, offering for sale and selling such product or compound, importing such product or compound (to the extent applicable) and</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">2<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">conducting [***].  When used as a verb, &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialize</u>&#8221; means to engage in Commercialization.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.14</font><a name="_cp_blt_1_176"></a><a name="_cp_blt_2_175"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercially Reasonable Efforts</u>&#8221; means, with respect to the efforts to be expended by a party with respect to the objective that is the subject of such efforts, reasonable, good faith efforts and resources to accomplish such objective that such party would normally use to accomplish a similar objective under similar circumstances, it being understood and agreed that with respect to the Development or Commercialization of the Licensed Product in the Territory by Pfizer, such efforts shall be similar to those efforts and resources consistent with the usual practice of Pfizer in pursuing the Development or Commercialization of drug products owned by it or to which it otherwise has rights that are of similar market potential as a Licensed Product in the Territory, taking into account all relevant factors, including the orphan drug status (if any) of the Licensed Product and other regulatory matters, safety and efficacy matters, product labeling or anticipated labeling, pricing, present and future market potential, past performance of the Licensed Product, past performance of Pfizer&#8217;s own drug products that are of similar market potential (taking into account that the Licensed Product is intended for the treatment of a rare disease), financial return [***]<font style="white-space:pre-wrap;">, medical and clinical considerations, present and future regulatory environment and competitive market conditions, all as measured by the facts and circumstances at the time such efforts are due.  It is anticipated that the level of effort </font>constituting Commercially Reasonable Efforts may change over time.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.15</font><a name="_cp_blt_1_178"></a><a name="_cp_blt_2_177"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Competing Product</u>&#8221; means [***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.16</font><a name="_cp_blt_1_180"></a><a name="_cp_blt_2_179"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance Questionnaire</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(s)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.17</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compound</u>&#8221; means (a) prGCD and (b) any analogs, derivatives and variants thereof.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.18</font><a name="_cp_blt_1_182"></a><a name="_cp_blt_2_181"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u>&#8221; means the Protalix Confidential Information or the Pfizer Confidential Information, as applicable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.19</font><a name="_cp_blt_1_184"></a><a name="_cp_blt_2_183"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Control</u>&#8221; or &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Controlled</u>&#8221; means, with respect to any compound, material, information, or intellectual property right, that a party owns or has a license to use, commercialize, manufacture, market, distribute or sell, and has the ability to grant to the other party access and/or a license or a sublicense (as applicable under this Agreement) to such compound, material, information, or intellectual property right as provided<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u>for herein without violating (a) the terms of any agreement or other arrangements with any Third Party existing before or after the Second Amendment Effective Date or (b) any law or governmental regulation applicable to such license or sublicense. <a name="_cp_text_1_186"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.20</font><a name="_cp_blt_1_188"></a><a name="_cp_blt_2_187"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Country</u>&#8221; means any generally recognized sovereign entity.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.21</font><a name="_cp_blt_1_190"></a><a name="_cp_blt_2_189"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Court</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">17.2</u>.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">3<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.22</font><a name="_cp_blt_1_192"></a><a name="_cp_blt_2_191"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development</u>&#8221; or &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Develop</u><font style="white-space:pre-wrap;">&#8221; means conducting pre-clinical studies and clinical trials, collecting, validating and analyzing pre-clinical and clinical trial data, preparing and submitting regulatory filings, obtaining Regulatory Approvals, and regulatory affairs related to the foregoing.  When used as a verb, &#8220;Develop&#8221; means to engage in Development.  For clarity, Development does not include Phase 4 Trials or any of the foregoing in connection therewith.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.23</font><a name="_cp_blt_1_194"></a><a name="_cp_blt_2_193"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Divestiture</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">18.7</u><font style="white-space:pre-wrap;">.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.24</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Drug Substance</u>&#8221; means the Compound component of a pharmaceutical drug product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.25</font><a name="_cp_blt_1_198"></a><a name="_cp_blt_2_197"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Early Access Program</u><font style="white-space:pre-wrap;">&#8221; means any program to provide patients with the Licensed Product prior to Regulatory Approval and prior to Launch in any Country in the Territory.  Early Access Programs include treatment INDs / protocols in the United States, named patient programs in the EU and compassionate use programs in other Countries in the Territory.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.26</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effective Date</u>&#8221; means the date of <a name="_cp_text_1_196"></a>the Original Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.27</font><a name="_cp_blt_1_200"></a><a name="_cp_blt_2_199"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EMEA</u>&#8221; means the European Agency for the Evaluation of Medicinal Products or any successor agency thereto.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.28</font><a name="_cp_blt_1_202"></a><a name="_cp_blt_2_201"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Laws</u>&#8221; means all applicable Laws relating to (a) safety (including occupational health and safety); conservation, preservation or protection of human health, drinking water, natural resources, biota and the environment; (b) the generation, use, storage, handling, treatment, transportation or disposal of Hazardous Materials or Waste, (c) Releases and threatened Releases of Hazardous Materials, or (d) chemical classification and labeling.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.29</font><a name="_cp_blt_1_204"></a><a name="_cp_blt_2_203"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Permits</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.3(a)(ii)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.30</font><a name="_cp_blt_1_206"></a><a name="_cp_blt_2_205"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">European Union</u>&#8221; or &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EU</u>&#8221; means the Countries that are members of the European Union as of the Effective Date or that become members of the European Union thereafter.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.31</font><a name="_cp_blt_1_208"></a><a name="_cp_blt_2_207"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Expansion Costs</u>&#8221; shall have the meaning assigned to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.2(b)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.32</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Facility</u>&#8221; means, as applicable, a party&#8217;s Manufacturing facility and such other facilities used by such party (or its Affiliates) in the Manufacture or storage of (a) Drug Substance, (b) Licensed Product or (c) materials utilized in the Manufacture of Drug Substance or Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.33</font><a name="_cp_blt_1_212"></a><a name="_cp_blt_2_211"></a>&#8220;Failure to Supply&#8221; shall have the meaning assigned to it in Section 5.21(a).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.34</font><a name="_cp_blt_1_214"></a><a name="_cp_blt_2_213"></a><a name="_cp_blt_1_216"></a><a name="_cp_blt_2_215"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FCPA</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(t)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.35</font><a name="_cp_blt_1_218"></a><a name="_cp_blt_2_217"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDA</u>&#8221; means the United States Food and Drug Administration or any successor agency thereto.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">4<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.36</font><a name="_cp_blt_1_220"></a><a name="_cp_blt_2_219"></a><a name="_cp_blt_1_222"></a><a name="_cp_blt_2_221"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FDCA</u>&#8221; means the U.S. Federal Food, Drug and Cosmetic Act, as amended, and the regulations promulgated thereunder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.37</font><a name="_cp_blt_1_224"></a><a name="_cp_blt_2_223"></a><a name="OLE_LINK39"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Field</u>&#8221; means enzyme replacement therapy for the treatment of Gaucher Disease.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.38</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fill/Finish</u><font style="white-space:pre-wrap;">&#8221; means (a) formulating the Licensed Product using Drug Substance and other excipients, (b) filling the Licensed Product into vials, (c) lyophilization of the Drug Substance for incorporation into the Licensed Product, and (d) testing, including ongoing stability testing, and release of the Licensed Product.  For the avoidance of doubt, Fill/Finish shall not include any activities included in the definition of Labeling and Packaging.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.39</font><a name="_cp_blt_1_228"></a><a name="_cp_blt_2_227"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Fiocruz</u>&#8221; means Funda&#231;&#227;o Oswaldo Cruz, an agency of the Brazilian Ministry of Health organized under the Laws of Brazil. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.40</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">First Amendment</u><font style="white-space:pre-wrap;">&#8221; shall have the meaning assigned to it in the Recitals.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.41</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Force Majeure Event</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">18.1</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.42</font><a name="_cp_blt_1_230"></a><a name="_cp_blt_2_229"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forecast</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.6(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.43</font><a name="_cp_blt_1_232"></a><a name="_cp_blt_2_231"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">FTE Rate</u>&#8221; means [***] per full time equivalent person engaged in scientific, regulatory, process development, manufacturing or other similar work, consisting of [***] hours per year of such qualified work. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.44</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GAAP</u>&#8221; means United States generally accepted accounting principles consistently applied.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.45</font><a name="_cp_blt_1_234"></a><a name="_cp_blt_2_233"></a><a name="_cp_blt_1_236"></a><a name="_cp_blt_2_235"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Good Manufacturing Practices</u>&#8221; or &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">GMP</u>&#8221; means all applicable Good Manufacturing Practices including, (i) the applicable part of quality assurance to ensure that products are consistently produced and controlled in accordance with the quality standards appropriate for their intended use, as defined in European Commission Directive 2003/94/EC laying down the principals and guidelines of good manufacturing practice, (ii) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Sections 210, 211, 601 and 610, (iii) the Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing Practice for Medicinal Products, (iv) the principles detailed in the ICH Q7A guidelines, and (v) the equivalent Laws in any relevant Country, each as may be amended and applicable from time to time.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.46</font><a name="_cp_blt_1_238"></a><a name="_cp_blt_2_237"></a><a name="_cp_blt_1_240"></a><a name="_cp_blt_2_239"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Government Official</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(r)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.47</font><a name="_cp_blt_1_242"></a><a name="_cp_blt_2_241"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governmental Authority</u>&#8221; means any court, agency, department, authority or other instrumentality of any national, state, county, city or other political subdivision.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.48</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Hazardous Materials</u>&#8221; means any and all materials (including substances, chemicals compounds, mixtures, products, byproducts, biologic agents, living or genetically modified materials, wastes, pollutants and contaminants), that are (a) (i) listed, classified,</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">5<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">characterized or regulated pursuant to Environmental Laws; (ii) identified or classified as &#8220;hazardous&#8221;, &#8220;dangerous&#8221;, &#8220;toxic&#8221;, &#8220;pollutant&#8221;, &#8220;contaminant&#8221;, &#8220;waste&#8221;, &#8220;irritant&#8221;, &#8220;corrosive&#8221;, &#8220;flammable&#8221;, &#8220;radioactive&#8221;, &#8220;reactive&#8221;, &#8220;carcinogenic&#8221;, &#8220;mutagenic&#8221;, &#8220;bioaccumulative&#8221;, or &#8220;persistent&#8221; in the environment; or (iii) in quantity or concentration capable of causing harm or injury to human health, natural resources or the environment, if Released or resulting in human exposure; or (b) petroleum products and their derivatives, asbestos-containing material, lead-based paint, polychlorinated biphenyls, urea formaldehyde, or viral, bacterial or fungal material.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.49</font><a name="_cp_blt_1_244"></a><a name="_cp_blt_2_243"></a><a name="_cp_blt_1_247"></a><a name="_cp_text_1_245"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Improvement Notice</u>&#8221; shall have the meaning assigned to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.5</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.50</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Increased Capacity Cap</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><a name="_cp_field_47_246"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.2(b)</u><a name="_cp_text_1_248"></a>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.51</font><a name="_cp_blt_1_250"></a><a name="_cp_blt_2_249"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IND</u>&#8221; means an investigational new drug application filed with the FDA in accordance with the FDCA with respect to a drug product or an analogous application or filing with any Regulatory Authority outside of the United States (including any supra-national agency such as the European Union) for the purpose of commencing clinical development of a drug product in such jurisdiction.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.52</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">15.3</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)</u>.<a name="_cp_blt_1_252"></a><a name="_cp_blt_2_251"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.53</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">15.3</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.54</font><a name="_cp_blt_1_254"></a><a name="_cp_blt_2_253"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Forecast</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.6(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.55</font><a name="_cp_blt_1_256"></a><a name="_cp_blt_2_255"></a><a name="_cp_blt_1_258"></a><a name="_cp_blt_2_257"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Inventories</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.2(c)</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.56</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Israel Grant</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(i)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.57</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IU</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.7(a)</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.58</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Labeling and Packaging</u>&#8221; means the final product labeling and packaging of the Licensed Product (whether in commercial or clinical packaging presentation), including materials to be inserted such as patient inserts, patient medication guides, professional inserts and any other written, printed or graphic materials accompanying the Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.59</font><a name="_cp_blt_1_260"></a><a name="_cp_blt_2_259"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Launch</u>&#8221; means the first shipment of a Licensed Product in commercial quantities for commercial sale by Pfizer, its Affiliates or its Sublicensees to a Third Party in a Country in the Territory after receipt by Pfizer of the first Regulatory Approval (and, in any Country in which Price Approval is necessary or relevant for a majority of the population to obtain access to drug products, Price Approval) for such Licensed Product in such Country.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.60</font><a name="_cp_blt_1_262"></a><a name="_cp_blt_2_261"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Laws</u>&#8221; means all laws, statutes, rules, regulations, codes, administrative or judicial orders, judgments, decrees, injunctions and/or ordinances of any Governmental Authority, and common law or other legal requirements of any kind, whether currently in existence or hereafter promulgated, enacted, adopted or amended.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.61</font><a name="_cp_blt_1_264"></a><a name="_cp_blt_2_263"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Licensed Product</u>&#8221; means any finished dosage form of a drug product that contains Drug Substance (excluding any Oral Formulation) and either: (a) the manufacture, sale, </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">6<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">offer for sale, importation, or use of such drug product (i) would, absent the license granted by Protalix to Pfizer herein, infringe at least one Valid Claim of a Protalix Patent Right, or (ii) embodies, incorporates or uses Protalix Technology; or (b) such drug product is supplied by Protalix to Pfizer under this Agreement (or is manufactured using Drug Substance supplied by Protalix to Pfizer under this Agreement) or is manufactured by Pfizer or a Third Party (or is manufactured using Drug Substance manufactured by Pfizer or a Third Party).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.62</font><a name="_cp_blt_1_266"></a><a name="_cp_blt_2_265"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Long Range Forecast</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.6(b)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.63</font><a name="_cp_blt_1_268"></a><a name="_cp_blt_2_267"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Losses</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">15.2</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.64</font><a name="_cp_blt_1_270"></a><a name="_cp_blt_2_269"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacture</u>&#8221; or &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing</u>&#8221; means all activities related to the manufacturing of the Drug Substance or Licensed Product, and/or any ingredient thereof, including manufacturing for clinical use or commercial sale, in-process and finished product testing, Fill/Finish, Labeling and Packaging, release of product, quality assurance activities related to manufacturing and release of product and ongoing stability tests and regulatory activities related to any of the foregoing.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.65</font><a name="_cp_blt_1_272"></a><a name="_cp_blt_2_271"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing Certificate of Analysis</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.10(a)(i)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.66</font><a name="_cp_blt_1_274"></a><a name="_cp_blt_2_273"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing Transition Plan</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.23</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.67</font>&#8220;Minimum Delivery Requirements&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.21(a)</u><font style="white-space:pre-wrap;">.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.68</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Minimum Shelf Life</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.8(b)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.69</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">NDA</u>&#8221; means a New Drug Application filed with the FDA in accordance with the FDCA with respect to a drug product or an analogous application or filing with any Regulatory Authority outside of the United States (including any supra-national agency such as the European Union) for the purpose of obtaining approval to market and sell a drug product in such jurisdiction.<a name="_cp_blt_1_275"></a><a name="_cp_text_1_276"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.70</font><a name="_cp_blt_1_278"></a><a name="_cp_blt_2_277"></a><a name="_cp_blt_1_280"></a><a name="_cp_blt_2_279"></a> &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Non-Conformance</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.10(a)(ii)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.71</font><a name="_cp_blt_1_282"></a><a name="_cp_blt_2_281"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Oral Formulation</u>&#8221; means an oral formulation of a drug product for the treatment of Gaucher Disease which contains any Compound as the active pharmaceutical ingredient.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.72</font><a name="_cp_blt_2_285"></a><a name="_cp_blt_1_295"></a><a name="_cp_text_1_289"></a><a name="OLE_LINK7"></a><a name="OLE_LINK8"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Original Agreement</u>&#8221; shall have the meaning assigned to it in the Recitals.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.73</font><a name="_cp_text_1_293"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Outside of the Scope Product</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section</u><a name="_cp_field_47_294"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.2</u><a name="_cp_text_1_296"></a>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.74</font><a name="_cp_blt_1_298"></a><a name="_cp_blt_2_297"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Application</u>&#8221; means any application for a Patent.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">7<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.75</font><a name="_cp_blt_1_300"></a><a name="_cp_blt_2_299"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Challenge</u>&#8221; has the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.7(a)</u><font style="white-space:pre-wrap;">.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.76</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Rights</u>&#8221; means Patents and Patent Applications.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.77</font><a name="_cp_blt_1_303"></a><a name="_cp_blt_2_302"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patents</u>&#8221; means issued patents, whether domestic or foreign, including all continuations, continuations-in-part, divisions, provisionals and renewals, and letters of patent granted with respect to any of the foregoing, patents of addition, supplementary protection certificates, registration or confirmation patents and all reissues, re-examination and extensions thereof.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.78</font><a name="_cp_blt_1_305"></a><a name="_cp_blt_2_304"></a>&#8220;Persistent Failure to Supply&#8221; shall have the meaning assigned to it in Section 5.21(b)<font style="white-space:pre-wrap;">.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.79</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Person</u>&#8221; means an individual, corporation, partnership, company, joint venture, unincorporated organization, limited liability company or partnership, sole proprietorship, association, bank, trust company or trust, whether or not legal entities, or any Governmental Authority.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.80</font><a name="_cp_blt_1_307"></a><a name="_cp_blt_2_306"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pfizer Confidential Information</u><font style="white-space:pre-wrap;">&#8221; means all information relating to the Compound or Licensed Product, as well as any other information regarding the business and operations of Pfizer, that is or has been disclosed (whether orally or in writing) by Pfizer to Protalix or its Affiliates to the extent that such information is not:  (a) as of the date of disclosure known to Protalix or its Affiliates; or (b) disclosed in published literature, or otherwise generally known to the public through no breach by or Protalix; of this Agreement or (c) obtained by Protalix or its Affiliates from a Third Party free from any obligation of confidentiality to Pfizer; or (d) independently developed by Protalix or its Affiliates without use of the Pfizer Confidential Information; or (e) in the good faith judgment of Protalix, after consultation with legal counsel, is required to be disclosed under Law; </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided </u>that, in the case of (e), Protalix provides Pfizer prior notice (to the extent practicable) of such disclosure and agrees to cooperate, at the request and sole expense of Pfizer, with Pfizer&#8217;s efforts to preserve the confidentiality of such information.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.81</font><a name="_cp_blt_1_309"></a><a name="_cp_blt_2_308"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pfizer Improvements</u>&#8221; has the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.6(d)</u><font style="white-space:pre-wrap;">.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.82</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pfizer Payment</u>&#8221; has the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.1</u><font style="white-space:pre-wrap;">.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.83</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Phase 4 Trial</u><font style="white-space:pre-wrap;">&#8221; means a clinical trial for the Licensed Product that is initiated in a Country after receipt of Regulatory Approval for the Licensed Product in such Country and is principally intended to support the marketing and Commercialization of the Licensed Product, including investigator initiated trials and clinical experience trials.  </font><a name="_cp_blt_2_317"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">prGCD</u>&#8221; means a plant cell expressed recombinant human Glucocerebrosidase enzyme having the sequence set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit A</u> to this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.84</font><a name="_cp_blt_1_319"></a><a name="_cp_blt_2_318"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Presentation</u>&#8221; means [***].</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">8<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.85</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Price</u>&#8221; means the price Pfizer pays to Protalix per IU of Drug Substance manufactured for and shipped to Pfizer. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.86</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Price Approval</u>&#8221; means, in any Country where a Governmental Authority authorizes reimbursement for, or approves or determines pricing for, drug products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing approval or determination (as the case may be).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.87</font><a name="_cp_blt_1_321"></a><a name="_cp_blt_2_320"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Product Mark</u>&#8221; shall have the meaning assigned to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.4(b)</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.88</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Product Specifications</u>&#8221; means those Manufacturing, performance, quality - control release, and Fill/Finish specifications for Drug Substance or Licensed Product in the Territory, which are initially as set forth in the applicable Regulatory Approval for a Licensed Product, as such specifications may be amended from time to time pursuant to the terms of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.89</font><a name="_cp_blt_1_323"></a><a name="_cp_blt_2_322"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Proposed Transaction</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11.7</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.90</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Confidential Information</u>&#8221; [***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.91</font><a name="_cp_blt_1_327"></a><a name="_cp_blt_2_326"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Improvement</u>&#8221; means any necessary or useful improvement, change, or modification to the Drug Substance, Licensed Product or Protalix Technology which may be developed, created, or acquired by Protalix after the Effective Date and before <a name="_cp_text_1_325"></a>termination of this Agreement<font style="white-space:pre-wrap;">, including new or improved methods of Manufacturing, means of delivery (other than an Oral Formulation), dosage, formulation (other than an Oral Formulation), and analysis.  To the extent an improvement, change or modification to prGCD also constitutes an analog, derivative or variant of prGCD, such improvement, change or modification shall be deemed to be a Compound and not a Protalix Improvement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.92</font><a name="_cp_blt_1_329"></a><a name="_cp_blt_2_328"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Patent Rights</u>&#8221; [***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.93</font><a name="_cp_blt_1_331"></a><a name="_cp_blt_2_330"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Payment</u>&#8221; has the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.2</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.94</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix System Patent Rights</u>&#8221; means Protalix Patent Rights that relate primarily to the System.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.95</font><a name="_cp_blt_1_333"></a><a name="_cp_blt_2_332"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Technology</u>&#8221; means any Technology owned or otherwise Controlled by Protalix or any of its Affiliates as of the Second Amendment Effective Date or at any time during the Term that is necessary or useful for the Development, Manufacture, use or Commercialization of Compound, Drug Substance or a drug product that contains Drug Substance, including the System.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.96</font><a name="_cp_blt_1_335"></a><a name="_cp_blt_2_334"></a><a name="_cp_blt_1_337"></a><a name="_cp_blt_2_336"></a> &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Withholding Tax Action</u>&#8221; has the meaning assigned to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.3(c)(iii)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.97</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase Order</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.6(a)</u>.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">9<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.98</font><a name="_cp_blt_1_339"></a><a name="_cp_blt_2_338"></a><a name="_Ref430680957"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quality Agreement</u>&#8221; means the Quality Agreement entered into between Protalix and Pfizer, dated January 4, 2011, with respect to the Drug Substance being Manufactured by Protalix [***] in the Territory. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.99</font><a name="_cp_blt_1_341"></a><a name="_cp_blt_2_340"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Redacted Agreement</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.5</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.100</font><a name="_cp_blt_1_343"></a><a name="_cp_blt_2_342"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Approval</u>&#8221; means any and all approvals, with respect to any Country, or authorizations (other than Price Approvals) of a Regulatory Authority, that are necessary for the commercial Manufacture, distribution, use, marketing or sale of a drug product in such Country.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.101</font><a name="_cp_blt_1_345"></a><a name="_cp_blt_2_344"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Authority</u>&#8221; means, in respect of a particular Country or jurisdiction, the Governmental Authority having responsibility for granting Regulatory Approvals in such Country or jurisdiction.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.102</font><a name="_cp_blt_1_347"></a><a name="_cp_blt_2_346"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Exclusivity</u><font style="white-space:pre-wrap;">&#8221; means any rights or protections which are recognized, afforded or granted by a Regulatory Authority in any Country or region of the Territory, in association with the Regulatory Approval of a Licensed Product, providing such Licensed Product:  (a) a period of marketing exclusivity, during which the Regulatory Authority recognizing, affording or granting such marketing exclusivity will refrain from either reviewing or approving a marketing authorization application or similar regulatory submission, submitted by a party other than Pfizer, its Affiliates or Sublicensees seeking to market a drug product in which the Drug Substance is the primary ingredient, or during which such an application or submission may be reviewed or approved by a Regulatory Authority, but the product may not be placed on the market or (b) a period of data exclusivity, during which a party, other than Pfizer, its Affiliates or Sublicensees, seeking to market a drug product in which the Drug Substance is the primary ingredient, is precluded from either referencing or relying upon a Licensed Product&#8217;s clinical dossier or relying on previous findings of safety or effectiveness with respect to a Licensed Product to support the submission, review or approval of a marketing authorization application or similar regulatory submission before the applicable Regulatory Authority. Regulatory Exclusivity shall include rights conferred in the United States pursuant to the Hatch-Waxman Act or the FDA Modernization Act of 1997 or in the European Union/European Economic Area pursuant to Section 10.1 of Directive 2001/EC/83 or section 14.11 of Regulation (EC) No. 726/2004.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.103</font><a name="_cp_blt_1_349"></a><a name="_cp_blt_2_348"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release</u>&#8221; means any release, spill, emission, leaking, pumping, injection, deposit, disposal, discharge, dispersal, leaching or migration into the indoor or outdoor environment, including the uncontrolled presence or the movement of Hazardous Materials through the ambient air, soil, subsurface water, groundwater, wetlands, lands or subsurface strata.<a name="_cp_blt_1_350"></a><a name="_cp_text_1_351"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.104</font><a name="_cp_blt_1_356"></a><a name="_cp_text_1_357"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Released Obligations</u>&#8221; has the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.5</u><font style="white-space:pre-wrap;">.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.105</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Resulting Companies</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">18.7</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)</u>. <font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.106</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Amendment Effective Date</u>&#8221; shall have the meaning assigned to it in the Recitals.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">10<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.107</font><a name="_cp_blt_1_359"></a><a name="_cp_blt_2_358"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublicense</u>&#8221; means the grant by Pfizer of a sublicense under, or an agreement of Pfizer not to assert, any of the rights licensed by Protalix to Pfizer pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.1</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.108</font><a name="_cp_blt_1_361"></a><a name="_cp_blt_2_360"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublicensee</u>&#8221; means a Third Party to whom Pfizer has granted a Sublicense.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.109</font><a name="_cp_blt_1_363"></a><a name="_cp_blt_2_362"></a><a name="_cp_blt_2_364"></a><a name="_cp_blt_1_367"></a><a name="_cp_blt_2_366"></a> &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supply Term</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.5</u><b style="font-weight:bold;">.</b></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.110</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">System</u>&#8221; means Protalix&#8217;s proprietary protein expression system, ProCellEx&#8482;.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.111</font><a name="_cp_blt_1_369"></a><a name="_cp_blt_2_368"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technology</u>&#8221; means proprietary materials, technology, data, results and non-public technical, scientific and clinical information, in any tangible or intangible form, including know-how, expertise, trade secrets, practices, techniques, methods, processes, developments, specifications, formulations, formulae, including any intellectual property rights embodying any of the foregoing, but excluding any Patent Rights.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.112</font><a name="_cp_blt_1_371"></a><a name="_cp_blt_2_370"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technology Transfer Agreement</u>&#8221; means the Technology Transfer and Supply Agreement between Protalix and Fiocruz, dated June 18, 2013. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.113</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 13</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.114</font><a name="_cp_blt_1_373"></a><a name="_cp_blt_2_372"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Territory</u>&#8221; means the entire world, excluding Brazil.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.115</font><a name="_cp_blt_1_375"></a><a name="_cp_blt_2_374"></a><a name="_cp_blt_1_377"></a><a name="_cp_blt_2_376"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party</u>&#8221; means any Person other than Pfizer, Protalix, or any of their respective Affiliates.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.116</font><a name="_cp_blt_1_379"></a><a name="_cp_blt_2_378"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Claim</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">15.3</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.117</font><a name="_cp_blt_1_381"></a><a name="_cp_blt_2_380"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party License</u>&#8221; means each license agreement between Protalix and a Third Party set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u> pursuant to which or from which Protalix licenses Protalix Patent Rights or Protalix Technology.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.118</font><a name="_cp_blt_1_387"></a><a name="_cp_blt_2_386"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Manager</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.7(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.119</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Period</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.7(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.120</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Plan</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.7(b)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.121</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Team</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.7(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.122</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Unmatured Note</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.21(b)(i)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.123</font><a name="_cp_blt_1_389"></a><a name="_cp_blt_2_388"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Uplyso Trademarks</u>&#8221; means the trademark &#8220;UPLYSO&#8482;&#8221; in certain countries in the world.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.124</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Valid Claim</u>&#8221; means (a) a claim of an issued and unexpired Patent (including the term of any patent term extension, supplemental protection certificate, renewal or other extension) which has not been held unpatentable, invalid or unenforceable in a final decision of a court or other Governmental Authority of competent jurisdiction from which no appeal may be or has been taken, and which has not been admitted to be invalid or unenforceable through </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">11<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">reissue, re-examination or disclaimer; or (b) a claim of a Patent Application, which claim has been pending less than five (5) years from the original priority date of such claim in a given jurisdiction, unless or until such claim thereafter issues as a claim of an issued Patent (from and after which time the same shall be deemed a Valid Claim subject to paragraph (a) above).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.125</font><a name="_cp_blt_1_391"></a><a name="_cp_blt_2_390"></a>[***] means [***].</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.126</font><a name="_cp_blt_1_393"></a><a name="_cp_blt_2_392"></a>[***]<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> License Agreement</u>&#8221; means that License Agreement by and between Protalix and [***]effective as of [***], as amended from time to time.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.127</font><a name="_cp_blt_1_395"></a><a name="_cp_blt_2_394"></a>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waste</u>&#8221; means all wastes which arise from the Manufacture, handling or storage of Drug Substance hereunder, or which is otherwise produced through the implementation of this Agreement, including Hazardous Materials.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.128</font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Work Plan</u>&#8221; shall have the meaning assigned to it in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.2(b)</u><font style="white-space:pre-wrap;">.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">1.129</font>&#8220;[***]</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><a name="OLE_LINK5"></a><a name="OLE_LINK6"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Construction</u><font style="white-space:pre-wrap;">.  Except where expressly stated otherwise in this Agreement, the following rules of interpretation apply to this Agreement: (a) &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; are not limiting and mean include, includes and including, without limitation; (b) definitions contained in this Agreement are applicable to the singular as well as the plural fo</font>rms of such terms; (c) references to an agreement, statute or instrument mean such agreement, statute or instrument as from time to time amended, modified or supplemented; (d) references to a Person are also to its permitted successors and assigns; (e) references to an &#8220;Article&#8221;, &#8220;Section&#8221;, &#8220;Exhibit&#8221; or &#8220;Schedule&#8221; refer to an Article or Section of, or any Exhibit or Schedule to, this Agreement unless otherwise indicated; (f) the word &#8220;will&#8221; shall be construed to have the same meaning and effect as the word &#8220;shall&#8221;; and (g) the word &#8220;any&#8221; shall mean &#8220;any and all&#8221; unless otherwise indicated by context.</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 2.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_Toc428350782"></a><a name="_Toc428351574"></a><a name="_Toc428409541"></a><a name="_Toc428410099"></a><a name="_Toc428410153"></a><a name="_Toc428410237"></a><a name="_Toc428736349"></a><a name="_Toc428736647"></a><a name="_Toc428736992"></a><a name="_Toc428737340"></a><a name="_Toc428738033"></a><a name="_Toc428739893"></a><a name="_Toc431831927"></a><a name="_Toc434628841"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">[INTENTIONALLY OMITTED]</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 3.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_Ref244602100"></a><a name="_Ref245192330"></a><a name="_Toc428350783"></a><a name="_Toc428351575"></a><a name="_Toc428409542"></a><a name="_Toc428410100"></a><a name="_Toc428410154"></a><a name="_Toc428410238"></a><a name="_Toc428736350"></a><a name="_Toc428736648"></a><a name="_Toc428736993"></a><a name="_Toc428737341"></a><a name="_Toc428738034"></a><a name="_Toc428739894"></a><a name="_Toc431831928"></a><a name="_Toc434628842"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">LICENSE</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.1</font><a name="_Toc428736994"></a><a name="_Toc428737342"></a><a name="_Toc428738035"></a><a name="_Toc428739895"></a><a name="_Toc431831929"></a><a name="_Toc431832263"></a><a name="_Toc434628843"></a><a name="_Ref244599833"></a><a name="_Ref244600245"></a><a name="_Ref245382836"></a><a name="_Ref245393050"></a><a name="_Ref246859749"></a><a name="_Toc428736649"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exclusive License</u><font style="white-space:pre-wrap;">.  Subject to the terms of this Agreement, including </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.2</u>, Protalix hereby grants to Pfizer and Pfizer hereby accepts an exclusive (even as to Protalix and its Affiliates, except as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.2</u>), irrevocable, perpetual, fully-paid (upon Pfizer&#8217;s payment of the Pfizer Payment pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.1</u><font style="white-space:pre-wrap;"> of the Agreement), royalty-free  license in the Territory and within the Field, including the right to Sublicense (subject to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.4</u>):</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref245393078"></a>under the Protalix Patent Rights to (i) use, sell, offer for sale, supply, cause to be supplied, and import the Licensed Product, (ii) conduct the Fill/Finish activities and Labeling and Packaging activities, (iii) engage in Development activities with respect to the Licensed Product, and (iv) make and have made the Drug Substance solely for incorporation in the Licensed Product; and</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">12<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font>to use Protalix Technology and Protalix Confidential Information in connection with (i) the conduct of the Fill/Finish activities and Labeling and Packaging activities, (ii) <a name="OLE_LINK48"></a>preparing and submitting regulatory filings and communicating with Regulatory Authorities with respect to the Licensed Product, (iii) the use, sale, offer for sale, supply and importation of the Licensed Product, (iv) Development activities with respect to the Licensed Product, and (v) making and having made the Drug Substance solely for incorporation in the Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.2</font><a name="_Toc428736995"></a><a name="_Toc428737343"></a><a name="_Toc428738036"></a><a name="_Toc428739896"></a><a name="_Toc431831930"></a><a name="_Toc431832264"></a><a name="_Toc434628844"></a><a name="_Ref246563610"></a><a name="_Toc428736650"></a><a name="_Ref245388736"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other License Provisions</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref246515676"></a>The licenses granted to Pfizer pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.1</u> shall be co-exclusive with Protalix only to the extent it is necessary for Protalix to perform its obligations under this <a name="_cp_text_1_401"></a><font style="white-space:pre-wrap;">Agreement.  During </font>the Term, and without limiting the scope of the licenses granted to Pfizer pursuant to <a name="OLE_LINK105"></a><a name="OLE_LINK106"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.1</u><font style="white-space:pre-wrap;">, neither Protalix nor any of its Affiliates shall (i) directly or indirectly, alone or in collaboration with any Third Party, Commercialize the Compound (other than the Oral Formulation), a drug product containing the [***].  </font>The parties expressly acknowledge and agree that the exclusivity grant in favor of Pfizer in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.1</u><font style="white-space:pre-wrap;"> shall not be construed as limiting Protalix&#8217;s right to Develop, Manufacture or Commercialize [***].  Notwithstanding anything to the contrary herein, Protalix may conduct or have conducted Manufacturing activities and engage in or have engaged in Development activities in Israel at any time in connection with its sale, offer for sale, supply or importation of the Licensed Product outside the Territory; </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided however</u><font style="white-space:pre-wrap;">, that Protalix shall not be permitted to conduct clinical studies of the [***] within Israel without the prior written consent of Pfizer.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font>For purposes of clarity, and without limiting the licenses granted under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.1</u>, Pfizer acknowledges that in the event Protalix does not have exclusive rights to Protalix Patent Rights licensed by Protalix from Third Parties [***] vis &#224; vis the Third Party licensor, Pfizer&#8217;s rights to such Protalix Patent Rights under the sublicenses granted under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.1</u> would not be exclusive vis &#224; vis the Third Party licensor.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.3</font>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.4</font><a name="_Toc428736997"></a><a name="_Toc428737345"></a><a name="_Toc428738038"></a><a name="_Toc428739898"></a><a name="_Toc431831932"></a><a name="_Toc431832266"></a><a name="_Toc434628845"></a><a name="_Ref244599128"></a><a name="_Ref244599858"></a><a name="_Ref245387881"></a><a name="_Ref245388231"></a><a name="_Ref245390096"></a><a name="_Ref245390482"></a><a name="_Toc428736652"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublicensing and Subcontracting</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref244600082"></a><a name="_Ref245387879"></a>Pfizer may grant Sublicenses subject to the terms and conditions set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.4</u>. Any Sublicense obligations required by the Third Party License to be included in a sublicense shall be deemed to be included in this Agreement as obligations of Pfizer.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref245390484"></a>Each Sublicense granted by Pfizer pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.4</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)</u><font style="white-space:pre-wrap;"> shall be subject and subordinate to the terms and conditions of this Agreement and shall contain terms and conditions consistent with those in this Agreement, and shall not in any way diminish, reduce or eliminate any of Pfizer&#8217;s obligations under this Agreement.  Without limiting the foregoing, each Sublicense agreement with Sublicensees shall contain the following provisions: (i) a requirement that such Sublicensee comply with the confidentiality and non-use provisions</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">13<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9</u> with respect to both parties&#8217; Confidential Information, (ii) a requirement to comply with all other applicable terms of this Agreement, and (iii) a provision prohibiting such Sublicensee from further sublicensing unless such further sublicense complies with the terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.4</u>. </p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Right to Subcontract</u><font style="white-space:pre-wrap;">.  Each party may, subject to </font><a name="_cp_field_47_404"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.4(d)</u>, subcontract its obligations under this Agreement to an Affiliate or Third Party as it would in the normal course of its business without the prior written consent of the other party. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref429827751"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Liability for Affiliates, Sublicensees and Subcontractors</u><font style="white-space:pre-wrap;">.  Each party shall ensure that each of its Affiliates, sublicensees and subcontractors accepts and complies with all of the applicable terms and conditions of this Agreement as if such Affiliates or sublicensees or subcontractors were parties to this Agreement and each party shall remain fully responsible for its Affiliates&#8217; and sublicensees&#8217; and subcontractors&#8217; performance under this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.5</font><a name="_Toc428736998"></a><a name="_Toc428737346"></a><a name="_Toc428738039"></a><a name="_Toc428739899"></a><a name="_Toc431831933"></a><a name="_Toc431832267"></a><a name="_Toc434628846"></a><a name="_Ref428297868"></a><a name="_Toc428736653"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Improvements</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_cp_blt_1_405"></a><a name="_Ref244598103"></a><a name="_cp_text_1_406"></a>During the Term, Protalix shall give written notice (an &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Improvement Notice</u><font style="white-space:pre-wrap;">&#8221;) to Pfizer within thirty (30) days of any actual or constructive reduction to practice of any Protalix Improvement.  The Improvement Notice shall set forth the nature and details of the Protalix Improvement and any data obtained or generated by Protalix.  Where such Protalix Improvements are to an invention, Protalix shall state in the Improvement Notice whether it intends to prepare and file patent applications related thereto.</font><font style="white-space:pre-wrap;">  For the avoidance of doubt, the Improvement Notice and its contents shall be deemed Protalix Confidential Information and subject to the confidentiality provisions set forth in </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9</u> hereof.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_cp_blt_1_408"></a><a name="_cp_blt_2_407"></a>Each Protalix Improvement shall be deemed to be included within the Protalix Technology licensed to Pfizer pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.1</u><font style="white-space:pre-wrap;"> of this Agreement, without the payment of any additional fees, including milestones or royalties.  Any Patent Application directed to a Protalix Improvement shall be considered to be a Protalix Patent Right licensed pursuant to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.1</u> of this Agreement, without the payment of any additional fees, including milestones or royalties.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.6.</font><a name="_cp_blt_2_409"></a><a name="_cp_blt_2_413"></a><a name="_cp_blt_2_415"></a><a name="_cp_blt_1_418"></a><a name="_cp_blt_2_417"></a><a name="_Toc428736999"></a><a name="_Toc428737347"></a><a name="_Toc428738040"></a><a name="_Toc428739900"></a><a name="_Toc431831934"></a><a name="_Toc431832268"></a><a name="_Toc434628847"></a><a name="_Toc428736654"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Implied License</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">; Brazil Activities</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref429865189"></a><a name="_Ref429822888"></a><font style="white-space:pre-wrap;">Except for the licenses and other rights granted to Pfizer herein, all right, title and interest in and to the Protalix Patent Rights, Protalix Technology, Protalix Confidential Information and Protalix Improvements shall remain solely with Protalix and its Third Party licensors, as applicable.  Except as expressly provided</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u>in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 3</u> or elsewhere in this Agreement, neither party will be deemed by this Agreement to have been granted any license or other rights to the other party&#8217;s intellectual property rights, either expressly or by implication, estoppel or otherwise.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref429845999"></a>Notwithstanding anything to the contrary in this Agreement, for the avoidance of doubt, Protalix shall have the (i) sole authority and exclusive right to determine all operating plans and strategies for the Drug Substance and Licensed Product outside the Territory and the exclusive right to research, Develop or Commercialize the Drug Substance or Licensed Product outside the Territory and to Manufacture (including Fill/Finish) the Drug Substance or </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">14<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">Licensed Product for sale outside the Territory, and (ii) right to enter into, and perform any of its obligations under, any agreements (including the Technology Transfer Agreement), including sublicenses, relating to Protalix&#8217;s rights in clause (i) of this sentence (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Brazil Activities</u>&#8221;), without obtaining any additional consents from Pfizer with respect thereto or having Pfizer participate therein. For the avoidance of doubt, as used in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.6(b)</u>, the term &#8220;Commercialize&#8221; includes the activities referred to in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 1.13</u><font style="white-space:pre-wrap;"> with respect to both Drug Substance and Licensed Product.  Without limiting the foregoing, Protalix shall have the right to engage Third Parties to perform Fill/Finish activities for, and/or supply Licensed Product to, Protalix for sale of such Licensed Product outside the Territory.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref431193049"></a><a name="_Ref431296179"></a><a name="_Ref429847218"></a><a name="_Ref429828799"></a>Pfizer acknowledges and agrees that Protalix is permitted to sublicense to Fiocruz (or any other sublicensee of Protalix in Brazil) the Brazil Uplyso Trademark and any other Product Marks required by applicable Laws to be included on the labeling and packaging of the finished packaged product for use in the Brazil Activities as they exist on the labeling and packaging of finished packaged product <a name="_cp_text_1_246"></a>at the time such finished packaged product is supplied to Fiocruz (or such sublicensee), and subject to the quality control provisions set forth in the Technology Transfer Agreement (or equivalent provisions in another agreement with the applicable sublicensee), which shall be at least as protective<a name="_cp_text_1_247"></a> as those set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.4(d)</u>.<font style="white-space:pre-wrap;">  For the avoidance of doubt, the rights granted pursuant to this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.6(c)</u> do not include grants to use the name or trade name of Pfizer (other than the right to sublicense such right to Fiocruz (or any other sublicensee of Protalix in Brazil) to the extent such right is granted to Protalix pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.5</u> or required to be made pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4.4(d)(iv)(B)</u><font style="white-space:pre-wrap;">).  Any such right to use such name or trade name shall be governed by </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.5</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref431232184"></a><a name="_Ref431467959"></a>Pfizer acknowledges and agrees that Protalix is permitted to sublicense to Fiocruz any drug product manufacturing-related enhancements that are specifically directed to, or new presentations of, the Licensed Product <a name="_cp_text_1_250"></a>developed or otherwise owned by Pfizer or its Affiliates (&#8220;<a name="_cp_text_66_251"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pfizer Improvements</u><font style="white-space:pre-wrap;">&#8221;), pursuant to the Technology Transfer Agreement  (or another agreement with the applicable sublicensee)</font><a name="_cp_text_1_253"></a>; <a name="_cp_text_66_254"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that the Pfizer Improvements are used solely for the Licensed Product by Protalix and Fiocruz (or the applicable sublicensee).<font style="white-space:pre-wrap;">  Pfizer agrees to consider in good faith any reasonable requests for technical support to transfer technical manufacturing information relating solely to the Pfizer Improvement in connection with such sublicense.  Such requests for technical support shall be limited to </font><a name="_cp_text_1_257"></a>[***] <font style="white-space:pre-wrap;">person hours and should additional technical support be required, Protalix shall provide to Pfizer a written request for such additional technical support.  Protalix shall reimburse Pfizer for all actual Pfizer costs associated with such technical support, including out-of pocket expenses and documented employee time at the FTE Rate.</font> For the avoidance of doubt, Pfizer shall be under no obligations to provide any technical support pursuant to this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.6(d)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:40.5pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">3.7.</font>[***]</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;padding-left:72pt;text-indent:-72pt;text-transform:uppercase;margin:0pt 0pt 12pt 0pt;"><font style="font-weight:normal;text-decoration-color:#000000;text-decoration-line:none;text-transform:none;">[***] Redacted pursuant to confidential treatment request.</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">15<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 4.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_Ref244605566"></a><a name="_Ref244605655"></a><a name="_Ref244607585"></a><a name="_Toc428350784"></a><a name="_Toc428351582"></a><a name="_Toc428409543"></a><a name="_Toc428410101"></a><a name="_Toc428410155"></a><a name="_Toc428410245"></a><a name="_Toc428736351"></a><a name="_Toc428736655"></a><a name="_Toc428737000"></a><a name="_Toc428737348"></a><a name="_Toc428738041"></a><a name="_Toc428739901"></a><a name="_Toc431831936"></a><a name="_Toc434628848"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">REGULATORY APPROVALS AND MARKETING</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.1</font><a name="_Toc428737001"></a><a name="_Toc428737349"></a><a name="_Toc428738042"></a><a name="_Toc428739902"></a><a name="_Toc431831937"></a><a name="_Toc431832270"></a><a name="_Toc434628849"></a><a name="_Ref244602231"></a><a name="_Ref244658411"></a><a name="_Ref244658599"></a><a name="_Ref244658600"></a><a name="_Ref245360287"></a><a name="_Ref245455514"></a><a name="_Ref245455643"></a><a name="_Ref245456624"></a><a name="_Toc428736656"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Affairs</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref245360288"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Affairs in the Territory other than Israel</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Copies of Regulatory Filings</u><font style="white-space:pre-wrap;">.  The parties acknowledge that Protalix has provided to Pfizer complete copies of all regulatory filings in the Territory (other than Israel) relating to the Licensed Product, including INDs, filings with the FDA or other Regulatory Authorities, supplements or amendments thereto, all written correspondence with the FDA or other Regulatory Authorities regarding such regulatory filings, and all existing written minutes of meetings and memoranda of conversations between Protalix (including, to the extent practicable, Protalix&#8217;s investigators) and the FDA or other Regulatory Authorities in Protalix&#8217;s possession (or in the possession of any of Protalix&#8217;s agents and subcontractors, such as contract research organizations used by Protalix), to the extent Protalix had the right to access and provide to Pfizer such materials.</font><font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer of Regulatory Filings</u><font style="white-space:pre-wrap;">.  The parties acknowledge that Protalix assigned and transferred to Pfizer (i) Protalix&#8217;s entire right, title and interest in and to the Regulatory Approvals for the Licensed Product in the Field in the Territory (other than Israel) and (ii) Protalix&#8217;s entire right, title and interest in and to any other regulatory filings in the Territory (other than Israel) with respect to the Drug Substance as incorporated into the Licensed Product (and for the avoidance of doubt, excluding any such regulatory filings with respect to the Drug Substance as a part of any Oral Formulation), or the Licensed Product, and any related data.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><a name="_Ref244602317"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Filings</u><font style="white-space:pre-wrap;">.  During the Term, and with respect to Israel, following the transfer of ownership of regulatory filings relating to the Drug Substance as incorporated into the Licensed Product (and for the avoidance of doubt, excluding any regulatory filings with respect to the Drug Substance as part of any Oral Formulation), or the Licensed Product in Israel, all regulatory filings with the FDA or other Regulatory Authorities pertaining to the Drug Substance as incorporated into the Licensed Product (and for the avoidance of doubt, excluding any such regulatory filings with respect to the Drug Substance as part of any Oral Formulation), or Licensed Product in the Territory shall be made in the name of Pfizer or its Affiliates in accordance with </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.1(g)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref428261938"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Affairs in Israel</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><a name="_Ref428309986"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer of Regulatory Filings</u>. Within the timeframe set forth by the Transition Team and to the extent permitted by applicable Law, (A) Protalix shall assign and transfer to Pfizer, Protalix&#8217;s entire right, title and interest in and to all regulatory filings and Regulatory Approvals in Israel with respect to the Drug Substance or Licensed Product in the Field (and for the avoidance of doubt, excluding any such regulatory filings or Regulatory Approvals with respect to the Drug Substance as a part of any Oral Formulation), and any related data, pursuant to instruments to such effect in </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">16<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:0pt;">form and substance reasonably satisfactory to Pfizer, and shall perform all other actions reasonably requested by Pfizer to effect and confirm such assignment and transfer. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Copies of Regulatory Filings</u><font style="white-space:pre-wrap;">. Protalix shall provide to Pfizer, at Pfizer&#8217;s expense, complete copies of any regulatory filings in Israel relating to the Licensed Product, including INDs, NDAs, filings with the Regulatory Authorities, supplements or amendments thereto, all written correspondence with Regulatory Authorities regarding such regulatory filings, and all existing written minutes of meetings and memoranda of conversations between Protalix (including, to the extent practicable, Protalix&#8217;s investigators) and Regulatory Authorities in Protalix&#8217;s possession (or in the possession of any of Protalix&#8217;s agents and subcontractors, such as contract research organizations used by Protalix), to the extent Protalix has the right to access and provide to Pfizer such materials.  To the extent available, Protalix shall provide such copies to Pfizer in electronic form. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref429842562"></a><a name="_Ref428262230"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Regulatory Affairs in Brazil</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><a name="_Ref429842726"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transfer of Regulatory Filings</u><font style="white-space:pre-wrap;">.  Within the timeframe set forth by the Transition Team and to the extent permitted by applicable Laws, Pfizer shall assign and transfer to Protalix Pfizer&#8217;s entire right, title and interest in and to all regulatory filings and Regulatory Approvals in Brazil with respect to the Drug Substance or Licensed Product, and any related data, pursuant to instruments to such effect in form and substance reasonably satisfactory to Protalix, and shall perform all other actions reasonably requested by Protalix to effect and confirm such assignment and transfer.</font> </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Copies of Regulatory Filings</u><font style="white-space:pre-wrap;">.  To the extent not already provided by Pfizer, Pfizer shall provide to Protalix, at Protalix&#8217;s expense, complete copies of any regulatory filings in Brazil relating to the Licensed Product, including INDs, NDAs, filings with the Regulatory Authorities, supplements or amendments thereto, all written correspondence with Regulatory Authorities regarding such regulatory filings, and all existing written minutes of meetings and memoranda of conversations between Pfizer (including, to the extent practicable, Pfizer&#8217;s investigators) and Regulatory Authorities in Pfizer&#8217;s possession (or in the possession of any of Pfizer&#8217;s agents and subcontractors, such as contract research organizations used by Pfizer), to the extent Pfizer has the right to access and provide to Protalix such materials.  To the extent available, Pfizer shall provide such copies to Protalix in electronic form. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cooperation</u><font style="white-space:pre-wrap;">.  The parties shall cooperate through the Transition Team to ensure that </font>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_DV_M42"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rights of Reference and Access to Data</u><font style="white-space:pre-wrap;">.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>[***]</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">17<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font><a name="_Ref429842273"></a>As the manufacturer and supplier of Drug Substance, Protalix shall provide to Pfizer original copies of any Certificate of Pharmaceutical Product (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CPP</u><font style="white-space:pre-wrap;">&#8221;) issued to Protalix as necessary to support Pfizer&#8217;s regulatory filings for the Licensed Product in the Field in the Territory.  Protalix shall use Commercially Reasonable Efforts to apply for and obtain such CPP.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref245455550"></a><a name="_Ref431828215"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment of Contracts</u><font style="white-space:pre-wrap;">.  Upon Pfizer&#8217;s reasonable request and to the extent legally permissible, Protalix shall assign to Pfizer any contract Protalix has entered into with a Third Party that solely relates to the Development of the Licensed Product in the Territory, </font><font style="white-space:pre-wrap;">to the extent Pfizer requests such contract to be assigned and such contract is assignable.  Protalix shall provide copies all such contracts to Pfizer&#8217;s Transition Manager. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref431195124"></a><a name="_Ref244605433"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Responsibility</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><a name="_Ref431552247"></a><font style="white-space:pre-wrap;">Pfizer shall have the sole authority and exclusive right to determine all regulatory plans and strategies for the Licensed Product in the Field in the Territory.  Without limiting the foregoing, subject to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.1(b)(i)</u><font style="white-space:pre-wrap;">, Pfizer (or, in any Country in the Territory, one or more of its Affiliates or Sublicensees) will own and be responsible for preparing, seeking, submitting and maintaining all regulatory filings and Regulatory Approvals for the Licensed Product in Field in the Territory, including preparing all reports necessary as part of a regulatory filing or Regulatory Approval.  </font><a name="_cp_text_1_436"></a><font style="white-space:pre-wrap;">Protalix shall provide (A) such assistance as Pfizer or its Affiliates or Sublicensees reasonably requires to obtain and maintain Regulatory Approvals for the Licensed Product in the Field in the Territory, (B) provide Pfizer with all reasonable assistance and cooperation to take all actions reasonably requested by Pfizer that are necessary to enable Pfizer to comply with any Law applicable to the Licensed Product and (C) provide reasonable assistance to enable Pfizer to obtain or maintain Regulatory Approvals for the Licensed Product in the Field in any Country in the Territory, including by providing CMC, facility, bioanalytical and clinical information and data that Pfizer is required to provide to Regulatory Authorities (to the extent such data is in Protalix&#8217;s possession and Control).  </font>Pfizer or its Affiliates or Sublicensees shall have the sole right to apply for and secure exclusivity rights that may be available under the Law of Countries in the Territory, including any Regulatory Exclusivity. <a name="_cp_text_1_437"></a> Protalix shall use Commercially Reasonable Efforts to cooperate with Pfizer and its Affiliates and Sublicensees, and to take such reasonable actions to assist Pfizer and its Affiliates and Sublicensees, in obtaining such exclusivity rights in each Country, as Pfizer may reasonably request from time to time.<font style="white-space:pre-wrap;">  Such requested cooperation and assistance referred to in this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.1(g)(i)</u> (including as referenced in the foregoing sentence and the foregoing subclauses (A), (B) and (C)) shall be provided at [***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>Once Protalix or its designee Fiocruz (or another applicable sublicensee) has successfully received Regulatory Approval for the Licensed Product in Brazil, Protalix shall have the sole authority and exclusive right to determine all</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">18<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="white-space:pre-wrap;">regulatory plans and strategies for the Licensed Product in Brazil.  Subject to the foregoing, Protalix or its designee Fiocruz (or another applicable sublicensee) shall have the sole authority and exclusive right to determine all regulatory plans and strategies for the Licensed Product outside the Territory, including the right to file a marketing authorization application in Brazil.  Without limiting the foregoing, subject to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.1(c)(i)</u><font style="white-space:pre-wrap;">, Protalix (or Fiocruz or such other sublicensee) will own and be responsible for preparing, seeking, submitting and maintaining its marketing application and all regulatory filings and Regulatory Approvals for the Licensed Product outside the Territory, including preparing all reports necessary as part of a regulatory filing or Regulatory Approval.  Pfizer shall provide such assistance as Protalix reasonably requires to obtain Regulatory Approvals for the Presentation of the Licensed Product Commercialized as of the Second Amendment Effective Date in Brazil.  Until Protalix or its designee Fiocruz (or such other applicable sublicensee) has successfully received Regulatory Approval for the Licensed Product in Brazil (and the corresponding marketing authorization held by Pfizer or its Affiliate in Brazil has been cancelled), Protalix and its designee Fiocruz (or such other applicable sublicensee) shall have express and irrevocable authorization and approval for Protalix and its designee Fiocruz (or such other applicable sublicensee) to import the Licensed Product and Drug Substance into Brazil under Pfizer&#8217;s or its Affiliates&#8217; Regulatory Approvals with Regulatory Authorities in Brazil, as allowed under applicable Law, which express authorization and approval is set forth in writing on Exhibit E.</font><font style="text-decoration-color:#000000;white-space:pre-wrap;">  </font><font style="white-space:pre-wrap;">Pfizer or its relevant Affiliate shall issue one or more of such authorizations as reasonably required by Protalix or its designee Fiocruz (or such other applicable sublicensee).  Protalix, Fiocruz, or such other sublicensee shall have the sole right to apply for and secure exclusivity rights that may be available in Brazil, including any Regulatory Exclusivity.  Pfizer shall use Commercially Reasonable Efforts to cooperate with Protalix, Fiocruz or such other sublicensee and to take such reasonable actions to assist Protalix, Fiocruz or such other sublicensee in obtaining such exclusivity rights in Brazil, as Protalix may reasonably request from time to time.  Such requested cooperation and assistance shall be provided [***]</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(h)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pharmacovigilance</u><font style="white-space:pre-wrap;">.  After the Second Amendment Effective Date and prior to[***], the safety units of each of the parties shall meet and agree upon an amendment to the written pharmacovigilance agreement that defines Pfizer&#8217;s pharmacovigilance responsibilities for the Licensed Product in the Territory and Protalix&#8217;s pharmacovigilance responsibilities for the Licensed Product outside the Territory and the process for exchanging adverse event reports and other safety information relating to a Licensed Product that will permit each party to comply with applicable Laws and requirements of Regulatory Authorities.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_cp_blt_1_438"></a><a name="_cp_text_1_439"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">C</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ommunications with Regulatory Authorities in the Territory</u>.<a name="_DV_M452"></a><a name="_cp_text_1_441"></a> For so long as [***]: </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><a name="_cp_blt_1_448"></a><a name="_cp_text_1_442"></a>Protalix shall provide Pfizer notice of all meetings, conferences, and discussions (including meeting of experts convened by any Regulatory Authority in Israel concerning any topic relevant to the Licensed Product) scheduled with any Regulatory Authority in Israel concerning any regulatory matters relating to the</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">19<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="white-space:pre-wrap;">Licensed Product promptly after the scheduling of such meeting, conference, or discussion (to the extent Protalix is made aware of them in advance).  Pfizer or its designee (or such other applicable sublicensee) shall be entitled to have one or more representatives present at all such meetings unless prohibited by applicable Law or unless reasonably impracticable under the circumstances. Pfizer or its designee (or such other applicable sublicensee) and Protalix shall use all reasonable efforts to agree in advance on the scheduling of such meetings, conferences and discussions and on the objectives to be accomplished at such meetings, conferences and discussions and the agenda for the meetings, conferences and discussions with such Regulatory Authority; </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that [***];</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>Protalix shall provide Pfizer or its designee (or such other applicable sublicensee) with copies, which copies may be in draft form, of all material submissions to any Regulatory Authority in Israel relating to the Licensed Product, to be provided sufficiently in advance of such planned submission to such Regulatory Authority in order to allow Pfizer or its designee (or such other applicable sublicensee) to provide comments regarding such submission, which comments shall be considered by Protalix in good faith with respect to such submission; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that [***];</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>Protalix shall provide to Pfizer, as soon as reasonably practicable but in no event more than three (3) Business Days after its receipt, copies of any material documents or other material correspondence received from any Regulatory Authority pertaining to the Licensed Product; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font>Protalix shall reasonably cooperate with Pfizer or its designee regarding (1) filings and communications with any Regulatory Authority, (2) patient advocacy and support, and (3) pharmacovigilance activities, in each case, in Israel with respect to the Drug Substance or the Licensed Product; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="white-space:pre-wrap;"> that [***].  For purposes of clarification, Protalix is not obligated to pursue additional indications and/or submissions in Israel other than required modifications due to those related to safety under the current, Protalix marketing authorization. </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(j)</font><a name="_cp_blt_1_454"></a><a name="_Ref244602582"></a><a name="_cp_text_1_455"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Communications with Regulatory Authorities Outside the Territory</u><font style="white-space:pre-wrap;">.  Until any marketing authorization application for Licensed Product submitted by Protalix or its designee Fiocruz (or such other applicable sublicensee) is approved by the National Sanitary Surveillance Agency of the Brazilian Government (or any successor or replacement agency that has the authority to grant the necessary Regulatory Approvals) and any other required Regulatory Approval is obtained by Protalix or its designee Fiocruz (or such other applicable sublicensee), and with respect to any Pfizer or Pfizer Affiliate Regulatory Approvals and regulatory filings (including marketing authorizations) in Brazil and related data:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>Pfizer shall provide Protalix notice of all meetings, conferences, and discussions (including meeting of experts convened by any Regulatory Authority in Brazil concerning any topic relevant to the Licensed Product) scheduled with any Regulatory Authority in Brazil concerning any regulatory matters relating to the Licensed</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">20<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="white-space:pre-wrap;">Product promptly after the scheduling of such meeting, conference, or discussion (to the extent Pfizer is made aware of them in advance).  Protalix or its designee Fiocruz (or such other applicable sublicensee) shall be entitled to have one or more representatives present at all such meetings unless prohibited by applicable Law or unless reasonably impracticable under the circumstances. Protalix or its designee Fiocruz (or such other applicable sublicensee) and Pfizer shall use all reasonable efforts to agree in advance on the scheduling of such meetings, conferences and discussions and on the objectives to be accomplished at such meetings, conferences and discussions and the agenda for the meetings, conferences and discussions with such Regulatory Authority; </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that [***];</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>Pfizer shall provide Protalix or its designee Fiocruz (or such other applicable sublicensee) with copies, which copies may be in draft form, of all material submissions to any Regulatory Authority in Brazil relating to the Licensed Product, to be provided sufficiently in advance of such planned submission to such Regulatory Authority in order to allow Protalix or its designee Fiocruz (or such other applicable sublicensee) to provide comments regarding such submission, which comments shall be considered by Pfizer in good faith with respect to such submission; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that [***]; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>Pfizer and Protalix (or Protalix&#8217;s designee Fiocruz (or such other applicable sublicensee)) shall provide to the other, as soon as reasonably practicable but in no event more than three (3) Business Days after its receipt, copies of any material documents or other material correspondence received from any Regulatory Authority in Brazil; and </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font>Pfizer shall reasonably cooperate with Protalix and its Affiliates or its designee Fiocruz (or such other applicable sublicensee) regarding (1) filings and communications with any Regulatory Authority, (2) patient advocacy and support, and (3) pharmacovigilance activities, in each case, in Brazil with respect to the Drug Substance or the Licensed Product; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="white-space:pre-wrap;"> that [***].  For purposes of clarification, Pfizer is not obligated to pursue additional indications and/or submissions in Brazil other than required modifications due to those related to safety under the current, Pfizer marketing authorization.</font><b style="font-weight:bold;"> </b></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(k)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">[Reserved]</u><font style="white-space:pre-wrap;">.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(l)</font><a name="_cp_blt_1_457"></a><a name="_cp_blt_2_456"></a><a name="_Ref431828239"></a><a name="_Ref244628235"></a><a name="_Ref428262953"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Recalls or Other Corrective Action</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="white-space:pre-wrap;">Pfizer shall promptly notify Protalix of any material actions to be taken by Pfizer in the Territory with respect to any recall or market withdrawal or other corrective action related to the Licensed Product prior to such action, if reasonably practicable under the circumstances, to permit Protalix a reasonable opportunity to consult with Pfizer with respect thereto.  </font>[***]</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">21<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>Protalix shall promptly notify Pfizer of any material actions to be taken by Protalix outside the Territory with respect to any recall or market withdrawal or other corrective action related to the Licensed Product prior to such action, if reasonably practicable under the circumstances, to permit Pfizer a reasonable opportunity to consult with Protalix with respect thereto. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.2</font><a name="_Toc428737002"></a><a name="_Toc428737350"></a><a name="_Toc428738043"></a><a name="_Toc428739903"></a><a name="_Toc431831938"></a><a name="_Toc431832271"></a><a name="_Toc434628850"></a><a name="_Ref245354767"></a><a name="_Toc428736657"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Commercialization and Pricing</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref431235579"></a><font style="white-space:pre-wrap;">Pfizer shall have the sole authority and exclusive right to Commercialize, and shall be responsible for paying all costs and expenses (except as otherwise expressly set forth in this Agreement) associated with the Commercialization of, the Licensed Product in the Field in the Territory, including marketing, promoting, selling, distributing and [***] for the Licensed Product and obtaining any necessary Price Approvals.  Protalix hereby agrees to refrain from selling Licensed Product outside the Territory to any Person if Protalix has knowledge or reason to believe that such Licensed Product is intended for transshipment or delivery by such Person in the Territory.  Pfizer hereby agrees to refrain from selling the Licensed Product in the Territory to any Person if Pfizer has knowledge or reason to believe that such Licensed Product is intended for transshipment or delivery by such Person outside the Territory.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref429753967"></a><a name="_Ref431301526"></a>Notwithstanding anything to the contrary in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.2(a)</u>, Protalix shall continue to Commercialize the Licensed Product in the Field in Israel following the Second Amendment Effective Date until such time that Pfizer has received the necessary Regulatory Approvals for Pfizer to commence Commercialization of the Licensed Product in the Field in Israel, but in no event extending longer than [***] after the Second Amendment Effective Date (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Israel Transition Period</u>&#8221;), and during the Israel Transition Period, (i) Protalix shall not materially alter its usual activities and practices with respect to inventory levels (including samples) of the Licensed Product maintained at the wholesale, pharmacy or institutional levels in Israel, without the consent of the Transition Team, (ii) Protalix shall not take any non-routine action that deviates from the ordinary course of business with respect to the Commercialization of the Licensed Product in the Field in Israel without consulting with the Transition Team, and (iii) Protalix shall inform the Transition Team of any allegations, inquiries, or investigations of violations of Protalix&#8217;s policies or Laws related to commercialization of the Licensed Product in Israel.<font style="white-space:pre-wrap;">  Pfizer shall provide Protalix written notice immediately upon becoming aware that Pfizer has received the necessary Regulatory Approvals for Pfizer to commence Commercialization of the Licensed Product in the Field in Israel.  Pfizer shall consider in good faith whether to continue to participate in any [***] at the end of the Israel Transition Period.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref429753988"></a><font style="white-space:pre-wrap;">Following the Second Amendment Effective Date, Pfizer shall purchase all remaining finished goods inventories of Licensed Product relating to Israel [***].  Such shipment shall be accompanied by a Manufacturing Certificate of Analysis and shall be subject to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.10(a)</u> through <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(d)</u><font style="white-space:pre-wrap;">, and such invoice shall be payable to Protalix within forty-five (45) days of receipt of the invoice.  Any disputes with respect to such invoice shall be escalated to the Transition Team for resolution.  If the Transition Team is unable to resolve such dispute, then such dispute shall be escalated to the Supply Chain Committee to resolve pursuant to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.1</u>.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">22<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.3</font><a name="_Toc431831939"></a><a name="_Toc431832272"></a><a name="_Toc434628851"></a><a name="_Ref431550521"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Trademarks</u><font style="white-space:pre-wrap;">.  Protalix hereby grants to Pfizer a license to use any trademarks (including Protalix&#8217;s name or trade names) Controlled by Protalix solely for the purposes of selling, and solely to the extent reasonably necessary to sell, the Inventories in Israel pursuant to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.2(c)</u>, subject to quality control provisions substantially equivalent to those set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.4(d)</u>, which shall apply mutatis mutandis hereto.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.4</font><a name="_Toc428737003"></a><a name="_Toc428737351"></a><a name="_Toc428738044"></a><a name="_Toc428739904"></a><a name="_Toc431831940"></a><a name="_Toc431832273"></a><a name="_Toc434628852"></a><a name="_Ref245477468"></a><a name="_Ref245798467"></a><a name="_Ref246644581"></a><a name="_Ref246644972"></a><a name="_Ref246645151"></a><a name="_Toc428736658"></a><a name="_Ref244605767"></a><a name="_Ref244627748"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pfizer Trademarks</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment</u><font style="white-space:pre-wrap;">.  The parties acknowledge that Protalix transferred and assigned to Pfizer all of its worldwide rights, title and interest to the Uplyso Trademarks, including any goodwill associated with such Uplyso Trademarks.  Pfizer shall be responsible for paying all costs and expenses associated with recording the trademark assignment instrument with the appropriate governmental authorities throughout the world.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref429828749"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Choice of Trademarks</u><font style="white-space:pre-wrap;">.  Pfizer may choose, in its sole discretion, to use the Uplyso Trademarks or any other trademarks to Commercialize the Licensed Product in the Field in the Territory and Pfizer shall own all such trademarks (collectively, the &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Product Marks</u>&#8221;).<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref431301868"></a><a name="_Ref432163208"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License to Protalix</u><font style="white-space:pre-wrap;">.  Pfizer hereby grants to Protalix an exclusive license, free of charge, to use the Brazil Uplyso Trademark and any other Product Marks required by applicable Laws to be included on the labeling and packaging of the finished packaged product outside the Territory solely in connection with the packaging, sale, marketing, promotion, advertising, disposition and distribution of the Licensed Product in the Field outside the Territory.</font><a name="OLE_LINK52"></a><a name="OLE_LINK53"></a><font style="white-space:pre-wrap;">  Pfizer acknowledges and agrees that Protalix is permitted to sublicense to Fiocruz (or any other sublicensee of Protalix in Brazil) the Brazil Uplyso Trademark and any other Product Marks required by applicable Laws to be included on the labeling and packaging of the finished packaged product outside the Territory as set forth in </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.6(c)</u>.<font style="white-space:pre-wrap;">  For the avoidance of doubt, the rights granted pursuant to this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.4(c)</u> do not include grants to use the name or trade name of Pfizer (other than to the extent such right is granted to Protalix pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.5</u> or required to be made pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.4(d)(iv)(B)</u><font style="white-space:pre-wrap;">).  Any such right to use such name or trade name shall be governed by </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.5</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref429829007"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quality Control</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>The quality of the Licensed Product sold by Protalix outside the Territory under or in connection with the Brazil Uplyso Trademark (and any Product Marks licensed to Protalix pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.6(c)</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u>and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.4(c)</u>) must be of a sufficiently high quality to be generally comparable to the quality of the Licensed Product sold by Pfizer in the Territory under or in connection with the Product Marks.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>Protalix shall comply with all applicable Laws pertaining to the proper use and designation of the Brazil Uplyso Trademark (and any Product Marks licensed to Protalix pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.6(c)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.4(c)</u>).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>Protalix agrees to use the Brazil Uplyso Trademark (and any Product Marks licensed to Protalix pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.6(c)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.4(c)</u>) only in the form and manner and with appropriate legends as prescribed from time to time by Pfizer.&#160;</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">23<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font>Additionally, Protalix shall:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(A)</font>display the proper form of trademark notice associated with the Brazil Uplyso Trademark (and any Product Marks licensed to Protalix pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.6(c)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.4(c)</u>);</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(B)</font><a name="_Ref432012724"></a>on any item which bears the Brazil Uplyso Trademark (and any Product Marks licensed to Protalix pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.6(c)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.4(c)</u>), include where practicable a statement identifying Pfizer or its Affiliate, as applicable, as the owner of the Brazil Uplyso Trademark or Product Mark and where possible indicating that Protalix or its Affiliate, as applicable, is an authorized user of the Brazil Uplyso Trademark or Product Mark;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(C)</font>not use any Product Mark as a corporate name, business name, or trade name; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(D)</font>not use any Product Mark in a manner that would reasonably be expected to materially impair the validity, reputation, or distinctiveness of any Product Mark; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(E)</font>not use any Product Mark in a manner that would reasonably be expected to materially impair the reputation of Pfizer or any of its Affiliates.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref244605786"></a><a name="_Ref245477454"></a><a name="_Ref246644586"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Prosecution and Maintenance of Product Marks</u><font style="white-space:pre-wrap;">.  </font><a name="_Ref246645386"></a><font style="white-space:pre-wrap;">Pfizer shall have the sole right, but not the obligation, through counsel of its choosing, to prosecute and maintain the Product Marks in the Territory and the first right, but not the obligation, through counsel of its choosing, to prosecute and maintain the Product Marks outside the Territory.  In the event Pfizer elects not to prosecute or maintain the Brazil Uplyso Trademark outside the Territory, Pfizer shall provide reasonable prior written notice to Protalix of its intention not to prosecute or maintain any such Product Mark outside the Territory, and Protalix shall have the right to prosecute or maintain the Brazil Uplyso Trademark on behalf of Pfizer.  All costs and expenses incurred by Pfizer in the filing, prosecution and maintenance of Product Marks in the Territory shall be [***].</font><font style="white-space:pre-wrap;">  All costs and expenses incurred by either party in the filing, prosecution and maintenance of Product Marks (in the case of Pfizer) or the Brazil Uplyso Trademark outside the Territory as provided in this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.4</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(e)</u> shall be [***].<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(f)</font><a name="_Ref246645154"></a><a name="_Ref244605806"></a><a name="_Ref246644974"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Enforcement of Product Marks</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><a name="_Ref246645155"></a><font style="white-space:pre-wrap;">Pfizer will promptly notify Protalix in the event of any actual, potential or suspected infringement of the Brazil Uplyso Trademark by any Third Party and Protalix will promptly notify Pfizer in the event of any actual, potential or suspected infringement of the Brazil Uplyso Trademark or a Product Mark by any Third Party.  Pfizer shall have the sole right, but not the obligation, to institute litigation or take other remedial measures in connection with Third Party infringement of Product Marks in the Territory and the first right, but not the obligation, to institute litigation or take other</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">24<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="white-space:pre-wrap;">remedial measures in connection with Third Party infringement of Product Marks outside the Territory.  If Pfizer fails to initiate litigation or take other remedial measures against a Third Party who is infringing the Brazil Uplyso Trademark outside the Territory within ninety (90) days after becoming aware of the basis for such litigation or action, then Protalix may, in its discretion, provide Pfizer with written notice of Protalix&#8217;s intent to initiate a suit or take other appropriate action.  If Protalix provides such notice and Pfizer fails to initiate litigation or take such other appropriate action within thirty (30) days after receipt of such notice from Protalix, then Protalix shall have the right to initiate litigation or take other appropriate action that it believes is reasonably required to protect its right to use the Brazil Uplyso Trademark outside the Territory.  Upon request of Protalix, Pfizer agrees to timely join as party-plaintiff in any such litigation, and in any event to cooperate with Protalix in connection with such infringement action.  All costs and expenses incurred by Pfizer in enforcing the Product Marks in the Territory shall be borne by Pfizer and any recoveries resulting from such litigation or other appropriate action, in pursuing such litigation or other appropriate action, shall be retained by Pfizer.  All costs and expenses incurred by Protalix in enforcing the Brazil Uplyso Trademark outside the Territory shall be [***] and Protalix shall reimburse Pfizer for any and all costs or expenses incurred by Pfizer in connection with such enforcement by Protalix outside the Territory.  Protalix shall retain all recoveries received by Protalix as a result of its enforcement of the Brazil Uplyso Trademark outside the Territory.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.5</font><a name="_cp_blt_2_470"></a><a name="_Toc428737004"></a><a name="_Toc428737352"></a><a name="_Toc428738045"></a><a name="_Toc428739905"></a><a name="_Toc431831941"></a><a name="_Toc431832274"></a><a name="_Toc434628853"></a><a name="_Ref245479369"></a><a name="_Toc428736659"></a><a name="_Ref431296212"></a><a name="_Ref431550385"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Names</u>.<font style="white-space:pre-wrap;">  </font><a name="_Ref246645841"></a><a name="_Ref245479372"></a><font style="white-space:pre-wrap;">No right, expressed or implied, is granted by this Agreement to a party to use in any manner the name or any other trade name of the other party or its Affiliates in connection with this Agreement.  Notwithstanding the foregoing, </font><a name="_Ref246645845"></a><a name="_Ref429830092"></a><font style="white-space:pre-wrap;">Protalix shall have the right to use the Pfizer corporate name, subject to Pfizer&#8217;s trademark usage guidelines provided to Protalix from time to time, including at least sixty (60) days prior to the date of Protalix&#8217;s first use of the Pfizer corporate name, on package inserts, packaging or trade packaging associated with the Licensed Product outside the Territory solely as required by applicable Laws outside the Territory.  Protalix will submit for Pfizer&#8217;s approval (which approval shall not be unreasonably withheld or delayed) a sample of each such proposed use of the Pfizer corporate name within sixty (60) days before the first use permitted pursuant to this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.5</u>.  Notwithstanding anything to the contrary in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.5</u>, Pfizer shall have the right to use the name of Protalix or its Affiliates or any other trade name of Protalix pursuant to and in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.3</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.6</font><a name="_cp_blt_1_475"></a><a name="_Toc428737005"></a><a name="_Toc428737353"></a><a name="_Toc428738046"></a><a name="_Toc428739906"></a><a name="_Toc431831942"></a><a name="_Toc431832275"></a><a name="_Toc434628854"></a><a name="_cp_text_1_473"></a><a name="_Toc428736660"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">A</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ccess to Information</u><font style="white-space:pre-wrap;">.  At Pfizer&#8217;s reasonable request during the Term, Protalix shall provide Pfizer, its designated Affiliate or its agents and representatives with reasonable access [***], during regular business hours to (a) information concerning the Drug Substance, Licensed Product, Protalix Patent Rights and/or Protalix Technology that may be reasonably necessary for Pfizer to seek Regulatory Approval for Licensed Product, Manufacture (including performing Fill/Finish activities on) the Drug Substance or the Licensed Product or Commercialize the Licensed Product, in each case, in the Field in the Territory and (b) </font><a name="_Ref244626933"></a>Protalix-designated employees who possess the information described in clause (a) of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section</u><a name="_cp_field_47_474"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.6</u><a name="_cp_text_1_476"></a>, in each case, solely for the purpose of enabling Pfizer to exercise the licenses granted to Pfizer</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">25<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">hereunder.  </font><a name="_cp_blt_1_481"></a><a name="_cp_blt_2_480"></a><a name="OLE_LINK49"></a>Such requested cooperation and assistance shall be provided at no cost to Pfizer, except that [***] </p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.7</font><a name="_Toc428737007"></a><a name="_Toc428737355"></a><a name="_Toc428738048"></a><a name="_Toc428739908"></a><a name="_Toc431831943"></a><a name="_Toc431832276"></a><a name="_Toc434628855"></a><a name="_Toc428736662"></a><a name="_cp_text_1_483"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Assistance</u><font style="white-space:pre-wrap;">.  During the Transition Period, each party shall use Commercially Reasonable Efforts to cooperate with the other party and to take such reasonable actions to assist the other party, as</font><font style="text-decoration-line:none;"> the other party may reasonably request, (i) to ensure the smooth transition of the Commercialization of the Drug Substance or Licensed Product from Protalix to Pfizer (or a Third Party designated by Pfizer) in Israel and from Pfizer to Protalix (or a Third Party designated by Protalix) in Brazil, and (ii) to ensure the continuity of patient care in Brazil and Israel. Except as set forth in this Agreement, the parties shall no longer have any obligations under the Agreement to Commercialize or Develop the Licensed Product, conduct any pre-clinical or clinical studies or participate in any committees with the other party other than the Supply Chain Committee and the Transition Team</font>.<font style="white-space:pre-wrap;">    </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref428304239"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Team</u><font style="white-space:pre-wrap;">.  Within five (5) days following the Second Amendment Effective Date, Pfizer and Protalix shall each appoint a person (each a &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Manager</u>&#8221; and together, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Team</u>&#8221;)<font style="letter-spacing:2.45pt;"> </font>to<font style="letter-spacing:2.35pt;"> </font>facilitate a<font style="letter-spacing:-0.1pt;"> </font>smooth transition of the Commercialization of the Drug Substance or Licensed Product from Protalix to Pfizer (or a Third Party designated by Pfizer) in Israel and from Pfizer to Protalix (or a Third Party designated by Protalix) in Brazil, and to implement<font style="letter-spacing:0.05pt;"> </font>the<font style="letter-spacing:-0.1pt;"> </font><font style="white-space:pre-wrap;">Transition Plan (as defined below).  Each party shall</font><font style="letter-spacing:2.45pt;"> </font>notify<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.75pt;"> </font>other<font style="letter-spacing:0.75pt;"> </font>party<font style="letter-spacing:0.6pt;"> </font>in<font style="letter-spacing:0.7pt;"> </font>writing<font style="letter-spacing:0.6pt;"> </font>of<font style="letter-spacing:0.75pt;"> </font>the<font style="letter-spacing:0.6pt;"> </font>identity<font style="letter-spacing:0.6pt;"> </font>and<font style="letter-spacing:0.7pt;"> </font>contact<font style="letter-spacing:0.75pt;"> </font>information<font style="letter-spacing:0.7pt;"> </font>for<font style="letter-spacing:0.75pt;"> </font>their<font style="letter-spacing:2.15pt;"> </font>respective<font style="letter-spacing:1.45pt;"> </font>Transition<font style="letter-spacing:1.4pt;"> </font>Manager,<font style="letter-spacing:1.4pt;"> </font>which<font style="letter-spacing:1.45pt;"> </font>shall<font style="letter-spacing:1.45pt;"> </font>be<font style="letter-spacing:1.3pt;"> </font>the<font style="letter-spacing:1.45pt;"> </font>primary<font style="letter-spacing:1.3pt;"> </font>contact<font style="letter-spacing:1.8pt;"> </font>for<font style="letter-spacing:1.45pt;"> </font>each<font style="letter-spacing:1.45pt;"> </font>party<font style="letter-spacing:1.3pt;"> </font>with<font style="letter-spacing:2.05pt;"> </font>respect<font style="letter-spacing:1pt;"> </font>to<font style="letter-spacing:0.95pt;"> </font>the<font style="letter-spacing:0.95pt;"> </font>transition<font style="letter-spacing:0.95pt;"> </font>and<font style="letter-spacing:1.05pt;"> </font>the<font style="letter-spacing:0.95pt;"> </font>Transition<font style="letter-spacing:1.05pt;"> </font>Plan<font style="letter-spacing:1.05pt;"> </font>and<font style="letter-spacing:0.95pt;"> </font>all<font style="letter-spacing:1pt;"> </font>activities<font style="letter-spacing:0.95pt;"> </font><font style="white-space:pre-wrap;">thereunder.  For [***] following the Second Amendment Effective Date</font><font style="letter-spacing:2.4pt;"> </font>(the<font style="letter-spacing:2.25pt;"> </font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition</u><u style="letter-spacing:2.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Period</u>&#8221;),<font style="letter-spacing:2.25pt;"> </font>the<font style="letter-spacing:2.55pt;"> </font>Transition<font style="letter-spacing:0.55pt;"> </font>Managers<font style="letter-spacing:0.7pt;"> </font>shall<font style="letter-spacing:0.6pt;"> </font>meet<font style="letter-spacing:0.75pt;"> </font>(in<font style="letter-spacing:0.7pt;"> </font>person,<font style="letter-spacing:0.75pt;"> </font>by<font style="letter-spacing:0.55pt;"> </font>teleconference,<font style="letter-spacing:1pt;"> </font>video-conference<font style="letter-spacing:0.6pt;"> </font>or<font style="letter-spacing:0.75pt;"> </font>other<font style="letter-spacing:2.65pt;"> </font>reasonable<font style="letter-spacing:0.7pt;"> </font>means,<font style="letter-spacing:0.6pt;"> </font>in<font style="letter-spacing:0.7pt;"> </font>each<font style="letter-spacing:0.55pt;"> </font>case<font style="letter-spacing:0.6pt;"> </font>as<font style="letter-spacing:0.7pt;"> </font>mutually<font style="letter-spacing:0.55pt;"> </font>agreed<font style="letter-spacing:0.7pt;"> </font>upon<font style="letter-spacing:0.7pt;"> </font>by<font style="letter-spacing:0.55pt;"> </font>the<font style="letter-spacing:0.6pt;"> </font>Transition<font style="letter-spacing:0.55pt;"> </font>Managers)<font style="letter-spacing:0.75pt;"> </font>as<font style="letter-spacing:2.25pt;"> </font>reasonably<font style="letter-spacing:1.65pt;"> </font>necessary, but not less frequently than a weekly basis, as mutually agreed upon by the Transition<font style="letter-spacing:0.55pt;"> </font>Managers<font style="letter-spacing:0.6pt;"> </font>to<font style="letter-spacing:0.7pt;"> </font>facilitate<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.7pt;"> </font>implementation<font style="letter-spacing:0.55pt;"> </font>of<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.45pt;"> </font>Transition<font style="letter-spacing:0.7pt;"> </font>Plan.<font style="letter-spacing:2.45pt;"> </font><font style="letter-spacing:-0.1pt;">In</font><font style="letter-spacing:1.4pt;"> </font>the<font style="letter-spacing:1.3pt;"> </font>event<font style="letter-spacing:1.35pt;"> </font>that<font style="letter-spacing:1.35pt;"> </font>the<font style="letter-spacing:1.2pt;"> </font>Transition<font style="letter-spacing:1.3pt;"> </font>Plan<font style="letter-spacing:1.3pt;"> </font>has<font style="letter-spacing:1.35pt;"> </font>not<font style="letter-spacing:1.35pt;"> </font>been<font style="letter-spacing:1.3pt;"> </font>implemented<font style="letter-spacing:1.3pt;"> </font>within [***] following the Second Amendment Effective Date,<font style="letter-spacing:1.3pt;"> </font>the<font style="letter-spacing:1.95pt;"> </font>parties<font style="letter-spacing:0.75pt;"> </font>shall<font style="letter-spacing:0.85pt;"> </font>mutually<font style="letter-spacing:0.7pt;"> </font>agree<font style="letter-spacing:0.85pt;"> in good faith </font>on<font style="letter-spacing:0.7pt;"> </font>a<font style="letter-spacing:0.85pt;"> </font>new<font style="letter-spacing:0.65pt;"> </font>Transition<font style="letter-spacing:0.7pt;"> </font>Period, and<font style="letter-spacing:0.8pt;"> </font>following<font style="letter-spacing:0.7pt;"> </font>such<font style="letter-spacing:0.85pt;"> </font><font style="letter-spacing:-0.1pt;">agreement</font><font style="letter-spacing:0.85pt;"> </font>the<font style="letter-spacing:2.35pt;"> </font>term<font style="letter-spacing:0.85pt;"> </font>Transition<font style="letter-spacing:1.05pt;"> </font>Period<font style="letter-spacing:1.05pt;"> </font>shall<font style="letter-spacing:1pt;"> </font>refer<font style="letter-spacing:1pt;"> </font>to<font style="letter-spacing:1.05pt;"> </font>such<font style="letter-spacing:1.05pt;"> </font>new<font style="letter-spacing:1pt;"> </font>period<font style="letter-spacing:0.95pt;"> </font>as<font style="letter-spacing:1.1pt;"> </font>so<font style="letter-spacing:0.95pt;"> </font>agreed<font style="letter-spacing:1.05pt;"> </font>upon<font style="letter-spacing:1.05pt;"> </font>by<font style="letter-spacing:0.95pt;"> </font>the<font style="letter-spacing:0.95pt;"> </font>parties. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref428304284"></a><u style="letter-spacing:-0.1pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition Plan</u><font style="letter-spacing:-0.1pt;white-space:pre-wrap;">.  In</font><font style="letter-spacing:0.6pt;"> </font>connection<font style="letter-spacing:0.6pt;"> </font>with<font style="letter-spacing:0.45pt;"> </font>the<font style="letter-spacing:0.5pt;"> </font>transition of Israel and Brazil,<font style="letter-spacing:0.5pt;"> </font>during<font style="letter-spacing:0.45pt;"> </font><font style="letter-spacing:-0.1pt;">the</font><font style="letter-spacing:2.45pt;"> </font>Transition<font style="letter-spacing:0.35pt;"> </font>Period,<font style="letter-spacing:0.35pt;"> </font>the<font style="letter-spacing:0.35pt;"> p</font>arties<font style="letter-spacing:0.35pt;"> </font>shall<font style="letter-spacing:0.4pt;"> </font>use<font style="letter-spacing:0.35pt;"> </font>Commercially<font style="letter-spacing:0.2pt;"> </font>Reasonable<font style="letter-spacing:0.35pt;"> </font>Efforts<font style="letter-spacing:0.35pt;"> </font>to<font style="letter-spacing:0.35pt;"> </font>accomplish<font style="letter-spacing:0.35pt;"> </font>all<font style="letter-spacing:2.05pt;"> </font>of<font style="letter-spacing:0.6pt;"> </font>the<font style="letter-spacing:0.6pt;"> </font>transition<font style="letter-spacing:0.55pt;"> </font>activities<font style="letter-spacing:0.5pt;"> </font>described<font style="letter-spacing:0.6pt;"> </font>in<font style="letter-spacing:0.8pt;"> </font><u style="text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">Exhibit</u><u style="letter-spacing:0.6pt;text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#231f20;text-decoration-line:underline;text-decoration-style:solid;">F</u> to effect<font style="letter-spacing:0.6pt;"> </font>a<font style="letter-spacing:1.85pt;"> </font>reasonably<font style="letter-spacing:1.8pt;"> </font>smooth<font style="letter-spacing:1.9pt;"> </font>and<font style="letter-spacing:1.9pt;"> </font>orderly<font style="letter-spacing:1.8pt;"> </font>transition<font style="letter-spacing:1.9pt;"> </font><font style="letter-spacing:-0.1pt;">(the</font><font style="letter-spacing:2.95pt;"> </font>&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Transition</u><u style="letter-spacing:1.3pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Plan</u>&#8221;).<font style="letter-spacing:1.3pt;"> </font>Pfizer and Protalix will commence delivery of the items specified in the Transition Plan as soon as reasonably practicable and shall use Commercially Reasonable Efforts to meet the timelines specified in the Transition Plan. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">4.8</font><a name="_Toc431831944"></a><a name="_Toc431832277"></a><a name="_Toc434628856"></a><a name="_Ref431469019"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Records</u><font style="white-space:pre-wrap;">.  Each party will maintain accurate records and books relating to its activities in relation to the Development of the Drug Substance and the Licensed Product, including any activities conducted under the Development plans between the parties</font><a name="_cp_blt_2_489"></a><a name="_cp_blt_2_491"></a> pursuant to the Amended Agreement.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">26<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 5.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_cp_blt_1_493"></a><a name="_Ref244605874"></a><a name="_Ref244605934"></a><a name="_Ref244606135"></a><a name="_Ref244607613"></a><a name="_Ref244608759"></a><a name="_Ref244629913"></a><a name="_Ref244658877"></a><a name="_Ref245389505"></a><a name="_Ref245801132"></a><a name="_Ref246500572"></a><a name="_Toc428350785"></a><a name="_Toc428351590"></a><a name="_Toc428409544"></a><a name="_Toc428410102"></a><a name="_Toc428410156"></a><a name="_Toc428410253"></a><a name="_Ref428540994"></a><a name="_Ref428731305"></a><a name="_Toc428736352"></a><a name="_Toc428736663"></a><a name="_Toc428737008"></a><a name="_Toc428737356"></a><a name="_Toc428738049"></a><a name="_Toc428739909"></a><a name="_Toc431831945"></a><a name="_Toc434628857"></a><a name="_cp_text_1_494"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">M</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">ANUFACTURE AND SUPPLY</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">.</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:none;text-transform:uppercase;white-space:pre-wrap;">  </b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.1</font><a name="_cp_blt_1_495"></a><a name="_Toc428737009"></a><a name="_Toc428737357"></a><a name="_Toc428738050"></a><a name="_Toc428739910"></a><a name="_Toc431831946"></a><a name="_Toc431832278"></a><a name="_Toc434628858"></a><a name="_Ref245826034"></a><a name="_Toc428736664"></a><a name="_cp_text_1_496"></a><a name="_Ref245637229"></a><a name="_Ref244605902"></a><a name="_Ref244606165"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">S</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">upply Chain Committee</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_cp_blt_1_497"></a><a name="_Ref429870062"></a><a name="_cp_text_1_498"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">F</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ormation and Membership</u><font style="white-space:pre-wrap;">.  The parties shall continue to maintain a Supply Chain Committee (the &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supply Chain Committee</u><font style="white-space:pre-wrap;">&#8221;) during the Supply Term.  The Supply Chain Committee shall consist of representatives appointed by each party.  The Supply Chain Committee will provide a forum for the discussion of matters related to the Manufacture of and supply chain for the Drug Substance and Licensed Product.</font> <a name="_cp_blt_1_499"></a><a name="_cp_text_1_500"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref429870071"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">M</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">eetings</u><font style="white-space:pre-wrap;">.  During the Supply Term, the Supply Chain Committee shall meet monthly or as otherwise determined by the parties (each such meeting, a &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supply Chain Committee Meeting</u><font style="white-space:pre-wrap;">&#8221;).  Upon the request of the Supply Chain Committee, each party will provide written materials relating to its Manufacturing and related activities in advance of a Supply Chain Committee Meeting.  All Supply Chain Committee Meetings may be conducted in person, by videoconference or by teleconference at such times and such Pfizer or Protalix locations as shall be determined by the Supply Chain Committee.  In-person meetings of the Supply Chain Committee will alternate between appropriate offices of each party.  The parties shall each bear all expenses of their respective representatives relating to their participation on the Supply Chain Committee.  The members of the Supply Chain Committee also may convene or be polled or consulted from time to time by means of telecommunications, video conferences, electronic mail or correspondence, as deemed necessary or appropriate.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_cp_blt_1_501"></a><a name="_cp_text_1_502"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">R</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">esponsibilities</u><font style="white-space:pre-wrap;">.  The Supply Chain Committee will have the following roles and responsibilities:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><a name="_cp_blt_1_505"></a><a name="_cp_text_1_503"></a>Discuss each party&#8217;s requirements for Drug Substance and Licensed Product for Development activities in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section</u><a name="_cp_field_47_504"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.3</u><a name="_cp_text_1_506"></a>;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><a name="_cp_blt_1_509"></a><a name="_cp_text_1_507"></a>Act as a forum pursuant to which the parties may discuss Manufacturing issues<a name="_cp_text_1_510"></a>, and any issues that may affect patient access to the Licensed Product in the Territory;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><a name="_cp_blt_1_515"></a><a name="_cp_text_1_516"></a>Be informed of requests for and results of regulatory inspections related to Drug Substance and Licensed Product and review steps to be taken by Protalix to address any deficiencies noted; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font><a name="_cp_blt_1_517"></a><a name="_cp_text_1_518"></a>Monitor logistical strategies, Protalix&#8217;s capacity for Manufacturing Drug Substance and inventory levels for Drug Substance and Licensed Product for consistency with the Forecasts and Long Range Forecasts and address any Failure to Supply and Persistent Failure to Supply;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font><a name="_cp_blt_1_519"></a><a name="_cp_text_1_520"></a>Be informed of and discuss proposed changes in Manufacturing sites, testing sites, and responsibilities in the supply chain for Drug Substance and Licensed Product; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(vi)</font><a name="_cp_blt_1_521"></a><a name="_cp_text_1_522"></a>Be informed of and address any quality-related issues concerning the Drug Substance and Licensed Product including non-conformance; </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">27<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(vii)</font><a name="_cp_blt_1_523"></a><a name="_cp_text_1_524"></a>Provide updates on the Supply Chain Committee&#8217;s activities and achievements to the parties, as applicable, no less frequently than once each quarter after the Second Amendment Effective Date; and </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(viii)</font><a name="_cp_blt_1_525"></a><a name="_cp_text_1_526"></a>Such other roles and responsibilities provided<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u>for in this Agreement or as may be assigned to the Supply Chain Committee in writing by mutual agreement of the parties.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_cp_blt_1_530"></a><a name="_cp_text_1_527"></a><a name="OLE_LINK90"></a><a name="OLE_LINK91"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">D</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ecision-Making</u><font style="white-space:pre-wrap;">.  Except for a decision to create a Technical Subcommittee as described in </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section</u><a name="_cp_field_47_528"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.1</u><a name="_cp_field_47_529"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(e)</u><a name="_cp_text_1_531"></a>, the Supply Chain Committee will have no decision-making authority, but instead will act in an advisory capacity to the parties, unless otherwise agreed by the parties in writing. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_cp_blt_1_532"></a><a name="_Ref245826037"></a><a name="_Ref429851521"></a><a name="_cp_text_1_533"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">T</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">echnical Subcommittee</u><font style="white-space:pre-wrap;">.  The Supply Chain Committee may, from time to time, create a subcommittee (a &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technical Subcommittee</u><font style="white-space:pre-wrap;">&#8221;) to advise the Supply Chain Committee and the parties on and analyze any technical issues relating to Manufacturing Drug Substance or Licensed Product, including issues relating to quality or process, identified by either party or by the Supply Chain Committee.  Any Technical Subcommittee shall consist of representatives from each party with the appropriate technical expertise to analyze and provide advice with respect to any such technical issues, and such representatives may or may not also be representatives on the Supply Chain Committee.  Each Technical Subcommittee will continue to operate until resolution of the identified problem, as determined by the Supply Chain Committee.</font> If the Supply Chain Committee is unable to reach agreement with respect to the issue identified by the Supply Chain Committee, Pfizer&#8217;s Vice President of Global External Supply and Protalix&#8217;s Chief Operating Officer<font style="color:#1f497d;"> </font>will meet promptly to attempt to resolve the dispute by good faith negotiations. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.2</font><a name="_cp_blt_1_534"></a><a name="_Toc428737010"></a><a name="_Toc428737358"></a><a name="_Toc428738051"></a><a name="_Toc428739911"></a><a name="_Toc431831947"></a><a name="_Toc431832279"></a><a name="_Toc434628859"></a><a name="_Ref246394626"></a><a name="_Ref246396392"></a><a name="_Ref246398201"></a><a name="_Ref246425191"></a><a name="_Ref246517669"></a><a name="_Ref246848984"></a><a name="_Toc428736665"></a><a name="_cp_text_1_535"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">C</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">apacity</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref245646420"></a><a name="_Ref429851713"></a><a name="_cp_text_1_537"></a>Protalix shall [***].</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref245637230"></a><a name="_Ref245645809"></a><a name="_cp_text_1_538"></a><a name="_Ref246398202"></a><a name="_Ref432012442"></a><a name="_Ref246394627"></a>[***] Along with such request, Pfizer shall [*** ]If Protalix determines [***] Protalix shall<a name="_cp_text_1_542"></a> [***] Pfizer and Protalix shall agree [***] Pfizer shall [***] Notwithstanding the foregoing, in no case shall Protalix [***] Pfizer shall [***] Protalix shall [***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_cp_blt_1_545"></a><a name="_cp_text_1_543"></a><a name="_Ref246396395"></a>Protalix shall dedicate at least [***] of its Drug Substance Manufacturing capacity in order to Manufacture Drug Substance for Pfizer&#8217;s clinical and commercial use in the Field in the Territory and may dedicate all remaining capacity to Manufacture Drug Substance for Protalix&#8217;s clinical and commercial use in the Field outside the Territory (such allocation between the Territory and outside the Territory, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Allocation Percentage</u><font style="white-space:pre-wrap;">&#8221;).  Subject to the Current Capacity Cap or, after achieving the Increased Capacity Goal, the Increased Capacity Cap (collectively, the &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Capacity Cap</u>&#8221;), subject to the Allocation Percentage, and subject to and in accordance with the terms of this<a name="_cp_field_47_544"></a> <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u> <a name="_cp_text_1_546"></a>and the Quality Agreement, Protalix shall supply all quantities of the Drug Substance ordered by Pfizer under this Agreement for clinical and commercial use in the Field in the Territory.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">28<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_cp_blt_1_547"></a><a name="_cp_text_1_548"></a>In the event either party reasonably believes that capacity for the Manufacture of Drug Substance in excess of the Increased Capacity Cap is necessary to meet projected future clinical and commercial need for Licensed Product in the Territory, the parties shall discuss such matter in good faith, including the funding of any capital expenditures necessary to increase such Manufacturing capacity beyond the Increased Capacity Cap.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.3</font><a name="_Toc428737011"></a><a name="_Toc428737359"></a><a name="_Toc428738052"></a><a name="_Toc428739912"></a><a name="_Toc431831948"></a><a name="_Toc431832280"></a><a name="_Toc434628860"></a><a name="_cp_text_1_549"></a><a name="_Ref244602216"></a><a name="_Ref245733057"></a><a name="_Ref245825574"></a><a name="_Toc428736666"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Development Supply of Drug Substance</u><font style="white-space:pre-wrap;">.  Subject to the Capacity Cap and the Allocation Percentage, Protalix shall Manufacture and supply Pfizer&#8217;s requirements of the Drug Substance for incorporation into Licensed Product for Development activities to be performed by Pfizer in the Field in the Territory, which supply shall be subject to and in accordance with the terms of this</font><a name="_cp_field_47_550"></a> <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u><a name="_cp_text_1_551"></a>.<a name="_cp_text_1_556"></a> <a name="OLE_LINK94"></a><a name="OLE_LINK95"></a> For the avoidance of doubt, in no event shall Protalix be obligated to Manufacture or supply quantities of Drug Substance in excess of the Capacity Cap unless otherwise agreed by the parties.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.4</font><a name="_cp_blt_1_559"></a><a name="_Toc428737012"></a><a name="_Toc428737360"></a><a name="_Toc428738053"></a><a name="_Toc428739913"></a><a name="_Toc431831949"></a><a name="_Toc431832281"></a><a name="_Toc434628861"></a><a name="_cp_text_1_557"></a><a name="_Toc428736667"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">C</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ommercial Supply of Drug Substance</u><font style="white-space:pre-wrap;">.  </font><a name="OLE_LINK60"></a><a name="OLE_LINK69"></a>Subject to the Capacity Cap and the Allocation Percentage, Protalix shall Manufacture and supply Pfizer&#8217;s requirements of the Drug Substance for incorporation into Licensed Product and commercial sale in the Field in the Territory pursuant to this Agreement, which supply shall be subject to and in accordance with the terms of this<a name="_cp_field_47_558"></a> <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u> <a name="_cp_text_1_560"></a><font style="white-space:pre-wrap;">and the Quality Agreement.  For the avoidance of doubt, in no event shall Protalix be obligated to Manufacture or supply quantities of Drug Substance in excess of the Capacity Cap unless otherwise agreed by the parties.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.5</font><a name="_cp_blt_1_562"></a><a name="_cp_blt_2_561"></a><a name="_cp_blt_1_565"></a><a name="_cp_blt_2_564"></a><a name="_Toc431831950"></a><a name="_Toc431832282"></a><a name="_Toc434628862"></a><a name="_Ref429868683"></a><a name="_Ref429826674"></a><a name="_Ref431204814"></a><a name="_Toc428737013"></a><a name="_Toc428737361"></a><a name="_Toc428738054"></a><a name="_Toc428739914"></a><a name="_Ref245651645"></a><a name="_Ref245651673"></a><a name="_Ref245696219"></a><a name="_Ref246409952"></a><a name="_Ref246410886"></a><a name="_Ref246410925"></a><a name="_Ref246414610"></a><a name="_Ref246500841"></a><a name="_Ref246554980"></a><a name="_Ref246555250"></a><a name="_Ref246557114"></a><a name="_Ref246855168"></a><a name="_Toc428736668"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supply Term</u><font style="white-space:pre-wrap;">.  The terms of this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u> shall be effective as of the Second Amendment Effective Date and, unless this Agreement is earlier terminated pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14</u>, shall remain in effect only until terminated in accordance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u> (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supply Term</u>&#8221;).&#160; The initial term for the supply of Drug Substance under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u> shall be for ten (10) years after the Second Amendment Effective Date (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Supply Term</u>&#8221;).&#160; If Protalix determines not to extend the supply of Drug Substance to Pfizer hereunder beyond such Initial Supply Term, Protalix shall have the right to provide written notice of termination of the Supply Term, at least three (3) years prior to the effective date of termination of the Supply Term set forth in such notice (which shall in no event be prior to the end of the Initial Supply Term) (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supply Termination Notice</u>&#8221;); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that notwithstanding the timely issuance of a Supply Termination Notice by Protalix in accordance with the foregoing sentence Pfizer shall have the right to extend the Supply Term for up to two additional periods of thirty (30) months each (each, a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Renewal Supply Term</u>&#8221;) by providing to Protalix a written extension notice at least one (1) year prior to the end of the Initial Supply Term or the first Renewal Supply Term, as applicable (with the first Renewal Supply Term commencing at the end of the Initial Supply Term and the second Renewal Supply Term commencing at the end of the first Renewal Supply Term).&#160; For the avoidance of doubt, (i) in the event Pfizer does not provide a written extension notice at least one (1) year prior to the end of the Initial Supply Term in accordance with the foregoing sentence, the Supply Term shall terminate upon the stated effective date of termination in the Supply Termination Notice, (ii) in the event Pfizer provides a written extension notice for the first Renewal Supply Term in accordance with the foregoing sentence, but does not provide a written extension notice for the second Renewal Supply Term at least one (1) year prior to the end of the first Renewal Supply Term in accordance with the foregoing sentence, the Supply Term shall terminate upon the end of the first Renewal Supply Term, and (iii) in the event Pfizer provides a written extension notice for the first and second Renewal Supply Terms in accordance </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">29<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">with the foregoing sentence, the Supply Term shall terminate fifteen (15) years after the Second Amendment Effective Date. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.6</font><a name="_Toc431831951"></a><a name="_Toc431832283"></a><a name="_Toc434628863"></a><a name="_Ref429830167"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forecasting and Ordering</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref244598063"></a><a name="_Ref245651646"></a><a name="_Ref246409953"></a><a name="_Ref246555251"></a><a name="_Ref247093415"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forecasts; Purchase Orders</u><font style="white-space:pre-wrap;">.  [***], Pfizer shall deliver to Protalix Pfizer&#8217;s quarterly projection of the quantities of Drug Substance that Pfizer anticipates ordering from Protalix pursuant to this Agreement</font><a name="_cp_text_1_568"></a> for the four (4) calendar quarters commencing with the first quarter that includes the first requested delivery date (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Initial Forecast</u>&#8221;), together with a firm purchase order (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Purchase Order</u><font style="white-space:pre-wrap;">&#8221;) for Drug Substance for the first calendar quarter covered by such Initial Forecast.  The quantities of Drug Substance specified for the following quarter of such Initial Forecast shall be binding as provided in this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.6</u><font style="white-space:pre-wrap;"> and the remaining two (2) quarters of such Initial Forecast shall be non-binding.  Thereafter, ninety (90) days prior to the first business day of each subsequent calendar quarter during the Term, Pfizer shall deliver to Protalix a rolling four (4) calendar quarter forecast updating the prior forecast (together with the Initial Forecast, each a &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Forecast</u><font style="white-space:pre-wrap;">&#8221;), together with a Purchase Order for the first calendar quarter of such Forecast.  The quantities of Drug Substance specified for the following quarter of such Forecast shall be binding as provided in this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.6</u><font style="white-space:pre-wrap;"> and the remaining two (2) quarters of such Forecast shall be non-binding.  Unless agreed separately between the parties, each Purchase Order shall specify no more than three (3) delivery dates for the Drug Substance in each calendar quarter.  Purchase Orders shall be in writing, and no verbal communications or e-mail shall be construed to mean a commitment to purchase or sell.</font><font style="white-space:pre-wrap;">  Each Purchase Order delivered by Pfizer to Protalix pursuant to this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.6(a)</u> shall be binding on Protalix to the extent provided by <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.6(c)</u><font style="white-space:pre-wrap;">.  Protalix shall confirm receipt of any [***].</font><font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref429825045"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Long Range Capacity Planning</u><font style="white-space:pre-wrap;">.  Concurrent with the Initial Forecast, for the purposes of discussion and planning of Manufacturing capacity, Pfizer shall provide a non-binding forecast of its projected Drug Substance needs for the eight (8) calendar quarters following that specified in the Initial Forecast as described in </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.6(a)</u> (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Long Range Forecast</u><font style="white-space:pre-wrap;">&#8221;).  Each Long Range Forecast shall be deemed to be revised by any subsequent Forecast.  In the event Protalix anticipates that it will be unable to supply the quantities of Drug Substance reflected in a Long Range Forecast, Protalix shall promptly notify Pfizer and the </font><a name="_cp_text_1_570"></a>Supply Chain Committee shall work to remedy the shortfall in accordance with and subject to the terms of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u><font style="white-space:pre-wrap;"> in an effort to assure that the necessary capacity exists.  Unless otherwise agreed to by the parties during the Term, the Long Range Forecast shall be updated by Pfizer annually by July 1 of each calendar year during the Term.</font><font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref244606228"></a><a name="_Ref245696220"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maximum Quantities</u><font style="white-space:pre-wrap;">.  Unless otherwise agreed in writing by Protalix, in no event shall Protalix be obligated to deliver quantities of Drug Substance [***]  </font><a name="_cp_text_1_571"></a>The foregoing limitation shall be in addition to the Capacity Cap.<font style="white-space:pre-wrap;">  </font>Protalix shall, however, use Commercially Reasonable Efforts, but will be under no obligation, to supply Drug Substance [***].<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref246410888"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Minimum Quantities</u><font style="white-space:pre-wrap;">.  If the quantities of Drug Substance specified in a Purchase Order for a quarter are less than [***] of the quantities specified by Pfizer for the same</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">30<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">period in the Forecast delivered [***], then, at the election of Pfizer set forth in a notice which Pfizer shall deliver to Protalix within [***], (i) Protalix shall, [***]</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(e)</font><a name="_Ref246410926"></a><font style="white-space:pre-wrap;">Receipt and Acceptance.  Subject to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.6(c)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.6(d)</u><font style="white-space:pre-wrap;">, Pfizer shall purchase all Drug Substance ordered and specified in a Purchase Order.  Purchase Orders may be delivered electronically or by other means to such location as Protalix shall designate.  Nothing in any such Purchase Order or written acceptance shall supersede the terms and conditions of this Agreement or the Quality Agreement.  All Purchase Orders, confirmations of receipt of Purchase Orders and other notices contemplated under this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.6(e)</u> shall be sent to the attention of such persons as each party may identify to the other in writing from time to time in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">18.9</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.7</font><a name="_cp_blt_2_572"></a><a name="_cp_blt_1_575"></a><a name="_cp_blt_2_574"></a><a name="_Toc428737014"></a><a name="_Toc428737362"></a><a name="_Toc428738055"></a><a name="_Toc428739915"></a><a name="_Toc431831952"></a><a name="_Toc431832284"></a><a name="_Toc434628864"></a><a name="_Ref244606185"></a><a name="_Ref245826840"></a><a name="_Ref246410559"></a><a name="_Ref246414613"></a><a name="_Ref246854050"></a><a name="_Toc428736669"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pricing and Invoicing</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref245826841"></a><a name="_Ref431456001"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Supply Delivery Price</u>.<font style="white-space:pre-wrap;">  </font><a name="_cp_text_1_578"></a>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref431204429"></a><a name="_Ref431204736"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Invoices</u><font style="white-space:pre-wrap;">.  Following the release of the Drug Substance subject to the Purchase Order hereunder and the submission to Pfizer of the Manufacturing Certificate of Acceptance and the Certificate of Compliance (as defined in the Quality Agreement) relating to such released Drug Substance, </font><font style="text-decoration-color:#000000;white-space:pre-wrap;">each delivery of Drug Substance under a Purchase Order hereunder shall be accompanied by an invoice.  Protalix shall invoice Drug Substance at </font>[***]<font style="text-decoration-color:#000000;white-space:pre-wrap;">  Protalix shall include the following information, where applicable, on all invoices: the type, description, and quantity of the product delivered; the date of shipment; the prices; any applicable taxes, transportation charges or other charges provided for in the applicable Purchase Order; and the applicable Purchase Order number.</font><font style="text-decoration-color:#000000;white-space:pre-wrap;">  </font>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Taxes</u><font style="white-space:pre-wrap;">.  All sales and use taxes which Protalix is required by law to collect from Pfizer with respect to the Manufacture and supply of Drug Substance to Pfizer shall be separately stated in Protalix&#8217;s invoice and shall be paid by Pfizer to Protalix unless Pfizer provides an exemption to Protalix.  Protalix shall be solely responsible for the timely payment of all such taxes to the applicable taxing authority, and Protalix shall pay (without reimbursement by Pfizer), and shall hold Pfizer harmless against, any penalties, interest or additional taxes that may be levied or assessed as a result of the failure or delay of Protalix to pay any such taxes.</font><a name="_cp_text_1_592"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.8</font><a name="_cp_blt_1_594"></a><a name="_cp_blt_2_593"></a><a name="_Toc428737015"></a><a name="_Toc428737363"></a><a name="_Toc428738056"></a><a name="_Toc428739916"></a><a name="_Toc431831953"></a><a name="_Toc431832285"></a><a name="_Toc434628865"></a><a name="_Ref244606521"></a><a name="_Ref244607060"></a><a name="_Ref245713583"></a><a name="_Ref245713610"></a><a name="_Ref245826877"></a><a name="_Ref246415420"></a><a name="_Toc428736670"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shipping and Delivery</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref245713612"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Storage</u><font style="white-space:pre-wrap;">.  Protalix shall maintain dedicated freezer storage (i.e., freezers that is used only to store Drug Substance manufactured for Pfizer) for Drug Substance manufactured but not yet delivered to Pfizer pursuant to a Purchase Order.  Such dedicated freezers shall be maintained in compliance with cGMP requirements and shall be stored in a secure area to prevent unauthorized access and/or manipulation. Procedures shall be in place for reporting and neutralizing unauthorized entry into such dedicated freezers.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref431489022"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delivery</u><font style="white-space:pre-wrap;">.  Subject to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.5</u>, Protalix shall deliver (or have delivered) to Pfizer in accordance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.8</u> the quantities of the Drug Substance specified for a given delivery date in each Purchase Order with, in the case of Drug Substance, no less than:</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">31<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">[***]  Such decision by the Supply Chain Committee shall be intended to ensure sufficient supply of Drug Substance meeting the requirements of the applicable Regulatory Authorities and Regulatory Approvals throughout the Territory.  If the Supply Chain Committee determines to increase the Minimum Shelf Life, then the Minimum Shelf Life shall be increased by [***] of such approved increase in shelf life.  All dates for delivery of Drug Substance are </font>[***]</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref428729206"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delivery Terms</u><font style="white-space:pre-wrap;">.  The Drug Substance shall be supplied to Pfizer [***].  The Drug Substance shall be shipped [***].  Pfizer shall be responsible for[***]  For the avoidance of doubt, title and risk of loss shall not transfer to Pfizer until the Drug Substance is delivered to Pfizer or its designee in accordance with this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.8(c)</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Retention</u><font style="white-space:pre-wrap;">.  Unless the parties agree otherwise, Protalix shall maintain analytical samples of each batch of Drug Substance in storage for a time period based upon Protalix&#8217;s sample retention policy.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.9</font><a name="_cp_blt_2_595"></a><a name="_cp_blt_1_598"></a><a name="_cp_blt_2_597"></a><a name="_Toc428737016"></a><a name="_Toc428737364"></a><a name="_Toc428738057"></a><a name="_Toc428739917"></a><a name="_Toc431831954"></a><a name="_Toc431832286"></a><a name="_Toc434628866"></a><a name="_Ref246853119"></a><a name="_Toc428736671"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance; Quality Control Obligations</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><font style="white-space:pre-wrap;">The parties shall determine if the Quality Agreement needs to be updated, and if necessary, shall update the Quality Agreement within sixty (60) days following the Second Amendment Effective Date.  The Quality Agreement shall set forth the parties&#8217; compliance obligations with respect to the Drug Substance Manufactured by Protalix for clinical and commercial requirements in the Territory.  To the extent there are any inconsistencies or conflicts between this Agreement and the Quality Agreement with respect to quality issues, the terms and conditions of the Quality Agreement shall control.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.10</font><a name="_cp_blt_1_600"></a><a name="_cp_blt_2_599"></a><a name="_Toc428737017"></a><a name="_Toc428737365"></a><a name="_Toc428738058"></a><a name="_Toc428739918"></a><a name="_Toc431831955"></a><a name="_Toc431832287"></a><a name="_Toc434628867"></a><a name="_Ref244607542"></a><a name="_Toc428736672"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Certificate of Analysis; Acceptance and Returns</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref430158737"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing Certificate of Analysis; Notice of Non-Conformance</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><a name="_Ref428514994"></a><a name="_Ref244598253"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Following Manufacture</u><font style="white-space:pre-wrap;">.  Following the release of the Drug Substance subject to an applicable Purchase Order by Protalix and before issuing an invoice for such Drug Substance pursuant to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.7(b)</u>, Protalix shall supply to Pfizer the applicable batch number for the Drug Substance, and such other information as the parties may set forth in the Quality Agreement with respect to the Manufacture (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing Certificate of Analysis</u>&#8221;) for such Drug Substance.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><a name="_Ref429825862"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Following Delivery</u><font style="white-space:pre-wrap;">.  Pfizer shall (within the time period specified in </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.10(b)</u>) inspect, or cause to have inspected, each shipment of the Drug Substance for any damage, defect or shortage and give Protalix written notice of any such damaged, defective or short shipment (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice of Non-Conformance</u>&#8221;) within the time periods specified in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.10(a)(iii)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.10(b)</u>, as applicable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><a name="_Ref244607111"></a>Latent defects shall be communicated to Protalix, together with appropriate detail, within fifteen (15) Business Days of the date on which such latent defect was first discovered by Pfizer or was notified to Pfizer by the relevant party discovering the defect.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">32<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref244598564"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Rejection</u><font style="white-space:pre-wrap;">.  Pfizer shall have [***] following its receipt of each shipment of the Drug Substance to inspect such shipment.  If Pfizer determines that any shipment of the Drug Substance does not conform to the Product Specifications (or is otherwise a short shipment), it shall promptly notify Protalix within [***] following such determination in compliance with the procedures set forth in the Quality Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disputes</u><font style="white-space:pre-wrap;">.  If Pfizer delivers a Notice of Non-Conformance in respect of all or any part of a shipment of the Drug Substance, and Protalix does not agree with Pfizer&#8217;s determination that such shipment fails to meet the Product Specifications (or is otherwise a short shipment), the parties shall in good faith attempt to resolve such dispute</font><a name="_cp_text_1_601"></a> at the Supply Chain Committee<font style="white-space:pre-wrap;">.  Protalix and Pfizer shall have thirty (30) days, unless otherwise agreed in writing by the parties, from the date of Protalix&#8217;s receipt of a Notice of Non-Conformance to resolve such dispute regarding whether all or any part of such shipment was Manufactured in conformance with the Product Specifications (or was otherwise a short shipment).  If the dispute regarding whether all or any part of a shipment rejected by Pfizer was Manufactured in conformance with the Product Specifications (or was otherwise a short shipment) is not resolved in such thirty (30) day period, then [***]</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref430158747"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Destruction</u><font style="white-space:pre-wrap;">.  In the event any shipment of Drug Substance is rejected pursuant to this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.10</u> as a result of any act or omission of Protalix, then Pfizer shall, at the direction of Protalix, either (x) destroy such rejected Drug Substance or Licensed Product at Protalix&#8217;s expense (in accordance with applicable Law) or (y) return such rejected Drug Substance or Licensed Product to Protalix, at a location designated by Protalix and at Protalix&#8217;s expense; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided </u>that if Protalix requests the return of such rejected Drug Substance or Licensed Product, Protalix shall not use such Drug Substance or Licensed Product for any purpose, shall destroy such rejected Drug Substance or Licensed Product and certify to Pfizer that it has destroyed such rejected Drug Substance or Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(e)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Refund, Replacement of Non-Conforming Product</u><font style="white-space:pre-wrap;">.  Pfizer may return to Protalix at Protalix&#8217;s expense any Drug Substance rejected pursuant to this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.10</u><font style="white-space:pre-wrap;"> as a result of any act or omission of Protalix, its Affiliates or their respective agents, vendors, suppliers or subcontractors.  In addition to any other rights or remedies of Pfizer hereunder, Protalix shall at Pfizer&#8217;s sole discretion (i) replace any Drug Substance rejected by Pfizer, at no additional cost to Pfizer, as soon as reasonably practicable on an expedited basis; or (ii) provide a credit or refund to Pfizer for the full amount invoiced to and paid by Pfizer for such Drug Substance.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(f)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Shortages</u><font style="white-space:pre-wrap;">. In the event that the materials and/or Manufacturing capacity required by Protalix to Manufacture and to deliver to Pfizer the Drug Substance required as specified in Purchase Orders are in short supply, Protalix shall notify Pfizer of such shortage and the Supply Chain Committee shall promptly meet to discuss the shortage.  Protalix shall provide to the Supply Chain Committee a written plan of action stating in reasonable detail the proposed measures to address such shortage and the date such shortage is expected to end.  Protalix shall use its Commercially Reasonable Efforts to minimize the duration of any shortage, including using all capacity at its Facility to Manufacture Drug Substance (including stopping the</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">33<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">manufacture of all other products at the Facility for sales by Protalix or Third Parties).  During any such shortage, Protalix shall allocate the materials and resources used in the supply of the Drug Substance such that Pfizer receives [***] of the Drug Substance for the Territory and Protalix receives [***] of the Drug Substance for outside the Territory. </font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.11</font><a name="_Toc428737018"></a><a name="_Toc428737366"></a><a name="_Toc428738059"></a><a name="_Toc428739919"></a><a name="_Toc431831956"></a><a name="_Toc431832288"></a><a name="_Toc434628868"></a><a name="_Toc428736673"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Product Specification and Manufacturing Changes</u><font style="white-space:pre-wrap;">.  Product Specification and Manufacturing changes, including those resulting from a request received by a party from a Governmental Authority, shall be dealt with pursuant to the Quality Agreement; </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u> that all applicable Regulatory Approvals shall be prepared and filed by the parties in accordance with the provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.12</font><a name="_Toc428737367"></a><a name="_Toc428738060"></a><a name="_Toc428739920"></a><a name="_Toc431831957"></a><a name="_Toc431832289"></a><a name="_Toc434628869"></a><a name="_Toc428737019"></a><a name="_Toc428736674"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Change Control</u><font style="white-space:pre-wrap;">.  Protalix shall not make any changes to its process, raw materials, supply sources, manufacturing locations or facilities (including Drug Substance storage facilities and equipment) used to make Drug Substance for Pfizer under this agreement, including any such changes that may require Pfizer to provide notification to Regulatory Authorities, except to the extent permitted under the Quality Agreement.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.13</font><a name="_Toc428737020"></a><a name="_Toc428737368"></a><a name="_Toc428738061"></a><a name="_Toc428739921"></a><a name="_Toc431831958"></a><a name="_Toc431832290"></a><a name="_Toc434628870"></a><a name="_Toc428736675"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Practices</u><font style="white-space:pre-wrap;">.  Protalix shall comply with current Good Manufacturing Practices (cGMP) as it applies to receipt, storage, handling and control of materials and the Drug Substance.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.14</font><a name="_Toc428737021"></a><a name="_Toc428737369"></a><a name="_Toc428738062"></a><a name="_Toc428739922"></a><a name="_Toc431831959"></a><a name="_Toc431832291"></a><a name="_Toc434628871"></a><a name="_Ref428515103"></a><a name="_Toc428736676"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pest Control</u><font style="white-space:pre-wrap;">.  Protalix shall manufacture and store Drug Substance, and shall store all ingredients, raw materials and components used to manufacture Drug Substance, in a clean, dry area, free from insects and rodents, in a manner to prevent entry of foreign materials and contamination of Drug Substance.  Protalix&#8217;s pest control measures shall include adequate cleaning of the facility, control of food and drink, protection of Drug Substance from the environment, monitoring of flying and crawling pests, and logs detailing findings and actions taken. Protalix&#8217;s pest control program shall be described in a written procedure subject to review and approval of Pfizer.  Failure of Protalix to comply with this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.14</u> shall be deemed a material breach of this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.15</font><a name="_Toc428737022"></a><a name="_Toc428737370"></a><a name="_Toc428738063"></a><a name="_Toc428739923"></a><a name="_Toc431831960"></a><a name="_Toc431832292"></a><a name="_Toc434628872"></a><a name="_Ref428515160"></a><a name="_Toc428736677"></a><a name="_Ref431469009"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Records and Audits</u>.<font style="white-space:pre-wrap;">  Protalix shall maintain complete and accurate records of all matters relating to the Manufacturing of Drug Substance that enable Protalix to demonstrate compliance with its obligations under this Agreement, including Protalix&#8217;s compliance with applicable Laws, in accordance with the terms of the Quality Agreement. As used in this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.15</u><font style="white-space:pre-wrap;">, records include all books, documents, and other data specified in the Quality Agreement regardless of type or form.  Protalix shall maintain such records for the period of time set forth in the Quality Agreement.  Pfizer or its representatives may (at Pfizer&#8217;s sole cost and expense), subject to the confidentiality provisions in </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9</u><font style="white-space:pre-wrap;">, audit such records of Protalix in accordance with the terms of the Quality Agreement at any time during the Supply Term and for the [***] period following the expiration or termination of (x) the Supply Term or (y) the last Purchase Order in effect, whichever occurs later, during normal business hours and upon reasonable advance written notice to Protalix.  Protalix shall make such records readily available for such audit, and Pfizer or its representatives may copy any and all such records in connection with any such audit.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">34<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.16</font><a name="_cp_blt_1_603"></a><a name="_cp_blt_2_602"></a><a name="_Toc428737023"></a><a name="_Toc428737371"></a><a name="_Toc428738064"></a><a name="_Toc428739924"></a><a name="_Toc431831961"></a><a name="_Toc431832293"></a><a name="_Toc434628873"></a><a name="_Toc428736678"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Quality Assurance</u><font style="white-space:pre-wrap;">.  Protalix shall have a formal quality assurance program and appropriate written quality control procedures covering its operations.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.17</font><a name="_Toc428737024"></a><a name="_Toc428737372"></a><a name="_Toc428738065"></a><a name="_Toc428739925"></a><a name="_Toc431831962"></a><a name="_Toc431832294"></a><a name="_Toc434628874"></a><a name="_Toc428736679"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technical Support</u><font style="white-space:pre-wrap;">.  Protalix shall provide means for Pfizer to contact Protalix&#8217;s service representative twenty-four (24) hours a day, seven (7) days a week during the Supply Term.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.18</font><a name="_Toc431831963"></a><a name="_Toc428737025"></a><a name="_Toc428737373"></a><a name="_Toc428738066"></a><a name="_Toc428739926"></a><a name="_Toc431832295"></a><a name="_Toc434628875"></a><a name="_Ref428507740"></a><a name="_Toc428736680"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Technical Assistance;</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> Facility Access</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(A)</font><a name="_Ref432012774"></a>Pfizer shall have the right to provide technical assistance and advice to Protalix on an ongoing basis, including in-person at Protalix&#8217;s Facility;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(B)</font><a name="_Ref432012783"></a>Pfizer may physically inspect Protalix&#8217;s Facility, including being present during Manufacturing operations, quality control, quality assurance, pack out and shipping;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(C)</font><a name="_Ref432012797"></a>Protalix shall provide Pfizer with reasonable ongoing access to its Facility and all relevant Manufacturing records and personnel (wherever located) of Protalix and will use Commercially Reasonable Efforts to facilitate access to any Third Party suppliers of materials for the Drug Substance; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:108pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(D)</font><a name="_Ref432012806"></a>Protalix shall reasonably cooperate with Pfizer and its representatives in connection with the activities described above and, upon mutual agreement of the parties as to any deficiencies, Protalix shall use its Commercially Reasonable Efforts to promptly correct any such deficiencies if and to the extent mutually agreed by the parties.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Pfizer and its representatives shall carry out the activities described in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.18</u><font style="white-space:pre-wrap;"> during Protalix&#8217;s regular business hours at times reasonably agreed upon by Pfizer and Protalix, with as minimal disruption to Protalix&#8217;s operations as reasonably practicable [***].  Such requested cooperation and assistance pursuant to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.18(C)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.18(D)</u>, shall be provided [***]</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.19</font><a name="_Toc428737026"></a><a name="_Toc428737374"></a><a name="_Toc428738067"></a><a name="_Toc428739927"></a><a name="_Toc431831964"></a><a name="_Toc431832296"></a><a name="_Toc434628876"></a><a name="_Toc428736681"></a><a name="_Ref429857728"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Assistance by Pfizer</u><font style="white-space:pre-wrap;">.  Protalix acknowledges that Pfizer has expertise with respect to manufacturing and pharmaceutical sciences and is able to provide assistance to Protalix in the following areas:  (a) registering with the FDA and EMEA a manufacturing technology for commercial supply of Drug Substance, including the preparation of a complete, approvable chemistry, manufacturing, and controls section of an NDA and other regulatory filings packages, (b) the regulatory review process, (c) addressing regulatory review feedback or post-approval requirements by any Regulatory Authority, (d)  bioprocess, analytical or formulation development, (e) validation, (f) characterization and stability studies, (g) preparing for and supporting pre-approval inspections; and (h) preparing Protalix&#8217;s Facility to make it suitable for Regulatory Approval, including finalizing any required changes to the facility or equipment train, IQ/OQ/PQ, and equipment cleaning and cleaning validation (collectively, the &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Advisory Services</u><font style="white-space:pre-wrap;">&#8221;).  At any time during the Term, Pfizer shall have the right to provide</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">35<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">Advisory Services to Protalix and upon reasonable advance written notice from Pfizer, Protalix shall reasonably consider in good faith the recommendations of Pfizer with respect to such Advisory Services.  Pfizer shall be responsible for and bear [***] of the costs and expenses it incurs in providing Advisory Services to Protalix.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.20</font><a name="_cp_blt_1_604"></a><a name="_Toc428737027"></a><a name="_Toc428737375"></a><a name="_Toc428738068"></a><a name="_Toc428739928"></a><a name="_Toc431831965"></a><a name="_Toc431832297"></a><a name="_Toc434628877"></a><a name="OLE_LINK37"></a><a name="OLE_LINK38"></a><a name="_cp_text_1_605"></a><a name="_Toc428736682"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">M</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">aster Cell Bank</u><font style="white-space:pre-wrap;">.  During the Term, Protalix shall, as the supplier of Drug Substance, maintain half of the master cell bank relating to the Drug Substance in a location selected by Protalix and the other half of the master cell bank relating to the Drug Substance at a different location selected by Protalix and approved by Pfizer (such approval not to be unreasonably withheld or delayed), which may include the Facility where Pfizer performs Fill/Finish activities (</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided </u>that Pfizer obtains all required approvals from the applicable Regulatory Authority necessary to store the master cell bank in such Facility).<a name="OLE_LINK34"></a><a name="OLE_LINK35"></a><a name="_cp_text_1_665"></a><a name="_Ref244598014"></a><a name="_Ref244599142"></a><a name="_Ref244599818"></a><a name="_Ref244608038"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.21</font><a name="_cp_blt_1_667"></a><a name="_cp_blt_2_666"></a><a name="_cp_blt_1_705"></a><a name="_cp_blt_2_704"></a><a name="_Toc428737029"></a><a name="_Toc428737377"></a><a name="_Toc428738070"></a><a name="_Toc428739930"></a><a name="_Toc431831967"></a><a name="_Toc431832299"></a><a name="_Ref246429499"></a><a name="_Toc428736684"></a>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.22</font><a name="_Toc431831968"></a><a name="_Toc431832300"></a><a name="_Ref431304374"></a>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">5.23</font><a name="_Toc434628878"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing Transition Assistance</u><font style="white-space:pre-wrap;">.  Upon Pfizer&#8217;s request, in order to ensure continuity of supply of the Drug Substance following expiration or termination of this Agreement or Pfizer&#8217;s election to exercise its right to Manufacture or have a Third Party Manufacture the Drug Substance, Protalix shall provide reasonable assistance to Pfizer in arranging for the Manufacture of the Drug Substance by Pfizer or by an alternative supplier chosen by Pfizer, including providing technical consulting services to Pfizer or such alternative supplier and transferring know-how and other information relating to the Manufacture of the Drug Substance to Pfizer or such alternative supplier. [***] </font>Protalix shall provide such assistance in accordance with a written transition plan (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing Transition Plan</u><font style="white-space:pre-wrap;">&#8221;) that details the actions and timelines for transitioning the Manufacture of the Drug Substance to Pfizer or such alternative supplier in a timely and efficient manner without material risk or disruption to either Protalix or Pfizer and no later than the end of the Term (if in connection with the expiration or termination of the Agreement) or no later than the time agreed to by the parties (if in connection with Pfizer&#8217;s exercise of its right to Manufacture or have a Third Party Manufacture the Drug Substance).  Protalix shall provide the proposed Manufacturing Transition Plan to Pfizer for Pfizer&#8217;s written approval, which shall not be unreasonably withheld, within </font>[***]<font style="white-space:pre-wrap;"> following Pfizer&#8217;s request.  In addition, upon Pfizer&#8217;s request, Protalix shall use Commercially Reasonable Efforts to cause the counterparty to any contract relating to the Manufacture of the Drug Substance (a) to consent to the partial assignment to Pfizer or such alternative supplier of those rights necessary for such manufacture by Pfizer or such alternative supplier or (b) to otherwise reasonably cooperate with Pfizer in Pfizer&#8217;s efforts to establish a new contractual relationship with such counterparty on substantially the same terms as the terms of its contract with Protalix.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">36<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 6.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_cp_blt_1_707"></a><a name="_cp_blt_2_706"></a><a name="_cp_blt_1_709"></a><a name="_cp_blt_2_708"></a><a name="_Ref244608903"></a><a name="_Toc428350786"></a><a name="_Toc428351611"></a><a name="_Toc428409545"></a><a name="_Toc428410103"></a><a name="_Toc428410157"></a><a name="_Toc428410256"></a><a name="_Toc428736353"></a><a name="_Toc428736685"></a><a name="_Toc428737030"></a><a name="_Toc428737378"></a><a name="_Toc428738071"></a><a name="_Toc428739931"></a><a name="_Toc431831969"></a><a name="_Toc434628879"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">FINANCIAL PROVISIONS</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.1</font><a name="_Toc428737031"></a><a name="_Toc428737379"></a><a name="_Toc428738072"></a><a name="_Toc428739932"></a><a name="_Toc431831970"></a><a name="_Toc431832301"></a><a name="_Toc434628880"></a><a name="_Ref246517003"></a><a name="_Ref247367098"></a><a name="_Ref428305088"></a><a name="_Toc428736686"></a><a name="_cp_text_1_711"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Second Amendment Effective Date Payment</u><font style="white-space:pre-wrap;">.  Within thirty (30) days following the Second Amendment Effective Date, Pfizer shall pay to Protalix the amount of thirty-six million dollars (US $36,000,000) (the &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pfizer Payment</u>&#8221;) in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.2(a)</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.2</font><a name="_Toc428737032"></a><a name="_Toc428737380"></a><a name="_Toc428738073"></a><a name="_Toc428739933"></a><a name="_Toc431831971"></a><a name="_Toc431832302"></a><a name="_Toc434628881"></a><a name="_Toc428736687"></a><a name="_Ref429830460"></a><a name="_Ref428289505"></a><a name="_Ref431260860"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deferred Payment</u><font style="white-space:pre-wrap;">.  Within thirty (30) days of the fifth (5</font><sup style="font-size:9pt;vertical-align:top;">th</sup>) anniversary of the Second Amendment Effective Date, Protalix shall pay to Pfizer the non-refundable, non-creditable amount of four million three hundred thousand seven hundred sixteen dollars and forty-six cents (US $4,300,716.46) (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Payment</u>&#8221;) in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.2(b)</u><font style="white-space:pre-wrap;"> and as set forth in the promissory note delivered by Protalix to Pfizer.  Protalix shall have delivered a promissory note in the form of </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit H</u> on the Second Amendment Effective Date (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Promissory Note</u>&#8221;). </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.3</font><a name="_Toc431831972"></a><a name="_Toc431832303"></a><a name="_Toc434628882"></a><a name="_Toc431253136"></a><a name="_Toc428737381"></a><a name="_Toc428738074"></a><a name="_Toc428739934"></a><a name="_Toc428737033"></a><a name="_Toc428736688"></a><a name="_Ref429858643"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments With Respect to Commercialization in Israel</u><font style="white-space:pre-wrap;">.  During the Israel Transition Period,</font> [***] </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.4</font><a name="_Toc431831973"></a><a name="_Toc431832304"></a><a name="_Toc434628883"></a><a name="_Ref431304291"></a><a name="_Ref431303102"></a><a name="_Ref431462690"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Payments With Respect to Commercialization in Brazil</u><font style="white-space:pre-wrap;">.  Until such time that Protalix has provided written notice to Pfizer permitting Pfizer to cancel its Brazilian marketing authorization with respect to the Licensed Product, </font><font style="white-space:pre-wrap;">[***]  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">6.5</font><a name="_Toc431831974"></a><a name="_Toc431832305"></a><a name="_Toc434628884"></a><a name="_Ref432012395"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Release of Payment Obligations</u><font style="white-space:pre-wrap;">.  Upon (i) the payment by Pfizer to Protalix of the Pfizer Payment, Pfizer shall be deemed to have fully satisfied and discharged, and Protalix hereby fully and forever releases Pfizer and its Affiliates from, all payment obligations under Section 6 of the Amended Agreement that have accrued as of the Second Amendment Effective Date, including milestone payments and profit sharing payments, and (ii) the later to occur of (A) the delivery of the promissory note for the Protalix Payment by Protalix to Pfizer as required under </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.2</u> and (B) Protalix providing Pfizer with written notice permitting Pfizer to cancel its Brazilian marketing authorization with respect to the Licensed Product, Protalix shall be deemed to have fully satisfied and discharged, and Pfizer hereby fully and forever releases Protalix and its Affiliates from, all payment obligations under Section 2 of the First Amendment (which, for the avoidance of doubt, shall no longer be in effect as of the Second Amendment Effective Date) and Section 6 of the Amended Agreement that have accrued as of the Second Amendment Effective Date (except to the extent such payments under Section 2 of the First Amendment are payable pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.4</u> of this Agreement) (collectively, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Released Obligations</u>&#8221;)<font style="white-space:pre-wrap;">, other than payment of the Protalix Payment in accordance herewith.  In addition, the Released Obligations include all associated reporting obligations, reconciliation payments and procedures and payments in respect of reimbursable expenses that may have accrued under Section 7 of the Amended Agreement.  In connection with the foregoing release, each party hereby waives any and all rights to inspect or audit the books and records of the other party and its Affiliates and sublicensees relating to the Released Obligations and to seek any adjustment or modification of any amounts paid or payable in connection with any such audit or inspection.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">37<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 7.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_Toc428350787"></a><a name="_Toc428351615"></a><a name="_Toc428409546"></a><a name="_Toc428410104"></a><a name="_Toc428410158"></a><a name="_Toc428410257"></a><a name="_Toc428736354"></a><a name="_Toc428736689"></a><a name="_Toc428737034"></a><a name="_Toc428737382"></a><a name="_Toc428738075"></a><a name="_Toc428739935"></a><a name="_Toc431831975"></a><a name="_Toc434628885"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">ACCOUNTING AND PROCEDURES FOR PAYMENT</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.1</font><a name="_Toc428737035"></a><a name="_Toc428737383"></a><a name="_Toc428738076"></a><a name="_Toc428739936"></a><a name="_Toc431831976"></a><a name="_Toc431832306"></a><a name="_Toc434628886"></a><a name="_Toc428736690"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Currency</u><font style="white-space:pre-wrap;">.  All payments to be made hereunder by one party to the other party shall be computed and paid in United States dollars.</font><font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.2</font><a name="_Toc428737036"></a><a name="_Toc428737384"></a><a name="_Toc428738077"></a><a name="_Toc428739937"></a><a name="_Toc431831977"></a><a name="_Toc431832307"></a><a name="_Toc434628887"></a><a name="_Ref246845646"></a><a name="_Ref246845647"></a><a name="_Toc428736691"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Method of Payments</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref246845504"></a>Each payment to be made hereunder by Pfizer to Protalix shall be made by electronic transfer in immediately available funds via either a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at Protalix&#8217;s election, to the account designated on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.2</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)</u><font style="white-space:pre-wrap;">.  With respect to any payment invoiced by Protalix to Pfizer, Protalix may designate a different bank account on such invoice.  With respect to any other payment, Protalix may designate a different bank account at least forty-five (45) days before such payment is due.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="OLE_LINK84"></a>Each payment to be made hereunder by Protalix to Pfizer shall be made by electronic transfer in immediately available funds via either a bank wire transfer, an ACH (automated clearing house) mechanism, or any other means of electronic funds transfer, at Pfizer&#8217;s election, to the account designated on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.2</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(b)</u>, or to such other bank account as Pfizer shall designate in a notice at least fifteen (15) Business Days before the payment is due.<a name="_Ref247367196"></a><a name="_Ref247367231"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">7.3</font><a name="_Toc428737037"></a><a name="_Toc428737385"></a><a name="_Toc428738078"></a><a name="_Toc428739938"></a><a name="_Toc431831978"></a><a name="_Toc431832308"></a><a name="_Toc434628888"></a><a name="_Toc428736692"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Matters</u>.<a name="_cp_text_1_718"></a> </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">VAT</u><font style="white-space:pre-wrap;">.  It is understood and agreed between the parties that any payments made by Pfizer under this Agreement are inclusive of any value added or similar tax imposed upon such payments.</font><a name="_cp_text_2_133"></a> It is understood and agreed between the<a name="_cp_text_1_134"></a> parties that any payments<a name="_cp_text_1_137"></a> made by Protalix to Pfizer under this Agreement are <a name="_cp_text_2_138"></a>exclusive of any value added or similar tax (VAT)<a name="_cp_text_2_140"></a>, which shall be added thereon as applicable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Tax Cooperation</u>. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.3(c)</u> to the extent Pfizer is required to deduct and withhold taxes on any payments to Protalix, Pfizer shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Protalix an official tax certificate or other evidence of such withholding sufficient to enable Protalix to claim credits for such payments of taxes. &#160;Protalix shall provide to Pfizer any tax forms that may be reasonably necessary in order for Pfizer not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty. &#160;Protalix shall use reasonable efforts to provide any such tax forms to Pfizer at least thirty (30) days prior to the due date for any payments for which Protalix desires that Pfizer apply a reduced withholding rate. &#160;Each party shall provide the other with reasonable assistance to enable the recovery, as permitted by law, of withholding taxes, VAT, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the party bearing such withholding tax or VAT. Each party further agrees to provide reasonable cooperation to the other party, at the other party&#8217;s expense, in connection with any official or unofficial tax audit or contest relating to payments made by Pfizer to Protalix under this Agreement.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">38<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="text-decoration-color:#000000;">Subject to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">7.3(c)</u><font style="text-decoration-color:#000000;">, to the extent Protalix is required to deduct and withhold taxes on any payments to Pfizer, Protalix shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to Pfizer an official tax certificate or other evidence of such withholding sufficient to enable Pfizer to claim </font><a name="_cp_text_1_153"></a><font style="text-decoration-color:#000000;">credits for </font><font style="text-decoration-color:#000000;white-space:pre-wrap;">such payments of taxes.  Pfizer shall provide to Protalix any tax forms that may be reasonably necessary in order for Protalix not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty.  </font><a name="_cp_text_1_154"></a><font style="text-decoration-color:#000000;white-space:pre-wrap;">Pfizer shall use reasonable efforts to provide any such tax forms to Protalix at least thirty (30) days prior to the due date for any payments for which Pfizer desires that Protalix apply a reduced withholding rate.  </font><font style="text-decoration-color:#000000;">Each party shall provide the other with reasonable assistance to enable the recovery, as permitted by Law, of withholding taxes, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the </font><a name="_cp_text_1_159"></a><font style="text-decoration-color:#000000;">party </font><font style="text-decoration-color:#000000;white-space:pre-wrap;">bearing such withholding tax.  Each party further agrees to provide reasonable cooperation to the other party, at the other party&#8217;s expense, in connection with any official or unofficial tax audit or contest relating to payments made by Protalix to Pfizer under this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font>[***]</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 8.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_cp_blt_2_727"></a><a name="_cp_blt_1_730"></a><a name="_cp_blt_2_729"></a><a name="_Ref247364866"></a><a name="_Toc428350788"></a><a name="_Toc428351620"></a><a name="_Toc428409547"></a><a name="_Toc428410105"></a><a name="_Toc428410159"></a><a name="_Toc428410258"></a><a name="_Toc428736355"></a><a name="_Toc428736693"></a><a name="_Toc428737038"></a><a name="_Toc428737386"></a><a name="_Toc428738079"></a><a name="_Toc428739939"></a><a name="_Toc431831979"></a><a name="_Toc434628889"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">PATENTS AND INFRINGEMENT</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.1</font><a name="_Toc428737039"></a><a name="_Toc428737387"></a><a name="_Toc428738080"></a><a name="_Toc428739940"></a><a name="_Toc431831980"></a><a name="_Toc431832309"></a><a name="_Toc434628890"></a><a name="_Ref244608957"></a><a name="_Ref244629779"></a><a name="_Ref245539609"></a><a name="_Toc428736694"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Filing and Prosecution</u><font style="white-space:pre-wrap;">.  Protalix shall have the exclusive right, subject to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.2</u> through <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.5</u>, to:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font>file Patent Applications on any invention included in the Protalix Patent Rights;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font>take all reasonable steps to prosecute all pending and new Patent Applications included within the Protalix Patent Rights;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font>respond to oppositions, interferences, nullity actions, re-examinations, revocation actions and similar proceedings filed by Third Parties against the grant of Patents for such Patent Applications; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font>maintain in force any patents in the Territory included within the Protalix Patent Rights by duly filing all necessary papers and paying any fees required by the relevant patent laws and regulations of the particular Country in which the patent was granted.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(e)</font>[***] shall be responsible for bearing [***] of the expenses and costs incurred by [***] in connection with the exercise of its rights under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.1</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.2</font><a name="_Toc428737040"></a><a name="_Toc428737388"></a><a name="_Toc428738081"></a><a name="_Toc428739941"></a><a name="_Toc431831981"></a><a name="_Toc431832310"></a><a name="_Toc434628891"></a><a name="_Ref244608924"></a><a name="_Ref245540443"></a><a name="_Ref246561628"></a><a name="_Toc428736695"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Correspondence</u><font style="white-space:pre-wrap;">.  [***] will keep [***] fully-informed of the status of the [***] Patent Rights to the extent the Protalix Patent Rights [***], and will provide [***] with copies of all substantive documentation submitted to, or received from, the patent offices in connection therewith.  With respect to any substantive submissions that [***] is required to or otherwise intends to submit to a patent office regarding such Protalix Patent Rights, [***] shall use</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">39<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">Commercially Reasonable Efforts to provide a draft of such submission to [***] at least thirty (30) days prior to the deadline or intended filing date, whichever is earlier, for submission of such documentation.  [***] shall have the right to review and comment upon any such submission by [***] to a patent office that could affect the scope of coverage or validity of any claim of the Protalix Patent Rights to the extent covering the Compound or Licensed Product, or the Development, Manufacture, or Commercialization of [***], and will provide such comments, if any, no later than ten (10) days prior to the applicable deadline or intended filing date.</font><font style="white-space:pre-wrap;">  Notwithstanding the foregoing, when such substantive documentation submitted to or received from the patent offices is solely related to [***], [***] shall have the right, but no obligation, to fully inform [***] of the status of these Protalix Patent Rights.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font>Upon [***] written request, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided </u>that [***] submits such written request reasonably in advance of any relevant filing deadline or intended filing date, [***] will file Patent Applications directed to the rights licensed to [***] under this Agreement [***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font>With respect to Protalix Patent Rights that are [***][***] shall consider in good faith all comments provided<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><font style="white-space:pre-wrap;">by [***] with respect to a Protalix Patent Right to the extent relating to [***], and incorporate all such comments that [***] deems reasonable and appropriate.  If [***] disagrees with any such comment provided</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><font style="white-space:pre-wrap;">by [***] after giving such comments due consideration, [***] shall provide [***] with an explanation of the basis for such disagreement.  If a failure to incorporate [***]&#8217;s comment would reasonably be expected to impair the Licensed Product in the Field in the Territory, [***] shall have final-decision making authority with respect to filings and prosecution of such Protalix Patent Rights (other than the Protalix System Patent Rights).  [***] shall have final-decision making authority with respect to filings and prosecution of Protalix Patent Rights relating solely to an [***] and with respect to filings and prosecution of Protalix Patent Rights that [***]</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><font style="white-space:pre-wrap;">Notwithstanding the foregoing, [***]&#8217;s obligation to keep [***] informed of the status of the Protalix System Patent Rights will be limited to situations where changes to the status of the Protalix System Patent Rights would reasonably be expected to impair the Licensed Product in the Field in the Territory.  With respect to the Protalix System Patent Rights, [***] shall reasonably consider all comments provided</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u>by [***], but [***] shall have final-decision making authority with respect to filings and prosecution of the Protalix System Patent Rights.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.3</font><a name="_Toc428737041"></a><a name="_Toc428737389"></a><a name="_Toc428738082"></a><a name="_Toc428739942"></a><a name="_Toc431831982"></a><a name="_Toc431832311"></a><a name="_Toc434628892"></a><a name="_Ref244629792"></a><a name="_Ref246861623"></a><a name="_Toc428736696"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Maintenance</u><font style="white-space:pre-wrap;">.  Protalix will maintain for the full life thereof all Patent Rights under the Protalix Patent Rights where the abandonment for non-payment would [***].  Protalix will notify Pfizer of any decision (a) not to file applications for, or (b) not to enter the national phase for a PCT patent application (or not to validate a patent in a particular Country) for, or (c) to cease prosecution and/or maintenance of, or (d) not to pursue, or (e) to cease to pay the expenses of prosecution or maintenance of, any Protalix Patent Rights in any Country in the Territory.  Protalix will provide such notice upon the earlier of (i) its decision with respect to any of the foregoing, or (ii) ninety (90) days prior to any filing or payment due date, or any other due date that requires action, in connection with such Protalix Patent Rights.  In such event, Pfizer shall have the right to make the filing, or to continue the prosecution and maintenance of such</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">40<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">Patent Rights (other than Protalix System Patent Rights) in its own name and at its sole expense, and such Patent Rights shall be assigned to Pfizer and shall no longer be part of the Protalix Patent Rights.<font style="white-space:pre-wrap;">  Notwithstanding the foregoing, Protalix shall have no obligation to provide such notice where the subject Protalix Patent Rights are directed solely to an [***].</font><font style="white-space:pre-wrap;">  </font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.4</font><a name="_Toc428737042"></a><a name="_Toc428737390"></a><a name="_Toc428738083"></a><a name="_Toc428739943"></a><a name="_Toc431831983"></a><a name="_Toc431832312"></a><a name="_Toc434628893"></a><a name="_Ref246562504"></a><a name="_Toc428736697"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices and Encumbrances</u><font style="white-space:pre-wrap;">.  Protalix agrees that it will, and will cause its Affiliates to, (a) execute and file those notices and other filings as Pfizer shall request be made, from time to time with the United States Patent and Trademark Office (or any successor agency) or any analogous patent office in the Territory with respect to the rights granted under this Agreement and, (b) maintain (subject to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.3</u><font style="white-space:pre-wrap;">) at all times during the Term sole ownership of the Patents and Patent Applications under the Protalix Patent Rights (other than Protalix Patent Rights directed solely to [***]), free and clear of any and all mortgages, liens, pledges, security interests, charges or encumbrances.  Protalix shall also keep the Protalix Technology (other than Protalix Technology directed solely to or solely embodied in [***]), free and clear of any and all mortgages, liens, pledges, security interests, charges or encumbrances during the Term.  For the sake of clarity, encumbrances as contemplated in this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.4</u> specifically exclude licenses to Protalix Patent Rights and Protalix Technology, wherein such licenses are [***] [***] [***].</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.5</font><a name="_Toc428737043"></a><a name="_Toc428737391"></a><a name="_Toc428738084"></a><a name="_Toc428739944"></a><a name="_Toc431831984"></a><a name="_Toc431832313"></a><a name="_Toc434628894"></a><a name="_Ref244601751"></a><a name="_Ref244608936"></a><a name="_Ref245541445"></a><a name="_Toc428736698"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Term Extensions</u><font style="white-space:pre-wrap;">.  Pfizer shall have the first right, but not the obligation, to seek, in Protalix&#8217;s name if so required, patent term extensions, and supplemental protection certificates and the like available under Law, including 35 U.S.C. &#167; 156 and applicable foreign counterparts, in any Country in the Territory in relation to the Protalix Patent Rights covering the Compound (other than Protalix Patent Rights directed solely to the Compound [***]) or Licensed Products.  In the event that Pfizer decides not to seek such patent term extension or supplemental patent protection in any Country in the Territory, Protalix shall have the right to seek such patent term extension or supplemental patent protection in any such Country.  Protalix and Pfizer shall cooperate in connection with all such activities, and Pfizer, its agents and attorneys will give due consideration to all suggestions and comments of Protalix regarding any such activities, but in the event of a disagreement between the parties, as it relates to the Compound ([***]) or Licensed Product, Pfizer will have the final decision-making authority.  Any costs incurred by Pfizer in connection with this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.5</u> shall <a name="_cp_text_2_736"></a>be <a name="_cp_text_1_737"></a>borne <font style="white-space:pre-wrap;">[***].  Any costs incurred by Protalix in connection with this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.5</u> shall be borne [***].</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.6</font><a name="_Toc428737044"></a><a name="_Toc428737392"></a><a name="_Toc428738085"></a><a name="_Toc428739945"></a><a name="_Toc431831985"></a><a name="_Toc431832314"></a><a name="_Toc434628895"></a><a name="_Ref245543476"></a><a name="_Toc428736699"></a><a name="_Ref244608995"></a><a name="_Ref244629805"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Infringement</u><font style="white-space:pre-wrap;">.  Each party will promptly notify the other in the event of any actual, potential or suspected infringement of a Patent under the Protalix Patent Rights by any Third Party.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref245543477"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Infringement of Protalix Patent Rights in the Field</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><a name="_Ref246563244"></a><font style="white-space:pre-wrap;">Pfizer shall have the sole right, but not the obligation, to institute litigation or take other remedial measures in connection with Third Party infringement of the Protalix Patent Rights occurring in the Field within the Territory (other than Protalix Patent Rights directly solely to [***]), where such Third Party infringement would reasonably be expected [***].  In order to establish standing, Protalix, upon request of</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">41<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="white-space:pre-wrap;">Pfizer, agrees to timely commence or to join in any such litigation, at [***] and in any event to cooperate with Pfizer at [***].  Any costs and expenses incurred by Pfizer with respect to any such litigation or remedial measures shall be </font><a name="_cp_text_1_739"></a>[***] and any recoveries resulting from such litigation or measures relating to a claim of a Third Party infringement in pursuing such claim, will be [***].<font style="white-space:pre-wrap;">   </font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><a name="_Ref245543478"></a><font style="white-space:pre-wrap;">Protalix shall have the sole right, but not the obligation, to institute litigation or take other remedial measures in connection with Third Party infringement of any Protalix Patent Rights occurring [***] and with respect to Third Party infringement of any Protalix Patent Rights directed solely to [***] and any such litigation or remedial measures shall be [***].  Protalix shall retain [***]  received by Protalix as a result of its enforcement of Protalix Patent Rights under this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.6</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(ii)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref245543497"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Infringement of Protalix Patent Rights </u>[***]<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">.</u><font style="white-space:pre-wrap;">  Protalix shall have the sole right, but not the obligation, to institute litigation or take other remedial measures in connection with Third Party infringement occurring [***] and any such litigation or remedial measures shall be [***].  Protalix shall either (i) provide Pfizer with prior written notice of Protalix&#8217;s intent to initiate a suit, take other appropriate action, or to not file suit or seek other redress or (ii) convene a meeting of the </font><a name="_cp_text_1_745"></a>parties to <font style="white-space:pre-wrap;">discuss what would be in the parties&#8217; best interest with respect to the Third Party infringement occurring [***].   Protalix shall retain [***] received by Protalix as a result of its enforcement of Protalix Patent Rights under this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">8.6</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(b)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.7</font><a name="_Toc428737045"></a><a name="_Toc428737393"></a><a name="_Toc428738086"></a><a name="_Toc428739946"></a><a name="_Toc431831986"></a><a name="_Toc431832315"></a><a name="_Toc434628896"></a><a name="_Ref245558088"></a><a name="_Ref246563766"></a><a name="_Ref246563913"></a><a name="_Toc428736700"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Paragraph IV Notices</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref246563767"></a>If either party receives a notice under 21 U.S.C. &#167;355(b)(2)(A)(iv) or 355(j)(2)(A)(vii)(IV) directed to a Compound ([***]) or Licensed Product, concerning any Protalix Patent Right (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Paragraph IV Notice</u><font style="white-space:pre-wrap;">&#8221;), then it shall provide a copy of such notice to the other party promptly and in any event no later than two (2) Business Days after its receipt thereof.  Pfizer shall have the exclusive right, but not the obligation, to initiate patent infringement litigation based on a Paragraph IV Notice directed to a Compound ([***]) or Licensed Product, concerning a Protalix Patent Right, and any expenses incurred by Pfizer with respect to such infringement litigation shall </font><a name="_cp_text_1_747"></a>be <font style="white-space:pre-wrap;">[***].  Upon request of Pfizer, Protalix agrees to timely join as party&#8722;plaintiff in any such litigation, and in any event to cooperate with Pfizer in connection with such infringement action, including timely filing such action in Protalix&#8217;s name if required.  Pfizer shall promptly notify Protalix of its intention not to initiate patent infringement litigation based on such Paragraph IV Notice.  The amount of any recovery from any such infringement suit with respect to activities in the Field in the Territory will be [***].</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref244609030"></a><font style="white-space:pre-wrap;">Protalix and Pfizer are aware of currently proposed legislation in the United States that may create or affect the regulatory pathway for a follow-on biologic product to the Licensed Product.  [***]  To the extent required to establish standing, and possibly to comply with heretofore unknown regulations accompanying this regulatory pathway, [***], shall reasonably cooperate with [***] in any litigation or administrative action at [***] expense and shall commence or join in any such litigation or administrative action at [***] request and</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">42<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">expense.  The amount of any recovery from any such proceedings shall first be used to pay reasonable costs, including attorneys&#8217; fees and the remaining amount of the recovery will be [***].</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.8</font><a name="_Toc428737046"></a><a name="_Toc428737394"></a><a name="_Toc428738087"></a><a name="_Toc428739947"></a><a name="_Toc431831987"></a><a name="_Toc431832316"></a><a name="_Toc434628897"></a><a name="_Ref244629818"></a><a name="_Toc428736701"></a><a name="_Ref429865285"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Other Actions by a Third Party</u><font style="white-space:pre-wrap;">.  Each party shall promptly notify the other in the event of any (a) </font><a name="OLE_LINK78"></a>claims by a Third Party of alleged patent infringement by Pfizer or Protalix or any of their respective Affiliates with respect to [***] of a Compound ([***]) or Licensed Product or (b) legal or administrative action by any Third Party involving a Protalix Patent Right <a name="OLE_LINK108"></a><a name="OLE_LINK109"></a>(other than Protalix Patent Rights directed solely to [***]) <font style="white-space:pre-wrap;">of which it becomes aware, including any nullity, revocation, reexamination or compulsory license proceeding.  Pfizer shall have the first right, but no obligation, to defend against any such action involving such Protalix Patent Right in the Territory when the alleged patent infringement would reasonably be expected to [***], and any such defense shall be </font><a name="_DV_C12"></a>[***].<font style="white-space:pre-wrap;">  Protalix, upon request of Pfizer, agrees to join in any such action [***] and in any event to cooperate with Pfizer [***]  If Pfizer fails to defend Protalix against any such action involving a Protalix Patent Right, then Protalix shall have the right to defend such action, and any such defense shall be[***].  Pfizer, upon request of Protalix, shall reasonably cooperate with Protalix in any such action </font>[***].</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.9</font><a name="_Toc428737047"></a><a name="_Toc428737395"></a><a name="_Toc428738088"></a><a name="_Toc428739948"></a><a name="_Toc431831988"></a><a name="_Toc431832317"></a><a name="_Toc434628898"></a><a name="_Toc428736702"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation to Inventors</u><font style="white-space:pre-wrap;">.  </font>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.10</font><a name="_Toc428737048"></a><a name="_Toc428737396"></a><a name="_Toc428738089"></a><a name="_Toc428739949"></a><a name="_Toc431831989"></a><a name="_Toc431832318"></a><a name="_Toc434628899"></a><a name="_Toc428736703"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Patent Marking</u><font style="white-space:pre-wrap;">.  Each party shall comply with the patent marking statutes in each Country in which a Licensed Product in the Field is made, offered for sale, sold or imported by such party, its Affiliates and sublicensees.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">8.11</font><a name="_Toc428737049"></a><a name="_Toc428737397"></a><a name="_Toc428738090"></a><a name="_Toc428739950"></a><a name="_Toc431831990"></a><a name="_Toc431832319"></a><a name="_Toc434628900"></a><a name="_Ref247370216"></a><a name="_Toc428736704"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">In-Licensed Patents</u><font style="white-space:pre-wrap;">.  With respect to this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8</u>, &#8220;Protalix&#160;Patent Rights&#8221; shall include Patent Rights that are Controlled by Protalix or any of its Affiliates pursuant to a Third Party License (<i style="font-style:italic;">i.e.,</i> such Patent Rights are not owned by Protalix or any of its Affiliates) only if [***]</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 9.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_Ref244600172"></a><a name="_Ref244602174"></a><a name="_Ref244609085"></a><a name="_Ref244628784"></a><a name="_Ref246300655"></a><a name="_Toc428350789"></a><a name="_Toc428351632"></a><a name="_Toc428409548"></a><a name="_Toc428410106"></a><a name="_Toc428410160"></a><a name="_Toc428410259"></a><a name="_Toc428736356"></a><a name="_Toc428736705"></a><a name="_Toc428737050"></a><a name="_Toc428737398"></a><a name="_Toc428738091"></a><a name="_Toc428739951"></a><a name="_Toc431831991"></a><a name="_Toc434628901"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">CONFIDENTIALITY; PUBLICATION</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.1</font><a name="_Toc428737051"></a><a name="_Toc428737399"></a><a name="_Toc428738092"></a><a name="_Toc428739952"></a><a name="_Toc431831992"></a><a name="_Toc431832320"></a><a name="_Toc434628902"></a><a name="_Ref244629445"></a><a name="_Toc428736706"></a><a name="_Ref244658922"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><font style="white-space:pre-wrap;">Pfizer and Protalix each agree that during the Term and for five (5) years after the Term, it will keep confidential, and will cause its Affiliates to keep confidential, all of the other party&#8217;s Confidential Information that is disclosed to it, or to any of its Affiliates.  Pfizer and Protalix each agree to take such action, and to cause its Affiliates to take such action, to preserve the confidentiality of Protalix Confidential Information and Pfizer Confidential Information, respectively, as it would customarily take to preserve the confidentiality of its own similar types of confidential information.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font>Each of Pfizer, Protalix and their respective Affiliates agree (i) to use Protalix Confidential Information and Pfizer Confidential Information, respectively, only as expressly permitted in this Agreement and (ii) not to disclose Protalix Confidential Information</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">43<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">and Pfizer Confidential Information, respectively, to any Third Parties under any circumstance without the prior consent of the other party, except as expressly permitted in this Agreement.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.2</font><a name="_Toc428737052"></a><a name="_Toc428737400"></a><a name="_Toc428738093"></a><a name="_Toc428739953"></a><a name="_Toc431831993"></a><a name="_Toc431832321"></a><a name="_Toc434628903"></a><a name="_Ref244629461"></a><a name="_Ref245627715"></a><a name="_Toc428736707"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Permitted Disclosure of Confidential Information</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure of Protalix Confidential Information</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>Notwithstanding anything to the contrary in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9</u><font style="white-space:pre-wrap;">, Pfizer may disclose Protalix Confidential Information:  (A) to Governmental Authorities (x) to the extent desirable to obtain or maintain Regulatory Approvals for the Compound or Licensed Product within the Territory, and (y) in order to respond to inquiries, requests or investigations relating to this Agreement; (B) to Sublicensees, outside consultants, contractors, advisory boards, managed care organizations, and non-clinical and clinical investigators, in each case to the extent desirable to Develop, register or Commercialize the Compound or Licensed Product; </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided </u>that Pfizer shall obtain the same confidentiality obligations and degree of care from such Third Parties as it obtains with respect to its own similar types of confidential information; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided further</u> that no Protalix Confidential Information consisting of non-public information relating to Protalix&#8217;s manufacturing know-how may be disclosed (and, notwithstanding anything to the contrary herein, Protalix shall not have any obligation under this Agreement to disclose any such manufacturing know-how) to any Sublicensee that is a direct competitor of Protalix in the field of plant cell expressed biologics manufacturing, except to the extent such disclosure is necessary for Pfizer to identify and establish an alternative source of supply of Drug Substance pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.21(d)</u>; (C) in connection with filing or prosecuting Patent Rights or trademark rights as permitted by this Agreement; (D) in connection with prosecuting or defending litigation as permitted by this Agreement; (E) in connection with or included in scientific presentations and publications relating to the Compound or Licensed Product, including abstracts, posters, journal articles and the like, and posting results of and other information about clinical trials to clinicaltrials.gov or PhRMA websites; and (F) to the extent necessary or desirable in order to enforce its rights under this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="white-space:pre-wrap;">If Pfizer is required or requested to disclose Protalix Confidential Information (x) as required by Law or legal proceedings or (y) as required to be contained in Pfizer&#8217;s financial statements prepared in accordance with GAAP, as applied on a consistent basis, Pfizer shall (1) with respect to disclosures described in clause (x), use Commercially Reasonable Efforts to obtain confidential treatment of financial and trade secret information, and (2) with respect to disclosures described in clauses (x) and (y), if reasonably practicable under the circumstances, give Protalix sufficient advance notice of the text so that Protalix will have the opportunity to seek, at its own cost, an appropriate protective order or other remedy or waive compliance with the provisions of this Agreement.  If Protalix seeks a protective order, Pfizer will cooperate.  If Protalix fails to obtain a protective order or waive compliance with the relevant portions of this Agreement, Pfizer will disclose only that portion of information concerning the Compound or Licensed Product which its legal counsel determines it is required to disclose.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">44<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclosure of Pfizer Confidential Information</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><a name="_Ref244609126"></a>Notwithstanding anything to the contrary in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 9</u>, Protalix may disclose Pfizer Confidential Information to: (x) Governmental Authorities in order to respond to inquiries, requests or investigations relating to this Agreement or to comply with applicable Laws and (y) to the extent necessary or desirable in order to enforce its rights under this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>If Protalix is required or requested to disclose Pfizer Confidential Information (x) as required by Law or legal proceedings or in connection with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.2(b)(i)</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><font style="white-space:pre-wrap;">above or (y) as required to be contained in Protalix financial statements prepared in accordance with GAAP, as applied on a consistent basis, Protalix shall (1) with respect to disclosures described in clause (x), use Commercially Reasonable Efforts to obtain confidential treatment of financial and trade secret information, and (2) with respect to disclosures described in clauses (x) and (y), if reasonably practicable under the circumstances, give Pfizer sufficient advance notice of the text so that Pfizer will have the opportunity to seek, at its own cost, an appropriate protective order or other remedy or waive compliance with the provisions of this Agreement.  If Pfizer seeks a protective order, Protalix will cooperate.  If Pfizer fails to obtain a protective order or waive compliance with the relevant portions of this Agreement, Protalix will disclose only that portion of information concerning the Compound or Licensed Product which its legal counsel determines it is required to disclose.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><a name="_Ref244609162"></a>If Protalix desires to disclose Pfizer Confidential Information that (x) has been announced previously in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.4</u> (Publicity), or (y) has been announced previously by Pfizer, such disclosure is permitted so long as (1) it is consistent with such previously announced statement and (2) Pfizer is permitted a review and comment period of no fewer than sixty (60) days prior to the planned disclosure to redact any Pfizer Confidential Information and ensure the disclosure is within the scope of previous disclosures as set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.2(b)(iii)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.3</font><a name="_Toc428737053"></a><a name="_Toc428737401"></a><a name="_Toc428738094"></a><a name="_Toc428739954"></a><a name="_Toc431831994"></a><a name="_Toc431832322"></a><a name="_Toc434628904"></a><a name="_Ref245627736"></a><a name="_Ref245627780"></a><a name="_Ref246430313"></a><a name="_Ref246430328"></a><a name="_Ref246430368"></a><a name="_Ref246430402"></a><a name="_Ref246430576"></a><a name="_Ref246430710"></a><a name="_Ref246517179"></a><a name="_Ref246517212"></a><a name="_Ref246517237"></a><a name="_Ref246517263"></a><a name="_Toc428736708"></a><a name="_Ref244609182"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Publication</u>.<font style="white-space:pre-wrap;">  </font><a name="_Ref246430711"></a><a name="_Ref246430326"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="OLE_LINK29"></a><a name="OLE_LINK32"></a><a name="_Ref246430403"></a><a name="_Ref246517238"></a>Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.3</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(d)</u>, neither Pfizer nor any of its Affiliates or their respective employees, consultants, contractors and agents shall publish or present any information, including the results of any preclinical or clinical studies, with respect to the Compound or Licensed Product unless Pfizer has used Commercially Reasonable Efforts to provide Protalix with thirty (30) days&#8217; notice prior to any such publication or presentation.<a name="_DV_M748"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref431237946"></a>Subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.3</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(c)</u> and <a name="_DV_M749"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.3</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(d)</u>, neither Protalix nor any of its Affiliates or their respective employees, consultants, contractors, licensees and agents shall publish or present any information, including the results of any preclinical or clinical studies, with respect to the Compound ([***]) or Licensed Product without the prior written approval of Pfizer ([***]), except as may be required by Law or legal proceedings.<a name="_DV_M750"></a><a name="_Ref246430577"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">45<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref246517214"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.3</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)</u> does not prohibit: (i) Protalix and its Affiliates (and their respective employees, consultants, contractors, licensees and agents) from publishing or presenting information relating to the development or use of the System that does not contain information with respect to the Compound (other than the Oral Formulation) or Licensed Product; (ii) Protalix and its Affiliates (and their respective employees, consultants, contractors, licensees and agents) from publishing or presenting information relating to the Oral Formulation; or (iii) Protalix and its Affiliates (and their respective employees, consultants, contractors, licensees and agents) from publishing or presenting information that has been either previously published or presented by Protalix in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.3</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)</u><font style="white-space:pre-wrap;"> or by Pfizer.  Protalix will use Commercially Reasonable Efforts to provide Pfizer a copy of any such proposed publication or presentation described in clauses (i) or (ii) of this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.3</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(c)</u> at least thirty (30) days prior to any such publication or presentation.<a name="_DV_M751"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font><a name="_Ref246517182"></a>Nothing in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.3</u> shall be construed to (a) limit the rights of either party&#8217;s Third Party clinical investigators to publish the results of their studies or (b) prevent either party from complying with applicable Law with respect to the disclosure of clinical study data and results or of any other material matter or information.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.4</font><a name="_Toc428737054"></a><a name="_Toc428737402"></a><a name="_Toc428738095"></a><a name="_Toc428739955"></a><a name="_Toc431831995"></a><a name="_Toc431832323"></a><a name="_Toc434628905"></a><a name="_Ref246430736"></a><a name="_Toc428736709"></a><a name="_Ref244609146"></a><a name="_Ref244609204"></a><a name="_Ref245627757"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Publicity</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref246430734"></a>The public announcement of the execution of this Agreement is set forth on <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit I</u> attached hereto and shall be promptly disseminated as a press release following the execution of this Agreement by Protalix. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref246430793"></a>Except as set forth in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.3</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.4</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)</u> or <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.4</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(c)</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u>or with respect to any activities or contemplated activities by Protalix outside of the Territory, Protalix shall not make (and shall cause its Affiliates not to make) any public statement (written or oral), including in analyst meetings, concerning the terms of, or events related to, this Agreement or concerning the Licensed Product in the Territory without the prior written approval of Pfizer (which may be withheld in its sole and final discretion) except where such statement: (i) is required by Law or legal proceedings (or to respond to a specific request of the securities exchange upon which Protalix&#8217;s securities are listed); (ii) is required to be contained in Protalix financial statements prepared in accordance with GAAP; (iii) has been announced previously in accordance with this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.4</u><font style="white-space:pre-wrap;">; or (iv) has been announced previously by Pfizer; so long as, in the case of (iii) or (iv), such public statement is consistent with such previously announced statement.  In the case of any public statement (written or oral) that is required by Law or legal proceedings, Protalix shall (and shall cause its Affiliates to) (x) use Commercially Reasonable Efforts to obtain confidential treatment of financial and trade secret information (except in connection with press releases) and (y) if reasonably practicable under the circumstances, give Pfizer sufficient advance notice of the text so that Pfizer will have the opportunity to comment upon the statement, and give due consideration to any specific reasonable comments of Pfizer on such text timely received from Pfizer.</font><font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_Ref246430754"></a><a name="_Ref431237930"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.4(b)</u><font style="white-space:pre-wrap;"> does not prohibit Protalix from making public announcements that any of the following has commenced or has been completed:  any [***]; </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">46<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="white-space:pre-wrap;"> that such public announcement complies with all applicable Laws.  Protalix will provide Pfizer a copy of any such proposed public announcement at least ten (10) Business Days prior to such announcement so that Pfizer will have the opportunity to comment upon the announcement, and give due consideration to any specific reasonable comments of Pfizer on such text timely received from Pfizer.</font><font style="white-space:pre-wrap;">  For the avoidance of doubt, this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.4(c)</u> shall be subject to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.3(b)</u>.<font style="white-space:pre-wrap;">  </font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">9.5</font><a name="_Toc428737055"></a><a name="_Toc428737403"></a><a name="_Toc428738096"></a><a name="_Toc428739956"></a><a name="_Toc431831996"></a><a name="_Toc431832324"></a><a name="_Toc434628906"></a><a name="_Ref244598824"></a><a name="_Toc428736710"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Filing, Registration or Notification of the Agreement</u><font style="white-space:pre-wrap;">.  If a party determines that it is required by Law to publicly file, register or notify this Agreement with a Governmental Authority, such party shall provide to the other party a redacted version of this Agreement indicating the sections of the Agreement to be redacted in such filing and both parties shall agree in good faith upon a final redacted version of the Agreement for such filing (the &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Redacted Agreement</u><font style="white-space:pre-wrap;">&#8221;).  The disclosing party shall (a) initially file the Redacted Agreement, (b) request, and use Commercially Reasonable Efforts to obtain, confidential treatment of all terms redacted from this Agreement, as reflected in the Redacted Agreement, for a period of at least ten (10) years, (c) permit the other party to review and approve such request for confidential treatment and any subsequent correspondence with respect thereto at least five (5) Business Days prior to its submission to such Governmental Authority, (d) promptly deliver to the other party any written correspondence received by it or its representatives from such Governmental Authority with respect to such confidential treatment request and promptly advise the other party of any other communications between it or its representatives with such Governmental Authority with respect to such confidential treatment request, (e) upon the written request of the other party, request an appropriate extension of the term of the confidential treatment period for this Agreement, the Original Agreement and the First Amendment, and (vi) if such Governmental Authority requests any changes to the redactions set forth in the Redacted Agreement, use Commercially Reasonable Efforts to support the redactions in the Redacted Agreement as originally filed and shall not agree to any changes to the Redacted Agreement without first discussing such changes with the other party and taking the other party&#8217;s comments into consideration when deciding whether to agree to such changes.  Each party shall be responsible for its own legal and other external costs in connection with any such filing, registration or notification.</font><font style="white-space:pre-wrap;">  Notwithstanding the foregoing or anything to the contrary herein, Pfizer acknowledges and agrees that Protalix BioTherapeutics, Inc. shall have the right to describe (and, as reasonably necessary, include) this Agreement in its U.S. Securities and Exchange Commission (&#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SEC</u>&#8221;) filings; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that Protalix shall give Pfizer sufficient advance notice of the text describing this Agreement in its filings with the SEC so that Pfizer will have the opportunity to comment upon such description, and Protalix shall give due consideration to any specific reasonable comments of Pfizer on such description timely received from Pfizer.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 10.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_Toc428350790"></a><a name="_Toc428351638"></a><a name="_Toc428409549"></a><a name="_Toc428410107"></a><a name="_Toc428410161"></a><a name="_Toc428410260"></a><a name="_Toc428736357"></a><a name="_Toc428736711"></a><a name="_Toc428737056"></a><a name="_Toc428737404"></a><a name="_Toc428738097"></a><a name="_Toc428739957"></a><a name="_Toc431831997"></a><a name="_Toc434628907"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">REPRESENTATIONS, WARRANTIES AND COVENANTS</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.1</font><a name="_Toc428737057"></a><a name="_Toc428737405"></a><a name="_Toc428738098"></a><a name="_Toc428739958"></a><a name="_Toc431831998"></a><a name="_Toc431832325"></a><a name="_Toc434628908"></a><a name="_Ref244658465"></a><a name="_Ref244658510"></a><a name="_Ref245019748"></a><a name="_Ref245623860"></a><a name="_Ref245796481"></a><a name="_Ref246824882"></a><a name="_Toc428736712"></a><a name="_Ref429830654"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Representations, Warranties and Covenants</u><font style="white-space:pre-wrap;">.  </font>Protalix hereby represents and warrants as of the Second Amendment Effective Date (unless otherwise indicated) and covenants to Pfizer as follows: </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font>Protalix has the corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder, and the execution, delivery and </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">47<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="white-space:pre-wrap;">performance of this Agreement by Protalix have been duly and validly authorized and approved by proper corporate action on the part of Protalix, and Protalix has taken all other action required by Law, its certificate of incorporation, by-laws or other organizational documents or any agreement to which it is a party or to which it may be subject, required to authorize such execution, delivery and performance.  Assuming due authorization, execution and delivery on the part of Pfizer, this Agreement constitutes a legal, valid and binding obligation of Protalix, enforceable against Protalix in accordance with its terms.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font>The execution and delivery of this Agreement by Protalix and the performance by Protalix contemplated hereunder does not and will not violate any Laws (as in effect on the Second Amendment Effective Date), except for such violations that would not have an adverse effect on the ability of Protalix to perform its obligations under this Agreement, or any order of any court or Governmental Authority in effect on the Second Amendment Effective Date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><font style="white-space:pre-wrap;">To the knowledge of Protalix, the Protalix Patent Rights owned by Protalix or its Affiliates are valid and enforceable and no Third Party (i) is infringing any such  Protalix Patent Rights or (ii) has challenged the validity or enforceability of the Protalix Patent Rights owned by Protalix or its Affiliates (including by way of example through the institution or written threat of institution of interference, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign entity).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font>To the knowledge of Protalix, neither (i) the Manufacture, use or Development (including the use or provision of Licensed Product in Early Access Programs) by Protalix (or its Affiliates) of the Drug Substance or Licensed Product on or prior to the Second Amendment Effective Date has infringed nor (ii) the Manufacture, use, Development, sale, offer for sale, supply or importation by Protalix or Pfizer (or their respective Affiliates) of the Drug Substance or Licensed Product (as currently constituted) on or prior to the Second Amendment Effective Date or as contemplated by this Agreement has infringed or would infringe any issued Patent of any Third Party that exists on the Second Amendment Effective Date or, if and when issued, any valid claim within any Third Party Patent Application published before the Second Amendment Effective Date.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(e)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u> contains a complete and correct list as of the Second Amendment Effective Date of all Patents and Patent Applications owned by or otherwise Controlled by Protalix (and indicating which entity owns or Controls each Patent and Patent Application and which are owned and which are Controlled) covering the Compound, any Licensed Product and the System. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(f)</font><a name="OLE_LINK76"></a><a name="OLE_LINK77"></a>Protalix is the sole and exclusive owner of all the Protalix Patent Rights and Protalix Technology (other than Patent Rights licensed to Protalix as described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u>), <font style="white-space:pre-wrap;">free of any lien, encumbrance, charge, security interest, mortgage or other similar restriction, and no Person (including any Affiliate of Protalix) has any right, interest or claim in or to, and neither Protalix nor any of its Affiliates has entered into any agreement granting any right, interest or claim in or to any Protalix Patent Rights owned by Protalix or its Affiliates or Protalix Technology to any Third Party, including any academic organization or agency.  </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">48<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(g)</font><a name="_Ref245623862"></a>Protalix has complied in all material respects with all applicable Laws, including any disclosure requirements, in connection with the filing, prosecution and maintenance of the Protalix Patent Rights (other than Patent Rights licensed to Protalix) in the Territory.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(h)</font><font style="white-space:pre-wrap;">Prior to the Second Amendment Effective Date, to the extent such activities have been conducted by Protalix, its Affiliates or Third Parties acting on behalf of Protalix, the Compound, Drug Substance and Licensed Product have been Developed, Manufactured, stored, labeled, distributed and tested by Protalix and its Affiliates and, to the knowledge of Protalix, by any Third Parties acting on behalf of Protalix, in compliance in all material respects with all applicable Laws.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(i)</font><a name="_Ref428305475"></a>Other than Patent Rights licensed to Protalix as described in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u>, none of the rights of Protalix or its Affiliates under the Protalix Patent Rights were developed with federal funding from the United States government or any other Governmental Authority, other than grants received by Protalix from the Office of the Chief Scientist of the Israeli Ministry of Industry, Trade and Labor (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Israel Grant</u><font style="white-space:pre-wrap;">&#8221;), a copy of which Protalix has provided to Pfizer prior to the Second Amendment Effective Date.  No obligations, restrictions or covenants have been imposed upon Protalix or its licensees, the Drug Substance or the Licensed Product in connection with the Israel Grant.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(j)</font>Protalix has obtained assignments from the inventors of all inventorship rights relating to the Protalix Patent Rights (other than Patent Rights licensed to Protalix), and all such assignments of inventorship rights covering the Protalix Patent Rights (other than Patent Rights licensed to Protalix) are valid and enforceable.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(k)</font><font style="white-space:pre-wrap;">Each Third Party License as heretofore delivered by Protalix to Pfizer represents the complete agreement and understanding between the Third Party licensor(s) under such Third Party License and Protalix relating to the Protalix Patent Rights and Protalix Technology which are the subject of such Third Party License.  No Third Party License has been modified, supplemented or amended, other than by amendments thereto provided</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><font style="white-space:pre-wrap;">to Pfizer prior to the Second Amendment Effective Date.  Except for the Third Party Licenses listed on </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit C</u><font style="white-space:pre-wrap;">, there are no agreements to which Protalix or any of its Affiliates is a party pursuant to which Protalix or any of its Affiliates has a license, or an option to obtain a license, or holds an immunity from suit, with respect to patents which (i) are pending, applied for, granted or registered, and (ii) but for Protalix&#8217;s rights under such agreements, could be asserted by Third Parties to be infringed by the Manufacture, distribution, use, marketing or sale of the Drug Substance or Licensed Product.  Each Third Party License is in full force and effect, all payments to date required to be made thereunder by Protalix have been made, and Protalix is in compliance in all respects with its respective obligations thereunder.  [***]  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(l)</font>Protalix has previously delivered to Pfizer all of its material agreements with any Third Parties regarding the Development, supply and Manufacture of all goods and services relating to the Drug Substance and Licensed Product to the extent requested by Pfizer, none of which have been modified, supplemented or amended in any material respect, other than </div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">49<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">by amendments thereto provided<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><font style="white-space:pre-wrap;">to Pfizer prior to the Second Amendment Effective Date.  Each such agreement is in full force and effect, all payments to date required to be made thereunder by Protalix have been made, and Protalix is in compliance in all respects with its respective obligations thereunder.</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(m)</font>Protalix has heretofore disclosed to Pfizer all material scientific and technical information and all material information relating to safety and efficacy known to it or its Affiliates with respect to the Drug Substance and Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(n)</font>Protalix has heretofore disclosed to Pfizer all material correspondence and contact information between Protalix and the FDA and any other Governmental Authorities regarding the Drug Substance or Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(o)</font><a name="_Ref244658467"></a>Neither the execution and delivery of this Agreement nor the performance hereof by Protalix requires Protalix to obtain any permits, authorizations or consents from any Governmental Authority or from any other Person, and such execution, delivery and performance will not result in the breach of or give rise to any right of termination, rescission, renegotiation or acceleration under, or trigger any other rights under, any agreement or contract to which Protalix is a party or to which it may be subject that relates to the Protalix Patent Rights, Protalix Technology, Drug Substance or Licensed Product.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(p)</font>There is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the knowledge of Protalix, threatened against Protalix, any of its Affiliates or any Third Party, in each case in connection with the Protalix Patent Rights owned by Protalix, Protalix Technology owned by Protalix, the Drug Substance, the Licensed Product, the System, Protalix&#8217;s business practices relating to the Drug Substance or the Licensed Product, Protalix&#8217;s compliance with the Foreign Corrupt Practices Act of 1977, as amended and the U.K. Bribery Act, or relating to the transactions contemplated by this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(q)</font>To the knowledge of Protalix, information provided by Protalix in response to any of Pfizer&#8217;s due diligence requests prior to the Second Amendment Effective Date was in all material respects complete, truthful and accurate.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(r)</font><a name="_Ref432012926"></a><a name="_Ref244598087"></a><font style="white-space:pre-wrap;">Protalix and, to Protalix&#8217;s knowledge, any agent or subcontractor of Protalix engaged in activities related to this Agreement has not and will not directly or indirectly offer or pay, or authorize such offer or payment, of any money or anything of value or improperly seek to influence any Government Official or any other person in order to gain an improper advantage, and has not accepted, and will not accept in the future such payment in connection with this Agreement.  For purposes of this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1</u>, a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Government Official</u><font style="white-space:pre-wrap;">&#8221; is defined as and includes:  (i) any elected or appointed government official (e.g., a member of a ministry of health); (ii) any employee or person acting for or on behalf of a Government Official, agency, or enterprise performing a governmental function; (iii) any political party, officer, employee, or person acting for or on behalf of a political party or candidate for public office; (iv) an employee or person acting for or on behalf of a public international organization; or (v) any person otherwise categorized as a Government Official under local Law where &#8220;Government&#8221; </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">50<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="white-space:pre-wrap;">includes all levels and subdivisions of non-U.S. governments (i.e., local, regional, or national and administrative, legislative, or executive).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(s)</font><a name="_Ref431295356"></a><a name="_Ref242513527"></a>To the knowledge of Protalix, all information provided by Protalix or its Affiliate to Pfizer during pre-contractual due diligence, including the information provided in the compliance questionnaire (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance Questionnaire</u><font style="white-space:pre-wrap;">&#8221;), is in all material respects complete, truthful and accurate.  Further, Protalix undertakes to promptly update this representation and warranty if (during the Term) Protalix, or any of its employees, or individuals, or subcontractors who will be primarily responsible for performing under this Agreement, or a relative of such an employee or individual or subcontractor, becomes a Government Official or, if a government or Government Official becomes an owner of five percent (5%) or more of Protalix.</font> </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(t)</font><a name="_Ref245796489"></a>Protalix will comply in all material respects with Pfizer&#8217;s Anti-Bribery and Anti-Corruption Principles set forth on <a name="OLE_LINK30"></a><a name="OLE_LINK31"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(t)</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(u)</font>Protalix will complete and submit to Pfizer an executed copy of the compliance certification attached hereto as <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit K</u> on the Second Amendment Effective Date. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(v)</font>[***] </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(w)</font>Protalix has implemented, and will maintain, a system of internal accounting controls designed to ensure the making and keeping of fair and accurate books, records, and accounts with respect to Protalix&#8217;s business or any services provided under the Agreement, as and to the extent required under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.8</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.15</u> hereof.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(x)</font>Protalix undertakes to promptly inform Pfizer if it becomes aware of any compliance issues related to any allegations of improper payments to healthcare professionals or Government Officials that have not been previously reported and related to any discussions, notices or changes with respect to any investigation by Governmental Authorities or Regulatory Authorities or prosecution involving allegations of corruption or serious criminal misconduct involving its business.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(y)</font>Protalix will, subject to and in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.15</u> hereof, permit, during the Supply Term and for [***] after final payment has been made under the Agreement, Pfizer&#8217;s internal and external auditors access to any relevant books, documents, papers, and records of Protalix involving transactions related to the Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(z)</font>With respect to the Commercialization of the Licensed Product in Israel, since January 1, 2015, Protalix has not (i) materially altered its activities and practices with respect to inventory levels of the Licensed Product maintained at the wholesale, pharmacy or institutional levels, including its practices with respect to product samples, or (ii) sold, transferred or given any supplies or samples of the Licensed Product to any Third Party in or for use in Israel, in each case, except in the ordinary course of business that is consistent with past practice.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(aa)</font><font style="white-space:pre-wrap;">[***]  </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">51<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.2</font><a name="_Toc428737058"></a><a name="_Toc428737406"></a><a name="_Toc428738099"></a><a name="_Toc428739959"></a><a name="_Toc431831999"></a><a name="_Toc431832326"></a><a name="_Toc434628909"></a><a name="_Ref245797921"></a><a name="_Ref245797927"></a><a name="_Ref246431158"></a><a name="_Toc428736713"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Manufacturing Representations, Warranties and Covenants</u><font style="white-space:pre-wrap;">.  Each party hereby represents and warrants as of the Second Amendment Effective Date (unless otherwise stated) and covenants to the other party as follows:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref245797923"></a>All Drug Substance and Licensed Product Manufactured and supplied hereunder by, or under authority of, such party shall be Manufactured and supplied such that:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><font style="white-space:pre-wrap;">Any Facility and all equipment, tooling and molds utilized in the Manufacture and supply of Drug Substance and Licensed Product hereunder by such party shall, during the Term, be maintained in good operating condition and shall be maintained and operated in accordance with all applicable Laws.  The Manufacturing and storage operations, procedures and processes utilized by such party in Manufacture and supply of Drug Substance and Licensed Product hereunder (including any Facility) shall be in full compliance with all applicable Laws, including GMP and health and safety Laws.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="white-space:pre-wrap;">Such party shall perform all of its Manufacturing and supply obligations under this Agreement in full compliance with all applicable Laws.  Such party shall hold during the Term all licenses, permits and similar authorizations required by any Governmental Authority for such party to perform its Manufacturing and supply obligations under this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref245797928"></a>The Drug Substance and Licensed Product, as applicable, furnished by such party [***]:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>shall be Manufactured, packaged, labeled, handled, stored and shipped in accordance with, shall be of the quality specified in, and shall conform to, the Product Specifications;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>shall be Manufactured, packaged, labeled, handled, stored and shipped in compliance with all applicable Laws including GMP, and in accordance with the Quality Agreement (with respect to Drug Substance and/or Licensed Product furnished by Protalix to Pfizer under this Agreement) and any other quality assurance requirements provided in writing to such party by the other party, and this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>shall not contain any material that has not been used, handled or stored in accordance with the Product Specifications, all applicable Laws, the Quality Agreement (with respect to Drug Substance and/or Licensed Product furnished by Protalix to Pfizer under this Agreement) and any other quality assurance requirements of the other party or the supplier of such material, and this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font>shall not contain any material that would cause the Drug Substance or Licensed Product to be adulterated or misbranded within the meaning of any Laws;</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">52<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font>shall be free from defects in material and workmanship; and</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(vi)</font>shall, at the time delivered, have a remaining shelf-life as specified in the Quality Agreement (with respect to Drug Substance and/or Licensed Product furnished by Protalix to Pfizer under this Agreement) and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.8(a)</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font>Such party does not currently employ and will not employ during the Term, and such party does not use as a subcontractor and will not use during the Term, and such party&#8217;s subcontractors do not currently employ and will not employ or engage during the Term, any Person that has been debarred or is subject to debarment or has otherwise been disqualified or suspended from performing scientific or clinical investigations or otherwise subjected to any restrictions or sanctions by the FDA or any other Governmental Authority or Regulatory Authority or professional body with respect to the performance of scientific or clinical investigations; any other Person who by virtue of any Laws is or may be disqualified, restricted or prevented in any way from performing the services to be <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided </u>under this Agreement; or any Person convicted of a criminal offense in relation to:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>In respect of a company, partnership or association, the development or approval, including the process for development or approval of an abbreviated drug application;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>In respect of an individual:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(A)</font>the development or approval of any drug product or otherwise relating to the regulation of any drug product; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(B)</font>bribery, payment of illegal gratuities, fraud, perjury, false statement, racketeering, blackmail, extortion, falsification or destruction of records or interference with, obstruction of an investigation into a prosecution of any criminal offense.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font>Notwithstanding the foregoing in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.2</u>, Pfizer shall not be responsible for any failure to conform to the representations and warranties under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.2</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.2</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(b)</u><font style="white-space:pre-wrap;">, and shall have no liability to Protalix with respect thereto to the extent that Pfizer&#8217;s failure to conform to such representations and warranties is as a result of an act or omission of Protalix, Protalix&#8217;s Affiliates or their respective agents, consultants or contractors in respect of the Manufacture of Drug Substance.  Notwithstanding the foregoing in this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.2</u>, Protalix shall not be responsible for any failure to conform to the representations and warranties under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.2</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)</u> and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.2</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(b)</u>, and shall have no liability to Pfizer with respect thereto to the extent that Protalix&#8217;s failure to conform to such representations and warranties is as a result of an act or omission of Pfizer, Pfizer&#8217;s Affiliates or their respective agents, consultants or contractors in respect of their Fill/Finish activities or supply of Licensed Product to Protalix for Commercialization in Israel or in respect of the Drug Substance after acceptance by Pfizer of the Drug Substance supplied to Pfizer, such as a failure to properly store the Drug Substance.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">53<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.3</font><a name="_Toc428737059"></a><a name="_Toc428737407"></a><a name="_Toc428738100"></a><a name="_Toc428739960"></a><a name="_Toc431832000"></a><a name="_Toc431832327"></a><a name="_Toc434628910"></a><a name="_Toc428736714"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Representations, Warranties and Covenants</u><font style="white-space:pre-wrap;">.  Each party hereby represents and warrants as of the Second Amendment Effective Date (unless otherwise indicated) and covenants to the other party as follows:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance With Environmental Laws</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>To the knowledge of such party, there is no pending or threatened governmental enforcement action or private claim against such party pursuant to applicable Environmental Law, no Release or threatened Release of Hazardous Materials, nor any other existing environmental conditions, events or circumstances that are reasonably likely to limit, impede or otherwise jeopardize such party&#8217;s ability to meet its Manufacturing obligations under this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><a name="_Ref244597906"></a>Such party shall perform all of the Manufacturing services to be <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided </u>by it hereunder in compliance with all Environmental Laws and all licenses, registrations, notifications, certificates, approvals, authorizations or permits required under applicable Environmental Laws (&#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental Permits</u>&#8221;), except where such non-compliance would not be reasonably likely to limit, impede or otherwise jeopardize such party&#8217;s ability to meet its Manufacturing obligations under this Agreement. Such party shall abate any condition or practice, regardless of whether such condition or practice constitutes non-compliance with Environmental Laws, with respect to its usage, handling, storage or disposal of Hazardous Materials, that would be reasonably likely to limit, impede or otherwise jeopardize such party&#8217;s ability to fulfill its Manufacturing obligations under this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notice to Other Party</u><font style="white-space:pre-wrap;">.  Such party shall provide the other party with reasonably prompt notice in the event of any significant event, occurrence or circumstance, including any governmental or private action in connection with such party&#8217;s compliance with applicable Environmental Laws or with respect to such party&#8217;s usage, handling, storage or disposal of Hazardous Materials, which would be reasonably likely to limit, impede or otherwise jeopardize such party&#8217;s ability to fulfill its Manufacturing obligations under this Agreement.  These could include, but are not limited to: (i) material revocation or modification of any of such party&#8217;s Environmental Permits, (ii) any action by Governmental Authorities that may reasonably lead to the material revocation or modification of such party&#8217;s Environmental Permits, (iii) any Third Party claim against the management or ownership of any Facility pursuant to applicable Environmental Law that could reasonably and materially impact such party&#8217;s obligations under this Agreement, (iv) any fire, explosion, significant accident (one causing serious injury or fatality), or catastrophic Release of Hazardous Materials, (v) any significant non-compliance with Environmental Laws, and (vi) any environmental condition or operating practice that may reasonably be believed to present a significant threat to human health, safety or the environment.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment</u><font style="white-space:pre-wrap;">.  Such party shall be solely responsible for the safe operation and maintenance of all equipment used to fulfill its Manufacturing obligations under this Agreement, and all associated employee training, regardless of whether the equipment is owned by such party, the other party or a Third Party.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">54<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Environmental, Health and Safety Reviews</u><font style="white-space:pre-wrap;">.  Each party shall permit the other party reasonable access to conduct periodic reviews during regular business hours of the environmental and health and safety practices and performance of the Facility(ies) where such party&#8217;s performance is occurring.  In connection with such audit or evaluation, such party shall assist in the other party&#8217;s completion of an Environmental Health &amp; Safety survey of such party or the scheduling of an Environmental Health &amp; Safety audit of any Facility, as applicable.  Such party will provide copies of all Environmental Permits to the other party upon request in connection with such review.  The other party shall share its findings with such party as soon as practicable and such party shall correct, at no expense to the other party, such deficiencies in its environmental and health and safety management practices that materially jeopardize its ability to fulfill its Manufacturing obligations under this Agreement.  Such party acknowledges that such reviews and evaluations conducted by the other party are for the benefit of the other party only; they are not a substitute for such party&#8217;s own environmental and health and safety management obligations under this Agreement and accordingly, such party may not rely upon them.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.4</font><a name="_Toc428737060"></a><a name="_Toc428737408"></a><a name="_Toc428738101"></a><a name="_Toc428739961"></a><a name="_Toc431832001"></a><a name="_Toc431832328"></a><a name="_Toc434628911"></a><a name="_Toc428736715"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pfizer Representations, Warranties and Covenants</u><font style="white-space:pre-wrap;">.  Pfizer hereby represents and warrants as of the Second Amendment Effective Date (unless otherwise indicated) and covenants to Protalix as follows:</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><font style="white-space:pre-wrap;">Pfizer has the corporate power and authority to execute and deliver this Agreement and to perform its obligations hereunder, and the execution, delivery and performance of this Agreement by Pfizer have been duly and validly authorized and approved by proper corporate action on the part of Pfizer, and Pfizer has taken all other action required by Law, its certificate of incorporation or by-laws, or any agreement to which it is a party or to which it may be subject, required to authorize such execution, delivery and performance.  Assuming due authorization, execution and delivery on the part of Protalix, this Agreement constitutes a legal, valid and binding obligation of Pfizer, enforceable against Pfizer in accordance with its terms.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font>The execution and delivery of this Agreement by Pfizer and the performance by Pfizer contemplated hereunder does not and will not violate any Laws, except for such violations that would not have an adverse effect on the ability of Pfizer to perform its obligation under this Agreement, or any order of any court or Governmental Authority.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font>Neither the execution and delivery of this Agreement nor the performance hereof by Pfizer requires Pfizer to obtain any permits, authorizations or consents from any Governmental Authority (other than any Regulatory Approvals relating to the Manufacture, use, importation or sale of the Compound or Licensed Product) or from any other Person, and such execution, delivery and performance will not result in the breach of or give rise to any right of termination under any agreement or contract to which Pfizer is a party or to which it may be subject, except for those breaches or rights that would not adversely affect the ability of Pfizer to perform its obligations under this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font>There is no action, claim, demand, suit, proceeding, arbitration, grievance, citation, summons, subpoena, inquiry or investigation of any nature, civil, criminal, regulatory or otherwise, in law or in equity, pending or, to the knowledge of Pfizer, threatened against Pfizer </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">55<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;">or any of its Affiliates or any Third Party relating to the transactions contemplated by this Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">10.5</font><a name="_Toc428737061"></a><a name="_Toc428737409"></a><a name="_Toc428738102"></a><a name="_Toc428739962"></a><a name="_Toc431832002"></a><a name="_Toc431832329"></a><a name="_Toc434628912"></a><a name="_Ref246865250"></a><a name="_Toc428736716"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclaimer of Warranty</u><font style="white-space:pre-wrap;">.  EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND WITH RESPECT TO THE COMPOUND, DRUG SUBSTANCE, ANY LICENSED PRODUCT, PROTALIX IMPROVEMENT, PROTALIX PATENT RIGHTS, PROTALIX TECHNOLOGY OR CONFIDENTIAL INFORMATION.  EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, EACH PARTY EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT.</font></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 11.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_Toc428350791"></a><a name="_Toc428351644"></a><a name="_Toc428409550"></a><a name="_Toc428410108"></a><a name="_Toc428410162"></a><a name="_Toc428410261"></a><a name="_Toc428736358"></a><a name="_Toc428736717"></a><a name="_Toc428737062"></a><a name="_Toc428737410"></a><a name="_Toc428738103"></a><a name="_Toc428739963"></a><a name="_Toc431832003"></a><a name="_Toc434628913"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">ADDITIONAL COVENANTS</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.1</font><a name="_Toc428737063"></a><a name="_Toc428737411"></a><a name="_Toc428738104"></a><a name="_Toc428739964"></a><a name="_Toc431832004"></a><a name="_Toc431832330"></a><a name="_Toc434628914"></a><a name="_Ref244626155"></a><a name="_Ref244626160"></a><a name="_Ref244626174"></a><a name="_Ref246646969"></a><a name="_Toc428736718"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Restrictions on Transfers and Liens</u>.<font style="white-space:pre-wrap;">  Protalix shall not (and shall cause its Affiliates not to) sell, assign or otherwise transfer to any Person any Protalix Patent Rights or any Protalix Technology (or agree to do any of the foregoing), except to the extent permitted by, and in compliance with, </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">18.6</u> (including, for the avoidance of doubt, to any permitted assignee of the Agreement permitted by and in compliance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">18.6</u><font style="white-space:pre-wrap;">). In addition, Protalix hereby covenants and agrees that Protalix shall not incur or permit to exist (and shall cause each of its Affiliates not to incur or permit to exist), with respect to any Protalix Patent Rights owned by Protalix and/or Protalix Technology owned by Protalix, any lien, encumbrance, charge, security interest, mortgage, liability, grant of license to Third Parties in the Field in the Territory or other restriction (including in connection with any indebtedness).  For purposes of clarity, this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11.1</u> is not intended to prohibit Protalix from (i) licensing to an Affiliate of Protalix or a Third Party rights under any Protalix Patent Rights or any Protalix Technology to the extent such rights have not been licensed to Pfizer pursuant to this Agreement and to the extent such license by Protalix does not otherwise conflict with the terms of this Agreement, or (ii) otherwise entering into any collaboration, license, assignment or other commercial agreement with a Third Party with respect to the Protalix Patents or Protalix Technology in relation to any products (excluding the Licensed Product) outside of the Field.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.2</font><a name="_Toc428737064"></a><a name="_Toc428737412"></a><a name="_Toc428738105"></a><a name="_Toc428739965"></a><a name="_Toc431832005"></a><a name="_Toc431832331"></a><a name="_Toc434628915"></a><a name="_Ref246342853"></a><a name="_Ref246343972"></a><a name="_Toc428736719"></a><a name="_Ref429830714"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Licenses and Agreements</u><font style="white-space:pre-wrap;">.  Protalix (a) shall not execute or otherwise permit, and shall cause its Affiliates to refrain from executing or otherwise permitting, any amendment, modification or waiver to any of the Third Party Licenses without the prior written consent of Pfizer, (b) shall not make any election or exercise any right or option (or omit to take any action) which would, and shall cause its Affiliates to refrain from making any election or exercising any right or option (or omitting to take any action) which would, terminate or relinquish in whole or in part any right under a Third Party License, (c) shall comply, and shall cause its Affiliates to comply in all respects, with all of its, and its Affiliates&#8217;, obligations under the Third Party Licenses, (d) shall take, and shall cause its Affiliates to take, such actions as shall be necessary to keep in full force and effect the Third Party Licenses, and (e) shall give prompt notice to Pfizer, together with a detailed summary of outstanding issues if Pfizer so requests, of any notice received from the Third Party, of any actual or alleged defaults, breaches, violations, proposed amendments or proposed modifications of, or any proposed waivers under, any of the Third Party Licenses by any of the parties thereto.  Protalix shall not assign or otherwise transfer </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">56<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="white-space:pre-wrap;">any Third Party License or any of its rights or obligations thereunder to any Person (or agree to do any of the foregoing) except to the extent permitted by, and in compliance with, </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">18.6</u>.<font style="white-space:pre-wrap;">  This </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11.2</u> shall apply to the [***] to the same extent it applies to a Third Party License.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.3</font><a name="_Toc428737065"></a><a name="_Toc428737413"></a><a name="_Toc428738106"></a><a name="_Toc428739966"></a><a name="_Toc431832006"></a><a name="_Toc431832332"></a><a name="_Toc434628916"></a><a name="_Toc428736720"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compliance with Laws</u><font style="white-space:pre-wrap;">.  Each of Protalix and Pfizer shall conduct, and shall use reasonable efforts to cause its Affiliates to conduct, all its activities contemplated under this Agreement in accordance with all applicable Laws of the Country in which such activities are conducted.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.4</font><a name="_cp_blt_1_756"></a><a name="_Toc428737066"></a><a name="_Toc428737414"></a><a name="_Toc428738107"></a><a name="_Toc428739967"></a><a name="_Toc431832007"></a><a name="_Toc431832333"></a><a name="_Toc434628917"></a><a name="_Toc428736721"></a><a name="_Ref431828790"></a><a name="_cp_text_1_757"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">C</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">oordination outside the Territory</u><font style="white-space:pre-wrap;">.  Protalix and its Affiliates shall not, unless required by applicable Law, (a) conduct, or consent to or support any activities by a Third Party, with respect to the Licensed Product in the Field outside the Territory (including investigator-initiated research) if, in the good faith and reasonable judgment of Protalix, such activities would reasonably be expected to adversely impact the market for the Licensed Product in the Field in the Territory in any material respect, or (b) make any revisions to the labeling for the Licensed Product in the Field outside the Territory without first discussing such activities with Pfizer.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.5</font><a name="_Toc428737067"></a><a name="_Toc428737415"></a><a name="_Toc428738108"></a><a name="_Toc428739968"></a><a name="_Toc431832008"></a><a name="_Toc431832334"></a><a name="_Toc434628918"></a><a name="_Ref428259330"></a><a name="_Toc428736722"></a><a name="_cp_text_1_761"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Non-Compete</u><font style="white-space:pre-wrap;">.  From the Second Amendment Effective Date until the earlier of (a) the effective date of termination of this Agreement or (b) the [***] anniversary of the Second Amendment Effective Date, neither Protalix nor any of its Affiliates shall, directly or indirectly, alone or in collaboration with any Third Party, Commercialize in any Country in the Territory any Competing Product.</font> </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.6</font><a name="_Toc431832009"></a><a name="_Toc431832335"></a><a name="_Toc434628919"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Limitation on Non-Compete Restrictions</u><font style="white-space:pre-wrap;">.  Notwithstanding anything to the contrary herein, neither Protalix nor any of its Affiliates will be deemed to be in breach of the restrictions set forth in </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11.5</u>, if Protalix or any of its Affiliates undergoes [***] (and such Commercialization shall not be deemed to be a breach of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11.5</u>). </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.7</font>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.8</font>[***]</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">11.9</font>[***]</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 12.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_Toc428350792"></a><a name="_Toc428351652"></a><a name="_Toc428409551"></a><a name="_Toc428410109"></a><a name="_Toc428410163"></a><a name="_Toc428410262"></a><a name="_Toc428736359"></a><a name="_Toc428736724"></a><a name="_Toc428737069"></a><a name="_Toc428737417"></a><a name="_Toc428738110"></a><a name="_Toc428739970"></a><a name="_Toc431832012"></a><a name="_Toc434628920"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">[Reserved.]</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 13.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_Ref245273989"></a><a name="_Ref246491429"></a><a name="_Toc428350793"></a><a name="_Toc428351653"></a><a name="_Toc428409552"></a><a name="_Toc428410110"></a><a name="_Toc428410164"></a><a name="_Toc428410263"></a><a name="_Toc428736360"></a><a name="_Toc428736725"></a><a name="_Toc428737070"></a><a name="_Toc428737418"></a><a name="_Toc428738111"></a><a name="_Toc428739971"></a><a name="_Toc431832013"></a><a name="_Toc434628921"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">TERM</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Agreement shall be effective as of the Second Amendment Effective Date and shall remain in effect until the later of (i) the end of the term of the last to expire of the Protalix Patent Rights and (ii) the expiration of the Supply Term, unless earlier terminated pursuant to <a name="_cp_text_1_767"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14</u> (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Term</u>&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">57<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 14.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_cp_blt_1_768"></a><a name="_Ref244627076"></a><a name="_Ref245375526"></a><a name="_Ref245375949"></a><a name="_Ref245628239"></a><a name="_Toc428350794"></a><a name="_Toc428351654"></a><a name="_Toc428409553"></a><a name="_Toc428410111"></a><a name="_Toc428410165"></a><a name="_Toc428410264"></a><a name="_Toc428736361"></a><a name="_Toc428736726"></a><a name="_Toc428737071"></a><a name="_Toc428737419"></a><a name="_Toc428738112"></a><a name="_Toc428739972"></a><a name="_Toc431832014"></a><a name="_Toc434628922"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">T</b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">ERMINATION</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.1</font><a name="_cp_blt_1_770"></a><a name="_cp_blt_2_769"></a><a name="_cp_blt_2_778"></a><a name="_cp_blt_1_782"></a><a name="_cp_blt_2_781"></a><a name="_Toc428737072"></a><a name="_Toc428737420"></a><a name="_Toc428738113"></a><a name="_Toc428739973"></a><a name="_Toc431832015"></a><a name="_Toc431832339"></a><a name="_Toc434628923"></a><a name="_Ref428289310"></a><a name="_Toc428736727"></a><a name="_Ref244629507"></a><a name="_Ref246517591"></a><a name="_Ref244605986"></a><a name="_Ref244609061"></a><a name="_Ref244628849"></a><a name="_Ref244629556"></a><a name="_Ref244629838"></a><a name="_Ref244629940"></a><a name="_Ref244658978"></a><a name="_Ref245544827"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pfizer Termination Right for Convenience</u><font style="white-space:pre-wrap;">.  At any time and for any reason, Pfizer shall have the right, at Pfizer&#8217;s sole discretion, to terminate this Agreement in its entirety, or with respect to a particular Country or Countries within the Territory, such termination to be effective upon thirty (30) days prior written notice to Protalix.</font><font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.2</font><a name="_Toc428737073"></a><a name="_Toc428737421"></a><a name="_Toc428738114"></a><a name="_Toc428739974"></a><a name="_Toc431832016"></a><a name="_Toc431832340"></a><a name="_Toc434628924"></a><a name="_Ref428289367"></a><a name="_Toc428736728"></a><a name="_Ref432012937"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pfizer Termination Right for Breach</u><font style="white-space:pre-wrap;">.  If Protalix materially breaches or materially defaults in the performance or observance of any of its obligations under this Agreement related to the Manufacture of the Drug Substance (including a Failure to Supply) or a violation of any applicable anti-corruption law, and such breach or default is not cured within ninety (90) days after Pfizer provides Protalix with written notice specifying such breach or default, then, in addition to all other remedies available at law or in equity, Pfizer shall have the right to terminate this Agreement by providing Protalix written notice within ten (10) days following the expiration of such ninety (90)-day period (such termination to be effective upon receipt of such notice).</font><font style="white-space:pre-wrap;">  For the avoidance of doubt, and notwithstanding the foregoing, a breach of </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.1(r)</u> shall be considered a material breach for purposes of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">14.2</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.3</font><a name="_Toc428738115"></a><a name="_Toc428739975"></a><a name="_Toc431832017"></a><a name="_Toc431832341"></a><a name="_Toc434628925"></a><a name="_Toc428737074"></a><a name="_Toc428737422"></a><a name="_Toc428736729"></a><a name="_Ref429830762"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Right of Termination</u><font style="white-space:pre-wrap;">.  Protalix shall have no right to terminate this Agreement for any reason</font> other than as set forth in this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">14.3</u>.<font style="white-space:pre-wrap;">    If Pfizer materially breaches or materially defaults in the performance or observance of any of its obligations under this Agreement, and such breach or default is not cured within ninety (90) days after Protalix provides Pfizer with written notice specifying such breach or default, then Protalix shall have the right to terminate this Agreement by providing Protalix written notice within ten (10) days following the expiration of such ninety (90)-day period (such termination to be effective upon receipt).  For purposes of this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">14.3</u>, material breaches or material defaults in the performance or observance of any of Pfizer&#8217;s obligations under this Agreement (for which a termination right may be triggered if such breach is not cured as set forth above) shall be limited to: (i) Pfizer&#8217;s failure to pay the Price for the Drug Substance in accordance with the terms of this Agreement and such failure to pay is not being disputed in good faith; and (ii) Pfizer&#8217;s breach of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.7</u><font style="text-decoration-color:#000000;">.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.4</font><a name="_Toc428737075"></a><a name="_Toc428737423"></a><a name="_Toc428738116"></a><a name="_Toc428739976"></a><a name="_Toc431832018"></a><a name="_Toc431832342"></a><a name="_Toc434628926"></a><a name="_Ref428308751"></a><a name="_Toc428736730"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Continuing and Accrued Obligations and Surviving Provisions</u>.<font style="white-space:pre-wrap;">  Termination of this Agreement for any reason (i) shall be without prejudice to and shall not impair or limit in any manner (A) Protalix&#8217;s right to receive any payment from Pfizer that accrued in accordance with this Agreement prior to the effective date of such termination, including for any Drug Substance ordered by Pfizer pursuant to this Agreement prior to the effective date of such termination, whether or not the due date for such payment is after such effective date of termination, (B) Pfizer&#8217;s right to receive the Protalix Payment from Protalix, which such payment to be made in accordance with </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">14.5(b)</u>, and any payment from Protalix that accrued pursuant to this Agreement prior to the effective date of such termination (subject to the last two sentences of Section 5.21(b)(i)) and (C) any remedies that either party may have and (ii) shall not release a party hereto from any indebtedness, liability, payment or other obligation incurred hereunder (including liability for breach of this Agreement) by such party prior to the effective date of termination. </div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">58<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.5</font><a name="_cp_blt_1_795"></a><a name="_cp_blt_2_794"></a><a name="_Toc428737076"></a><a name="_Toc428737424"></a><a name="_Toc428738117"></a><a name="_Toc428739977"></a><a name="_Toc431832019"></a><a name="_Toc431832343"></a><a name="_Toc434628927"></a><a name="_Ref428308758"></a><a name="_Toc428736731"></a><a name="_Ref244627386"></a><a name="_Ref244627409"></a><a name="_Ref244628193"></a><a name="_Ref244628657"></a><a name="_Ref244629524"></a><a name="_Ref245628276"></a><a name="_Ref245628366"></a><a name="_Ref245798706"></a><a name="_Ref246217035"></a><a name="_Ref246645922"></a><a name="_Ref246646114"></a><a name="_Ref246647564"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Effects of Termination or Expiration</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">License Grants</u>. The licenses granted to Pfizer under <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.1</u> shall be perpetual and irrevocable such that the expiration or termination of this Agreement <a name="_cp_text_1_784"></a>for any reason shall not affect or limit any of the rights granted thereunder. <a name="_cp_text_1_785"></a>Upon the effective date of termination of this Agreement in accordance with this<a name="_cp_field_47_786"></a> <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 14</u><a name="_cp_text_1_787"></a>, except as otherwise provided in <a name="_cp_text_1_789"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">14.4</u>, this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section</u><a name="_cp_field_47_790"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">14.5</u><a name="_cp_text_1_793"></a>, and <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">18.4</u>, all other licenses and rights provided for herein, and all obligations of the parties hereunder, shall terminate and this Agreement shall cease to be of further force or effect. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><a name="_Ref428288744"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Deferred Payment</u>. If the Agreement is terminated by Pfizer pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">14.1</u> or by Protalix pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">14.3</u> before Protalix has made the Protalix Payment, Protalix shall pay to Pfizer the Protalix Payment in accordance with <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.2</u><font style="white-space:pre-wrap;">.  If the Agreement is terminated by Pfizer pursuant to </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">14.2</u>, Protalix shall pay to Pfizer the Protalix Payment within thirty (30) days following the effective date of termination of this Agreement as provided in the Promissory Note. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><a name="_cp_blt_1_884"></a><a name="_cp_text_1_882"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidential Information</u><font style="white-space:pre-wrap;">.  F</font>ollowing any termination of this Agreement, each of Pfizer and Protalix shall, upon request of the other party, return or destroy all Protalix Confidential Information and Pfizer Confidential Information, respectively, disclosed to it pursuant to this Agreement, including all copies and extracts of documents, as promptly as practicable following receipt of such request, except (i) that one (1) copy may be kept for the purpose of complying with continuing obligations under this Agreement and (ii) to the extent and for so long as necessary to perform its obligations or exercise its rights under this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section</u><a name="_cp_field_47_883"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">14.5</u><a name="_cp_text_1_885"></a><font style="white-space:pre-wrap;">.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">14.6</font><a name="_cp_blt_1_887"></a><a name="_cp_blt_2_886"></a><a name="_Toc428737077"></a><a name="_Toc428737425"></a><a name="_Toc428738118"></a><a name="_Toc428739978"></a><a name="_Toc431832020"></a><a name="_Toc431832344"></a><a name="_Toc434628928"></a><a name="_Toc428736732"></a><a name="_Ref429865309"></a><a name="_Ref431828996"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bankruptcy</u><font style="white-space:pre-wrap;">.  All rights and licenses granted under or pursuant to this Agreement by Protalix are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to &#8220;intellectual property&#8221; as defined under Section 101 of the U.S. Bankruptcy Code.  The parties agree that Pfizer, as the licensee of intellectual property under this Agreement, shall retain and may fully exercise all of its rights and elections under the U.S. Bankruptcy Code.  Without limiting the foregoing, Section 365(n) shall apply to any case commenced under Chapter 15 of the U.S. Bankruptcy Code and, if the foreign representative in such a case rejects or repudiates rights of licenses granted under or pursuant to this Agreement, Pfizer shall be entitled to make the election and exercise the rights described in Section 365(n).  The parties further agree that, in the event of a rejection of this Agreement by Protalix in any bankruptcy proceeding by or against Protalix under the U.S. Bankruptcy Code or rejection or repudiation by a foreign representative in a foreign bankruptcy proceeding, (a) Pfizer shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual property, which, if not already in the possession of the licensee, shall be promptly delivered to it upon Pfizer&#8217;s written request therefor, and (b) Protalix shall not interfere with Pfizer&#8217;s rights to intellectual property and all embodiments of intellectual property, and shall assist and not interfere with Pfizer in obtaining intellectual property and all embodiments of intellectual property from another entity.  The term &#8220;embodiments&#8221; of intellectual property includes all tangible, intangible, electronic or other embodiments of rights and licenses hereunder, including all compounds and products embodying intellectual property, Licensed Products, regulatory filings, clinical studies and related rights, and Technology.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">59<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 15.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_cp_blt_1_889"></a><a name="_cp_blt_2_888"></a><a name="_Ref245649900"></a><a name="_Ref245733963"></a><a name="_Ref245740671"></a><a name="_Ref245801759"></a><a name="_Ref246320895"></a><a name="_Ref246499939"></a><a name="_Ref246515858"></a><a name="_Toc428350795"></a><a name="_Toc428351661"></a><a name="_Toc428409554"></a><a name="_Toc428410112"></a><a name="_Toc428410166"></a><a name="_Toc428410265"></a><a name="_Toc428736362"></a><a name="_Toc428736733"></a><a name="_Toc428737078"></a><a name="_Toc428737426"></a><a name="_Toc428738119"></a><a name="_Toc428739979"></a><a name="_Toc431832021"></a><a name="_Toc434628929"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">INDEMNIFICATION AND INSURANCE</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">15.1</font><a name="_cp_blt_1_891"></a><a name="_cp_blt_2_890"></a><a name="_Toc428737079"></a><a name="_Toc428737427"></a><a name="_Toc428738120"></a><a name="_Toc428739980"></a><a name="_Toc431832022"></a><a name="_Toc431832345"></a><a name="_Toc434628930"></a><a name="_Ref244628703"></a><a name="_Ref245628294"></a><a name="_Ref245628326"></a><a name="_Ref245628350"></a><a name="_Ref245799197"></a><a name="_Ref245799465"></a><a name="_Ref245799543"></a><a name="_Ref247350566"></a><a name="_Ref247350679"></a><a name="_Ref247350719"></a><a name="_Ref247350797"></a><a name="_Ref247353396"></a><a name="_Ref247355111"></a><a name="_Ref247361414"></a><a name="_Toc428736734"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnification</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref245628327"></a>Protalix will indemnify, defend and hold Pfizer and Pfizer&#8217;s Affiliates, and their respective directors, officers and employees harmless from and against all Third Party Claims (defined in <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">15.3</u> below) and associated Losses, in each case to the extent arising out of:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>the breach of any covenant, warranty or representation made by Protalix under this Agreement;</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>the negligence, recklessness, or willful misconduct of, or violation of law by, Protalix or any of its Affiliates; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>any acts or omissions of Protalix or any of its Affiliates, agents, consultants or contractors (A) in connection with the research, Development, Manufacture or Commercialization of the Drug Substance or Licensed Product prior to the Effective Date, (B) in connection with the research, Development, Manufacture (including Fill/Finish) or Commercialization of the Drug Substance or Licensed Products in Brazil following the Amendment Effective Date, (C) in connection with the research, Development, Manufacture (including Fill/Finish) or Commercialization of the Drug Substance or Licensed Product prior to the Second Amendment Effective Date and during the Israel<a name="_cp_text_1_897"></a> Transition Period or (D) in connection with the Manufacture of the Drug Substance for supply to Pfizer pursuant to<font style="color:#1f497d;"> </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u>; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iv)</font><a name="_cp_blt_2_898"></a><a name="_cp_text_2_899"></a>(A) any claim made by an [***] against Pfizer for any consideration allegedly owed to an [***] in connection with Commercialization of the Licensed Product in Brazil, or the Technology Transfer Agreement, or (B) any inquiry, investigation, litigation or proceeding by a governmental authority or Third Party regarding any ATME Person in connection with the Commercialization of the Licensed Product in Brazil by Protalix, the Technology Transfer Agreement, or any other actions of an ATME Person on behalf of Protalix<a name="_Ref245628297"></a><a name="_Ref244598227"></a><a name="_Ref244628680"></a><a name="_Ref244628734"></a>; or</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(v)</font><font style="white-space:pre-wrap;">any and all claims asserted by [***] against any Pfizer Indemnified Party with respect to the Drug Substance, the Licensed Product [***], including any claims of infringement or misappropriation or for royalties, milestone payments, license fees or other payments due thereunder, in relation to Pfizer&#8217;s exercise (in accordance with this Agreement) of the license granted hereunder to Pfizer under the Protalix Patent Rights licensed by Protalix from VTIP [***]; provided however, Protalix shall not indemnify, defend and hold Pfizer harmless to extent any such claim asserted by [***] relates to [***] intellectual property that has not been licensed to Protalix under the [***].  For the avoidance of doubt, (a) in no event shall Pfizer be responsible for any royalties, milestone payments, license fees or other payments payable to VTIP under the [***], and (b) Protalix shall be solely responsible to [***] for any amounts owed to [***] under the [***]. </font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">60<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Protalix shall be obligated to so indemnify, defend and hold Pfizer harmless only to the extent that such Losses (i) do not arise from the negligence, recklessness or willful misconduct of Pfizer and (ii) are not Losses as to which Protalix is entitled to indemnification pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">15.1</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(b)</u>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font>Pfizer will indemnify, defend and hold Protalix, its Affiliates, and their respective directors, officers and employees harmless from and against all Third Party Claims and associated Losses, to the extent arising out of:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>the breach of any covenant, warranty or representation made by Pfizer under this Agreement; </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>the negligence, recklessness, or willful misconduct of, or violation of law by, Pfizer or any of its Affiliates;<a name="_cp_text_1_900"></a> or</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><a name="_cp_text_1_901"></a>(A) any acts or omissions of Pfizer or any of its Affiliates, agents, consultants or contractors in connection with the research, Development, Manufacture (including Fill/Finish) or Commercialization of the Drug Substance or Licensed Product in the Field inside the Territory (other than Israel or Brazil) after the Effective Date, (B) any acts or omissions of Pfizer or any of its Affiliates, agents consultants or contractors in connection with the research, Development, Manufacture (including Fill/Finish) or Commercialization of the Drug Substance or Licensed Product in the Field in Brazil prior to the Amendment Effective Date, or (C) any acts or omissions of Pfizer or any of its Affiliates, agents, consultants or contractors in connection with the research, Development, Manufacture (including Fill/Finish) or Commercialization of the Drug Substance or Licensed Product in the Field in Israel after the Israel Transition Period.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Pfizer shall be obligated to so indemnify, defend and hold Protalix harmless only to the extent that such Losses (i) do not arise from the negligence, recklessness or willful misconduct of Protalix and (ii) are not Losses as to which Pfizer is entitled to indemnification pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">15.1</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">(a)</u>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">15.2</font><a name="_cp_blt_1_904"></a><a name="_cp_blt_2_903"></a><a name="_Toc428737080"></a><a name="_Toc428737428"></a><a name="_Toc428738121"></a><a name="_Toc428739981"></a><a name="_Toc431832023"></a><a name="_Toc431832346"></a><a name="_Toc434628931"></a><a name="_Ref245799995"></a><a name="_Toc428736735"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Losses</u><font style="white-space:pre-wrap;">.  </font>For purposes of this Agreement, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Losses</u>&#8221; means any and all damages (including all incidental, consequential, statutory and treble damages), awards, deficiencies, settlement amounts, defaults, assessments, fines, dues, penalties, costs, fees, liabilities, obligations, taxes, liens, losses and expenses incurred by or awarded to Third Parties with respect to a Third Party Claim by reason of any judgment, order, decree, stipulation or injunction, or any settlement entered into, and all other documented costs and expenses incurred in investigating, preparing or defending any Third Party Claim litigation or proceeding, commenced or threatened, or in complying with any judgments, orders, decrees, stipulations and injunctions (including court costs, interest and reasonable fees of attorneys, accountants and other experts).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">15.3</font><a name="_cp_blt_1_906"></a><a name="_cp_blt_2_905"></a><a name="_Toc428737081"></a><a name="_Toc428737429"></a><a name="_Toc428738122"></a><a name="_Toc428739982"></a><a name="_Toc431832024"></a><a name="_Toc431832347"></a><a name="_Toc434628932"></a><a name="_Toc428736736"></a><a name="_Ref244598117"></a><a name="_Ref244599036"></a><a name="_Ref244628634"></a><a name="_Ref245628067"></a><a name="_Ref245628395"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Defense Procedures; Procedures for Third Party Claims</u>.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref429825648"></a>For purposes of this Agreement, &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Claim</u><font style="white-space:pre-wrap;">&#8221; means a claim asserted by a Third Party (in no event to include any Affiliate of either party) against a party or any of its Affiliates, or any of their respective directors, officers and employees.  In the event a Third Party Claim is asserted with respect to any matter for which a party or any of its Affiliates, </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">61<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="white-space:pre-wrap;">or any of their respective directors, officers and employees (the &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnified Party</u>&#8221;) is entitled to indemnification hereunder, then the Indemnified Party shall promptly notify in writing the party obligated to indemnify the Indemnified Party (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Indemnifying Party</u>&#8221;) thereof; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u>, that no delay on the part of the Indemnified Party in notifying the Indemnifying Party shall relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is prejudiced thereby.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><font style="white-space:pre-wrap;">The Indemnifying Party shall assume direction and control of the defense, litigation, settlement, appeal or other disposition of the Third Party Claim (including the right to settle the claim solely for monetary consideration) with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party.  The Indemnified Party shall have the right to join in (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at its own expense, the defense of any Third Party Claim that the Indemnifying Party is defending as </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided </u><font style="white-space:pre-wrap;">in this Agreement.  Notwithstanding anything to the contrary contained herein, an Indemnified Party shall be entitled to assume the defense of any Third Party Claim with respect to the Indemnified Party, upon written notice to the Indemnifying Party, in which case the Indemnifying Party shall be relieved of liability under </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">15.1</u>, as applicable, solely for such Third Party Claim and related Losses.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><font style="white-space:pre-wrap;">Neither party will enter into any settlement of any suit involving Licensed Products that materially affects the other party&#8217;s rights or obligations with respect to the Licensed Product without the other party&#8217;s prior written consent.  Without limiting the foregoing, the Indemnifying Party shall not, without the written consent of the Indemnified Party (which consent shall not be unreasonably withheld), effect any settlement of any pending or threatened litigation in which the Indemnified Party has sought indemnification hereunder by the Indemnifying Party, unless such settlement involves solely monetary damages and includes an unconditional release of the Indemnified Party from all liability on claims that are the subject matter of such litigation.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">15.4</font><a name="_cp_blt_1_908"></a><a name="_cp_blt_2_907"></a><a name="_cp_blt_1_926"></a><a name="_cp_blt_2_925"></a><a name="_Toc428737082"></a><a name="_Toc428737430"></a><a name="_Toc428738123"></a><a name="_Toc428739983"></a><a name="_Toc431832025"></a><a name="_Toc431832348"></a><a name="_Toc434628933"></a><a name="_Ref244628830"></a><a name="_Ref246510674"></a><a name="_Toc428736737"></a><a name="_Ref429830901"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Disclaimer of Liability for Consequential Damages</u><font style="white-space:pre-wrap;">.  IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS RESPECTIVE AFFILIATES BE LIABLE UNDER THIS AGREEMENT FOR SPECIAL, INDIRECT, INCIDENTAL OR CONSEQUENTIAL DAMAGES, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE, STRICT LIABILITY OR OTHERWISE, INCLUDING LOSS OF PROFITS OR REVENUE, SUFFERED BY PFIZER, PROTALIX OR ANY OF THEIR RESPECTIVE AFFILIATES, EXCEPT TO THE EXTENT THE DAMAGES RESULT FROM A PARTY&#8217;S WILLFUL MISCONDUCT OR INTENTIONAL BREACH OF ITS OBLIGATIONS UNDER THIS AGREEMENT AND EXCEPT FOR ANY PERSISTENT FAILURE TO SUPPLY PAYMENTS AS EXPRESSLY PROVIDED IN </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.21</u><font style="white-space:pre-wrap;">.  THE FOREGOING SENTENCE SHALL NOT LIMIT THE OBLIGATIONS OF EITHER PARTY TO INDEMNIFY THE OTHER PARTY FROM AND AGAINST THIRD PARTY CLAIMS UNDER </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Section 15</u> OR LIABILITIES RESULTING FROM A BREACH OF THE CONFIDENTIALITY OBLIGATIONS UNDER <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9</u> ABOVE AND PROVIDED<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u>THAT THIS <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SECTION </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">15.4</u> SHALL NOT RELIEVE EITHER PARTY FROM ITS PAYMENT OBLIGATIONS UNDER THIS AGREEMENT.</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">62<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">15.5</font><a name="_cp_blt_1_928"></a><a name="_cp_blt_2_927"></a><a name="_Toc428737083"></a><a name="_Toc428737431"></a><a name="_Toc428738124"></a><a name="_Toc428739984"></a><a name="_Toc431832026"></a><a name="_Toc431832349"></a><a name="_Toc434628934"></a><a name="_Toc428736738"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sole Remedy</u><font style="white-space:pre-wrap;">.  EXCEPT AS EXPRESSLY PROVIDED</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><font style="white-space:pre-wrap;">IN THIS AGREEMENT AND EXCEPT FOR ANY EQUITABLE REMEDIES THAT MAY BE AVAILABLE TO A PARTY, INDEMNIFICATION  PURSUANT TO </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">Section 15</u><font style="text-transform:uppercase;"> </font>SHALL BE THE SOLE AND EXCLUSIVE REMEDY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER LEGAL THEORY) AVAILABLE TO PROTALIX OR PFIZER FOR THE MATTERS COVERED THEREIN.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">15.6</font><a name="_cp_blt_1_930"></a><a name="_cp_blt_2_929"></a><a name="_Toc428737084"></a><a name="_Toc428737432"></a><a name="_Toc428738125"></a><a name="_Toc428739985"></a><a name="_Toc431832027"></a><a name="_Toc431832350"></a><a name="_Toc434628935"></a><a name="_Toc428736739"></a><a name="_Ref429907143"></a><a name="OLE_LINK9"></a><a name="OLE_LINK10"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Insurance Requirements</u><font style="white-space:pre-wrap;">.  As of the Second Amendment Effective Date, Protalix shall provide and maintain such insurance coverage, in minimum types and amounts as described in </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection (b)</u><font style="white-space:pre-wrap;"> below.  As of the Second Amendment Effective Date, Pfizer shall self insure or provide and maintain such insurance coverage, in minimum types and amounts as described in </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection (d)</u> below.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Insurance Generally</u><font style="white-space:pre-wrap;">.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><a name="_Ref429863618"></a>Any and all deductibles for Protalix&#8217;s insurance policies (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Insurance Policies</u><font style="white-space:pre-wrap;">&#8221;) shall be assumed by, for the account of, and at Protalix&#8217;s sole risk.  All deductibles and self-insured retention amounts shall be assumed by Protalix.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="white-space:pre-wrap;">Such Protalix Insurance Policies shall be primary and non-contributing with respect to any other similar insurance policies available to Pfizer or its Affiliates.  Except for employers&#8217; liability and property insurance policies, Protalix will add Pfizer and its Affiliates on all such Protalix Insurance Policies as additional insureds with respect to liability incurred by Pfizer or its Affiliates arising from any acts or omissions of Protalix, and Protalix will require that the property insurance policy included in the Protalix Insurance Policies include a waiver of subrogation in favor of Pfizer and its Affiliates.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><font style="white-space:pre-wrap;">Prior to the Second Amendment Effective Date, Protalix has provided Pfizer with original certificates and additional insurance endorsements evidencing the specified insurance coverage, and at each renewal thereof or expiration of any one coverage, whichever occurs first, Protalix shall furnish to Pfizer original certificates and additional insurance endorsements evidencing the specified insurance coverage.  Such certificates shall provide that not less than thirty (30) days prior written notice of any policy cancellation or detrimental change shall be given to Pfizer.  The certificate(s) of insurance shall be signed by a person authorized by the insurer(s) to bind coverage on its (their) behalf.  Protalix shall provide, pay for, and maintain in effect, the Protalix Insurance Policies with a minimum &#8220;A-&#8221; A.M. Bests rating or S&amp;P minimum of BBB or their substantial equivalent (in the case of such policies in Israel, to the extent such ratings or substantial equivalents are available).</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Protalix Insurance Requirements</u><font style="white-space:pre-wrap;">.  The insurance required under </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection (a)</u> shall be written for not less than any limits of liability specified herein or as required by law, whichever is greater; Protalix has the right to provide the total limits required by any combination of primary and excess/umbrella coverage; said Protalix insurance to include, without limitation, the following:</div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">63<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>Insurance for liability applicable with respect to persons performing the work hereunder and employer&#8217;s liability insurance covering all claims by or in respect to the employees of Protalix and all subcontractors, providing:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>Employer&#8217;s liability insurance with a limit of the greater of the equivalent of [***] for each occurrence and in the aggregate in the Protalix Insurance Policies.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>Commercial General/Public Liability insurance with the following limits and forms/endorsements:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(A)</font><font style="white-space:pre-wrap;">Each occurrence and in the aggregate:  [***]</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(B)</font><font style="white-space:pre-wrap;">Clinical Trials Coverage or Products &amp; Completed Operations Aggregate once products are marketed:  $[***].</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(C)</font>Pfizer and its Affiliates as additional insureds with respect to any legal liability of Pfizer or its Affiliates, arising out of Protalix&#8217;s performance hereunder.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">If Protalix has care, custody or control of Pfizer property or inventory, Protalix shall be responsible for any loss or damage to it, and provide all risk property coverage included within the Protalix Insurance Policies at full replacement cost for same.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pfizer Insurance Generally</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font><a name="_Ref429863654"></a>Any and all deductibles for Pfizer&#8217;s insurance policies (the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pfizer Insurance Policies</u>&#8221;) shall be assumed by, for the account of, and at Pfizer&#8217;s sole risk.<font style="white-space:pre-wrap;">  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font><font style="white-space:pre-wrap;">To the extent of its negligence, such Pfizer Insurance Policies shall be primary and non-contributing with respect to any other similar insurance policies available to Protalix or its Affiliates.  Except for workers compensation/employers&#8217; liability, Pfizer will add Protalix and its Affiliates, as additional insureds, and Pfizer will require that the Pfizer Insurance Policies provide a waiver of subrogation in favor of Protalix and its Affiliates.  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font><font style="white-space:pre-wrap;">Prior to the Second Amendment Effective Date of the Agreement and, at Protalix&#8217;s request, at each renewal thereof or expiration of any one coverage, whichever occurs first, Pfizer shall furnish to Protalix original certificates evidencing the specified insurance coverage.   Such certificates shall provide that not less than thirty (30) days prior written notice of any policy cancellation or detrimental change shall be given to Protalix.  The certificate(s) of insurance shall be signed by a person authorized by the insurer(s) to bind coverage on its (their) behalf.  Pfizer</font><b style="font-weight:bold;"> </b>shall provide, pay for, and maintain in effect the Pfizer Insurance Policies with minimum &#8220;A-&#8221; A.M. Bests rated insurance carriers.</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">64<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(d)</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Pfizer Insurance Requirements</u><font style="white-space:pre-wrap;">.  The insurance required under </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection (c)</u> shall be written for not less than any limits of liability specified herein or as required by law, whichever is greater; Pfizer has the right to provide the total limits required by any combination of self insurance, primary and excess/umbrella coverage; said Pfizer Insurance to include, without limitation, the following:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(i)</font>Insurance for liability under the workers&#8217; compensation or occupational disease laws of any state or other jurisdiction in which Pfizer performs activities pursuant to this Agreement (or be a qualified self-insurer in those states and jurisdictions) or otherwise applicable with respect to persons performing hereunder and employer&#8217;s liability insurance covering all claims by or in respect to the employees of Pfizer, providing:</div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><a name="OLE_LINK107"></a><a name="OLE_LINK110"></a>Employer&#8217;s liability insurance with a limit of [***] </p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(ii)</font>Commercial General Liability insurance with the following limits and forms/endorsements:</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(A)</font><font style="white-space:pre-wrap;">Each occurrence:  [***]</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(B)</font>Products &amp; Completed Operations Aggregate: [***] </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:72pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(C)</font>Protalix and its Affiliates as additional insureds with respect to any legal liability of Protalix or its Affiliates, arising out of Pfizer&#8217;s performance hereunder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:36pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">(iii)</font>Umbrella (Excess) Liability Coverage (follow form) in an amount not less than [***] per occurrence.</div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 16.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_cp_blt_1_932"></a><a name="_cp_blt_2_931"></a><a name="_Toc428350796"></a><a name="_Toc428351669"></a><a name="_Toc428409555"></a><a name="_Toc428410113"></a><a name="_Toc428410167"></a><a name="_Toc428410266"></a><a name="_Toc428736363"></a><a name="_Toc428736740"></a><a name="_Toc428737085"></a><a name="_Toc428737433"></a><a name="_Toc428738126"></a><a name="_Toc428739986"></a><a name="_Toc431832028"></a><a name="_Toc434628936"></a><a name="_cp_text_2_933"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">[RESERVED.]</b></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:none;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 17.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_Toc428350797"></a><a name="_Toc428351670"></a><a name="_Toc428409556"></a><a name="_Toc428410114"></a><a name="_Toc428410168"></a><a name="_Toc428410267"></a><a name="_Toc428736364"></a><a name="_Toc428736741"></a><a name="_Toc428737086"></a><a name="_Toc428737434"></a><a name="_Toc428738127"></a><a name="_Toc428739987"></a><a name="_Ref431565224"></a><a name="_Toc431832029"></a><a name="_Toc434628937"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;white-space:pre-wrap;">GOVERNING  LAW AND JURISDICTION</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">17.1</font><a name="_cp_blt_2_934"></a><a name="_cp_blt_2_936"></a><a name="_cp_blt_2_938"></a><a name="_cp_blt_2_940"></a><a name="_cp_blt_2_942"></a><a name="_cp_blt_2_950"></a><a name="_cp_blt_2_956"></a><a name="_cp_blt_2_965"></a><a name="_cp_blt_2_972"></a><a name="_Toc428737087"></a><a name="_Toc428737435"></a><a name="_Toc428738128"></a><a name="_Toc428739988"></a><a name="_Toc431832030"></a><a name="_Toc431832351"></a><a name="_Toc434628938"></a><a name="_Ref246329424"></a><a name="_Ref246865165"></a><a name="_Toc428736742"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Governing Law</u><font style="white-space:pre-wrap;">.  This Agreement shall be governed by and construed in accordance with the substantive laws of the State of New York, without regard to conflicts of law rules.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">17.2</font><a name="_Toc428737088"></a><a name="_Toc428737436"></a><a name="_Toc428738129"></a><a name="_Toc428739989"></a><a name="_Toc431832031"></a><a name="_Toc431832352"></a><a name="_Toc434628939"></a><a name="_Ref245214660"></a><a name="_Ref246329427"></a><a name="_Ref246865166"></a><a name="_Toc428736743"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Jurisdiction</u><font style="white-space:pre-wrap;">.  In the event of any controversy, claim or counterclaim arising out of or relating to this Agreement, the parties shall first attempt to resolve such controversy or claim through good faith negotiations for a period of not less than thirty (30) days following notification of such controversy or claim to the other party.  If such controversy or claim cannot be resolved by means of such negotiations during such period, then such controversy or claim shall be resolved by the United States District Court for the Southern District of New York or, in the event federal subject matter jurisdiction is lacking, a New York State court sitting in New York, New York (the &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Court</u><font style="white-space:pre-wrap;">&#8221;).  Each party (a) irrevocably submits to the exclusive jurisdiction of the Court for purposes of any action, suit or other proceeding relating to or arising out of this Agreement and (b) agrees not to raise any objection at any time to the laying or maintaining of</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">65<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">the venue of any such action, suit or proceeding in the Court, irrevocably waives any claim that such action, suit or other proceeding has been brought in an inconvenient forum and further irrevocably waives the right to object, with respect to such action, suit or other proceeding, that the Court does not have any jurisdiction over such party.  The provisions of the U.N. Convention on Contracts for the International Sale of Goods shall not apply to this Agreement.  Protalix hereby irrevocably designates, appoints and empowers CT Corporation System, 111 Eighth Avenue, New York, NY&#160; 10011, as its true and lawful agent and attorney-in-fact in its name, place and stead to receive and accept on its behalf service of process in any action, suit or proceeding in the Court with respect to any matters as to which it has submitted to jurisdiction as set forth in the immediately preceding sentence.</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;table-layout:fixed;text-transform:uppercase;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;text-decoration-line:none;text-transform:uppercase;vertical-align:text-top;white-space:nowrap;width:72pt;padding:0pt;">Section 18.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;"><a name="_Toc428350798"></a><a name="_Toc428351673"></a><a name="_Toc428409557"></a><a name="_Toc428410115"></a><a name="_Toc428410169"></a><a name="_Toc428410268"></a><a name="_Toc428736365"></a><a name="_Toc428736744"></a><a name="_Toc428737089"></a><a name="_Toc428737437"></a><a name="_Toc428738130"></a><a name="_Toc428739990"></a><a name="_Ref431829034"></a><a name="_Toc431832032"></a><a name="_Toc434628940"></a></b><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;">MISCELLANEOUS</b></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.1</font><a name="_Toc428737090"></a><a name="_Toc428737438"></a><a name="_Toc428738131"></a><a name="_Toc428739991"></a><a name="_Toc431832033"></a><a name="_Toc431832353"></a><a name="_Toc434628941"></a><a name="_Ref244598042"></a><a name="_Toc428736745"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Force Majeure</u><font style="white-space:pre-wrap;">.  Neither party hereto shall be liable to the other party for any losses or damages attributable to a default under or breach of this Agreement that is the result of war (whether declared or undeclared), acts of God, revolution, acts of terror, fire, earthquake, flood, pestilence, riot, enactment or change of Law (following the Second Amendment Effective Date), accident(s), labor trouble, shortage of or inability to obtain material equipment or transport or any other cause beyond the reasonable control of such party (each, a &#8220;</font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Force Majeure Event</u>&#8221;); <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided </u><font style="white-space:pre-wrap;">that if such a cause occurs, then the party affected will promptly notify the other party of the nature and likely result and duration (if known) of such cause and use its Commercially Reasonable Efforts  to avoid or remove such causes of nonperformance as soon as is reasonably practicable.  Upon termination of the Force Majeure Event, the performance of any suspended obligation or duty shall promptly recommence.  If the event lasts for a period of longer than one (1) month, the parties shall meet and work diligently to implement appropriate remedial measures.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.2</font><a name="_Toc428737091"></a><a name="_Toc428737439"></a><a name="_Toc428738132"></a><a name="_Toc428739992"></a><a name="_Toc431832034"></a><a name="_Toc431832354"></a><a name="_Toc434628942"></a><a name="_Toc428736746"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severability</u><font style="white-space:pre-wrap;">.  If and solely to the extent that any provision of this Agreement shall be invalid or unenforceable, or shall render this entire Agreement to be unenforceable or invalid, such offending provision shall be of no effect and shall not affect the enforceability or validity of the remainder of this Agreement or any of its provisions; </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided, however</u>, the parties shall use their respective reasonable efforts to mutually agree to replace the invalid provisions in a manner that best accomplishes the original intentions of the parties.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.3</font><a name="_Toc428737092"></a><a name="_Toc428737440"></a><a name="_Toc428738133"></a><a name="_Toc428739993"></a><a name="_Toc431832035"></a><a name="_Toc431832355"></a><a name="_Toc434628943"></a><a name="_Toc428736747"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Waivers</u><font style="white-space:pre-wrap;">.  Any term or condition of this Agreement may be waived at any time by the party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such term or condition.  Neither the waiver by any party of any term or condition of this Agreement nor the failure on the part of any party, in one or more instances, to enforce any of the provisions of this Agreement or to exercise any right or privilege, shall be deemed or construed to be a waiver of such term or condition for any similar instance in the future or of any subsequent breach hereof. All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative and none of them shall be a limitation of any other remedy, right, undertaking, obligation or agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.4</font><a name="_Toc428737093"></a><a name="_Toc428737441"></a><a name="_Toc428738134"></a><a name="_Toc428739994"></a><a name="_Toc431832036"></a><a name="_Toc431832356"></a><a name="_Toc434628944"></a><a name="_Toc428736748"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Entire Agreements; Amendments</u><font style="white-space:pre-wrap;">.  This Agreement, together with the Quality Agreement(s), sets forth the entire agreement and understanding between the parties as to the </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">66<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="white-space:pre-wrap;">subject matter hereof and supersedes all agreements or understandings, verbal or written, made between Protalix and Pfizer before the Second Amendment Effective Date with respect to the subject matter hereof, including the Confidential Disclosure Agreement between the parties, dated June 11, 2009 and the Amended Agreement, except as otherwise provided in </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.4</u>. <font style="font-style:italic;font-weight:bold;"> </font><font style="white-space:pre-wrap;">All Confidential Information disclosed by either party to the other party prior to the Second Amendment Effective Date will be deemed to have been disclosed pursuant to this Agreement.  None of the terms of this Agreement shall be amended, supplemented or modified except in writing signed by the parties.</font> <a name="_Toc428737094"></a><a name="_Toc428737442"></a><a name="_Toc428738135"></a><a name="_Toc428739995"></a><a name="_Ref244627429"></a><a name="_Toc428736749"></a><a name="_Ref429830861"></a></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.5</font><a name="_Toc431832037"></a><a name="_Toc431832357"></a><a name="_Toc434628945"></a><a name="_Ref431565187"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Survival</u><font style="white-space:pre-wrap;">.  </font><a name="_Ref244629614"></a><a name="_Ref245628177"></a><a name="_Ref245628202"></a>The provisions of <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.1</u> (Exclusive License), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><a name="_cp_field_47_975"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.3</u> (Non-Assertion of Rights)<a name="_cp_text_1_977"></a>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.4</u> (Sublicensing and Subcontracting), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">3.6(a)</u> (No Implied License; Brazil Activities), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.1(f)</u> (Assignment of Contracts), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.1(g)(i)</u> (Responsibility), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.1(l)</u> (Recalls or Other Corrective Action), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.2(a)</u> (Commercialization and Pricing), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.4</u> (Pfizer Trademarks), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">4.5</u> (Use of Names), <a name="_cp_text_1_980"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.15</u> (Records and Audits), <a name="_cp_text_1_982"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.21(f)</u> (Damages), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">5.23</u> (Manufacturing Transition Assistance), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">6.2</u> (Deferred Payment), <a name="_cp_text_1_984"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8</u> (Patents and Infringement), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sections </u><a name="_cp_field_47_986"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.1</u> and <a name="_cp_field_47_988"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.2</u> (Confidentiality)<a name="_cp_text_1_990"></a>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.3</u> (Publication), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">9.4</u> (Publicity), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><a name="_cp_field_47_992"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10.5</u> (Disclaimer of Warranty)<a name="_cp_text_1_994"></a>, <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11.1</u> (Restrictions on Transfers and Liens), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11.2</u> (Third Party Licenses and Agreements), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">11.4</u> (Coordinating outside the Territory), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">14.4</u> (Continuing and Accrued Obligations<a name="_cp_text_1_999"></a> and Surviving Provisions), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">14.5</u> (Effect of Termination or Expiration)<a name="_cp_text_1_1001"></a>,<a name="_cp_field_47_1002"></a> <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">14.6</u> (Bankruptcy), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 15</u> (Indemnification<a name="_cp_text_1_1003"></a>)<a name="_cp_text_1_1005"></a> other than Section 15.6 (Insurance Requirements), <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 17</u><a name="_cp_field_47_1008"></a> (Governing Law and Jurisdiction) and this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 18</u> (Miscellaneous), as well as (x) any other Sections or defined terms referred to in such Sections or necessary to give them effect and (<a name="_cp_text_1_1013"></a>y<font style="white-space:pre-wrap;">) any other provision that by its terms expressly survives termination of this Agreement, shall survive termination of this Agreement and remain in force until discharged in full.  Furthermore, any other provisions required to interpret and enforce the parties&#8217; rights and obligations or to wind up their outstanding obligations under this Agreement shall survive to the extent required.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.6</font><a name="_Toc428737095"></a><a name="_Toc428737443"></a><a name="_Toc428738136"></a><a name="_Toc428739996"></a><a name="_Toc431832038"></a><a name="_Toc431832358"></a><a name="_Toc434628946"></a><a name="_Ref428100788"></a><a name="_Toc428736750"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Assignment; Binding Effect</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font><a name="_Ref244626914"></a>Neither this Agreement nor any rights or obligations of either party to this Agreement may be assigned or otherwise transferred by either party without the consent of the other party; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided, however</u><font style="white-space:pre-wrap;">, either party may, without such consent, assign this Agreement, in whole or in part:  (i) to any of its respective Affiliates, </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided </u><font style="white-space:pre-wrap;">that such assigning party shall remain jointly and severally liable with such Affiliate in respect of all obligations so assigned;  (ii) to a Third Party where a party or its Affiliate is required, or makes a good faith determination based on advice of counsel, to divest a Licensed Product in order to comply with Law or the order of any Governmental Authority as a result of a merger or acquisition; or (iii) to a Third Party successor to all or substantially all of the assets of such party whether by merger, sale of stock, all or substantially all of a party&#8217;s assets or other similar transaction, so long as such Third Party agrees in writing to be bound by the terms of this Agreement.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font>Any purported assignment in violation of this <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">18.6</u><font style="white-space:pre-wrap;"> shall be void.  Any permitted assignee shall assume all obligations of its assignor under this Agreement.</font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">67<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(c)</font>Pfizer may assume this Agreement in any proceeding under the U.S. Bankruptcy Code upon satisfaction of the conditions set forth in U.S. Bankruptcy Code Section 365(b)(1).</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.7</font><a name="_Toc428737096"></a><a name="_Toc428737444"></a><a name="_Toc428738137"></a><a name="_Toc428739997"></a><a name="_Toc431832039"></a><a name="_Toc431832359"></a><a name="_Toc434628947"></a><a name="_Ref428735503"></a><a name="_Toc428736751"></a><a name="_Ref431304921"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Divestiture</u>.<font style="white-space:pre-wrap;">  For the avoidance of doubt, nothing in this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">18.7</u> shall prevent Pfizer from assigning its rights and obligations under this Agreement pursuant to <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">18.6</u>.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(a)</font>Notwithstanding anything to the contrary contained in this Agreement, to the extent related to or arising in connection with a divestiture (whether by sale, spin-off, or similar transaction) by Pfizer of all or any portion of a Pfizer business or business unit (a &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Divestiture</u>&#8221;), Pfizer may, without prior written notice to or consent of Protalix, without any penalty, and at no additional cost to Pfizer or to any affiliate of Pfizer or to the company or the group of companies resulting from such Divestiture (collectively, such companies, the &#8220;<u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Resulting Companies</u>&#8221;): (1) assign its rights and obligations under this Agreement, in whole or in part to one or more of the Resulting Companies, or (2) split and assign, in whole or in part, its rights and obligations under this Agreement to one or more of the Resulting Companies so as to retain the benefits of this Agreement for both Pfizer and the applicable Resulting Companies following such Divestiture; <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="white-space:pre-wrap;"> that [***]  </font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:72pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;white-space:nowrap;">(b)</font>From and after any partial assignment or split the rights and obligations of Pfizer hereunder shall be divided between Pfizer and the Resulting Companies to whom such rights and obligations are transferred as specified by Pfizer, such that all such rights and obligations related to the business of the applicable Resulting Companies shall be enforceable only by and against the applicable Resulting Companies, and all other such rights and obligations shall be enforceable only by and against Pfizer.&#160; Protalix will, [***], work cooperatively with Pfizer and the applicable Resulting Companies to ensure a smooth and orderly transition, including, to the extent requested by Pfizer, entering into separate agreements with Pfizer and the applicable Resulting Companies on substantially the same terms and conditions (as adjusted to take into account the nature of the separate contracts while maintaining the economic, business and other purposes of the Agreement).  </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.8</font><a name="_Toc428737097"></a><a name="_Toc428737445"></a><a name="_Toc428738138"></a><a name="_Toc428739998"></a><a name="_Toc431832040"></a><a name="_Toc431832360"></a><a name="_Toc434628948"></a><a name="_Toc428736752"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Independent Contractor</u><font style="white-space:pre-wrap;">.  The relationship between Protalix and Pfizer is that of independent contractors.  Protalix and Pfizer are not joint venturers, partners, principal and agent, employer and employee, and have no other relationship other than independent contracting parties.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.9</font><a name="_Toc428737098"></a><a name="_Toc428737446"></a><a name="_Toc428738139"></a><a name="_Toc428739999"></a><a name="_Toc431832041"></a><a name="_Toc431832361"></a><a name="_Toc434628949"></a><a name="_Ref244606269"></a><a name="_Ref244629638"></a><a name="_Toc428736753"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Notices</u><font style="white-space:pre-wrap;">.  Each communication and document made or delivered by one party to another under this Agreement shall be made in the English language.  All notices, consents, approvals, requests or other communications required hereunder given by one party to the other hereunder shall be in writing and made by registered or certified air mail, express overnight courier or delivered personally to the following addresses of the respective parties:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><font style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">68<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">If to Protalix:<font style="display:inline-block;width:43.34pt;"></font>Protalix Ltd.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 108pt;">2 Snunit Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 108pt;">Science Park</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 108pt;">P.O.B. 455 </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 108pt;">Carmiel 20100, Israel</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 108pt;"><font style="white-space:pre-wrap;">Attention:  </font><font style="display:inline-block;width:17.34pt;"></font>Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 108pt;"><font style="margin-left:0pt;visibility:hidden;background:#ffff00;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"><a name="OLE_LINK74"></a><a name="OLE_LINK75"></a></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">If to Pfizer:</font></font>Pfizer Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>235 East 42<sup style="font-size:9pt;vertical-align:top;">nd</sup> Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>New York, New York, 10017-5755</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 108pt;">U.S.A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:108pt;text-indent:-108pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"></font>Attention: <font style="display:inline-block;width:20.34pt;"></font>President of the Global Innovative Products Business Unit</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">with a copy to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"></font>Pfizer Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>235 East 42<sup style="font-size:9pt;vertical-align:top;">nd</sup> Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>New York, New York, 10017-5755</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 108pt;">U.S.A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:108pt;text-indent:-108pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"></font>Attention: <font style="display:inline-block;width:20.34pt;"></font>Chief Counsel, Global Innovative Products Business Unit</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:108pt;text-indent:-108pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"></font>Pfizer Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>235 East 42<sup style="font-size:9pt;vertical-align:top;">nd</sup> Street</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>New York, New York, 10017-5755</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 108pt;">U.S.A.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:108pt;text-indent:-108pt;margin:0pt 0pt 12pt 0pt;"><font style="display:inline-block;text-indent:0pt;width:108pt;"></font>Attention: <font style="display:inline-block;width:20.34pt;"></font>Senior Vice President, Business Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">Notices hereunder shall be deemed to be effective (a) upon receipt if personally delivered, (b) on the tenth (10th) Business Day following the date of mailing if sent by registered or certified air mail and (c) on the second (2nd) Business Day following the date of delivery to the overnight courier if sent by overnight courier.  A party may change its address listed above by sending notice to the other party in accordance with this </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section </u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">18.9</u>.</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.10</font><a name="_Toc428737099"></a><a name="_Toc428737447"></a><a name="_Toc428738140"></a><a name="_Toc428740000"></a><a name="_Toc431832042"></a><a name="_Toc431832362"></a><a name="_Toc434628950"></a><a name="_Toc428736754"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Third Party Beneficiaries</u><font style="white-space:pre-wrap;">.  None of the provisions of this Agreement shall be for the benefit of or enforceable by any Third Party, including any creditor of either party.  No Third Party shall obtain any right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of any debt, liability or obligation (or otherwise) against either party.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.11</font><a name="_Toc428737100"></a><a name="_Toc428737448"></a><a name="_Toc428738141"></a><a name="_Toc428740001"></a><a name="_Toc431832043"></a><a name="_Toc431832363"></a><a name="_Toc434628951"></a><a name="_Toc428736755"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Binding Effect</u><font style="white-space:pre-wrap;">.  This Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, successors and permitted assigns.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.12</font><a name="_Toc428737101"></a><a name="_Toc428737449"></a><a name="_Toc428738142"></a><a name="_Toc428740002"></a><a name="_Toc431832044"></a><a name="_Toc431832364"></a><a name="_Toc434628952"></a><a name="_Ref246329354"></a><a name="_Toc428736756"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Performance by Affiliates</u><font style="white-space:pre-wrap;">.  To the extent that this Agreement imposes obligations on Affiliates of a party, such party agrees to cause its Affiliates to perform such obligations.  Pfizer may use one or more of its Affiliates to exercise its rights or perform its obligations and </font></div></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">69<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:0pt;"><font style="white-space:pre-wrap;">duties hereunder, </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided </u>that Pfizer shall remain liable hereunder for the prompt payment and performance of all of its obligations hereunder.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.13</font><a name="_Toc428737102"></a><a name="_Toc428737450"></a><a name="_Toc428738143"></a><a name="_Toc428740003"></a><a name="_Toc431832045"></a><a name="_Toc431832365"></a><a name="_Toc434628953"></a><a name="_Toc428736757"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Corporate Integrity Agreement</u><font style="white-space:pre-wrap;">.  Protalix acknowledges that (a) Pfizer develops and promotes its products in compliance with the statutes, regulations and written directives of Medicare, Medicaid and all other federal health care programs (as defined in 42 U.S.C. &#167; 1320a-7b(f)) and with the statutes, regulations, and written directives of the Food and Drug Administration, and (b) Pfizer shall not be obligated to take any action pursuant to this Agreement that it believes, in its sole discretion, constitutes a violation of any of Pfizer&#8217;s obligations set forth in </font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">subsection (a)</u> above or such Corporate Integrity Agreement.</div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.14</font><a name="_Toc428737103"></a><a name="_Toc428737451"></a><a name="_Toc428738144"></a><a name="_Toc428740004"></a><a name="_Toc431832046"></a><a name="_Toc431832366"></a><a name="_Toc434628954"></a><a name="_Toc428736758"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Counterparts</u><font style="white-space:pre-wrap;">.  This Agreement may be executed in any counterparts, each of which, when executed, shall be deemed to be an original and which together shall constitute one and the same document.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.15</font><a name="_Toc428737104"></a><a name="_Toc428737452"></a><a name="_Toc428738145"></a><a name="_Toc428740005"></a><a name="_Toc431489967"></a><a name="_Toc431832047"></a><a name="_Toc431832367"></a><a name="_Toc434628955"></a><a name="_Toc428736759"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Headings</u><font style="white-space:pre-wrap;">.  Headings in this Agreement are included herein for ease of reference only and shall have no legal effect.  References to the parties, Sections, Schedules, and Exhibits are to the parties, Sections, Schedules and Exhibits to and of this Agreement unless otherwise specified.</font></div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-left:0pt;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-decoration-line:none;text-indent:0pt;vertical-align:baseline;white-space:nowrap;">18.16</font><a name="_Toc428737105"></a><a name="_Toc428737453"></a><a name="_Toc428738146"></a><a name="_Toc428740006"></a><a name="_Toc431832048"></a><a name="_Toc431832368"></a><a name="_Toc434628956"></a><a name="_Toc428736760"></a><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equitable Remedies</u><font style="white-space:pre-wrap;">.  The parties agree that irreparable damage may occur in the event that any of the provisions of this Agreement were not performed in accordance with their specific terms or were otherwise breached.&#160; It is accordingly agreed that, without limitation of other remedies which may be available to a party for breach of this Agreement by the other party, the parties shall be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically the terms and provisions of this Agreement.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;">70<a name="_cp_textHF_2_1047"></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:10pt;margin:0pt;"><font style="font-size:10pt;visibility:hidden;">&#8203;</font></p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt 0pt 36pt 0pt;">IN WITNESS WHEREOF the parties hereto have caused this Agreement to be executed by their duly authorized officers upon the date set out below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Protalix Ltd.<font style="display:inline-block;width:182.34pt;"></font>Pfizer Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:24pt 0pt 0pt 0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:99.89%;"><tr style="height:14.7pt;"><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0.15pt 5.4pt 0.15pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">By :</p></td><td style="vertical-align:top;width:31.76%;border-bottom:1px solid #000000;margin:0pt;padding:0.15pt 5.4pt 0.15pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">/s/ Moshe Manor</p></td><td style="vertical-align:top;width:10.57%;margin:0pt;padding:0.15pt 5.4pt 0.15pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:6.03%;margin:0pt;padding:0.15pt 5.4pt 0.15pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">By: </p></td><td style="vertical-align:top;width:36.33%;border-bottom:1px solid #000000;margin:0pt;padding:0.15pt 5.4pt 0.15pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">/s/ Michael Goettler</p></td><td style="vertical-align:top;width:7.64%;margin:0pt;padding:0.15pt 5.4pt 0.15pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="white-space:pre-wrap;">Name:  Moshe Manor</font><font style="display:inline-block;width:137.36pt;"></font><font style="white-space:pre-wrap;">       Name :Michael Goettler</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:274.5pt;text-indent:-274.5pt;margin:0pt;"><font style="white-space:pre-wrap;">Title:    President and Chief Executive Officer</font><font style="display:inline-block;width:17.24pt;"></font><font style="white-space:pre-wrap;">        Title:   Global Commercial Officer, Senior Vice President</font><font style="display:inline-block;width:15.19pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="white-space:pre-wrap;">        </font><font style="visibility:hidden;">&#8203;</font></p><p style="display:none;font-size:12pt;line-height:0pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">[***]</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;background:#ff0000;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">Protalix Biotherapeutics, Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:39.36%;"><tr style="height:14.7pt;"><td style="vertical-align:top;width:19.4%;margin:0pt;padding:0.15pt 5.4pt 0.15pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">By :</p></td><td style="vertical-align:top;width:80.59%;border-bottom:1px solid #000000;margin:0pt;padding:0.15pt 5.4pt 0.15pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">/s/ Moshe Manor</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="margin-bottom:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="white-space:pre-wrap;">Name:  Moshe Manor</font><font style="display:inline-block;width:137.36pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">Title:    President &amp; Chief Executive Officer</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="white-space:pre-wrap;">Date:  October 12, 2015</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">[***] Redacted pursuant to confidential treatment request.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>plx-20250930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.1.0.82--><!--Created on: 11/13/2025 10:02:14 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">I, Dror Bashan, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36.05pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">5.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:24.5pt;text-indent:-24.5pt;margin:0pt 0pt 0pt 24.5pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:98.94%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;13, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>plx-20250930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.1.0.82--><!--Created on: 11/13/2025 10:02:14 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CERTIFICATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:24.5pt;margin:0pt 0pt 10pt 0pt;">I, Gilad Mamlok, certify that:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">I have reviewed this quarterly report on Form 10-Q of Protalix BioTherapeutics, Inc.;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">3.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">4.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">c)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">d)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36.05pt;text-indent:-36.05pt;margin:0pt 0pt 10pt -0.04pt;">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">a)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">b)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;13, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Gilad Mamlok</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gilad Mamlok</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sr. Vice President &amp; Chief Financial Officer,</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Treasurer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>plx-20250930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.1.0.82--><!--Created on: 11/13/2025 10:02:14 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2025 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Dror Bashan, President and Chief Executive Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;13, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Dror Bashan</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>plx-20250930xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  11.1.0.82--><!--Created on: 11/13/2025 10:02:21 AM (UTC)--><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT&#160;32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">PROTALIX BIOTHERAPEUTICS, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CERTIFICATION</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;">In connection with the quarterly report of Protalix BioTherapeutics, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended September&#160;30, 2025 as filed with the Securities and Exchange Commission (the &#8220;Report&#8221;), I, Gilad Mamlok, Senior Vice President and Chief Financial Officer of the Company, hereby certify as of the date hereof, solely for the purposes of Title 18, Chapter 63, Section&#160;1350 of the United States Code, that to the best of my knowledge:</p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">1)</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the Report fully complies with the requirements of Section&#160;13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and</p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">2) </p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Certification has not been, and shall not be deemed, &#8220;filed&#8221; with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: November&#160;13, 2025</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 2pt;">/s/ Gilad Mamlok</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Gilad Mamlok</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Senior Vice President and Chief Financial Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>plx-20250930x10q005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250930x10q005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %\!#@# 2(  A$! Q$!_\0
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MO+6436UQ&LL4B]'1AD$?4$5/3:MHQ)WU04444AA1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9+*>=[>=$-K+:AA"\/R<'YB3OW@^E1:?^S1H>G1>(BOB3Q3)?ZY]E:ZU-]3
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M+/VI_P#H2_ __?Z3_P"2:^EJ*.?R0?V<_P#H(J?>O\CYI_X2S]J?_H2_ _\
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MI';%5/OC_P#('S-_PLC]IW_HDN@?^#2'_P"2J/\ A9'[3O\ T270/_!I#_\
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M)+H'_@TA_P#DJOIFBCG7\J_'_,/[/J_]!53_ ,D_^0/F;_A9'[3O_1)= _\
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M+_X[1_PMO]HO_HC>G?\ @UB_^.U]+T4<Z_E7X_YA]0K?]!4__)/_ ) ^:/\
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M4?\ X,T_QH_X7=\>_P#HB4?_ (,T_P :^F**.=?RK\?\P^H5_P#H*G_Y)_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDG ZT#Q!IQ!/VI,#KUK@?^%K^"?^AQT#_P &D'_Q5'_"U_!/_0XZ!_X-(/\
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M"7^9WXU[3RVW[4F<;L<],9_E0-?T\J"+I".G -<!_P +7\$_]#CH'_@T@_\
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M?^#2#_XJCEEV#Z]A?^?L?_ E_F=\/$.G$$B[3 Z]:#XATY0I-VF",CK7 _\
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M4?V_8?\ /ROY'_"G44 !URQ"!_M"[22 <'J,>WN*/[:L@Y7[0NX9R,'M110
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MX"9QEB>G/&>*;>_#:%M8U'4=+UK4] EU+:;V+3VB,<[*H4/MDC?:VT!=RX)
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M.-3#'9QH8R"Z.PD+;AO P=@KW>BJYW>XN1)61Y)<?"[7KKQ@+Z./2-)@:_\
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M !RCVM/^9?>']BYI_P! M3_P"7^1Y=17J/\ PS'\3/\ H66_\#;;_P".4?\
M#,?Q,_Z%EO\ P-MO_CE'M:?\R^\/[%S3_H%J?^ 2_P CRZBO4?\ AF/XF?\
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MO_ VV_\ CE'M:?\ ,OO#^Q<T_P"@6I_X!+_(\NHKU'_AF/XF?]"RW_@;;?\
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M%:"625A@^<T.7SAOE %;OP,CTS1M6CT_3X=,U.*;2GEO=7TRUDLIE92H"ZC
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MIZQ3YOK89N9R,S+T,KD'KZ5UU<[IO^JG_P"OJX_]'/0 S^V]._Y_[7_O\O\
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M -!2]_\  A_\:/\ A)-7_P"@I>_^!#_XUG44<J[!S/N:/_"2:O\ ]!2]_P#
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MK_\ 04O?_ A_\:/^$DU?_H*7O_@0_P#C6=11RKL',^YHGQ'JQZZI>G_MX?\
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M_A&*VC\'[O4]<M->UO7TO]=BOK6Y::VL?(@$-OYA2".,R,R@F5V+,[$D] ,
M"UMZJ_IIM_7IT!Z)^FGKKO\ I\KBW?Q4UVWBU2:+PG'>0:$@_MG[/J69(Y/+
M$CQVJF(>>55@26,6<@#)Z26_QIL;KPU?:E%9[KNWU&+3X[(S8,WFE&AD#;>%
M:*19.G ##G:34^O_  QU&_O-<72O$?\ 8^EZ_P ZG +,2S[C&(V:WEW@1,R*
M 2R2=,@ TX_!S21XWTG7D<I:Z=8"TCTW9F-I%1HXYBV<[EBDEC''1_85*O\
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M1!XSO=?^T%C<V,-E]GV?=\MY&W;L\Y\S&,=JF.ROY_F[?H.6[MY?DK_J>?\
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MBVM?] B__P# 9_\ "CF7<.678RZ*U/\ A%M:_P"@1?\ _@,_^%'_  BVM?\
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M1?\ _@,_^%',NX<LNQET5J?\(MK7_0(O_P#P&?\ PH_X1;6O^@1?_P#@,_\
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M_A&=8_Z!-]_X#/\ X4<R[ARR[&;7W3^PK_R2/5_^PY-_Z3V]?%'_  C.L?\
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MDH**** "BBB@ HHHH **** 'Q?ZQ:*(O]8M% %NBBB@ HHHH **** "BBB@
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M 'R*/(C_ .>:?]\B@#G:*Z+R(_\ GFG_ 'R*/(C_ .>:?]\B@#G:*Z+R(_\
MGFG_ 'R*/(C_ .>:?]\B@#G:*Z+R(_\ GFG_ 'R*/(C_ .>:?]\B@#G:<GWU
M^M=!Y$?_ #S3_OD4>1'_ ,\U_P"^10!5HJYL7^Z/RHV+_='Y4 4Z*N;%_NC\
MJ-B_W1^5 %.BKFQ?[H_*C8O]T?E0!3HJYL7^Z/RHV+_='Y4 4Z*N;%_NC\J-
MB_W1^5 %.BKFQ?[H_*C8O]T?E0!3HJYL7^Z/RHV+_='Y4 9]Q_J'^E9==(44
MC!4$?2F^1'_SS3_OD4 <[171>1'_ ,\T_P"^11Y$?_/-/^^10!SM%=%Y$?\
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MB@#G:*Z+R(_^>:?]\BCR(_\ GFG_ 'R* .=HKHO(C_YYI_WR*/(C_P">:?\
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M -"NW_@QNO\ X[1RT/YG]R_^2#FQ'\D?_ G_ /(GLE%>-_\ #(7PG_Z%=O\
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M=O\ P8W7_P =H_X9"^$__0KM_P"#&Z_^.T<M#^9_<O\ Y(.;$?R1_P# G_\
M(GLE%>-_\,A?"?\ Z%=O_!C=?_':/^&0OA/_ -"NW_@QNO\ X[1RT/YG]R_^
M2#FQ'\D?_ G_ /(GLE%>-_\ #(7PG_Z%=O\ P8W7_P =H_X9"^$__0KM_P"#
M&Z_^.T<M#^9_<O\ Y(.;$?R1_P# G_\ (GLE%>-_\,A?"?\ Z%=O_!C=?_':
M/^&0OA/_ -"NW_@QNO\ X[1RT/YG]R_^2#FQ'\D?_ G_ /(GLE%>-_\ #(7P
MG_Z%=O\ P8W7_P =H_X9"^$__0KM_P"#&Z_^.T<M#^9_<O\ Y(.;$?R1_P#
MG_\ (GLE%>-_\,A?"?\ Z%=O_!C=?_':/^&0OA/_ -"NW_@QNO\ X[1RT/YG
M]R_^2#FQ'\D?_ G_ /(GLE%>-_\ #(7PG_Z%=O\ P8W7_P =H_X9"^$__0KM
M_P"#&Z_^.T<M#^9_<O\ Y(.;$?R1_P# G_\ (GLE%>-_\,A?"?\ Z%=O_!C=
M?_':/^&0OA/_ -"NW_@QNO\ X[1RT/YG]R_^2#FQ'\D?_ G_ /(GLE%>-_\
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M$?R1_P# G_\ (GLE%>-_\,A?"?\ Z%=O_!C=?_':/^&0OA/_ -"NW_@QNO\
MX[1RT/YG]R_^2#FQ'\D?_ G_ /(GLE%>-_\ #(7PG_Z%=O\ P8W7_P =H_X9
M"^$__0KM_P"#&Z_^.T<M#^9_<O\ Y(.;$?R1_P# G_\ (GLE%>-_\,A?"?\
MZ%=O_!C=?_':/^&0OA/_ -"NW_@QNO\ X[1RT/YG]R_^2#FQ'\D?_ G_ /(G
MLE%>-_\ #(7PG_Z%=O\ P8W7_P =H_X9"^$__0KM_P"#&Z_^.T<M#^9_<O\
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M -"NW_@QNO\ X[1RT/YG]R_^2#FQ'\D?_ G_ /(GLE%>-_\ #(7PG_Z%=O\
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M=O\ P8W7_P =H_X9"^$__0KM_P"#&Z_^.T<M#^9_<O\ Y(.;$?R1_P# G_\
M(GLE%>-_\,A?"?\ Z%=O_!C=?_':/^&0OA/_ -"NW_@QNO\ X[1RT/YG]R_^
M2#FQ'\D?_ G_ /(GLE%>-_\ #(7PG_Z%=O\ P8W7_P =H_X9"^$__0KM_P"#
M&Z_^.T<M#^9_<O\ Y(.;$?R1_P# G_\ (GLE%>-_\,A?"?\ Z%=O_!C=?_':
M/^&0OA/_ -"NW_@QNO\ X[1RT/YG]R_^2#FQ'\D?_ G_ /(GLE%>-_\ #(7P
MG_Z%=O\ P8W7_P =H_X9"^$__0KM_P"#&Z_^.T<M#^9_<O\ Y(.;$?R1_P#
MG_\ (GLE%>-_\,A?"?\ Z%=O_!C=?_':/^&0OA/_ -"NW_@QNO\ X[1RT/YG
M]R_^2#FQ'\D?_ G_ /(GLE%>-_\ #(7PG_Z%=O\ P8W7_P =H_X9"^$__0KM
M_P"#&Z_^.T<M#^9_<O\ Y(.;$?R1_P# G_\ (GLE%>-_\,A?"?\ Z%=O_!C=
M?_':/^&0OA/_ -"NW_@QNO\ X[1RT/YG]R_^2#FQ'\D?_ G_ /(GLE%>-_\
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M$?R1_P# G_\ (GLE%>-_\,A?"?\ Z%=O_!C=?_':/^&0OA/_ -"NW_@QNO\
MX[1RT/YG]R_^2#FQ'\D?_ G_ /(GLE%>-_\ #(7PG_Z%=O\ P8W7_P =H_X9
M"^$__0KM_P"#&Z_^.T<M#^9_<O\ Y(.;$?R1_P# G_\ (GLE%>-_\,A?"?\
MZ%=O_!C=?_':/^&0OA/_ -"NW_@QNO\ X[1RT/YG]R_^2#FQ'\D?_ G_ /(G
MLE%>-_\ #(7PG_Z%=O\ P8W7_P =H_X9"^$__0KM_P"#&Z_^.T<M#^9_<O\
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M -"NW_@QNO\ X[1RT/YG]R_^2#FQ'\D?_ G_ /(GLE%>-_\ #(7PG_Z%=O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU2\C4O\ G\MO_ 5O_CE.,.H?+_I=O_M?Z,W/T^?B@"UY2;]^Q=_]['-<%?\
MP9TC4/BY8_$*2[O!JMI;FV2U!3R&78ZY(V[LX<]^PKM/)O\ Y_\ 2K?G[O\
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M<Z=2U/ Q/:@]_P#1VY_\?I/[2U7_ )^+3_P&;_XY0!T=%<Y_:6J_\_%I_P"
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M6J_\_%I_X#-_\<H Z.BN=74M3!^:>U(]!;L/_9Z/[2U/:?W]KNSP?L[?_%T
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M/GQ(P5G7U 8@'ZUT% !67XI_Y%C5_P#KSF_] -:E9?BG_D6-7_Z\YO\ T T
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M_LR?\R#^UZ?\C/MZBOB'_A8OBC_H8-2_\"7_ ,:/^%B^*/\ H8-2_P# E_\
M&C^S)_S(/[7I_P C/MZBOB'_ (6+XH_Z&#4O_ E_\:/^%B^*/^A@U+_P)?\
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M]HYE^Q-*,<[25W<_7W^G9[[7/B#J7B'PGK'A'5?#_AUXI(X_$,&IP#[6NY0
MBQL9$WJ2<D# !'4BM]?AGX271M1TD>&]+_LS49?/O+3[(GE7$G'SNN,,WRKR
M?05T<,*6\211H$C10JJHP !T H5E%1>N_P"/^73RMV#7FYNNGX?Y]3YF^%7@
M'3/$7[*>J>'YFNK72;>]U7_1[.X:+S(XKF;;$[#DH< $9Y P>]8S:!8>+O@O
M^SWHE_XKC\*PM#!=)(T.]YWCLV"K&SHT2L-Y/[SKSC)%?4>G>'-*TC3)=-L=
M.MK33Y6D9[:&)5C8N27)4<'<22?7)JAJ7P\\+ZSX:MO#U_X>TR]T*V55@TV>
MU1X(@HPH5",# X&*-6FO\/X7&K)_^!?B?+^B^,=5U'PU\#/$;/%/JT7BRXT+
M[5;Q"%+VT=I87D"* ,,J*_'&1FOL&N(U/X7V6H>+O"&I((+72?#*3O9Z9! %
M03N@C5^#@!4+@#'5LYXKMZINZMYO]/\ )OYD6UOY?J_\[?(*R_%/_(L:O_UY
MS?\ H!K4K+\4_P#(L:O_ -><W_H!J2B:BBO%=,D3Q[I&I^+=<\2:]I-L-2N;
M+3;?2+N:!+1(9VB5FCA_USL8RQ\T.N#C &<M:L3T/:J*\PT?XGWNH6FC:5H
MM?&VM26+W5S?F8V%KLCD,19CLD8.SJRA N,JV2H%6?!?QGM?&GB:XT:+2;FQ
MFMM*_M"<7+KOBE%Q+!) RKD95H6^8,0<C%-Q:=O7\/\ AA*2:OZ?C:WYH]&H
MKRGP)\3/$/C7QW9HFG65MX:N_#]KJBJUXS7$3RLX^[Y.&Y4+C>!@;NIVCU:B
M47'<(R4MOZTN%%%%24%%%% !1110 5\3_%#_ )*+XD_Z_P";_P!"-?;%?$_Q
M0_Y*+XD_Z_YO_0C7L99_$EZ'@YO_  H^OZ'+T445]&?*A1110 4444 %%%%
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M[C2:T3[C3NV@HHHJ2C,\2>'++Q7I$FF:BC26DCQR,J,5.4D61>1_M**TZ**
M"BBB@ HHHH **** 'Q?ZQ:*(O]8M% %NBJ]U%<2;?(G6''7='OS^HJ#[-?\
M_/\ 1_\ @/\ _94 7Z*I+;WP8%KV-AW'D8S_ ./4"WOMA!O(]V1AO(Z#G/&[
MZ?E0!=HJG]GO=X/VR/;@9'D=>/\ >IGV:_\ ^?Z/_P !_P#[*@"_15#[-?\
M_/\ 1_\ @/\ _94XV]]\O^F1\=?W'7G_ 'J +M%4_L][\_\ ID?/W?W'3G_>
MYXI&M[XA<7L8(')\CJ<_[U %VBJ'V:__ .?Z/_P'_P#LJ/LU_P#\_P!'_P"
M_P#]E0!?HJD;>^V@?;8]V3D^1V_[Z^M+]GO=Y/VM-N#@>3WQ_O>M %RBJ1M[
M[8!]MCW9.3Y'4?\ ?7UIOV:__P"?Z/\ \!__ +*@"_15#[-?_P#/]'_X#_\
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M['_WX_\ LJ/LU]_S^Q_]^/\ [*C^TY?RA_8\?Y_P/B+_ (1/7/\ H#:A_P"
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M?_?C_P"RH NT55,%YNS]J3;MQCR>^.O7UYIOV>]VX^V1[L]?(_\ LJ #4/\
MEG^/]*ITNHP7F8\7: 8Z>3WP,]ZI^1>?\_<?_?G_ .RH MT54\B\_P"?N/\
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M5YFWR-RCY?*W8R-^*]$Z54-O>[ !=Q[LG+>3U'&.-WU_.F_9K[_G]C_[\?\
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MB/Q#9^%_#>IZY>R;;#3[62\F=>?W:(6./P%?!GQ)T"]TKP3+>^+/#.LW[/\
M#JUM-)O3922#3KI&8SB1\?N&P026QE<KSG!^B_C[9Z]KW[/&C^&O#EG)=ZEX
MA_L_3-RHYCAC?89'E95)2,*I#-C@&JDG9J.][?BU^ER8M7BY;-7_  3_ %_
M]#^$7Q:TSXO> ;?Q3903:9;O)+%-;7I426[HQ!#X.!Q@_0BM+6/B/X=T+6M
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MNWEQ_9P0J,^<K+("$QD8S6E;:!J]IXC^'>LOX2UG6O$,>FZ1!/::QHLKQ_*
M'EM[Q#NMGCW-O24*&*]#QFTKRMYI?G_E^-]M1R:5VO-_BK?@_P .Y]O"^MFN
MC;"XB-R!N,(<;P/7'6N1\5?%"R\*?$'P?X3GLYY[OQ*;D03QE=D/DH';=DYY
M!XQ7SAX3\"ZP?CY)<:E8:Q:Z_%XLN[\:G::'E)-/.?+62^9U4P&,A?* +*W(
M7O7JGQ:T34;_ /:)^#-_;6%U<6-FVI?:;F*%FB@W0J%WL!A<G@9ZT1UY&^O^
M5_\ @?(4M.9+I_G_ %]Y[A1112 **** "LOQ3_R+&K_]><W_ * :U*R_%/\
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M-'_"6ZY_T&+_ /\  E_\:/[,E_,']L0_D?WGVE17Q;_PENN?]!B__P# E_\
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M^T?46U6?5K?5[2!0T;R3M+Y;Q$D2)\VT@D;AZ5Z-]CO?^@@?^_*TXVEW\O\
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M8=NT_+Y0]*R_LUU_S^G_ +]"@"W153[-=?\ /Z?^_0IPM[C<I^U<#&1Y8YH
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M]A'VTEB00WE+P.>/Y?E0!<HJE]DO/^?\_P#?E:/LEY_S_G_ORM %VBJ:VMV
MP-Z6)& ?*7@Y'/\ GUH-K=_+_IIXZ_NEYH N454^S77S_P"FGG[O[I?EY_7T
MIOV2\_Y_S_WY6@#0B_UBT55L[>YCN4:2[,J=U\L#/XT4 :M%%9VO^(])\*:9
M)J6MZI9:/IT9 >[U"X2")23@ NY &3QUH T:*R?#?BW0_&-@;[0-9T_7+(,4
M-SIMTEQ&&'4;D)&?:M:@ HHHH ***I7NM:?IU[8V=W?VUK=WSM':033*DEPR
MJ698U)RQ"@D@9P!F@"[13)IH[:%Y99%BBC4L[N<*H')))Z"N?\,?$?PEXWGF
MA\.^*-%U^:%0TL>EZA#<M&#T+!&.!]: .CHHHH **** "BBB@ HHHH ****
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M4VG"N, N,X-5?A7I"1>(]=U6*36&CN8+>%C?Z2--A=DW\I$51RP# %BH! 4
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M*^B_%3XKZUX?^&]C+XUL--U/QK9W&I#5CI<++916\"MY84@*S2$[F)'RYPH
MIC_M'^/_ !?HFF7NFZMI_AF2T\$S>);Q9+)95OY@\D01=Y^11Y>\$9Y89##B
MOHO7/@5X#\2>#M)\*ZGX<MKS0M*"BQMG>3=;@# "R!MXXX/S<]\UYK\?OV:;
MKXCIH5MX;T[PG!I^GV$NG)%JUM,C6:-P'@,)PVT=(W&W(!ZTIZM\O5_H[?I]
MU^I4;67-V_57_7TZ&5X7^*?C;6O&;O>>*[32_#6D>$M,\0ZD;BPC<R/)!(TG
M*J"J$C<V.1L 7&37!6W[1GQ'LO#/C_S=;>]N;71['6M)U&\T>"T*K-=+&0D0
M+9A*_=,@\S!R<<5]1^&/A)X=\.V C:PCO;N;1[;1;VXGRPN[>&/8JLA)7&"W
M0<YYS6-IO[-'PST?3[^QLO"=M:VM_;K:W2133#SHUE\U58[\G#@$'J  ,XXJ
MYV<G;;7\W_P/Q,X745??3\$K_K]Z/$9OBW\4_#OBV\M-0\5V&HV6D^+=)TR=
M(])CB:[@OE5FC)R=BQ[OE(RQ[L>E=C\*_BMXNN_CCJWA_P 8:RD%I>R70T;3
MDTZ,VEQ'$<AK:\C8EW" ETDY!SC&,#UJ]^$'A#4;R[N[C1DDN+N^M=2G<S2#
M?<VX @DX;C: .!P>X-5_#WP0\"^%/&-WXJTGPU9V6OW)<R7B;C@O]\HI)5"W
M<J!G)SU-$6E:_G^2_5/[P:;6GE^;_1K[CN:***DH**** "BBB@ HHHH *R_%
M/_(L:O\ ]><W_H!K4K+\4_\ (L:O_P!><W_H!H FHHKQOPQX+/BNP\4:H_B'
MQ'9ZO%K6I16]Q!KEWY4(29UC MVD,)50!\I3'%&FM_43Z6ZGLE%>$Z;\<)+'
MPY;^(M0M'EO&\/6%W/YM^T%BKRSO$7==C") <LTN#A.WRUMZY\?(/#/AG2;W
M54\/V%_JMR]O9R3>(HUTN4*F\RB],8^3! '[O<3QMQS6C@T0II_UY7/6Z*\B
MT/X\2^+]#>Z\.Z7I.IW-M=R6E[='7HQI4#*J,&6\2-S(&#KMQ%G(8,%(JN/V
MB5O[#PQ+INFZ6;C6H;B5/[3UM;6W=H9/+>*WF$3B>0G+*,*"HW$BER2O;^NX
M^>-KGLM%>)^-OVG]'\':SJ5C*^A1/I$,<NHVFJ>(8;.^R\2R^7;0%6$[!6'5
MT!)P">VQH?QR'B?QI+H^E:;8SVD3PJWG:JL.HO')&LBW$=HT?SP8?[_F G:V
M%.*%"3U0G.*T;/5****@T"BBB@ KXG^*'_)1?$G_ %_S?^A&OMBOB?XH?\E%
M\2?]?\W_ *$:]C+/XDO0\'-_X4?7]#EZ***^C/E0HHHH **** "BBB@ HHHH
M *]Z_9L\1F2UU+0Y6SY;"YASZ'AA^84_B:\%KW/]FOPZ2VJ:W(ORC%K"?4\,
M_P#[+^=<&.Y?82YCTLNYOK,>7^D>ZTY/OK]:;3D^^OUKY,^V-:BBB@ HHHH
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M!">G^[7H?VI+^3\3S/['C_/^!\4?\(YJW_0+O?\ P'?_  H_X1S5O^@7>_\
M@._^%?:_]G-L/^F3YSUPG_Q-/.G'S/\ CZGQLZ83KMZ_=_&C^U)?R?B']CQ_
MG_ ^)?\ A'-6_P"@7>_^ [_X4?\ ".:M_P! N]_\!W_PK[5_LY_^?VX_*/\
M^)H_LY_^?VX_*/\ ^)H_M27\GXA_8\?Y_P #XJ_X1S5O^@7>_P#@._\ A1_P
MCFK?] N]_P# =_\ "OM>/3FWKF\G(R.,)_\ $T+IS;6_TR?IQPG'_CM']J2_
MD_$/['C_ #_@?%'_  CFK?\ 0+O?_ =_\*/^$<U;_H%WO_@._P#A7VT-..Z+
M_2Y_?A.>3_LU%_9S_P#/[<?E'_\ $T?VI+^3\0_L>/\ /^!\5?\ ".:M_P!
MN]_\!W_PKZR^&_AX^&/!>EV+ILF$0DE'<.WS$'Z9Q^%='_9S_P#/[<?E'_\
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MN3_L_P J +U%9ICN,G_39O\ OF/_ .)H\NX_Y_I_^^8__B: -*BJ!CG\E?\
M3)L[CD[4YZ?[/^<TICF\UO\ 2YL8.!M3CC_=H O450,<_DK_ *9-NW'+;4R>
M!_L_YS3/+N/^?Z?_ +YC_P#B: -*BLWR[C_G^G_[YC_^)IXCG\EO],FW;A@[
M4XZ_[/\ G% %^BJ(CF\U/]+FQQD;4Y_\=I!'/Y+?Z9-NW##;4R.#_L_YQ0!?
MHK-\NX_Y_I_^^8__ (FCR[C_ )_I_P#OF/\ ^)H TJ*H1QS[),WDQ.W@E4XY
M'^S2&.?Y/],FZ<_*G//^[0!H451\N;,W^ES=./E3CD?[-1^7<?\ /]/_ -\Q
@_P#Q- &K%_K%HJEIZ2BZ3?=2RKS\K! #Q[*#10!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>plx-20250930x10q006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250930x10q006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &N K0# 2(  A$! Q$!_\0
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M-2_[_FC_ (7'XW_Z&C4O^_YKCJ*[_9P_E1YGMJG\S^\['_A<?C?_ *&C4O\
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M#%\Q/T]*S#^PSJL6CWLS^(;4W\"LRV\:94@<C/H36:Q6%?5?<:/"8U=']_\
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M2_[_ )KCJ*?LX?RH/;5/YG]YV/\ PN/QO_T-&I?]_P T?\+C\;_]#1J7_?\
M-<=11[.'\J#VU3^9_>=C_P +C\;_ /0T:E_W_-'_  N/QO\ ]#1J7_?\UQU%
M'LX?RH/;5/YG]YV/_"X_&_\ T-&I?]_S1_PN/QO_ -#1J7_?\UQU%'LX?RH/
M;5/YG]YV2_&3QN"#_P )1J0/;]\:]E^ W[6.O:5XAM-(\5WK:GI5TXB^TSG]
MY"3P#GN.U?-%/@8QSQLO#!@01]:QJX:G4@XN)O1Q52E-24F?K[#(LL*.A!1@
M"".XHK"\ 3-=^"-"EDY=K*(D_P# 117Q,ERMH_0X/FBGW/A']LG_ )*_<?\
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M[PM=K\/ULO$5NZV=Q&UT(I#\B@#.ZJ_C7XH^$-0^.>DZM;^,AIUO%8^6+RU
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MZ_UI*6/_ %J?7^M)[,M;H_5SX<?\B%X?_P"O*+_T$44?#C_D0O#_ /UY1?\
MH(HKX&I\;/TFE\$?1'PO^V3_ ,E?N/\ KBM>%5[K^V3_ ,E?N/\ KBM>%5]I
MA?X$/0^ QO\ O$_4****ZSB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HJ:RC2:[ACE;RXW=5=O[H)P37Z!>&O@7X%TW0=!AM_!T.NPWL:F?4&.=GRY
MW-SW]JXL1BHX:W,KW/0PN#GB[\KM8_/>BOKG2_@EX3B_:<ET.SM([O1H;8SS
M6;_,D3'^'\Z]'^(7@#P=X;T'5IX_AEYZ11.%N+= <'!PV,YP#S7/+'PBXQ2;
MNK_>=,,LJ24I.25FU]Q^?]%6'M9I)V"0289R% 4^M?0OPL_9,\57FH:)K>J6
MEHVEO(LDMI/)AVC/JO\ 2NVI7A25YNQP4L-4K2M%7/G*BOJ/]HSX(I?_ !+T
M70/!>BP6LMQ;;WCA&Q!SRS'M7*:S^QKX\TC2Y[W_ $"Z\E"[Q0S9? &3@5C#
M&4I1BV[7-ZF!KQDXQC>W5'@]%>I7?[._B6V\ #Q<'M9]/XW1QOF1><$$>QJI
MXW^!.N^ /"5AX@U2:U6VO<>7$LG[PY&>16RKTV[*7D8/#54FW'1*_P CSBBO
MH+]CGP;HGC/QEJEOK>FP:C#';;D29<@'.,BO<OB'X7\$^%=/U<?\*ME>WMH6
M/]H11#RQQ]X'-<M7&QI5?9<MV=E#+Y5J7M>9)?,^"Z*]D\&?LP>,?B)I[:OI
M]M!8:=,Q,)NY-A8=L#TK;^&WP,U#PE\:M)T/QCI45Q:SABN3OBD 'KWK>6*I
M*]G=KH<ZP=:3C[MD^IX!17W'X;^$WA&Y^/OB/29-!LWTZ&S1X[8Q_*K'TKP8
M_L^^(/B)\0?$5OX:L(;;3+2[>,2RG9$F#]T>M94\93G>^EE?4UJ8"I32MJV[
M:'BM%>P^)OV6O&?A/4+&WOEM?L]Y*(4NXY<Q*QZ!O3-)+^R[XOC\<1>&/]%:
M\D@^T"97S&%]SZUM]:HVOS(Y_JE>]N1]CQ^BO7M/_9A\6ZAXPU+P\#;1W5A&
M))99'_=%3T(/>O--6\/7.E:S/IS@320RF(R1@[2<XR#Z5I&M3F[1=R)T*E->
M]&QF45ZUKO[-?B?P_8Z)=W,UH8M6E2* +)DAF'&[TJW=_LK^++/QA9>'7FLO
MMUU$9HV$GR[1ZGUK/ZS17VB_JE:_P/\ X<\:HKWC4?V,_'^GV-U=%;&7R 6\
MN.;+N!Z"O#;BUDL[Q[>9#'-&Y1U;L<\BKIUJ=7X'<BIAZM%KVD;7(:#UK[Z\
M-?#WX?Z)\)M%US4_"$&HR201[S#;EY&+<9P*XG]I+X Z"^@:/JG@_1_L&HW<
MJQ"T@7;YFX=QV(KACF$)5/9M->?H>C++*D:7.I)[.Q\=T5[R_P"QA\04T[[3
MML3*$WFV$PW_ $^M8/@7]F;Q?X]@U!K-+>VELI3!-%<R;6#"NOZS1=Y<RL<3
MP==22Y'=GDE%?7/PG_9VO/!^H:K8>(]!TKQ!<FW$J*]QS$/6O(_#7[._BOXF
M:QJTNC64%E807#IYDTFV-<'HI[UG'%TFWKHK:FLL#6BEI=OH>145Z9\0?V>_
M&'PZN+2._LEN([MQ'%-:OO4L>@)KV#X-_LD:]I?BC3-3\46%C=:2REI;1Y-S
M#(XR*J>*I0AS\U_U(IX.O.IR<K7?R/E.BO7/VH/#>F>%?BM>Z?I-E#86:(A6
M*)<*.*ZC]FCX6:3K6D:_XM\0VBWFFZ;"VRWD&59@,YQ3>(BJ*K-;B6%DZSHI
M[=3Y[HKVCP]^SCXF^*FG7/B708[*+3KBX<16V[:P&>F.PJGXR_9E\6> Y]*&
MK&V2VOIU@%Q%)N6-F]:?UFE?EYM1?5*]N;E=NYY'17T['^P_J#HK?\);I@R,
MXP?\:\W;X :N_P 4AX-LYTU!T*F:[@'R(G<FE'%4972EL4\'7@DW'?0\JHK[
M7^+GP7\%^"O@+J,NF6%K<ZE9HJ/J"C,A?(W<_P!*N_!_X-^"T^%6D:NOAF/Q
M7?W@4SN3\R9.#WX KF>80Y'.SWL=:RNI[3V?,MKGPW17U/\ &[P'X*^&/Q5\
M*RV>FP?9;QQ]LTM^8PIXSC\:X7]J/X56?P\\5VUYH\*PZ1J<8EAC3HA]![5M
M3Q4:G*K;['-5P4Z:DV[\NYXE1117<>>%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4L?^M3Z_UI*=%_K$^H_G2>S+6Z/U;^
M''_(A>'_ /KRB_\ 0113OAM_R(/A_P#Z\HO_ $$45\#4^-GZ32^"/HCX;_;-
MLY;?XL--(A6.> ,A(Z@<5X)7Z'_M ?!%?C-I<(LV2WUJS!,$S_=93U4U\:ZU
M^SY\0=#NW@G\,7LF"0)(4WHWN"*^IP6)IRI*+=FCXW,,)5C6E-1NF>=45VG_
M  I;QS_T*VI?]^31_P *6\<_]"MJ7_?DUZ'M8?S(\OV%3^5_<<717:?\*6\<
M_P#0K:E_WY-'_"EO'/\ T*VI?]^31[2'\R#V%7^5_<<717:?\*6\<_\ 0K:E
M_P!^31_PI;QS_P!"MJ7_ 'Y-'M(?S(/85?Y7]QQ=%=I_PI;QS_T*VI?]^31_
MPI;QS_T*VI?]^31[2'\R#V%7^5_<<717:?\ "EO'/_0K:E_WY-'_  I;QS_T
M*VI?]^31[2'\R#V%7^5_<<717:?\*6\<_P#0K:E_WY-'_"EO'/\ T*VI?]^3
M1[2'\R#V%7^5_<<717:?\*6\<_\ 0K:E_P!^31_PI;QS_P!"MJ7_ 'Y-'M(?
MS(/85?Y7]QQ=%=I_PI;QS_T*VI?]^31_PI;QS_T*^I?]^31[2'\R'["I_*_N
M.:T">VM=<L)KQ-]JDZ-*N,Y4,,_I7Z.IK,/B.'PQ?^&O%NGZ9HMLH:YM/,0>
M:F/N]>,5\#_\*6\<_P#0K:E_WY-2)\'_ !]&I5?#>JJI[+&0*X<32IXAI\Z5
MO1GHX2K5PO,O9MI^JV/J+7_%G@[6_P!H)ULO$LFAW#6JPR:A9.HCFDS]TL>/
MQKM='NH?A3H7BF_\2^.(=?LK@,UK%),K.HP?EQGDDFOB7_A3/CK.?^$7U+/_
M %Q-.?X/^/I5"MX:U1@.FZ(FL)82FTH^TTT[=/,ZHXVJFY>RUU[]?(]BM?VM
M='M],333X)LV4'9]I*KNQG[W3K7T%J=UI_Q"B\&Z[IGBRUTRRLG666'[0%\P
M$?=(SU^M?#'_  I;QS_T*VI?]^34B_![Q\J[1X:U4*#D 1'%54PM&5G&=G]^
MY%+&8B-^>#:TZ6_)'V7XP?P_KGQ[TDW>OK:)'I^8VM[H()&W?=+ ^G:O0-.U
M#1=-DU>V34M-$LT;,H2\WR,,$ L6/7Z5^>C_  ?\?.P9O#6JEAT8Q'-*/A#\
M0 Q8>'-6#'J?+;)K!X*$DE[39'1',*B;?LGJ_/\ R/J#]F'Q#%XC?Q9X(U5#
M-;+<O-$#RI4MR ?K7F?[:'C--2\9VGARU;_1-*B"LJGC>:W_ (?_ !&^)'P]
M\*Q:59_#5Y;N*,HM\T)$A]"V.M>,>(OAM\1?%&MWFJW_ (:U*2ZNI&D=O).,
MGM6E&G%5W4DTETUZ]S.O6D\,J<$V^NCV['I_[#U];6'CG6'NKB*W!M  TKA,
M\]LFJWQ__: \61>-?$/AVUU:*706;RA$J*P*$<C<*\KC^#OCV$DQ^&M41C_=
MB(IK?!GQW(Q9O"^IL3U)A-=+I495W5E),XU6KQH*A&+5NNNI]@6%_IWQ@^$/
MAVRT'Q1;Z%<V1B,Z-+Y;#;C*D9'I5[Q5\0O#]W\5_!NC6^I6UW=V08SW*R J
MOR]-W2OC./X.>/8<E/#6J)GKMB(I!\'?'B/N'AG5 W][RB#7-]4I<S?M--;;
M=3L6-K**7LW?2^_0^S?"^M:>O[1_B>=K^V6%K% )#*H4_0YYJEX$\7:)XCT3
MQKX3@UN#2-7DNIPDS2!<[CPP.>?PKY"'PA\?ABX\.:L&/4B-LFF#X.>/ V\>
M&=4#?WO*.:7U2G_S\[?@/Z[5_P"?3Z]^I]5?%+Q?IWPM^"%OX=NM?AU[7P5\
MN2.0.Y(;.X\\8KN=+^*N@1_"ZW\;R3VS:I%8A"K2+YA(ZKC.>M?#C_!SQY*V
M7\,ZFS>K0DTO_"GO'VPI_P (UJFS^[Y1Q^5#P=&44G/6]WYB6.KQE=4]+66_
MWGVUXW^)^@Z?\*M1\86<ULNJZA9*F%D7?DC & <\5\\67[5.G1>$8]&F\'VD
MEQY(B>](7?GNW3K7EA^#WCYHPA\-:H5'13$2*9_PI;QS_P!"MJ7_ 'Y-:4L+
MAZ:]Z5]>YE6Q>(J-.,6M+;?\ ^X9%\.?$CP7X/O'\0VEE'I\L5S@S+EF ^Z>
M>*75;^UO_P!H3PZUK<PW"C3W&Z)PP_,5\0K\'_'R*%'AK50O4#RC@5V_PCTO
MX@_"SQ;'K@\&ZEJ+)&4\J1& Y[YK"6$A%-QG?>RTZG5#&SDXQG3:U5WKT^1]
M>6]E;>#?'GB;Q)JOBJW;3YX@!823C,) Y&TG]!7YZ^.]3M]9\<:Q?6AS;7%V
M[QGU4MQ7H'Q.\*_$#XB^,+_77\(:G9_;"&-NB$J,"N2_X4MXY_Z%;4O^_)KJ
MPE.%+WI33;7D<F,K3K^[&#23\]3[2;XIP_#K]G[2M4L7LKV]@M8P+:24<GZ
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M-O@5X6O[VZCU*>*6":>(2JTCXZYP:^8-7^%OCO4=1N[B+PIJ=K#-(SB!8SA
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M $P/2C ]*6B@!,#THP/2EHH 3 ]*,#TI:* $P/2C ]*6B@!,#THP/2EHH 3
M]*,#TI:* $P/2FR*&1E/<&GTAH Q[8[$91V8BBFV_23_ 'S10!9T+_CQ/^\:
MTJS="_X\3_O&M*@ HHHH **** "BBB@ KAO&F@RW7BOPSJ-K:>;/#-())><*
M-GRY]!FNYHH \I\$>'=?TWXEZI?ZG:*5NK1?,NTD+*6#'"CZ#M7H^I//;PF:
M*4*J8RI7.>0.M7ZI:Q_R#IO^ _\ H0HZ6#K<N*<@4M(OW1]*6@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-:FZ-25-] G%PDXL6BBBLB HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *0TM(: ,2VZ2?[YHHMNDG^^:* +6A?\ 'B?]
MXUI5FZ%_QXG_ 'C6E0 4444 %-9@BDL0 .233JXWQ_\ #T_$&.UM;G5[VPTM
M,F>VLI/+-QZ!G'('TH U'\=>'4O/LC:YIZW.<>5]I3=_.MJ.195#(P93R&4Y
M!KQKQ/\  /X9>%?"NHZG/X7BN$LH&G=O,;S6P/[V>M;?P9\(0:)I%OJ>D:GJ
M!T+4+=)8=+OI/-\@GGY7/.,=J /3JK7%E!=21O-$DCQY*%ADKD8.*LT4 96G
M>&M+TB4R65C#;2'.6C7'7K65\1]!@\0^%+RTN%9HVQD*Q'\0KJ>O-4-<0/I=
MPI'''\Q5TY.$U)="HRY6FCS+]G?1XM(\.ZE#&\F([Z:+RV;*C#'! [<5ZX*\
MQ^#N;?4/%MH?^66IN0/3=S7IV>:Z<9)SKRD^IK6UFV+1117&8!1110 4444
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M8KXT^Z7Y&U;XD_)#J***Y3$**** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !534K^'2K*:[GW^5$"S;%+'
M'T%6Z:RA@0PR#U!&0: /.Y_CKX92%F1KMGQD VS $_6J&G_M Z'=3;9X;F!
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M%N,8KV;1M1.KZ5:WIMY+0SQK)Y,XPZ9'0^] %^F2+YB,N2N1C(ZBGT4 >?\
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M&.4TJT*$I2O*^O+*VGR_(]6&58J<'-15EYK_ #/6,<YJ)[J&.01M,BR'HI8
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MS1!-&XR"1CK7N$,*6\:Q1HL<:C"JHP /05X%IO[./B[2?$&HZW:_$N]BU+4
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M<QM<0JQ0^V15E-+LXYO-6VB638(]P0 [?[OTIEEK-E?V%M>Q7,;6]R@>*0L
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M 4444 %(:6D- &);=)/]\T46W23_ 'S10!:T+_CQ/^\:TJS="_X\3_O&M*@
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MOT-1+#-KFI/F7EO]PG3=KPU1Z-15:._MIC'LGC;S1F/:P.X>HJS7*9!1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %,D<(,DX]Z?5'5M+@UFPGL[C=Y,R[6V,5./8CI0K=1JU]1\^HVU
MK"\LLR(B#+$MP!5:V\1:;>3)%#>0R.Z>8JJP.5]:X"Z_9X\+R6TD<3:@CLN
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M@\2>"O"B:K<Z1IFJW+F\DM)/+D=47(7=VKV^N+^(7PG\/_$TV7]MPS.UFS-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M _"M.:NMXI_/_@%7J=E]_P#P#T#-'4\UYV/AEK-IG[#XSU2(=DG*R ?G2?\
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MF3<>&[!F/<1 ']*5\++HU]S_ ,@_=>9TUOKVG7:@P7]K,#TV2J?ZU>5PZY#
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&XT4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>plx-20250930x10q007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250930x10q007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '/ K4# 2(  A$! Q$!_\0
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M?^9CO_\ OZ:3_A;GC'_H8K__ +^FN1HKN]E3_E7W'G>VJ?S/[SKO^%M>,?\
MH8K_ /[^FC_A;7C'_H8K_P#[^FN1HH]E3_E7W![:I_,_O.N_X6UXQ_Z&*_\
M^_IH_P"%M>,?^ABO_P#OZ:Y&BCV5/^5?<'MJG\S^\Z[_ (6UXQ_Z&*__ ._I
MH_X6UXQ_Z&*__P"_IKD:*/94_P"5?<'MJG\S^\Z[_A;7C'_H8K__ +^FC_A;
M7C'_ *&*_P#^_IKD:*/94_Y5]P>VJ?S/[SKO^%M>,?\ H8K_ /[^FC_A;7C'
M_H8K_P#[^FN1HH]E3_E7W![:I_,_O.N_X6UXQ_Z&*_\ ^_IH_P"%M>,?^ABO
M_P#OZ:Y&BCV5/^5?<'MJG\S^\Z[_ (6UXQ_Z&*__ ._IH_X6UXQ_Z&*__P"_
MIKD:*/94_P"5?<'MJG\S^\Z[_A;7C'_H8K__ +^FC_A;7C'_ *&*_P#^_IKT
M7]E'X8Z!\3_%.IV7B"U:ZMX;?S$57*X.:N7'PI\.1_M0IX.%H_\ 81F">1YA
MSC;GK7)*I1C4<''5*^R.Z-+$2IQJ*>C=MV>7?\+:\8_]#%?_ /?TT?\ "VO&
M/_0Q7_\ W]->P_M$? *TT/QSHFA>!M*E>XO+=I3!YFXL0>O->8:S\!/'OA_3
MKN_O_#EU;VEJ,RRMC _6G3J8>I%2LE?O856EB:4W&[=NU[&;_P +:\8_]#%?
M_P#?TT?\+:\8_P#0Q7__ ']-:^D_L\_$/6]/CO;3PQ=O;R+N1F 7</7!-:WP
ML_9XUWQI\0&\/ZO9W6D16HWWCL@W1J>GYU3GAXIO33T(C'%2:2YM?4Y+_A;7
MC'_H8K__ +^FC_A;7C'_ *&*_P#^_IKO?VC_ (&O\,O%%I'H^GW!T6>..&&9
MSN,TV/F ]ZYN+]G7XBS6 O$\*7QA*[Q\HW$>N,T1GAY04]$GZ!.&)A-PU;7:
MYC?\+:\8_P#0Q7__ ']-'_"VO&/_ $,5_P#]_37+WEE/IUU+;74+P7$3;7CD
M&&4CL17U#^RG\#O"7Q-\':E?Z_8R7-Q#=>6C+*5PN/:G6G1H0]HXZ>@8>-?$
M5/9*3OZL\&_X6UXQ_P"ABO\ _OZ:/^%M>,?^ABO_ /OZ:^BM*_9ET"3]H74]
M!N+.1O#4%B+I(_,(/S< ;OK7-_M8?!CPW\-;?P__ ,(S8R02WLCHX,A<M@<
M5S1Q&'G.,%'5Z[(Z9X7%4Z<IREI%VW9XS_PMKQC_ -#%?_\ ?TT?\+:\8_\
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MMKQC_P!#%?\ _?TU]F:_^SQ\'/#%WIEIJ=H]K/J,GE6RO<-\[^E<!XN_9?\
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MN^(XN4@_X1>\+NN\8 QCZYJM8_ #X@ZE<7D,'A>^:2U;;*"@&#Z#/6IYL/\
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M1AO7!]A6EZ%[:7^1C;%6YO>M\S/_ .%M>,?^ABO_ /OZ:/\ A;7C'_H8K_\
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M'9?J?:O8M-_M=OV;=*'PW,?]I>3'M\O&[.?GS[U\3>+OBQXM\=0+!KFN75_
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M %%%% 'WG^QPVWX-P_\ 7Y-_,45'^QW_ ,D=A_Z_)OYBBOB,5_&EZGZ)@_\
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MBSX7T[3K%K73K>X58HW.6(R"S-Z<"M7]MKQE9ZAXCT;PW9NL@TJ',S*<[7/
M7\JTHPG"=*+5FD[^AA7J0G3KRB[Q;5O4^9:***]X^;"BBB@ HHHH **** "B
MBB@ HHHH ^[OV//^2/0_]?DW\Q14_P"Q_;2VWP?M_-5X_,N977(ZJ3P:*^(Q
M7\:7J?HF#_W>'H=9\3_V>/#OQBL+2YO&DL-3B3:MY !N*^C#O7EW_# >E_\
M0UWG_@.E?4VD_P#(/A^E7,BIABZ]./+&6@5,%AZTN><-3Y-_X8#TO_H:[S_P
M'2C_ (8#TO\ Z&N\_P# =*^L<T9-:_7\1_,9?V=A?Y#Y._X8#TO_ *&N\_\
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M_P" Z4?\,!Z7_P!#7>?^ Z5]8Y-&31]?Q'\P?V=A?Y3Y._X8#TO_ *&N\_\
M =*/^& ]+_Z&N\_\!TKZQR:,FCZ_B/Y@_L["_P I\G?\,!Z7_P!#7>?^ Z4L
M?[!&FPR+(GBN\5U(96$"Y!'>OK#)HS1]?Q'\P?V=A?Y3YWU;]E75]<TTZ??_
M !)UFYLR,&%T7:1Z&N6_X8#TO_H:[S_P'2OK&C'MBICC:\?A=ODBY8##S^*-
M_FSY._X8#TO_ *&N\_\  =*/^& ]+_Z&N\_\!TKZQR:,FJ^OXC^8C^SL+_(?
M)W_# >E_]#7>?^ Z4?\ # >E_P#0UWG_ (#I7UCDT9-'U_$?S!_9V%_E/D[_
M (8#TO\ Z&N\_P# =*/^& ]+_P"AKO/_  '2OK')HR:/K^(_F#^SL+_(?)W_
M  P'I?\ T-=Y_P" Z4?\,!Z7_P!#7>?^ Z5]8Y-&31]?Q'\P?V=A?Y3Y._X8
M#TO_ *&N\_\  =*/^& ]+_Z&N\_\!TKZQR:,FCZ_B/Y@_L["_P I\G?\,!Z7
M_P!#7>?^ Z4?\,!Z7_T-=Y_X#I7UCDT9H^OXC^8/[-PO\A\ZZ/\ LH:GX?T.
M31]/^(>J6NF2[M]M'"@4YZUS!_8$TMCD^*[S/_7NE?6)Q1CVJ5C:Z;:>_DBW
M@,/))..WFSY._P"& ]+_ .AKO/\ P'2C_A@/2_\ H:[S_P !TKZQS1DU7U_$
M?S$?V=A?Y3Y._P"& ]+_ .AKO/\ P'2C_A@/2_\ H:[S_P !TKZQR:,FCZ_B
M/Y@_L["_R'R=_P ,!Z7_ -#7>?\ @.E'_# >E_\ 0UWG_@.E?6.31DT?7\1_
M,']G87^0^3O^& ]+_P"AKO/_  '2C_A@/2_^AKO/_ =*^L<FC)H^OXC^8/[.
MPO\ (?)W_# >E_\ 0UWG_@.E'_# >E_]#7>?^ Z5]8Y-&31]?Q'\P?V=A?Y#
MY._X8#TK_H:[S_P'2MC4?V,Y=6T>UTN\\=ZE<Z?:_P"IMY(E*Q_2OIK%&/:I
M>.KO>0UE^&6T?Q9\F_\ # >E_P#0UWG_ (#I1_PP'I?_ $-=Y_X#I7UCDT9-
M5]?Q'\PO[.PO\I\G?\,!Z7_T-=Y_X#I1_P ,!Z7_ -#7>?\ @.E?6.31DT?7
M\1_,']G87^0^3O\ A@/2_P#H:[S_ ,!TH_X8#TO_ *&N\_\  =*^L<FC-'U_
M$?S!_9V%_E/E[0OV)(_#6H)?:7XUU"RNU!"S10(&&:KZC^PI::I>37=YXQO[
MBYF;=)+)"I9CZDU]4F@?2I^O5[WYB_[/P]K<NGJSY._X8#TO_H:[S_P'2C_A
M@/2_^AKO/_ =*^L<FC)JOK^(_F(_L["_R'R=_P ,!Z7_ -#7>?\ @.E'_# >
ME_\ 0UWG_@.E?6.31DT?7\1_,']G87^0^3O^& ]+_P"AKO/_  '2C_A@/2_^
MAKO/_ =*^L<FC)H^OXC^8/[.PO\ (?)W_# >E_\ 0UWG_@.E'_# >E_]#7>?
M^ Z5]8Y-&31]?Q'\P?V=A?Y#Y._X8#TO_H:[S_P'2C_A@/2_^AKO/_ =*^L<
MFC-'U_$?S!_9V%_D/D[_ (8#TL?\S7>?^ Z5=T?]@[0+._BFOM?O+ZW4Y:#R
MU3=[9%?4G-%+Z]B']H:R[#)WY#E['1[+PU!'IUA MM:6\21QQH.  **OWW_(
M0E_W5_K17'S-ZGHJ*2L7](_Y!\/TJY5/2/\ D'P_2KE24%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !24M% "48I:* ,2^_Y"$O^ZO\ 6BB^_P"0A+_NK_6B
M@"_I'_(/A^E7*IZ1_P @^'Z5<H **** "BBB@ HHHH **BFF2WC:21UCC499
MF. *YUOB'HITR"_BN'N8;B5H8A!&6:1E^]@>U '3T5C/XJTQ/#XUDW ^P%=P
MD Y/.,8]<\8J30_$5GXAADDM2X:)MDD4J%71O0CM0!JT444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M8E]_R$)?]U?ZT47W_(0E_P!U?ZT4 7](_P"0?#]*N53TC_D'P_2KE !1110
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MCU%(751R0* NAU%1M,B]74?4TTW,2\F5 /\ >%.S"Z)<BC(J'[9!_P ]X_\
MOH4S^TK3_GZA_P"_@_QHY9=A<R[EJBJ?]KV/_/Y;_P#?Q?\ &L^?QAI5OJMI
MIQO(FNKG/EHC!NGKCI34)/H2YQ74W****DT"BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** ,2^_Y"$O^ZO\ 6BB^_P"0A+_NK_6B@"_I'_(/
MA^E7*IZ1_P @^'Z5<H **** "BBDW#UH 6BBB@ HHI"0.IQ0 M%%-!##(.:
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M2CX27K1[9/&>N/ZGS%']*]'HJ?K57O\ @O\ (?U:GV_%GFZ?!Z4 A_%FMO\
M]MP*$^"T2MEO$NML/3[617H^?\YHS1]:K?S?@A?5J78\V_X4?I[2;VUW7&.<
MG-\W-.;X'Z2QR=4U<G_K]>O1\^]%/ZU6_F#ZK1_E/.V^"&B/C=>:FV/6\?\
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MF'PTG\2W?PL\10:G%<B :"IC:X=3_P M!SC:*J^(OVEKCPM\-M+\6ZA\.O%
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MY_*IPO%.!QU!8B@I-/M%]/.UOQ(J997IU/9SM?U7Y;_@//A[QM(.?$EJG/\
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M17?T47ZDG$_$'PM?^(M5\*3V2HT>G:B+F?<VW"!2./4UV]%%!04444 %%%%
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MOTWQ:/ >K227=[):'3PI\V,(,[SQT-9_@S]M>]\67M] WP]UBQ%M9RW8>92
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M  UMH[H7^MW,FMZCUW7!_=H?]E>E=G'&L2A44*HX"J, 4^BM!A1110 4444
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M$3Q2+!-$DB0\;R7P%7ZY-3>&_$_]NS7UM-9O8WUDZK-;NX?&X9!!'7BN=N/
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M%4='MA9:590 8$4*)^2@5=Z5Q5)<TY2[L[:<>6$5V05R'Q5UAM%\#ZC)$?\
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M+Q5=YPL>DVC2*3_OXP*Q/ '[*FCZ;JJZKXJBA\1:A''L$MT[S&1R<F0[N![
M<5[AINAZ?HL BT^QM[.,# 6"((/T%;36'IOW;R_!&4?;S6MH_B>.GX@_%WQA
MQH/@>U\.V[=+G7;C+J/78O7Z4'X,^//%HSXL^(UU%$WW[30HA;I]-W6O<OI3
M2/;]:GZPX_!%+Y7_ #*]@I?')O\ KR/*= _9C\ Z)*L\NE-K%TIS]HU69KAB
M?7YC7I6GZ-8:3$([&SM[.,<!8(E0?H*NTN!6$ZLY_$VS:%.$/A04&CH*R=?\
M3Z9X:M&N=3O8;.%1G=*X!/T'>HC%R=HJ[-4FW9&KG(JGJ>KV6C6K7%]=16D"
MC)DF<*!^=>93?%+7_&DC6W@C0WE@)VG5=2!BA7W4=6JQI?P675+E+_QEJD_B
M2\SN%O(=MM&?0(.OXUVK#QIZUY6\EJ_^!\S;V:C\;MY=1EY\8KKQ%</9>"-&
MFUJ7.#?S QVJ>^X]?PI+7X1:CXHF2[\<:U-JAZC3K4F.V7V('WOQKTVQL;?3
M;=(+6".WA086.-0H'X"K&:/K*AI0CR^>[^_I\@]KRZ4U;\RCI.AV.A6J6UA:
M0VD"C 2% HJ]T]Z.E &:XFW)W9BW?5CJ***!!1110 4444 %-S2UF77B72K*
M9H;G4[.WE7K'+<(K#Z@FA1<MD)M+<TSS0*Q6\8:"@)_MG3\#G_CZ3_&L[P_\
M3_#'B2R-W9ZU9M")&B)DG5#N4X/!-:>QJ6ORNWH1[2%[7.LI*QQXOT+_ *#.
MG_\ @5'_ (U@>//&]WHYTC3M!A@O]9U>0I:^:_[I5 RTC$=0!Z5#C*.Z*33V
M9W%%>>:)?>.M$UZWM_$*V&K:3<(S/?V*&(VI SAE/5?>ETWXY>%]4UB"PBDO
M$6XE\B"]EMF6VFDZ;5DZ$TBCT&EKQO0/V@=/B?4(=>6X1X-4DLA<6UJS0Q*&
M 3S'' )KI?$7QK\-^'-3EL9FO+IX #<2V5LTL=N",@R,/N\4NEP._HK@-8^-
M7AW2=4@T]!?:E=SVZW4<>GVQFW1MT;CM4?P=^);_ !,T2]O);&XLY+>[DAQ-
M 8P5#8&,]3CK3 ]#HKP#6?C%JLWQ"U?2K;Q)IFBV%C=):JMU9/*7. 6)<<+Z
M<U[S;,7MXV+K(2H)=>C<=10M5<'H[$U%%% !1110!B7W_(0E_P!U?ZT47W_(
M0E_W5_K10!?TC_D'P_2KE4](_P"0?#]*N4 %%%% '%_%/Q/XD\*>&?MOA7PZ
M?$VI^:J_8@^WY3U;->,3_&GXY7T,EO%\(?LTDJE%FDG.U"1C)YKZ;KS_ ,0?
M'GX?>%=3ET[5O%NG6-_"<2022'<I]#@4O)AYHS?V=OAYJ?PW^'<=EK+(=6N[
MF6]N4C.51Y&R5'TKU$<"L+PCXST;QWI*ZIH5]'J-@7,:W$6=I(ZXK='(JG>^
MHEL+1163KGB&T\.PQR7(E<R-M2.&,N[8&3P/04AFM16,WBK3%T#^V_M*G3BF
M\2COSC&/7/%.T+Q':>(DF-MYB20MLEAF0HZ$C(R/I0!Y)^UDP_X0/3ER-W]H
M1G'>NJ^ ;D_#FR!_A=Q^M<3^UEY<N@Z'%Y7[V2]4+-G@>V.]=M\"8'M/ T<$
MC!F2:3IZ9XK"OB:'M:&'YESVD[=;75STU3E]4<[:77ZD>GG^Q_CCJ$'W4U33
MUG7W9#@T[XS$W2>&M.7DW>IQ9'LO--^(8_LGXA^#-7'R[I9+)V_V7&<?G1XV
MQJ'Q5\$V/40>=>'\!@5[T-9PJO\ E?X)K]$?+2TC.GYK\6CTI1M4 =N*=117
MD'K#2<9KS;P/_P 5!\0_$NMM\T,!6Q@8],+RQ'XUV7BS6%T'P]J%\YP((F8?
M7''ZUA_"71WTKP59-,,7-UNN9B>I9SFO-K?O,1"GTC>3_)?F>E1_=X:I4ZRM
M%?F_R7WG9T=:2LKQ#X@M_#>G/>76XHI PO4D]JZ:]>EA:4JU:7+&*NV]DD>?
M"$JDE"*NV:N?7%8.O>*X=)D6V@4W>H/PEM'R?J?05S]KXSN_&J_9M$B-H!_K
M;J7GR_8#UKI-$\-VF@1-(I,MPW,EQ*<LWX]A7SL,RGF\5_9C_=O>HUIZ13W?
MGL=[H+"O_:%[W\O^;Z&9I_AB?5+@:AKK^?,.8[9?]7'^'<U0\0>*[O4]0.@>
M&%62\^[<7G_+.V7_ .*J'5_$E_XVOY-%\.N8K1#MN]4 ^51W5/4UUGASPU8^
M%]/6TLH]HZN[<L[=R3W->WA,%2P2]Q7;U<GJV^[9RU*TJKO+9;+HO0K^$O"%
MIX4LV2+,UW*=T]U)R\C>I-6?$WB*S\*:#>:M?R"*UM(S(['V[?4UJYY'K7B?
MC.9_C!\1[?PC:L6\/:*ZW6KR*?EFD_@AS^IKV</256?O:16K]/ZV.*K-P6F[
MV+_P5\/W>LWM_P"/M=B*ZIK'%I$XYM[4?<4>A(Y->O\ :H88([>)8HU"(@"J
MJC  '05+BHKUO;5'+;LNRZ(=.')&PZBBBL34**** "BBB@ HHI#0 @HK'U[Q
M1I7A>U\_4[^&S0#/[QN3]!U->"W_ ,9O%7C7QQ_8.@6TEAI]UB-)VA)E6//,
MHSTXK@KXRGA[)ZM]$<]2M&G9/=]#UGQG\2XM'NUTC1X#J^OS<):P\B/_ &G/
M855\*_#:5M0&N^*+C^U=;/**?]3;>R+_ %K=\&> ]-\%6C):HTUS)\TUW,=T
MLK=R373>U5&DZC4ZWR71?YL%!R?-/[A0,4M%075U#8VTD]Q(D,,8W/)(V%4#
MN37:CH)<<=*X#XE?&30OAG#'%<N^H:Q<?+:Z39C?/,W8!1T'N:X?7OC-KOQ*
MU2?P]\+;47"H=EUXFN%_T2W]0G]]OI77?#/X(:1X!FDU2ZEEUWQ-<?-<ZO?'
M?(S=PF?NCV%=:HQI+FJ[]NOS['(ZDIZ4MN_3Y=SBM-^%WBCXSWL6K_$F9M/T
M0$26WA6U<A,=09V_B/M7N6F:9::+8Q65C;1VEK"NV.&)0JJ!Z"KG6CH?:L:E
M6531Z)=.AI3I1AKNWU'44E+61N)^%'/I2$\>E<KXM^)6@^#%"ZA?(+AON6T?
MSRN?0*.:N$)5':*NQQBY.R1U0X'2L'Q/XWT3P=:&?5M0AM ?NHQR[>P7J:X+
M^WO'OQ%^72+(>$])?_E\OEW7#KZJG;\:W/#'P;T30;K[?>^;KFJDY:\U!O,.
M?]D'@5U^PITM:TM>RU?S>R-O9QA\;^2,1O'7C#Q^QB\*Z0=(TYN/[6U1<$CU
M2/J?QK2T'X*:;#>+J7B&ZG\3:KG=YUZ<QH?]E.@KT955%PH"@=@*4'BIEB6E
MRTERKRW^;$ZK6D%9#888[:-8XD6.-1@*HP!4M%%<9B%%%% !1110 4444 %%
M%% !1110 G:O+/&G[-_@?QYKL^LZK83-?3 >8\4[(&QWQZUZF.*0_G6E*M4H
M2YJ<FGY&<X1FK25T?/OB3]C'P3?:+<PZ1'/I^H.N(KB6=G5#ZE>]8/@3]B#1
M=(N+EO$FH-K,#J!$EN6A*-GDD]Z^H,DT#':O1CFN,C!P51V?W_?N<KP=!R4N
M5'B/_#'?PVX_XE]V!_U]M70>*O ESX>A\+ZAX5LOM,GAW=%'8/+@RP,,,H8_
MQ?6O3B/;-(17%5Q-:NDJDG*W=G13I0IW<(I7/*KC6/&/Q#G.GP:#<>&-(:&5
M+N;4MOF2DJ0JH >F3UKDX]#\5:YX8\/^!YO"\^G_ -FW4+3ZL[+Y'EQMG=&>
MI8^GO7T&3Q0>HKG6CN;'AG_"":ROPI\8:8--D^WWFJ2SPPX&Z1#(I##\!45O
M8>*/ K^*-,@\+7&N1Z\WG6]U"R[(V:,(5EST ->\$TF>E*_0-M3QSX5?#S5?
M!_C.)KR$M;PZ##:?:@<J90Y+*/IFM_X.V.IZ+IVK:7J6FSV+PZA-+'-)@QSH
M[9!4BO1:*=[B/%_$D?B%[?Q'X;7P8+AM6E<0ZI:!5@*M@!Y2>0P_I7JOAS2W
MT30-.T^24S26MND+2'^(JH&:U**%HK!UN%%%% PHHHH Q+[_ )"$O^ZO]:*+
M[_D(2_[J_P!:* +^D?\ (/A^E7*IZ1_R#X?I5R@ HHHH :>U?''B'X&:OI#:
MMK%UX-A\07EAKSWX*D,^HVL@.4_X#7V/W&*^+;Z:T\0>-?%"^,OC!J/A?4[:
M_>*+3[611$L/\!!^E3]K^O(?0][_ &:=#U;0?AJD&JZ7_8IDNYIK?3V W00L
MV54^]>LUY_\ !*UTZT\#01Z7XGG\76OFOC4KAMS,<\KGVKT"M);D1V"N>\8&
M=M/$*6$U]!,&CF-JVV:,$=5KH:*AZE'E4GA+5W^%T&@-;O\ ;H-LZ!<!2JR[
MA&6_O8KHO!6GWK:[K^L75K+8QZ@\7E038W@(N"2.V379T55P/#/VI;)7\-:/
M<%F+)J,05<\#/6NH^!-PUWX0F+XW+=RKP.P(Q7&?M57%XFFZ#"J_Z&UZA9L?
MQ9X%=?\  <HOAJ]1.BWCY^IQ7RM:K2GG-%<OO*$U>WFKZ^9]%R2667;TNOU+
M/QRMF'@M+Z,?O=/O(;H,!R K#/Z53TVX77?C0ERF&CM=(5A[&0YKL_'6F#6?
M"&KV9&3);/CZ@9'\J\J_9POI/$%YKFK3*PDCC@LOF_V%YK] H:X2<_Y;K[[?
M\$^&K:8F,/YK/[OZ1[I1117D'KGG'QAN&O[32= B/[S4[M$8#_GFIRU>@6L*
MV]O%$HVK&H4#V Q7G</_ !4?QD>3[]OHMKM'H)7_ *XKTD'@UYN&_>5*E;N[
M+T7_  ;GI8K]W2I4>RN_5_\  L(>_%</XN7_ (3"]30;?_4QL)+F8#.S'0#W
MK8\5Z^VF0):VB^;J%R=D*#M_M'V%06UH?!GAZ6Y$?VN8?OKERV&;NQ_"O(Q]
MLUJ?V='6G_R\?ETCZOKV1-#_ &9+$/XOL_Y_(D\->%[#P583;)"$/SR2R$#I
M7-W>I:A\3;Q['2WDLO#T;;;B^'#3^JI[>]5K&:_^+Y2:0/IWAA&_U:M\]T1Z
M^BUZ596,&FVL=M;1+#!&-JH@P *]W"X2A@:,</AX*,8[);(Y*E6=:;J5'=L@
MT?1K30;"*SLH5A@C& %'7W/J:T**@N;F.RMY9YG$<4:EW8G   R3789'$_%_
MQZW@?PP?L2^?K=^XM=/MQR7E;@''H.M2_"?P"O@#PK%;2OY^IW+&YOKAOO23
M-RW/H.E<5\/;>3XL^/[KQU>H3HNGLUKHD3]&QP\V/?M7M? KOK6H05!;[R]>
MB^7YG+3_ 'DO:/;I_F**6BBN Z@HHHH ***AGN8K6)I)I%CC49+.P 'XT; 2
M9)'%&<=Z\^U?XQ:<ETUCH-K/XBU'./+LUS&I_P!I^@J@/"_C/QN=VNZF/#]@
MW_+CIIS(P]&?_"N-XF+?+37,_+;[S!U4](JYTGB7XGZ#X8;R9[K[3>'[MI:#
MS)2?3 KF_P"U/'?CDXL+2/PMIK?\O%U\]PP]E[5U?AGX>Z%X2&;"Q19S]ZXD
M&^5CZEC72C@5/LJM3^)*R[+_ #W%RSG\;MY+_,X30?A!HVEW0O=0:;7-1SDW
M-^V_GV7H*[*/3[6.<3I;1+*%V"0( P7TSZ5:&*3(Z9K>G1ITU:,;&L81BK)!
MVHXJ.:9((VDD=4C49+,< #U)KQ/Q5\<=2\5ZO-X8^&5DNM:FK>7<ZO+D6=GZ
MG=_$P]!773I2J/3_ (")G4C!:G=_$?XM>'_ACIXFU2YWW<O%O86XWW$[=@J#
MFO,K;P/XR^/-Q'J'C:27PYX3W!X/#MLY$LZ]09V'_H-=5\._@?IOA*_;Q!XA
MOF\2^+9N9=3OB#Y?^S&IX4"O1;KQ+I-B,SZE:0@?WYU']:Z;JEI15WW_ ,O\
MS-4IU=9[=O\ ,70?#VG>&-+AT_2K.*QLH5VI#"H50*TA7'7GQ<\'V.X2^(+,
M%>NV3=_*L>?]H#P=%_J+FZOCV^R6CR9_(5G]7KSU46_D=L:,[646>D\FD(]Q
M7E[?')+H@:=X5UR]ST/V8QC]:R/%?Q+\=W&@W[:1X)O+*40L4N)Y%)3W"CJ:
MUC@JTFD[*_=I?J6J$V[/3YGLYY'45Q?BSXL^'_"<GV>2X:_U%N$L;(>;*Q],
M#I^-?/\ \%Y?B%\4;R^T_6M=U6RTB/YI92FUV/\ <#$<#Z5]&>$OAOH'@R,_
MV=8(L[<O<R_/*Y]2QYK>OA:>"FX59<S71?JS2I1A1E:;N_+_ #.,*_$#XC]2
MO@W1F]/GNW7^2UU'A/X3^'_"3_:(K8WVHM]^^O3YLK'ZGI7:49S7)+$SE'DA
M[L>R_7J8RJR:M'1>0H %+117*9!1110 4444 %%%% !1110 4444 %%%% !1
M110 T?3%127<,3;7FC1O1F -38X-</KOPA\/>(=3FO[N.Y-Q*<OY=RZ@_@#6
M-1U$OW:3?F[$2;2]U7.LGU.SMX6EDN84C0;F8N, "LOPYXXT7Q5:R3Z;?PSQ
MQN8VPP!!'M7*77P \*W%O)%LO%+J1N^U.<?AFL?PI^S3X?T.RDCO)[J]G=RW
MF1RM$ O88%<3J8OG24%;U_X!@Y5N96BK>O\ P#UL7UN/^7B+_OL5R/Q!\87^
MB3:3I6APPW.MZM(4M_/)\N-5&6D;'4 5G?\ "AO"O_/.\_\  M_\:/&_@Z_L
MV\.ZMX;MEN[S0694LY9,>="RX90Q_B^M==.55O\ >127D[_H;P<G?F5B31;G
MQUH&N01>();'6='F1FDOK2+R6M2!GYAGE?>FZ=\<_#FIZM;V:+?1P7,OD6^H
M36S+;329QM5^]9TNH^,_B%.;%-#F\*Z.894NI;YE:68LI 5 .@R<YKE8_#OB
MW6_#.@>"+CPVVGQZ;=0M/JYE4PM'&V0T?<L?2NA;ZEO8VM _: M(#J,>O171
M^SZI+9?:K6U)@A4, GF-V)S73>(?C5H'A[4Y[)DOKXVP!NIK&V:6*V!&078=
M..:X_P#X0+6E^%7B_2QI[_;[W5)9X8N,R(9%(;\A4-OI7BOP-)XGTVT\,R:W
M%KS>;!=1RJ$A9HPA67/0"E_D)':ZK\:M!T[5(-.MXK[5KN>V6[C33[<RYB;H
MW':F_!KXD7'Q'T.^N[FPN;.6"[DA'G0^6"H; QZD=ZP/A7\.M3\&^,HVNXM]
MM#H4-I]I'W3*'W,H^F:Z#X/6&IZ'IVKZ7J>FRV1BU":6*=B"DZ.Q8%<55DOZ
M\PZ?<<;J7Q<UC4O$=['I6MZ'ID%K>&TAT_4/]9>%2 QW_P 'M7MMN[O;QO(J
MK(5!95.0#CG![UX#>> =4T%?%>@P>$$U?^W+N2XMM8!3;"'Q]\GD%3TQ7NF@
MV$FEZ'864TIGFMX$B:0]6(4 FDOA0WN:5%%% !1110!B7W_(0E_W5_K11??\
MA"7_ '5_K10!?TC_ )!\/TJY5/2/^0?#]*N4 %%%% #3]TU\8P6,G@_Q3XH@
MO?@M?>+8KC499X=2D52[*QZ<]O2OLX_=-?$WBGXE>)/&>LOX67Q1/8WVJ>()
MH;F*W^1]/LX1][V!ZU/VM/ZU0_LZ_P!:'T_\&;J.\\%0R1^%)/!B^:X_LN0
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M7 ]*6BI)(XXDBR$14!Y.T8J2BB@ I*6B@ HHHH **** "BBB@ HHHH ****
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M5JB^)]Y-\3?&EE\/M.D86$)6ZUN>,\+&#E8L^K5Z9JFM:/X&T2-KJ:*QLK=
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M0"I<5$ZS:Y(*T>W^?<<**B^:3O+O_D%&*6BL#H"BBB@ HHHH **** "BBB@
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MZ1\O\RE\-OA'X?\ AE9NNFPM<7\WS7.I7)WW$[=RS'^5=R!BJ']JG_GSN_\
MOU_]>C^U3C_CSN_^_7_UZXI2E-WD[LZXQC!<L59&A16?_:Q_Y\[O_OU_]>C^
MUC_SYW?_ 'Z_^O4EFA16?_:Q_P"?.[_[]?\ UZ8^MI&Z(UK=!GX4>5U_6@#3
MHK/_ +6/_/G=_P#?K_Z]']K'_GSN_P#OU_\ 7H T**S_ .UC_P ^=W_WZ_\
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M_?K_ .O0!H45F1:VDV_9:W3;6*G]UT([=:?_ &L?^?.[_P"_7_UZ -"BL_\
MM8_\^=W_ -^O_KT?VL?^?.[_ ._7_P!>@#0HK/\ [6/_ #YW?_?K_P"O1_:Q
M_P"?.[_[]?\ UZ -"BLPZXBRK&;6ZWL,@>5_]>G_ -K'_GSN_P#OU_\ 7H T
M**S_ .UC_P ^=W_WZ_\ KT?VL?\ GSN_^_7_ ->@#0HK/_M8_P#/G=_]^O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M'_(/A^E7*IZ1_P @^'Z5<H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%)N [
MB@!:*3</44;AZB@!:*3</44%@.XH 6D(K%\6^)(/"/AN_P!8N1NBM8RY4'&X
M] /Q.*Y3X5?$K4?'LNH1W^GV=O\ 9]K)-I]V+B/G^!B.CCN*%J&QZ-17D=U\
M9-6@\022QZ'"_A*'41I<VHFXQ,),X+!/[H.!6\_QR\"*TZ_\)+9Y@5F<9;@
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M* -.BLS^VO\ IW;_ +Z%']M?].[?]]"@#3HK,_MK_IW;_OH4?VU_T[M_WT*
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0VB+*6/4\FBKL4.%HH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>plx-20250930x10q008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 plx-20250930x10q008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #A K4# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#ZP^,?B#6]
M*^*&K066MZA9P>3;N(89L*"4.<#%<?\ \)EXF_Z&75?^_P#_ /6KI/CG_P E
M8U;_ *]K;_T UPU?4X>G!THMI;'QV)J3C6FE)[FK_P )EXF_Z&75?^__ /\
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MO;0BY2D_O/M+X+W%U??#'1;BZNKB[N)!(SS2N79CN/4T4WX'?\DHT'_=D_\
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M_P#9^DVB//$NEN'MY$?# ^Y[T*-7J^W_  0YZ2V11^)%PVGZ:MXVL3:;#&&
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MSH.FW4=Q#:$O&695=RRAFZG'K5C2? ^CZ+??:[6UV3#(3<Q(C!ZA0>E>V?\
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MKVZ'K%>7>/O#NJW7BV2]MXKNYAELEAMU@4-&LH<$^9G^$BH/^$?M/^FW_?\
M?_&C_A'[3_IM_P!_W_QJ?8ZWN/ZQY'J=JKK:PB0 2!%#!>F<<U+7D_\ PC]I
M_P!-O^_[_P"-'_"/VG_3;_O^_P#C3]EYA[?R/0O%G_(MZC_UQ:K>D_\ (*LO
M^N*?^@BO(?$6@VBZ'?$>=GRC_P MW_QJSIOA^T.G6I_??ZI?^6[^@]Z?L=-Q
M>WUV/8*XSXJ:'K'B/PU-8Z683'(C^?$Y(:4;3A5(]37-?\(_:?\ 3;_O^_\
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M4,71,NTD^G'I78^-/$.I0:O:V-C<&R7[!-?/)Y8;<4&0G-'MNM@^KO:Y@_\
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M%'EA?*;?C;QU&*/:^0OJ_F9/_"2Z?_SV?_OR_P#\31_PDNG_ //9_P#OR_\
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MIZ/JVL/OTW4=2\JXL]/6ZN[I8@#O;G '3 %+VOD5]7?<R/\ A)=/_P">S_\
M?E__ (FC_A)=/_Y[/_WY?_XFE;5?$:>!X]3?69/MU]<^78Q^2O*NV$W?AS7<
MZW-JFC^#[B6&:.XU&WMF9II%PI95)+8'N.E#K6Z!]7UM<X7_ (273_\ GL__
M 'Y?_P")J-O%FEQR)&URRR29VJ87R<=<?+73:+XMO'N/"JW3+*NL618[5QME
M5 Q/T(-:VM?\C;X=_P"WC_T"J]KY$NCYG#_\)+I__/9_^_+_ /Q-'_"2Z?\
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M[.'8?M9]S.62U6V:$>$I &<.7^WKOR!@?-UZ<58;4XVL19_\(HZVR@!8UOD
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M[TO_ *&:*\^?Q,]"'PHYW6/"MSK/Q!\12IJTEHH6V 185;_EF?6G?\*]O/\
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M:1T5;A6%N#CY<DY;.#S[T>TG8/9T[E#3X[;4(]XU^^@_?)"RSV2*59QE2>>
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M:M_X#?\ UZ.;S#E?8;_8>G_\^,'_ 'P*/[#T_P#Y\8/^^!3OM5]_T M6_P#
M;_Z]'VJ^_P"@%JW_ (#?_7HYO,.5]AO]AZ?_ ,^,'_? H_L/3_\ GQ@_[X%.
M^U7W_0"U;_P&_P#KT?:K[_H!:M_X#?\ UZ.;S#E?8;_8>G_\^,'_ 'P*/[#T
M_P#Y\8/^^!3OM5]_T M6_P# ;_Z]'VJ^_P"@%JW_ (#?_7HYO,.5]AO]AZ?_
M ,^,'_? H_L/3_\ GQ@_[X%.^U7W_0"U;_P&_P#KT?:K[_H!:M_X#?\ UZ.;
MS#E?8BC\.Z9#OV6%NNYBS80<D]33_P"P]/\ ^?&#_O@57L=:N;_[1Y6AZJ?)
MF:%O]'_B'7O[U:^U7W_0"U;_ ,!O_KT7\PY7V&_V'I__ #XP?]\"C^P]/_Y\
M8/\ O@4[[5??] +5O_ ;_P"O1]JOO^@%JW_@-_\ 7HYO,.5]AO\ 8>G_ //C
M!_WP*/[#T_\ Y\8/^^!3OM5]_P! +5O_  &_^O1]JOO^@%JW_@-_]>CF\PY7
MV(I?#NF3*!)86[ '<,H.HI_]AZ?_ ,^,'_? JO?ZU<Z='&\NAZJ%>18Q_H_<
M].]6OM5]_P! +5O_  &_^O1?S#E?8;_8>G_\^,'_ 'P*/[#T_P#Y\8/^^!3O
MM5]_T M6_P# ;_Z]'VJ^_P"@%JW_ (#?_7HYO,.5]AO]AZ?_ ,^,'_? H_L/
M3_\ GQ@_[X%.^U7W_0"U;_P&_P#KT?:K[_H!:M_X#?\ UZ.;S#E?8;_8>G_\
M^,'_ 'P*8/#NF"8RBPM_,(VEM@Z5+]JOO^@%JW_@-_\ 7JJNM7+ZA)9C0]5\
MY(Q(1]G[$X]:+^8<K[%C^P]/_P"?&#_O@4?V'I__ #XP?]\"G?:K[_H!:M_X
M#?\ UZ/M5]_T M6_\!O_ *]+F\PY7V&_V'I__/C!_P!\"C^P]/\ ^?&#_O@4
M[[5??] +5O\ P&_^O1]JOO\ H!:M_P" W_UZ?-YAROL-_L/3_P#GQ@_[X%-D
MT#39$9&L8"K#!&P<BI/M5]_T M6_\!O_ *]176I7=I;2SOH6K!(T+M_H_8#)
M[T<WF'*^PL>@:;&BHMC %48 V#@4[^P]/_Y\8/\ O@4RUU*[N[:*=-"U8I(@
M=?\ 1^Q&1WJ7[5??] +5O_ ;_P"O1S>8<K[#?[#T_P#Y\8/^^!1_8>G_ //C
M!_WP*=]JOO\ H!:M_P" W_UZ/M5]_P! +5O_  &_^O1S>8<K[#?[#T__ )\8
M/^^!1_8>G_\ /C!_WP*=]JOO^@%JW_@-_P#7H^U7W_0"U;_P&_\ KT<WF'*^
MQ$WAW3'D20V%N73.UM@XSUI_]AZ?_P ^,'_? JO-K5S!?6UJVAZKYLX8H/L_
M]T9/>K7VJ^_Z 6K?^ W_ ->B_F'*^PW^P]/_ .?&#_O@4?V'I_\ SXP?]\"G
M?:K[_H!:M_X#?_7H^U7W_0"U;_P&_P#KT<WF%GV&_P!AZ?\ \^,'_? H_L/3
M_P#GQ@_[X%.^U7W_ $ M6_\  ;_Z]'VJ^_Z 6K?^ W_UZ.;S#E?8;_8>G_\
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M*=]JOO\ H!:M_P" W_UZ/M5]_P! +5O_  &_^O3YO,.5]AO]AZ?_ ,^,'_?
MIC>'=,>1)&L+<NF=K;!QGK4OVJ^_Z 6K?^ W_P!>JL^M7-O>VMJ^AZJ)+C=L
M'V?^Z,GO1?S%R^18_L/3_P#GQ@_[X%']AZ?_ ,^,'_? IWVJ^_Z 6K?^ W_U
MZ/M5]_T M6_\!O\ Z]'-YCY7V&_V'I__ #XP?]\"C^P]/_Y\8/\ O@4[[5??
M] +5O_ ;_P"O1]JOO^@%JW_@-_\ 7HYO,.5]AO\ 8>G_ //C!_WP*/[#T_\
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MM+7//,V=,\XG)D^S?-^=-T9,/K$.QB_ 'XG:_P".VUJVUZ6&>>UVLDEO!L0
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M_P"_)J#4-6\2WUA<VQN[)1-$T>?)/&01_6FJ,KB=:-CN_#O_ " -,_Z]8O\
MT 5HUYGI^K>);&PMK87=DPAB6//DGG  _I4__"0>)O\ GZLO^_)H]C(%6C8[
MZ^:5+&X:$9F$;%!_M8./UKR[X:7,K:[IPBFDE:>PDDU$-(S;9O,(&0>A_I6G
M_P )!XF_Y^K+_OR:BAU77K9G:%]-B:0Y=DM\%CZG'6DJ,KC]O&UCTJBO.O\
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M\)!XF_Y^K+_OR:H:'>>)=&TV.T%Y8N%9CGR3W8G^M/V4K6%[:-[GJE%>=?\
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M_<21R2OILDD?*,]ODK]#VJ?8RN5[>)Z+;,[6\1DXD* M]<<U+7G7_"0>)O\
MGZLO^_)H_P"$@\3?\_5E_P!^33]C(7MHG7^+/^1;U'_KBU6])_Y!5E_UQ3_T
M$5YGXDU_Q(V@WX:YLBIB;.(C5G3?$'B4:;: 7-ECRDQ^Z/\ =%/V,K"]M&YU
M?Q"CN)/!NJ&VN9+65(&<-#]XX'0'M7''6(I$9=<O9[33;31X)2T;E&<L!N.>
MY[?C5YM>\22*5:XL64\$&$D&J=S-K%Y<)/-_9LKHAC&ZWR-I[$>E3[&1?MX&
MEX+O9--\,ZE>VQ-VDTKRV.G),))$7'"=>IZX[5QFBZYK$>@^+[N\:_CU"UOX
M9HQ=(4 )(_=J,].<8KI;>^UJSP(!I<(!R/+M0N#Z\4V]NM;U!%2>2P=1(LI'
MDD98="?6G[&5[B]O ]-A8R0HS#:S*"1Z5@ZU_P C;X=_[>/_ $"N;_X2#Q-_
MS]67_?DU0O+SQ+=:KI][]LL0;7S,+Y)YW+BFJ4KDNM&QZI17G7_"0>)O^?JR
M_P"_)H_X2#Q-_P _5E_WY-3[&0_;1+?Q+DS>>'X;F0Q:5+/(+IMY0<)E,D>]
M:GPWN+JZ\%Z;)>%FG*MR^<E0Q"G\L5SEQK'B"[C,<\FGS1_W9+?</R-/77O$
MB*%6YL54< "$X%'L9#]O$]&HKSK_ (2#Q-_S]67_ 'Y-'_"0>)O^?JR_[\FC
MV,A>VB=UX _Y%.U_ZZS?^AFBJ'PM>[E\"V#S.C3-),6*+@??-%826K.B+T1S
MGB;_ )*%KW_7.V_] -5JU]0\&Z-K?C_Q'->V*W$NVV^9G8?\LSZ&N \7W6G^
M%_&6FZ!#\.YM2_M%F6VNH]0"*^T9;@G(P*ZX58Q21R2HRE)R1U%%<5X-\1:!
MXR\0'3X/!*6]NER]L]Q)JR;U*'!/E;MQ%3:7XJ\$:IKWB/35\,RQ#2899HKA
MIVV7HC^_Y?S=CZU7MH"^KSV.OHKF?AC?:!\2&1QX.BTZTDA\Y)?[56=L'H"B
M-E?QKH]$T7PGK7B77M'30_*DTEHUDE:9]K[UW<?-QBCVL2?82'T50M+[X67T
MNIQP3V<CZ:I>Z ED^10<$]>>?2JDGB#X3KH*:NDUK):22-%'M>7<TBC)7;G.
M?PI>VAN/ZO,VJ*Y#0/&7PYU;3S?WFF1Z59"V2Y,L]R[$!W*J" <\D5MG5OA2
M-'BU3S[7['),;=7WRY,@ZKMSGCZ4_;1#V$S4HK$\3:Q\-_#7A.P\1&R6]TR^
MN$MX);=I#N+-C/7H*TM/;X9ZIK_]BVK6LNI=H1))R<9(!SC/MUH]M$/82+-%
M<AXX\3>#_!?C"/P^/"<VH3^4D\LD=R8]J,V!M#-ES["KWAWQ%\-/$6M:AIB6
M7V:YM+M;("=I5\R1AD!>:2K1>P.A-;G0T5A^)->^%WAO1WOYA;S?+*8H8Y)"
MTC1YW*.>.1C)XJSH5Y\.-:T>VOOL\-LTIAC:WDED+I)*N40X/)-/VT6'L)K<
MTZ*YCQ=?:)X=\676B6/@2?6FL[(7]S/#>;!'&21PK'+'CM5RU\0?"JX2'<88
MI9+5;PQ,TNY(R,Y;!P*7MHA]7F;=%5=1D^&6DPS27;6L2PK$SYDD)Q(,I@ Y
M.1Z5I^&_#O@7Q?IOV_2+:&]M-[1^9'))C<.HY-/VT1>PD5J*D\+_  _\/W?]
MK>=IRR>5J$T2;I7^51C ^]6W_P *S\,_] I/^_C_ /Q5#JQ0*C)F!16__P *
MS\,_] I/^_C_ /Q5'_"L_#/_ $"D_P"_C_\ Q5'MHA["1@45O_\ "L_#/_0*
M3_OX_P#\51_PK/PS_P! I/\ OX__ ,51[:(>PD8%%2>+/A_X?L[*U:#3EC9K
MN)"5E?E2>1]ZMO\ X5GX9_Z!2?\ ?Q__ (JCVL=P]C(P**W_ /A6?AG_ *!2
M?]_'_P#BJ/\ A6?AG_H%)_W\?_XJCVT0]A(P**W_ /A6?AG_ *!2?]_'_P#B
MJ/\ A6?AG_H%)_W\?_XJCVT0]A(P**W_ /A6?AG_ *!2?]_'_P#BJQ+?X?\
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MD_[^/_\ %4?\*S\,_P#0*3_OX_\ \51[:(>PD8%%;_\ PK/PS_T"D_[^/_\
M%4?\*S\,_P#0*3_OX_\ \51[:(>PD<=XD_Y %]_UR:K.F_\ (-M/^N2?^@BM
M3Q1\-_#<7A_4'32T#+"Q!\Q__BJM:7\-?#3:9:,=+0DPH3^\?^Z/]JG[:-A>
MQE<RJ*W_ /A6?AG_ *!2?]_'_P#BJ/\ A6?AG_H%)_W\?_XJE[:(_82,"BM_
M_A6?AG_H%)_W\?\ ^*H_X5GX9_Z!2?\ ?Q__ (JCVT0]A(P**W_^%9^&?^@4
MG_?Q_P#XJL/5?A_X?A\3:' FG*L,WG>8@E?#83(S\WK0JL6#HR0RBM__ (5G
MX9_Z!2?]_'_^*H_X5GX9_P"@4G_?Q_\ XJCVT0]A(P**W_\ A6?AG_H%)_W\
M?_XJC_A6?AG_ *!2?]_'_P#BJ/;1#V$C HK?_P"%9^&?^@4G_?Q__BJ/^%9^
M&?\ H%)_W\?_ .*H]M$/82-+X7?\B)IW^]+_ .AFBD^&NEVMEX,LX((?+B22
M;:FX\?.?>BN.5KL[H?"A8O\ D>/$G^[:_P#HLUG>(/!HUSQ9X<UHW'E'2&F8
M1;<^9O7;U[8K1B_Y'CQ)_NVO_HLUJT=@[GC'AWX$ZEX9UZ]OK/5=-V7%Q-.)
M'TY3<)YF>!)UXS5:T_9@L-)BTZ?3]7NHM4BCFCN[B1RZW"RJ0XVGA>3GCTKW
M"N(^-&O7_AGX;ZOJ.F7'V2^B5!'-M#;-SJN<'V-3LK%IMOU,7X2_".^^&LR(
M][IMS;+!Y/\ HU@L,S8Z%G'6K%Q\./$-KXVUC6=)\06]I9:L8_M-I-:"1L*N
MWY6SQD5Q&J?$'Q%X)OKS2;K6VUQ!!:W27HB1)(S)*$:-L<=\U?7]I46FL:]:
M:CHIM8M/BDDA_? R3["!TZ8.?7BG>^_F)7Z>15TS]E:UTBVUR.UU80RWT3PP
M7"0?O8PS[SN.?FYXJ31_V9YM LXC8:^L.H1W4LZS-;!DVR)M==I/Y&MJX^-&
ML6>FZ:DV@6PUG4K@0VL"7R-#M*;]SO\ P\=JQ[K]I"]DM[>73?#?VK%A+?7:
MO<!?*$4FQPI_B]J+=/Z[AKO_ %V)[']FU+735M7U@R_N;>(L8@,^5*7SCWSB
ML_XB?!_Q!IEPFK^%$2^U!M1FNFB;8H2.1-C !N#4</QF\27>J:JT\4=MIT>J
MV5O;>2P,GERIN*L/ZUH:?^T5?S6\US=^'!;VC6EW<VLBW 8R>0Q# CMG%#U7
M]>H:_P!?<;&D_"._NO@YHGAF\O%LM3LY8[HRJH=5D5R^,=^N*70_@6^E>);2
M]FUHW&F6M[)J4-F( KBX<?,2_4K[56UK]H*'2['4)DLX99;>WLY(U:? =YUW
M!<^U<4/VBO$7B)HKVRL8]/TM]'GNY%W@RK+')L)7/4>U.^K?]?UH)+2W]?UJ
M>@?%'X)3_$;6/M/]M"VM71(WAEMED:+:<[HGZHQJG=? 2[6YNYK#Q ;=VOH=
M0MVD@#M'(B[3N_O BH+7]H&5;RW5M(,NEI/!837C3 3>?(@((CZE?>M+X>_&
MB_\ &'B*RL;S0AI]I?QSO:W"SARWE.5;([9I)=%_74&WU_KH8LG[.-W'ID,5
MKXD\N]:"YM;FXDM5<2QS,6.%/W2">M2^'_@W>6?Q0TJ]EB9-%TG3XHC(S@B\
MN$7:DFP=-HSUKH6^+=S'-=-+IT:6:7-U:1NKDN7A7=DCT-4+_P 6^*=,NM.U
M!U:72YK59694&SYD+-D^H[>PH7<;N[IFCXN^&.M:QXRO-;TC7X]+2^L%T^YB
M>V$K&,$G*D]#S4-E\"["PLM<LX;MA!J.FQ:<IV@O&$!^;/?).:NP_$47>E:3
M?VSR,GVV.SNHY$P6WCAA_.O0Z+:6%=IW_K^M#YV\4? OQ1I>F_VIIVI)KWB"
M">UD@5HUB55A4KC!X/'K7H_P-\)ZKX/\$_9M:58]1N+J:ZDC0@[-[9QQQ^5>
MA44[[B.>\'_\QO\ ["D__LM=#7/>#_\ F-_]A2?_ -EKH:<MR8[!7 7GQ!O(
M?$$\2Q0_V;;ZA%ISYSYA=QG<.V!7?US-QX!T^XUPZDTDXW3I<O;AOW;2J,*Q
M'K26Y?0Z:BBBD(Y[QK_R#K+_ *_8?YUT-<]XU_Y!UE_U^P_SKH:;V1*W9Q6I
M>/I]*\1:K9W-FL5G9V'VM)-V6D._:!["DU'QU?:7J>A03V*+;WL$DTTN[H5C
MW[5%:VM>"[+6KJ]NI"PN+JS^QDY^4+NW X]<TO\ PB<-Z-'EOV\ZYT^-HU*G
M"MN7:V1]*70O2_\ 7D8O@+QY=>++O]]%'#!/!]H@7:RN5W8[_>'N*=-X@U]?
M%]SID'V.XMK>V:YE;:P9,_<7/J:T=)\!V>BS>9;W%P'6/R8=SY\F/=N*K[9J
MZOAR.UFUBZM787NHJ SR'(4A=JX]A0_(1+X9UR/Q'H5GJ,8VK.F2OH0<$?F#
M5*U_Y'F]_P"O-/\ T*KWAO1(_#NAV>G1'<L";2WJ2<D_F35&U_Y'F]_Z\T_]
M"JUU)?0Z&BBBH*.&\8^.+[1=6N+6RB@9+.R^W7!FSEEW[=JX[UV=G<B\LX+A
M1A98UD ^HS6%XB\#V7B2]%S--/ [1>1*(6P)8]V[:WMFN@AB6"%(D&U$4*H]
M .!3Z#8^L[Q%_P @#4_^O67_ - -:-9WB+_D :G_ ->LO_H!H6Y+V#P[_P @
M#3/^O6+_ - %:-9WAW_D :9_UZQ?^@"M&A[@MB*ZN%M+6:=N5B1G/T S7%>#
M_'-]K6I64-[% L6H6K7=OY.<HJOC#9[XKN)(UEC9'&Y6&"/4&N=\/^!;+P[?
M"YAFGG:.,PPK,^1"A;<57\:2W*Z'24444".>U;_D<-!_W+C_ -!%=#7/:M_R
M.&@_[EQ_Z"*Z&K?0E;L*YKQAXBN]'N-)L;!8C>:C,T://G8H5=Q)Q72UC^(O
M#,'B)+;S)9;:>VD\R&>!L.AQ@X^HJ"T-\':^WB;P[::@Z".23<'5>@96*G'M
MQ6U5#0]&M_#^EV]A:@B"$8&XY)R<DGWR:OTV(*Y[P%_R+-O_ +\G_H;5T-<]
MX"_Y%FW_ -^3_P!#:GT9/VD=#1114E' ?\+!O/[>9?)A_LL:F-+QSYN_'WO3
M&:[^N9_X0&P_MPZB99R#<?:_LN[]UYV,;\>M=-3Z#>^@5SOC;_D%VW_7W#_Z
M%715SOC;_D%VW_7W#_Z%3CN1+8Z*BBBI*,/QIXB;PMX=N=01!)(A5$5NFYF"
MC/MS4'A+Q!=ZI<:I8WZQ?;-/F$;O #L8,,@C-:FN:+;^(-+GL+H,890,E3@@
M@Y!'N"*K^'O#<'AV.Y\N:6YGN9/,FGG;+N<8&?H*:'T->BBB@1SVC?\ (W>(
M_I;?^@&NAKGM&_Y&[Q']+;_T UT-.6Y,=@KA?&'CJ]T75[JVLXH&BL;-;RX\
M[.64N%VKCO7=5S?B'P+8^(K_ .U32SPLT0@F6%L"6,-NVM^-26K=3?M;@75K
M#.HPLB*X'U&:EIL<:PQK&@VHH"@>@%.H$9/BS_D6]1_ZXM5O2?\ D%67_7%/
M_0153Q9_R+>H_P#7%JMZ3_R"K+_KBG_H(JOLD]2GXLU>XT'P_>W]K;?:IH(V
M<1EMHX!.3[5A6?C+4-:6"#3K>!KPZ?'=R^<Q"(SXP/YFNKU+3XM5T^YLYL^5
M<1M&^TX.",&N5OOAS%-NAMKR>SM9K);*5H7VRE4^Z0WKC@U)>A=\'^(KW6K7
M43=112/:3M"DUOGRY\#JN??BLBU^(=X="U;4KJRCA&GZB;62(-D^6"!G/K\U
M=%X?\,KX=LX+6&\GD@AX5'QC&.E9^I> X+C2;^PMI#'%J%Y]JN2YR3D@L!^0
MH#0ZE'$B*RG*L,@U@:U_R-OAW_MX_P#0*WU41JJJ,*HP!6!K7_(V^'?^WC_T
M"KCN1+8Z&BBBH*.6\8>)+S2;[2]/T]83=WQD(><':JHNX]/6M+PGKG_"2>';
M+4B@C,Z$E1T!!(/ZBF>(_"]OXD^RO)--:SVS,T4UNV&&X88?0BKVCZ3;Z'IM
MO8VJE8(5VKDY/UH6PV7****8BIX _P"13M?^NLW_ *&:*/ '_(IVO_76;_T,
MT5G+<N.R.4U?Q<=$^('B&$Z==7.5MB&B Q_JS3_^%D#_ * M_P#D/\:J>)O^
M2@Z]_P!<[;_T U7KOA3C**;//E4E&32-/_A9 _Z M_\ D/\ &L_7_%&G>*-(
MN-+U7PW>7MA<+ME@D VL,Y[&F457LH=B?;3[F-IUCX2TG3I;&U\$S1VLSK)(
MA&[<RG*DDL3P:6*T\)0ZE>:@O@B3[7=HR32%,[U;[PP3@9]JV**/90[![:?<
MP5TCP:FC/I0\#2_8&D\XQ8_C]=V[(_.KROX9CA6)?!DRQK:FR"J@ \DG)3KT
M)YK0HH]E#L'MI]S*,/A4WC71\%S>>QB8OMZF,8C.,]0*EBD\-0PQ1)X-F$<4
M<L2+L& LAS(.O\6>:T**/90[![:?<YR+P_X(AT^>R3P%(MM,R-(FT\E/NG.[
M/':I1I'@Q8H(QX%D"0H\<:A> KG+CKT)K>HH]E#L'MI]S*$/A4:S#JP\%2_V
MA"H5)M@R !@<9QD#OUJ[INJ:'H\UI+9^$[BWDM ZP,BC,8<Y?'/<U8HH]G#L
M'MI]R!M6T5T9?^$5N@&EDF^Z/ON,.W7J14UCXFM+73;6SET.^NDMD,<;2*N0
MI&,=?3BEHH]E#L'MI]R@E]I-N+*.U\.WMM:VMQ]I$$:C:\F."<GM71?\+('_
M $!;_P#(?XUF44>S@'MI=S3_ .%D#_H"W_Y#_&C_ (60/^@+?_D/\:S**/90
M[![:8SP_XUETW^TO-T6]_P!(O9+A-H'W6QC^5:W_  L@?] 6_P#R'^-9E%/V
M<7T$JLUU-/\ X60/^@+?_D/\:/\ A9 _Z M_^0_QK,HI>RAV'[:9I_\ "R!_
MT!;_ /(?XT?\+('_ $!;_P#(?XUF44>RAV#VTQGB/QK+JEK;QPZ+>[H[B.4[
M@!PIYK6_X60/^@+?_D/\:S**?LX]A>UGW-/_ (60/^@+?_D/\:/^%D#_ * M
M_P#D/\:S**7LH=A^VF:?_"R!_P! 6_\ R'^-'_"R!_T!;_\ (?XUF44>RAV#
MVTS3_P"%D#_H"W_Y#_&LF'QK+'XFN;\Z+>^3);K$.!G(.:?13]G'L+VL^YI_
M\+('_0%O_P A_C1_PL@?] 6__(?XUF44O90[#]M,T_\ A9 _Z M_^0_QH_X6
M0/\ H"W_ .0_QK,HH]E#L'MIFG_PL@?] 6__ "'^-5-6\?->Z5>V\>BWWF30
MO&N0,9*D"J]%'LX=A>UGW+&D^/FLM*LK>31;[S(84C; &,A0#5O_ (60/^@+
M?_D/\:S**/9P[![6?<T_^%D#_H"W_P"0_P :/^%D#_H"W_Y#_&LRBCV4.P_;
M3-/_ (60/^@+?_D/\:/^%D#_ * M_P#D/\:S**/90[![:8R^\:RW'B#2[U=%
MO?*MEE#Y S\RX&*UO^%D#_H"W_Y#_&LRBG[./87M9]S3_P"%D#_H"W_Y#_&C
M_A9 _P"@+?\ Y#_&LRBE[*'8?MIFG_PL@?\ 0%O_ ,A_C1_PL@?] 6__ "'^
M-9E%'LH=@]M,T_\ A9 _Z M_^0_QK)\+^-9='T:*UGT6]\Q6<G: 1RQ(_G3Z
M*?LX[6%[6=[W-/\ X60/^@+?_D/\:/\ A9 _Z M_^0_QK,HI>RAV'[:9I_\
M"R!_T!;_ /(?XT?\+('_ $!;_P#(?XUF44>RAV#VTS3_ .%D#_H"W_Y#_&LG
MQ)XVEU6RABAT6]W+/'(=P X!R:?13]G%=!.K-]33_P"%D#_H"W_Y#_&C_A9
M_P"@+?\ Y#_&LRBE[*'8?MIFG_PL@?\ 0%O_ ,A_C1_PL@?] 6__ "'^-9E%
M'LH=@]M,T_\ A9 _Z M_^0_QH_X60/\ H"W_ .0_QK,HH]E#L'MIC-/\:RVN
MO:O>/HM[Y5T(=F ,_*I!S6M_PL@?] 6__(?XUF44_9Q["]K-=33_ .%D#_H"
MW_Y#_&C_ (60/^@+?_D/\:S**7LH=A^VF:?_  L@?] 6_P#R'^-'_"R!_P!
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M]LT4=P=JL]P)  ?3;WJ/XA?#?4/ >G275MI;:AHW]K6]Q_94#.Z.HCVL7 Y
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M#K+_ *_8?YUT-/VDK+4GV4+['#?\*\U+_H9'_P# */\ QH_X5YJ7_0R/_P"
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M3_PKS4O^AD?_ , H_P#&JNK>!]4LM+O+A/$;EX87D ^Q1]0I/K7H=9WB+_D
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MC?\ /V__ 'XD_P#B:.5]@YEW.6\=^./$NE^--,\/>'-/TVZFNK22[>34)'0
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M'#0?]RX_]!%=#7"ZIXPTF3Q7HDJW+F-$GW-Y$G&5&/X:W?\ A-M&_P"?M_\
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M $,T57^'5_!<>#[216.TRS8W*RG[Y[$45G*]S6.QU\'_ !_7?_ ?Y59]***
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MBB@ HHHH AO/^/67_=-/A_U,?^Z***?074?1112&%%%% !5:?_C]M?\ @?\
A*BB@19HHHH&%%%% !1110!4LO^/5?]YOYT445+-%L?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>plx-20250930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2025 10:02:23 AM-->
<!--Modified on: 11/13/2025 10:02:23 AM-->
<xsd:schema xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2025" xmlns:xl="http://www.xbrl.org/2003/XLink" targetNamespace="http://www.protalix.com/20250930" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:plx="http://www.protalix.com/20250930" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ecd-sub="http://xbrl.sec.gov/ecd-sub/2025">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" id="StatementCondensedConsolidatedStatementsOfOperations">
        <link:definition>995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" id="DisclosureInventoriesScheduleOfInventoryDetails">
        <link:definition>99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" id="DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails">
        <link:definition>99940402 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetailsCalc2" id="DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetailsCalc2">
        <link:definition>40402 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)- Calc2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" id="DisclosureEarningsLossPerShareDetails">
        <link:definition>99940601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails" id="DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails">
        <link:definition>99940701 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" id="DisclosureSegmentInformationScheduleOfSegmentInformationDetails">
        <link:definition>99940801 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" id="DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails">
        <link:definition>99940901 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" id="StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
        <link:definition>995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" id="DisclosureSignificantAccountingPoliciesDetails">
        <link:definition>99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" id="DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails">
        <link:definition>99940401 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" id="DisclosureOperatingLeasesAdditionalInformationDetails">
        <link:definition>99940403 - Disclosure - OPERATING LEASES (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" id="DisclosureStockTransactionsDetails">
        <link:definition>99940501 - Disclosure - STOCK TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails" id="DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails">
        <link:definition>99940702 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Additional Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" id="DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails">
        <link:definition>99940802 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" id="DisclosureSubsequentEventsDetails">
        <link:definition>99941001 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>995200090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" id="DisclosureSignificantAccountingPolicies">
        <link:definition>995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventories" id="DisclosureInventories">
        <link:definition>995210201 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" id="DisclosureFairValueMeasurement">
        <link:definition>995210301 - Disclosure - FAIR VALUE MEASUREMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeases" id="DisclosureOperatingLeases">
        <link:definition>995210401 - Disclosure - OPERATING LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureStockTransactions" id="DisclosureStockTransactions">
        <link:definition>995210501 - Disclosure - STOCK TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShare" id="DisclosureEarningsLossPerShare">
        <link:definition>995210601 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefit" id="DisclosureTaxesOnIncomeTaxBenefit">
        <link:definition>995210701 - Disclosure - TAXES ON INCOME (TAX BENEFIT)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>995210801 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" id="DisclosureSupplementaryFinancialStatementInformation">
        <link:definition>995210901 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>995211001 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" id="DisclosureSignificantAccountingPoliciesPolicies">
        <link:definition>99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" id="DisclosureInventoriesTables">
        <link:definition>99930203 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesTables" id="DisclosureOperatingLeasesTables">
        <link:definition>99930403 - Disclosure - OPERATING LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" id="DisclosureEarningsLossPerShareTables">
        <link:definition>99930603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables" id="DisclosureTaxesOnIncomeTaxBenefitTables">
        <link:definition>99930703 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>99930803 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" id="DisclosureSupplementaryFinancialStatementInformationTables">
        <link:definition>99930903 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="plx-20250930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="https://xbrl.org/2023/calculation-1.1" schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/ecd-sub/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd" />
  <xsd:element name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element id="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" name="ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" name="GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="ChangeInOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_ChangeInOperatingLeaseRightOfUseAssets" substitutionGroup="xbrli:item" xbrli:balance="credit" />
  <xsd:element name="NatureOfOperationsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="plx_NatureOfOperationsPolicyTextBlock" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
  <xsd:element name="AmendedPfizerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_AmendedPfizerAgreementMember" substitutionGroup="xbrli:item" />
  <xsd:element name="ProtalixBioTherapeuticsIncorporationMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_ProtalixBioTherapeuticsIncorporationMember" substitutionGroup="xbrli:item" />
  <xsd:element name="SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_SignificantAccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" name="CollaborativeArrangementRevenuesExpensesSharingPercentage" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element name="DisclosureOfLeasesOperatingLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="plx_DisclosureOfLeasesOperatingLineItems" substitutionGroup="xbrli:item" />
  <xsd:element name="PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" substitutionGroup="xbrli:item" />
  <xsd:element id="plx_PfizerMember" name="PfizerMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementalInformationAbstract" name="SupplementalInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_SupplementaryBalanceSheetsInformationTableTextBlock" name="SupplementaryBalanceSheetsInformationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_PfizerAgreementMember" name="PfizerAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_FiocruzMember" name="FiocruzMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" name="AccountsPayablePropertyAndEquipmentSuppliersCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="plx_ChiesiMember" name="ChiesiMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_ShortTermBankDeposits" name="ShortTermBankDeposits" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="plx_ChiesiAgreementsMember" name="ChiesiAgreementsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="plx_InterestReceivedNet" name="InterestReceivedNet" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" name="LesseeOperatingLeaseNumberOfRenewalTermExtensions" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" name="SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="SupplyAndTechnologyTransferAgreementWithFiocruzMember" id="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ConvertibleNotesDue2021And2024Member" id="plx_ConvertibleNotesDue2021And2024Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfGlobalLicensingAndSupplyAgreements" id="plx_NumberOfGlobalLicensingAndSupplyAgreements" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ProceedsFromWithdrawalOfShortTermDeposits" id="plx_ProceedsFromWithdrawalOfShortTermDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PayableToCustomerCurrent" id="plx_PayableToCustomerCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccountsPayableAndAccruedLiabilitiesOtherCurrent" id="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" id="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" id="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromWarrantsAndStockOptionExercises" id="plx_ProceedsFromWarrantsAndStockOptionExercises" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SalesAgreementMember" id="plx_SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" id="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CommonStockValueOfCapitalSharesReservedForFutureIssuance" id="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="GrossProceedsFromIssuanceOfCommonStock" id="plx_GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" id="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SingleReportableSegmentMember" id="plx_SingleReportableSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" id="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" id="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OptionsExercised" id="plx_OptionsExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfFacilitiesLeased" id="plx_NumberOfFacilitiesLeased" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod" id="plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" id="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LesseeOperatingLeaseRightOfUseAssetAdjustment" id="plx_LesseeOperatingLeaseRightOfUseAssetAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="LesseeOperatingLeaseLiabilityAdjustment" id="plx_LesseeOperatingLeaseLiabilityAdjustment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LesseeOperatingLeaseTerminationAdvancedNoticeTerm" id="plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="OutstandingStockOptionsAndUnvestedRestrictedStockMember" id="plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="BankGuarantee" id="plx_BankGuarantee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>plx-20250930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2025 10:02:23 AM-->
<!--Modified on: 11/13/2025 10:02:23 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetailsCalc2" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetailsCalc2" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSegmentInformationScheduleOfSegmentInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638986249425962342" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638986249425962342" xlink:to="plx_ShortTermBankDeposits_638986249425962342" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638986249425962342" xlink:to="us-gaap_AccountsReceivableNetCurrent_638986249425962342" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638986249425962342" xlink:to="us-gaap_OtherAssetsCurrent_638986249425962342" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638986249425962342" xlink:to="us-gaap_InventoryNet_638986249425962342" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638986249425962342" order="2" use="optional" weight="1" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638986249425962342" order="3" use="optional" weight="1" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638986249425962342" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638986249425962342" order="5" use="optional" weight="1" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_Liabilities_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638986249425962342" xlink:to="us-gaap_LiabilitiesNoncurrent_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638986249425962342" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent_638986249425962342" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638986249425962342" order="2" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638986249425962342" xlink:to="us-gaap_LiabilitiesCurrent_638986249425962342" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638986249425962342" xlink:to="us-gaap_AccountsPayableTradeCurrent_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638986249425962342" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638986249425962342" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638986249425962342" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638986249425962342" order="3" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_CommitmentsAndContingencies_638986249425962342" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity_637041422967477240" xlink:to="us-gaap_StockholdersEquity_638986249425962342" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638986249425962342" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638986249425962342" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638986249425962342" xlink:to="us-gaap_NonoperatingIncomeExpense_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638986249425962342" xlink:to="us-gaap_OtherNonoperatingIncome_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" xlink:label="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638986249425962342" xlink:to="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_638986249425962342" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638986249425962342" xlink:to="us-gaap_OperatingIncomeLoss_638986249425962342" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638986249425962342" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638986249425962342" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638986249425962342" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638986249425962342" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638986249425962342" xlink:to="us-gaap_CostOfRevenue_638986249425962342" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638986249425962342" xlink:to="us-gaap_Revenues_638986249425962342" order="4" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638986249425962342" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638986249425962342" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638986249425962342" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638986249425962342" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638986249425962342" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ProceedsFromWarrantsAndStockOptionExercises" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638986249425962342" xlink:to="plx_ProceedsFromWarrantsAndStockOptionExercises_638986249425962342" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638986249425962342" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638986249425962342" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638986249425962342" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ProceedsFromWithdrawalOfShortTermDeposits" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638986249425962342" xlink:to="plx_ProceedsFromWithdrawalOfShortTermDeposits_638986249425962342" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638986249425962342" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638986249425962342" order="3" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638986249425962342" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638986249425962342" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249425962342" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249425962342" xlink:to="us-gaap_ProfitLoss_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249425962342" xlink:to="us-gaap_ShareBasedCompensation_638986249425962342" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249425962342" xlink:to="us-gaap_Depreciation_638986249425962342" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249425962342" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638986249425962342" order="4" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249425962342" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638986249425962342" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249425962342" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638986249425962342" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249425962342" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638986249425962342" order="7" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249425962342" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638986249425962342" order="8" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249425962342" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638986249425962342" order="9" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249425962342" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638986249425962342" order="10" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249425962342" xlink:to="us-gaap_IncreaseDecreaseInInventories_638986249425962342" order="11" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249425962342" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638986249425962342" order="12" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638986249425962342" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638986249425962342" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" xlink:type="extended" xlink:title="99940402 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:label="plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_638986249425962342" order="1" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638986249425962342" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638986249425962342" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638986249425962342" order="4" use="optional" weight="1" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638986249425962342" order="5" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetailsCalc2" xlink:type="extended" xlink:title="40402 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)- Calc2">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability_638986249425962342" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" xlink:to="us-gaap_DilutiveSecurities_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" xlink:to="us-gaap_NetIncomeLoss_638986249425962342" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638986249425962342" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638986249425962342" order="3" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit_1" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638986249425962342" order="2" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638986249425962342" order="1" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_Depreciation_638986249425962342" order="2" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_InvestmentIncomeInterest_638986249425962342" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_InterestExpenseNonoperating_638986249425962342" order="4" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_638986249425962342" order="5" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_LaborAndRelatedExpense_638986249425962342" order="6" use="optional" weight="-1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="us-gaap_Revenues_638986249425962342" order="7" use="optional" weight="1" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638986249425962342" order="1" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_AccruedVacationCurrent_638986249425962342" order="2" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638986249425962342" order="3" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638986249425962342" order="4" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638986249425962342" order="5" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="us-gaap_TaxesPayableCurrent_638986249425962342" order="6" use="optional" weight="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_PayableToCustomerCurrent" xlink:label="plx_PayableToCustomerCurrent_638986249425962342" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="plx_PayableToCustomerCurrent_638986249425962342" order="7" use="optional" weight="1" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>plx-20250930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2025 10:02:23 AM-->
<!--Modified on: 11/13/2025 10:02:23 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureOperatingLeasesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSegmentInformationScheduleOfSegmentInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="plx-20250930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="us-gaap_ShortTermDebtTypeAxis_1" xlink:title="us-gaap_ShortTermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="us-gaap_ShortTermDebtTypeDomain_1" xlink:title="us-gaap_ShortTermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShortTermDebtTypeAxis_1" xlink:to="us-gaap_ShortTermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShortTermDebtTypeAxis_1 To us-gaap_ShortTermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentRedemptionPeriodAxis_1" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentRedemptionPeriodAxis_1 To us-gaap_DebtInstrumentRedemptionPeriodDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_1" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis_1" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ChangeInAccountingEstimateByTypeAxis_1 To us-gaap_ChangeInAccountingEstimateTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="us-gaap_RetirementPlanTypeAxis_1" xlink:title="us-gaap_RetirementPlanTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="us-gaap_RetirementPlanTypeDomain_1" xlink:title="us-gaap_RetirementPlanTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RetirementPlanTypeAxis_1" xlink:to="us-gaap_RetirementPlanTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RetirementPlanTypeAxis_1 To us-gaap_RetirementPlanTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis_1" xlink:title="us-gaap_LongtermDebtTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_1" xlink:title="us-gaap_LongtermDebtTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LongtermDebtTypeAxis_1" xlink:to="us-gaap_LongtermDebtTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LongtermDebtTypeAxis_1 To us-gaap_LongtermDebtTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" xlink:title="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1 To us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis_1" xlink:title="us-gaap_BalanceSheetLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_1" xlink:title="us-gaap_BalanceSheetLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_BalanceSheetLocationAxis_1" xlink:to="us-gaap_BalanceSheetLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_BalanceSheetLocationAxis_1 To us-gaap_BalanceSheetLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CostOfRevenue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" xlink:label="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherNonoperatingIncome" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate202006Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_AmendedPfizerAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="srt_StatementGeographicalAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_BR" xlink:label="country_BR" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_BR" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="plx_ConvertibleNotesDue2021And2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_SalesAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940403 - Disclosure - OPERATING LEASES (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_VehiclesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeLeaseDescriptionTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_NumberOfFacilitiesLeased" xlink:label="plx_NumberOfFacilitiesLeased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_NumberOfFacilitiesLeased" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm" xlink:label="plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod" xlink:label="plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_BankGuarantee" xlink:label="plx_BankGuarantee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_BankGuarantee" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseRightOfUseAssetAdjustment" xlink:label="plx_LesseeOperatingLeaseRightOfUseAssetAdjustment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_LesseeOperatingLeaseRightOfUseAssetAdjustment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseLiabilityAdjustment" xlink:label="plx_LesseeOperatingLeaseLiabilityAdjustment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_LesseeOperatingLeaseLiabilityAdjustment" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="plx_SalesAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_GrossProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember" xlink:label="plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_NetIncomeLossAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_DilutiveSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_StatementBusinessSegmentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_SegmentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SingleReportableSegmentMember" xlink:label="plx_SingleReportableSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentDomain" xlink:to="plx_SingleReportableSegmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_LaborAndRelatedExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ProfessionalAndContractServicesExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InterestExpenseNonoperating" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_PfizerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_FiocruzMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="plx_ChiesiMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseAndServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_PfizerAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="plx_ChiesiAgreementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromCustomers" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="1" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>plx-20250930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2025 10:02:23 AM-->
<!--Modified on: 11/13/2025 10:02:23 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document and Entity Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Securities Act File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED BALANCE SHEETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShortTermBankDeposits" xlink:to="plx_ShortTermBankDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term Bank Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShortTermBankDeposits_lbl" xml:lang="en-US">Short-term bank deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xml:lang="en-US">Other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Total inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_lbl" xml:lang="en-US">Funds in respect of employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl" xml:lang="en-US">Deferred income tax asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals:</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Accounts payable and accruals - other:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Accounts Payable, Trade, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Other, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Other</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_lbl" xml:lang="en-US">Accounts payable and accruals - other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">LONG TERM LIABILITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_lbl" xml:lang="en-US">Liability for employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total long term liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Ending balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Beginning balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Product [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">GOODS</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProductMember_lbl" xml:lang="en-US">Goods</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServiceMember" xlink:to="us-gaap_LicenseAndServiceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and Service [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">LICENSE AND R&amp;D SERVICES</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LicenseAndServiceMember_lbl" xml:lang="en-US">License and R&amp;D Services</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">TOTAL REVENUE</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues from customers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">Cost of Revenue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CostOfRevenue_lbl" xml:lang="en-US">COST OF GOODS SOLD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">RESEARCH AND DEVELOPMENT EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">OPERATING INCOME (LOSS)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" xlink:label="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" xlink:to="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_lbl" xml:lang="en-US">Amount of expense related to nonoperating activities, classified as other, net of amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_lbl" xml:lang="en-US">Other Nonoperating Expense, Net of Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_lbl" xml:lang="en-US">FINANCIAL EXPENSES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncome" xlink:to="us-gaap_OtherNonoperatingIncome_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">Other Nonoperating Income</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncome_lbl" xml:lang="en-US">FINANCIAL INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">FINANCIAL INCOME (EXPENSES), NET</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">INCOME (LOSS) BEFORE TAXES ON INCOME</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Taxes on income (tax benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total taxes on income (tax benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">TAXES ON INCOME (TAX BENEFIT)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET INCOME (LOSS)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net income (loss)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average shares of Common Stock outstanding for basic calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - DILUTED (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average shares of Common Stock outstanding for diluted calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate202006Member" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US">Accounting Standards Update 2020-06 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_lbl" xml:lang="en-US">ASU 2020-06</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_lbl" xml:lang="en-US">Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock under the Sales Agreement, net (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation related to stock options</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Amount of recognized equity-based compensation during the period for restricted stock awards.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_lbl" xml:lang="en-US">Share-based compensation related to restricted stock awards (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Value of stock issued as a result of the exercise of warrants and stock options.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Value, Warrants and Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants and options</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Number of shares issued as a result of exercise of warrants and stock options.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants and Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_lbl" xml:lang="en-US">Exercise of warrants and options (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Unrealized Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_lbl" xml:lang="en-US">Financial expenses, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Cost (Reversal of Cost)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_lbl" xml:lang="en-US">Changes in accrued liability for employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Changes in deferred income tax asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain (loss) on amounts funded in respect of employee rights upon retirement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_lbl" xml:lang="en-US">Gain on amounts funded in respect of employee rights upon retirement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Gain on sale of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Decrease (Increase) in accounts receivable-trade and other assets</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amount of Net Change in Operating Lease Right Of use Assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Change in Operating Lease Right Of use Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Changes in operating lease right of use assets, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl" xml:lang="en-US">Decrease (increase) in inventories</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Decrease in accounts payable and accruals</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ProceedsFromWithdrawalOfShortTermDeposits" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromWithdrawalOfShortTermDeposits" xlink:to="plx_ProceedsFromWithdrawalOfShortTermDeposits_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_lbl" xml:lang="en-US">The amount of cash inflow from the withdrawal of short-term deposits during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_lbl" xml:lang="en-US">Proceeds From Withdrawal Of Short-Term Deposits</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_lbl" xml:lang="en-US">Short-term deposit withdrawal</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_lbl" xml:lang="en-US">Amounts funded in respect of employee rights upon retirement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Payment for convertible notes redemption</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock under the Sales Agreement, net</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ProceedsFromWarrantsAndStockOptionExercises" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProceedsFromWarrantsAndStockOptionExercises" xlink:to="plx_ProceedsFromWarrantsAndStockOptionExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_lbl" xml:lang="en-US">The cash inflow associated with the amount received from holders exercising their stock warrants and stock options.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_lbl" xml:lang="en-US">Proceeds from Warrants and Stock Option Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_lbl" xml:lang="en-US">Exercise of warrants and options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OptionsExercised" xlink:label="plx_OptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OptionsExercised" xlink:to="plx_OptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OptionsExercised_lbl" xml:lang="en-US">Reflects the exercise price of exercised stock options not yet paid.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OptionsExercised_lbl" xml:lang="en-US">Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_OptionsExercised_lbl" xml:lang="en-US">Exercise of options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right of use assets obtained in exchange for new operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Tax paid</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_InterestReceivedNet" xlink:to="plx_InterestReceivedNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Amount of cash received for interest.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest Received, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_InterestReceivedNet_lbl" xml:lang="en-US">Interest received</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORIES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENT</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LessorDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorDisclosureAbstract_lbl" xml:lang="en-US">OPERATING LEASES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">OPERATING LEASES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">TAXES ON INCOME (TAX BENEFIT)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME (TAX BENEFIT)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingAbstract_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementalInformationAbstract" xlink:to="plx_SupplementalInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementalInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_lbl" xml:lang="en-US">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NatureOfOperationsPolicyTextBlock" xlink:to="plx_NatureOfOperationsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations Policy</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">Nature Of Operations [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NatureOfOperationsPolicyTextBlock_lbl" xml:lang="en-US">General</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net earnings (loss) per share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Debt, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently issued accounting pronouncements, not yet adopted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturity Analysis of Operating Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Earnings (Loss) per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of Taxes on Income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_lbl" xml:lang="en-US">Schedule of Segment Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_lbl" xml:lang="en-US">Schedule of Disaggregation of Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for supplemental balance sheets information.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Supplementary Balance Sheets Information [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_lbl" xml:lang="en-US">Schedule of Supplemental Information of Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesTable" xlink:to="plx_SignificantAccountingPoliciesTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AmendedPfizerAgreementMember" xlink:to="plx_AmendedPfizerAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AmendedPfizerAgreementMember_lbl" xml:lang="en-US">Amended Pfizer Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">All Entities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ProtalixBioTherapeuticsIncorporationMember" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_lbl" xml:lang="en-US">Protalix Bio Therapeutics Incorporation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_SegmentGeographicalDomain_lbl" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_BR" xlink:label="country_BR" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_BR" xlink:to="country_BR_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_BR_lbl" xml:lang="en-US">BRAZIL</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="country_BR_lbl" xml:lang="en-US">Brazil</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ConvertibleNotesDue2021And2024Member" xlink:to="plx_ConvertibleNotesDue2021And2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Represents information pertaining to convertible notes due 2021 and 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ConvertibleNotesDue2021And2024Member_lbl" xml:lang="en-US">Notes 2021 and 2024</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_lbl" xml:lang="en-US">2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SalesAgreementMember" xlink:to="plx_SalesAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SalesAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to sales agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SignificantAccountingPoliciesLineItems" xlink:to="plx_SignificantAccountingPoliciesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Represents the number of global licensing and supply agreements.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number Of Global Licensing And Supply Agreements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_lbl" xml:lang="en-US">Number of global licensing and supply agreements</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expense sharing percentage.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative Arrangement Revenues Expenses Sharing Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_lbl" xml:lang="en-US">Collaborative arrangement revenues and expenses sharing percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares remain for sale</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" xlink:to="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Amount of increase in gross sales price of shares available for future issuance.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Increase in Gross Sales Price of Shares Reserved for Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Increase in aggregate gross sales price</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" xlink:to="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Aggregate value of common shares reserved for future issuance.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Value of Capital Shares Reserved for Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Shares remain available, total gross proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_lbl" xml:lang="en-US">Raw materials</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_lbl" xml:lang="en-US">Work in progress</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_lbl" xml:lang="en-US">Finished goods</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_DisclosureOfLeasesOperatingLineItems" xlink:to="plx_DisclosureOfLeasesOperatingLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_lbl" xml:lang="en-US">Disclosure of Leases Operating</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_lbl" xml:lang="en-US">Disclosure of Leases Operating [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_lbl" xml:lang="en-US">OPERATING LEASES</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">First year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Second year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Third year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Fourth year</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:label="plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:to="plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl" xml:lang="en-US">Amount of lessee's undiscounted obligation for lease payment for operating lease due Five fiscal year and after following current fiscal year.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Five And Thereafter</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_lbl" xml:lang="en-US">Fifth year and thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted cash flows</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: imputed interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of operating lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeaseDescriptionTable" xlink:to="us-gaap_LesseeLeaseDescriptionTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeaseDescriptionTable_lbl" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VehiclesMember" xlink:to="us-gaap_VehiclesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_VehiclesMember_lbl" xml:lang="en-US">Vehicles</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xml:lang="en-US">Option to extend</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_NumberOfFacilitiesLeased" xlink:label="plx_NumberOfFacilitiesLeased" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_NumberOfFacilitiesLeased" xlink:to="plx_NumberOfFacilitiesLeased_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_NumberOfFacilitiesLeased_lbl" xml:lang="en-US">Number of facilities leased during the period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_NumberOfFacilitiesLeased_lbl" xml:lang="en-US">Number Of Facilities Leased</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="plx_NumberOfFacilitiesLeased_lbl" xml:lang="en-US">Number of facilities leased</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:to="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" xml:lang="en-US">Lessee Operating Lease, Number Of Renewal Term Extensions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" xml:lang="en-US">Lessee Operating Lease, Number Of Renewal Term Extensions</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_lbl" xml:lang="en-US">Operating lease, renewable term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US">Operating lease, term of agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm" xlink:label="plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm" xlink:to="plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm_lbl" xml:lang="en-US">Period of advance notice to be given by the company if it intends to terminate lease before an automatic extension is to take effect.
In 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm_lbl" xml:lang="en-US">Lessee, Operating Lease, Termination, Advanced Notice Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm_lbl" xml:lang="en-US">Notice period for termination of lease agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod" xlink:label="plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod" xlink:to="plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod_lbl" xml:lang="en-US">Rent increase rate applied at the start of each additional option renewal period after the third option period ends under lease agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod_lbl" xml:lang="en-US">Lessee, Operating Lease, Rent Increase Rate For Renewal Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod_lbl" xml:lang="en-US">Operating lease rent increase rate for renewal period</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" xml:lang="en-US">Percentage of Change in Operating Lease Monthly Rental Payments.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" xml:lang="en-US">Percentage of Change in Operating Lease Monthly Rental Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_lbl" xml:lang="en-US">Percentage of change in operating lease monthly rental payments</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_BankGuarantee" xlink:label="plx_BankGuarantee" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_BankGuarantee" xlink:to="plx_BankGuarantee_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_BankGuarantee_lbl" xml:lang="en-US">Bank guarantees to secure the fulfillment of obligations under an agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_BankGuarantee_lbl" xml:lang="en-US">Bank Guarantee</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_BankGuarantee_lbl" xml:lang="en-US">Bank guarantee</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseRightOfUseAssetAdjustment" xlink:label="plx_LesseeOperatingLeaseRightOfUseAssetAdjustment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LesseeOperatingLeaseRightOfUseAssetAdjustment" xlink:to="plx_LesseeOperatingLeaseRightOfUseAssetAdjustment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_LesseeOperatingLeaseRightOfUseAssetAdjustment_lbl" xml:lang="en-US">Adjustment amount of lessee's right to use underlying asset under operating lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_LesseeOperatingLeaseRightOfUseAssetAdjustment_lbl" xml:lang="en-US">Lessee, Operating Lease, Right-of-Use Asset, Adjustment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_LesseeOperatingLeaseRightOfUseAssetAdjustment_lbl" xml:lang="en-US">ROU asset adjustment</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseLiabilityAdjustment" xlink:label="plx_LesseeOperatingLeaseLiabilityAdjustment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_LesseeOperatingLeaseLiabilityAdjustment" xlink:to="plx_LesseeOperatingLeaseLiabilityAdjustment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_LesseeOperatingLeaseLiabilityAdjustment_lbl" xml:lang="en-US">Adjustment to the present value of lessee's discounted obligation for lease payments from operating lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_LesseeOperatingLeaseLiabilityAdjustment_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Adjustment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_LesseeOperatingLeaseLiabilityAdjustment_lbl" xml:lang="en-US">Lease liability adjustment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedStockMember_lbl" xml:lang="en-US">Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share Based Compensation Award Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share Based Compensation Award Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">STOCK TRANSACTIONS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Exercise of warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Warrants and rights outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_GrossProceedsFromIssuanceOfCommonStock" xlink:to="plx_GrossProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">The gross cash inflow from the additional capital contribution to the entity.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross Proceeds From Issuance Of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross stock issuance proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Stock issuance costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Cash proceeds from stock options exercised</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Term of award</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options to purchase shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_lbl" xml:lang="en-US">Number of quarterly increments during which the equity instruments will be vested under share-based payment arrangement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Vesting Installments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_lbl" xml:lang="en-US">Number of vesting installments on a quarterly basis</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xml:lang="en-US">Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants In Period, Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_lbl" xml:lang="en-US">Aggregate fair value of the options</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield (as percentage)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility (as percentage)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk -free interest rate (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected life (Years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Granted (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Vested (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl" xml:lang="en-US">Fair value of equity instruments other than options  granted under share-based payment arrangement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants In Period, Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_lbl" xml:lang="en-US">Aggregate fair value of the restricted stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember" xlink:label="plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember" xlink:to="plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember_lbl" xml:lang="en-US">Represents the information pertaining to outstanding stock options and unvested shares of restricted stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember_lbl" xml:lang="en-US">Outstanding Stock Options And Unvested Restricted Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember_lbl" xml:lang="en-US">Outstanding Stock Options and Unvested Restricted Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" xlink:to="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_lbl" xml:lang="en-US">Represents the information pertaining to outstanding stock options, unvested shares of restricted stock and warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_lbl" xml:lang="en-US">Outstanding Stock Options, Unvested Restricted Stock and Warrants [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_lbl" xml:lang="en-US">Outstanding Stock Options, Unvested Restricted Stock and Warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" xlink:to="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_lbl" xml:lang="en-US">Represents the information pertaining to outstanding stock options, unvested shares of restricted stock, warrants and convertible notes.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_lbl" xml:lang="en-US">Outstanding Stock Options, Unvested Restricted Stock, Warrants and Convertible Notes [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_lbl" xml:lang="en-US">Outstanding Stock Options, Unvested Restricted Stock, Warrants and Convertible Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Numerator:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DilutiveSecurities" xlink:to="us-gaap_DilutiveSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DilutiveSecurities_lbl" xml:lang="en-US">Financial expenses of 2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net income (loss) for diluted calculation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_lbl" xml:lang="en-US">Denominator:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_lbl" xml:lang="en-US">Weighted average dilutive effect of 2024 Notes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xml:lang="en-US">Weighted average dilutive effect of stock options and restricted stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive securities excluded from computation of earnings (loss) per share, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Current taxes on income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate (as a percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory income tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_lbl" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementBusinessSegmentsAxis_lbl" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDomain" xlink:to="us-gaap_SegmentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDomain_lbl" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SingleReportableSegmentMember" xlink:label="plx_SingleReportableSegmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SingleReportableSegmentMember" xlink:to="plx_SingleReportableSegmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SingleReportableSegmentMember_lbl" xml:lang="en-US">Represents information pertaining to single reportable segment.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SingleReportableSegmentMember_lbl" xml:lang="en-US">Single Reportable Segment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SingleReportableSegmentMember_lbl" xml:lang="en-US">Single operating segment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingInformationLineItems_lbl" xml:lang="en-US">SEGMENT INFORMATION</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xml:lang="en-US">Number of reportable segments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LaborAndRelatedExpense" xlink:to="us-gaap_LaborAndRelatedExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LaborAndRelatedExpense_lbl" xml:lang="en-US">Employee salaries and related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfessionalAndContractServicesExpense" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Professional and Contract Services Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_lbl" xml:lang="en-US">Sub-contractors expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest Expense, Nonoperating</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestExpenseNonoperating_lbl" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemAmount" xlink:to="us-gaap_SegmentReportingOtherItemAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemAmount_lbl" xml:lang="en-US">Other segment expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" xml:lang="en-US">Segment Reporting, Other Segment Item, Composition, Description</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_lbl" xml:lang="en-US">Segment reporting description</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerMember" xlink:to="plx_PfizerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Global except for Brazil</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerMember_lbl" xml:lang="en-US">Pfizer</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_FiocruzMember" xlink:to="plx_FiocruzMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_FiocruzMember_lbl" xml:lang="en-US">Fiocruz</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiMember" xlink:to="plx_ChiesiMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Global except Brazil and Italy</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiMember_lbl" xml:lang="en-US">Chiesi</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Payroll and related expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Accrued Vacation, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Provision for vacation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Royalties payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxesPayableCurrent_lbl" xml:lang="en-US">Income tax payable</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_PayableToCustomerCurrent" xlink:label="plx_PayableToCustomerCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PayableToCustomerCurrent" xlink:to="plx_PayableToCustomerCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PayableToCustomerCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of the obligations incurred through that date and payable to customers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PayableToCustomerCurrent_lbl" xml:lang="en-US">Payable To Customer, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PayableToCustomerCurrent_lbl" xml:lang="en-US">Payable to customer</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Accounts Payable, Property And Equipment Suppliers, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_lbl" xml:lang="en-US">Property and equipment suppliers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_PfizerAgreementMember" xlink:to="plx_PfizerAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_PfizerAgreementMember_lbl" xml:lang="en-US">Pfizer</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Represents information pertaining to supply and technology transfer agreement with Fiocruz.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Brazil Agreement with Fiocruz</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_lbl" xml:lang="en-US">Fiocruz (Brazil)</link:label>
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="plx_ChiesiAgreementsMember" xlink:to="plx_ChiesiAgreementsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="plx_ChiesiAgreementsMember_lbl" xml:lang="en-US">Chiesi Agreements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromCustomers" xlink:to="us-gaap_ProceedsFromCustomers_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xml:lang="en-US">Proceeds from Customers</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromCustomers_lbl" xml:lang="en-US">Total proceeds from sale of products</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>plx-20250930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  11.1.0.0 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/13/2025 10:02:23 AM-->
<!--Modified on: 11/13/2025 10:02:23 AM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#StatementCondensedConsolidatedStatementsOfOperations" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSignificantAccountingPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureInventories" roleURI="http://www.protalix.com/role/DisclosureInventories" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureFairValueMeasurement" roleURI="http://www.protalix.com/role/DisclosureFairValueMeasurement" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureOperatingLeases" roleURI="http://www.protalix.com/role/DisclosureOperatingLeases" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureStockTransactions" roleURI="http://www.protalix.com/role/DisclosureStockTransactions" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureEarningsLossPerShare" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShare" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureTaxesOnIncomeTaxBenefit" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefit" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSegmentInformation" roleURI="http://www.protalix.com/role/DisclosureSegmentInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSupplementaryFinancialStatementInformation" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSubsequentEvents" roleURI="http://www.protalix.com/role/DisclosureSubsequentEvents" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSignificantAccountingPoliciesPolicies" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureInventoriesTables" roleURI="http://www.protalix.com/role/DisclosureInventoriesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureOperatingLeasesTables" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureEarningsLossPerShareTables" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureTaxesOnIncomeTaxBenefitTables" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSegmentInformationTables" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSupplementaryFinancialStatementInformationTables" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSignificantAccountingPoliciesDetails" roleURI="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureInventoriesScheduleOfInventoryDetails" roleURI="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureOperatingLeasesAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureStockTransactionsDetails" roleURI="http://www.protalix.com/role/DisclosureStockTransactionsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureEarningsLossPerShareDetails" roleURI="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails" roleURI="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSegmentInformationScheduleOfSegmentInformationDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" roleURI="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" roleURI="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" />
  <link:roleRef xlink:type="simple" xlink:href="plx-20250930.xsd#DisclosureSubsequentEventsDetails" roleURI="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements" roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" />
  <link:presentationLink xlink:role="http://www.protalix.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="995200090 - Document - Document and Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638986249426275029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638986249426275029" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638986249426275029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638986249426275029" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638986249426275029" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638986249426275029" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638986249426275029" order="7" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638986249426275029" order="8" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638986249426275029" order="9" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638986249426275029" order="10" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638986249426275029" order="11" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638986249426275029" order="12" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638986249426275029" order="13" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638986249426275029" order="14" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638986249426275029" order="15" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638986249426275029" order="16" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638986249426275029" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638986249426275029" order="18" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638986249426275029" order="19" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638986249426275029" order="20" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638986249426275029" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638986249426275029" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638986249426275029" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638986249426275029" order="24" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638986249426275029" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638986249426275029" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638986249426275029" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638986249426275029" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638986249426275029" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638986249426275029" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_AssetsAbstract_638986249426275029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638986249426275029" xlink:to="us-gaap_AssetsCurrentAbstract_638986249426275029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638986249426275029" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638986249426275029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShortTermBankDeposits" xlink:label="plx_ShortTermBankDeposits_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638986249426275029" xlink:to="plx_ShortTermBankDeposits_638986249426275029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638986249426275029" xlink:to="us-gaap_AccountsReceivableNetCurrent_638986249426275029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638986249426275029" xlink:to="us-gaap_OtherAssetsCurrent_638986249426275029" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638986249426275029" xlink:to="us-gaap_InventoryNet_638986249426275029" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638986249426275029" xlink:to="us-gaap_AssetsCurrent_638986249426275029" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsNoncurrentAbstract" xlink:label="us-gaap_AssetsNoncurrentAbstract_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638986249426275029" xlink:to="us-gaap_AssetsNoncurrentAbstract_638986249426275029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638986249426275029" xlink:to="us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_638986249426275029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638986249426275029" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638986249426275029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638986249426275029" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_638986249426275029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract_638986249426275029" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638986249426275029" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638986249426275029" xlink:to="us-gaap_Assets_638986249426275029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract_637041422967320790" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638986249426275029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638986249426275029" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638986249426275029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638986249426275029" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426275029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="us-gaap_AccountsPayableTradeCurrent_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426275029" xlink:to="us-gaap_AccountsPayableTradeCurrent_638986249426275029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426275029" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638986249426275029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426275029" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638986249426275029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638986249426275029" xlink:to="us-gaap_LiabilitiesCurrent_638986249426275029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638986249426275029" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_638986249426275029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent" xlink:label="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638986249426275029" xlink:to="us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent_638986249426275029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract_638986249426275029" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638986249426275029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="us-gaap_LiabilitiesNoncurrent_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638986249426275029" xlink:to="us-gaap_LiabilitiesNoncurrent_638986249426275029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638986249426275029" xlink:to="us-gaap_Liabilities_638986249426275029" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638986249426275029" xlink:to="us-gaap_CommitmentsAndContingencies_638986249426275029" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638986249426275029" xlink:to="us-gaap_StockholdersEquity_638986249426275029" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638986249426275029" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638986249426275029" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations" xlink:type="extended" xlink:title="995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_637041422967477240" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_637041422967477240" xlink:to="us-gaap_StatementTable_638986249426275029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638986249426275029" xlink:to="srt_ProductOrServiceAxis_638986249426275029" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638986249426275029" xlink:to="srt_ProductsAndServicesDomain_638986249426275029" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638986249426275029" xlink:to="us-gaap_ProductMember_638986249426275029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638986249426275029" xlink:to="us-gaap_LicenseAndServiceMember_638986249426275029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638986249426275029" xlink:to="us-gaap_StatementLineItems_638986249426275029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="us-gaap_Revenues_638986249426275029" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="us-gaap_CostOfRevenue_638986249426275029" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638986249426275029" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_638986249426275029" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="us-gaap_OperatingIncomeLoss_638986249426275029" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax" xlink:label="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax_638986249426275029" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="us-gaap_OtherNonoperatingIncome_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="us-gaap_OtherNonoperatingIncome_638986249426275029" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="us-gaap_NonoperatingIncomeExpense_638986249426275029" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638986249426275029" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638986249426275029" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638986249426275029" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="us-gaap_NetIncomeLoss_638986249426275029" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638986249426370320" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="us-gaap_EarningsPerShareBasic_638986249426370320" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638986249426370320" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="us-gaap_EarningsPerShareDiluted_638986249426370320" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638986249426370320" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638986249426370320" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638986249426370320" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426275029" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638986249426370320" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="extended" xlink:title="995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_676" xlink:to="us-gaap_StatementTable_638986249426374478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638986249426374478" xlink:to="us-gaap_StatementEquityComponentsAxis_638986249426374478" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638986249426374478" xlink:to="us-gaap_CommonStockMember_638986249426374478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638986249426374478" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638986249426374478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638986249426374478" xlink:to="us-gaap_RetainedEarningsMember_638986249426374478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638986249426374478" xlink:to="us-gaap_EquityComponentDomain_638986249426374478" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638986249426374478" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638986249426374478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingStandardsUpdate202006Member" xlink:label="us-gaap_AccountingStandardsUpdate202006Member_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638986249426374478" xlink:to="us-gaap_AccountingStandardsUpdate202006Member_638986249426374478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_638986249426374478" xlink:to="us-gaap_TypeOfAdoptionMember_638986249426374478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638986249426374478" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAxis_638986249426374478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638986249426374478" xlink:to="srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_638986249426374478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_638986249426374478" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_638986249426374478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638986249426374478" xlink:to="us-gaap_StatementLineItems_638986249426374478" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426374478" xlink:to="us-gaap_StockholdersEquity_638986249426374478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426374478" xlink:to="us-gaap_CommonStockSharesIssued_638986249426374478" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426374478" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638986249426374478" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426374478" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638986249426374478" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426374478" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638986249426374478" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426374478" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638986249426374478" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares" xlink:label="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures_638986249426374478" xlink:to="plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares_638986249426374478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426374478" xlink:to="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_638986249426374478" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised" xlink:label="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised_638986249426374478" xlink:to="plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised_638986249426374478" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638986249426374478" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426374478" xlink:to="us-gaap_NetIncomeLoss_638986249426374478" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6389862494263744781" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426374478" xlink:to="us-gaap_StockholdersEquity_6389862494263744781" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638986249426374478" xlink:to="us-gaap_CommonStockSharesIssued_638986249426389846" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" xlink:type="extended" xlink:title="995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638986249426389846" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_738" xlink:to="us-gaap_CommonStockSharesAuthorized_638986249426389846" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_746" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_ProfitLoss_638986249426389846" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_ShareBasedCompensation_638986249426389846" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_Depreciation_638986249426389846" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossUnrealized" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossUnrealized_638986249426389846" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PensionAndOtherPostretirementBenefitExpense" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitExpense_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitExpense_638986249426389846" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638986249426389846" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement" xlink:label="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" xlink:to="plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement_638986249426389846" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638986249426389846" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638986249426389846" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638986249426389846" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638986249426389846" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ChangeInOperatingLeaseRightOfUseAssets" xlink:label="plx_ChangeInOperatingLeaseRightOfUseAssets_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638986249426389846" xlink:to="plx_ChangeInOperatingLeaseRightOfUseAssets_638986249426389846" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638986249426389846" xlink:to="us-gaap_IncreaseDecreaseInInventories_638986249426389846" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638986249426389846" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_638986249426389846" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638986249426389846" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638986249426389846" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ProceedsFromWithdrawalOfShortTermDeposits" xlink:label="plx_ProceedsFromWithdrawalOfShortTermDeposits_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638986249426389846" xlink:to="plx_ProceedsFromWithdrawalOfShortTermDeposits_638986249426389846" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638986249426389846" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638986249426389846" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_PaymentsForProceedsFromOtherInvestingActivities_638986249426389846" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638986249426389846" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638986249426389846" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_638986249426389846" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638986249426389846" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ProceedsFromWarrantsAndStockOptionExercises" xlink:label="plx_ProceedsFromWarrantsAndStockOptionExercises_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638986249426389846" xlink:to="plx_ProceedsFromWarrantsAndStockOptionExercises_638986249426389846" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638986249426389846" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638986249426389846" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_638986249426389846" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638986249426389846" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638986249426389846" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638986249426389846" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638986249426435141" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638986249426435141" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638986249426435141" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OptionsExercised" xlink:label="plx_OptionsExercised_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638986249426435141" xlink:to="plx_OptionsExercised_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_638986249426435141" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_746" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638986249426435141" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638986249426435141" xlink:to="us-gaap_IncomeTaxesPaidNet_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638986249426435141" xlink:to="us-gaap_InterestPaidNet_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_InterestReceivedNet" xlink:label="plx_InterestReceivedNet_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638986249426435141" xlink:to="plx_InterestReceivedNet_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPolicies" xlink:type="extended" xlink:title="995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_802" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_802" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventories" xlink:type="extended" xlink:title="995210201 - Disclosure - INVENTORIES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8" xlink:to="us-gaap_InventoryDisclosureTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureFairValueMeasurement" xlink:type="extended" xlink:title="995210301 - Disclosure - FAIR VALUE MEASUREMENT">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_23" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_23" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeases" xlink:type="extended" xlink:title="995210401 - Disclosure - OPERATING LEASES">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactions" xlink:type="extended" xlink:title="995210501 - Disclosure - STOCK TRANSACTIONS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShare" xlink:type="extended" xlink:title="995210601 - Disclosure - EARNINGS (LOSS) PER SHARE">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefit" xlink:type="extended" xlink:title="995210701 - Disclosure - TAXES ON INCOME (TAX BENEFIT)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967633303" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformation" xlink:type="extended" xlink:title="995210801 - Disclosure - SEGMENT INFORMATION">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation" xlink:type="extended" xlink:title="995210901 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION">
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967789587" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:label="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967789587" xlink:to="us-gaap_AdditionalFinancialInformationDisclosureTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="995211001 - Disclosure - SUBSEQUENT EVENTS">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_1" xlink:to="us-gaap_SubsequentEventsTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_NatureOfOperationsPolicyTextBlock" xlink:label="plx_NatureOfOperationsPolicyTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="plx_NatureOfOperationsPolicyTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="us-gaap_DebtPolicyTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock_638986249426435141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638986249426435141" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesTables" xlink:type="extended" xlink:title="99930203 - Disclosure - INVENTORIES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_101" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_101" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesTables" xlink:type="extended" xlink:title="99930403 - Disclosure - OPERATING LEASES (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareTables" xlink:type="extended" xlink:title="99930603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_1" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables" xlink:type="extended" xlink:title="99930703 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422967854703" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationTables" xlink:type="extended" xlink:title="99930803 - Disclosure - SEGMENT INFORMATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_1" xlink:to="us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables" xlink:type="extended" xlink:title="99930903 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)">
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422967854703" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SupplementaryBalanceSheetsInformationTableTextBlock" xlink:label="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422967854703" xlink:to="plx_SupplementaryBalanceSheetsInformationTableTextBlock_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_177" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SignificantAccountingPoliciesTable" xlink:label="plx_SignificantAccountingPoliciesTable_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_177" xlink:to="plx_SignificantAccountingPoliciesTable_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638986249426435141" xlink:to="us-gaap_TypeOfArrangementAxis_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638986249426435141" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_AmendedPfizerAgreementMember" xlink:label="plx_AmendedPfizerAgreementMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638986249426435141" xlink:to="plx_AmendedPfizerAgreementMember_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638986249426435141" xlink:to="dei_LegalEntityAxis_638986249426435141" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638986249426435141" xlink:to="dei_EntityDomain_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ProtalixBioTherapeuticsIncorporationMember" xlink:label="plx_ProtalixBioTherapeuticsIncorporationMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638986249426435141" xlink:to="plx_ProtalixBioTherapeuticsIncorporationMember_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638986249426435141" xlink:to="srt_StatementGeographicalAxis_638986249426435141" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis_638986249426435141" xlink:to="srt_SegmentGeographicalDomain_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_BR" xlink:label="country_BR_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain_638986249426435141" xlink:to="country_BR_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638986249426435141" xlink:to="us-gaap_DebtInstrumentAxis_638986249426435141" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638986249426435141" xlink:to="us-gaap_DebtInstrumentNameDomain_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ConvertibleNotesDue2021And2024Member" xlink:label="plx_ConvertibleNotesDue2021And2024Member_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638986249426435141" xlink:to="plx_ConvertibleNotesDue2021And2024Member_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member" xlink:label="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_ConvertibleNotesDue2021And2024Member_638986249426435141" xlink:to="plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638986249426435141" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638986249426435141" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638986249426435141" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638986249426435141" xlink:to="plx_SalesAgreementMember_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SignificantAccountingPoliciesLineItems" xlink:label="plx_SignificantAccountingPoliciesLineItems_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesTable_638986249426435141" xlink:to="plx_SignificantAccountingPoliciesLineItems_638986249426435141" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_NumberOfGlobalLicensingAndSupplyAgreements" xlink:label="plx_NumberOfGlobalLicensingAndSupplyAgreements_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638986249426435141" xlink:to="plx_NumberOfGlobalLicensingAndSupplyAgreements_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_CollaborativeArrangementRevenuesExpensesSharingPercentage" xlink:label="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638986249426435141" xlink:to="plx_CollaborativeArrangementRevenuesExpensesSharingPercentage_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638986249426435141" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance" xlink:label="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638986249426435141" xlink:to="plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance_638986249426435141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance" xlink:label="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638986249426435141" xlink:to="plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance_638986249426435141" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638986249426435141" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638986249426435141" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SignificantAccountingPoliciesLineItems_638986249426435141" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638986249426435141" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails" xlink:type="extended" xlink:title="99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_261" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_261" xlink:to="us-gaap_InventoryNet_638986249426435141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails" xlink:type="extended" xlink:title="99940401 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeasePayments_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638986249426435141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails" xlink:type="extended" xlink:title="99940402 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638986249426435141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter" xlink:label="plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter_638986249426435141" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638986249426435141" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638986249426435141" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability_638986249426435141" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails" xlink:type="extended" xlink:title="99940403 - Disclosure - OPERATING LEASES (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LessorDisclosureAbstract" xlink:label="us-gaap_LessorDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="us-gaap_LesseeLeaseDescriptionTable_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LessorDisclosureAbstract" xlink:to="us-gaap_LesseeLeaseDescriptionTable_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638986249426435141" xlink:to="srt_RangeAxis_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638986249426435141" xlink:to="srt_RangeMember_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638986249426435141" xlink:to="srt_MinimumMember_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638986249426435141" xlink:to="srt_MaximumMember_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638986249426435141" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638986249426435141" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638986249426435141" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VehiclesMember" xlink:label="us-gaap_VehiclesMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638986249426435141" xlink:to="us-gaap_VehiclesMember_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_DisclosureOfLeasesOperatingLineItems" xlink:label="plx_DisclosureOfLeasesOperatingLineItems_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeLeaseDescriptionTable_638986249426435141" xlink:to="plx_DisclosureOfLeasesOperatingLineItems_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638986249426435141" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_NumberOfFacilitiesLeased" xlink:label="plx_NumberOfFacilitiesLeased_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638986249426435141" xlink:to="plx_NumberOfFacilitiesLeased_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions" xlink:label="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638986249426435141" xlink:to="plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638986249426435141" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638986249426435141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm" xlink:label="plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638986249426435141" xlink:to="plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm_638986249426435141" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod" xlink:label="plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638986249426435141" xlink:to="plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod_638986249426435141" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments" xlink:label="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638986249426435141" xlink:to="plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments_638986249426435141" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_BankGuarantee" xlink:label="plx_BankGuarantee_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638986249426435141" xlink:to="plx_BankGuarantee_638986249426435141" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseRightOfUseAssetAdjustment" xlink:label="plx_LesseeOperatingLeaseRightOfUseAssetAdjustment_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638986249426435141" xlink:to="plx_LesseeOperatingLeaseRightOfUseAssetAdjustment_638986249426435141" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_LesseeOperatingLeaseLiabilityAdjustment" xlink:label="plx_LesseeOperatingLeaseLiabilityAdjustment_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_DisclosureOfLeasesOperatingLineItems_638986249426435141" xlink:to="plx_LesseeOperatingLeaseLiabilityAdjustment_638986249426435141" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureStockTransactionsDetails" xlink:type="extended" xlink:title="99940501 - Disclosure - STOCK TRANSACTIONS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_ScheduleOfStockByClassTable_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638986249426435141" xlink:to="us-gaap_AwardTypeAxis_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638986249426435141" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638986249426435141" xlink:to="us-gaap_RestrictedStockMember_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638986249426435141" xlink:to="us-gaap_EmployeeStockOptionMember_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638986249426435141" xlink:to="us-gaap_VestingAxis_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638986249426435141" xlink:to="us-gaap_VestingDomain_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638986249426435141" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638986249426435141" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638986249426435141" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638986249426435141" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SalesAgreementMember" xlink:label="plx_SalesAgreementMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638986249426435141" xlink:to="plx_SalesAgreementMember_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638986249426435141" xlink:to="us-gaap_PrivatePlacementMember_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable_638986249426435141" xlink:to="us-gaap_ClassOfStockLineItems_638986249426435141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_ProceedsFromWarrantExercises_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638986249426435141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_GrossProceedsFromIssuanceOfCommonStock" xlink:label="plx_GrossProceedsFromIssuanceOfCommonStock_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="plx_GrossProceedsFromIssuanceOfCommonStock_638986249426435141" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638986249426435141" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638986249426435141" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638986249426435141" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638986249426435141" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638986249426435141" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments_638986249426435141" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue_638986249426435141" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_SharePrice_638986249426435141" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_638986249426435141" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638986249426435141" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638986249426435141" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638986249426435141" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638986249426435141" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638986249426435141" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638986249426435141" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue" xlink:label="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems_638986249426435141" xlink:to="plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue_638986249426435141" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails" xlink:type="extended" xlink:title="99940601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_3" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638986249426435141" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638986249426435141" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember" xlink:label="plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638986249426435141" xlink:to="plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638986249426435141" xlink:to="plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember" xlink:label="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638986249426435141" xlink:to="plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638986249426435141" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638986249426435141" xlink:to="us-gaap_NetIncomeLossAbstract_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638986249426435141" xlink:to="us-gaap_NetIncomeLoss_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecurities" xlink:label="us-gaap_DilutiveSecurities_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638986249426435141" xlink:to="us-gaap_DilutiveSecurities_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638986249426435141" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638986249426435141" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638986249426435141" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities" xlink:label="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638986249426435141" xlink:to="us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638986249426435141" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_638986249426435141" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638986249426435141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638986249426435141" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails" xlink:type="extended" xlink:title="99940701 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails" xlink:type="extended" xlink:title="99940702 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Additional Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract_637041422968852328" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails" xlink:type="extended" xlink:title="99940801 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_2" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638986249426435141" xlink:to="us-gaap_StatementBusinessSegmentsAxis_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementBusinessSegmentsAxis_638986249426435141" xlink:to="us-gaap_SegmentDomain_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SingleReportableSegmentMember" xlink:label="plx_SingleReportableSegmentMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentDomain_638986249426435141" xlink:to="plx_SingleReportableSegmentMember_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638986249426435141" xlink:to="us-gaap_SegmentReportingInformationLineItems_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638986249426435141" xlink:to="us-gaap_NumberOfOperatingSegments_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638986249426435141" xlink:to="us-gaap_NumberOfReportableSegments_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638986249426435141" xlink:to="us-gaap_Revenues_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense" xlink:label="us-gaap_LaborAndRelatedExpense_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638986249426435141" xlink:to="us-gaap_LaborAndRelatedExpense_638986249426435141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfessionalAndContractServicesExpense" xlink:label="us-gaap_ProfessionalAndContractServicesExpense_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638986249426435141" xlink:to="us-gaap_ProfessionalAndContractServicesExpense_638986249426435141" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="us-gaap_InterestExpenseNonoperating_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638986249426435141" xlink:to="us-gaap_InterestExpenseNonoperating_638986249426435141" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638986249426435141" xlink:to="us-gaap_InvestmentIncomeInterest_638986249426435141" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638986249426435141" xlink:to="us-gaap_Depreciation_638986249426435141" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount" xlink:label="us-gaap_SegmentReportingOtherItemAmount_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638986249426435141" xlink:to="us-gaap_SegmentReportingOtherItemAmount_638986249426435141" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638986249426435141" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638986249426435141" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638986249426435141" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638986249426435141" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638986249426435141" xlink:to="us-gaap_NetIncomeLoss_638986249426435141" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemCompositionDescription" xlink:label="us-gaap_SegmentReportingOtherItemCompositionDescription_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638986249426435141" xlink:to="us-gaap_SegmentReportingOtherItemCompositionDescription_638986249426435141" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails" xlink:type="extended" xlink:title="99940802 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract" xlink:label="us-gaap_SegmentReportingAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingAbstract_3" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638986249426435141" xlink:to="srt_MajorCustomersAxis_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638986249426435141" xlink:to="srt_NameOfMajorCustomerDomain_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_PfizerMember" xlink:label="plx_PfizerMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638986249426435141" xlink:to="plx_PfizerMember_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_FiocruzMember" xlink:label="plx_FiocruzMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638986249426435141" xlink:to="plx_FiocruzMember_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ChiesiMember" xlink:label="plx_ChiesiMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638986249426435141" xlink:to="plx_ChiesiMember_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638986249426435141" xlink:to="srt_ProductOrServiceAxis_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638986249426435141" xlink:to="srt_ProductsAndServicesDomain_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638986249426435141" xlink:to="us-gaap_ProductMember_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseAndServiceMember" xlink:label="us-gaap_LicenseAndServiceMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638986249426435141" xlink:to="us-gaap_LicenseAndServiceMember_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="us-gaap_SegmentReportingInformationLineItems_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_638986249426435141" xlink:to="us-gaap_SegmentReportingInformationLineItems_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentReportingInformationLineItems_638986249426435141" xlink:to="us-gaap_Revenues_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails" xlink:type="extended" xlink:title="99940901 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)">
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SupplementalInformationAbstract" xlink:label="plx_SupplementalInformationAbstract_637041422969008821" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="plx_SupplementalInformationAbstract_637041422969008821" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426435141" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426435141" xlink:to="us-gaap_AccruedVacationCurrent_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426435141" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426435141" xlink:to="us-gaap_AccruedRoyaltiesCurrent_638986249426435141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent" xlink:label="us-gaap_TaxesPayableCurrent_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426435141" xlink:to="us-gaap_TaxesPayableCurrent_638986249426435141" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_PayableToCustomerCurrent" xlink:label="plx_PayableToCustomerCurrent_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426435141" xlink:to="plx_PayableToCustomerCurrent_638986249426435141" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent" xlink:label="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426435141" xlink:to="plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent_638986249426435141" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent" xlink:label="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract_638986249426435141" xlink:to="plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent_638986249426435141" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.protalix.com/role/DisclosureSubsequentEventsDetails" xlink:type="extended" xlink:title="99941001 - Disclosure - SUBSEQUENT EVENTS (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_2" xlink:to="us-gaap_SubsequentEventTable_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638986249426435141" xlink:to="us-gaap_SubsequentEventTypeAxis_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638986249426435141" xlink:to="us-gaap_SubsequentEventTypeDomain_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638986249426435141" xlink:to="us-gaap_SubsequentEventMember_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638986249426435141" xlink:to="us-gaap_TypeOfArrangementAxis_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638986249426435141" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_PfizerAgreementMember" xlink:label="plx_PfizerAgreementMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638986249426435141" xlink:to="plx_PfizerAgreementMember_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember" xlink:label="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638986249426435141" xlink:to="plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="plx-20250930.xsd#plx_ChiesiAgreementsMember" xlink:label="plx_ChiesiAgreementsMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638986249426435141" xlink:to="plx_ChiesiAgreementsMember_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638986249426435141" xlink:to="us-gaap_AwardTypeAxis_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638986249426435141" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638986249426435141" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638986249426435141" xlink:to="us-gaap_EmployeeStockOptionMember_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638986249426435141" xlink:to="us-gaap_SubsequentEventLineItems_638986249426435141" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCustomers" xlink:label="us-gaap_ProceedsFromCustomers_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638986249426435141" xlink:to="us-gaap_ProceedsFromCustomers_638986249426435141" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638986249426435141" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638986249426435141" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638986249426435141" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638986249426435141" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638986249426435141" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended" xlink:title="995445 - Disclosure - Insider Trading Arrangements" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Nov. 01, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-33357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROTALIX BIOTHERAPEUTICS,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">65-0643773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 University Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hackensack<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">696-9345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,421,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001006281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 13,647<span></span>
</td>
<td class="nump">$ 19,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShortTermBankDeposits', window );">Short-term bank deposits</a></td>
<td class="nump">15,723<span></span>
</td>
<td class="nump">15,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">14,425<span></span>
</td>
<td class="nump">2,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other assets</a></td>
<td class="nump">1,452<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">21,255<span></span>
</td>
<td class="nump">21,243<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">66,502<span></span>
</td>
<td class="nump">60,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Funds in respect of employee rights upon retirement</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">4,724<span></span>
</td>
<td class="nump">4,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income tax asset</a></td>
<td class="nump">2,679<span></span>
</td>
<td class="nump">2,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">7,810<span></span>
</td>
<td class="nump">5,430<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">82,264<span></span>
</td>
<td class="nump">73,417<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade</a></td>
<td class="nump">5,375<span></span>
</td>
<td class="nump">4,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent', window );">Other</a></td>
<td class="nump">15,173<span></span>
</td>
<td class="nump">19,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">1,397<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">21,945<span></span>
</td>
<td class="nump">25,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent', window );">Liability for employee rights upon retirement</a></td>
<td class="nump">631<span></span>
</td>
<td class="nump">559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">6,780<span></span>
</td>
<td class="nump">4,026<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long term liabilities</a></td>
<td class="nump">7,411<span></span>
</td>
<td class="nump">4,585<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">29,356<span></span>
</td>
<td class="nump">30,206<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="nump">52,908<span></span>
</td>
<td class="nump">43,211<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 82,264<span></span>
</td>
<td class="nump">$ 73,417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShortTermBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShortTermBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480535/715-20-45-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 17,851<span></span>
</td>
<td class="nump">$ 17,959<span></span>
</td>
<td class="nump">$ 43,622<span></span>
</td>
<td class="nump">$ 35,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">COST OF GOODS SOLD</a></td>
<td class="num">(8,324)<span></span>
</td>
<td class="num">(8,375)<span></span>
</td>
<td class="num">(22,374)<span></span>
</td>
<td class="num">(20,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="num">(4,467)<span></span>
</td>
<td class="num">(2,998)<span></span>
</td>
<td class="num">(13,934)<span></span>
</td>
<td class="num">(8,846)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">SELLING, GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="num">(2,929)<span></span>
</td>
<td class="num">(2,595)<span></span>
</td>
<td class="num">(8,156)<span></span>
</td>
<td class="num">(9,194)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">OPERATING INCOME (LOSS)</a></td>
<td class="nump">2,131<span></span>
</td>
<td class="nump">3,991<span></span>
</td>
<td class="num">(842)<span></span>
</td>
<td class="num">(3,292)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax', window );">FINANCIAL EXPENSES</a></td>
<td class="num">(180)<span></span>
</td>
<td class="num">(299)<span></span>
</td>
<td class="num">(808)<span></span>
</td>
<td class="num">(1,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">FINANCIAL INCOME</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">818<span></span>
</td>
<td class="nump">1,186<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">FINANCIAL INCOME (EXPENSES), NET</a></td>
<td class="nump">108<span></span>
</td>
<td class="num">(148)<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE TAXES ON INCOME</a></td>
<td class="nump">2,239<span></span>
</td>
<td class="nump">3,843<span></span>
</td>
<td class="num">(832)<span></span>
</td>
<td class="num">(3,162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">TAXES ON INCOME (TAX BENEFIT)</a></td>
<td class="num">(116)<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="nump">$ 2,355<span></span>
</td>
<td class="nump">$ 3,236<span></span>
</td>
<td class="num">$ (1,100)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share)</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)</a></td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC (in shares)</a></td>
<td class="nump">79,281,685<span></span>
</td>
<td class="nump">73,549,745<span></span>
</td>
<td class="nump">78,225,112<span></span>
</td>
<td class="nump">73,301,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - DILUTED (in shares)</a></td>
<td class="nump">80,814,564<span></span>
</td>
<td class="nump">81,217,068<span></span>
</td>
<td class="nump">78,225,112<span></span>
</td>
<td class="nump">73,301,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Goods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 17,673<span></span>
</td>
<td class="nump">$ 17,839<span></span>
</td>
<td class="nump">$ 43,108<span></span>
</td>
<td class="nump">$ 34,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">License and R&amp;D Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 178<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 514<span></span>
</td>
<td class="nump">$ 361<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to nonoperating activities, classified as other, net of amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Adjustment</div>
</th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Adjustment</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance (ASU 2020-06) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (381,549)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,569<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">72,952,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">681,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,562)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,562)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(384,887)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,437<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">73,633,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">416,631<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(388,123)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,581<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">73,292,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">340,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,236<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">417,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(384,887)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,437<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">73,633,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">421,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(378,393)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,211<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2024</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">75,850,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under the Sales Agreement, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,812<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under the Sales Agreement, net (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2,775,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,004<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">559,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised', window );">Exercise of warrants and options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised', window );">Exercise of warrants and options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,156,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">432,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(379,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,908<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">80,341,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(381,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,903<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning balance (in shares) at Jun. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">79,732,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation related to stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures', window );">Share-based compensation related to restricted stock awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares', window );">Share-based compensation related to restricted stock awards (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">559,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised', window );">Exercise of warrants and options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised', window );">Exercise of warrants and options (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,355<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 432,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (379,493)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,908<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending balance (in shares) at Sep. 30, 2025</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">80,341,325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Common stock, $0.001 par value; Authorized &#8211; as of September&#160;30, 2025 and December&#160;31, 2024 &#8211; 185,000,000 shares.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of recognized equity-based compensation during the period for restricted stock awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued as a result of exercise of warrants and stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of warrants and stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate202006Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common Stock, Shares Authorized</a></td>
<td class="nump">185,000,000<span></span>
</td>
<td class="nump">185,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (1,100)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,565<span></span>
</td>
<td class="nump">2,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized', window );">Financial expenses, net</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitExpense', window );">Changes in accrued liability for employee rights upon retirement</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Changes in deferred income tax asset</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement', window );">Gain on amounts funded in respect of employee rights upon retirement</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Decrease (Increase) in accounts receivable-trade and other assets</a></td>
<td class="num">(11,768)<span></span>
</td>
<td class="nump">3,069<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ChangeInOperatingLeaseRightOfUseAssets', window );">Changes in operating lease right of use assets, net</a></td>
<td class="num">(62)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Decrease (increase) in inventories</a></td>
<td class="num">(12)<span></span>
</td>
<td class="nump">1,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and accruals</a></td>
<td class="num">(4,033)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(14,023)<span></span>
</td>
<td class="nump">4,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromWithdrawalOfShortTermDeposits', window );">Short-term deposit withdrawal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,235)<span></span>
</td>
<td class="num">(857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Amounts funded in respect of employee rights upon retirement, net</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(1,254)<span></span>
</td>
<td class="nump">19,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment for convertible notes redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,420)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under the Sales Agreement, net</a></td>
<td class="nump">6,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ProceedsFromWarrantsAndStockOptionExercises', window );">Exercise of warrants and options</a></td>
<td class="nump">2,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">9,180<span></span>
</td>
<td class="num">(20,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(6,113)<span></span>
</td>
<td class="nump">3,775<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">19,760<span></span>
</td>
<td class="nump">23,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD</a></td>
<td class="nump">13,647<span></span>
</td>
<td class="nump">27,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_OptionsExercised', window );">Exercise of options</a></td>
<td class="nump">52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">3,104<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTARY DISCLOSURE ON CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Tax paid</a></td>
<td class="nump">1,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_InterestReceivedNet', window );">Interest received</a></td>
<td class="nump">$ 258<span></span>
</td>
<td class="nump">$ 1,481<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ChangeInOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Change in Operating Lease Right Of use Assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ChangeInOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on amounts funded in respect of employee rights upon retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_InterestReceivedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash received for interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_InterestReceivedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_OptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the exercise price of exercised stock options not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_OptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromWarrantsAndStockOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants and stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromWarrantsAndStockOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ProceedsFromWithdrawalOfShortTermDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash inflow from the withdrawal of short-term deposits during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ProceedsFromWithdrawalOfShortTermDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossUnrealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossUnrealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activity, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (reversal of cost) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#8220;Company&#8221;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients and children four years of age and greater with Gaucher disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Elelyso was first approved by the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others. In May 2023, both the European Commission (&#8220;EC&#8221;) and the FDA announced the approval of Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia, Singapore, Australia and Taiwan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases (neutrophil extracellular traps).</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company, through its wholly-owned subsidiary, Protalix Ltd., has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio through two exclusive global licensing and supply agreements. On October&#160;19, 2017, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">2015, Protalix Ltd. and Pfizer entered into an amended and restated exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;">On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). After giving effect to the sales under the Sales Agreement in January 2025, no shares of common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $20.0&#160;million. As of September&#160;30, 2025, approximately $15.7&#160;million in shares of Common Stock remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel. Since October 2023, following an infiltration by Hamas terrorists of Israel&#8217;s southern border from the Gaza Strip and attacks on civilian and military targets, Israel has been engaged in military activity on a number of fronts, including with the Hamas in the Gaza Strip, Hezbollah in Lebanon, Iran, the Houthis terrorist group that controls parts of Yemen, and others. Such clashes may escalate in the future into a greater regional conflict. On October&#160;9, 2025, Israel and Hamas entered into a ceasefire agreement intended to permanently end the war between Israel and Hamas. However, there are no assurances regarding continued compliance with such agreement. While the conflict created and continues to create heightened security concerns, disruptions to business operations, and economic instability within Israel, the ceasefire may contribute to improved regional stability. However, the security situation remains fluid and any renewed military actions, restrictions, or government-imposed measures could adversely affect the Company&#8217;s business, operations and financial condition. The Company&#8217;s facilities are deemed an &#8220;essential enterprise&#8221; which means it operates or can be operated for the purposes of state defense or public security or for the maintenance of essential supplies or services, allowing the Company to maintain operations during emergencies. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss. As of the issuance of these financial statements, the impact of the military action has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of September&#160;30, 2025, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;) on March&#160;17, 2025. The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Net earnings (loss) per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of Common Stock outstanding for each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the Company had the option to settle such notes may be settled wholly or partly in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">e.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;">Recently issued accounting pronouncements, not yet adopted</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company expects the adoption of this standard to result in expanded disclosures in its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2024, the FASB issued ASU&#160;2024-03 &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures<span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">In July 2025, the FASB issued ASU 2025-05,&#160;Financial Instruments - Credit Losses&#160;(Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This amendment introduces a practical expedient for the application of the current expected credit loss (CECL) model to current accounts receivable and contract assets.&#160;The </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">amendments will be effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods, on a prospective basis, with early adoption permitted. Based on the Company&#8217;s evaluation of this guidance, no material impact is expected on its consolidated financial statement disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;2&#160;- INVENTORIES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at September&#160;30, 2025 and December&#160;31, 2024 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>FAIR VALUE MEASUREMENT</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">NOTE&#160;3&#160;&#8211; FAIR VALUE MEASUREMENT</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The fair value of the financial instruments included in the working capital of the Company is identical or close to their carrying value.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">OPERATING LEASES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 4 &#8211; OPERATING LEASES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company is a party to several lease agreements for its facilities that included varying lease periods and options for extensions. The Company is currently in the second option period for each of the three leases, which periods are not uniform. In the three months ended September&#160;30, 2025, the Company amended all of the facility leases, collectively, to provide that the third option period for each lease will end on December&#160;31, 2031 and will be associated with a unform rent increase equal to 7.5%. Thereafter, each lease will extend automatically, on an individual basis, for up to four additional five-year periods unless the Company provides the lessor with six months&#8217; advance notice that it does not intend that any individual option extension become effective. Each option to renew a lease in each of the four option periods shall include a rent increase equal to 5% of the rent payable for the applicable previous option period. Prior to the amendment, the options to extend the leases were associated with increases of either 7.5% or 10%. The Company expects to exercise the options in future periods. As of September&#160;30, 2025, the Company provided bank guarantees of approximately $0.6&#160;million, in the aggregate, to secure the fulfillment of its obligations under the lease agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company adjusted the operating lease right of use assets by $3.1&#160;million reflecting the amount of remeasurement of the lease liability using a new discount rate at the amendment date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company is a party to several three-year leases for vehicles which are regularly amended as new vehicles are leased.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The following table sets forth data regarding the Company&#8217;s operating leases for the three and nine months ended September&#160;30, 2024 and 2025:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:28.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:29.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">%</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The following table sets forth a maturity analysis of the Company&#8217;s operating lease liabilities as of September&#160;30, 2025:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#009999;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2025</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">First year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,397</p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Second year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141</p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Third year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,074</p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fourth year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,040</p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fifth year and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,273</p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,925</p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,748</p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,177</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCK TRANSACTIONS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 5 &#8211; STOCK TRANSACTIONS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the nine months ended September&#160;30, 2025, the Company issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">908,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2.1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from such exercises. All such exercises were effected during the first quarter of 2025 and all unexercised warrants expired on March&#160;11, 2025. Accordingly, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">as of March&#160;12, 2025, </span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">no</span><span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> warrants remained outstanding</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the nine months ended September&#160;30, 2025, the Company sold, in the aggregate, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2,775,215</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock under the Sales Agreement. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company generated </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">gross proceeds equal to approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$7.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in connection with such sales (issuance costs were </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million). All such sales were effected during the first and second quarters of 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the nine months ended September&#160;30, 2025, the Company issued, in the aggregate, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">248,625</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock in connection with the exercise of options to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">248,625</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock by certain current and former employees of the Company. The Company received cash proceeds equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.2</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million in connection with such exercises. All such exercises were effected during the third quarter of 2025.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the three months ended September&#160;30, 2025, the Company granted, with the approval of the Company&#8217;s compensation committee, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10-year</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> options to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,448,990</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock, in the aggregate, to certain of the Company&#8217;s officers, directors, other employees and a consultant under the Company&#8217;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#8220;Plan&#8221;). The options generally vest over a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three-year</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> period in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;equal quarterly increments. Vesting of the options granted to executive officers is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the applicable dates of grant </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">using the Black-Scholes option-pricing model to be approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.5</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million using the following assumptions (weighted average): stock price equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.56</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, exercise price equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.56</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, dividend yield of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, expected volatility of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">73.64%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, risk-free interest rate of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3.9%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and expected life in years, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">5.75</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">e.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">During the three months ended September&#160;30, 2025, the Company granted, with the approval of the Company&#8217;s compensation committee, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">559,210</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of restricted Common Stock, in the aggregate, to certain of the Company&#8217;s officers, directors, other employees and a consultant under the Plan. The shares of restricted Common Stock generally vest over a </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three-year</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> period in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">12</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;equal quarterly increments, with </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">52,910</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of such shares of restricted Common Stock fully vested upon grant (September&#160;22, 2025). Vesting of restricted Common Stock granted to executive officers is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the restricted stock on the applicable dates of grant to be approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.9</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million using stock prices equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.64</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.89</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><div style="margin-top:10pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 6 &#8211; EARNINGS (LOSS) PER SHARE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted earnings (loss) per share attributable to common stockholders were calculated as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#160;&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,562)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,236</p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (503)</p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,562)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,733</p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,225,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,301,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,281,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,549,745</p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,667,323</p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of stock options and restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,532,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,225,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,301,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,814,564</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,217,068</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3pt 0pt 10pt 36pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include 11,288,007 shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock and warrants for the nine months ended September&#160;30, 2025 because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include 3,745,682 shares of Common Stock underlying outstanding stock options and unvested shares of restricted stock for the three months ended September&#160;30, 2025 because the effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Diluted earnings (loss) per share do not include 30,515,287 shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock, warrants and the 2024 Notes for the nine months ended September&#160;30, 2024, and 20,173,438 shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock and warrants for the three months ended September&#160;30, 2024, because the effect would be anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (TAX BENEFIT)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME (TAX BENEFIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME (TAX BENEFIT)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 7 &#8211; TAXES ON INCOME (TAX BENEFIT)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (175)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164</p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 443</p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income (tax benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (116)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 607</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The Company had an effective tax rate of (32)% for the nine months ended September&#160;30, 2025 compared to an effective tax rate of (13)% for the nine months ended September&#160;30, 2024. For the nine months ended September&#160;30, 2025, the difference between the Company&#8217;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of forecasted profits derived primarily from U.S.&#160;taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act of 2017 (the &#8220;TCJA&#8221;), which was enacted in December 2017.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">On July&#160;4, 2025, tax reform legislation was enacted in the United States through the passage of H.R.1, One Big Beautiful Bill Act (&#8220;HR1&#8221;), which includes significant corporate tax changes, including a restoration of the current deductibility for domestic research expenditures beginning in 2025, with transition options for previously capitalized amounts.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 8 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SEGMENT INFORMATION</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company operates in Israel as a </span><span style="-sec-ix-hidden:Hidden_QJxRIWVBeUCE75e_V0YVVg;"><span style="-sec-ix-hidden:Hidden_bTovpeYB_EG_cx9KDkApfQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">single</span></span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> operating segment. The Company&#8217;s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Segment information:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from customers</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,959</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee salaries and related expenses</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,502</p></td><td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,091</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,853</p></td><td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,734</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-contractors expense</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,348</p></td><td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,413</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,886</p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,649</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,021</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (817)</p></td><td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (970)</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (289)</p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (212)</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,078</p></td><td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 970</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 372</p></td><td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 329</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment expenses*</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,343</p></td><td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,818</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,790</p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,356</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income (loss) before taxes on income</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (832)</p></td><td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,162)</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,239</p></td><td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,843</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxes on income (tax benefit)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (116)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 607</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net income (loss)</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,562)</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,236</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;">* Other expenses included in net income includes raw materials, rent and utilities and others.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Gaucher disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer (Ireland)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,430</p></td></tr><tr><td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiocruz (Brazil)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,048</p></td></tr><tr><td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Fabry disease:</i></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi (Italy)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,361</p></td></tr><tr><td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">43,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">34,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">17,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">17,839</p></td></tr><tr><td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">120</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">d.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Long lived assets are located in Israel.</span></td></tr></table><div style="margin-top:10pt;"></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 9 &#8211; </b><b style="font-weight:bold;background:#ffffff;">SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><b style="font-weight:bold;">Balance sheets:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,343</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,811</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,568</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,080</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,476</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable to customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,056</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,588</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">NOTE 10 &#8211; SUBSEQUENT EVENTS</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since the end of the quarter ended September&#160;30, 2025 and through the issuance of these financial statements, the Company collected approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$3.0</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from sales to Fiocruz (Brazil), approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$9.9</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from sales to Chiesi and </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.4</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">&#160;million from sales to Pfizer.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since the end of the quarter ended September&#160;30, 2025, the Company issued, in the aggregate, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">79,856</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock in connection with the exercise of options to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">79,856</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> shares of Common Stock by a former employee and a current employee of the Company. The Company received cash proceeds equal to approximately $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">94,200</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in connection with such exercise.</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 2,355<span></span>
</td>
<td class="nump">$ 3,236<span></span>
</td>
<td class="num">$ (1,100)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NatureOfOperationsPolicyTextBlock', window );">General</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">a.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">General</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#8220;Company&#8221;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#8217;s proprietary ProCellEx<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> protein expression system (&#8220;ProCellEx&#8221;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">&#174;</sup> (taliglucerase alfa) for the treatment of adult patients and children four years of age and greater with Gaucher disease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Elelyso was first approved by the U.S.&#160;Food and Drug Administration (&#8220;FDA&#8221;) in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others. In May 2023, both the European Commission (&#8220;EC&#8221;) and the FDA announced the approval of Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia, Singapore, Australia and Taiwan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company is committed to leveraging its record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company&#8217;s product pipeline currently includes, among other candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-115, the Company&#8217;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#8211; a chemically modified enzyme to treat uncontrolled gout; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">(2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">PRX-119, the Company&#8217;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases (neutrophil extracellular traps).</span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#8217;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">The Company, through its wholly-owned subsidiary, Protalix Ltd., has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#8220;Pfizer&#8221;), and in Brazil to Funda&#231;&#227;o Oswaldo Cruz (&#8220;Fiocruz&#8221;), an arm of the Brazilian Ministry of Health (the &#8220;Brazilian MoH&#8221;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#8220;Chiesi&#8221;) for the development and commercialization of Elfabrio through two exclusive global licensing and supply agreements. On October&#160;19, 2017, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi Ex-US Agreement&#8221;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#8220;Chiesi US Agreement&#8221;), with respect to the commercialization of Elfabrio in the United States.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">2015, Protalix Ltd. and Pfizer entered into an amended and restated exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;">On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#8220;Brazil Agreement&#8221;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#8217;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;">On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#8220;Sales Agreement&#8221;) with H.C.&#160;Wainwright &amp; Co., LLC, as the Company&#8217;s sales agent (the &#8220;Agent&#8221;). After giving effect to the sales under the Sales Agreement in January 2025, no shares of common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;), remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $20.0&#160;million. As of September&#160;30, 2025, approximately $15.7&#160;million in shares of Common Stock remain available to be sold under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;">Because the Company&#8217;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel. Since October 2023, following an infiltration by Hamas terrorists of Israel&#8217;s southern border from the Gaza Strip and attacks on civilian and military targets, Israel has been engaged in military activity on a number of fronts, including with the Hamas in the Gaza Strip, Hezbollah in Lebanon, Iran, the Houthis terrorist group that controls parts of Yemen, and others. Such clashes may escalate in the future into a greater regional conflict. On October&#160;9, 2025, Israel and Hamas entered into a ceasefire agreement intended to permanently end the war between Israel and Hamas. However, there are no assurances regarding continued compliance with such agreement. While the conflict created and continues to create heightened security concerns, disruptions to business operations, and economic instability within Israel, the ceasefire may contribute to improved regional stability. However, the security situation remains fluid and any renewed military actions, restrictions, or government-imposed measures could adversely affect the Company&#8217;s business, operations and financial condition. The Company&#8217;s facilities are deemed an &#8220;essential enterprise&#8221; which means it operates or can be operated for the purposes of state defense or public security or for the maintenance of essential supplies or services, allowing the Company to maintain operations during emergencies. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss. As of the issuance of these financial statements, the impact of the military action has not had an adverse effect on the Company&#8217;s operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;">The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of September&#160;30, 2025, are sufficient to satisfy the Company&#8217;s capital needs for at least 12&#160;months from the date that these financial statements are issued.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">b.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;">Basis of presentation</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;">These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#8220;Commission&#8221;) on March&#160;17, 2025. The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net earnings (loss) per share</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">c.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;">Net earnings (loss) per share</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of Common Stock outstanding for each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#8220;if-converted&#8221; method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Convertible notes</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">d.</p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;">Convertible notes</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#8220;2024 Notes&#8221;). The repayment of the convertible notes at maturity was financed entirely with available cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Prior to January&#160;1, 2024, the Company&#8217;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the Company had the option to settle such notes may be settled wholly or partly in cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting pronouncements, not yet adopted</a></td>
<td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="width:36pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;background:#ffffff;">e.</b></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><b style="font-weight:bold;">Recently issued accounting pronouncements, not yet adopted</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-09 &#8220;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#8221; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company expects the adoption of this standard to result in expanded disclosures in its consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">In November 2024, the FASB issued ASU&#160;2024-03 &#8220;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#8221; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures<span style="font-family:'Palatino Linotype';background:#ffffff;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">In July 2025, the FASB issued ASU 2025-05,&#160;Financial Instruments - Credit Losses&#160;(Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This amendment introduces a practical expedient for the application of the current expected credit loss (CECL) model to current accounts receivable and contract assets.&#160;The </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;">amendments will be effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods, on a prospective basis, with early adoption permitted. Based on the Company&#8217;s evaluation of this guidance, no material impact is expected on its consolidated financial statement disclosures.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NatureOfOperationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nature Of Operations Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NatureOfOperationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Inventories at September&#160;30, 2025 and December&#160;31, 2024 consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,983</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,255</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21,243</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The following table sets forth data regarding the Company&#8217;s operating leases for the three and nine months ended September&#160;30, 2024 and 2025:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:28.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:29.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:42.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating lease costs</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,195</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 476</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 420</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,338</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,207</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 457</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 413</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term (in years)</p></td><td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate</p></td><td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">%</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;">%</span></p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturity Analysis of Operating Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">The following table sets forth a maturity analysis of the Company&#8217;s operating lease liabilities as of September&#160;30, 2025:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:82.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">(<i style="font-style:italic;">U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="color:#009999;font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;2025</b></p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">First year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,397</p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Second year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,141</p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Third year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,074</p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fourth year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,040</p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fifth year and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,273</p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total undiscounted cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,925</p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,748</p></td></tr><tr><td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Present value of operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="color:#009999;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,177</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>EARNINGS (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earnings (Loss) per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;">Basic and diluted earnings (loss) per share attributable to common stockholders were calculated as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(In&#160;thousands,&#160;except&#160;share&#160;data)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><span style="font-family:'Aptos Narrow';">&#160;&#160;&#160;&#160;&#160;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,562)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,236</p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Add:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financial expenses of 2024 Notes*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (503)</p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net income (loss) for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,562)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,733</p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for basic calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,225,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,301,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,281,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,549,745</p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of 2024 Notes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,667,323</p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average dilutive effect of stock options and restricted stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,532,879</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average shares of Common Stock outstanding for diluted calculation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,225,112</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 73,301,091</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 80,814,564</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,217,068</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3pt 0pt 10pt 36pt;">* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (TAX BENEFIT) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME (TAX BENEFIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Taxes on Income</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"><span style="background:#ffffff;">The following table summarizes the Company&#8217;s taxes on income:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 91</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (175)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 164</p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred taxes on income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 177</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 59</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 443</p></td></tr><tr><td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total taxes on income (tax benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (116)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 607</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Schedule of Segment Information</a></td>
<td class="text"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Segment information:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:42.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from customers</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43,622</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 35,181</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 17,959</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less:</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Employee salaries and related expenses</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,502</p></td><td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,091</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,853</p></td><td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,734</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Sub-contractors expense</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,348</p></td><td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,413</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,886</p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,649</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest expense</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,021</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 260</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (817)</p></td><td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (970)</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (289)</p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (212)</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,078</p></td><td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 970</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 372</p></td><td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 329</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment expenses*</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,343</p></td><td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,818</p></td><td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,790</p></td><td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,356</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income (loss) before taxes on income</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (832)</p></td><td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,162)</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,239</p></td><td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,843</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:42.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Taxes on income (tax benefit)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (116)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 607</p></td></tr><tr><td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Segment net income (loss)</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,562)</p></td><td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,236</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;">* Other expenses included in net income includes raw materials, rent and utilities and others.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Disaggregation of Revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The following table summarizes the Company&#8217;s disaggregation of revenues:</span></td></tr></table><div style="margin-top:10pt;"></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Gaucher disease:</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Pfizer (Ireland)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">15,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">11,431</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,805</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">3,430</p></td></tr><tr><td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Fiocruz (Brazil)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,121</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">9,314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">6,105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">2,048</p></td></tr><tr><td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">Fabry disease:</i></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Chiesi (Italy)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,556</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14,075</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,361</p></td></tr><tr><td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total revenues from selling goods</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">43,108</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">34,820</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">17,673</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">17,839</p></td></tr><tr><td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues from license and R&amp;D services</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">514</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">361</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">178</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">120</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementalInformationAbstract', window );"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock', window );">Schedule of Supplemental Information of Balance Sheets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(U.S. dollars in thousands)</i></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2025</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accounts payable and accruals &#8211; other:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 745</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,343</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Provision for vacation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,209</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,811</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,126</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9,568</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Royalties payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 558</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,080</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,476</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payable to customer</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 920</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,056</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Property and equipment suppliers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 230</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 254</p></td></tr><tr><td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 15,173</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 19,588</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementalInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementalInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SupplementaryBalanceSheetsInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for supplemental balance sheets information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SupplementaryBalanceSheetsInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2015</div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>agreement </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 17, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2025 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfGlobalLicensingAndSupplyAgreements', window );">Number of global licensing and supply agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares remain for sale | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance', window );">Increase in aggregate gross sales price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance', window );">Shares remain available, total gross proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, Par or Stated Value Per Share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member', window );">2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember', window );">Amended Pfizer Agreement | Protalix Bio Therapeutics Incorporation | Brazil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_SignificantAccountingPoliciesLineItems', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage', window );">Collaborative arrangement revenues and expenses sharing percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CollaborativeArrangementRevenuesExpensesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement revenues and expense sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CollaborativeArrangementRevenuesExpensesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in gross sales price of shares available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfGlobalLicensingAndSupplyAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of global licensing and supply agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfGlobalLicensingAndSupplyAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_AmendedPfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=plx_ProtalixBioTherapeuticsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_BR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_BR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Schedule of Inventory) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 4,983<span></span>
</td>
<td class="nump">$ 4,549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in progress</a></td>
<td class="nump">5,355<span></span>
</td>
<td class="nump">11,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">10,917<span></span>
</td>
<td class="nump">5,449<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 21,255<span></span>
</td>
<td class="nump">$ 21,243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Schedule of Operating Leases) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">$ 420<span></span>
</td>
<td class="nump">$ 1,395<span></span>
</td>
<td class="nump">$ 1,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">$ 457<span></span>
</td>
<td class="nump">$ 413<span></span>
</td>
<td class="nump">$ 1,338<span></span>
</td>
<td class="nump">$ 1,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">22 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">22 years 7 months 6 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">13.40%<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
<td class="nump">13.40%<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorDisclosureAbstract', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">First year</a></td>
<td class="nump">$ 1,397<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Second year</a></td>
<td class="nump">1,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Third year</a></td>
<td class="nump">1,074<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Fourth year</a></td>
<td class="nump">1,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter', window );">Fifth year and thereafter</a></td>
<td class="nump">22,273<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted cash flows</a></td>
<td class="nump">26,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">18,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of operating lease liabilities</a></td>
<td class="nump">$ 8,177<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due Five fiscal year and after following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATING LEASES (Additional Information) (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>item </div>
<div>facility</div>
</th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Option to extend</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_NumberOfFacilitiesLeased', window );">Number of facilities leased | facility</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, term of agreement</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm', window );">Notice period for termination of lease agreement</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod', window );">Operating lease rent increase rate for renewal period</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments', window );">Percentage of change in operating lease monthly rental payments</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_BankGuarantee', window );">Bank guarantee</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_LesseeOperatingLeaseRightOfUseAssetAdjustment', window );">ROU asset adjustment</a></td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_LesseeOperatingLeaseLiabilityAdjustment', window );">Lease liability adjustment</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember', window );">Vehicles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease, term of agreement</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments', window );">Percentage of change in operating lease monthly rental payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_DisclosureOfLeasesOperatingLineItems', window );"><strong>OPERATING LEASES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions', window );">Operating lease, renewable term | item</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments', window );">Percentage of change in operating lease monthly rental payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_BankGuarantee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Bank guarantees to secure the fulfillment of obligations under an agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_BankGuarantee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_DisclosureOfLeasesOperatingLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of Leases Operating</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_DisclosureOfLeasesOperatingLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LesseeOperatingLeaseLiabilityAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to the present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_LesseeOperatingLeaseLiabilityAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease, Number Of Renewal Term Extensions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent increase rate applied at the start of each additional option renewal period after the third option period ends under lease agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LesseeOperatingLeaseRightOfUseAssetAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_LesseeOperatingLeaseRightOfUseAssetAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of advance notice to be given by the company if it intends to terminate lease before an automatic extension is to take effect.
In 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_NumberOfFacilitiesLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of facilities leased during the period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_NumberOfFacilitiesLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of Change in Operating Lease Monthly Rental Payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_VehiclesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK TRANSACTIONS (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 12, 2025 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Term of award</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options to purchase shares</a></td>
<td class="nump">1,448,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments', window );">Number of vesting installments on a quarterly basis | installment</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue', window );">Aggregate fair value of the options | $</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (as percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as percentage)</a></td>
<td class="nump">73.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk -free interest rate (in dollars per share)</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (Years)</a></td>
<td class="text">5 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember', window );">Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,775,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_GrossProceedsFromIssuanceOfCommonStock', window );">Gross stock issuance proceeds | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Exercise of warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants and rights outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting Period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments', window );">Number of vesting installments on a quarterly basis | installment</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">559,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">52,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue', window );">Aggregate fair value of the restricted stock | $</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Share Based Compensation Award Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="nump">$ 1.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock | Share Based Compensation Award Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>STOCK TRANSACTIONS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from stock options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of equity instruments other than options  granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of quarterly increments during which the equity instruments will be vested under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=plx_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 2,355<span></span>
</td>
<td class="nump">$ 3,236<span></span>
</td>
<td class="num">$ (1,100)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecurities', window );">Financial expenses of 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(503)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income (loss) for diluted calculation</a></td>
<td class="nump">$ 2,355<span></span>
</td>
<td class="nump">$ 2,733<span></span>
</td>
<td class="num">$ (1,100)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of Common Stock outstanding for basic calculation</a></td>
<td class="nump">79,281,685<span></span>
</td>
<td class="nump">73,549,745<span></span>
</td>
<td class="nump">78,225,112<span></span>
</td>
<td class="nump">73,301,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities', window );">Weighted average dilutive effect of 2024 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,667,323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Weighted average dilutive effect of stock options and restricted stock</a></td>
<td class="nump">1,532,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of Common Stock outstanding for diluted calculation</a></td>
<td class="nump">80,814,564<span></span>
</td>
<td class="nump">81,217,068<span></span>
</td>
<td class="nump">78,225,112<span></span>
</td>
<td class="nump">73,301,091<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember', window );">Outstanding Stock Options and Unvested Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings (loss) per share, amount</a></td>
<td class="nump">3,745,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember', window );">Outstanding Stock Options, Unvested Restricted Stock and Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings (loss) per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,173,438<span></span>
</td>
<td class="nump">11,288,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember', window );">Outstanding Stock Options, Unvested Restricted Stock, Warrants and Convertible Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings (loss) per share, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,515,287<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-42<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME (TAX BENEFIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current taxes on income</a></td>
<td class="num">$ (175)<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
<td class="nump">$ 164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes on income</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total taxes on income (tax benefit)</a></td>
<td class="num">$ (116)<span></span>
</td>
<td class="nump">$ 607<span></span>
</td>
<td class="nump">$ 268<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>TAXES ON INCOME (TAX BENEFIT) (Additional Information) (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>TAXES ON INCOME (TAX BENEFIT)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate (as a percent)</a></td>
<td class="num">(32.00%)<span></span>
</td>
<td class="num">(13.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Schedule of Segment Information) (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues from customers</a></td>
<td class="nump">$ 17,851<span></span>
</td>
<td class="nump">$ 17,959<span></span>
</td>
<td class="nump">$ 43,622<span></span>
</td>
<td class="nump">$ 35,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE TAXES ON INCOME</a></td>
<td class="nump">2,239<span></span>
</td>
<td class="nump">3,843<span></span>
</td>
<td class="num">(832)<span></span>
</td>
<td class="num">(3,162)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income (tax benefit)</a></td>
<td class="num">(116)<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="nump">$ 2,355<span></span>
</td>
<td class="nump">$ 3,236<span></span>
</td>
<td class="num">$ (1,100)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemCompositionDescription', window );">Segment reporting description</a></td>
<td class="text">Other expenses included in net income includes raw materials, rent and utilities and others.<span></span>
</td>
<td class="text">Other expenses included in net income includes raw materials, rent and utilities and others.<span></span>
</td>
<td class="text">Other expenses included in net income includes raw materials, rent and utilities and others.<span></span>
</td>
<td class="text">Other expenses included in net income includes raw materials, rent and utilities and others.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=plx_SingleReportableSegmentMember', window );">Single operating segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues from customers</a></td>
<td class="nump">$ 17,851<span></span>
</td>
<td class="nump">$ 17,959<span></span>
</td>
<td class="nump">$ 43,622<span></span>
</td>
<td class="nump">$ 35,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Employee salaries and related expenses</a></td>
<td class="nump">5,853<span></span>
</td>
<td class="nump">4,734<span></span>
</td>
<td class="nump">16,502<span></span>
</td>
<td class="nump">15,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfessionalAndContractServicesExpense', window );">Sub-contractors expense</a></td>
<td class="nump">1,886<span></span>
</td>
<td class="nump">1,649<span></span>
</td>
<td class="nump">9,348<span></span>
</td>
<td class="nump">6,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(289)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
<td class="num">(817)<span></span>
</td>
<td class="num">(970)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">372<span></span>
</td>
<td class="nump">329<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment expenses</a></td>
<td class="nump">7,790<span></span>
</td>
<td class="nump">7,356<span></span>
</td>
<td class="nump">18,343<span></span>
</td>
<td class="nump">15,818<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE TAXES ON INCOME</a></td>
<td class="nump">2,239<span></span>
</td>
<td class="nump">3,843<span></span>
</td>
<td class="num">(832)<span></span>
</td>
<td class="num">(3,162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Taxes on income (tax benefit)</a></td>
<td class="num">(116)<span></span>
</td>
<td class="nump">607<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="nump">$ 2,355<span></span>
</td>
<td class="nump">$ 3,236<span></span>
</td>
<td class="num">$ (1,100)<span></span>
</td>
<td class="num">$ (3,562)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfessionalAndContractServicesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfessionalAndContractServicesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemCompositionDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of composition of other segment item not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemCompositionDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=plx_SingleReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=plx_SingleReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 17,851<span></span>
</td>
<td class="nump">$ 17,959<span></span>
</td>
<td class="nump">$ 43,622<span></span>
</td>
<td class="nump">$ 35,181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">17,673<span></span>
</td>
<td class="nump">17,839<span></span>
</td>
<td class="nump">43,108<span></span>
</td>
<td class="nump">34,820<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember', window );">LICENSE AND R&amp;D SERVICES</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">178<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">361<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_PfizerMember', window );">Pfizer | GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">2,805<span></span>
</td>
<td class="nump">3,430<span></span>
</td>
<td class="nump">15,431<span></span>
</td>
<td class="nump">11,431<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_FiocruzMember', window );">Fiocruz | GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">6,105<span></span>
</td>
<td class="nump">2,048<span></span>
</td>
<td class="nump">9,121<span></span>
</td>
<td class="nump">9,314<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=plx_ChiesiMember', window );">Chiesi | GOODS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 8,763<span></span>
</td>
<td class="nump">$ 12,361<span></span>
</td>
<td class="nump">$ 18,556<span></span>
</td>
<td class="nump">$ 14,075<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_FiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_FiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=plx_ChiesiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=plx_ChiesiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract', window );"><strong>Accounts payable and accruals - other:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">$ 745<span></span>
</td>
<td class="nump">$ 1,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Provision for vacation</a></td>
<td class="nump">2,209<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">8,126<span></span>
</td>
<td class="nump">9,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties payable</a></td>
<td class="nump">558<span></span>
</td>
<td class="nump">1,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income tax payable</a></td>
<td class="nump">2,385<span></span>
</td>
<td class="nump">3,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_PayableToCustomerCurrent', window );">Payable to customer</a></td>
<td class="nump">920<span></span>
</td>
<td class="nump">2,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent', window );">Property and equipment suppliers</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent', window );">Accounts payable and accruals - other</a></td>
<td class="nump">$ 15,173<span></span>
</td>
<td class="nump">$ 19,588<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_plx_PayableToCustomerCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable to customers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">plx_PayableToCustomerCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>plx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483070/710-10-25-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 13, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">248,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options</a></td>
<td class="nump">79,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from stock options exercised</a></td>
<td class="nump">$ 94,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Total proceeds from sale of products</a></td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Fiocruz (Brazil)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Total proceeds from sale of products</a></td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Chiesi Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>SUBSEQUENT EVENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCustomers', window );">Total proceeds from sale of products</a></td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash receipts from customers during the current period which are usually for sales of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_PfizerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=plx_ChiesiAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>93</ContextCount>
  <ElementCount>210</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995200090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>995210201 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>995210301 - Disclosure - FAIR VALUE MEASUREMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureFairValueMeasurement</Role>
      <ShortName>FAIR VALUE MEASUREMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>995210401 - Disclosure - OPERATING LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeases</Role>
      <ShortName>OPERATING LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>995210501 - Disclosure - STOCK TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactions</Role>
      <ShortName>STOCK TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>995210601 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShare</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>995210701 - Disclosure - TAXES ON INCOME (TAX BENEFIT)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefit</Role>
      <ShortName>TAXES ON INCOME (TAX BENEFIT)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>995210801 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformation</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>995210901 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>995211001 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>99930203 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventories</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>99930403 - Disclosure - OPERATING LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesTables</Role>
      <ShortName>OPERATING LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeases</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>99930603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShareTables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureEarningsLossPerShare</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>99930703 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables</Role>
      <ShortName>TAXES ON INCOME (TAX BENEFIT) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefit</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>99930803 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformationTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSegmentInformation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>99930903 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails</Role>
      <ShortName>INVENTORIES (Schedule of Inventory) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureInventoriesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>99940401 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails</Role>
      <ShortName>OPERATING LEASES (Schedule of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>99940402 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails</Role>
      <ShortName>OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>99940403 - Disclosure - OPERATING LEASES (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails</Role>
      <ShortName>OPERATING LEASES (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureOperatingLeasesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>99940501 - Disclosure - STOCK TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureStockTransactionsDetails</Role>
      <ShortName>STOCK TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureStockTransactions</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>99940601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureEarningsLossPerShareTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>99940701 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails</Role>
      <ShortName>TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>99940702 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails</Role>
      <ShortName>TAXES ON INCOME (TAX BENEFIT) (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>99940801 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails</Role>
      <ShortName>SEGMENT INFORMATION (Schedule of Segment Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>99940802 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails</Role>
      <ShortName>SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>99940901 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails</Role>
      <ShortName>SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="plx-20250930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>99941001 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.protalix.com/role/DisclosureSubsequentEventsDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.protalix.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>38</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>plx-20250930.xsd</File>
    <File>plx-20250930_cal.xml</File>
    <File>plx-20250930_def.xml</File>
    <File>plx-20250930_lab.xml</File>
    <File>plx-20250930_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="plx-20250930x10q.htm">plx-20250930x10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>plx-20250930x10q005.jpg</File>
    <File>plx-20250930x10q006.jpg</File>
    <File>plx-20250930x10q007.jpg</File>
    <File>plx-20250930x10q008.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="415">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>61
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "plx-20250930x10q.htm": {
   "nsprefix": "plx",
   "nsuri": "http://www.protalix.com/20250930",
   "dts": {
    "schema": {
     "local": [
      "plx-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-sub-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "plx-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "plx-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "plx-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plx-20250930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "plx-20250930x10q.htm"
     ]
    }
   },
   "keyStandard": 176,
   "keyCustom": 34,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 17,
   "memberCustom": 14,
   "hidden": {
    "total": 9,
    "http://fasb.org/us-gaap/2025": 4,
    "http://xbrl.sec.gov/dei/2025": 5
   },
   "contextCount": 93,
   "entityCount": 1,
   "segmentCount": 31,
   "elementCount": 422,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 415,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4
   },
   "report": {
    "R1": {
     "role": "http://www.protalix.com/role/DocumentDocumentAndEntityInformation",
     "longName": "995200090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "995200100 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
     "longName": "995200200 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "us-gaap:CostOfRevenue",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "995200300 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3QCYXsKzjkqrL_Tqx7sWEg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3QCYXsKzjkqrL_Tqx7sWEg",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
     "longName": "995200305 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "link:footnote",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "995200400 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies",
     "longName": "995210101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.protalix.com/role/DisclosureInventories",
     "longName": "995210201 - Disclosure - INVENTORIES",
     "shortName": "INVENTORIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.protalix.com/role/DisclosureFairValueMeasurement",
     "longName": "995210301 - Disclosure - FAIR VALUE MEASUREMENT",
     "shortName": "FAIR VALUE MEASUREMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeases",
     "longName": "995210401 - Disclosure - OPERATING LEASES",
     "shortName": "OPERATING LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactions",
     "longName": "995210501 - Disclosure - STOCK TRANSACTIONS",
     "shortName": "STOCK TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShare",
     "longName": "995210601 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefit",
     "longName": "995210701 - Disclosure - TAXES ON INCOME (TAX BENEFIT)",
     "shortName": "TAXES ON INCOME (TAX BENEFIT)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformation",
     "longName": "995210801 - Disclosure - SEGMENT INFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation",
     "longName": "995210901 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEvents",
     "longName": "995211001 - Disclosure - SUBSEQUENT EVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R18": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies",
     "longName": "99920102 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "plx:NatureOfOperationsPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesTables",
     "longName": "99930203 - Disclosure - INVENTORIES (Tables)",
     "shortName": "INVENTORIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesTables",
     "longName": "99930403 - Disclosure - OPERATING LEASES (Tables)",
     "shortName": "OPERATING LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShareTables",
     "longName": "99930603 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables",
     "longName": "99930703 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Tables)",
     "shortName": "TAXES ON INCOME (TAX BENEFIT) (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformationTables",
     "longName": "99930803 - Disclosure - SEGMENT INFORMATION (Tables)",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables",
     "longName": "99930903 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
     "longName": "99940101 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA",
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "unitRef": "Unit_Standard_agreement_FXubWDLurk-D3rwvgsKCMg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA",
      "name": "plx:NumberOfGlobalLicensingAndSupplyAgreements",
      "unitRef": "Unit_Standard_agreement_FXubWDLurk-D3rwvgsKCMg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "plx:NatureOfOperationsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
     "longName": "99940201 - Disclosure - INVENTORIES (Schedule of Inventory) (Details)",
     "shortName": "INVENTORIES (Schedule of Inventory) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:InventoryDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails",
     "longName": "99940401 - Disclosure - OPERATING LEASES (Schedule of Operating Leases) (Details)",
     "shortName": "OPERATING LEASES (Schedule of Operating Leases) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails",
     "longName": "99940402 - Disclosure - OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)",
     "shortName": "OPERATING LEASES (Schedule of Maturity Analysis of Operating Leases) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails",
     "longName": "99940403 - Disclosure - OPERATING LEASES (Additional Information) (Details)",
     "shortName": "OPERATING LEASES (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:LesseeOperatingLeaseOptionToExtend",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
     "longName": "99940501 - Disclosure - STOCK TRANSACTIONS (Details)",
     "shortName": "STOCK TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
     "longName": "99940601 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ",
      "name": "us-gaap:DilutiveSecurities",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails",
     "longName": "99940701 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details)",
     "shortName": "TAXES ON INCOME (TAX BENEFIT) (Summary of Taxes on Income) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "us-gaap:CurrentIncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails",
     "longName": "99940702 - Disclosure - TAXES ON INCOME (TAX BENEFIT) (Additional Information) (Details)",
     "shortName": "TAXES ON INCOME (TAX BENEFIT) (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
     "longName": "99940801 - Disclosure - SEGMENT INFORMATION (Schedule of Segment Information) (Details)",
     "shortName": "SEGMENT INFORMATION (Schedule of Segment Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "us-gaap:SegmentReportingOtherItemCompositionDescription",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SegmentReportingOtherItemCompositionDescription",
       "us-gaap:SegmentReportingOtherItemCompositionDescription",
       "us-gaap:SegmentReportingOtherItemCompositionDescription",
       "p",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
     "longName": "99940802 - Disclosure - SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)",
     "shortName": "SEGMENT INFORMATION (Schedule of Disaggregation of Revenues) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_tGVlUvMwNESS1QuVEsIxCg",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
     "longName": "99940901 - Disclosure - SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "shortName": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION (Accounts Payable and Accruals - Other) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "plx:SupplementaryBalanceSheetsInformationTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
     "longName": "99941001 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CrvjSyzu0kePIviFTWVKvA",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_71PZO8VDYEeOr9oCkh_Hog",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "unitRef": "Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "plx-20250930x10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingStandardsUpdate202006Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingStandardsUpdate202006Member",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update 2020-06 [Member]",
        "terseLabel": "ASU 2020-06",
        "documentation": "Accounting Standards Update 2020-06 Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities, Current [Abstract]",
        "terseLabel": "Accounts payable and accruals:",
        "verboseLabel": "Accounts payable and accruals - other:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "AccountsPayableAndAccruedLiabilitiesOtherCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of other obligations incurred through that date and due within one year (or the operating cycle, if longer).",
        "label": "Accounts Payable and Accrued Liabilities, Other, Current",
        "terseLabel": "Other",
        "totalLabel": "Accounts payable and accruals - other"
       }
      }
     },
     "auth_ref": []
    },
    "plx_AccountsPayablePropertyAndEquipmentSuppliersCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "AccountsPayablePropertyAndEquipmentSuppliersCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable to property and equipment suppliers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Property And Equipment Suppliers, Current",
        "terseLabel": "Property and equipment suppliers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableTradeCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r36"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r898"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Royalties, Current",
        "terseLabel": "Royalties payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r653"
     ]
    },
    "us-gaap_AccruedVacationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedVacationCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Vacation, Current",
        "terseLabel": "Provision for vacation",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r38"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "auth_ref": [
      "r775"
     ]
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r886",
      "r887",
      "r888",
      "r889",
      "r939",
      "r993"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r121",
      "r122",
      "r123",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r154",
      "r217",
      "r218",
      "r221",
      "r222",
      "r223",
      "r224",
      "r236",
      "r237",
      "r239",
      "r271",
      "r272",
      "r273",
      "r274",
      "r334",
      "r335",
      "r336",
      "r337",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r429",
      "r430",
      "r439",
      "r440",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation related to stock options",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r757",
      "r767",
      "r799"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "auth_ref": [
      "r750",
      "r760",
      "r770",
      "r802"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Pension Adjustments Service Cost [Member]",
        "terseLabel": "Aggregate Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r771",
      "r795",
      "r803",
      "r807",
      "r815"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "plx_AmendedPfizerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "AmendedPfizerAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Pfizer Agreement [Member]",
        "label": "Amended Pfizer Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings (loss) per share, amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r84",
      "r104",
      "r131",
      "r132",
      "r133",
      "r178",
      "r187",
      "r205",
      "r209",
      "r220",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r385",
      "r389",
      "r431",
      "r506",
      "r507",
      "r512",
      "r591",
      "r672",
      "r673",
      "r684",
      "r708",
      "r725",
      "r726",
      "r738",
      "r906",
      "r907",
      "r950"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r110",
      "r131",
      "r132",
      "r133",
      "r220",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r385",
      "r389",
      "r431",
      "r708",
      "r906",
      "r907",
      "r950"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r810"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]",
        "terseLabel": "Award Timing Disclosures"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "country_BR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "BR",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "BRAZIL",
        "terseLabel": "Brazil"
       }
      }
     },
     "auth_ref": []
    },
    "plx_BankGuarantee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "BankGuarantee",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank guarantees to secure the fulfillment of obligations under an agreement.",
        "label": "Bank Guarantee",
        "terseLabel": "Bank guarantee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "verboseLabel": "Purchase of property and equipment",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r16"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r103",
      "r651"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r61",
      "r130"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r61"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChangeInOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "ChangeInOperatingLeaseRightOfUseAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Change in Operating Lease Right Of use Assets.",
        "label": "Change in Operating Lease Right Of use Assets",
        "negatedLabel": "Changes in operating lease right of use assets, net"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "plx_ChiesiAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "ChiesiAgreementsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chiesi Agreements [Member]",
        "label": "Chiesi Agreements",
        "terseLabel": "Chiesi Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ChiesiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "ChiesiMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except Brazil and Italy",
        "label": "Chiesi"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]",
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]",
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r781"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "terseLabel": "STOCK TRANSACTIONS",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107",
      "r180",
      "r278",
      "r283",
      "r284",
      "r285",
      "r287",
      "r290",
      "r295",
      "r297",
      "r391",
      "r557",
      "r558",
      "r559",
      "r560",
      "r685",
      "r825",
      "r878",
      "r880"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants and rights outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "plx_CollaborativeArrangementRevenuesExpensesSharingPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "CollaborativeArrangementRevenuesExpensesSharingPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement revenues and expense sharing percentage.",
        "label": "Collaborative Arrangement Revenues Expenses Sharing Percentage",
        "verboseLabel": "Collaborative arrangement revenues and expenses sharing percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "COMMITMENTS",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r77",
      "r513",
      "r578"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares remain for sale",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "plx_CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in gross sales price of shares available for future issuance.",
        "label": "Common Stock, Increase in Gross Sales Price of Shares Reserved for Future Issuance",
        "terseLabel": "Increase in aggregate gross sales price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r730",
      "r732",
      "r733",
      "r734",
      "r735",
      "r886",
      "r887",
      "r889",
      "r939",
      "r990",
      "r993"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common Stock, Par or Stated Value Per Share (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r579"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "plx_CommonStockValueOfCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "CommonStockValueOfCapitalSharesReservedForFutureIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of common shares reserved for future issuance.",
        "label": "Common Stock, Value of Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares remain available, total gross proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "auth_ref": [
      "r791"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "auth_ref": [
      "r790"
     ]
    },
    "plx_ConvertibleNotesDue2021And2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "ConvertibleNotesDue2021And2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to convertible notes due 2021 and 2024.",
        "label": "Notes 2021 and 2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Revenue",
        "negatedLabel": "COST OF GOODS SOLD",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r131",
      "r132",
      "r133",
      "r220",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r431",
      "r672",
      "r906"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Adjustment"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r139",
      "r147",
      "r154",
      "r221",
      "r224",
      "r237",
      "r353",
      "r354",
      "r367",
      "r369",
      "r394",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r410",
      "r413",
      "r415",
      "r416",
      "r459"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r139",
      "r147",
      "r154",
      "r221",
      "r224",
      "r237",
      "r353",
      "r354",
      "r367",
      "r369",
      "r394",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r410",
      "r413",
      "r415",
      "r416",
      "r459"
     ]
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "auth_ref": [
      "r90",
      "r139",
      "r147",
      "r154",
      "r221",
      "r224",
      "r237",
      "r353",
      "r354",
      "r367",
      "r369",
      "r394",
      "r396",
      "r397",
      "r399",
      "r400",
      "r401",
      "r410",
      "r413",
      "r415",
      "r416",
      "r459"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit)",
        "terseLabel": "Current taxes on income",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r878",
      "r884"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r37",
      "r38",
      "r75",
      "r76",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r706",
      "r878",
      "r879",
      "r881",
      "r885",
      "r900",
      "r901",
      "r902",
      "r945",
      "r946",
      "r959"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "verboseLabel": "Interest rate (as a percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r256"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r706",
      "r878",
      "r879",
      "r881",
      "r885",
      "r900",
      "r901",
      "r902",
      "r945",
      "r946",
      "r959"
     ]
    },
    "us-gaap_DebtPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Convertible notes",
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income tax asset",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r342"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Changes in deferred income tax asset",
        "verboseLabel": "Deferred taxes on income",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r86",
      "r878",
      "r884"
     ]
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Funds in respect of employee rights upon retirement",
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r299",
      "r300",
      "r301",
      "r303",
      "r590",
      "r690",
      "r960"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation",
        "verboseLabel": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r26",
      "r120",
      "r657",
      "r658",
      "r660",
      "r662"
     ]
    },
    "us-gaap_DilutiveSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DilutiveSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share",
        "terseLabel": "Financial expenses of 2024 Notes",
        "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "plx_DisclosureOfLeasesOperatingLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "DisclosureOfLeasesOperatingLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of Leases Operating",
        "label": "Disclosure of Leases Operating [Line Items]",
        "terseLabel": "OPERATING LEASES"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r742"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r774"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]",
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year"
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - BASIC (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r117",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r156",
      "r158",
      "r170",
      "r171",
      "r172",
      "r177",
      "r274",
      "r336",
      "r371",
      "r382",
      "r416",
      "r417",
      "r505",
      "r520",
      "r664"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "EARNINGS (LOSS) PER SHARE OF COMMON STOCK - DILUTED (in dollars per share)",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r117",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r158",
      "r170",
      "r171",
      "r172",
      "r177",
      "r274",
      "r336",
      "r371",
      "r382",
      "r416",
      "r417",
      "r505",
      "r520",
      "r664"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net earnings (loss) per share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r19",
      "r174"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r173",
      "r175",
      "r176"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "terseLabel": "EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate (as a percent)",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r694"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory income tax rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r134",
      "r344",
      "r358",
      "r694"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related expenses",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Options",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Employee Stock Option",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Entities [Member]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r740"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Footnote [Text Block]",
        "terseLabel": "Equity Awards Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]",
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Awards Adjustments [Member]",
        "terseLabel": "Equity Awards Adjustments"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]",
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table"
       }
      }
     },
     "auth_ref": [
      "r820"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r90",
      "r97",
      "r98",
      "r113",
      "r114",
      "r115",
      "r136",
      "r137",
      "r138",
      "r141",
      "r149",
      "r151",
      "r153",
      "r179",
      "r221",
      "r224",
      "r237",
      "r273",
      "r298",
      "r336",
      "r353",
      "r354",
      "r367",
      "r368",
      "r369",
      "r372",
      "r381",
      "r382",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r415",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r442",
      "r461",
      "r519",
      "r544",
      "r545",
      "r546",
      "r563",
      "r616"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "auth_ref": [
      "r789"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "auth_ref": [
      "r747",
      "r757",
      "r767",
      "r799"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r754",
      "r764",
      "r796"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FAIR VALUE MEASUREMENT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureFairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "FAIR VALUE MEASUREMENT",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r418",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r503",
      "r701",
      "r703"
     ]
    },
    "plx_FiocruzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "FiocruzMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fiocruz"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossUnrealized",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrealized Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "Financial expenses, net",
        "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r598",
      "r736",
      "r942",
      "r943",
      "r992"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r771",
      "r803"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r771",
      "r803"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r771",
      "r803"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r771",
      "r803"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r771",
      "r803"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]",
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year"
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "plx_GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) on amounts funded in respect of employee rights upon retirement.",
        "label": "Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement",
        "negatedLabel": "Gain on amounts funded in respect of employee rights upon retirement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Gain on sale of fixed assets",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "plx_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross cash inflow from the additional capital contribution to the entity.",
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "terseLabel": "Gross stock issuance proceeds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "INCOME (LOSS) BEFORE TAXES ON INCOME",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r79",
      "r83",
      "r506",
      "r508",
      "r516",
      "r659",
      "r661",
      "r663",
      "r667",
      "r672",
      "r892",
      "r894",
      "r895",
      "r896",
      "r897"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "TAXES ON INCOME (TAX BENEFIT)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefit"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES ON INCOME (TAX BENEFIT)",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r134",
      "r340",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r359",
      "r361",
      "r362",
      "r363",
      "r511",
      "r555",
      "r561",
      "r694"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitSummaryOfTaxesOnIncomeDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Taxes on income (tax benefit)",
        "totalLabel": "Total taxes on income (tax benefit)",
        "verboseLabel": "TAXES ON INCOME (TAX BENEFIT)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r87",
      "r131",
      "r152",
      "r153",
      "r178",
      "r195",
      "r209",
      "r343",
      "r344",
      "r360",
      "r521",
      "r659",
      "r661",
      "r663",
      "r694"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Tax paid",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r129",
      "r350",
      "r351"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Decrease in accounts payable and accruals",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Decrease (Increase) in accounts receivable-trade and other assets",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Decrease (increase) in inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToConversionOfDebtSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToConversionOfDebtSecurities",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Conversion of Debt Securities",
        "terseLabel": "Weighted average dilutive effect of 2024 Notes",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible debt securities using the if-converted method."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r167",
      "r172"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Weighted average dilutive effect of stock options and restricted stock",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r172",
      "r306"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r771",
      "r795",
      "r803",
      "r807",
      "r815"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]",
        "terseLabel": "Insider Trading Arrangements:"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]",
        "terseLabel": "Insider Trading Policies and Procedures:"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r819"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r819"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "auth_ref": [
      "r743",
      "r819"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense, Nonoperating",
        "terseLabel": "Interest expense",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r659",
      "r663",
      "r831"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r127",
      "r128"
     ]
    },
    "plx_InterestReceivedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "InterestReceivedNet",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash received for interest.",
        "label": "Interest Received, Net",
        "terseLabel": "Interest received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "INVENTORIES",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r654"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Total inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r652",
      "r708"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Raw materials",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r656"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesScheduleOfInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in progress",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r655"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r190",
      "r209",
      "r672",
      "r830"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Labor and Related Expense",
        "terseLabel": "Employee salaries and related expenses",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r661",
      "r829"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Schedule of Operating Leases",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r446",
      "r455"
     ]
    },
    "plx_LesseeOperatingLeaseLiabilityAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "LesseeOperatingLeaseLiabilityAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to the present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Lessee, Operating Lease, Liability, Adjustment",
        "terseLabel": "Lease liability adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "verboseLabel": "Schedule of Maturity Analysis of Operating Leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted cash flows",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r879",
      "r885",
      "r959"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "First year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r879",
      "r885",
      "r959"
     ]
    },
    "plx_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due Five fiscal year and after following current fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Due Year Five And Thereafter",
        "terseLabel": "Fifth year and thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Fourth year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r879",
      "r885",
      "r959"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Third year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r879",
      "r885",
      "r959"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "Second year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r879",
      "r885",
      "r959"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "verboseLabel": "Less: imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "plx_LesseeOperatingLeaseNumberOfRenewalTermExtensions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "LesseeOperatingLeaseNumberOfRenewalTermExtensions",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease, Number Of Renewal Term Extensions",
        "label": "Lessee Operating Lease, Number Of Renewal Term Extensions",
        "terseLabel": "Operating lease, renewable term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease, term of agreement",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r947"
     ]
    },
    "plx_LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rent increase rate applied at the start of each additional option renewal period after the third option period ends under lease agreement.",
        "label": "Lessee, Operating Lease, Rent Increase Rate For Renewal Period",
        "terseLabel": "Operating lease rent increase rate for renewal period"
       }
      }
     },
     "auth_ref": []
    },
    "plx_LesseeOperatingLeaseRightOfUseAssetAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "LesseeOperatingLeaseRightOfUseAssetAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment amount of lessee's right to use underlying asset under operating lease.",
        "label": "Lessee, Operating Lease, Right-of-Use Asset, Adjustment",
        "terseLabel": "ROU asset adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "plx_LesseeOperatingLeaseTerminationAdvancedNoticeTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "LesseeOperatingLeaseTerminationAdvancedNoticeTerm",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of advance notice to be given by the company if it intends to terminate lease before an automatic extension is to take effect. \nIn 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Termination, Advanced Notice Term",
        "terseLabel": "Notice period for termination of lease agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "OPERATING LEASES",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_LessorDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LessorDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING LEASES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r37",
      "r38",
      "r39",
      "r41",
      "r42",
      "r43",
      "r44",
      "r131",
      "r132",
      "r133",
      "r220",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r386",
      "r389",
      "r390",
      "r431",
      "r577",
      "r666",
      "r684",
      "r738",
      "r906",
      "r950",
      "r951"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r78",
      "r514",
      "r708",
      "r725",
      "r726",
      "r878",
      "r883",
      "r899",
      "r941"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r102",
      "r131",
      "r132",
      "r133",
      "r220",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r386",
      "r389",
      "r390",
      "r431",
      "r708",
      "r906",
      "r950",
      "r951"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total long term liabilities",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r41",
      "r42",
      "r43",
      "r44",
      "r131",
      "r132",
      "r133",
      "r220",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r386",
      "r389",
      "r390",
      "r431",
      "r906",
      "r950",
      "r951"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "LONG TERM LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseAndServiceMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Service [Member]",
        "terseLabel": "LICENSE AND R&amp;D SERVICES",
        "verboseLabel": "License and R&amp;D Services",
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r909",
      "r910"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r686",
      "r689",
      "r718",
      "r723",
      "r961",
      "r962",
      "r963",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r242",
      "r243",
      "r244",
      "r245",
      "r304",
      "r329",
      "r330",
      "r331",
      "r338",
      "r419",
      "r467",
      "r540",
      "r541",
      "r554",
      "r569",
      "r570",
      "r621",
      "r623",
      "r625",
      "r626",
      "r628",
      "r632",
      "r633",
      "r635",
      "r636",
      "r646",
      "r647",
      "r677",
      "r685",
      "r691",
      "r695",
      "r696",
      "r697",
      "r702",
      "r703",
      "r704",
      "r705",
      "r719",
      "r908",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r242",
      "r243",
      "r244",
      "r245",
      "r304",
      "r329",
      "r330",
      "r331",
      "r338",
      "r419",
      "r467",
      "r540",
      "r541",
      "r554",
      "r569",
      "r570",
      "r621",
      "r623",
      "r625",
      "r626",
      "r628",
      "r632",
      "r633",
      "r635",
      "r636",
      "r646",
      "r647",
      "r677",
      "r685",
      "r691",
      "r695",
      "r696",
      "r697",
      "r702",
      "r703",
      "r704",
      "r719",
      "r908",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r216",
      "r686",
      "r689",
      "r718",
      "r723",
      "r961",
      "r962",
      "r963",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "plx_NatureOfOperationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "NatureOfOperationsPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature Of Operations Policy",
        "label": "Nature Of Operations [Policy Text Block]",
        "verboseLabel": "General"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r64"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCOME (LOSS)",
        "verboseLabel": "Net income (loss)",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r64",
      "r80",
      "r98",
      "r100",
      "r111",
      "r112",
      "r115",
      "r131",
      "r132",
      "r133",
      "r135",
      "r140",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r152",
      "r153",
      "r168",
      "r220",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r274",
      "r277",
      "r279",
      "r281",
      "r336",
      "r371",
      "r382",
      "r417",
      "r431",
      "r518",
      "r599",
      "r614",
      "r615",
      "r659",
      "r661",
      "r663",
      "r736",
      "r906"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income (loss) for diluted calculation",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r157",
      "r162",
      "r163",
      "r164",
      "r165",
      "r169",
      "r172"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recently issued accounting pronouncements, not yet adopted",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "auth_ref": [
      "r751",
      "r761",
      "r771",
      "r795",
      "r803"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "FINANCIAL INCOME (EXPENSES), NET",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "plx_NumberOfFacilitiesLeased": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "NumberOfFacilitiesLeased",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of facilities leased during the period",
        "label": "Number Of Facilities Leased",
        "verboseLabel": "Number of facilities leased"
       }
      }
     },
     "auth_ref": []
    },
    "plx_NumberOfGlobalLicensingAndSupplyAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "NumberOfGlobalLicensingAndSupplyAgreements",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of global licensing and supply agreements.",
        "label": "Number Of Global Licensing And Supply Agreements",
        "terseLabel": "Number of global licensing and supply agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r673",
      "r893"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r676",
      "r893"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "OPERATING INCOME (LOSS)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r659",
      "r663",
      "r667",
      "r892",
      "r894",
      "r895",
      "r896",
      "r897"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease costs",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r707"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfMaturityAnalysisOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "verboseLabel": "Present value of operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r444"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r449"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right of use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r443"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted average discount rate",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r707"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesScheduleOfOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted average remaining lease term (in years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r707"
     ]
    },
    "plx_OptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "OptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the exercise price of exercised stock options not yet paid.",
        "label": "Options Exercised",
        "verboseLabel": "Exercise of options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Current",
        "terseLabel": "Other assets",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r708"
     ]
    },
    "plx_OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to nonoperating activities, classified as other, net of amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.",
        "label": "Other Nonoperating Expense, Net of Gain (Loss), Foreign Currency Transaction, before Tax",
        "negatedLabel": "FINANCIAL EXPENSES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Nonoperating Income",
        "terseLabel": "FINANCIAL INCOME",
        "documentation": "Amount of income related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r787"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r749",
      "r759",
      "r769",
      "r801"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r752",
      "r762",
      "r772",
      "r804"
     ]
    },
    "plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "OutstandingStockOptionsAndUnvestedRestrictedStockMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to outstanding stock options and unvested shares of restricted stock.",
        "label": "Outstanding Stock Options And Unvested Restricted Stock [Member]",
        "terseLabel": "Outstanding Stock Options and Unvested Restricted Stock"
       }
      }
     },
     "auth_ref": []
    },
    "plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to outstanding stock options, unvested shares of restricted stock and warrants.",
        "label": "Outstanding Stock Options, Unvested Restricted Stock and Warrants [Member]",
        "terseLabel": "Outstanding Stock Options, Unvested Restricted Stock and Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to outstanding stock options, unvested shares of restricted stock, warrants and convertible notes.",
        "label": "Outstanding Stock Options, Unvested Restricted Stock, Warrants and Convertible Notes [Member]",
        "terseLabel": "Outstanding Stock Options, Unvested Restricted Stock, Warrants and Convertible Notes"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "plx_PayableToCustomerCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "PayableToCustomerCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable to customers. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Payable To Customer, Current",
        "terseLabel": "Payable to customer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Amounts funded in respect of employee rights upon retirement, net",
        "documentation": "Amount of cash (inflow) outflow from investing activity, classified as other."
       }
      }
     },
     "auth_ref": [
      "r826",
      "r874"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Stock issuance costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability, Pension and Other Postretirement and Postemployment Benefits, Noncurrent",
        "terseLabel": "Liability for employee rights upon retirement",
        "documentation": "Amount of liability, recognized in statement of financial position, for pension, other postretirement and postemployment benefits, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r42",
      "r72"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PensionAndOtherPostretirementBenefitExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Cost (Reversal of Cost)",
        "terseLabel": "Changes in accrued liability for employee rights upon retirement",
        "documentation": "Amount of cost (reversal of cost) for pension and other postretirement benefits."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r788"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "plx_PercentageOfChangeInOperatingLeaseMonthlyRentalPayments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "PercentageOfChangeInOperatingLeaseMonthlyRentalPayments",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of Change in Operating Lease Monthly Rental Payments.",
        "label": "Percentage of Change in Operating Lease Monthly Rental Payments",
        "terseLabel": "Percentage of change in operating lease monthly rental payments"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PfizerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "PfizerAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer Agreement",
        "label": "Pfizer Agreement [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "auth_ref": []
    },
    "plx_PfizerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "PfizerMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global except for Brazil",
        "label": "Pfizer"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Prior Service Cost [Member]",
        "terseLabel": "Pension Adjustments Prior Service Cost"
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Adjustments Service Cost [Member]",
        "terseLabel": "Pension Adjustments Service Cost"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension Benefits Adjustments, Footnote [Text Block]",
        "terseLabel": "Pension Benefits Adjustments, Footnote"
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromCustomers",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Customers",
        "verboseLabel": "Total proceeds from sale of products",
        "documentation": "Cash receipts from customers during the current period which are usually for sales of goods and services."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under the Sales Agreement, net",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash proceeds from stock options exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r8"
     ]
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromWarrantExercises",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Exercise of warrants",
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "plx_ProceedsFromWarrantsAndStockOptionExercises": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "ProceedsFromWarrantsAndStockOptionExercises",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants and stock options.",
        "label": "Proceeds from Warrants and Stock Option Exercises",
        "terseLabel": "Exercise of warrants and options"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ProceedsFromWithdrawalOfShortTermDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "ProceedsFromWithdrawalOfShortTermDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash inflow from the withdrawal of short-term deposits during the period.",
        "label": "Proceeds From Withdrawal Of Short-Term Deposits",
        "terseLabel": "Short-term deposit withdrawal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product [Member]",
        "terseLabel": "GOODS",
        "verboseLabel": "Goods",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r658",
      "r663",
      "r686",
      "r687"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r468",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r649",
      "r658",
      "r661",
      "r663",
      "r686",
      "r687",
      "r717",
      "r719",
      "r720",
      "r724",
      "r727",
      "r827",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r870",
      "r871",
      "r872",
      "r873",
      "r904",
      "r905",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r212",
      "r468",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r649",
      "r658",
      "r661",
      "r663",
      "r686",
      "r687",
      "r717",
      "r719",
      "r720",
      "r724",
      "r727",
      "r827",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r870",
      "r871",
      "r872",
      "r873",
      "r904",
      "r905",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "us-gaap_ProfessionalAndContractServicesExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfessionalAndContractServicesExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Professional and Contract Services Expense",
        "terseLabel": "Sub-contractors expense",
        "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r100",
      "r111",
      "r112",
      "r125",
      "r131",
      "r132",
      "r133",
      "r135",
      "r140",
      "r149",
      "r152",
      "r153",
      "r220",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r274",
      "r336",
      "r371",
      "r382",
      "r384",
      "r387",
      "r388",
      "r417",
      "r431",
      "r506",
      "r508",
      "r517",
      "r562",
      "r599",
      "r614",
      "r615",
      "r698",
      "r699",
      "r737",
      "r828",
      "r906"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r454"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r454",
      "r510",
      "r515",
      "r708"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r454"
     ]
    },
    "plx_ProtalixBioTherapeuticsIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "ProtalixBioTherapeuticsIncorporationMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Protalix Bio Therapeutics Incorporation [Member].",
        "label": "Protalix Bio Therapeutics Incorporation"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r242",
      "r243",
      "r244",
      "r245",
      "r302",
      "r304",
      "r329",
      "r330",
      "r331",
      "r333",
      "r338",
      "r419",
      "r465",
      "r466",
      "r467",
      "r540",
      "r541",
      "r554",
      "r569",
      "r570",
      "r621",
      "r623",
      "r625",
      "r626",
      "r628",
      "r632",
      "r633",
      "r635",
      "r636",
      "r646",
      "r647",
      "r677",
      "r685",
      "r691",
      "r695",
      "r696",
      "r697",
      "r702",
      "r703",
      "r704",
      "r705",
      "r719",
      "r730",
      "r903",
      "r908",
      "r940",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r182",
      "r242",
      "r243",
      "r244",
      "r245",
      "r302",
      "r304",
      "r329",
      "r330",
      "r331",
      "r333",
      "r338",
      "r419",
      "r465",
      "r466",
      "r467",
      "r540",
      "r541",
      "r554",
      "r569",
      "r570",
      "r621",
      "r623",
      "r625",
      "r626",
      "r628",
      "r632",
      "r633",
      "r635",
      "r636",
      "r646",
      "r647",
      "r677",
      "r685",
      "r691",
      "r695",
      "r696",
      "r697",
      "r702",
      "r703",
      "r704",
      "r705",
      "r719",
      "r730",
      "r903",
      "r908",
      "r940",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957"
     ]
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Schedule of Segment Information",
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]",
        "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure"
       }
      }
     },
     "auth_ref": [
      "r744",
      "r754",
      "r764",
      "r796"
     ]
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfConvertibleDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Payment for convertible notes redemption",
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "negatedLabel": "RESEARCH AND DEVELOPMENT EXPENSES",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r648",
      "r659",
      "r660",
      "r672",
      "r958"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "auth_ref": [
      "r745",
      "r755",
      "r765",
      "r797"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r746",
      "r756",
      "r766",
      "r798"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "auth_ref": [
      "r753",
      "r763",
      "r773",
      "r805"
     ]
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "verboseLabel": "Restricted Stock",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r97",
      "r98",
      "r136",
      "r137",
      "r138",
      "r141",
      "r149",
      "r151",
      "r153",
      "r221",
      "r224",
      "r237",
      "r273",
      "r336",
      "r353",
      "r354",
      "r367",
      "r368",
      "r369",
      "r372",
      "r381",
      "r382",
      "r394",
      "r397",
      "r398",
      "r401",
      "r415",
      "r439",
      "r442",
      "r544",
      "r546",
      "r563",
      "r993"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues.",
        "terseLabel": "TOTAL REVENUE",
        "verboseLabel": "Revenues from customers",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r116",
      "r131",
      "r132",
      "r133",
      "r178",
      "r188",
      "r189",
      "r203",
      "r209",
      "r212",
      "r214",
      "r216",
      "r220",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r431",
      "r506",
      "r508",
      "r672",
      "r700",
      "r725",
      "r726",
      "r906"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right of use assets obtained in exchange for new operating lease liabilities",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r450",
      "r707"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "plx_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to sales agreement.",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r173"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureTaxesOnIncomeTaxBenefitTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Taxes on Income",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Earnings (Loss) per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenues",
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureInventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Schedule of Inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r50",
      "r51",
      "r52"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r22"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r69",
      "r70",
      "r71",
      "r105",
      "r106",
      "r107",
      "r180",
      "r283",
      "r284",
      "r285",
      "r287",
      "r290",
      "r295",
      "r297",
      "r391",
      "r557",
      "r558",
      "r559",
      "r560",
      "r685",
      "r825",
      "r878",
      "r880"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r741"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r84",
      "r178",
      "r184",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r216",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r240",
      "r241",
      "r376",
      "r377",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r669",
      "r672",
      "r673",
      "r678",
      "r722",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r214",
      "r215",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r506",
      "r507",
      "r508",
      "r509",
      "r566",
      "r567",
      "r568",
      "r622",
      "r624",
      "r627",
      "r629",
      "r632",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r650",
      "r665",
      "r686",
      "r688",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r721",
      "r730",
      "r961",
      "r962",
      "r963",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "SEGMENT INFORMATION",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r178",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r199",
      "r201",
      "r202",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r216",
      "r668",
      "r670",
      "r671",
      "r672",
      "r674",
      "r675",
      "r676"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfDisaggregationOfRevenuesDetails",
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "SEGMENT INFORMATION",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Amount",
        "terseLabel": "Other segment expenses",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r201",
      "r202",
      "r209",
      "r672"
     ]
    },
    "us-gaap_SegmentReportingOtherItemCompositionDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemCompositionDescription",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Other Segment Item, Composition, Description",
        "terseLabel": "Segment reporting description",
        "documentation": "Description of composition of other segment item not separately disclosed."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r201",
      "r202",
      "r209",
      "r672"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "SELLING, GENERAL AND ADMINISTRATIVE EXPENSES",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r658",
      "r659",
      "r660",
      "r663",
      "r869"
     ]
    },
    "plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to seven point five percentage senior secured convertible notes due 2024.",
        "label": "2024 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r692"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of equity instruments other than options  granted under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants In Period, Fair Value",
        "terseLabel": "Aggregate fair value of the restricted stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested (in shares)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r322"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "verboseLabel": "Exercise price (in dollars per share)",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield (as percentage)",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r330"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "verboseLabel": "Volatility (as percentage)",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk -free interest rate (in dollars per share)",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r331"
     ]
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of quarterly increments during which the equity instruments will be vested under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number Of Vesting Installments",
        "terseLabel": "Number of vesting installments on a quarterly basis"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options granted. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants In Period, Fair Value",
        "terseLabel": "Aggregate fair value of the options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options to purchase shares",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Award Types",
        "terseLabel": "All Award Types",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share Based Compensation Award Tranche One",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share Based Compensation Award Tranche Two",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937"
     ]
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of recognized equity-based compensation during the period for restricted stock awards.",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures",
        "terseLabel": "Share-based compensation related to restricted stock awards"
       }
      }
     },
     "auth_ref": []
    },
    "plx_ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "label": "Share Based Compensation Restricted Stock Awards Net Of Forfeitures Shares",
        "terseLabel": "Share-based compensation related to restricted stock awards (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharePrice",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price",
        "verboseLabel": "Stock price (in dollars per share)",
        "documentation": "Price of a single share of a number of saleable stocks of a company."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "verboseLabel": "Term of award",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r693"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life (Years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r328"
     ]
    },
    "plx_ShortTermBankDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "ShortTermBankDeposits",
     "crdr": "debit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of deposits held with banks for short period, usually less than one year or the normal operating cycle, whichever is longer.",
        "label": "Short-term Bank Deposits",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "SignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Line Items]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "SignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Accounting Policies [Table].",
        "label": "Significant Accounting Policies [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SingleReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "SingleReportableSegmentMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to single reportable segment.",
        "label": "Single Reportable Segment [Member]",
        "terseLabel": "Single operating segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSegmentInformationScheduleOfSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r83",
      "r84",
      "r99",
      "r178",
      "r184",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r209",
      "r210",
      "r211",
      "r216",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r238",
      "r240",
      "r241",
      "r376",
      "r377",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r669",
      "r672",
      "r673",
      "r678",
      "r722",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r46",
      "r47",
      "r48",
      "r90",
      "r97",
      "r98",
      "r113",
      "r114",
      "r115",
      "r136",
      "r137",
      "r138",
      "r141",
      "r149",
      "r151",
      "r153",
      "r179",
      "r221",
      "r224",
      "r237",
      "r273",
      "r298",
      "r336",
      "r353",
      "r354",
      "r367",
      "r368",
      "r369",
      "r372",
      "r381",
      "r382",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r415",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r439",
      "r442",
      "r461",
      "r519",
      "r544",
      "r545",
      "r546",
      "r563",
      "r616"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r181",
      "r214",
      "r215",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r506",
      "r507",
      "r508",
      "r509",
      "r566",
      "r567",
      "r568",
      "r622",
      "r624",
      "r627",
      "r629",
      "r632",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r650",
      "r665",
      "r686",
      "r688",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r721",
      "r730",
      "r961",
      "r962",
      "r963",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r179",
      "r275",
      "r276",
      "r278",
      "r280",
      "r442",
      "r468",
      "r556",
      "r564",
      "r565",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r616",
      "r661",
      "r663",
      "r731",
      "r991"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED BALANCE SHEETS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r137",
      "r138",
      "r179",
      "r219",
      "r275",
      "r276",
      "r278",
      "r280",
      "r442",
      "r468",
      "r556",
      "r564",
      "r565",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r579",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r616",
      "r661",
      "r663",
      "r731",
      "r991"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "auth_ref": [
      "r748",
      "r758",
      "r768",
      "r800"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock under the Sales Agreement, net (in shares)",
        "verboseLabel": "Number of shares issued (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r45",
      "r46",
      "r71",
      "r557",
      "r616",
      "r630"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of options",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r45",
      "r46",
      "r71",
      "r315"
     ]
    },
    "plx_StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued as a result of exercise of warrants and stock options.",
        "label": "Stock Issued During Period, Shares, Warrants and Stock Options Exercised",
        "terseLabel": "Exercise of warrants and options (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "verboseLabel": "Issuance of common stock under the Sales Agreement, net",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r45",
      "r46",
      "r71",
      "r563",
      "r616",
      "r630",
      "r737"
     ]
    },
    "plx_StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of warrants and stock options.",
        "label": "Stock Issued During Period, Value, Warrants and Stock Options Exercised",
        "terseLabel": "Exercise of warrants and options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedBalanceSheets",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r48",
      "r65",
      "r580",
      "r597",
      "r617",
      "r618",
      "r708",
      "r738",
      "r878",
      "r882",
      "r883",
      "r899",
      "r941",
      "r993"
     ]
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCK TRANSACTIONS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "STOCK TRANSACTIONS",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r282",
      "r284",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r296",
      "r298",
      "r391",
      "r406",
      "r619",
      "r620",
      "r631"
     ]
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r463"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r463"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r463"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r463"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r463"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r464"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "SUPPLEMENTARY DISCLOSURE ON CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementalInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "SupplementalInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplementaryBalanceSheetsInformationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "SupplementaryBalanceSheetsInformationTableTextBlock",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for supplemental balance sheets information.",
        "label": "Supplementary Balance Sheets Information [Table Text Block]",
        "verboseLabel": "Schedule of Supplemental Information of Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.protalix.com/20250930",
     "localname": "SupplyAndTechnologyTransferAgreementWithFiocruzMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to supply and technology transfer agreement with Fiocruz.",
        "label": "Brazil Agreement with Fiocruz",
        "terseLabel": "Fiocruz (Brazil)"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "auth_ref": [
      "r794"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails": {
       "parentTag": "plx_AccountsPayableAndAccruedLiabilitiesOtherCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureSupplementaryFinancialStatementInformationAccountsPayableAndAccrualsOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current",
        "terseLabel": "Income tax payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r786"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.protalix.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r817"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "auth_ref": [
      "r815"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "auth_ref": [
      "r818"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "auth_ref": [
      "r816"
     ]
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r91",
      "r92",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r98",
      "r121",
      "r122",
      "r123",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r154",
      "r217",
      "r218",
      "r221",
      "r222",
      "r223",
      "r224",
      "r236",
      "r237",
      "r239",
      "r271",
      "r272",
      "r273",
      "r274",
      "r334",
      "r335",
      "r336",
      "r337",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r429",
      "r430",
      "r439",
      "r440",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureSignificantAccountingPoliciesDetails",
      "http://www.protalix.com/role/DisclosureSubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r383"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_VehiclesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VehiclesMember",
     "presentation": [
      "http://www.protalix.com/role/DisclosureOperatingLeasesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vehicles [Member]",
        "terseLabel": "Vehicles",
        "documentation": "Equipment used primarily for road transportation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.protalix.com/role/DisclosureStockTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]",
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year"
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - DILUTED (in shares)",
        "totalLabel": "Weighted average shares of Common Stock outstanding for diluted calculation",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r172"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.protalix.com/role/DisclosureEarningsLossPerShareDetails",
      "http://www.protalix.com/role/StatementCondensedConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING EARNINGS (LOSS) PER SHARE - BASIC (in shares)",
        "verboseLabel": "Weighted average shares of Common Stock outstanding for basic calculation",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r172"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]",
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested"
       }
      }
     },
     "auth_ref": [
      "r780"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "710",
   "SubTopic": "10",
   "Section": "25",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-3"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-6"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "40",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-42"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-2"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480535/715-20-45-3"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r855": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r856": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r857": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r858": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r859": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r860": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r861": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r862": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r863": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r864": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r865": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>62
<FILENAME>0001104659-25-110824-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-25-110824-xbrl.zip
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MZV,P0[X+>'=R.VQ)$-S;25NO2S^G.&KD"6O44A?Z$;75/'"[2Q.5YAIKC-]
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M*'\$\_L" U(-O3[6MP%66^[?!)NZ7GL1R^_9".<^_O4. 5!,S]N'";+;[=\
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MRB+U'8[#%43;A-M"TL"3;]IQ*S\P'L09W7\:39:#\>1N.O\TI$_B#/Z6-SJ
MJT'6[*#0[C>6Q+1DK,W!#J+T,O"!Q>M]]E'Q+1WUFHQD"W.B-" KQJ0;8)QQ
M)(HOD92Q-4)$6Z7E/&%"S.:GBXP?<4;F,HU%(1I*9EC21QE*1Z&FQ$H"D!H,
M-8RL47[293&]+;MYIJD<(C?%&*PQ=%8W/IG(V?8O*6KVT%(''B<#L/HX]UI/
M';.U_.&MP7RTX'G?^?2V.%#JJET S;+]S/'Q]\K0(M,:JX M[HNF:F-ALTQO
M<_ $0GZB[>-G6W:#=75R1&*9!AZ<1XB&H3<' 5DET:1Z9&W%VWCPB&W)S%M7
M.SQ<ENEJAN"*+%\3!M(8LL1!M0#HR7<!%NM.M; MR7OKZE(5IV6ZS2^?9_Q-
M8 CS69?KJ1>4L"6;;UTM"L%9ISH:[9GZN&B(0LX[5V\\<ELR^=97&@^991J[
M!3L$7#]!Q N"*I'8DE6WKF;*:"S31A54<BN30A$>,TA+69._MO:N6X;0,CT>
M [32DXN0,!U3OM.1&X;X&A#D(*5;.B]T-B:3,Q&?'SIHGPB"C/3414#$'"2B
MD@RE';9H3>+:^L-QA]*QTO8(AFS!< U"HC&QW3"HK4E&VTSG#&26Z>M5A(.W
M[9>Q.CR<.]O0(VB(_?3@%KO(WPF63=JU6),1MO59FH?8[M-Z0N6LUPBLLYB#
MW'%5X\S^K?:9?;EQ^I>\^3^/[EM C%%40$M^.R(EOWS]Y/P;HIL81V2(0JPS
M>A[1[^I0G@>RHQ%:HI/TJ=02/\Q3> FM!:?Q8@O+)2_ T,TQ_&SE_P80]]2]
M_-GT(;N21>2'[676NY'>G0]=%/_&%5_EN^D#42WY57CO1H W&Q]@GRN_\F?3
M!Y-:XBNS;F;TG"'HQ6XT19GWGS.GL<D,S6J\#6'S68T-TZAF:"J$_&2&.Z\)
M:"V9UT1V5I$^"X7YS5_&G.2!^1*-#7.AU(HJ!X-%_LT+_8'P&V)P9%XH?BZU
M#9.JEB*X2,RKY,_XOS]\_)^](4DMNXHU0I*Z]TC%CQC\)R8P1D\T4$W7VW1U
MR;@A\OEZ,?KG9^IP&GTA_R[,NI#*"(4^(B:I@:ZP)'5/5X6[C()[&QQ:RUQ#
M B44NP8'C/GYJ7BOE,R?$\+(\2]+\A-VW.1D3[B4T*[%@F6VDDV6[M;I@NS2
MOS1<(P"$USLX=*97V0T-K^R+.D'7T<V:>+<+]H3+)7 W(0S@>I]PN"IP\(L?
M;63.JYKUV+(N:*BRFNB[=),=VN5GIN01FG:=M:04'CSS,U-U:B5-B6YY\J@M
M<[HIKA>X<*S4B_@:)Y_>HE6 Q-HDNK''[U9A3KAJX]#:LD*0&II *?8,8\D[
M(9+!JT)C:,CB!2<I#ED5$.8E+WW5!?.>=3E"";U9X(32!P:Z:<JBX9%IQ5J/
M-M62@'DC&FUW =P#4$C&+1Q3!?36C*L=]HNB20A$85ZOE5'MQ*\IGBH?K/&_
M2V"(UBVOVJD^0] %P$L#T?/X'_XY(XO6EFVUC@XY4&R+_*4]?HQQ#+S;&/GA
M.GW^+,UB5GS6('^DGOM,8HV*;-F8:W7-&C@MTWG1,G54K%#.FJOZ-3MJ705R
M#LFR/]-_Z./ /_T_4$L#!!0    ( %DW;5N>3HS'BTX  ,(>!  4    <&QX
M+3(P,C4P.3,P7VQA8BYX;6SE?7]SX[B1Z/^I>M\!;U_5RTR5O;NSN;MZN^^2
M5[(LSZKBD1Q),YN]K:L434(V+S2ID)1MY=,_-,#?!$"0HM3P7%6R8YO=S6ZP
MN]$ &MW__O]>GP+R3./$C\(_?O/AV^^_(31T(\\/'_[XS3[=7OZ?;_[?G_['
M[_[]?UY>_O5J=4N\R-T_T3 E;DR=E'KDQ4\?R2;:[9R0?*)Q[ <!N8I][X$2
M\N'#MXSBM]^3R\L_<1)73L)0HI!P6C]\^R%_,,VH1>%/#.N[#W_X[H?O?_A7
M\N'[G[[_X:<?_D FGW+(3XRWK=\-&OCAWW^"_]RS=Q(F99C\\9O'--W]]-UW
M+R\OW[[>Q\&W4?S L+__PW<YX#<"\J?7Q*]!O_PAA_WPW5\_W:[=1_KD7/IA
MDCJA6V(!&1G>AQ]__/$[_I2!)OY/"<>_C5PGY>/>R1=10L!OESG8)?SI\L,/
MEW_X\.UKXN5\M=CJ$)X]]=("H0K\K]^)A]_\Z7>$B#&.HX"NZ)9P\7Y*#SOZ
MQV\2_VD7 #W^M\>8;N6O#^+X.\#_+J0/\/V!_Q^!_P__!OS_K^S/M\X]#;XA
M /EY-5=*\F.-5H;T7<EI '^Y93_5>*6O*0T]ZN7< @W-8/%7\"\)A O2D5LC
M&L"GC>+V""3Y@";4_?8A>O[.HSY78/CA$G[@@K-?_C:-F%U.[I,T=MPTI\1E
M^.,WDN??U?@!L$E<9\J)W9P,^[%#S@SB.S=B"KY++P,QG )]&T=/4B:RUT62
MAW\+[@,9ES468YI$^]BEO3Y&E3/5^(BW,_UF$.#::'CY>?W-GZYS=^:$'IF%
MJ9\>R#S<1O$3M\Q__ZXD>NK/G;.R810ETM0?XWQL&8OYMZX^._NG;K]<_:4!
M!N.[_F7OQ"F-@\.*[J)89M!*2-ROK6"\^>$;8&@Z(.5#K0X%.!'P&*IQ1V,_
M\F:A=\TF+HUH#3A<M9 RW52*&A":2DBX4"N$ &:3@4< '&4*B)TP\6$"ZO05
M;5#DJ4'!>FN::,#A31E21C331P&/X#!$A'+C!W2Q?[JGL42N-@B.0JA8S16A
M^?SL"B!GH/7AU]3=Q^Q[TX1,W)0 /!$(Y__P*_K@0S@;I@OG2391R,$P%4#.
M<ET)ZC!(BB!CHJ4,V0JAA"4 ?'Y%F(=N%#/GPQ<IZY1-4]-H'Z;Q81IY:KWH
MP,)4$R.!ZEJC14%2(@.>5#I50[T@')E$,<D($*!P?D7;.*]SCTU[_M87>U4=
M\XX2'E.Y.H2HJY4"&$FAM-RH5(DAD3H6VHPU\3PV*$GVSZT?T@]*6:6PF'JC
M8;ZN,Q) )'U1<J+2E0SR(O^!  Y9A@B^ILW[#SWD_,$V7?G!5%=^L$97?ABB
M*YN7"$U7INS'9;R)7L(N*:N0%NA)FW&IEI1@N#K2Y*-30P !HA= 0=,.'D,M
MX[LX>O9#5QT7J\ MT!.%"%)E:<#B:HR4F4ZU*:+>' ]-=^ZB)'6"__!WVA65
M'-@"O9&R+]6:&B2NSDA8Z=08@4,8TME72.#C)C%U%!I2?XQT.BMAL3B<K3P[
M_]ELZ^6M+\VG$( Y^X>%O(S@[C$*U;NL;1"<#ZQB-?_(S>=G_]!R!EH?FX,1
M#H>P5LWV> \??KC?^&D@L^8V",X'5[&:?_#F\[-_<#D#K0_.GY%H2S[\\.[^
M/<FQSOG5-[$#:6[KP]-])).D\1SG>TN9S#]V[>'9O[3D[>W/+&"( ,*PZ=FK
M^\@XHHH3$SD8KFW+6&[:=Q4&S<;;3*B.SPXDAT4Z,9GNXYB&J3BR!:UE*XU]
MHHQ(5>"8H;U>A'IP+X=%"N]US*@"_ R'%$A$8&&<M:44,@C]9WKMI$[&F.8(
M2 Z.>[JF$Z%YK":#13M/4S.C/D@K<""!Q\E5"2=/(YXZ*7V(XH,V Z$"A9VM
MT6*XG;!1@"#F;#1X4"D#!R4Y[/E58/WD!,'5/O%#FJAGFP84I@I(&:ZK0 T$
M204D/*A4@(.2'/;\*C![HO$#F\ ^QM%+^CB-GG9.J/8&"FA,E= *4%<-*2B2
MBFAX4:E*CD($#LF0$-S&(PV"+E6I Z$Z#0F[#9]1@<!R&2T6E!X#(/$^/GOQ
M$V0/1>[?UX\.&XCE/H5[9K"05L?86B3498N!.(W%BP8#:PG3R9)R(<,Q"4>]
M( *95+ 1](L%P[$3S$./OOZ9JOU+"PY5B^1,-Q2G#H2E*S(NE.HA@ F')@S\
MK"=88F5TXR>N$_Q*G5A]!44-BG2RU<%Z<<JE@#O_B9>6D?;I5[;_(> )(*!>
M22GYOF%_D2UEE)"X%U(4C#?OHS3 T*ZC2/E0WT:IJ@='P-,-<6_*3#MJL#;H
MAX1YN894 )%UI,5)IY9D-]O.KB<3QH3'&0\<603;>(ZC#U(F<QVH/3S[=Y>\
MO?6M"Q@"0.-]W:V3W',V]\GE@^/LQ">F09KD?RF_=?:'O_$L+N!EN;WQ0R=T
M?::MD;@TIZAGT _U_!HR1#10GCYX9]6K_HRU0Y3EXGJV6,^N"?MIO;R=7T\V
M[)>KR>UD,9V1]<^SV69MB29NG/M66H<*R +MJK$KU2,.@:LQ%1;:Q[XY$/F-
M@_VG)7IPZX=TSGYLAB@Z0 OTH<6V5"<**%R]:+"ATPT )1P664$F24+3I&-R
M:@+A*8:<W:I2U"%0%$+&0CMNX4#DMQQ,K0>C\)O2.*&W1S.]7J-/;8+1;)O
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M.?!69X$K8N].EV. 9]UR3^\6.I%L6O1UJJ!NW6>--1XOG+UKOTX+LF[J-9Y
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MV@&+JAQJYAL:T@;$4A,5)V:Z(C"0VP1EG'VB3_<T5OC/!@QJ;: VLXUB0"4
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MZN $'^-HOV,8['=HI."'>^IE&;#,42D^A0V,X3D6&Z1O.RQ\KE <H2UBMV,
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MHTTCDH/@)#ZH6,VS&YK/T5(8Y(Q(DNVV 5M<)SPA@>9GTSL6/G(-R/_2R#6
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MQXZ#":8]&F6ZR]"-9H6>]5B'"TQ2H%KJDX^0<&2CDEXDJ%Y@Z[Y<:82!<\'
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M/.'K4"STY/(8F2O#L**AI%R8A?-$M3TFN]%LLX^V2-U*7N)8I*E-IDS5[8(
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ME[+%(!4(D4)$6NYH#*)H@!W#"?2>[?@$"1.G@^0M!HM'DA2QII<U]BH^\?S
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M'*J&![NN-04.LM*M9!.*0@-R8MU)(2!UK1>C-T.0"?06:,X6R1$?]8\6>V8
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M5"/KP&OSX?-GX:,/_@I1,?UG](^P&_SY&6E]]G;6_^=WO!#;_PW].VO6M_U
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M_?XK@*;M[W::#_L-X8)T9),D+6AX^5"VG8GPJC"?CC0J)W0-\^N:7%^BM_K
M_+CTGC\!TXI?/'1]&TDPAX:% ^-E3$).GY?/5U>?#SU>DD([2:F=_6*12(E
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MW23XG?LT.TK-2<V\6,JE,&W:PXB.EJE;B>A&VIY/.@_]GP,S/)V5A!^1EV0
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M'W_%&RJ@OL3%4ZUZ^-OKH*Z;/B3=GRPLF@(44^*Z'4UH>KG1()]A_'0UBH[
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M14>F0>FZQ1B$2?;![L/.<=@_\<W&Q%AVPX/W*B(;QF:O*-C=F/E:L+?A6<@
M;!K CA]O;Y!!3OQ.?9?-)L?.+LE69(*-C\"B#>J[("I\"OVWH*GM  6$WAQ.
MK/L(*UJYR)^P9RC@B.M#@]<=6\$YW6UE$V\L>T_GLY ?#SJL)1#^>#.EOZ[#
MO;,_B9UY#R!68*/!!,XJ^%'8'OXR&,^FLZ!4CQN.)!QNL)_&8>L>5'GEWMR7
MS3AYJEC*=QPXF'6UH& Q]&3/=W=V]OF[L30S%J.6('-88EINET:S-O^*U/2"
MZZH.8^_U0T2/CQ+MM7].YO_>[XWE..[YCIYY<<4Z]C"X!'$N$$>A$,JIE$V
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M8D!%%E!D&@SE(-PHVI;9!*9F.0^LE&B,)LA/)Y!>>/3J9!3:=HP$/2/KKG>
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M."Y)VQQA:;^8Z<:+:.04)/L: 5Z"\^XMRX]O7!X\HPJ)CZI"G+C!R.^D"IO
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MLL:[8W7.PQH*-1?3HV8^L%9$HQR8F<%F%,6L@4)VH%@8'+&#(W8^>\3.:U[
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M']VII,#5K-1?Y-]XG[J<(G-GRP<O';QT_L"X5I=F<#MG4'CQ)&GQ%(!A:F:
M%\]E%D^6NZ?%TW,/>.>NCCZN=J")C87;/@O99[S>'Y6Z!B;7\T$EP3$C.$0D
M.<L$(^>6D(.CK1(K) PE#"4,)0PE?!)Y5R>1R8 2=AXDWWEP@BL$)[V1EZ#2
M7A\^ XH+8V%OP3M<L23YI[Y8AOB:O2=?K+!P0R<XA3/V>[VA;__2-  ,([%\
MDE-MU=% 2@U25=4)56^;(A]2J*;=Z5#$WY1$SL&P%Q_]N\HEOBJ.,]12%'RE
M9: B!G1<2I%6'JL>HH?M2Z")JQ 26=Y=+%T'E8(2-J;_W&H?"AT?]S< \A(K
M&8[4UFNE/)2I3461,X)?)P7A9?7%2K/XKOJ++]ZQWU,JOA\"_6A]9R''C55;
MM%0R.QLQHUEKR@H*AVJ)9*B'+$L]D-2Q,JPGW*,NN[YN4:4C;XN#_OM$RV/O
M1?@,]"-+!449.[WLLNHYEE03V6A+I_WF=GIU[DG3[Z*>^.$S.'K@^?N^/+,.
M_<PZJV*]MB#=@B6WZ*T_*8^I8!6A>C\L*BJ/V0:S#6:;VV>;[^D1T!6?BO,8
MI_;$/+EU5!CT.C5"FK7"=C:L^74E.C?SR-Z\OXUZ2D2$!LO6@RKH&&-4DXS_
M\@]#L@\$PV+ZP?2#Z></))'Z*UG\TP6!:CI %U7/@5+S'XE';O94NL*&66L%
M>NML<3H@%6%Z:N*!\H0/.L) C4)F1BS*JBZ'Z_IJUAK)9:X8%S DO_Q#\^0#
MRV0/*.BTEPHP![WE%.I3<M!U!GY#*I!I:0UVPU0SLIIQ=&_M-WK,H'-NM:5%
M^GK'W4VG<CKM[_A&M5CPXU*J) -)@WY@N4/.2'A<[H<6?'ZF.E/X)CWT8)]2
MP0RD(,6#-+1N@UEJ"=_EZBG@Z$!/26 9@._1F#3Q6(@<.8F_G=1+?/4T/;<0
M:/OS:?,;=(XK1U@F^B#M/@*<+K:\SQZ7]&Z-^N0)P_!BQ8L5+U:\6/%BQ8OU
MQH(S+[A8+S"2$RS6>XC?J4"[VU3ME*J[R]@B=XV4(,DH2(=($]R-QN@D'JS7
M"-VY5=L.+YVK'\$D7BC7.)[!>+J+I8/QE! \O5LK._^)IN\%2GZ?X=)< ]$P
M@!:T8_=URQ >-:;X4/--#?5YZ ?H7/3QJ/-[),;3/_A%UX.R$C0-18M#X;8]
MUX$?M?@X]:?XC>=&3^/TY:6N!@"I;@3WTSM.$1-"=_*CH5_;S:V55U=ZJTW&
M'XB7.YKU_'Z?$48!0P!K1&7&#N6NTX+"H^ 0.GL8E_8W9DS,F)^:,0\.9\]^
M_OK9"/,702Q>U)B*I7:_0$@C<I2N"?2JP)W]&-I*5P1''*PCN;3.4G.GT"_:
M\P@2)(I=H8[>$\ $>2\1*HD72A*C5[!*^2<,N2R/&K7L="INZ4XGO6"'3=T]
M.;G]4@W<:)-5P9JT'3E-%LM$N^*TLG6D!J)@&_)(I,W?-QQF$]\/2T]4'Z!;
MM8LE<'PU7I9Q56#X9>#"+J#4QOL%X=]"N$SBJ>HR839)E@ ^3DMTVJ [RA*4
M9 E@%& 47#URXNQ&?"'T8IU"(9581V64GJMD%9K8_W)*#V):B8KJUL^FY4&[
MM77<%1 IYB/W65_HN3WW%^^.=:A8A<J_T*"Z  [#AY,N 6]M:F"O6G>!YDZ=
M^"E]U0[!$?VS$+%\<4<4NO*VZS%;M\8YA98 !<9#]?.!S)+G,[,_,PXQ$UT\
M:]^M'&A^YD61Z)1\]Y&!+^D;=!XP7#T[')BB%)2GDTJ1"PNMC_ACKK"I3NP9
M(9*DNR56 U?-=&RPK(41'&3LU/G-KGH/<7AO<?1XP \\4T._[7T^:H1<=#A&
M[WYB],[&->_(H'52>^ PIPU;!YGRJDQ$XM9Q,C(!ZG*TC/XDG];2WGR+<9,[
MY*$GI,1O%F*<-$'0,HJN9P S"*$P]KFWCF3=6L^68-K)#@4YW<J,>Q:_$!>L
MH) $2KO%\>0#PQZ[SXG/TG"P 0XVN!$_Q9_PTAO5J _2TA'MB*JLW1ZH3G<6
M%6:7$WDS+8SD*2(D%FI'F(HP%6$JNETJNI#+]/2TM"IU?*[-UT86D*NL987]
M73CH(%J*7:$,D<'4A*GI<U'3K?I0\=+!$7RW&,%W[:W^9,[7TV_/-2(4C9W2
MK<K 'A%C,;L%M!1;#7NG*D/P)W>J7M&#"B62LEW?1\*.4T[M\TS=0D#<A?-'
M7;&J1N(Y#I\H/JJ2UZV\<L&D*!@-& T8#4E!PPV:3A@>&!Z7+TAVA;M,)_5Z
M_N+F9%34:@NS59]8@*MUB-[88L?^1^Z80[.@XFCN M2A;?#:O:*M9!-EE0D&
M<MJSF56V,E'(GJ"0Y#[U]P/+46>\8OZY283Y-"22@)$FFD1.'LSV9OR/@%":
M-8EY4ZP5(D_HKJH=<MV)\<^\ ?_W$(3VUF*.KR7MQI4=SQEZEJ!RNDDM_7BZ
MB!#.)IIJOD?Z8LN9TP-QV'>6XH4J/Y9GM;2\+L_28E[-F'F#)YSV5D 7R5'I
M1_J!0V4%>%R,[<J52'YQZGIMF/XQBYV]7-*U)9/T6B:79*]SY* QF'5E.'?"
M0%RTTWUCEHTF91 AWD+%(W&I6LQ7F*\P7_TNZ$TSZ84E\*8CAE-ILRREBV''
M.WO^+"I?+HF4X3ERNCX:Z<(4-(ARK'/%Y2<S#Q1+8 +#!(8)[)X*6)[8@4W*
MT8)-.Y(I E(.0D/+E=/$Y;)CA7:;C"HY<V=M==*:D+N6T"S'^M>^@"7SP/.'
M8;FX@&4B"EA>&ZL)8+&$2N9VU#"C9089EXW:!-2O-O5A.!M,I;.;?>2Z:2F%
M_GH@@DVN7)KEB+Y3[L2T@YSGU -#'[L,\'+1W%S X5N]Y575"55OFR(?4G"&
MV'LI:GEI;_C=(?S=GNWG+*(?=PZ1N2K#"-)J*X96?CFPJIS>+UW(M>VF?;<R
M=Z(AL7#<K+D&9B]P(%?0L6N;?>!9XH'*L.>UM+!"DJ0Z=Q<TD>Z.1OXP$_$E
M..0<FH;(ENG-@&FLY85G9@J%948J(B<-'3N8.<P:F#4P:R2&-5YW\U;KPJ(.
MYM.:.!CEF2SMA#- GMW-VZCF "LOBK15(U:A/4[O>JX6,PAR\U+D TL=NQB%
M:033R W32")\K7_,([]PMLK2QO"&.]*S\J.>UMQ5^ITQ<7(5Y)?.UIVD+E=D
MM>%8J_'";*J>I0ZUV)*)G:T9_N$7=:DPE]QH-LR$<$G2,EY>5R7)YVBN1GKL
M6$X3.2,#N\7.^F=7(\:[;KH35$=3F?/MY;IC-UL9/58CD,N3H1\H\EAJIH^[
M/&\H*#8_4YTI?),>>K!/\:UL2-\@#2W)8/9X03L%'!WHK\44L]]P4/&=YK,\
M$,?Q2NN?YD#R;I,%)0<&24Q8AF& 88!A@&& 88!A@&'P:3*^)0D&R4OM]D88
MW%S<$ J,B&.#7 .5>H"V<&I?S@'*'>Q3ETFJ#=\F3#T0NT8?4@X(<,S0;<<,
M7:!2 _OR+CW[X0-^L&YOI16W',BE8,1FR9QMU3/3CP0)Q4_?!P858I?0OD#,
M/F (BCW^IV,E&6QN7$R7I)QAI:O#>BVL#5I;M:.0+(H9HAXR&?:!(H^%#-VW
ME_T^#NAN[YSAZJ=Y%T][>G%J^1.7_2&SQ/6F#HGENQ=?E:OU,NDK@B6MNDIO
M8-4:V>$4$0O[Y9]CU^LQH6!"P81R94)Y/:PH+*M>:%;K([%D2\I6"$O6VOZ3
M2BX?)9?LK &*DBSS<FD\81U[O)W:HPB1"__E'^Z!)\Y81BJA\,($<Z<$@[-W
MWB).$EP\]EHX25ILS84WXJ54']<+K#<B5E6W&Q6)M&=IU]@\QX$C2JHSGA(E
MB7>\(:4:JW:\>:+X&KA[DH?Y^.XKM.8M-6'WGD-WB;Z_U4JP2?,:XI.1FSXN
MNF88^V<%SM5*;6'@W)Q0,$Z2=<YZ;8TST:X?09^'?H!ZY??<7[P[UM,FAV6[
MX#!\N XDX*U-#>S5WB[0W*D3/R76@(\HOH/YE.@-@30G!F.NS')BM5(H=122
MVY?5)(AC610Q66&RN@>RNE4W$@8.CJ9*=#35M7?YD_N5KK SY\I*=UM=T(*8
M)WB^-5*<EL#%._.^HN;K6_/-!:J]Q?_D/1<G?71%J7%Y4ARLAH/5;C58[8.5
M>/?!;$=BV"1MVR_*[0I/K+BH;$Q$JVF3D4)F4 P;RV8?*/)8>N'[/N>ZIK,.
MBR31$2C_[][7/E[J>*ECC]N)MMTCZGHK8$UV3JQS%J4'NV%1:]KIL(,V7!YN
MN-RQ[ R8<##AW"#AW*K7+*&K! =?X>"KVW:2G7XS[4]RW4QW%ZD$%[@#SA*C
M!N@+:#-%OJ_7=]-[",82-\#33#^^M0EEYJE034K!V<>Q5S<<>X7]8N_UB[UV
M@7/P" O!V7-+:X^,)^0<RP4/2CK;X#Q^(:[2IL85<[I2"2.%Y)%/C'P@6>Z!
MH\YXK_-VCNT^3U3;[4D)1_4D^(;H*[05G_.]F;6^ZT)L+E,JDMEF733=\L!5
M9QM38SN(M5C(6IBM[C@Z!Y/3YR.G2SI 3TM45<$TJ-["RLA;OUT3@R57(&<"
M(BH>I<U@R#->0+T=7&*R^M1D=:O.T]M92W<;<GB+ ,.AB>?UNIYV!Y],*X-1
M.O(M<:55F(KEU%>;46QJ(+<KW,*IUV*&;B[DL F"E.WZ/I)VG EOGR,>AQ/^
M@2?UAY*YY'*3\EW;U"]1,?<&]HH$GSY>U=-WO463'/P\*J%7QL^I--)K+:<$
M(PP#"@/J)DP\C)]K+YJ;(MVKX^S=*;U/7F?PI([?7U0=[ E1!-@-K5H+ \J=
MWZ5Y9OR1JVS0ZJDXFKL =6CZO%9PD"HY^>$\VS"M5;!R-W0P8*A(4,AL7'"0
M?"")0VOP;\Q&I_,N839ZMZL)L]'E[L2^F4C80GW36DIS1:ZU!:^:#WJ"V.K$
M1,*\@4CN(:#O5?4WI]IQB08U>+4P(:Y+>,[ OQ^I@X;4H;OAQ 9)X([SE$!]
M1]C@O@KJZ>)M&NY@V"F5:,52F:V99@%?Z XZ'RGV\.(=^_C O5?\2!2@3D9K
ML;(AIF*+[F>WA>FH6YQ,X;A0%"!//- ,^4 ?#0,\%?QNZC@M8:& UX;I'[/8
M:6N[)U R2:_A?$GV.D<):,%<6&R%\"FYM2DP[<W"S?2MF+=8Q%N8KS!?8;["
M?/6; ,(-U:=:4;CM6B5W+>2S5F/7(C^<<?MWW+6R5C--Z($"(;E\!43D6LM:
M N(N'E6OIZ#"];OR]9C ,(%A OMC;]/K!'9J5]3'&.P7GO#IAAN2&J%/B;0Z
M<1O-7+%6+'VXC-?/U/5++U907T23G406"+6X6I+AK#P<.C&'(7<XG<D^,-G#
M&EY_8Q:[*(O](N#PVEA- (LE5#*WHX8-04ZU!0GDY#21F8PRQ856G0CG5IVF
M0;95W*590N26=$LVV[.9T^O$M(.NPE,/68+_C>IT<X&9;_665T,''#K*F9,Z
MRA/#KYIKN]ZW?QE&C,HKG$HF+W'D==S@W",C,!]V)(T,9]TSUH)(U(*F'(RM
M2&(%X3)N<$ O*!O,^[3(*9MR;TC5Y%4;JC,D<H-GZ <J2SUPF6,I9D^HSR0&
M7%<+.4HJRY[6>KH[TGB?#G%)QCB'#D(0@[JVR[<C>:$/U6V>ZOC;]A1Q!8NX
M G,$Y@C,$5?BB-?=O;/L1FV'1E&0![.*HNQJQ*"@G_VHJE7T-IE::VK)^776
M7]F>7!EF8KY [EZ2>^#H,[M[,6E@TO@,+M8_98U?N%BW<F96FY5I6URTJ.5$
M:1=:T^CDZL4O7:SC0D!KH[;2EP<-H[.=+L5MLQ;;)+&+E><?2.K<+M;/S1P7
M2(F9 .9(6N+/JZH;LZ*[I7G']\6T4EEX=M9RO=-C_F>HK\-UJ;>8!RZQ!2'9
MZSO3 I^+8JBCJ^;\ \O_3D6X^[C@_$QUIO!->GRU/[ZA'LP\ -+0* QFC[?5
M4\#1@?Y:X##S[88CAV_21YID$5WM>B$6"D[1=#LIFI*]=#">,)XPGC">,)XP
MGI*X=#"><,; TX:I)51*[Q'*S85AO:4D[[X.[ZG+DB1FMA/B4$B,/*ZVFWQN
M"> B=U<I<I?L18%A@6&1M$/QRV57SNR3W# OD]R<-G:FE]T4U:#?,65.VSB1
MJV2J\_%'#L8$?1[Z >J5WW-_\>Y8YYH<UM&#P_#AI$O 6YL:V*=Y[@+-G3KQ
M4^*,S\>.V<P5:+=&_,X:3%3*&(51RUQ/%8I&D3@T>^SF &8FS$PWR$PWL"@P
M+' 1VL3'HEQXP[8&D3ND<O)&!J%:-"HS>1U8'PE0O<(FFZUUQU.B-%Z*G$W/
M_&)+&A0* MID42S+Z[OL/02QO,5/Y#U7 GYT&:EQ+6 <E7*O42F)JG9["F/A
M\#).>D,H$W$YJ\A4C7&]H:3S&2;ZXVJW?UY!>W_5[\@E/U=N#MABCJ[(:CDJ
MB]:.GA<Z4/UGT"4_FB$>L@0NRH9/5).E$7WF"I+7(JKWU)SZ<YXZHCNEVW)S
M/"TW.M:V9_4&>:TZSRH18BA<W19S$^:F.^.F"WE<3\]3R]9N3-K<,F^UN'HC
M&C=EH*\%Q%.HN"V'F0HSU6=GJAM8.AA/."[M9N+2DK[SG\QU>_K=NE,:SY0Y
MOZQ"JV(2:$)05VRJ@W;K^'8A1]U;&5LS+L1R@X5L;].3>IN5F? Q)ZXEF-3M
M-0DU.Y.]J#"L,*PPK#"L,*P^/:R2;AF>)!?50/96-?C56M[24K=J]%:+E?.1
M\-N?ZU7^;#3RI0X5%?A&2T[3Y&35S#K,QA,4BMUGGWJ@: Z'RY[1!84IZ([*
MW5Z;@DX>5_@[]J@6ZZ5<M;CV+(D9[<:[38E/UZ.8/9C?L\<]A &>H,;M:5/W
M)]FIG11/%BX(\H%"N!^/S.%LHJGF>Z0OMIPY/1"'?6<I7J@"0!WPP"DUG;1,
M*7ZW-U76&Y&'^@[W6 & H^D'EC]S=N\D8S1)I]O71N4?$_^G+L.6A$R?ER2K
M<V0*G>C5P*RRO".VYK/2,A\T<MG6%-$4*CYPY@(EF)XP/6%Z2B(]O1Y)J)GT
MPA)XTQ'#J;19EM+%L..=O>[!C 227C'*0U&:=]JY>3-77)8B1%5QW8/, \7B
M.MV8KS!?_2%?O4]49ZYJ>R(W-RE'"S;M2*8(2#D(#2U73A,G9ZI?EEQH],>:
MT.X.:;&USHDLWS"RF69,6?N2"\P#SV=P5=M$1&1>&YH)(*V$2N9VE"RC9089
MEXW:!-2>-O5A.!M,I;/;<&PCN]F,(YF6%T5%F]CCV:PT[L0L@YSCU -#'Y+,
MIRYBR^(BMK>93_%&7-C<<UGKCWJ%IKVT6O!GM;Y5\JJKK+((EL&?W8)_OPM;
M#-P,2 \]2EPPE<8P(NQ2;@EY)1.[L+,/&4@M),E^DEIS5P<7KCQWPQ3R9_6C
M+L$?Y]!(LATMG[:%6E',.QM3)7=9*ZW'S,%^^8<_LY<F,8R!.0)S1/(XXG77
MKK4DMNK263!$*4<2VXZRU4L?B@M\6PGL 3,%IK!:6JJ_S!N:QBA%14!\@5R[
M-/G 97!)6TP:MTT:B?"O_BEK_,*_.NT4_+[4:>5$R:'4P'4R#2M_.?]J?QHU
M"FF+F,K;M6PMUM4)7P 1XHV]?Y5\X)G#_("XI.W-Y!Q-"',D+8WH5=4-G@I#
MMR?*E@56ZPD[<L/"L'CVTU^+K #1+PIS FCKGB4,B=FP$JL(R,G)9!^RQ.^"
MZ>X^#/A$)6U97-+V^H'"B1'1U>X-)EDH5U\WR4_4='41)3]+T]5%A(&&@8:!
MAH&6#!%AH&&@8:#AG(37%U'R"^6>2D0W%_B%R^9>'QZX;&["7/]77Q$)J\EW
M=7G@@GP)0PC&Q#VB('%Y<MB7>7).&YG3<L2=U ->55[8=790*C#E,7UCM?R8
MB5=4VM5U3BYE.AG6([;IREA0J&P<YT,<"R7&1(2)*/E$E'@)8!0DNCXN+H=[
MB>UXN&[/&K2XHXD6/\WQ?&FQ%OWI;6VA0.)$4L_O(B)=9G8-I:D5FEJ\A<9Q
M,*_NH?<0 (/+X2;<],7E<$]@"AQ>Y)&B=<><EZ>4O%A;2\?LE.F9U$E2.5QO
MTRE8M9%8%,TJ-5A,JX'8&T6Q +[\P[+9!XH\=O,''_G@L]4$B.AJ9ZOONS)P
M=24ZZ5C#Z$J&4' UUQMQ!YZ^/MS 7';ZW2P_M&I9T6A5%UK:EP4D!?[+/V3V
M6)@^)B9,3'=,3(D7"H;/309*?9+0J*3OZR?S*YY^+R[V'%I<;N5(SG.6N6NW
MN^NI'^_%R%WX^F9\<[%AX@9XFNF#E&O@Z*_;C?["WKSW>O/0D_=IO KQU<_]
M:<+>4S=0/4]%/7+VU-': ^,)*\<2?PWKXU7&M/F.2-7%>3>HZU:V&BDT&7OR
MB >X\#[!2?W5@9:P<_NKRR-YX43_[_Y6/5[G>&5CS]COMM;X=/[-.^MW=7QN
M9"I&?3.;$"UJD+7HXMC2&O'.RL.=E?H$NRKFEWODEUL]R?K,BP('Q.& N),Z
MKDZ[5>:93KE6".R V [FH5_,6!V[W4%;)?)<O;I7OMUQ]:N5D<C0MR8(4F9<
M)1=-29S>:9_2"0>V):BFZ\W4UL8'2\E85V\LHY7@=75U$;ZQWE:"18BAF12A
MW#H8,?QN0V@8?AA^]PN_I%N^)\E^WM.J7M#C2%E.=_L;X#O"H-_]R'TR:.%5
M8@.O[OK'HCGL7GDQY<3Z1$PWFY5QH<L,*@UH$U-QOG/J@6;/>(4:4]6?%)+$
M5/4'-28Q59WSUNKO6*8UJ>QJXK25D54M- 9L-MC,PBAF&>;W+'-S46-O+27Y
M6L9T7$_RG"ZW3U=_]MT%)T\7F=9P!\-.J40KELILS30+^$)W\$>1:>\O.%FH
M=*0MEVW,1:Z\R=370;9!ZH)"TRCNC"<>:(9\H"E<</*RQABNBQV;5Y^.A/ZL
M"/8E&.@<]64FQ86VF/@K631[9D25M?YNRTX1]^"2E9AE,,O<-LN\'C&XH?I4
M*PJW7:ODKH5\UFKL6N39B^1F:@VF7MM,1+%%ZY$XGNMJB/)ET/NBE]#.HG#1
M2TP[GYUVWB>7,Y7-/+'C>+KAAJ1&Z%,BK4[<1C-7K!5+'W'IO*]L9B[PY\7U
M9DV("[>I "IO-0=D;&?%93,SV0?FR,5 7#;SQ*YCS#U)$,/MJ#Q#D%-M00(Y
M.4UD)J,,M%BJD[/7YAZ5F^6QPU9'Q,)J]".1GM"-;6P8[>,P'[+$88G=(X4W
M_QVH<%9/#^]?XYE\;O=\KD"]'>+G[F=R>_;R>,:(_X>NNG7!T@,^VN%2L*FZ
M@/\>I, J5&V4<M$&OI\*9O!?_IO\>AMB5.,5KJ@4(&B.816*8VB%(3E>R5*<
MKI T(!A#-4B"5^$[_ZT^_X5&P^TQ0S$*D<FJ"L-G=$7-$+3"T3K-TYQ!:ISQ
M^!=GV<O0(!_YZ"_R[_TA!*(>PW4#QPU :K.PO]FJ,_V_+\!)R](>R@I'P''J
ML+.9##M1&)KE%)76#<68 $KEM D_,3)?_MG[8U)QWLR'U'^_3FD%<VWJ(":T
M1Y>U5='[)(C:-6MA,!LN%/7%['<NZ]_SV@=<SFW5:WFQLK:/1&\#+_9"_^Q^
M;JJ>IRC3)6BN5MV!N)4D(](6JMJ"/?GG?%(@J?A:-0%74SY'<S728\=0##DC
M S<==M8_E>?]76)@)8]KD*9*R6'=R:HJ83GK9N?+/W K)(Z9I#]]D5JJ7FJ-
MWO*?E! &,]>#*UE/(0B2Y']2JH_R,QR>IJ708H#<HJ<*0'OY3V3\3\SS \Y_
MB'+6%;D_!/DNF*-3,!&[.S7K+Z?R(LR'#3*JYGKSSN]6XI^/_5+K\$V#'_&,
M4@7\JBA3*K%N.#R7-6O3+_^0/(MR#_PB_\#/JW O@Z_Q/SQ1XRGWI!>*HP:W
M1>"]PM.OZHV]&4BI&DIFK#I;5+@;]13NLAY .ZT)'SWUX"X+414@Y*!['W "
MX;ZVSX'LQ)$2<>YCPW141S-A8__)/$4"F%QF*WZK[:2;ZW_^%_YX/NBR@>HA
M:V'VD[I&HY<\FDP$\3]GN:EX,'7P+<R+?L8__^ME=[^K1^G'([I'0^7%.&;[
M":9BFV4*TA,/J%9:->"KOJEVI&[]IQ-N_BO%/!E!WYZ-'33R%(NB 5+?/Z+Q
M'PAOH6[2+T3T:"&E;6 $W_9_]?15;-T\?>?ZL3_T6YPUVUP#].P?GAK/0^ N
MSS<)/Z&%)KZC14W-/,1-_^JU\D?5>_09HATRD/V?EXAZ_ IB"AD;""UY1'40
M!L\K4'W+*OQ1IL>$]:0+ZB1+9-2)0FL,IS"LJBD35:<4G32R*JGQ!L^1)]4%
M#_CC-VNYW6WUA'IEF,I56KVRV!7:HMRKY*7'X)5*,__UA3:<;S4+8E,2"_"#
MU*I7"D)/+$@]^+,A-GM2JY@7I'*QWKKJD)X[F7K9R]3W;J9:Q13J: KV="!=
MB/*1-BY_E;ZF=->V5<^'Q VIV@U]N"7[?U^R$XX:ZB;<#OY.O;1SH/(_@;H-
MKY"\FE&8B<HI61T 10.TFM%U*C-AV1_L''1$,<I+V;%!2:(T;T]'3FXS5[J1
M$N<!^K'EH%L*>X+@K(G6=$NW"KS86^VF"G78DB&S[6W%L#)B>KL$A8PV-%I4
M![8\>/NBH\[HK*@.9:X'FNNR5Y7\1:30"G'0S]ZP428]"\@K)^S.0Y(.0RI2
MF,.6TQ%%L.7ISA,7PEPJ\HU2;53NP)8'_>3T&<6;46\D#^ICHV4X3-$;"+#E
M03^[N=5X/A(%2ZYU&S.H+@]6TF2JL(=O[^W:D6,+NF6%U'954FB)JF4Z"G?8
MDA+Y^G!J!67+]$66#'H5(V='2N:P)0!KW2GTE Q1:EK+;#^:A[M21^$/6[;$
MKM)7QIFRR,'7CRB_M%R4IU#M/6C9*%0%RZH-/8*;UO1P51OMJ@M!(8G#IFR/
MG(\WX_Y<+(VXQ=BM6X[A3Q62/&PZ8_-4N%MG"];*H@6]60'6@HV0ZGG0E#0R
M0\D3,JI8ZA55=4I4[,D<-CTR]YULK=WJ;=B67#*5;+,\V0RD&NSKD<GO!MF\
MDLD.5'DU6K75B663U2IL>F2F=#"V?;NI=<75.!0%I]ERR'9'(8],E=3-D>WE
MNKJ4U8D^4=+U4/))V/3(7.W IK[JK6NTO,C.YUQ>SE:[(A36D<GB-_9FOE@7
MY\1VMY/35,%P=WS<]&"E!ED@;VW7K!,K@@IKY<&VO^P+J.G!4JW4]'Y.J52[
M\M:9*FJ!*'2#A@#U_B-K($.E.\!K[T30K1.#]+:F;WNPZ9&)Y?SIJJTHP[18
MFD^[A#U@M^,P0DT/.L!;8TK*5*F6F&\VL@UST<YW3<@31]9  >2J8FY.EV5*
MFW8[RV"N^TR$FAY(P&W3=:)&Z+!I<Q*L"Q")VP'DE"/+93<<BJX\*O6MEEC?
MU2)9EL4"?.J1Y9)I4<U9T-P,K#QI6(PE5>I+%S[UR'(QF[G.MNWT58MK]QIL
M?51?-YM3U/2@K_YL)BT8DR<LT 2CKIRM+->KN.F!L.94C["!.)I##BP+W R(
M.TJ&'3BRLH1ZEY0R4=L5\[F&#18]TNW!14@=65G]RBR?Z:^'&6NAZE.ZTQ#I
M&C=%30\Z4%RU)RK@FPTY%$*F*!-N.EV.4+&90\!P3(;+R5%)5.F@[?(-KNII
M4]3T0 )SAU,5LT_EB'1E4NUPI='"YN,2-MS/3>5QR[451AS*P%F30EM>[!9R
M7%/BH -*G\NN^J$Q(L*BL!IGJ*5=*\29+@^>6B_-9G-BD;'%O-#AMZ0?]MQ1
MG%K@X*D,R.H]V+$=L2A-B^NB2C= >_J8"N_'IIM"FUWH*K$D5MEIY*TW57*3
MB7/[',A5!+7T:EDFBF+>KBS[E:91E8@XPOJ@ TUIMLNO,EYDU=KAT%WT-^.=
M-T5-#SJ@27 +W%7:'I$NZL%&FTH.T8IOAQQN6:N,7:!<JR^KN^Q *=>;,SG7
M04[]0W"K]C1G;/H1D1Y23'U!]0?=/.SK$< P4K>4MO/SCI7FQF1EFQ&41@<V
M/0(8?T+R%;?+JD1:H>;C5J&PL(93U/1@6&T]E(ID7F1EM2)904:<>!-TZ>4[
M8.*3A6?S;'^>I"$M;.F#;T\?7JI1'-24'DTTI.MK>QOA1^/IQ7G3H^ET: @%
MWM-;'Y]&[NV7MX6^<]S7#//:2>@+Z^3%\UWX3,-VHR<C^^GW-#I:^[:W-",H
MA-\:>8]6=OSBIZ;JQ'?M, "7L/C><B9+ON-,]KN]_L&#2>HK^>J5!#POUYD7
M\BN=P?.2P'FA8R<6GIBD30PFLF3."R:RA,X+]36+B>Q\$_/.NZ&_59#O/U3P
M=PQ^50D<..[?*1)HFJ$O_^\+^^4/Q4.37\F?0PBO>7G\^$'PVT,(FZ8#4@WX
M_<Q/B8X.]-212+I[ =!'ET]"$?6AV-K]J=SASX.0VV?L4'^*'9+YRE'W!)X+
M7-#'B^?[XJ$_R^)A3L'!2<N>\YHLOI^=IXK=5B/5:HM=H5=IEE)"OE?I5WH5
M4?IV4D0E3#I/L#G!30]DZ"5L='\4M'4*!U'2JRO_R)EX:>.E_6:7P6TN[5LR
M)^*K'?LDZ+;KGZ*P7\)LZPM=/7S=\WC^,?_WZ?:31"'LY#>/G]/"D4?3PBVE
M^KA>8+T1L:JZW:A(I#U+^TC2@K;G&F;PF!/NEW>')7/E;Z- RLGFJ+4R)P6]
M-DE/%4:AO_Q#/I!'(O/_QE#]S%#]G4O]'J'*O(0JH^0!P]6SPX$I2D%Y.JD4
MN;#0^DA&H[=!57?'H$WRVYIEAEX--,ET6R^C"%;NRS_T \L=EE#Y^VZLW$=M
M0=#GH1_$]V!2'EB%I@=T=%W5 W#Z--,&*>=1GT#?HL^:ZL]22\]%5_KTU&2;
M^BM$UVQ,Y^^4NP1HFIUI"HEK;08F\+_=JYUP+;Y+F!A.9R[=A@E\^6G'J_\S
MK/[;L)+_>-IOT)".;^*F)^K^$NEB"1P_UF&PMGZCVOJIMZIK(O-R.=<O9%S'
M:,LAL.5?8.V(TMYQ)VE9%(I9<2%N[/8F5RPVJE.%V]O7+'>6 @\8L+<-V.O;
MV!<'[+E-[#<#=E0>$)E2;AY8IC4UB]MFM>1T(PA8#M5*8+/9T]5*2*B174"9
MH33SM-I#8@:)#8+/8P[?G=KQ$II'N"NP6[5.)*>W(HB*BYRR;*IMT%$R>V6#
MR!Q+[(?QC?%]JP;_W6DIO\'WCNZ6Y^Y*JQ'2KBDLY;P)M-(4XAOJ)MG,L21:
M-^S0*#XGOP(;I+ !_R'VZ&/[Z-/;1]BA<7+-HNAZ (XT'WH><+1MSU.AB12/
MI*2:#CJ:E!T/0&GLD_S]\I"2]'O5K3]8=2VJQV0&>D K&C55^%@%H3GL[<!H
MQMZ.L^L1IT*SV%8E9J#GM]: *??);%#+KGHH&154.,C,84V!>W.%Y&>J,P5Q
M[C=5T[P0Z"G;5/?H1O.1 HNE[6X!2,5KRD^%2[A8/!"87IRM$YM7V+S"[I/$
M*#EM:$; UPF.W@IFP&N[?O =JSG@ ,,,Q+VQ<80,TU4/#LQJ]$4P6RZIAFU/
M%B[*MX=4&P:[5C#VL6LEN2K1Q[#?*:F=&<.T!!'(I9X;*K-16$/81[&7AX&7
M-^UX>:'TZ,  GA?'2Z("XZE W:14WP>G4VP^(Y-]LC%C;\T9SH'VN*S$L.RI
MFT?F>N2Q(P1FU?(D-U&)K,B9=&DSW92F(S)"*8"1]I+)8,<,1CCVX"1'77D_
MPBNJ/K0&J_1<IJIC=L=D<K5>-D[RC2)77G6]WH>S!KFV4NY3+3,_981QQAT3
M.63\)=#B:BO888.-MKMUV!R,]V8OL2[MS;<G5W7+$?:(+L: KCC=/9Q;AO@(
MYFZ,91E"N?N,Y",,R;J*I]6'2UWDP*:<H[6>O#$$5-L Z4"'P3&GN^F:,!A@
M-O@,+IS+L\&YE**SL$&QPJQ&4Z[H6URH&K9)=?,CNX/8 .E+K]Y[OT&GSI-R
MY*O[.EJ&N8&Z4>S+P;DW;M74NZ>(F@1,*%[$GV3,U_=7W,_>_.2P^+X_2W"+
M:1EM#^57"+9M6W4"5(U^^8M]>$FGC7#';%IB6*;::C;+D?QTBLJ(H;.5^\]I
M\>*XY45&BGACCJLG/P6<X.P4V""Y,_<$SDZ!5__G-<<_1W8*?KF_4ZIY0/5!
MZJ^*L__T]V-0Y=Y7[P$-F&M4]RT=>*H.XIW/18$:V$:];?7^KFW4F_6O/VGM
M3VA\PF?%$1XAV7U&Y!&=?2Y/+696\@U"-3VYLZ+RM$IU4)%>Y$DG'S+<.;WI
M&,*W"N'K&]YW%RCP1@3_\HI'CP7#AFDTRH0:B'JGWFP(4SJNMQVGE22X>TYX
MP?_: K=C=25>/\A?'L)?]II(? L5FR+8%+DC0_QF]1AT,KB';\5I/6&WCJ ;
MGP*V#-D'0@S;(]3'TSYKI$MY0@1]0B?%TIIFA4@A6:3%O)Y.%Z,>H_[6'!!W
MH_J\"_2_5'SZZ]S4)4I61E0!-&5R;KIHS*<(_>ARZ^GOMB;$_V*^]+^8SAHX
M@>N9 #M8L'6&'2R7<+!4OF/N""N%(VX6SD2N(*9S]4J.XIOJ;M)1R'W"T'/J
M)!BWMXI;[%6Y@%?E1]C^4JM8><3088<]4E[,FI91&S.449LB_"*MXH%G[OD>
MQD^ZQLL#GJ6Z19ZH^%PG3J4!9P6;4V<WIZY8T#4)3I9K#_^SZSI/KNCV'OV"
MHPO[-#KU[T%-K['I-L^(-N\;@57R[%S B+ZZ*4-M*,YHRCP0]*OQ89A5,*N<
MPXES[>$GBU6N=\#UIZPB9I=+2APKJJB6C8P,QE((>E/$*E!'XX[D4;W1JQ]<
M_(KF^ZN@89OR(WR98'(\8;'6:P\S621X;M4*@C@/,=Q^A'!N*_OH[MNS]UMX
MQNZKQ*?KHTINJPH$9^A6N\VJU88'B6^?G17J4]0Y]2E,!G=(!H]*4H+)X.Y\
M4^_B@I\IH%66F 5GU2U"VLTK;A]T#,**$ 5PR*+B^#M.ZGHM*L#F9'+/_*^6
M#^W3RP&C J,B"2$SG_Z*SN,K)C^\(@)(CX*]M'44(2M(Y52QWAI(J6*WU4A5
MFGU1ZE6:I920[U7ZE5Y%E+[][[\G^!8^/HU.8!0)3B6!%_&MA51<>R]*S$[\
M7-_<]8)T +P%M)R7KF\&J<@,9KJG1JJ-U5&LCMZ)D783&QM>'TF$R2D=NLE:
M^'?CPT57%]J>"R6J^T7/70R>M["6$>]P/;C!%?;[VS'W+3G9K;TQ64[+K:PS
MVXHM@BK6!85Z3%KXP!Q)7'B;5NGCMM\./6V&@@E= QU@QRFEXB!"\)12"FOK
M-ZJMG_ P.E&;\LT?-K?5+0*6WW,%#:+, S_D<A,<_;5T;M&DLML$34D3)6?5
MG]F4UJJ-.@I%[8N04S2+CYCO!L(X=^-=A-A]"/!$OFXK>75F$J&]ZM>'/8=2
MMP("/%1)>/:PLLS=97!\4NA2!M3HGC,LGUE;28P0L F&/1784Y'<]8%A@OT:
ME],D7O@VCN2!_HTJ,1&JS9XW!T,"T(NI8XXJO5X(;0?Z>"KHFW9L"!^H4G7:
M%%2?C @2'Y=[\GN1"0[.O5_G2='U7I)A7'08W2'W?QNBV^FD>;6_<SL66/GY
M'$ES49V"!M4^N>9A.C[L/L%,</MA^O?K5?ES)I!F=)9<J)PBAIQ>KXB] E==
M3A$3H-.>5QVI]^%9^<W=1?-)BN>XNY@8623.<KPVC5SJAF/R1IXL KW2I<?C
MW/G+2X]C:TV7&*UAR(-.O33MUOA19PF-2O;Q0(IE< X)3"(7#*2Y]L@_E4/J
M71SR,W4P?L;95$?9KIA>=P(K'2FK.1DAZD#)O+(/+$/>EU/J!W[8MTS;P CB
M+N# >7R.?^ICJT0I3/B:"%[MGR=JY;/>)WE\Q7NN.Q8K3:&9/^=UQZ1))SEV
MPB<3 X[FP##!,+G-:(YK;['7#8+<GW8@VQP9_'%W4<)GQPT JN^I@\42&<A8
M:\9:,[81\6I/^&H_H0LX4>OWYD_5NV#Y>*[>,O+?]YD"F!R+*$SWJ9Y.>D"S
M:N70+97R]9F)#G_X5^Y+WMTI^H_W$TS?#U5'B^\H:.YBX2)HNYJ50H&(7BJ8
M@12*W/13PM0#9P@W3(QTL Y_L7/S3W6D=?8(PQ?!1)5',",N1%"6$)*/\&!]
MP-H\YP1]<2M5G1U-2H[%"0J5C4M=/O!'*DMAP-\UX+'1_BMZ0 ,GJ?_<M#4N
M;H"GF?NT"9'J>2JZ:H N(KJQ$8XS_-]KR/#U7-8XJN4RY:Y_2!_S"&W!T>.=
MOQ6C^PG\QT)::J)G6U47N&)+%S/SS*1=F.XZJ*=0$: >:(X_GR+PR7"!N>(6
M[R&<31](C/[WMMAZPW2@88%CZW%8+(ZMOQ\%XC=AL<4GT+\:%MN>EZ:L4N1T
M676# 1NIU9E&01V"1#I$]H'D7\M!AYD#,\<G"JB_OP.8=U''+V_E%.5<OT.-
MZX2<GTV%1:>7L7120!QRQH.9Q 8<BL6BF.^E6L64.,R7A69)3'6%GIC:?Y92
MK68JCDD4FH7]![$C5_I"76SV)%QVX8Y--%RP\485+-$P@!:T#'&CS51G"KIJ
M %H.(D[T?Y0$9PT9T0G\+O #S]0"H*-_$!S]QR]>M*PXFAVB>2F8_M+U5;L$
MM\$E_ OX.QJJZ81 ?ZP"YSJOLJ_%3]F&FB%<D2,5,)N-]&'/@>R[3]+)X103
MF&#NRZMS?VI8L@FFZM=GM4;3,J%Z-^2]BM$L9SH1(ABDWKV:P^;&O6MOT/::
M8B]5:>:[HB")J;\*XO[3W_"["VEY21-6<HSH^\CVD\@XG/O3\3Y$MFTH0!?:
MS9H'5!\4P/Z_SQ3\DM;W5/\:W>[ZI?&X-Z!WUJK% 7E=7OG9':1;>A_>0Y+G
MK.N=,!AA-CDQF]Q(V,Z-ZW,7)Y.?.22;XW.CZMH7B*VP,H:#><"3(P%Q"$J^
M^I#)'.8;NUM_7$ZH"\V\B!QRO]3(4D(OE1-+E68370R&+=MBM](J8'?<'5O+
MGRDUZ]D95O"5EJ&0%'+Z[SDU1W,UTF/'<IK(&1GX9G;6OQJG'J'(8%%L#LE<
M;2SF*VNEOAAVMD:EH]"/F5D?,MP93SXQ%]PK%R3??79I+J 5T](:[(:I9F0U
MX^C>VF_TF$&2N* <4E[!5,I#8B!I92('W($D"H@+D(>+?N#HP[R"G\G)]585
M2H3?GT=Y2IJTDF.7_D@U-*0:W0W19?TD\.HEH\RN,/0$T.QWE]@0Y%1;D$ .
M:ER9R2A37&C5B9 @E@4;)V=82JLJITLN41&UXJX^@"R[3]X*698YK"^&"003
MR*6"S3XW@3"*T3*#C,M&;<(,S$U]&,X&4RE)!#(>LKV&F+8)<3&VE$P8T/84
M=!"!(#4M\\ 0AX>1/ZEI_PY4.+^G7[D_0_I%P^=VS^8 BME_(^;/W<]K]^P%
M #0XZ\#[F0U0E]ZBHO9F(*5JFKN '=RBFP[[7$6J![]V4B9\]-13[=12]>*B
M3"@S L0"'!VZ(P$_Q?:9"I?ATV4)V-@/X!=Q>HJOS\KLN2?DK7N!;J[_^5_X
MX^GO-!NH'J+"V4^KC48O>21"@OB?LW#7P=3!M[ O^AG__*^7W?U.QFG-M5WO
MVQ/COAC';#_!5$R^4Y">>$"UTJH!7_5-M2-UZS^.B^=?.."^/;,V&GF*_<KS
M_Y/Z_A&-_T!X"W63?B&B1ZK?9TO>_]735S%+/WV'"KM#COGF 5L-S#5 S_[A
MJ?$\!.[R?)/P$UIHXCM:U-3,0S3_KUXK?Y2=T&?(E9#.[?^\1-3C5Q!3B"L1
M6O)HUX P>%Z!ZEM6X8\R/2:LT\C@@ U^LS+;W59/J%>&J5REU2N+7:$MRKU*
M7GK8>X$JS?S7$T+]O;W+MYH%L2F)T,)N-:56O5(0>O 7J0?_TX@-[2<K/$YJ
M>B$NAAW[2_XJ?84*DFVKGH]JW 4S-_2ASN'_?<E..&JH0T5/_SMUN;>>:,M4
M8T5&83B5)6@CJTQ@4X6A>491 0F43):F-$VC*5;EONQ!ICZI/HT&6;0G@=VT
M*,_@IKULV@B'$3K-_+GE>&Z,^7!+UBPSI_96:F;$95'=Q<.6<'T-!\MV-2)J
MH5I;FMM.?4Y/84OVYY:[,".J&MGK6V#5'I2U7C/2D.6F$#^W+#:WS;'0K8DR
M%\VK!6>R+:GMJ<(<MO2:DZI'.]9,#I>3PIQ;*_*XWX$M#_K)KDJDUNPH5=GL
M-%K,REV5Y9$ 6Q[TT^&'G;(R#@1KT2#K<I==Y"(H)?;P[5(VN^PMTFG:&NC#
MGCNI"42?1RT/WAXIS3[;+%M#B](6=&DCJG./[<"6!V]G&RH1#80&(:OL<M6T
M.^7(74Z56#O]24K^7"/(S2R2![L%8%AJ.._H@L(=]K/:%Z=VH]*=6*%;+_9W
M5(5,NQW8\J"?JVU %ENER"32Q<" ZB]9BBSTS(-^+@TM'$3-5<D*=[7M-FMM
M/&LG*/SAVP&1(S61(W(RQ:[*V4&1HX2T $V&PWG?+/++ I4'%L@MRFK6((41
MC5H>]+.A&Z.^SI0<N32Q]'#6JCC^J*.0Q.%#^]5>02FO(TL$6=X9&41>,@L"
M:GKPU$U_0?>&M<:.V J&L/*<K)8K1*@I_7/346E=\<61,"!J3JM7&3/MH;"8
MHJ8'DAK6Q9%%;C,>T<KV.G*U*5>&2]A7\K"OT^FP-^K7@X+<RLK$4&YTYW4V
M;GK05Y&3H7G4%?LB6!,;, K,8K2=HJ9/'8B-E&=5:6^D:HAXES[X]O3A)8=Q
MD(0>U26T[VK[_?I)$XSU&#4,W*<O]EI,_,T/NLX+._>QS:'>$GA/'7M\(;FG
MR+<YOS/DU\RKYU\OE(D7SW?A,PW;C9[H]>GW-#+SO^T5PPC*Z;<ZV2-KQR]^
M:JI.H/(?!N 2"MJOG4 _6HSO,@,>?W[0/92A\;PD<5Y8'L]+ N>%^(KG)8GS
M@GDLH?/"D7A>$C@OQ-?,J^F9\<1\:&+>&1SR6_WX:D+@WR&$LS+X525PX,U[
MITB@\8:^_+\O[)<_/<[FOK)7#3#CWW)L\XX+=*8#4@WX_<Q/B0Y*7?5CX! &
M4.( Q/]. *_-]][)?OCS(%SL&2K4GT*%I+[2_#UA10++ "PFP-N+C"8>CRQ0
M_,^)PNWPXOF$BX<Y!>4F+<+J55G([78]/DX3NJ-4I5EL=1M"K])JHNP\E69?
ME'IQA<!FX6B]P%2SA6Y]]UOU/OJ'[Z=QIRHDN$=ATB1ZA9@UY/S"8HA]35@,
M&!3?/2E8#'O'Q;W(X9;,G*=21*&GS=1]78*EYRYA=[=Q70*P"LTEBIN[!7TT
MB4M[O^U=.SCY[''9^VWMVL-,5&:"\Z<Y69J!:HN;)7!T,P@]@#)%A9X']%P8
M--U@!(*V:NI'HJ\%<[8NC7;CB%@P.6(XRN=VLV&DQ/=E*?HLEV4_)_CC[?W:
MJ+@ ^#,'EX(_._K/GY?DC]%OTG(ZTR6'57G;-R2?!:NT5D7A>MR7?QCBM8IC
M-^Y-.%*$Z71UE[!)\[J=?W5ZN) .E,"1)XH8SUF#:5]GR7\"^#'RZY!V+F2S
M@X:5SJQ5Q\MG!$H2E/CB*GN6:HN8&%[W=5P='I?2CQ(X]'<Q0_JF71R/"7*=
M:<I&2=A2\7B1"A#"7U3?!X&?<B>!:CIQI:44>$S.AK@GY< ^N#\]P#;5&#2G
M*<#T.>TC[!Q)*-9O50MX+D>/1M@R9!\("-JM1V!7G*><BT77>V:$.L)S_1'.
MVR-* Z<*[;H<6#;16F?%/AWQ1*F!+N30* 4C2;R64@@S O:88(]) CPFIZ6$
M%3W5QL75T+?4%A\5U?IF4NQ/(26@K*R9PU(==^-$N1XU8#/J)N(H7OS=>Z*M
M[SRLXBI2P9#!418XRN+Z+HC'5[P]C+%0D?+UEB1WQ><:@X\I0FXC,CB)R_\W
MMV_O<LR_N=EZA>HRUU(</]G$_^:*YBVEX?[=K<8K+.(?[RO<B6'WZ"?OJ9O4
M4C5UK'_B(W%\)'X7SO"*H[D+ ($-?!02U 3'Z@S)LSS7V2J=MK4=CJ(BO^QU
MBH,.ZM:7?\@'DL=GX]A"O5L+]3(J["V9K(_:0 5=5 1^<%J5X),M:WS,G=2=
M/8V7-#ZGQ>>TB3JG?=IR?JVJTMN*7E&]'D5LLT.68:IY.VC':3\YI*NR]/W'
ML#_ORQ[0@+D&V%S'YCHVUV_;7$<1[$^X[C["^C@!^N(\L,P&E296"JTM"D&/
M&) "2CN,+O"Q/#;5<1@[#F._,_WH[?10YR=NFV2-J3BH #7+U0:E4BZFAU@_
M8G@2UU:ZK=I*R>W9[59]TDU_::M;!(/'!/QOEH%M.B#]F$+UK0N<>/O,)+\B
M%(<K0NWGX8XK0N&*3H>]:[9ZHK3O2:^5^D5]I\<T<T+]1:6G*S'NBQI+)ZGR
MM2]\@J1 2I52LU*LY(5F3\CG6W(3I=EK0R'D*Z*$"B Q3X55]JI&,US X6BG
ML*Q^]!?E5-_T6T8;ZD50'/'S!$>7H'Q, ZJW3B# 725T4%1_&^X1F@G\'NQ
MSG8UZU%EFBA%%FR*["C-BYRA]J4\NZ#%?K17]$PG!+H0O-).0<W(+RD 5;$E
M[%K@A>!D+'"P1G^>[N^T@"9FOSK)_7_2J1?3E/H^3ZFGB8I7Q9DF""FL316E
MIF@9CQ<KX#8=S\'V< ;DG&=';KC<R/EP,HM:\UI6VAV9@>/M?C$#;ZN^\[RW
M?/G9,[C' \W];+C\^Q4[*L8GW!=>L:3X<QE"OU@KS^KA]UTEWKGV[U:_'K,.
MD]._$G#@XK$O9*)\QQ3+['<DSPW@S&Y2.=.%2BJ<1A#"^?8?4A5'^YKZ"RTC
MH"&&M+>IR QF*3/P4WXX\4W=5+WM0ZRK(C6/(OZ3W^NW\6_D?_Z.<ZRAYM$,
M/F6;=B-T^_CEWSZ_O1[H7Q]B=7ABNLN9"K=Q+>X(U'/W6C,D-FA':B%2B%TG
M?JL.8*_<.(%;_"K8<(%R(\ G[F(X(@7  _#K"5*: _1'3P-$B> "8#I^:J*^
M>.2+$9"9__AQNCC/! 'L+>IL'MBVN/E?/UP>JL"9K] *_T%YCG>:IYG^&4<0
M0G&H789!VG&X_.>I1RFP64*V]U'__:T/5?S47X_R?>[!DX2_IGIN"MD%#R][
MGYJI:(HT#3[%"*'DGR0%QQE$;@HXN^T"0,E "T&++8A'R2 9_R5V>_[?_TF)
MMJ%./-,]TV#_6H)IZ)A3U8:+ 5TX5^'[_HZOHZ.1!%!A#N*>P2E4]=!&9_2!
MB32Y_2I4$74:IK> 8X*+:>K #=U'C8NPUW# IA]?8T?+0K3AVO7/-A"T@*=V
MJ$$!OFL8\8J=F;;N 0?^0>BEM@ 5K$0MI_N>3]&? V\_XI(::G"6GH9V2D7Q
M%7YX%%XJ@DL*BMN'2%O"A;J&8I]LXS&B:IO[_;CHNGK<[X(73E."OC =TP_V
M.^/S&BX6A&=^@(N]H6Y3%$%2>Z[PH5T<?7\#$B/LFP7BQ 2P-44__H[J>FIV
MB#@\E?/4G6E#PO(]%=CQ@URTGOVOD,,>7T#1#RFD!\8]%D.4!!+:%! O"W./
MM*?NB?D?V LUASV&GQVH96E@_\V^@Y":X%P]X>0A]?^S]YW-B3-9H]_OKU#-
MNWOOS"U@)9'GV3M5 D0P.1GL+Y1  F0)"11(O_[VZ9:$",9A3+#-4[6S-FZD
M[I-3GR,)@S'>\OOI-42E8)/N\TWT)42!^)V.S3,9_4<948B=T9> EQ>2I)B4
MJ)N(9D*^S2#U/!AO"07D44G00(NR= HAL];H!AF:I43;P,!%&_7+4]-"#PQ@
M2=*7$($^CQ-, QI8X503(A)F8!O(Z&^Z%J!R0,L(5S)<3 U03025M62H",A(
M#4B&[>(O0#5LA!(!+4$O$*:Z@;;!V4!'JBQ@I+0$>2%H9V* E@^$LHEUC&Q9
M!(PJX$$8N? #56.(@%1'^ *<_2A (!R!:)<<HMA58A#Y<26&B2%MD @1>JB!
MM*+FT@DA;;!A+ Q<_TL<DU*W3=#8NH'(PU%N0]NPL 39T9N2AA[M* *T!3B*
MIVDH2QJ,-5W51ZL0!;Z& 3RGKK;?B0"#+&'-!036TP @35H 7QA(^6." @B(
M]L"BD.<BXH 6  C1!3XVHB81"5ML2./3>T0,0$#_&R,!3=G:1++0DR61#/>5
MC EF)&D(#M& ='8UA:%DH4UNI 22LHAA-_!K;0 -9W8SS@M950&P@"8B,4;(
M0 .# 1Z+'(F@^[OO47Y(0+A!Q(>'UBO;L$3ZUH)8.'Y6C<^M5"(;D57O=5L)
M -$L)-B%2>08-=%%@?P1"&L,?S G EHQT9%M9JL242;(PI'[NHB?@5YO"0J"
MFCA''P/DT2$!?"IL44/"!4PZ2I\B_K(@12#O'00]5$6"'UDCJFZ0D"4BF\T9
M/,* KYZ?%[?(7$+"TL;4--4AW$/"HTCS2".$J8VX@O@J,K?-L3PU_7#&SA)R
ME @Z,)L*$X=)D4&ZX0$,Z&?M4XR%@2!*$_16\-@% Z$+&9F6;-F8K)&(7@ZD
MJ44>C99,D7$-V'(EM]]BV3'JD$=!Q EB:E5$SI9TP.+%43Y,?D!ZA'[\1JR?
M]S=,>'[\^2UL+!&F\E0",XS";1XU"Q,J,"]FB8F.L$=.L]GU;[SK-\R@_;LC
M'?/C\":"JK#2;>OW4%Y*HC]FZKK@Q-D\Y(03 &TYWG^UXS=[[?M1@#\_F5\O
MN,U[@=F_\IQ?CNIBFX6)!@Z[:BJX> /$T4''@T)*VN_].0(7?8I,G@$8ZS\A
M (2DX!*[(+^P&\LP_X"Q-@8>%L!W0M)7'LJ2Z+I-(%JQMD+V(-JD 0XR,M41
MXO\!YO4"S7N^_-D)];O0*7N==)I\ YUN:--/L6,;;8K*5!!Q.@F"?0,*&THJ
MB$?L4")#69^@_8I.[ !"GK*!C 2B'AQ[O:\B5\T$,I[@[U?XEAG$H7#LGA##
MAOJI(16'= =R4I$9@-0I;!H]"3DD""'FK]#SM'XXE\0X^""!^I.K&]($!_3^
MQ@+P7+==!>S8YSO 1? BQH:-.!T;1:($/8FQJ7PX9.1TU<$J>#)5O?@*,EG!
M)P E;$@C0(B.?D0XFH+G,+-EQS<C;?H<2\]U! ,8N\BP0#8$MFOP$XF52VQX
MU_IU#/A]0WO;O!N 1PL%EH*I:PAG<'@)6=]DJT@ZP*4J)Q4-80T( 1(K\>RF
M K"1H=NC\9MBB>"YJO* 9-#A3!O+R&\U2907X?"LJI_$T+# X2+!A5_PM=H0
M+3><N*@;D<.?N2$#@B79_19\*6MKHO"__X<-,_^@?]GX/SI5-1>"*NI4VK#7
MF["(K _0[_XG(9=GXA8#D ?*Z,,R":I@1.<E0454_-,7@O4MU/.;,*%[2$3
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MT8G'&29^,!*/.\S(C7RO0<H<G#1J),_A'!(ZT";,0)ZP,1=VM@HXOA,T ";
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MTP:(Q!63?N,3(1T_!M29#US.?15T;B32M,%>W3J(-DDELAU"'I:.Z4FS$>A
M$(B4"+>3H'+(POL#T6>KECQ%S*'J Y=P<>V_0Z18WFP*"#R:13M$N!BY,1P$
M; 7^KB+3S36@X'/9L0(VY52'FG@0ZD7DA?;I?G.'-/'AH&QK+&"D.T3GNNG/
M%*1M@'?"K'_B8.D6#G4.W*JK3?0(J1#;\ ?;2$P443YF*4=R:Q(2DH[X%LD7
MO:)Z4@[G50Z9  /=<&];^>HC7E,,UY<03<[=NRCPC0'2)T0JP@]0G8?\:>_:
MGCE&KPI",(Y"&DV!FD#(I^$K!4>-9G00TX9*/=GQR4R$&'.X.HBW 3$MG:LN
M.'ALX>F\D 1T[$$$T[&YL0M$0HHX!O@<G>%= $E*8L@K6/#GY,[5TV"G<\'J
MN;OSB8(4[SS269J>520]VIT/\ZL5MY]Y/+SN=G?^-7?3-VD!W]7T_M5<G3^X
M/4Q&P&]37W.,L]ZC9[>%WE:#)]O-S;^ED9,K]S?*S$U,H#,B*YA8ZKL%42/2
M0@!LCP%<+@*+P.,M"-"@UTS5C5S=+GYSRS-S'%?;*L[$=^+DB6^CR(7!?C()
M$.QD.E:4J&/EY%S;\>=4?5]T[M%9DJ_J&7E#\'8BXS0DAM3#;:Z@U@J7)T]E
MS4E"([0)(R>U*^"K>T^VZ=SK^PE7J2E2$P-U];9![K'AKAV_,#:01H<-;$JS
M\1:0F24;FQ=O,L,F,A1,S\IQ 83TJZR+IDN'Z'D;O#G $)%[X4U8/_X<Q]JW
MO$W)^"H4N1DYEW8W@Z6]X]T2;>NSWW"V'*Z5AYXM3=N6_-=?G):X%:?=BM-N
MQ6FWXK07B]/8-Q6GA9]_QU'#\CRVA2F]TZ! K@J$)_J@, 1L/:#O/-D:\2>]
M )[OT2\\T+$A.**F&Q)<( ?/,XNXVTE-T<&BIX% ^5 D$I9!^LSG%3'8*XH$
MT&O433<1U_+Q=K9I+](D@0;WHK4[V'RKB\=.+HY\[%DU^L$4&O$%L>E&:HV0
M4Z=BZ\H<2Y(%7M?AK6_"J$@_R',OM>^#YV$'S"):&Z",7V[X2U TB'N 00#1
M('Q"#'1]QV'V6WA.XS=P/T7DYQARGQB*\)V7,?IJ5%W(7>0%W%G"=-.WS_F)
M$=V>I_CZTZS-1AZZY5RDS"5'W,WS>Z$K&7O(MQI<C>MW>'\5Q)>20Q?43PBX
M_=JDY"_52PT<TL'SVW+:QTQM)^TD0O$%=D@D[#3!A4OG.XXP)%#!A0/09T;R
M)6.>2?]!E-(M& .^QCV)B%]QIHN;&5G%!_3 L'U^0<5WD7<@0*)]'A1VCA]\
MU_'=0/$& OYZ!MUS4_&[O0>[/75 1!Y^!Q;="ZQ5-T+;_V*9.&A>)Q+HOP9
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M4-!L%M8XDK\O60N8=H. H$@6[O NPTP&;QC:UAG)7+3SP=[7;-IK;2N9(,;
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M_L03 9:-!AAF/Z'TF5/2EV:+2]U]O?2YKZ%)[^7EP9LSS>>5!R6MVAZVDM*
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M1H78?-5O2[VUR*K5(*>5%]"_.AZ)!F*)_<#;WS 4YI77\)3+1M;8D&Y\=**
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M8J!1SFM7=NKLLC)XJ-V8E>+59:.R)#%0CA</CV[/1G?]=/6X/^H<G>[7-*Q
M R9^,99*+\_"7[-=LB*C?\VH\(9^@"\N*UZO,?R5K"BDV94ZW+FZKI23W9WL
MJ5:93*I+\@WT;YP=]U _>TS6D[J^T[-SHZ/]+LB*',J*3"J[/-? FFV357D+
MUHP,;^A ^*K2XK=]"G\E+8[O+UBSG6:92KETE7%S!:_^,/Z;5@O/2(M<+5TO
M:_;I=?)H4FKIYG5JUV*H612^_<K'4LMT*JS9-EF5GV'-R/"&KH<O+BW>2;>(
MYPK53G:_DF[62HU1;]#MG%WO+<D.&>G=YG"2WW6;:F7_X;9\GKO<FZ"T0'=$
M.I;,%M[<';&^6.(]M65/?Q=)O/ZX@A7(P=6C$-Z!"IN ^OH%U%?#ZRL.OZ\!
MKV\BR5]DSJN/.Z\%MV]BJ%]BSJN/N+X=%3Y%\+#<TYFC*UM5T-FG2PT=KC O
M=,6AQ57/?#VZ(OYV[)&SYI^9_-WS4=Q)Q1];%?W&-LW2S>C"/5^2@["2Q>X/
MT_9^Y:K3.GIH[)2U'/640'1Q(9;+/=<><1-[7$KL<=5;;G6QR57/?*V$S>L=
MC'\C;-1;;??DL;I_7XF73G:,:2NIG626Y%\\]>K9]-G];KJBZD>7WFDE9Q:'
M*&P0UYR-);>7%([8!"^?"UZN>M.M+KBYZIFOA[CY[>CGWXB;9F;DF-;CM-*<
M'M4'Q_F'X^ZMMR1QH^EW@Y.3Y+E7.;);C^G'HW0Y?XF]K0K??A5BV_G,)OCY
M_L'/5>^YU05'5SWSM9(V[Z/<%([2K-0<E ?]*U/M#/-FHZR-ER1MXL>MHZ,'
M>_^@F3]K[ET^5/J3Z1%*&PR>IM*Q3/XY&.?'BYXV+%<U_)Y=2L>V!HK## ,;
M@'4MJ^V\G3\FLG$RL'':EH<]OCZ-S!#>EU7/<RW@%4^[6GYCX^_<7>SN=#)-
MM3_8FQQUC\N5E)==D@LE>9(OI$YN"]E^^7(_K4][R?91 7M8IK_]RF9BJ>1S
MJ(E-//EW_26KWB3OY1U9]3S721@LT!9^0QCL=IJ[]_5"SZNPPLW!Q>W9W=[>
MW9*R./>WS_*G1ZGK5+*<&AEG^OYT<)3$YK.Y;[\RV1CLB$WJ]IOZ,U:]3=[+
M>['J>:Z%.'C:5?$;XJ!R$D_O)K/I0?/HUBU=5+*3T_-EA5=N'./$&I:J@\K5
M76&_90^OJY,\Z@8%L FV8_GM)?H@OIPX6 <5^KW<"ZN>YSJ)@[_3#N*FUE,=
MX]1.>F.V?W9_Y<5OFDL2!_'3W?QI.U>ZK]3T?B]U.1EDO!RUNT^1/"ADBI\]
MX?LBXC P8&U,ARG  <K%?ZN#X<]=Q>%+]H;^@Y=\<9]13KP2T/%51<<?>AF.
M.;^6S+;XJQ B=UY.K3"WJ/?S@]S#X5EQW&KWER1$CC+MUG5Q;_LZR:K)>"=S
M>)EUQN<PB_2W7[GEY']N\!JOQVM\4F&RIE-?)V'RNWK(4\(DU[CLE9S3O?-*
M.I51]Z[L>W>_L"1_1>&HK@[M\L--,G]X=)5,-1J75K\$LT!_Q;,1BPT>XUWP
M&)]1G+P2D/%5Q<D?>CF>U$W&];U^SMP;-H\N!Z7=2W5X'5]6Y<IB\?[$V.]>
M-Y/EZ[$V*%:MU.X>ZB;D[UA*(&0#N/@=P,4G%2>O05Q\<7'R5MK)^8G%MN^;
MNSO-VL4P5XM?G%:'A67Y2]34PVW'N5&3JG-J)MGX["%SB>*$8RI>K([WCZO"
M<O^BVY VNNFI_+[EL#;\?RX[+P#X;3[R)^T_&3=8QR66>Z6,H/G(UPKVUK W
MY]!A/^0//]]@3G*PH2NN-:1?:0QQ0YU:GONCHT]8.]Q9F@]*;J.HMTH8DWG\
MVS_A/_S5@&?$!>TY&.LS J,PM]_;B5DA-",/PLOY5Z,-E1HP<8\8D>9WXM*W
M7\>6V54,?<3:BNHXS'44U6:*86FJ"Y=T4ZDZMLJ,A,\<<SP?Z@H>6L"4F(_H
MJ3VW+U2Y];+N=?6QD;V\;1Y5W>T+*Y--[[9**$KP:35TY^-9(]L>'I^U^_EN
M^;JG']V?U:?G<&=N]L[68Z.T;6L]5KG*3W-777:X9]GG=^F[Y.R=!XYWX[4[
ME4(E7F8/M_V;DQ/O>@QWSGU]>'2R[3[:VS?]VLZU>I3:U=IG+7SGW-<OC_/E
MSG!D[R4'Y<%)=O]P\%"^[-YEYK]N7VB>'C?BR>2T<75KMNX/'@K;6)9S[LY^
ML7$U3?>G5\G!M7&?SK/1X-88\^+\T3N+$SVU?>266\G:L%34[SS[EO7&O*9W
M],YV>7!<\'I=(\E:AT7/R.K7F2I6X9C[^F7NT3Z_/-&KR?+=V!NSH\'V.=R9
MG[]SV\RVND=&.I-43;M\5!R<:NWZ.1P-<W?FR]NNGML[U"L#=K<S4<U,;=_L
MWA7F[[S(WF\[^>9.LG_T<,]<O<#.,U=C$,YS=]YWR][=F;F;KZ1;=YGX46ZG
MGX%U3R7G;RUNNUJ[_>"QYL-NJG35V7FX."K!K0OX[F"<W]_=:]KY"M./RM/6
M926^=SG&6R5)^>%PZ@U@)VJ_XP<<UH]OCW=S]DWRX="Z&.\EXW9?&\\>7"60
M$/@2U=C33=74=-6HFOS@@ZN[NJ,9EN/9K %?W8&MVQ?G6NNN42K?>"=JTZK4
MM4XFG]/VCB8.J.0,3L A?,&U/;8L_2N5##2.9]NJUQH5I:C@(91*_52HE^33
M]X>UKP[]#UY1;YZ='5=.*J>-TL6-LE<]+9V6JZ5CI=XH->BR4CW=JUV<E!K5
MVJG?K')YL^8GS_/3WE$-6$HX8WL,I.X/?U1+XJ6A,?E1]X9#@PV8Z:KV5'R_
M3I\/L5,#I?H\)_7SDP-[='MK)@?95L$Z.75U]W*\+$Z"0Z3'J06::X3("\](
M>G(YV@T?%*ZG&-! G<1I5<RH<J5ZKB4OD [.KXCC/5# Y 5^#U[ARD(!=!I2
M9.2XQ/=20L%YR6REEVQG$NEG4\=#AW7H_1:\LV-88TDT^7L<E9D?+9NI_?@8
MR/1S:#DDB7Y@!R07M(:9=X:4.?]6M>58AN>RL/+V_K9QZ+G7\XE07OB_?]G"
MK+!9E[5<E_RSU50VZ[*B=4DF4L\6_M@LS$:0;=8EO"ZY9_-T-NNRFG4I)O+/
MYD]LUN6OUN5EJ-KOZ<<K(T+A-XBP5 '^UQ0HO$2 YZQBWDE[_E_?/):3!RL-
M*?*_W]+?_I00J<1V81;A^J[9LH5HY$8#DY+9?TZ[.ANZ%#KA),LD8T_0;L,X
M?\LXZ;E,B8_,.+M,"_--:B'?_)FD73&1GB7)LU69MYJ)>D)IHR_(=C .XO8L
MSU'-MO/]E26:5[Z?_N8HFN.2WSR;-N)Y;I>AD_:CB.(/SSJ?2T CD.)-I/&:
M@9>>FW-)TV"@KJ,,U2FYZS%U0]4TVU,-QX\666Z/V3_>=%NM&Y'>O<XP]XFN
M,QDB7RG9NFK .P^8,6(X3WR_:CKQ^8_\CJ7Y%N[+->M<LA:\M=EBOK=NG<FP
M]EN,.]8^[0[[>(ZM,W5J@[E$YS1Y(UE;89,A8CM?DV+YP73>=SR)UQTW_=>Q
MO$]0=J[DW-4Z(3#.-=M1C5*=[33CR>W6S?;>0#ML_4TN1&4P-*PI8Q=\9QWK
M*G&?SIRR9]M@7RQ"->]5KEN-8;/>WY^4M4'#:51WZMV[[%WFVZ_M[%)JX'[-
M7?I\Z.UC[-*7 E6?9I.FTG<9D:A0WLGDCU)V[A9VZ4YG&[Z<ZUW^38K!G^S2
MV[W\^=Y-/FU6O$EY=#]]+)?K.H* \]]^I6*9['.56SZ%&^#,MG"?POH"I961
MJA$.<6-L?!U[_@O;Y!]?,RFA3XZU+\6^?5K0M;.9ZVOS+#5*7B7K@Y'=NKSN
MY\=W.51'TK%T\KF2-!L9\-D=#E_7:? )])Y7RX#B42YSH,8/KOK[N5'.[9E6
MSO&Z( -(V2FD_JYT];JY1 19-FZ0C^X&69FV\@7DTO)5DU>98>K57O_.O$^G
M*]-!;KQW/CR8=/K=NSQJ)X58*KV4_F1?<S>OVEVR*KWC"VSF=U R7K6;'P9V
MZMY)C8;)FND<[EN96J\?QXQET#.*L5S^N0HQG\*I<F%-50-I)/$3&UMJXT_9
M^%,^CM+B;^"GA=S.V<U9NUR.WU6.*@?.].38=D<&=@("E2676TH1K(T(V+A3
M-NZ4=])T7B$"M-R!TTL5.WN5]/F):G2=_,5C'T4 ^5.2A1<K5WTH?TK5U*P!
M4UQU\N9:S=?:N!N/RF<634M43AKJA#EG?.\]+94NLD>3CMO,7/:/FLUR^::B
MLOLF-B>B2$^FL(&>;'PI&U_**C6,U^WCP[NALYWKWYPU!ZV+WFAX5- K ZS1
M!MI%)I;=?LXG^BF\*()"BFLIFF@8NS&B-GZ4C1]EC545K'0G]FW#DFV>GY9Q
M3N9Q/QVOGMY4ZM[9U?Y]ZR1S0Z5_05<I+J>+XF;_;YPH&R?*LE2<W]S_Y;/R
MSN7X>G"?G%KCL]/N;G+ +K$Q21YME63N[76<%6-MAS#"*67IL =/'V(Y4,7!
MRJ ZLS<(E;]295:7</XB361)CS=35U8\US407DO2763BNY!A<L>6S'9%[M>Z
MW*Y/B[7=SN-)7;L=]YOI!G,:-YT&,P94"AM],)DEZC5?;>>3$K/&.W]E&LU&
M0BQ+O7D;$;&O#?7[[0I+5O('R:+7OCR]F-R54$2@ZI-[KL'CIW#N;*H?K)OC
M9^5]E-XI%7H=I[X&XO)]%"J0DO-(PAK6$7I:5'8.[AY.AFY\V&?)Y."XO7\P
M.IQ0"Q#0IE*Y6&K[N2S-C;Q8DJ-HY9OF?9*RUW'F:R NWDF[^A-Y<3ZJ7!ZX
MY]/KOEJ:7A39Q463=4LH+Q"74XSE"B\"D&5[K;=FU-D='+K1OR_20>ZU6SS2
MN&;^]V7/X\]'ON3N376OY; '#QBE,H)_G/G>.A?Y>*E6+;-,)5]+68]N\>9B
M^^Y\#;LTI9)^X;UZ<Z=>.6]B;Z7*)?Q;]VOPO7OKP/"ES]P[4%VWWH%U'1M8
M@214F-E6K []^."IMLMLO,3:RGQ-:@6W#KF?W1Z<:=T>/:4[CD?ML/A;'*9T
M9*LSF)'J4M<J)T;WEJT!3'2*A4(-IF&9*74XM*T)R'&7&5-%[NWW)L=_+:WM
M>S(D?N ,267X;[*#ZHR$:4R'T0ZK,W\7_57E7_'V6J=DVZK9)3+3LW 0WI$/
M ;T*#:;U3,NPNM,&W.5TF%WJVHQNOM+=WIYNP?GX*-Y[62C=%>WD9-3/%_.W
MD]']X85:B.KNN=_"JIS9%B@];6?/M@8RGA,T<<US,7JJVO;=8*<U;FW?%XQD
M[?AL?ZP>-&OV3O?;KTQBD;]S-5S"-P)\PJ"*)S GQ8&).(@Q$814MG9L]5$W
MOL<VG+T<SB[W0(?3?29VQ(.=M'U:O*ZT+IO,J%W?:68^;V?'[\*ZD_,)<[O-
M^G:233N9^T;2WJT[P+K%Q**R&.O'NIRB)-<W7/I&7'K6 1($HE8\5QP:.ZV]
M>R.>W.^T&KOYPRPKWYZ_"Y.>)4TS<]U/EBOI';7>;F0SQWNL!!9-8I&S>/V8
ME!/TF5[&F[;7RU%=6Y]'=8WJH*BWLG:,-XA@BMJ%S=J%PSJV,BGX2B'H]%2;
M.7>-G%9.WL2S%_U\9=<SK%S=>MPY?U<YN)TZNZT5+G=O*JQF%ZUROW=W8'7#
M\JQZNO=; JWN@G5=I96!L0.7G0%!K7:=IDQ_K UQ0DYEPFQ-=UC;EW;)D+0K
M%Z?;>X>GV9U*N7EU>]<>J<Z##M)NNQ@K+(0%K6;!%;Z4R,3 E0-8<IHBLB2L
MHLDX&XQ!3^?\+N:,]UN<#"@:AYZM]52XO.';C\ZW%S?'5UV8Y6GR*M5+M?)'
MF?S^9??#\&UKJJA$-93$HIXF;_Z@:-SA&EP6@EM(XX32"(EFFVE,'X$@UU2G
MIPR%DH.@-]5 CH^:5O^UYGR_)DKKRTR?_&/=\_4<OK]?&)YE&ZJ9G%HW@\J]
M<]TX*9R#L92-I9/K8^HO$L&.I_5\&?R,)AKJX1C2#U-"7>(=$-_&(1SI4$[*
M(ZEX.BA!IOLC3E=FG<;I8=#D?H$3WF]V_H>Q W]B;=T9@B:,?_Q=M=O03>8W
MD7_>[[TX'.(O])_T,J+U":VA9C#5QG!?;\8 R.!GEM&(\[GV0_"55':VH>;_
MB?0-]4..:/]8]@\95PQ-1! W33S497'>EE3MP+=^J,98G3JRM7TAD<X&IHL<
M"$Y=R24*A7\KP8\!=T=VP"0>HE&$8_E3\A+%(N6U%WJCAO;5TE9AANLR(:Y3
ME9Z-$OM?C5IY(1.^*%\:9*W2^0D+;+J.SX+J:]@P2M-%Q%))Y-YIV?:VED^K
M=T76SM]EL\7MNV*!;=\5LKE,.ZFF,MJV^HU_E3]1!<,I?:*:*G=H.+NZHWD.
MEGB&TZQDJL;4T1VKLR<>6FE@"\<:ZG?X]*UA>W=H,VK%"\^G$XH23)7"8]L_
M'268,NDN<M*X6GM^9 /6K4U4IWLNF.,9+MU2&S)^C#M^6&WY4N&WR%8N-1O5
MVFGIXD:I-TJ-R@E& B\J^Z6+W>KIOK)7N[B"'^/'M=H1_N[?4W^!ROA9^Y]?
M+]Y5.MU5+JKU(V6O5&[4+NI*O7ER J-Y8WH]0YUGVT?>6![HMY9G8"\4M4U:
M:L<R#&L,4DII1YE##3&'Y=FAT)<681 [8!#+9Q!09;L,T0A<OX@^'X3.1,2-
MX2L)ATO]69Z]4S9Q,2V780M,S?#0+\(,AXWA>XP[/6#8>R"0L"FFV$;/$B:5
MC)_3%^!A'&O)-%$?OV!#RW85F.AOONR(BL;C<*<@VH3K1C8T?>U[,BGR[603
M2AWKBPBK0C>Y(HOD1Q5;!8VB[4_ZB36,*4,5_66>H=I@5M":P+H-00=$HP.G
M#!J-R:GLN+"(K#NE.>"?6IX#'W&<2!,=L4AF-R87P<$'QF 6Q W+ZB-'A98/
M/RG<40.FFO!7XIBZT$+3VR4Y0;@$9B85B2O!\.!JJIC)Q!05OC\@2L840=SH
MK3$:G__&5&7!&RL3K8<>[="KLPM?';Y1SG!F2NA3L^DB5M+57,[Y,:7%#)UU
M''P*SS_:#O!605:=TXGO/<_U;)90KGH,3"PGM(XV<1[WZH$\'/#>@NGD3Q5>
MJ.E#=.;1E=1/^1?Z[&CN,G-<LB;GKM.89Z]JJCEW"9A,-[VY%V@H1V8OTI3G
MK@[4Z>PE9+>Y:Q;12S7F_F"SMCX_6+"4[Q?,@4NXV:MCW9A[[QAOE->0>;![
M/2W6L&>K#G<#.#H(:=C$^H O"3 +K,I4; 2Y?31NW\?H%P>L5+VMJ_94$5MH
MX)_%\ (24BX7"O"XCB:-WID^LWV 1>0S\''5553#>&ZWM1B.X5YL;V0B1^V
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MW")V*VHBP'CXPK2 Y7;_Z7>!Y]M3A8=ST,E.TJ62O:(Y2(,A%BAZRKQ9P6=
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M $6?;-PH0Q;$:.)SFW7UQ3&I^7 @>JH?JQYZM@.K1FJ&",=IOI'<TX?^MO@
M4*G<!BJU@4J] )7Z<E)@WDL5AJ?,VP[<887Q$=0*,+0C5&D9$-,,51_P.# W
M!D'>,S105&TJ_&*J&W8,A+3;X.44323W'W/H;.:'"\4#Z28P:&>5)8S-P<T\
M]TL'92;T#-= /=,W:4&-05PQ0_>EKFU.]^@I$+91*1!/5_E=<.*#X ]@2H$#
ME7P)$;<HV;;2H^I;+CS.-AMCXUE]Q"(\"W6S)F&'ISK :C8<;R0-?AYHIT7
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MQG+H%*DS4X<%OP3;2CF#?4&)2[Z',YQ"7$./'M4T^XC:0^BK&!O[>]*_#&:
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M6)2,'_//RXAG3>Q#W/UC*RR#I6LNIN!,D  \5(CBAIF/TP$>O.1 X<4!_,#
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M$]4OX!?D1U"J;-:R+9[R0<;C?GDW1B<7+]8<(Z' 8[M^O-%ST6\B>E@Z%&R
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MK F!TR)@%5E5 D?MPT\^3*PRM8E5;F*5*XM5_D%\AF*'2PG/_'82T&]&.?V
M348$;#+)5&$[DY0!FU2:!VH4+(D7)X04:I,@]ADW,LC9'2>D*'^C"*CXOJG%
M(14_1R$26Y%UH>;BF>AM&9+7-CT;[GE%0(*202,!"7PU]QUR]1 M1*[,4R0Q
M<B_JSD0#QP_N"M,O:K[R* ;C=9=E6*FM"! MNI[X6X0A$0H'S [5/Q3?R0VO
M<V4UJL6@NA8TH1<GU&]RET0AA7(A0_U\.%X^$ID#GAL T3U1-P]^EGE'9-"$
MPD:8<XYP9<KN(WTGFN@'2O<8_DO,ED[/N-""6!FAFR6/!^I*V[.#XHJA%2>%
MZNE!A?V9(@U<'U)Y>C_R3J9$/)<H)N?"6TL+;!&_16-.G,\LK'.7*K[;2& ,
MX>AMQ#U]$DG3G*%7/I')O]LH.5G@_<O_U +&G6>59.9=IYY,R.# \C^(WL)P
MZR1^G(0"I[X_G4XCZ9]![HFZ<OQ"&KPZ80<%=_@:K[\08,9EI<39E *!TO0Q
MY%T+4:T+<FEGS(&I4NYATS=KV%.N0#A@MAIS$\#CB9@HN5V,B>YT3@A^@NF7
MC/H RP,(_N-Z#N]TQ\GQ3CTA0REYE [/K?<_%O[2O4=8V8CCAN?94U\/71P#
M)J^:BT^@%XHR80Q5) \.U'M>O K$:R@R.<""R);-.X4A@H/LW!&6NY4?)W25
M)/56D;M"R5FE$LOY?AU75'&2@-BG$E*XUX0GRCF8Z-\60PQ5J?;'$QJKJ3K
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M@SF/^)*R:GS\0?'=LMI@%\R(#CSNS;LX[NO[LC(N$A XH>LWX77Y6S,C7[4
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MWUGC,/PL7]#I35IGF0S,F<&4&&]RSGM3_,2>A]&+ELZ8#_?=CPM5F21),+R
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M0]A24+RJ<XF*+#W]'1@93"B,0]?7P^M']S %KO[<IQ8+7%>8\W^PNP;+NKW
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M:S6S,XK,R'@%N8N"T6/ U2CEP^D/F$4?D>9*M'ER-EROERAW,QC"WWH(>(>
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M4I2XQ%PC?DIVW.B-H @K[F;P5()[(79C+F<L]J(S$$][L>_ZA-Z->.*P.M_
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M3.:]HIX[G8K<AS#-4#/WW/C44//RQO!3@RV4\8U!;7>HW(P"DO6\!AO.<RN
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M;'/;^(MS?CSH/%/RN$X[YP'_KA8O(S=5I$FV]Q/P)9@^MF=A71[F5.#M=6>
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M)'F[-.?%WKVIBOTQ=X7U>=JPMNK7R^6#%1-M:-1&0T3?<[_:)*;$49JK'T4
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MMPKJ* ]_TX[RQ0(+'^J$*$+ZK<0W,3D\_=]Z1#X;54Y!9JHF-A/E[2<XQ-B
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M/CUVA+":FM*/#U)Y']%H:ZBJ3'H<:*/UZIC&T?-* S/["@7PJSN6\\0H+BR
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M\?&_X^A8W?;D%'JVZ7-F6SK5)RPGP=1:S<PA3!??/S#(C:237?"=\PN:3U]
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M1PIMWL%Y&5LG@%XE#=@@$NU:2VG+E*#W8KPAP\)O@^UB9=/)'F8>NB\<:_U
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MH"4H[T-MM4",1$"S83&D_]GQY\9_+0C]G?SHH] 2S48(A!O75Y%;$@:9$T0
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M!GVZ#"\2[8 /T07JK['5=FANC -U<,^!8,R&_9TL.K&@=,$L!ZZ6/P0E^FM
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MFH1>$VJ 0"YK[?7OO=8^]_^?>_9Y]CWGWIF,Y\F8W_SF'&/.4=[Q?2'^)"X
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M.BCX-#[[&;X*524".)1]F%D]F=W<.HI<7\O,_\U#FFM[6LEDZ>. 0(+FX_Q
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M.M1W;;78?=+O-"2;+D_T66<UGDI"WAMB"[L:>34MFV.[^ZZEW1_C$;[^0JP
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M(^=X$5.(GUO/QN)-WS_JLM/_>/G6*!Q,!+#M-SNCIR*>8<OBT#=TGUJCOBI
M?B2V$ 'Z>#Y$TRUT@G$;\CM71:KW9,8/GL]Q)TE!74NXQK>@D*'7RRG^IK%K
M >-G_-C0=Y_H>< GB(2:/+KB (93DT:-R@HEFB,X/W:X<YX6#VMK41OSE&T$
M&VJ#!^"B3(O23Q\]:9*R.*M0Y7=K>%KC6:3.U!MIH_N)JM-WPT%>>=1.?[>_
M:_&9^/>@E*#,[D12H_,+/*D[5^-$JY*RLQ@27DQX@CW(WMQ#;5@A@H.;/8;[
M4@PTCM^D03],F<%P0!2L<WJ>!I]+!'11?YYS!3:?,E>:-?*\$D.)BA6>JG(7
M2Z>>&A5:%20A]D%(<'M01H]M7%]%9$&\>,)GRZ_8LE]]0M-SC=ST,6K4RDI@
M=$X!)/WGS+K2<@8T(LK[\V,(?#A(Q$"JX-"=E6?TLT7E_1,B8,&X$W99K=TP
MH#USKIDN67EO./T-1GCE56$S-!]M*R8A[]",&-O6VHKPN:UYD5[3XWY.NK-.
MZ;_*5]!3&>+ZF>' &)_1SALTHL4ZZ47.8G+W;R0.VS#;.',5N8#8-MF@#;W-
M =N\ Q]4#^&U Y (@ NW[C-J >G4%C4N:KFS0"TBX%.LV((;]/F98$8;\!Y4
MZO0I$= 'JB,"*L0<6!TV_L:"7"//+ZG0O[S ZDW&X\*YL1MW7L4*?R+]IY39
M+Y.YS;'D*2GO9^FY_>J%86@8!+P "O.=I5"/FF_[L?%EKKL@1#W1'UH_,W-T
M6"&N+7H'[",VLW^S3@&]T[_EN#<7>[)B@+^!NM/JVN>KI*2[O>_B'K]GW?H]
M^=8Y<*@9B&9_J<R+:J:PR%*+<@C28HZLJ[W[XL6+GT,OZ&6'Q:'\&);W#:US
MOAWBQ3=$%&X\FYH)A8U8\$VZ"CUZHQ?ES4*NBMB7:A_^)=UEF1D54[Z>GIZ0
MWQ1WO2:U+]IEN.3"M+>*'5C2EC=?F'8\+!?3LCONCSU).HS'\V<0 4S[]F1M
M0>)L7V=L/2$H;@:?@5M;=@55IUSX/=W1E0LP=[=A]T%C%\TO*$EJF%4'I[Y)
MG,>4?'$8G/-.MWSM0X@*Z[HEK*HUQKT)H&S'-QFBEC#2?9P<V'8IF*L8 PM3
MW'FI?.,QFM84;%[3W)/!U'?:D9RE];QTS*/?09N>UEQPQO>B2A08$H9_:G7,
MOKR:)8U++_8L7_OB=K/'O9[)J9?B3B_<&Q^-@EW"6QI/]!!$?SG,(=G4D(SW
ME"M[YBAD!RRYN<Q#,B1^_=*42G-SF'IW8T^5.K<YM2V[BB(^E-]UJW3M\(>5
MZ]BMF^_KY=AXOZB(>:)JOPUJMH.XJC_2=RL^M&2KBA)+;1$!\#5O!#XI%OLU
M6Q&MV#:9FM3X]"2+1"ND!]4:,<=8CS]%JP@:7A[<7WT^@JFY12CI&6WB.!]N
MN8J/N4!U%N=<7Z*F[U<W0CJ_?DP6I)_E0Z0I.RG,G5B#S&Q^HWH[6E/>Z (I
M9]U4%3Q+;W)&J6ATSQV[APX'"D=*8C)NB?&%-4OK26TVHO$$+_8HM1&;75W5
M'X*6WQ^'#)>['Y3(M=Y6."]V.%P,20+F-@<;G_T&M2V"=)ABL7(CLU;:U].M
M@4=:QAKT07N&MAU3BA95JA\6#*_?_BT^.;SZ ^;JB45RN9''2 "_KZB9P_[S
M9R8.B(KSP5 A[%EB3("/;$Z<11K_2_%WUW[S:APMGSWO/Q>OPD5F1#N I6KM
M[SU+B,B6'%D/ :N5C8!<6DLL6K\1 :AAKMQFC,E9/ %6^'/6GK4RHY>\J6YY
MH([O59,<>M) J:?V'8V/]A*O;>4P?\5'-[]0"F_1Q^LC8*3VU+5/!_"6)EGL
M$>H\!OM>:TI6[8IZ4=]UQIV;TQG)<5X?J- P5ZF7BM2K7*K%"V? 3:Z$F5*&
MZC#_X_?17C]C48F/*1\>NLNNK ;='A#5SE!,"58"\HXX[!(!E=&=+&,M8S6=
M_<R!-<RT1(!Q^2,\^^$S'"SIT3C7H,16_M>W;3*6M]T?M3><5VG-V?7W,+=-
MF1HDSV;I:87X8+,/_9NPH3DE/R%)ZJ--ZM[NG45PK^^:DTU)':"JUMAS03!7
M=8/L6S8+!CO%P%2]&MFVU<)F9QY[P;D&,3>P.*U+?O[T:B KZUHV \RYE0.J
M6%>=>-[G(=#HQ6-FTW(@'D0*_JE*>]['=9B!3I VPVE%)DRF]-O8ZJ3ZT"3>
M%BV,S;_BLP<ZX,^B:UKW]D;,]QX;Q1X,(\,[@IPC0\4<UDX,W\JQN;RV$,Z@
MNE.1=^B"M_Z\8:/=BIYG0$HLOR]HGY98Y+1X)/W!#/*Z1+3*-N;QTPU%D:WQ
MX^W8PR3ZT"%507QQH1T^0SVQ7T(1C>JTF*[YPKF6V%Z,'SATPCF_7!F-*G-/
M09[XO;33$EQ*>#^9/>D*RGAO$F+:7%]OWYBEHQ6B!-Q4*U(4@[7;%M#$8R@(
MX,'IA<L51 !+=/CS%4/U'\69VR2[_ &";[T>.OGF5QI3.%#*\^XKE\2>@M K
M;3!RO-B"9)[DN\=@GV+KW+QU*NEKT(29B_C4B(4MS+\:0UDDE\*C'''V9PMF
M2JE[@D;TH8 *Y]\TDX>&@WG!8L5;*MFWD2L=OI;C1 !W$\4"/$J-%2HFD?6>
MXI<G3TB50:@C%61(C0L%<U.+M(#1*UNZ!^:U?UGC^O#$RM'H=0@%PMV8E>M#
MR?2FCWF;46:J!Z$QZX86BZ772N1_SC__BOZ1FT9@9<9%Y[Y9WQ$-:A;G/+#>
M2!01<+(;1P2HLYBU<,-ZP_^#M_PVCO]U8BCU2O4UWO-PL"I]'MUAR,^:""&[
M)E#$8_G*<A6V18+5"I5V?1$G9Q#B]IWYTO"1M;&Y+*X"<:H*5?^Q/4=)N!4L
M2$FJ:Q8D7\??4D@>4RBJ+_$K#^-#<\-J\NVXQ[N5AY:N%P60;8_:OI@;Z&AQ
MY*_,5,[68T+O[EFD\1+,JVO$OI @XLE#!/PH+X;-I^K\C:F.WKMZR I+.^MA
MU_+/QN8W^1 !&C7Y1$"H(?!O'-\H\'OX3_-SRR,>>U8DK#T=-WQ&A<PX.Y;Y
MZ^]@7=AM^L>6QZ 9+]]_(>#(UC5"KTHDZ/]%\4[^(1[P2S$!OJU03AH,MO=N
M!W?.NZ7FZ=<-/;PYO ;**R[K0-^!WH*AX&QK)\_BGN=4N"MW\KDY;A]@6+%J
M?Q7-5*B-" !JYUMV!)44;U:^$8MFUL^Z5CB4ULRYBA*=:-^3>H8,+75<EX!U
M9=%-$@$N0K923'TY,[(E'8(Y3]<%,N^?C?8D=3?:\ZT#(Q798ST)!IC7?J=B
M+P?!+*EBBO' #,[%%# :A#=351R"H=C'JX@ .T.%<WK\B3G5'-<$!]W[7,$O
MZ4SO]57'#)5\]Q3S$DK>9WR=<CB#)CU!G)7[!H?<DAE;>"_WP#_D<\EV=^B1
M$6*?K="OD* 1U]:P_0X]8'^[OV_2^O'I7=!-QB/=85 Y]-9?SV@\#AO<T]^H
M$X5X\&F1A+'+_+X$IW6W/RQTT;3[B4 H1*YZS;,/Z(1O(ZA50(-'#>=::F+X
MLG]#SJU>3:X-&?UVX@^_.X:@93=,M:PQ-#!D&N2^'=$T+T##0,VF$IIVO$H$
M4!"@FYQ-LB7IO!R=/OJJ#(2[-%80'PN:H&R)KV"*5Q$I#F-/?75N%KT/[5LG
M$ &])^&'CW$T#@(P-HB N:;LUYFF$;+^-(E>B@T'YU,7R*"L%"<2XCW1.B)3
M].IK,2:PG B()@(86ZY#5;!E-N;9'9;IV\+]$GL:]Z)_U"A.Q4/B4+6=(!9P
M0.;%R"B$B&3%9U?>IM3XK(E\+B_S63V9#,.@(VFXC3%-<9O<R>KA9A!L4R7$
M_3'FX^/M"O[:RS\ HW7W]Z8%2Z&PLT_*UNP)4$W4M+V-B"^;I_"]HC(JQMX9
ML7X,7@GS4^\6'OQ06VWV=2P8RHF;B;=NDBJN5-&+F#+(US:?M=:33K" <U%%
M/)EHV"@^)(\\_X@+1]%'/Z\&LMBN6LII"RC*M-C2UO4G)Z]9-IGCJ#N.8*P$
M[CS;=8NI '_U^".QJZ*M4H:S8I@[YW200YZWV,FB=QLU_"(4;?-\ MM\G!-D
ML.#^JU/R$R(^\ELRD]-^2FQR7V,=!N<-=GZ<RK>?3&:U5L-B5L"G3I%E#RAI
M2EC.Z )+'"[A_&/0*LS=+<SAMN&Z$XL-'ZX/7K7;5KZIL(*%OXEN!P*C))45
M2B^KZ"9\=0U?6$DB\_QS*87\ WW8WE[M@EK%!!&0;0P/+9P L32!"J$2^&N>
MJ.GR4-Y@$#FT7N"-4@JW4I+RD\:/4NB*,&#[!HR[3Z7*+=DJ0G14ZC?=];JA
MH*F.)*Q/3TH-J$/QO7RIAJ$4060'^%R$"+@R65QUVF+2LZ39-O+6U&?R*/2)
MU3HN;4)%PJEU+@2!@<6<T&5C2TUPD1\F!TK6V?1_LV8/U?W&0:%L.<P&0AA]
M9(]P'"G AGS.X-.-V=&U/]Z>59Q*!X;/J;JT VG=(G6T;C&)_#WDN!I01Q<T
MKX$<ELTK(;$)=[K*)6H)9-N<[!W93,KL"Z<].-K\MT'02KN%[_7/R+:S(/D3
MGEN>%[YO3(<H_RY/)7/$G?NB8X\51T4 XG:%35#E#Z4>*.>%V;>VJTBAZ=N'
MV7HJZ"^OV\1==U(N9GRYT@*F?'R-9<8Y9+-ZW4^36^%.MR]RPGYC;#$DT-/)
M?6&>#_*^,Q,>6SYMG'65/"(UOOWNHKO0/NOQ!J;9:-X:UUT9XN+C[N6_PWE@
M.F/Y"6J$A7?2OVZYV3H%:N?ZF#U]Q='CM7X\U6(KR@"R<A[I;G!.R%QO-XN4
M"C(S1"QZ.XH9M39RR*3NC9_JM8AT8#<.0T<1!NQ?FYM?3=Z4^/S6._3E<I-Q
M>S;"* <C%9L%;,#))S_.FZXGO:/36Z9#HP?G5:,@A/95XSW-Q<[FQ9--B("_
MA.5B5)&DAZO@[,$![WV':[M%79_+"X.!.4'9,0NQN(-@%6?UQ)[^V97!%_<C
M''_P6&9#1?#ACTM<LY0GGK161<XYWY+QOD2CD?60.1._>+&;1QE5YXS-ELY'
MT*I8Y@4B(,G1M!A5;LYR0,W8Y=-#KJ?5@Q3(M8Y\-MZ<2H#UGL@?/L!]..DN
MQU W>UHP&_7WI]A_)^FY0R;8D!U]+C"J[(,= &$_1C5ZYH*IO6Z_X[*/3D>%
M]5ZW[&,D\.'VK7^ARDVDIY[?,Y7ZP\- -.NQ(??N<4T6<'U8^EZ0MH7G&.NV
M*.1H&_.8:CF9.=E#LW<"Z0F*V(!(&5H#ZW#K\?)M_CVGQ+N+Y,KU%9.[8A(!
M:+HP]( GNXUF?I?'@Y]GG^EELI^C6VAAX0[*R5_G."9X3GXSU%5E@)S=I48U
M6Y'\"'2.'42)(-<+FOW772H//';TI@T\_(&(KAGV; [X8FVF N;6U5GFR[PJ
M6D'PS;- OO+3.Y!6HYKEW>MOOB9^9H5_G%^83UQV'T9]-!PNCDBUGV^W!<6
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M+O:_":S_DDHX]R45^IP?B4>BN4%XS0,):2,_<0]NTXC>*UOQOA6CE<I/^8F
M" /K/2<(_^GUQL6D'>&?WCK- "@.G1#<$[2<6N32D-29=.FZY2U$4[] QX6W
MP&V.=J(;K$:4&7.MXGZ#DS>7: M%;ZM>OJU2NM0:Q98\N#!]$7.I[!$CX;5F
M-TCJ[3[H>ONDB&T8TWXR)&W3BCZT8I0Z 1)PF.US%I)B+98') \12<<4AD0
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MX,="].:*46,@D[GH_<\E'I@OK+\L/')R;=QJ_2WE&3/2!P?:?;Y=?[0R%0M
M$X0P]L9F$]5M@=>]I]V2#:^;7']\7XDCL7E7!5PU)9F7.(AYUM%R\V:(EMFH
M,G>!2\96@#O/J_LW[P7T=U+V75$B!?\%5CV@R!H^C\$AQ_?9;:R!]N4.'^>:
M:KM2>L"XC';IXY+&<N?(;E2/AK3#IS*.RQ17]V6G7CML*02 4BL1AKF$Z(ND
MT?ODOSL9R/AH2>G# X-I(^B5=\5-KLX,]0"H##_#?^C);34*M>5E+M)W#5^A
M/TY"TN-Y-3UQT>W,%$)VB"2:AY=#6PYZ#F9N^Q_&[>AXMSW);*W*F"$">K<,
MKRE;BE%TMM+.?[X(/1/E\.NQ<F^[N)U>DPG6S?)Y\N$[M"Z21N: [:LNI]D;
M!8D2YBFZ;5<]?8:,E'PK8OVNF?NH%S26&]F\7=%#?K8)R8J&T[U%K&00 >QE
MU:S5U>/5I\>R/J2# >#').\WOQV(ZZCOV)T=]8B!@5SW*D-*S48\9$8"6/S9
MNG4H_"D][XJ9TCOFUE'/)W"1-R>^]WJ>T9 WW[.BZ>[X_&G&HSO7B];"'SA
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MX<HNHM;SZ\:8!T/9R^H[3P62CRV-3Q7)QSQV?..DN.8A/?>KPTR%@E^D_UC
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MCTXKC($&?YK1A+<Y%;@&C?NWCQM&?:R?VU9K4*12W(WV#]'4NBW"9I4\4BL
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M5K'Y5$:2X:_K)P,$\L%5Y(Z23A6'G>[,)J_*WYY;ZR:-[:QD#!G;IZB'2'<
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MHZ[L*I@;A,9SH.)ZISXRY4]9Q I'<]^]1RND6;"D+?\7OV#^7A--'SWM&+C
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M)H[,^XOBH)Y[3R&OWW'@N7.KQ!J,DJ/N9MNUV%S'5$B45:"S1X@D^B4S@9<
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M!QETBS]@A&1S^6[82Q11='\)4R9U!3->74 OSO+^V6'(OV^PKJ,GW>0ZGCY
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M$1)2.KG]A9-/@(5R].AMRS+R#TS-04]5*C%*B<Z;P?<&^%?X+X2(9Z-'=4^
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M'NWK6=1@E_AC\X<G%9=C/X2WZ.J\3]EUZ4S2^R!!D>:3S,]8=S\'EJ\UU1^
M/;TC4KU;G[6NY]4^O4UL4E3,[<X')<R2MZKDEU:]%6'\G+?Q0Y,O]^%[LC\J
METOF7WOW(S[^GLAM*0U+"^;&\UF_S&ZQ;MO>)?I[XP+'+\RB:HS/9351SU<@
M!Z]8/L%5V/#+2HD':9O2=E1OU_X>Z.]XKT'LJK&DW9)96E<$&^4?NS+4_[\)
M %!+ P04    " !9-VU;3GR> O+'   RW0  %P   '!L>"TR,#(U,#DS,'@Q
M,'$P,#<N:G!GU+L'5%-=URX:1$1!0:2#$!%$I8KT&A'I B(E](B(E B1'FI0
M!*2+""A5NDB)E-"+]":]!(*$WEM"#1"2R_N=[[_?]_[WO.\YY]Y[QOWO(G,,
M&'OOM>;SS+EFR6*3Q\DS@*M::IIJ (IS  #%V0^ / E0 5">._?'YVR</_M0
M7:2B.G^>BH::^L+%RS27+]/2T-)>H;MV]0H= QTM[566JPR,3,S,S)?I6=E8
MF-BN,3$S_3$)!>79,^>I+E%176*Z0GN%Z7]YD'\"&"Y2])]#45+<!)QCH*!D
MH""W H!G>E)1_&, _CDHSIWI>('ZXB4:VK,;4%<!YR@H*<^=I_Q#Z[.K_F?7
M ><9J*[QB"E?8-2WIK[IPG3_36S&1=Z')4W,3P=Q?.+/7=]>HF%A96/GN,5_
M^\Y= 0E)*6D963F51ZIJZAJ:6@:&1L9@$U,SFQ>V+^WL'1S=W#T\O>#>/D'O
M@D-"WX>%?XS[%)^0^/E+4F96=DYNWK?\[Z5EY:B*RJKJFN:6UK;VCLZN[J'A
MD=$Q]/@$9G9N?F%Q:7EE=0V_L[NW?W!(.#K^ Q<%@)+B/\9_%Q?#&:YSY\]3
MGJ?^ Q?%.:\_;F X3\4C=N&:LCZUM0OCS?MO+C(]C,TH:;K$*_X4Q_S<=9"&
MA4]B]A;^#VC_0/8_!^SM_RUD_R>P?^'" "Y34IP9CY(!  *<2!]\.,T$S1J;
M=^0X",2M5])6L2X^@VPSK$. CNE<"EX%%N7#A(1#M^N;ZIBL%:I7 <.)'[%^
M]GCJSXOO7 5$?P!<K, 0ZZ#FX> [%<43./B&K6-\#K,@WX8'&8"K5'B!6+)I
M) ,:<^-(+,N1B)7G__BCFD.P=L* 9'3([5613^S?EMLFF%N)D0$9X60 B90$
MFG6"=Y!"!,F DV-H;&:,K=X1^#<W)F\75+?>^&_7[,F 8-0\\)@-209LKQ:K
MA2O&@Q8AKWT=TW^1=HO_=#&+Q(+^M^7O'!B2 ?'^39O?$>(G?;7_?C'F3ZHL
MV&?]0U'J_^)Z[D$FU&>CW^!!;7*IB>^%S=:PG @Q9HMB.L?%CN9T.O63)WE!
MP5ED@#7[6V]NZSZIY2)7K1RVD=<NHX(;T2M#K5HICG=7IBKM$A'-&'S,Z64P
M&7"X-T@&T$+;07MB$#)@>MBJY>21W[GR :);IKW5A:$<WX@>ST]-2\Y"RNN]
MWB%E.,:.!N!P\?8V4=8#YN H+E0423^6*O?9)_9I*7C;VB@G+$>:L](979+\
MIUG5B<)(-C)@H U!!B!TH*N@LOY619A>],%P"RL,=G-+[1GKZ_TFR2)<V0$<
M[>> IZ@#%4Q,.3"811U&=TJKY>4M&RZ'AL-T%"]&NCQU$''RU]7^:Y:V$6>F
M>(/$];2QQ*X<^S<-VD7+6'_IFY<8/PH\+'86G4#/"8V=PRO<];,6K//+<N&N
MZF5(XWYB,'A[A3&$G_'U* JS)/TGA8&XBCH;,D"%F0PX/97LP9KJY5EJ.WG0
M-KDP.L$7V&QY2YCWZ3?R</+-$$8_KGS(^L%]B]\J'HM90CFOJP[RS-SM53 R
MJRML<'2KX8&6+JD0!_MK%ULI$CRP'> [S?!0O##7IX8;8;FYRKM[$20-<#Y&
M2Y^8^+'AIEO,$?1D0+.X#=\U;.?*3*=%!34 +.'"YMUW3W]TO53.+KC-(.]N
MMYGJI">\_V^@E$!/Y/U4ZX:#%ZQ8&NQ-O>@_7>!%LQ>;:^%$WTO6>^]I<_&O
MS1L]5,$4VOG,%ZL[;NB^0T(=5EQ A>WH)?3(X%][-0J%G-B=HP_=6X7!_,2]
MN JU:]0!4H-KKQT30TFTA/XVCG/K<L;!+KYY8@+\$=1\UQG"+<9](=I^H3UA
MC:+UB"_F?VU@1$3#54+CSR0_,&8KV"T/H^596$I1J13*)2C^T\>RH7)>D:5Y
MDW;28DJ=*9SN?O:N89:6_E*XCE^8*Y+]CF8YZ67HWU!R\++Q1,'O.JX-^\4A
M'Z-8>!R99E1:W^*WO6I!'=%H2P9<)D#G@<%"SS5S<:3BOH]F=:&N]R-QV/AE
M%?:0Y,K;,S7<*3B9;X*[T\[(_-W$OUEI!5@NVDP+H_,#![58T0UMW=HMBAW"
MW'_QO*/(32YT8QG/JE/R<0=!.U7(4+PL0''#9UYRE.:SMZI6%Z0^6NX3_DE*
MEN<F9DGT;Y8 !I%8" 4=R/LK9K?&OO+(O[!'TX0.Q&$+X3$S9$"DWRTO!]CW
M%2_CCY95T>?6=VJY X%FDX?7?]= %JQ)0_/]V^9+ZG^SD9W3)VKG9*HU0+.L
M=2+K=<\NVZPG%=G@*.?H<ER\+W.S-C@(F[_Z^I5-*4C1T?L'&3!%I%UL.TB<
M.V/Q+P.0H40C!3S4#'\^B2LAUL.EX%';"Y3AT4!T]5YQHL5I>L,-N)=. NFD
M!>QBUEJ;_0$PJ9[?E#MUL58^X'S'^GV=8B?%Q^E_$[^114K7 GXI,:,(_JP1
M=;[N@TU"5O#WG38:68K2W LCQJD<#$LI",K'"M YVQYV187^-,1?QGAD1@.?
M'R7!J8BH4(T7?8."%RT$FXZ^J.[6KOP^LW/%[_",XW=IHO@->J7@#$O(9$;3
M%]9+Z8^3DCSN&$;$%SFOM8WEO,^[1?=R&Y5L\]?+?/.8#E&Z@^M#.66O)4GV
MQN\/GP^1!7-;WZ:DSG'7.9$AJIJ/E)^M]!SWJVOI,D54=8?%6-2 IC3L9YN0
MMI/(&2&@OR9$[N1G#2E]3F^#-HI_2='NM;Y=F8CF'O/(&K"LL55'5,^W)X86
M6U0CLL2C+*"H<2'9G1GIY'^^H4QP,EG/ /C7>S1K%A)*XL&CB D^_'%NWRS4
M227/]:KW%0OTVJ:I%6QFH,H>1?;2QL;9\WVVW91;JL"JIXN>C9V,K3*[>8)^
MG7^=6(LT @"$@Z7N[BT@G64OU99":"1E+>^-_1P4@6&>"A^2/'NJHE9=4EUO
M7>D34YW^);282N05*''&J,0*$1;_-\[L*]V!G/ /X(;;:53A]E%]7PWG2/AQ
M&[[ +*YJR:7-$RD_=2IJXLW#:#[+GY$V;/U%=KJY'-G>\44[DJG7C61=:RL7
MW:C_FA#4;./; "D\!$.7.+M>^^FM"E,T$]5ENHN].BXX\?8DK_?N4\ G \6%
M6Z(+#,V6:IQHZG'CQ Q?!T1L5(GQTF'1KC@9\->>^)K0>'(W[XT";:Z5_=@A
M1]&"TY(C^/*#BY^YJ*V3.@CKN(Z6 ":"6Y:CG'JHI/#]X]FL:Q:_KV<M*M]P
M^XU6@,XN.YML;9;*Y82V-FDGZ9A"/+U!?Q-6"G("^J>O>A2)P3851'UOE14O
M//_*POV5T01#WSS-1(AK996[%1+C(E+P*B<'98T:H+= ZVUQ'0P/+) !#L-S
MZ)&XO^9I/.X 3@CC0HULSD*G!<9C>3#R'AT*8[??!;# D1VNNDG<81Z(A=32
M4I%SP(=Z/N"OPXX8'R92:9)>TO8(XJ^5ENAG)PKA]5H6PG5\5:N'9^/>?50]
MTMSKW+;(<6![^K'NJ7VWD:#R3E<YR<[R;[S$5<+(5P#1W3"GB-);0GBC_[J2
MLHAB^L>=,P>CH"^GRW\_J?Y&/AD@<!(T:4BR.TSU^AON.P?52_.(!5OT3@9'
MZ5B/Z3]A_'=MT+RJW-WI.\BJ_\>:]K,C!KK^NXH&$AKG566Y^48HR(#B]GKJ
MV?1-R[GMBVL_1$K\^5$Y+.=,EA='_0W1H?KZ0HIWBTU5.528S5*JLVX?IA=B
M6?!7\L(EY'6>MNLIC:U)QG*.'V36V1THCMRJ(8B]O/4RKKLZ0;+?]OPS?0BC
M57I9_IT#D'*&.>9IY$GZ+=(0<,=4094,L%3?85[R6$64>Q$31*^2 6A]8K!W
MCG\%D'!O3WUY'#G?/QK,I&])?4=?E0GP%T*Q9[>A@C1;15Q#"HO8FF37H019
MYJ-^T;GL(U]5$1CF+H$</N&_V8-**"]YP8YV*SE=(-2F5K\=T/H6F%\'APP5
M"Q^E6N[N7ZBG0M@WON^Q.[">*]@6=?Z]Q5FRW^9MA$/=TA_)'OO>MXP*:7\:
M?$NWT+RLIF2_,0PUJ:-]4(0;#:XKX*OPO':I(F73IH^^_O5T>7]KX[4I/[T2
M'%VJ&U5%LNO8QN/WLJX374IIHSL5$?.I7BVD&W*+T3D29B5\R9D3;FEU27K7
MX)/F>,\*27_S)PG;^D^^6HBU7'9?U=>C[)*I_*Z-%_&.4>"+'W8F T0Z5CVB
MDPL=ANSQCF;Q8QD"ITNE;ZP#78@!HRT$I&'UT-DFC;ELWB06,OUD>,$\^/HE
MS_1/0 MPVT[  /#JR[*0T3I]/^OW;[,0"NY=VZ:8Z;9M5GB$\8^1[?W:,!0M
M93(T,A!_>K'8WG:4"<E?0[IM469F41$)T?MYPCG'QY%$&N)F2S2_36*XV2WT
MKM4;XC#NUE'D@ZTN6.- O)]GP8AD?5-?]">\- I:4=Z&)&,%"/5S9 !'"Y2[
MK-@"FU-P]"'DQBO8]F6O(@TRP![R/M:!#+"!,$.\Y3W]9U/\771-_375!-95
MK54D<M@U)R9J]TZBTC')3U C)!%(+U7B^,OQMW/"W=-U'0K1^UOI):,G#ND7
MZL">Z0&7DI0)_-!YP8)\9#%?555\;IK:[QW9'K%]_AK(%;\G>- ["=]Z08W1
MEZ4_:OI3:6SH8X/2F^MIJNP4Y+)843%2T?<E\"*UYK]/F>OPW*D.,T'S+VB<
M;P_/*]]0=%6C7H*&$2I%TJ5C2$P-A392F^)2MB>UW9?M\,BP!4+MW*J"-$L@
M9K1IZ.9DZ22O?5/GJ2,]\Q^+1MF4Z-@9I^V97I_<DA%+UP^?S4OLNU]_<CJF
MR/&E\#:MZ\')=OZQ 7*M\MBY$7:@ ]0?>;Y#VF,4^*GX7G&]QT_:P7].-,:*
M9Z3\"\^ %:?,\\:P><ULSX5(F[QZOV#8B3)1!37<EA)PM^$J%>;^SP]*5<6(
MENEK"CJSEL_]#;3'G(M@6R#T8V3<[9.)=0,]D7RF?7,3#W$M5Y=#2R2"8+/7
MHQT"V:AW$$DZ=L4^XR< V)Q +NJJR#L$Y2(+./C ?0PE*&E459JPHQ$D8GAU
M^3JXLX0TT'@UJRYI 9Z&Z[F_X?_K8D>NH!(P,NU>Y8!SN?U^?MSC&A';2@LG
MIP[AH\'K-9DZ4B@H[GJ9EJZ6IB(C4>^'TCUH(K?8Z2>ZHF_G?7LBX+FN!6]J
M%=5S_.QPE20MZ5#0^K'H*4UN'0$UU[--@PQ9'N./4S6\*$PGM<E%Y2;GF>&2
M/:WL#>4)6:*^IGYSWYCKBM<L;BOR-O?&#E[F&SKE]H1@>C:"4^D. 39K6Q'K
MCUP5SI>O/I&_*<@V3I>E*-CL)X_'ZD4!RT'O,-C!PO(>?I?+NJZML3T<1\/M
M$*8Z_7F"\"QZWP'%-B.?92JV$V="XL+S9\TJ6ETQT*J&RJ_HVGR1*W(;[!F5
MD5\7]I>4*WCIFJK:DRVQ/W!2:S0HZ61^D%F=K-WXMF4#\UA'Z&,SW_/L>1IZ
MG_UI^I;722&9E4^G+6Q+:E8?ML+)@ 1'>?!2]C1;G8UT6&(KM54-1U6DZD'.
M*S%EXFU,><?F%?QEQPN'I&L1P[)ZHO(A4J>":=X>IGS%Y<9RLTGZ$;#XM2U_
M2YRXP8A[CQZKPRXA8';/<Z384E3H_>\ FWB,;'\.U._58*(!KC'4PT12L =J
MCZ)]98)% ']1JW0Z$I#JA,%Y/?IIK.4JZ48-*F%'16B6S<E3$;_^A! Q=QBI
M /: *A4@+:T4"\)XZ*8%[JT\V"]2RC+ ?$]4 V$,Z^."DT$/B/[S4WHM 0HX
MJ9B7-B?\1>+J+M7W-6AC@S!Y-?B*+.H.6E':C$B'. >D^[S=+XOKE$G$TU$E
M*?BPR:C$YL-=RZJT7;WG8Z45XNR\[$S+A-EY!P55[AK,?M.HS?N?E0K.%WW"
M>VU+2^LK$ @5<%+S5M=6PU;>N!(C;JG [405OG2H-2*\-_F"0?CG/:&/&AK]
M[*O[2(MAX1Q_H$GX!O8W[!KEP0P ]NGTIYQP@),9T1H?E1@FXK$BN?X-9?[A
M_'#!LT[J!ZJ.*B<J1)60-=\W<Q$M0C^IA7Y&THWG&8@6R"O99FIOT9BFLEGA
M?2L/4Y3JV4(M1FR,, 4N-X/W6CA.IO;P^,H#6]2P!.W[J(6$V(Z2=$Y+N0(?
M=V3_26T^K#BWZDMEKWBBY_YS5QUW[FN$V#D(15DJM4G-<-!.%R.Q:)]Y9>[>
M3A';3JW,FK>)A:&]KE\W/B&T<2J@2Z5YFF9;$L$$?ZMSGS1A9@#CW KE2ESS
M+Q@OG][T/$UVS\#][CC-6>BH[&G?6%[NK_?3F=N.X!;&C]!>J"ZVA/S,N\D.
M7.@?T)^E#\<*X:Z+7@@NMC1YT,%_9W*QO_B*F]XELVS_5?YM!&\Q&X8I;TLY
M>Q2)'CGQG3=_U$"'DUMO%R5H@,J%Q2)AT[&-W%C4,.&PHR8O-("/ %0M%XL0
M-@.;IW8EW*"[YPM>3JC$\[9B^<:<4)9Z)M7U#17/<%V"=CV\N=2.PZ-*DH1A
MT]&]S:=GUDXZT>.;?#S^Z\5^F\UINKRJ5'GC'.PTG[8K>VPZU&U+2H<'X9 '
M1;V'2'W(':EB%ZY-\9VK/G4%15^9[V= V-2_71D'VIR\OJ#8N'%RO-0@A%;B
M)Z2W6MVH'-M&181YF'O0,@\X%0?Z,)@G-I8#6Q55]*"R=09^ _<WG[&=4T<S
M^3_,=GJ9EC "P1CF_$J"FJ_F8?VC3L0%E&<1C)?:RAMX+!_"*H7#GF@?T*C#
MM.KQU*VE,<''O\TZ0B4O;IA1&R<^2;O_\P"4ZD<_BP#"0YN\AJSL:U!]Z2ZW
MC]O#2&=ES%BY@CG>JXTDBS)W@EG6-%08Q-)6L"I5,6F+)A?T>SA17>YCR.KJ
MWD).XI7F\*)1^T *OPLX;%X.V]AB<*%LK!>@\ $HQY8TE+2_%'.[Q5]MR WJ
MP9_];2>/&BJP!=2%SBOJG675"%34A6G5NK&\Y,>5=VPJ7SE9-GKM?*LSPD/:
MK*3*RRK&4&';&67^.,'YA5<VO,Q/>A;9\RLJ$6Y,NS+=='<5/UI].P$=_ AM
M+7,@<<=I.2!*6);$OVWP.G"BG1W1FZIX S."[8SBK3WU:,&(I1TK359/5CN9
M0V24)'VTE>RHA/M0,5'50S%\\W3X@UOY@EV,8S\^M W$!-_IPZ(M1W-';E3*
M9VJ*!<NT7?W9Y9IO^JUR]_HNFY(79QY?@_IO()4[[*H9\<:/M&UP@GWQ\]VL
MRJ'-D<?2U]/3J\^J5 =_K645@G>F(\O'+I@W+-_<*?7'B\<I4GK%<NC6-" !
M/8^@79G7'E90]79X]C4XV#R8>G@H:RQ #-[2*@<8]!!VG=O5[51ZG,VMW"F;
MLT^3ADY%07\C,.[U,3=U#TH.O#8?--RM)WCGZGW5OEOVT_]1>\L5!DHDRI30
M@+''5;9 -OT;)\@ 9]2NUUY[4R1)!AFQ<!:8PNI IU&WWQ=/Z^P0D;?>\]IO
M[GT/X">4S"'95J4P+Y&%.MXVKPS;:.=I'OQLDWGVLMK L:OR,-P[7MHSKE;3
MOV.%/C*Q?1//V:PS.PPDWD3LD &5;)-DP-IJ>&]8^=AI;HJIMQK.OF/35RQU
MDF1Q,M? ,T12/$L3:L.L>N5XQ3W/[[5&TLOV>^?'E(+PXJU8=K2S9"H(7!5J
M4/6T=(KE]Q9]OJ18SQK?Z%BOSW3UTU^KW6,14]*+SATK=F_JO/+A$7-VT1*"
M9>P_AA8>51H]OLZ\?+O^=?IY#R=UW0J\Q[L:JM8D<4=I>J[%,,Z&0\$W?=#Y
M4^EYNR@)?XC^J+#DY'L8ZMR57SV1G>J/1\RHVT79X59+:_[BD-IRW_S+9>=A
M\>/[?#Z#I^E\23J.B=C0T[P+<Q@?Z<F7_DXG)O993PER284<\8NH<F%N(1@H
MIO*/#&16@V0E/L'KQ?!J[$\YKC\)%X^/5CM2WF]S1:U8VW<'*YG*I^E*,UQ7
MU;47M&?25_7BAO]=.W"8OO%Z,N!*"QD B4.(J:J?<)$!75RAI$9^TO-P0B08
MG[,6$!9$!GB%9NQ,;W*2 ;<B6H'[(P@>*P>KQ!.ULYN?XZE//8"=X"0P>I8,
M"*)_Y"<B2-C=MU9E BMWGRD ^),8YP439;WGMJ^:K&!\"K!8C9MA)C,L2OOK
M+0=2A$@?$TSZB;,@^UB>#L:U9%"/WKBT7J8"[L2\SLU_^L4/-@O:( ,V:4T8
M-]&T4+J)-SV5#Z!)A#A<<BN0QGEC$[5B$ZZ=?5]UL>I5X&L'-92L1!;?%F/+
MZ%MG%\<.=E4FXPZ9,\SM_U#$,&%LV\.%B2&R+IHA('L&[(VGG@D-([&OLI@E
M5,*8C-$Z%;S7WX3)]-K=;1?FW[=M3UE(R2PW3T.<31-R!N[)O<R:],O$^WA@
M1'GME)[N\(LXW;*HG*35$-XG<I&'DCV&^?P8O><IMDS)9O<RZVEGMW_"V(C:
M);Y3K#JB+_+LJ[Z\Y04^\!T%O8=0*QCAFC)(V&$S+'OT^+)*-=NQW5C9P<A1
MM6Q\KV*PE6X V'F94=57+?&$ST]Y=&\2NNXK[T;5"A5P3J$LCPR?5;I)O(]6
M8EG[L7J\H-_B)A'@^'[Z]:269'Z?1<G'5_G6ZP8Q"IE#L@)WBD]FIYM C'YZ
MPTB8NSP\Y^W(YJ>N&T]E>AWNMM,FZ79V7XW7=&VR3+G"++E8F"#M9JXE)B2B
M'[A/?2'C.Z_3N? [7\^%;P5P$#GQP+:8"L0S9:9IVXXO2QJL[*N6J<L;;_!T
M[6/0L%>;[UYG:73T<P&Z"F]9?0(*9<?)68<4R.RJ"6>UKN1ILH>KJ9UT:X""
MK7"D4(\Y)\=^[=(GAUZN%S.-9:AB=*&^$Q9+FI4O[ :M<KX%]&+%A_W,<PFN
M4*A+_MK5.MR-3\^^[\L6@SK2*$<#KA-"=%A-HVXV1+&H&3JU7!E.:I=TZ,UA
MM\"X"PSK= N;+-MGAO_^>2<S7(7F3N;GMV<(K%7UK&U%<OQA#A<O."R8?.!.
M#OM)\MBT.9 A1#ZXV8T&[O\V%B_036_?<-(--D,O1'@J2(6O^2%P/:V@RRBF
M,G2AV>@"9]9KUVC%*-?1[!?9U9E;[S_94O?<>GG6?$-:^D-JT*VGSW7$5<)E
MG;-B>FUC#Z(:S6[=8NX5#F;K=M4/K[6[J_H*7MM<2:+!4RU%Y-_L\'><Y#-Z
M%1B BGGHJ+7R-"+"88OIZ;??#[C6!^IT<()M5M=PKY3NC C/ZH@\"^9Z0=7@
MG/+TTSSG77F+;\,IPR[@DN5/3P-- B]H%G>T(2X1E6<:KZSZ8)'."14U,?=X
M978OMKN"4=*W6.)\P^]]BG-XY5*NKWK_8;A@.<$7%]H&9%R*=^=2S L7X4N-
M'A\Y\[U<@TA6B=18ESR!F 2!C;F58C)@#OBSG]5/K#)\V7PXTO.CU&A56&7N
M]D-U%?, UM/$@!MPI$;$4]20,:=#HCO"_@/OO?TVN_UPBSIB=WLCN'"QIW-[
MQ5N8>0K9!&/*B^;%Q?=^G%B_'S78(1]L2GURN][-Z@ZN(6MFRG5=8]0)@SF>
MJ*AS(G:@#!V;=;N^='^:0]YR#M%ATC?[0L6D_^ _"]"+U('84<\D Y!=C9\S
MXPX4R("/BO2G 3K$-F8\&W)>>^24D9JT3:^RV(^1)FFSO@>M?R,]K!NJ!QU\
MK/Q('RFW&LM^/KJXFDN9"_I+<!U'!C2%9BJQ,A.]CW]DA@M^73SSG<!_%U%[
MGZGMD'VHI9[NER*D$^17N-%:T3H$3NI,OXHB ]YSTXUM[4\]U#YY+_)0;3OF
MDU.?X S-L?2!_>G7.D5<1/-Q17I!BX<0VB#LZL^OD4X=DDOS*S7E]>-8]:)$
ML"%4Q-L,]";1 2_?2KI+F,U9E2M&*BZEPXI(6Y<N8JI<J?QA>-YF*TI\:%2Y
MHGSKP=RN<1)6M:SRN><G:B'X-H3"/N!>V7"#D#GAH]&'\8YOR:7?E9QJPXCK
MV#KPR1,XQ(S0.*O'V 2#"TG4>C__8GIAQP3_QL(D4F$RM,RXU-=+'C?^S;4?
M4[Y]JQ&:"@QIM&N\:.:'0.]=VL-[91>G<OUFV2DYG11W%3>J<\,A9T.0<R<@
M"KCG@#ETR(K2Z_['QV(4"0!2?++MB2'!>'I>*F<N]^W>N(7#($;@'>?AW:[Y
MH3HO8T+G*Y*L!7S]452DVG*O1NY,*3=-TMVA5BW-+I0]Z99A47 >R]>XND9Z
MWM4.@B;.L[_=<YI^83#'_R74YEY*W !=;3V4>C9T ST;)3^'B' 7MNKR\!4T
MR4P:S+TM4#0^7Z].!ER!X9;\S409=68+T@F:68&M94[LE$ OKYS7T_1D %0Y
MA_@47:=>/%YKLA9;^%#0+2'8D%BU7YBEQ]S#AZP$CYU>R3&XD,.RV:@Z-*4[
M/0ML@E"O'Y !5SF?#&:EK*)W51U-TJ>^/7W -!T*H5*@G$6\.VO4\1YA(X^2
M%V^\.'*H"C:BK+=7/[&!TV&GP96HP>+"H15Q6/2]R\7=RB^+D(%@S$$>+O#;
MCQ*\U!?!3NL*[X<:7TODKW,+RGU$LE7KKEIZB*2\'DZQH=7,/O9OIV]%OE,Z
M-Z3$8 J/:TG2BQ.*F^RB:GUWE&S:8;;?'\8!"O+HO=T\EB8&D;J;J[')PS>[
M>$=NKAJ&43$-4B8 G1/Q*GD6Y0<GKZR?>6X^TT(6 Y W",DG.@2;=OJ9%CL8
M/'W\,-\%]#G0]N',7%D>354P"S++AQB5]S2:JUND>]5AVJJ](X8,L$VGG_*S
MPY'B<YR']Y+7O:JJ@\UE+J%A8S7C#8Q^G"-U-AXX$M=-PS&G3>+8YVOTNAGU
MT-Z FP%CGJSI5_TDY_3HS/IZ\MKQ%BJN4D?O.SX(YH%0E2T%EEJ(:Y-PQWG2
M-8>,'8SE5\8-\Z&:ZV*Z#/4'J]A37=LS4PB:!Q3DU# 2N4^3B>*P.='K]IC]
MMXY9NM7*4(GL!;6NV*&R@&M^G+CH>EQ>FUD.*>;ZX5@B.+9%D#'>\+8]43"!
MH'-BVG%6IK##TPWQMS[%*1=IE9(!63O/,?=8J2L$*ZI/D<3+6$ZT1($PQ[)N
M]"*?R3O]0*Z4ZV4V&;VR'<R>A5.;E7,Z=V<PNJMFQZ"?>Z+OY)#!_1M'PB,<
M-AU9RN<CO&#8IUG+O.L0*OC0B=9(G5'^E+UGD6UVCQ@4ZKD6-@YN]+M\FDV4
MG4$"K.#@UAJ/MM["CQK*[U[(@8QNUM&VHS'&.7/UNLLJ*"FS1V4L%97.WU*#
M/6?O:J4Z1N79E31%(6E&[GY#>=2L^??C5$ZI#UZAN'EJR(!W 3\?>D+,NTI5
M(ROIT]K+&AW?OQA18H4[;&A-KQ1X4_8']%8?N(0<]ON<U= A"!1]R":)HV5F
MFV-E9QJC HRK$:M^\<"5@AME/G>X";8N)B >#RCPY*"B4QV$7!E?7[BH$O^@
M(;YEWV?:9&EQ'2'(G3CVS=\\,3FG;LN?_G:;WGE'?8*7:D1KHG'<;ZJW4Z\J
MU:L#*<_'6HGCD0=0/"2J@5?]2G3E:0ZEV5&)4L[M7HZ0IL>'2WEEI]^5KD-?
M.TACR(!@2X]4>7I&%8Y-<,<MEU-H)TF$-"2W'>-G):G(O;2L4AXB>O/B;-QE
ML.RM]]M)[O?V,Y[BC*?] ^;$V H55LVRJRM*P7I+/K!FX,1Y# &[,]W>H#.%
MRJ854'E%!@B6<2_5HV<.B3R7\N"9]%1F]2F>PW6L^C]X'H=GO[!#^<7C5 X2
M1X@4<P7)_0QZ'D43EH]N?JK=<F_JY)7<\ %M0G&3+=.8_%Q[:<^;^TFF5C(=
MVR]X/SH\MY^SX\_QRIQ\U@QN;K[;/CB*/3E=!N'49V/>U#U.VLHH7/6J62HX
MZ&I\'2N=\%7L)W4&?PTD"@3P8\_P4SJS6YGN(%VR5-I@OV1626OL%D5L:+'@
M9X+I"1@.:29=K1G8=[J_0BE17&J&7Q(44SCF2.X EI]QU<#C=W]$X99U'M8$
M.WVGHL)4R?;\C\GJ^I5/+DICJ_*6_BT&S;XLQ<EEJT6]V^P!?0TL>"?D&P\(
MS6KLY#AV2@WFEZEQKW1A>06.!)X6EM/3P.7;#LSH0\K'"].PP/NK67R+R5^)
M!6MZ@7*>C;CA68D$DIA&4:+N-)_>4LCIV'U9Y-L&/G@IY#I\WF0LQVG:L>JE
MGFT?4X!1 WV:1])2G0TBM<\/5I87JI<P%%_C9+/:.,Z9%X[ QAR!7?!>3X;=
M3Z5;XR:)CVN"GF@L3.84=I5+B96Q]<+I-YKP/0\)"I+(S<_%+TY>]HMNK*>E
MH18AUQ1487/]7%"YMLS222L+B9)0MF?T188_2@O"/Z5%**NPT\C(-$&%W3?\
M]7+\V @>N*S9W/0Y/4Y,S_??TT>VOU\$#ET.!!P/$7IFI-[,;+/#&=NPK.#*
MX2V/B\;:GJ_>-,9;KUI,OT,XQM!"E<Z7X YC]NY*,M@S/-5 NS;TUVALJ-KY
M*9\6"-6!YQ"T;=;6PHDA[A'E5>YD0,)'IQF (J#02 %\UI+",%BUAN%+&Z-%
M0Q@H0GR%GGWW1 =.3VH"(XZO%M.W(2Z\"A )&/;I'$T-^9(W/MG%9__Z!=]5
M5J7X;D+H03:N.!\?T6)U)QR[8;):83#97<2&->WD98X ;8*AV7ZP1KSQ%SO)
M]C $E!G55M<HE"[JLFTZG&%U5Z9 R;C!2RH_K*5OS57'[?9.R>H8B+KAFI]N
M%9X^U%WQOC:7GJ:2P6\1,/UXC'[2<N.L,MRK'7@Q1X=7.QK$Y'#X?&C.OJOG
MOA+;_&\W39<3,SAMR[TU3&APG:R$W%+.;@_O5R.[#F/)IH#^QO+ZQI8I]5;1
M.8FJJHI1_I,G5R]O?DJ#[WV/4@ +?FQ(*$6$72MXMZP?CZIQ$KZVNJL8,P?;
MR)_M4J"'LH;NC82:5"902+QO_<)Z0PEA8-'8MCTQK#GF82G8''#I1UG)&$_%
MB>7&KH;RW<,'QW&]ACC89FCN*E81;YQ1H.[%'Q.P,J9_HT>-R>:\)Y*)$(<O
M .-!K45GL53Q=.QS)5NXJ/#!C_?N%XJCA,#WG_I"=_V5U.#A54IJ<TA_H5J1
M1G%, "WIE[X]A 'F#N'$F*V]V<-[T+0O!!\=+%4&,/M=PSE7SS>&L8 Q$FZ8
MU<0YP4?/73@VJ,_506;R-AG]9R#7E9!SFL6H*O[*$W'QAE4&M]C($W3U!&DB
MC;)\!,5:,>A<]'$%]G&6EV(ICJTG@*F@@RE[T\MCN HWW%35?F ,4Z\O!)^5
M-."?9AV!'E-ZYD,L^@Z^KKE&MUW;(U]3SYIBE0C"9S5H.^+\EI_ES.0EB54G
M&X<G)3>J#-X67O&:+ANKMP,UU7L9)U$JI1UZ&=0)R;[@^P@2V!%]3P:<!?87
M!%NW65&JE:'5P=_Y8<0FU/.GKN/[DI\4ZPHD6?:@Q6E>TNFC&<I:FJ9YPV!,
M1U_ 93(@MO;16?4\CM@3@^0%B ]YI!HZ".= H9G9C&$BTG>47&VVP(O3H=M9
M0_N;<CM/'AL?,G1/^LR:,!(+5F(PMP\2AP+X"#"]$MS\&HOT/9T&]><&@I$V
M0995&,8B&=?BY=3$N;NSJ[U=Z[FI_7:$S=DHSGE@=!W/+&- %!_]K='E#S]K
M6EG9^I_K.':=W"?*/,/8P%TR]8&L#<YT =7KD*M$$4(Z C?=89S&:XDN?E<X
MV+GPY>H^.S)74@^#GNW+W,[O_SK]V]'I*D3X<W!_'C5S%_C*^ZP>&J?R6B_Y
M;W,_4"G?C30U#S?T<*$'KW$I5G?QQ5$%$[E%=.FOWV(<...C$F7FZZ%PVH<$
M&R^\8CF0QK14QP%VIR[M+CO=S#AMRJZ5P]F3F0-$P6^$XA/3DB26T5SZ\U)9
MKNT9K\^Z+O$91+LEYRRZC0O::O8)3&\'YV,HU$XX2N:5S/Z&CDN.\Q7TKF5O
M80A]^_:M627BEMNX._W$_$,\LAW(X6B&3CJ6^O*:09C8K%TQH&F#!AA](DCC
M*N>![R2[ZGAM1+YXY\JW\C=!L'=N?_ )"I\A2IZ88.#0N9@P%(^-Y'3(_I='
M(?QS&IUL?8)0T].".LY9!*VC)_=YW%Z"=%+8RX_J#[YSA="F&_0^RI\K+O*/
MKQ4Y%)%\[5=\,#6M X%R-%P@ &=$*8A<>LSP[BX4>[;E3NG"D;?3USO%>0<9
M)Q2G*471"6P.BU_O75AC1'F'MJ1C8EI<B!(0&L*T9O)3#67]Q6)CHSXU?SI'
MT6A@>7IP  ]1$$)G?R!M;%#0_E3Z"0.SK]VJ>BE28+57VF[GAP#!?N!CD-8:
MUDO!;B8T9 YOUZ9'MXJF;<!JYSBPCJK+(+.4%/W3VX#EB""BH#\@4?VMS,AD
M&G,EXKA@"1:L) "A\GLT@/I"QU-1;1QW.MR$S"8#[,W7]6B(=CA(*^NT6^;O
MAY$O0M-K!^A_HIUODK!*T=B\]&#HVA 9<*TQ8Y45<DZ)81R.G51-UE+^#IDL
M_V'F[%3+NBT]5M5(1;P[H #$A[9A)+C9N7E^1%]\&<(N%7=ARZ77S6QY4V76
M27L>$DHTY:J?&2X4>ED1JW5E\3/^C94_7OP@8@2I=&O-ZB;.*L,CQQS;Q*17
M_> E1A[-+"?SQ;<49H2N[SO^'"GDOY*3M5)C<IQN@;,*XHX*Z,&UW_G\8$&)
M]RC H->(P)YGZH H6R)L)S[23'"X7?] G/Z7:\!7<*?7&;>MT )OGL360YWK
MX4:)T<ILO#E>H/,@!TM0$^E:'2XOPGU54H?#M57"[P/G]EVNMFM-Z"C^RE&$
M670:B%X@OTC"-V=L*D:?L#V[Z0H+&H": 2.R\71!Y[)CN'XY8AU#9EN\9 O)
M@#?IG"C1ZU"I>_!A8U)K>-N B2H-&\OF\2MGI6?4C@L!=P)&Y)C1@5]QB6\E
M0H?W]@5H']]C,*ITHOP]=I!XHD]41.]%W:TSFGV.R4UKUOC%<"7S@1*N35(M
MKV3QDVA!!?K!^M !<3#?B?FP#'AB;+'.?9V GCGU?>5BVMY9,=0>8!/"&60,
MV^SZ:D;;?YD0SG3)Q9\BVH*^/O#B[=UB6 >(J1CD (I08ATN7V=!#1=M,3^/
MZC.)?/L+FT(S>EI19VOW#1ZCAIM*+@S2"A6_G[+I]A/279YUJ=D]<S1)EQ3"
MO/;0?;U;!.]D/G*4$'X'"3\Z:_+O /Z34&YMC^^2-/9 ^T?2NTR&9$#):7G%
M-/4F<11.[/EBZ2J7K\ A."<&:4_,/^:G/\5RAYKB00=PW':[(*UV<OO'%H,P
MJ:(%@+/@2DN]MQ?Q'G<B&:!BN4RBS/'7.7/83B5@CD5G?HA(O<Q.NQG58Q;N
M\NKE*WIQB-G O<9CCFT0CNO.6:%.>>:S*] Z,N"G.[+034T'ND]4WV5'V%DC
M/AS)D]CHM<F C.)=,H!B*(;P3%&4%%+;3Z36.N[@CTQ2:GQ/>D;J:R8#>';^
MM#X0]],'<GK%*YU %[\?K<,NX8]@(#:=I@:35!:V_VT6T+]4$5R_GG3?_IC$
M>Q1T(D]+#.V:_M<<GQ M%*N(/4DL8D8./"8K\6+P#QVI#SQ9C^CC&O\&CJM]
M5]8Z(6:)?F-#= =X^]^FT2<#+E/GD $#:&\R(' 58K(P&*>.Q@-_ 2?&(0M*
MNG^>*>M//#24=&7QQR#G0)]!93\:._U2_SR7^I\L81.G]N^H6@XHA_J)O?]@
MIG&V?^+"8;-8C?U9PX_R5Y*2?1$B28.XC!Z"[V<W[6?C40N%BX2;\X$M35BQ
MRMYT<4+$@51R6RE?4D<,RE(U;NL(+TBQQUYH<W+.P8;T\I]V0=93,V5%(YEM
M>10:Z6][JY$!4O]##77 ?T#7^_\+H3I 2"OBWA\N^NE_WD7O_ME%A1 _U)(O
M1]R$%^,M-6RMSRTP8!M^=&7]RU,-EOW-#XQ&]WLE5@_/HKI'<O+]>];NEMD^
M'(N-_^ZV'&*;X9_GH1VSGD<W%P-;^N>B2*_^1UHA_\ :\[_&X>)_/0[_\S;_
MIVO\/H,EMT(&E(;DS9[2Z0#U"*'?S58_;DT[7;_#M%SD1GUP?FA\@5"\"]K?
MBM\/:V,[R#?!K%:DD30J UNZ^.8KD_]'4'O9)2%GZHO];^7E?U_X$_SG+.,C
M"!M9#R=NM'8='IOCEH<A _(K/]X2! XU)/W!"GQMV_N*+<&V','BE_P_M85%
M__"I]/\W]^6_;8C%3=H#OI@6L[<0AP#)$:'BD:MEJN<NL'\_CMFXZ_#=2L?+
M>Y[S).)+LOO'+IH$FS4=_Z?V0*UT)+C^*(+4WX+Y7>-3]K?1W['AC-#G_W7,
M]!=ZBO]?Z.OX9T#W4C\-*J>5)^0VH+=%BT86O^Z,2ON^ (^D#&JOCX<>A)1N
MW/=:D/7EXNYI>:*>9_*@8BP!S^?2'A0(R$1.(SH?0@[!QX,6?KUK/@)W!5GW
M8HZH6_8*XO4TR( /?B"MZJ=/_N:8];^$/'TZ^."2VEW[KY>UMX\N:I/6R "S
M.PUGZK]KW$+N9P:*K@)WZ$-7P0)IL63 #4) O.N?SCQH!.[F:L,QFEPV46JF
MGV=HELWGN,/=.T7GJGP_.]^R?WY5S33;]F2<>X1B>-"D?ZY(3$%),NZUTD_P
MZP]T>C+MBF[M CKTK<8!/"&:PMHA816:3-^,!NLO;C[@*/_/A\3_!>0YY#],
MKGI(?'>+#/! %#%1(/[#VH;_M/^G/QVF,PUTN#&J"PBV_V:V_@#MW$/2.#8
M@Q[4.RDYD %EVTAN;9-[YB^^T/P$_QA\P*UW^]V^*@%V(>[ (8DDVW84Y6/3
M.[6X?#*^:0EZ4W[2])T09%Q=D="GJ.8.?Y9BW?Q]GL^SUU/"H(J]DO2*E66(
MKX]YR?"L.@FEELPQE(0=N9YU\)](J( /_[TSLO\OA2UQ>N=JXNDHJ5S?_VR?
M7T),0=95 9 AT *0?JC82)&7I(P[%5C\$__,!D]&BMRK'E5Z,4RVZU)JC)\_
M-JJ9:>!_R%,U@+JFXI]@QWDK+/O]EH5?$T(+L,EQ/.5T93!)S*D2D5SEU%'L
MD.29[U"@LFSZ6]V-Q:5&JK/76] !D]K8-)O;9[G/<*,&;G1)23WUHQAIVW$M
M@/N^)3RH%3WF\GGORV+H!AE0*Y;/<Z_U'+6/YV^Z6F,R(%'T^$AO';Q^VXCQ
M-//7EA[OYJ6=F:UMLY' .YGA@+\2^QM[&07B9GB6Y-E)&Z4<[RO9#^SN5YT_
MI?:9Y2?D?(?'8Z:;COG0+3*D@;H+=ZBK^ODK@R^-C K+U[-BW?K*;VQ@ZVM2
M245%XRNQJK<VUL]IWHC2]K(90@K:?5#F'IV7RVLB QC@%:LB"NK%.2NT\:AW
MY?JM'54=9B/#2I>G5RON%7*+C!8Y&_I-VN[R@H+ C[X]T8?4HP<GCX_8U%!>
MMT_J%8WZ#;,[4-Z5Q)OI5R4V3B/:$M"![N;K%J3,3X[3U_:F]X^5$O._D@2]
MN\6(5]1'APFW67<KEY^32F#A5_R01]QQO?PZWB6$C.+Q9XY6-",V7-B)!%5F
M">!U/U"*E>HWA]Z!T]S!$?H.9I!AT2!D&-*9$Y8S.HG6^[7WX$'VFB_XKC5>
MN[DFSBG( B5ZBO;/VR\Z<;+JQEUXNW/IS6KI T21C8!!3!M+E,W3:QC-Q&_9
MG?O9OZ6=.J?0[$MEDERJ3$\H_B1BEI!XGE#=*TJ!-'?%U>PI[+-[V;]29<9)
MO QD"7\<HZ^F_NTK^!^_:5@:NC[X*A*JKU_>66^I/C*L\TN[*QY !L -RF@S
M+<+O"P KE,D Q7DRH"%8_$1KF!20008T!A'M%Q.MW406OPND']3'$$GF9,!T
M&QG T9_>SF'44."0Q]F9M+:L9,9[874]^M,(W_&U9>:1WYGA CK_[;\G_E[^
M5R-S]F_%,Y#_<+</'^12GIP;5)6XVG)C*5 6R49(:VD96A7T%DUPAC$P[B^<
M@#4NOK+)@7=T "])'N1D0QKR)?1[/9B_M[RI$#KK<0Z1YD-"$-VA3>'L*FA>
MR+T0NS7"%O3.R-.XMV;(D3'#%![V:4T(3G10E3G_PY]SB[K$*HQ3(?I;^'W3
M:$#6Z^MNX>)MKSG0[8K\8ROC*WB=N2O:,CM"8->@K2DJ.\0SPG0'M6?1-]&0
M\J5UN^=>CUL&TU$>ZE?XD/H[2$729I_Z^PB_'^  R)([]@XA]BOAR:NZ.E,1
M'^%"RE_Q,;F#%DUHHLM\4*7&<%R+CXW+P>26'>^H <J#FYT _0I_?)20H'UK
M<+$X[W2AT%^;8ZTD.L7@X%,^@D[:?_H(\;D^U2S]>F&MZ*X"&:!&D,TQMQ0^
M*%$@\8PH]Z<&3'X"VJX(UKV]N)G)T!K^OHY*/U! )>E%=,G=E\^^R_*E4)@8
M%LBN2[OYN&=<N5$HC^)2]4X/"Q!M@7YOR;,W=EOWTA8("_A%H7ND,R5N3-VZ
M:4F][<?Y/4]FWH&$6O0/"!4/C]^<D&K8BS$_D6?HSIZ''CJ JFO3(GKOH=/H
M(XK86QO8QGB7V7?$GXJV6RJZ+*V:%4+,C25(]:$D6"_M"8AQB/4D?<V'81FE
M+%DH31N6H:F>]0W45V5$F)J=^JF1B$MK5$Q^0_SN01B=53E$8D7$3SHM$%JH
MZ!;W;PT[5I"P=<W3]KZ,&7JZM<"(HFO=K_9_W4 (_*PB &?5Y8LV%G\X3]NF
MQ@&+S&+F68,6^!#.YD&_I91)1IZ@,"QSXM:Z9_KA+O/PY6[!F<*&W01O)W6\
M/L*-#.!-A055LB!V:/">*.O?=S]I@?!K\YD#"MZP8LYQ5&V7B%]_:9!B&KB[
M'RLC<XBT#.T( *9O.1Y$D0%.JB:E>*74;].21:@1 [F\SUHR"G;,$WKBVNIW
MNDF1\_D)]4>VG#Y9'\B =Y".Z3TI,S)@A@N(BR"<D$)Z](B42+5,Y/H?+[2+
M[O"NX;=(AR2[%#*@671^^YA3&(2CBR&H$L^RCHIM'HD"G36H/O;'"T60!2 X
MQNNP<5=AGL2  "(&)LX2=* [XE^/U7-_C"GZX^WWQDXE)/?V-F+)NY]XDZ1T
M5LF6HLD P%H:,M/OX8_AO#31:TT>-R^_SRP]2E[M]8D9&!S&)K5IRE<AJQ$?
MTKB%[:>Q_?2X_A _;^9?"9[8&Q\Q4TVIN55E,E@]@?O0;Y +\-6LUC2))]A\
M>\$AC2RFY<B4J7\L^WF6E]G9[K"LCQ<'C*S>58")5DP:901PPW]4]L_7_D*4
M.<>O_-9O.P,TX=]#C#@N5_@#>W)Z2 "_71?^()<ZL_G3A!(SX:U!')[:%'+X
M5.Q4< BO)M" ,NCY@P"CO.4_")AJ8%P;ND,_7^]2LI4^JZ5TS:K<]P4^K8J4
M]TO_5'!P)?]XU(H,>'N6MT_-TF%M:<[IU#F 4/S+"C+@X#<-XTRYU@3LVOHK
M1:4Q51\E1)]]+]"LB#C]EG4TWU-ADL04D#8$<_*RL$E)F9:66"( LTNZ1B5=
M$>O[ZX.[VZJ@(F/2L^,BX*+"9L-%^Y@H=%*RS1B>#&C_Y$>/P^L4\6=.FW><
M1=>M+:331H:#"+^&C96V/(!ZV4(W#^^K]M8&FL-WO+FL)]!]OT5I<P L:=$U
M:'6JS251.OV*#/ Z:P 2>S?>#\_ 0AY^Z/&9V*]%X+][35\DTF:T#F.W*R/I
M'A]&4N_F2\/)@+;0-[!97[7]TPT"Z<%HO?S,UL>XHK$BX?9:KY2CQ%*6)_X/
M]YA[3O,B"W*8-J=J16O=D"?2U.IF.^!-9J_#34)9?[&0 H.7ZS/<=L@VZN1-
M^\J"1RC>U3OWK->F\IA'MN2_?^5N^<O4)K*\_?+E:,TU*+9(J&B#Q^1K&$^4
MCY C$XTF[.O;.3:K%YHY?9T3@78=%G1[HD6&#F/?I\V%6=+?R\XZW.:0>+KJ
M58#64SUD?%C\X6MLD,P3MNCEZGS[S!JZ9TA9-,(>%M+ CA?#;17,ZW!W6)BR
M,%I+_KP6^OQ<L:+FS7J.*AV;F=! R>VKJ3!]7$B,=Z%$Q-WZI-''.2,+4AL>
M;$P4L<6D83* 1D&LT-+!#!FS)\^E-OK+;;+'75JMY9O2OF@(&>"@%XP5'3FK
M9_=@7"LU4=L)0T?W+-Y.&MHFKU!IYP?TI5_VB#C:AOG19DQ9_I;]:)I39FQG
M,Q*W;BPA&IA.5R?I?S EV&0F'(QMC^E[.VA4\:/E\GP&$X6!QFFV$AO\C0?+
M<)U')O:*%$M5[4[QFQT;:JK^'Y+!>*]V*:_7<(&Y_K:/*R3@J A;0UZ>+I,F
M]Z]B3NKPU?+I0""=1$@M5)3*OJ+(@U%9-GP0_"NJ82?]B:/>5:)T96,C+M)3
MRO.U X?0K_;^GG/W@J4""R*?K@5E*:0=MK/6"$*?$"#M<C%A>PM#+ZN2MA;K
M^DN[E69-[\DJQ4];^>F.[?G3:[.8,8R^L)3B+"CH*2BOC%RDX-'V7UIO\\"*
MX?Q\*M^B4H':E15E"0=3F9:Q[RQ;/628%[$W"'?GN-2-WH0[^!1E.?R8H-^\
MQ->6?-/IY2/J*W']$L<F/@@([UDO'8SUB))^P,T]F#WJX?_\0G5TUZ+)&)]!
MB-!R=!V]6:@A85DX4LXI:45MNA4<OH4)R')/Z+J6T2(6&WWQ=J[<F'0HZ2HA
MJTD.$8+<"RL_B8)I5B2TF_N^-6;/?"ETD3>#J8&/ )J#7(4XI/&.Q#W"7Z@]
M_U19,GCCD;GWJPD*/0LDTH=[[@:>OCUYRHK^$M;><U=RWG'3QCMG\E<AW^N\
M!1$9P30W2T8_%U(OJK%\3$*VD*@)E7@BDGC]K9YL-AE@K'_\[/B@,)2@,J>M
M**J<_-B)N\.P9,3L=*;R78<SA<5%PL*IP^$T-5%U3A/IIYJ/-34C?/NMK)CM
M.9N$Y:'SS+\=EY*2)$%J,+_$A7BG='/:L8$GL>68]![#4GKCQ% _[-U@#\MK
M#>O?W)FU:[NP2P255J\TR;.D4- F:G-E1"JD#].O)]09KFL:P9V-SAX<O/P?
M57CKOPJIB']55^=(_U%*Y?^SN/IOW_HGXO=CPB2Y6#>PK"/"[K6K0'HO#_:X
M'MU%<#62K^HTT>.*9M*N">'+W-UMI5W-RYD2P ?RX.]^VH3$;*(@;ON@KS11
MSYZ/X?D0H^#"W@SX S9@LI$^MSQ)L@+M=?]^#"$1Y&(P5=2!6=;&E363;@V)
M\J0_)KP!1A!%^.QSHX\5AS*LZ":H7_MR' 2\K1,]D$O>A%SBF%'G@TKE> @4
MAAM5E"V\X#A\* X6EG@)M51%RA.*=W7X0VT9.]C2O$2<+3^>.V='UZU\#,XT
M@O9P^A+J:K_Q5L7(3MX, 19I"^T4U#]?(;*\ZW#AM3Q7TKU!0(CV8G[16U9M
MKYX5LG2_]*%8_O(?<;^&>!* 9?$?.K]^Z@%H*JZ7D7Z5B1V]'.-*5JBOO2!U
M;#.4:I<WZ3!P9)R -U=/K[U&!<R17VL;P.MAH/KUY<-[]LV%4L*>Z0U8:8DO
M,Q2;5F6SLC!;W'Z0XT7>VIV?UBG+ R2C'3)@,SV/$*>/EKA0D40U;!VK6B<H
MNLUATS?7D (>:J27U/1(IUHY!,NK]IC?[/[N2OGFK6"QN_W#=XX&29^R]S77
MBG)SE3#9RQMY+)^,8^KWY7P$."/>%SUW>!E[%E'K(IGH6T=8,*BH]8W*^LJJ
M@-KG\2:D!VB>:L]J408B& <+V@=NG'JU'EO%^I>#)K9%AJ0Q/M<9A\H5#.8M
MZ9L\#X:A23G%7[A&>F#.SB]HE[I_"XCF2\Z2V$_3MDG\T+1[8P'B#F8B92SY
MHA-[FSS/-%F&1B]=Q#I+LUKW6]VA7!&6UB\?W;"N*ZD*WQJRG;X^4.7^VO>M
MW&@-7A%VX!ZG24#D$FQFD>$H^M"2U3*)L4VGD[VSI$492@):&P7P$N;G.IKU
MZ%? '%[!UH18F)/SA1+%E :=21D9829+^NMS@8I#91ZGGL,M23I]&;X";><O
M6B3(]*/@>2$@Z#8]H7MG76N8*#]W47)%7V\<5AAIGMH8**4ALVTIX"<^&G"C
MLY(D40^/XYD9*IQ^Y>+C#&J%5J0!$X:*CVP(C:K'*>*M;E828(E&JK76'X2>
M;X0^C 0.&5HLXLQFO26BV\FCM%QO'CKK63#GQ<HMAKY5;[%\HM3Z^2MWQ_6D
M#3_967/(9?^LC=+'))>G/;SG+ERX +ANO.6B"W_?K&,];SN-G"8]#+ZD>=MR
MZF#UD#U)-&1OFFY2B,,_12H6:3]P+B"OWB&Z_LZZEB^8-BZN+G4"DYE9^"%P
M0(\Y=HZ><36-K5Q:+G[(O)V:,^;V.-U^BU+E7,S[7S:#L_Z4JLY7]IM))&52
M\\$QFMGBL4-/O._01N59>1>])J,Y&B-_:#.U>9:2CWAS\)!6I]O-OV[80:>4
M"='=X[#XF&&4F^!L(Z/?(VNI>GG[)/GKQ<F.X_$=)[!3P6^XO)9>T>9G/>=?
MSNT??=QR:P"##(9J(EU,3F@^1T%K11?-_:8-$(5/6U9#P(F[BB3MO"5;^P#V
MX3KYEPD54K'*UW;.?>WSU]R"&M)X#47'KZB)O5T,+U58U35P?NKU2BI&64>,
M9RT<0>//;/RPFM:L><I:A0R@8*9T,';U7[<W7V<##14/77.4O7FH8O!QXLM'
M.$PK<7NUHF@_&-'\77LF]=RK[2%ASK.VYO_@Y#W#V?[CO]%HJUJ*:NW9EJI2
MI6K52A>*JIJQM54ETE [""EJKZ)H47L3,[&)VHHB1C2Q$JNVF$'$\?O?YUSG
MNJ_SZ#[/\B!7OOF,]VM\WZ/(?'K@CMS]Z$?.' ><)48Q6(1WG];68-M@[]#Z
MY3^P6(Z $NJUH4W[8_6 Y!=UQH*624ZO2\ZG9=CD^="/C<K+8_5<;K5?<#2;
M=_N<Z27:HCGV7Y,T^PJ0)X65T1Q)B[Q_#SK^3Z9U/6,O]?->25[BZ\[\M'?Q
MXQM]"_X+*H-L(>"B/AL017!>18<T2*<8:X526DQ2Y V.IY$92@HH(#!QDQ-L
M+8:^OEP;-WEW)9/:MZ:I;^V[7QZ53#>&.@4PMUZ:>_ABK\<1<[E%= 6?9IZ(
M7 S*LCF?E-)KY26T_WEVM/N\==#)E.EOU=0Q'UGT88J*M=#5<@,6F8VDV#'W
M0[_N8;-E#<B2),*4,D*\>]-*4W_D?04WLQ_D_?ON1A;TD$,2XFJ3(7@_52A,
MR:BR8G#C7@AH(HILI1_-I: ['HW31?3,NZ^*B4>D+OBYGP)469T&..:XTEG(
M"RA6+S_RT^D_XP_"18Z5;DF-)@188L+V+FS5AH!LQFF/-*$Y/$UQOEQ)PZB,
M27JWA'4K(5#!>/%QQB'_]#BBYRRZ_]&^N>^7QU&A<]%";?Z<V*8G+F10IT_9
MCU+[-5>'!I<Z&=MRQB83FXZ_3:#LY:-;,"O_6["&5?/J'5+=X\IG'UF?2*L$
MK1OSJ_+(-A<??_]I'FZ30-;$X3^4VY5VBM2 ]*<T^:.OR^I^Y?80TC=)A\T=
M8\5/ 4VMH%8;9G]!JL[PWI<*,D,0'"3ZPU=F,[[[]=5+.D(I&DLI>V+4.Q#6
M3O6M,_?$VN3LEB>;_8#T2$YFO*[+BRV-5%,>TJZ?&E'2WY1X"C!4\BAY=;?.
MXNQBM*IE)UB,9)T"S/P^9FR^S#D:N]L$SCPCD]+QCX8GJ\%GXOVPL<W'.6!O
M4VA%D+>.8D]:?0A>#"BVR4DU"W3;KMDX*>X.\,@(%I1NP&4*,7NL*Q\+\MQ)
MT07I)'(:OPQ:B/=_YS($ M[G\"L"QI\"'EJ,GWD]S+8J:8Y4&[2NN0G7RB\_
M:;I;VA@;F\&*M'B?+C%R@/!X+T(+;"II/06PT2Y3DMM2-IH+*":^DL!GCP\0
MT.';T6T)76-ODZ@27D\H@UO6QZU>_@\"F70D&?^\=98]4#)\WK.4B3>41525
MQ2-<3P'2)P?))(]XVK _7>PW'"?B:(ZI=K<X=/_;EB^BD(:M/P64><H(+;\N
M[YKYDN3/@"*[.1[I%H0ZY4D_\[W=TFDOU!Y=/P"9A'^@^-D25_WLY'ZJZ:J1
M@/(\;R5VR@N%YLS^M#!^\RY6SUO$GC"#ASK&X15CAZ+]/X .)T*?.(]8P^Z'
M*PI:I^_VJ@$M47:S6W?"%E\_3 IX[9]?Y @42*%9.,AF%8 ?3!4ZW$='YD;V
M&WSBN?[HUEDH$:]&FC8])X.B@M?;B2$9SI\JN@?UOO''6=K@V>_0-I_T#=0D
MSV.$F^UV"LI$JV+C00C78?C?W[K')I9\(W8,G^7"G9YT)R]VZ<T_--FS"<-P
MR1U+NP/IRI+X76[OM24)!?N41693G-LCYR<T[1S[1N]:G0+"5\V1Q7\U3P%2
MGUB/'8!=*-/O8D#HI?)4ZL9;,;%>WXM3C6=ZD4E(D0 3)H4@%>MQ[A90@X_S
MFFZ%'&&(5@:.B64?1*?OI2_RO,!@5.%G[DO]>G,!UCD><P*"_?X'^@%Z^6OC
MMY<Z!UG^DO<QLJ> "O3B*0"R8*JQOK9Y@!E(_9.D<"W^6RX.FCP9KRF-U^RR
M^.I2#G,:I$U.D8^&6JY0JM74AN>:9:1LJI?K:!]0=A1B/B?ARN/TS[TW](T)
MI/[:"X=>2AX-1TV=L?/T0JN27%1>)^MOFQ2T<T?WL0R$E-AL=PJX4'3FDS#=
MM:RIL>$@G>ZIP&%V4#0,<W;EKKG'1OKHKO&2QX@C"R:U$$*PQB=_"E[I0S.R
MR>>^8D;GU:=*<<Y.NBX*L5QA<#!S<U+F 7926D(V E1@>03*B")%+3'KZIT/
M6(3FCIXI&Z_W&U!-\5]CR9(^^S4-\GO6#4+/"<J]SGPO&@6^<5HN,?!'I&?6
MQ/8$BMRY;707^,30H]Q?QA447_E[EU&,GW%A3R_<FGO8.;>Z^<S.;N0HPM)?
M<AR-5T;EK].[W7TE#4JH'/T0,9=*.@4$&=G3KDD('1\:H<JC::QCDE$#I03\
MU[5TRX&0V3G@,PL_\^;R'MJB[5Z*0JW2\?#TTG1L5]TFQ6*:Y;^9-GTTFHE7
M3).]GPC^8APQ-4R-4*;,O9GF_")+/^F3<II[:<&K/&6WSI)#WK9<<9LDK8E=
M;8D_[C\EN@2OCK]+.NY@(K&RHIP.7*VZ*G6@ 5_[8G+P1<NG (&/FU+WTJ'7
M#:J&I0J.5<LJ90*NE+UB$'BL&EYZ,,R;GNWS6@D4_$](H%RV3L[; RKQ>K04
MZN$-M1M]\UBX1K?UAG#1*K[AI]N<<4U&X<R3 @?SF'I(P9N9:;/"O\YQC9CI
M&ZZ/"[#$>1\[CD40@@^:/PY%#; ^;\$MU57KS$,,BEL,7>+UM!-F0V,\8ODI
M_D>K9B/YE4E\?]]I?"VZDE4!Z"[0!NRF2/R&^\X!.<!JJEL#B<A2$Q_Z@2/"
MP*<U7IVH(D7]"5#Q8DPREP73_W0.GAF-:\>TI]=. 0V8\0@IS/Q-J>.2$X=,
MIB--:A#QR/AW02[B?RJ$_N>M,(L$*3^.9 5I5],,_E 19+ACM#'Z[IIF+480
MO1,;-$<9G(/MA;OWG?$&KT<?WCOZ7=! G-K6>?XK!W*[,[%PQY8+V.NO$W1:
MQF[)7'"OB.QW%YH6QK:\J<-2Z4AZUVTF_P&O[3G3U13<3=K4^O&2;O*$=-Y]
M$*T]-5$6L=3@_Z?E]FB3_M;Z?;EP21O#D!6(;W!UF$;8RH1$0/><=8&E?5OL
M)0=KABUHS0\B(;BYT@3,.Z\M(M/C_4'$2[11J;8^S9-1K.P9R:BKO?WA].V%
MA5(RM0*9-FT6KZ'X&K:4\"*GK)L[I[X<2&8>1\[.A.@G-:=O&@L:&5CU/%.T
M_\1-XREIN=S<$&M%OACKXB&W*\_*E:C:[N0J(/-$]3!+TK3!<FL&3P!A=W_:
M/_\^)8O_8BB"_=O5&-'U<$=(^R CQ'-?G_)0MZ[JWMNF<"?_#U-]5]) /3/H
MSV":]%2IM*6=Y(T9X>?/WW_]=-Y=+BZ3-M.0\7DWK$DAE\I%M@]?1QD?\ZUX
MWH3_$/"9B_7Y1^MNG_W7S:,].>*TW[PW-F/AY&R(-[_OIJN:; QE+4 X_'/7
MXX>)'Q-11^CFC' 57:B(N5UI LI9N%RY*D/Z/!*VV3Y#N2/T!2XQ.R4S/=<Q
M+1K9Z=)&/UYI6Z(=/+_B6:38*C?E/S@"<YN+#4LE+6P&R_T\WZ5O7I8VGC+Y
M$6/[[,_-00;A$L:C6_7]>C$BIX! ?\>CC&B5AR1FW[GD2*KZ*>#2.FG*U&Q%
M^C$YG\7SF-SE@YO8U7]\Y5:]5(3UC81V?_HQJ1N?DJUMDB_Z)#L!!/=P@J2F
MVHY0VO7!\ ;_D RUU&S2]HX [[,#]E. TG*[NG:!;$U,^0+-E[\N7([%N'$8
M_N?A+R"=$\H;"C> $A'7\6:]<JG-[<&^H=87/GM8!S8B LY0L.G)W""+92P/
MS%7O,BRI;;ET VI5S=[_Z-K3[LV;',NMM@'8)LC^3\IM)!6\%9+J3+2Y&LM(
MR=#!Q.SW&;];L,7[OS'6&XCK8N60*^EC4WBT\3M+0_9&ED#<V@_N < ;T* /
MXC/0 >R!%+<R)-F$9&(EM?WR^9AO]M?>\%NK3G]HU 3*7_T$?V,%T:-$EZ^*
M)TAT$YGHH\S%SO.]_VA_86>\SA$7S#WM-(-[M>3'RR'1EY2"65X9S-XH1Z[=
M\'82C>$>LOLQ :#W]B\@1T$.DLV]OD2C)VM^FR_22*^_6A2N=*>[6!X$8NP]
MH7KZ8U3]HIF9WL*7(S49MPE-+ALTH<Q=CE'*PWTHQ7M6X)E)RS 5R ]2*M5E
MGNN3Z%WLFC(*4>S\-,,63IL'<M$T_2HF=$\.3P'S)=13@'#2UF:8OX!?)(BL
M43FG"^R\[K BTM)@]J7B;] (8WTK\OE)L;_0)/Q1,SD]P<,/^<_$$%ER"K S
MU9'-&WQ<>/'% 0<>!B)R!5+9"J9,':RYL+M]RDU^V=R2W^[5T;:Z@='N24K&
M,3\^2JZ5SJ(^NT=<2N3:/L]!T Y6$A\RH<Z4*$J BJRF<S#SS9P]VU9Z^Y'Q
M>J'F7A%4Y5FIZZNK?LJ/4SZAMN\+=Y,;ZHFZ4I'^HG!]&V:8U^LSAW2ST,;Q
M07)3U9@<>RWD>CI'P_R)Q-_'YS]+WQT;>@-CZ*0_R9;:@\KHT?42=27T?&4A
M/1[&X)_W@>%&,<6J8)5';L>:YHYX$=ZQC,#-7>QK1P63;1W^3 2;^O)RQ-&Y
M","VA:K;'!LE1_7G8$B3H@K]HG2L?LP)C5#-?UWP0=H(_,Z<4*37M/SH?]-Z
MZ<#FSB%$+?,1@YJQYU6OVC?.?3_T\D]<_?::(09VAR35J:JO\GA:F&+/$O-Q
M%GSO F^VMK/E]2_+V_-><H9M,SQJMQS]6<F")4BXR"CJIY[N#7,PQ)L_UB\]
M[](9%NROB)WODFQ1@'V'RV9TU"*85-0O%G#T?'80MX6$&IX")!D4\>+E81@P
M))8)+H^E6A3"E<B/%1)D#99=+$HFS0MI"DM\$+S3_5NH0*W\N'<1<O<VN@%T
MHRF'C5V"<J,T%<@Z<9#YL))BPB,_997_I.G&=N:^WI*^09[2U7WTS^S:C9GG
MR29'-[1Z"W]9858VJS08POQE+*DN=54U-=@]J,*O#]==%+<C^F":IJD"%_V4
M< _RJ4;#[IBK8+Q'[1>X'>>A\35E*.-STZZU<_QI;WQPXX(7*0C;6<(EVVBV
M1:/+=2SL/F)K$B7XARF'41_,3C!BH_W7HQ4;VR[CIUTAWL#670>26G9N(>1.
M$Q(3K_<^-L,#P0/7Q])$_U)\GVTE%14[W'_=5VZMQ?N$-RZAVT SS\?(BZ80
MN- TH/8')BQB]_[75T]A;&/INRB<WK[L32IC=6ANJHU[F>;X9(NB.A5Y:'I(
M:"LANQ(ZS0<&H^%/KJ30=USK!-OF@S-DKW2LN79L&]FN6FY^:;DPX=#@5,V!
MZUA'&(VB)0EE4CD6?@$-A4;G(XX*%H3S7H^21@RF<ELLW,,\P)_/[Y6*+TPL
M(_H61# I2B=DR+:2V-Q;K>D'+AC[@@'9#7@[$1ABS4%!$)GUV@0EL07D.R%[
MX"2+R+_.N?5FEY;KG'['YOGJ!?IS4^5JM^S*PHDSK Y+[5][E]K??RV-RPVE
M5/S]53I@:[@538VW )N_Q \,'[ZH,. B.R5JMF.N-#VA'\4E(85"<URV":7!
M!'(W1[#2CS_,>/?$%]XZ-IT2)TOJH,^=$OE$H*Y0KX+MR/W[*#W&Y6%-";/E
M\8K8J8YSF38'1@CM>71Y^!U35 HKZ[)"0RI;+$K\^Y!@A^#>$L@D)39P;S^C
MP]QQ2EBAM]#2*87M%-"!RVV?:WXZ\QS2(]MS'_K4[G;5-YE8U[MEPNV_M$AW
M_[ HH4A3R&5$T^]\8W/Q^_=E#/[FE]). 3V=6QT(MMN-/YT^U-9",5)X]HHN
M[RYEG,[)C[FB!XV@D;D] IU<-!$8GM)2?J^R)L4YS54EGLL9)U=2 NL#C62!
MG;(JL43^C?JZI>VB-O*9<GOR3NRN[+'Z[@X:<TW<+G%Y=-\-?0):P,RJ4'R[
ML"QP+<<S$\J,%MH*IU3N+,)0A<#)VG-U12TBE 3+;^V9I2FI@BI]OJZ5K'[K
M^%I9YXNP;A!!M!'I%\TJRN=OL9Q2N)18>6VAC6@G)8^U\9N9AZJ43W2G-)MV
M]YG05IEQJ$.4& \:*#C@] 7>4Y$U=884Y0_'T& /7V_9]3OZF%'DCZH!/W87
MBPS7NL7F/ZS!1_P?!6&\V];;EH_>0=X1VO#&WP5UOS"= @ <QIS>X9ZQMQ6/
MZH&]-PV*/F>6B_UV'E0_D-3+^.@OL(S_\S4%$>8\/WJOW=F"24+ZG<G>O*T:
MJ0S3.L.TPIF-EV*VF;*(N>!:E>UOO"MNH7ZI[7F$ZF<.\5F3RK[*L6O&E4RO
MAD''!$1<9)=AI%.:I'^RYW%B;$;9*< ^5<!1Q[YN:R&'SYWMU^W):=OG.9G6
MBAREF.HF+J^X*:M7D9\RZ6X%]C\8.N<G0=  ,SM5!4O-F:2U>)X"L!_?[M6T
M<-_>QBRY#92V,"R;=+O7@JX#72TX2C,84?1OS"\+,6KP/HOQ/8%4=XF5Q&@E
M=TZ-&/A[(5+?J]CYQ]?F9\3-^WBM$3.7L8Y.^#*TIU26P],I:^>K]I2<N1"!
MDO/MIX JM3CBYI75(VU8=0<H?B6,36KSOHD64I4D\@DR3=9@.(.#+918B6&@
M=3BW=ND26:MZZ1_0CB\:2"S+(OH*A350E:('?@]RA8G&\#BMCWI$N];A_5;&
MEM9V2-]I_!,.O%X=C3UR?=[]591 /WF&%'?:W'WY@-URI^912=0_7DA)V#K)
MNER87@CY"1_;%<W]$HJ".:D\\4KS]F1+LCSB7#9_A52RN5[YI5B,^I)$M=L*
M(MGA0N"/[(FQ8>;^&26F\XY<N 85)RD_EN$#!.,"W#:;<OR23$NV9XUINO/!
MZ9:Q].3R1SM[P,6/0=OS2QPKWI1PTG0DA*@COW>R2Z$]'A? K>%L"RD1?2:8
M<6>I/,T9UP] V5Q7:5_&N:(PI$CS%ZER*UEJOYT!U'\#Z!]::7:OR)[QY:K(
M[PB!T3</;>.!O-7ZZM?:>36"&#/%!-ORRE\N7^<1D(@;:V&GZ%E@DO9/ 4]1
M]8W?%[6LO&U7O,M:OGL?%$<MZ$XSES][U/;0)%YO=&?*<%8A2&KM?:  )_Z/
M29?H\SZI1<>RU&,@[-7O;:T-V6/?CO>7;CEX%J?MS>Z5OQJX*8>M_/ZEWGMF
M^NV>-O-,G%\WB]IE"I\*Q;''%PJ<>TW!M2;K<H8CB.ZU-:,H!=%QO%[27>&W
M(5'I?P56,9UWB*;:2.VDI03/C8&WVNR;O>SE?P7-CYQC5;Q\*B#R^S3.8>S=
M:Z:23L^WK1[>?7WY/)V&VZKEKO4%<@LRVZ&%=;3TGN2NKCQ)P<]$(GI0Q:7&
MZ!(YT;8+,N50.A[2'9T18CY! 9.05]59"6AF#8OO7/U\V@\#97SY&4M;6,F8
M+Z)D^IC@@HD53Z7E'=W.SL&D\;+A+_ RM;>3[YHK>,V53.55<HB8MI-GOP0E
MM>8=%BMBU2,Z7O(M@I]M."=7+*)I' Z\N!!).2L%(U2$F/IN-<%271KQ2*#6
M%=.F[K6K[Y^;IM<AQ&1#B33>RMW7CA;\61CYXT!^\H:!XIX<85B=_O]/T=O-
M?VXV(JN@#':U.X[6HK3N(94[I0[F?I-)PWW>'QOG"6-/5.9!XWMD3 >3,R/E
M69?/5%DX.1!QN=-760N1U];R+C?ZH";MDZZ>/C):[^\J"1@.ET-D_CO*C\W%
M_U-:[Q]^ZMYU,[-.KZFTN0$T[C$KQ-#"2I&G.3/#<MJ/UO]4%BRS]?'?I*W5
M7G'=KCTVWMS+Q5R[BGYF.+PN]ST[9ONFC+IX?X2OS*Z<?T1\U(#AT^IQX23E
MGOYA':&DX23E%W]\?(Y'9*583"F>/ :_Y0TEG..F(A^FIR68C[YFZ!5":[9^
MWZ1"H7,'Y/NE=O7;J 6LRJ_]%R$L5IH'T;X*:\O$*> 9+7[,J8PJK$O26KS7
M&=GSBIN6&'W\RDJN/&170WKSBZ,^)[35+?U[6<*L2IMSJ&?=[#ULF:J:6Z=/
M50J,N[T8L:ANJO4J[<B,YK#K*);=E-WV7S45@GUU"&;[N'ET@T6X-JI"L*""
MNOJ#\B1SL(#BMV=!/@5<U[5^YO%(]3'0 T%GAKCZLPD\IRO4)DT=KXQ#%+(-
MB6<DLH[B\K/OO2C,<=#_S/#6*OYDC(.E:NS(_?A ,><87V8EG+VW E14+!V\
M"F'*<L"!!OB4G@;W6+<R8F]\J&.-JBT7^M*5<?ED/T_%LSBGZ,J,PK+U*]&<
M/ U#BSQ*>LNU>*3U55_YEHU\EF\J(+()]I&3O1++EY5+IBQWZAA:$%] 63!(
M&Z]-\+W@E@R'BE. ]^#]I=%:0W->XR\^)JD0\-6.3UV%#]8>@)1.)/C5.)[<
M'85C5V:6)PC7(Q-U1O+KW_I=._&E=K*COJ'__>^#H QXS<7H$OD/V/!/=W1O
M=5^[^\%3$<"2B]53,?G:-/*BLB/(33D-P. *:9-#VAJ?9.X5N:N>,W,_!5S
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M[8WELIIQFOV T-GJ2C"A+??KAFW_6]T][>C]$O?;?*Y! =T?1X\.UH.\LZC
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M\TEN3?,AU EOLPC/(&80BH]M<&NR711G)#ZR*%Y8-HQ@.^E21VVFURSSGSK
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M69$%$6"MLA& WMG'W+KJEFPHM/E1MUK:O=5:N:#(N3"H+>0,"48*7_Z-N=)
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M%2FH8,"(N]7L0$U)$=*#\[R^#_; XX& (.A D;DD6G2_<JYH3&_8^8*-(IK
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M6)2V3^^N#6AJ8V8A(PBIE%^@0Z]B4-G0G)QWU)$M@'Y'P5VH)3<E9WG.TD5
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MOW]DW9ZK+BRG&.-YY5],N4T&ST)C""@K4;+S!SD?R50E>]WI-+F+U7*%^]\
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M B0O['WN.>J]VWW.'6^\\18PQAJL]<]_EN_[YOP' 3."F09<EY:0D@#@7
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MM;)Y_P6G@M_O+S]R'/C_+-;"\U@=T<08P,>I,Q\6#&#4,BG_;LE6(LQ\X=C
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MKJ'! $I#SRY@CPTWEHX_ 7^;AF'W%\/\0.(E^EVY!W<UDS6IQ"**OU+@;N=
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ML"U[:S85CF23>LTU._IM+*S91D%;)*$/P9%(+ 16$*<*',1]]?BJAX2'I42
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M3\("K683WR@?1&QP23N.M&ZS>#L0"0PA7E2)">@N/.I&"=JSQ&&/D3YN+AB
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MA*F-G2E-=NC"C/8(8_<  19 @4Q_7M$'PU.)E(L>,#1Z12-FP#$BEER:G^A
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M6-@UHYH#&.]?'C5 B6@^V>MT'@H;Q735W-,EJG_=:GX5=1'10>: 9U8T?A6
MUP=V#IZEK'>3J'.VC509U32[*8B 53<C7A%N!B6)YF@1/R;J("Z.U%V=66>;
M;*5/SC&!+POQ54 / N:\03X>0Y<'[R2$!1B+P<P8KK:_ZV%RYY8*?45ZA\"D
ME#=NVCCUG3LETB83F8RPC'D2#U+C)XA**?,:7 \'.%5^H=UYN)^QX8[O&.6J
M;&XWKSXFC:AT*<A(;:>&ZDO6:][;N^=FBI*=[/ ?[H/U"AX;9IAB+E24E@P<
MZW$H=:9)!HD^TOI$IUW0(PW5Z9TI' 0O%1;!?S[0DJ"UKB P*5.EEABJ?HF<
MV6[6AJ=!C5V2U4>[..RWSG<APL!\'""M/=M])2W84ET\6;U3IO9WBG@[B @%
M*4'M@S9>^7.'W>^[!:&L _$J@E+Q3YV5ISP-"DHCG(YU0AJI;T=!DZAN&=,Y
MHY3E\61!I"9P,WNQ^^H<\]HSH[UWZUJI;\4](O^^JGOY6#^K'M$^QBF&<.(7
MKLSD*^?R\7Z;04[CD!4W$)E\S#FX5^WR'4,UO')CY,[:I(P^0":%FWYH6;:%
M;$#] $\J7F*DN7Y#9D=$9AXR] V"XPKV#CF,ES064,>*!315>K[, E !7BOV
M;+",ZS2)!O-VN][.-M,=%3/V&7:+VY&S:_P&L;,*PNSCEM;XNXJXHCH$"]C&
M!\*AP7A8P$\PY@>.1]=AW7WALKK6^L\HAF=J3[$&CDNK^FN7#2#'YX./S<MS
M+2'TIHBCF3YUEKM&F@YE5U&I(5[B-];D1D'E.DUT 7EGB81A.X^?^XB: 0L
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MU-7P7Z/Q-WJHGFS2NM?2:/"G:)=F7U?EW=1S%/PNY!68I:&E*XL7J6_P%MK
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MG$NXBYRC=FX ,@E>DB1[5219@!WY_P!02P,$%     @ 63=M6Q6K.]N170$
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M+C"Z0$<<5.;?-G4'^J6I'S,/41>HQ?RW(2PB$:)R:##JH:[,5DN*>BWU4)#
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M377PZG5V=;S&\R[-BR<%I%?LQ<)VPR@K2P@$^C+\)H!1GLAL$NM:D6.D[+^
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M06P<^#,,DKLE3-1"CPZ\P8S61$[DF,\Z5^.*$W'V1=9)H8*UO%+4.SA?F+J
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M>E:4>QBI^J?! $M-6AJB2-8.F?"!H=<-A&C.PT.5LCSY%$YO&YU\Y6XTE)Q
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MBU^+'#Y)"C!M^7MGR>9).@Y_G'B2> 1![PJM$"S2+&V9%HA7Q2!P7Z.X]?+
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M?26L@37AZ6$@Y#XG\1GFFCT\;_/S!,;4\25OY-_,*WQA<&4:A3;S+" GZH>
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MW/=3R'G!Y9&Q):&\-N8IB02B@OX(<LH"U1"/?JG(')N*5'@N+1\T52/X%X%
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M_O1Y'<A>X&TIB3E!F)\/_ZQ.YP$1TF3Z2PG/C&<X%)<!C!,\"%-1(ID[Z 3
MN5)2;FX]I-4C%B*=2>%[94;RBDA%HYQ?[1F_%NZZV@6%RFC+2E!H8W!GT.EN
M3.$=-CL;2[M'0SWZCP@*;43.:;?[5<@YND ,/*\]&@S[F^$F^BG:T#8$T'2%
M-C61HDG;U0,&=TMYEFD$;]AJZG"ITWQ200$B/S1+#"VD =U1UJM0UWX C,*L
MO0S_;=N$@!EH,(7GJAB!2;>OY*VFY<4NBMN]3G/?FMN/D6S@@DEHO >+DP)C
M8HH(>D[)A,,<7@H%.DS>DRZ9,E%0;ICV6)ZZ6-<LDD7V$_7<(ED]9['M>FE*
ME6YLGB[I$\:_#>:<0)B$.=\QGX42:D_>BKY:@NG,IY6H[$4PC-SL<WU,FJ'C
M<H$4"-M36GR:%WM8,K+?")<7R&4>\<7"LAS^;J"SF&R18V?=#S"6Y=&LJ=M
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M0=_S/+Q6]0GTM:&3QQ>N3>"!"]<:4>G[8.2G;9O6\!1/IU,O4]JL[R[?%TH
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M%*RT^)'TIB2_L*73=5RD^CWQ8_A%B/\I34+D89V@N.7&W,TO%%^TKMM'HPK
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M8]%:P9O!&QWRIO2[>OM2( #K8[U^&:ZR"E1)L;"XJ6CVT9^.;/E2N; ^  R
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M"@6ZAAU$^@N7\$(AU)_TW4V+Y."[A*6DKV=:>K54Y)0@.2LBSLB'>4N\@1@
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M,N,3;@1%C2A7?@\PDP'>#<KE-4<5(A'?$I1346FX)0R6?/09-^"O('YG( ]
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M^4U[EFM[/^E-2W0>6$F/&BG%I'QO7+#"AV*?6DC^UU<5PDWHSVU:XC7FZ=3
M;\Q471I+RZVGDE\65)1);V-#)FF(D$IS3,- 4[*NV,:U&B>M,TDSJ]H]?SB!
MU:%02U2&AA%ZLPH/R<KJ/_>49\?H*W'0E,2GL'HPN&#ISD,+P%>E&^^]6901
MP><B3G."Y)@[.IA,*&7-VP+12%F'HA<2B724(/*'"$2#)64!]'RN&;D,0-5*
M%[ 1'C175)5'\[.K'K<X'IC8P 4Y[08.38AFQ]&GNVTIC1$3'4<@QJ8<62 G
M"X+"C;:Q)48DXP5,NS#"^(H.1C)BC<:\;-J-R48/RI'B;?J6PQ&6 ;POM)3%
M(A0VS'-)=R1;$K%IB<*25PBD*(7\VZ2UKZT9A?:%-^HZ6V#24)Z.2\.EU:A;
M@ZCTNZ3.4^+;$KL#4^;5%G$72QOL=[&T+I;6Q=)>Q"$VW>PA9BHROO=S23EW
MR3K&17@;A7=?&4/2OC^J2U83^UH9"HUJ"JH^R +5OBFH=!E_7^6G,=0^*SG@
M;Y 67KD4JVJ9G4.OI,4GPL!J:A:EA8D"O0560,_T6E757O-)/.G($(4FP@B<
M.FQ)JAY!.7>W05Q((DV#AQ,.WB@O^>_+$:M:H:&!1*_JJS*)_Q;,%Z_5-.9%
M=AO6K"7-J((EWXI8<W&L\#KI2=7BJ#&55=4=RCQ4KH!)NHBX=D#3I2KVD"T6
M6(""I#@LG 8[+Q@AD32?YM&%_\?0"WQ@%E'@):\;^Y1YG**ZI6LH\"*MIG,J
M,J\L"XFD#2T)-&TH\ZS9>)GH:8A5@,)D0A"NA&NJKK!J#:.O7,!B5V@;S;#F
MB1SP.YGOQBS"\:QB6O)Y8\QY1Y5K.U>[F57 1F0W*Q7=<9C P&A 5T4[3.+[
MU_C7>^TNH,Q9\9?6" Q+J_0N67=@'^1U5'7<L"3%=7Q?V;MHWF';LC"6A0I-
MGC\->^SIP4+V6V A=@B'P$*<%-Y'._T&+;@!"[%>$UB(^]K>KO5[ @MQ?N_@
M<&>P05B(8!O_"#R(O/J1L" :%=J!0.H@D!6F3\U=D$O1UVR!WPV]17H72L5*
MG<N.A2ZY5"Q=$(X.FP"L,<2:0E,'3Q456R@O)45'WGEOU[LJWRD!NP2Z9O*
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MN,"^S JX2"!-SO,HT3OV5E'"?*A:1DBE*L6'P;:[3*\Y@UC.X6FX#"(L@XT
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M_<.=1C4!6.G_^'!Z]K?Z,^KO._T-2NG3)"\R2FV]")&)DCS\ZSCWCG/ER'^
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M"V>0$#HI+"W].JL>G!W:]<^&=AUT:-<.[?I2T:Z;%E>K'# H;.',+70^!ZD
M]9/ . /DH*93Q*^<0I0'E;-R5]9?M[ZO<;(@CG(<@@8RSE1178QO1EC=%IH7
MD5:09@67JY[!M_$%EJ]7P)A\Q/B-@/=*;?+++# ^,J>I'&,WP2T?8=7C%2&B
MK%*)TG;%A*VXNH3KE12F[;-MK/MY*QS)\+^3E EJ<JTPG:+L3!1X\#*(:7[>
M@U::&\6/$95WW]2%35)&#+^#IF:.U#3$'!J)XR\6:90(. C4Y/0.D_!.KJ!)
MH!M(5M/E?0XJM._M[.QX(QS;&^^8UHQOZE6__MO_V3GHO_9@_>_L4,H=J21@
M6M/+P?B=%3%H THW )TN!4/\'M8R[(4)33DE,<+QX'N4-,[4TLLPF++V/@FC
M6_XC&.J8.2BY/)S#X\%^N97,))K&/.=EU-1L'.O9BHQ@Y9/ %/ 7!F5&2RX
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MXOS^^6()"COY[^\;FTML.K"F<$#(SHF^H((O>P+_,BW$CMJ")GP!F9OTR@@
M-07OPG^C+5.F><!;+LK% *L4%D_NT4:]3:,IQT/FJ8YGX*MR#DHD)@(;;9&4
M;9(H+]<7&B%H%U%6%\B7SPNX!U;NW,A*Q+Y9YER"+<8WM/, 3*<$IR8=P[%3
MLD$4F'"I&!-X1,$"PJZBZ4/QC=+]'P?YLAEJB5/8TQD'6I!@8VNGY\UA[F]L
MH9]Y&/+@$P'M-"):G"4;RQ&F&["+>H$\9QG:9#B4:)WAHP'BY+L@K4-1: O2
MV@]U412<^C$H"L[#&10%NR[+BH);!]X;V*^QHM"F#!QL4!FXQ,1B.4+6":C.
MV#62QJ%R &DN*!)VQ,RB7$^6XUOK#5%R"_,N9W28S'"S!W32I8J:)@LEXQ7>
M@#ZKS&3.07J5L/JH<!/B:X6&*@69FI"WHVR3;@$)+$630KTJ_5LE=XI^OZ2G
M9!Y]("IE,&S@(&*]I=%==>0R35;IDWN]T?QU=6[YWDUZAQ./,VZ37G@6<+D2
M\46A<F(H!J&<!3#X\V)9T%%!839VD['OC'EP>'8-+R1ZQ$!%21*6I1@VQB#Y
M!+.7XRB_$1^JYAZ*$BGFIAV8TM:N@F]-,.ZU"48WE&S?#>0'P>@$ZX-@=%M)
M?3L$302C_1H+QK:$@\,-"L9?B%1MK6JY&$(&]46(4SGMS2(+YL$]$4;@!Z:5
MV+,@&EBS4P8.+OYES"Y>O#H.DW 6+14!F.^! 84"C 2=4,%IV19JTZ)(""92
M<0H'FK4B(@P:-6]:P&8.?P\GQ9)!%AB:2)2+V]B"'/+0.(Y&UPV3D<@*N&G"
M/J&UUV#%44LD,#$+HICJXI8ZLV8"PW<2D@/5,PS=IQDQARQ11<RI=I*(<26-
MEY8(25UPXU._HT8LN &.[I 3'[H?A]=DE<F 3_&YJ71&<'U\1%5Y^FP#IBUE
M@]N0FJX<^+-B*26!M;H[SC' #PT50YD7Q3;5R*2&YKYHEC@ M/B7 8)6X+=2
M19;Z9:K7.5E^<)BI:G[VHWM2S L.+BKR1L5L9\!U H/Y0]/3T:*@9MW[W,Q*
MV_R:]JX;UJG$=LF_WR;YG1(5)+]370;)[W0U@^1O<_VZT[3V[*D5(OG;TB".
M-BCY1S45$Y0T[:M9C[:HA@],K]DOI9&]_X7<*" &]4WD\ $1G8N,9L63FA-4
M<$W4%Q0.I-2.P^5=:#@1I**H'!C5/=-A@ X..@Q0AP%ZJ1B@1SHS5P<$U3"W
M0G-+=GF!5$_A%*4;DBZ7ZHHX^+5$!.4&Q,T8K,>2-M:'-TY#+2LKM!7"<34.
M9VD6KL3@6P=J2*)&L^6^4*$I[_^)B=-\&^63.$5OGZ%?6:2Y[TV)=_4_"U"Q
M$-RRV^\/J>5$(SQGEZ=QUH1,; V'0$FAI;W6H-)MTNN@( ET=&[B@P>H#Q5P
M!%O$*]T8X<Q/FC%B8M;E@5EAH:**79G-TX3<T=39*<\L6U"5P)DE0K98ASN:
MP@*EI0%/$1R,P&OE5]W4;&B6E9HZ62$VPZ=4X'EUH2=M(7YK-G#FZ92)W62Q
M(6,<;#4R"#5'<M5?0V/K6;54-[!AW^TL!2W5"98 +;5QC:.Q![N'^^ZL'- V
M;1DT6(9AKW]TH#3FS@*I6" #JP4B%H$5?"(6@?T:6P2V^>-DY)VC3?J"+HOL
M%@O)K:'\VRIYT-(;'C1SR#E!"[J\<VA/PL)KNWW9!DU4Y_,4XWL("2G^2IQ$
MDD[R(0*%/L<0^>:[;-H,(/;BZ3_V#_\Q/-PD<F,/7;PX(B# ?SS.<]RC[%6Y
M(%=/KTEQL@--E#7U&(.VF5'9YU&YI J#L$"(QA/.T,NR]";\Z5%6S68&X$#5
MX8:5X9UB' 5.7]DLK[TW6?"O*/:.-7'KLQV)_>V=K9F,!.P/.+GFDO&I$>[/
MNN_7/:(/QNY?J/IK9%(^ZU['NLN@L,1D#9Z3=GV29IFHSL?4KF<\#+M:!)0
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MN5]*'!'$=X$-,3LD),0&1I:S L>8G:& L@XL[M-0<Q[K.!FKXP3S:XDQ.D,
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M1/XT3J?W\*^;Y3S^Z_\/4$L#!!0    ( %DW;5NCR<%C:P@  #PP   7
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M0L]&\C!4QKME).=SKBKO=0E!(DV1B,LY=&^W)-2KO.L>420\;L^QO4U@("*
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M\"KB.:O@C"WA0N:D>.4T(_A>,<735Z%=7?$_&8I&]S2[U2X1?('"C:UAXW^
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M;'@M,C R-3 Y,S N>'-D4$L! A0#%     @ 63=M6X9YP6WL#@  BLD  !0
M             ( !( \  '!L>"TR,#(U,#DS,%]C86PN>&UL4$L! A0#%
M  @ 63=M6QYP6]_%(0  H]P! !0              ( !/AX  '!L>"TR,#(U
M,#DS,%]D968N>&UL4$L! A0#%     @ 63=M6YY.C,>+3@  PAX$ !0
M         ( !-4   '!L>"TR,#(U,#DS,%]L86(N>&UL4$L! A0#%     @
M63=M6X-NM*6L,   DSL# !0              ( !\HX  '!L>"TR,#(U,#DS
M,%]P<F4N>&UL4$L! A0#%     @ 63=M6W\C*?>HK $ D941 !0
M     ( !T+\  '!L>"TR,#(U,#DS,'@Q,'$N:'1M4$L! A0#%     @ 63=M
M6T7(P@)7T@  @A4! !<              ( !JFP" '!L>"TR,#(U,#DS,'@Q
M,'$P,#4N:G!G4$L! A0#%     @ 63=M6WC[R- 9A0  ]Y4  !<
M     ( !-C\# '!L>"TR,#(U,#DS,'@Q,'$P,#8N:G!G4$L! A0#%     @
M63=M6TY\G@+RQP  ,MT  !<              ( !A,0# '!L>"TR,#(U,#DS
M,'@Q,'$P,#<N:G!G4$L! A0#%     @ 63=M6ZR",4O">0  &IT  !<
M         ( !JXP$ '!L>"TR,#(U,#DS,'@Q,'$P,#@N:G!G4$L! A0#%
M  @ 63=M6Q6K.]N170$ 7@0- !<              ( !H@8% '!L>"TR,#(U
M,#DS,'AE>#$P9#$N:'1M4$L! A0#%     @ 63=M6Z/)P6-K"   /#   !<
M             ( !:&0& '!L>"TR,#(U,#DS,'AE>#,Q9#$N:'1M4$L! A0#
M%     @ 63=M6\A@$N21"   ZC   !<              ( !"&T& '!L>"TR
M,#(U,#DS,'AE>#,Q9#(N:'1M4$L! A0#%     @ 63=M6R@_SY"C!0  P1D
M !<              ( !SG4& '!L>"TR,#(U,#DS,'AE>#,R9#$N:'1M4$L!
M A0#%     @ 63=M6\Y+.2&J!0  W1D  !<              ( !IGL& '!L
K>"TR,#(U,#DS,'AE>#,R9#(N:'1M4$L%!@     /  \ ]0,  (6!!@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>plx-20250930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:plx="http://www.protalix.com/20250930"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="plx-20250930.xsd" xlink:type="simple"/>
    <context id="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gx6X1c0dg0-aboMNBFKFGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_x2V2OwuyRkGovAC9kMzO1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gQDsVSQOBESn2aton7MkCQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kp0yapnm40GB10yQ_ydGnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2025_82uuoTEUkkeqvb5YouDXFQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_USxfrXz1rkCYTcNzIVQZ0A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JLAmLejgKEWYC493nuhe1Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1Uwm5-nSiEe1UtufcBH-0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ci3mkA8inEugSxpG-FuQrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yU7hKhH3lEmO2pb_PDOgwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h9xaPufFAUWhI__zK0WDdQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_hFoy38nssE-_Imrl9korwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rwMgEGPVD0SY1Y-KA3qD6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3QCYXsKzjkqrL_Tqx7sWEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_upHYMK9ggEy3QQ-m5XNdoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate202006Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UNTa3I5u9kqeTv9FgW1_Ag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7BvwDWTQK0ShOuP9uKsL_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_JrP2MNklRUaZCBhVdKEU3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Ji-guYoHVUu8eVJ9spIzyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_tGVlUvMwNESS1QuVEsIxCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_LjReUd2e3ECAW3t58uSqwQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_U3vsnozyEUyKSmL6qLgZuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_EM-2D042mUKZtARE4xNQQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__wSFk5nFpUKVmADVapX-hA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_J35jXCLpZEemlLCh3xmZDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_TC6cWr1PVEmqOYnE9WVTEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_gQv-s1-zbEiYrnnAYvRtQQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_B_RDBf3UakmFxKgLCE1u4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__u5aEet9ik6m5qJP9wbdkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_zd9vtIegUUmVwTycldKD6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_-58If4GE2UOATvhmgfPXFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_8K2eAUmCmkWnafp6nTCcww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_-nchaslNr0uweGPjWu-YUQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_QMoe7jUDBUORp5O-RNIp8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_xIDPNJ0kwU6c6DEVa4EIhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_82eWapBWXEC0gB4NcExxIA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:FiocruzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_aZcDMzIGjE-AMBlyb0cM3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">plx:ChiesiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_DfUDjS8huEe8YHRZP_FF_g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_5TVhAsNFQE213aFWrjtG8g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zYmBSshLM0q2nl3i43mcsA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_71PZO8VDYEeOr9oCkh_Hog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-11-13</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CrvjSyzu0kePIviFTWVKvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_V8A_9r0xvk696ZxvjJRa8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:SupplyAndTechnologyTransferAgreementWithFiocruzMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-11-13</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_9plBbFjl-0GfbTD6J4eCZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:PfizerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-11-13</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_f2rN9XEbVUelOX_cn66r4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:ChiesiAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-11-13</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TcJrtT61UU-RVxesnAWVRg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TAwwe5x3akmfidt8z-84Zw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WUrqKarnvUy3SRJfTqmqnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wFcKmiOLbke6KQ0TZk5Zsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_r-Ghqyl9T0iF4Ti21qRoSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">plx:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_GGLx0RMJkEWOCKabwh15XA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">plx:SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MoWXQGG3_ka4yi-5e8DRWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gT-aDshKVkGrJq9_mtpt4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1BJ44ASqyEukCpWkJ6dVGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6l0NaCT1sEOnj3WEXVnpEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YfnvTfvAE0KtNUtZkwS5AA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_761cvv_HXU2xI_U7AsL1AA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_dH_SIULHC0imY02WiFQo7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-31</instant>
        </period>
    </context>
    <context id="As_Of_3_12_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_1UAWM1totEqWlXUe3rPvGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-12</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ikcM5x4J7Ua7ndrvsMT4WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember_-2H5wzF6b02WyHEkdfnNXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsAndUnvestedRestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_xH2ut0yotUKC0HIos63e3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_gq56zarwQUuh08Mxtq1EHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_xVbKyWax_0uHtrglZoisTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">plx:OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SwvQijHg2UmvkpniQH3hSQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_evPySq6pWUGtY591BlkL7g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OnEzSTerJUmlL5WGD4HZ3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uHaruiJLYEGlS_yAuGkvlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-x0_bEphIU2K4orXSd874w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T9xFatVQiU6cxnwo_7JjZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5Le7HqH0wEynn7U0eLUwpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-_wFays9-UWPOynoqeE24A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_D4u9NxlfVEGwyeTxPj6T4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_tPyaORiFkkOM-rUgWSubEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2025_srt_RangeAxis_srt_MinimumMember_C7QvDhrMDUq4S3iRN9FCdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2025_srt_RangeAxis_srt_MaximumMember_lTg-LzfNR0mwdU1OEzj4aQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_srt_RangeAxis_srt_MaximumMember_3zb9vtsmPUO-q5fMEz9RUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_O5qbhcAkvUyU14-GI5Itpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_OgxzvfhlIUigqCIom_Fjpw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_3_17_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_CFDzr7g43kS7D8I0mFf4kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">plx:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-17</instant>
        </period>
    </context>
    <context id="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_crdEnIEuZ0uz2yhEN1tslA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:BR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">plx:AmendedPfizerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">plx:ProtalixBioTherapeuticsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-01</startDate>
            <endDate>2015-10-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2025_iz7XutoutEWL2Qag_QvcBw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <instant>2025-11-01</instant>
        </period>
    </context>
    <context id="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001006281</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_item_D0AldO7cf0SCjEYMUWnWVg">
        <measure>plx:item</measure>
    </unit>
    <unit id="Unit_Standard_facility_0Iv5bNDqPUmCp-a8ET1QPQ">
        <measure>plx:facility</measure>
    </unit>
    <unit id="Unit_Standard_agreement_FXubWDLurk-D3rwvgsKCMg">
        <measure>plx:agreement</measure>
    </unit>
    <unit id="Unit_Standard_installment_La8zkqC6pUaqrn9vr4M5jA">
        <measure>plx:installment</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_m0Z75cdS8U2pVonlKC3GPQ">
        <measure>plx:segment</measure>
    </unit>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      id="Hidden_3kGEIIf6dEuB3tV0byXRYQ"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      id="Hidden_xRc61GuW2kicfqhaqXlXMA"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tc_fQw286d6a0mXbwhGk_299w_2_1">0001006281</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tc_A5M2oPkatUi8HJvvM72mag_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tc_TwVbeFNsgUCc0lWhBsJNDg_4_1">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tc_0zSE23xB30SAZ-wxzYjCXw_5_1">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tc_IGAZlHGoyE-_PSBu136iWg_6_1">false</dei:AmendmentFlag>
    <us-gaap:NumberOfReportableSegments
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="INF"
      id="Hidden_QJxRIWVBeUCE75e_V0YVVg"
      unitRef="Unit_Standard_segment_m0Z75cdS8U2pVonlKC3GPQ">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="INF"
      id="Hidden_bTovpeYB_EG_cx9KDkApfQ"
      unitRef="Unit_Standard_segment_m0Z75cdS8U2pVonlKC3GPQ">1</us-gaap:NumberOfOperatingSegments>
    <dei:DocumentType
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_rl93tMkoYUq7d3IewQAQdA">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_knY32YhavUS71z9Wj-Rz5w">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_UgtC-gnHRUK09_lt_-kePA">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_rhYds3_hMEOLIFQh5tnx1g">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_dd5JJosc40aqVs4Ty1nGIQ">001-33357</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_jwHrsgorE0m3ELnGsV5Cng">PROTALIX BIOTHERAPEUTICS,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tc_II1KWFRGikO7iyQGbFl2hA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_noOnhfkAVka7mU0np48waQ">65-0643773</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_mDOklUVrx0u2amqe7QZbbA">2 University Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_kou38x8q1keUTPjtFN4d-g">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_EFm6y7JLqk6Ka_X-I0pgMg">Hackensack</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_I4tVl-qKD0y-NkBYe86YYA">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tc_9CA4qp62ZkmWdiFwapBNvQ_4_1">07601</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_Uj3GTWVGJEOBOquQpLpPBA">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_Gq9uPc9V6UOcaZiGraeD2A">696-9345</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tc_912yUTkvAUaGRJGlqhaw_A_2_0">Common stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tc_1xraoRV4c0y8QUE7l7rRFw_2_2">PLX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tc_YRHZE-UjKk2UZvp8hugAAw_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_Azh_qlwgTEa907mMVLgqVA">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_gncDjS3ZaUWV8FJgXu4-vA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tc_7rupBYvUDkSnOpi5nKXUMw_2_0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tc_8lgawC9eoU28U0gCFdpd6g_2_3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tc_revsfCkg3USnHwnY-8pO7g_3_3">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_FXmbatbmlUmXhHnKVMJ38w">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_1_2025_iz7XutoutEWL2Qag_QvcBw"
      decimals="INF"
      id="Narr_I-ez9iU_e0GCfD1HSOhelA"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">80421181</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_0hIhu2HthkO-XAl8iCwC0w_6_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">13647000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_t_0PWsYDX0aOZffcGQ7yYQ_6_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">19760000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_EI525-bg40yGKRSARouvOg_7_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">15723000</plx:ShortTermBankDeposits>
    <plx:ShortTermBankDeposits
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_8guaM1ozfUaRtFlyXr9jDg_7_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">15070000</plx:ShortTermBankDeposits>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_4DWbJdkbA0yCaoDfivlqnA_8_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">14425000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_JD3vM8lbC0i-PhupNySTlw_8_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2909000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_Hog3m0yYn02xkltpRZYvpw_9_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1452000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_-v4qGg9YUEy5Oog9ACy7Yw_9_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1096000</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_Nw_a1uujUEmy0PVBiD288g_10_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">21255000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_CqkN3tXvpEO65KTzsgANmw_10_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">21243000</us-gaap:InventoryNet>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_0e75j5J17E6JKFOPqXFR6g_11_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">66502000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_uwRzT6qgpE-9z9a-v3g8Gg_11_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">60078000</us-gaap:AssetsCurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_DUWzUHZEWUOc0wc5-V6qEQ_14_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">549000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_sEPtgUJtWEyNHts-xQEtcw_14_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">462000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_JrhylNUjzkCufiSy_hNlAg_15_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">4724000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_qUV9-TH7a0mwqOluVsR2JQ_15_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">4591000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_PkMlwuosqkeekWuU0y1qlw_16_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2679000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_rxUn-H9QAUeE8BOTQgNstA_16_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2856000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_LZgJlpG-9U-3hvJvJouC8g_17_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">7810000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_2SDeYSoadEmHXVaNkthzig_17_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">5430000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_XQgSpRvT80KGf6adxu1gAA_18_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">82264000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_CS8deAAOhEahkuHvUC_ewQ_18_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">73417000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_eISZ_rJX30qgLKOMCptTUw_24_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">5375000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_LZ7-25jqa0yorRbk6QnMVw_24_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">4533000</us-gaap:AccountsPayableTradeCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_c-OiO0BQGEi5K5IOUe4xYA_25_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">15173000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_p9gmRkJFa0CLtcaUNryIUQ_25_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">19588000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_NMkF5rXJ3U2frS-FbhArzg_26_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1397000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_eBF9QJ_ReEOw86kijLEUlg_26_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1500000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_nwpEKZHG50OJr2RLCYFjVw_27_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">21945000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_BX3BoOiYQUOG5nicjXNctg_27_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">25621000</us-gaap:LiabilitiesCurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_jYNnxzMqSkqXUIh_FT7hQA_30_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">631000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_4AkCVdXJ60-cK5mQZ8ruaA_30_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">559000</us-gaap:PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_YGsHenF1jkiQRcPdQKG7iw_31_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">6780000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_awzQzOkztkmVEv9nTf8L9w_31_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">4026000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_aRqrENFzVk2JxjjHkN4tDg_32_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">7411000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_M8-lMyievEezxmvV8jyNLw_32_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">4585000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_2w4GIYnLg0eqWAyljHlLNQ_33_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">29356000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_sTgjVpD_BkOYC5c6vwvvIA_33_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">30206000</us-gaap:Liabilities>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_Q4D5tf9rv0mFvpB93lznzw_37_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">52908000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_mVtFTkij8UiABFmvbw2Wxw_37_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">43211000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_ZOCLFEt9r0eh7D2pj-FxRA_38_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">82264000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_EKO7lXv6T0G2UL_CbmZNCw_38_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">73417000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_B_RDBf3UakmFxKgLCE1u4Q"
      decimals="-3"
      id="Tc_iQNpBLv0kU61v-WhQy-1yA_3_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">43108000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_DfUDjS8huEe8YHRZP_FF_g"
      decimals="-3"
      id="Tc_36jeKvEkJkC4DHsEcFJa5g_3_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">34820000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_EM-2D042mUKZtARE4xNQQQ"
      decimals="-3"
      id="Tc_iRT3eaI3xkuk8mXg6lghxw_3_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">17673000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_-nchaslNr0uweGPjWu-YUQ"
      decimals="-3"
      id="Tc_3AOYD2-q80Cc91Kc12nuQQ_3_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">17839000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__u5aEet9ik6m5qJP9wbdkQ"
      decimals="-3"
      id="Tc_yH9vEGl1d0W9B-Ap1qFJuA_4_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">514000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_5TVhAsNFQE213aFWrjtG8g"
      decimals="-3"
      id="Tc_7YijXZcs70SMwnnj8eSHiw_4_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">361000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__wSFk5nFpUKVmADVapX-hA"
      decimals="-3"
      id="Tc_jDJVEgctGEWOyw5NpHpwWQ_4_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">178000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_QMoe7jUDBUORp5O-RNIp8Q"
      decimals="-3"
      id="Tc_JHXcktNkSkCR99KEp3aKuQ_4_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">120000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_pyA350x_LUGySuP84A5rxw_5_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">43622000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_3TlWARxkKUyFk9v0MoYdXw_5_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">35181000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_SpshFGR7lk62iT50p5NMEg_5_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">17851000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_PD1vrY0gLUiJ-Fbx4XKBFw_5_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">17959000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_hy3966HrfUmjT7WnTMBmEQ_6_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">22374000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_C1LG_avzMU2ERLL69jhulQ_6_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">20433000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_jOEQctBb8UqUYz-vGHQPvg_6_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">8324000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_x7imsZn2u06xCjkg87r56Q_6_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">8375000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_7ezfJfQNWECeTFjz3x2lSQ_7_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">13934000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_X-d6T5pI1kmyZmdhUhV4MQ_7_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">8846000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_B_8ccGI5aU-xJfwQ_EA6Mw_7_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">4467000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_8gY0xRx290KBfYsr63buGw_7_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2998000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_sIE2unldXESDIOoFZM1C3w_8_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">8156000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_SZkV_uSSnkCVQ1MSOdeYOQ_8_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">9194000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_WYI3fxHyD0ic89eC-2AzcA_8_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2929000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_xmS6Yi4XHkKlxx5loXDHcw_8_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2595000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_cvy_XbpD6U2h3P8tRDsJ-A_9_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-842000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_7vtegeVrj0aTqiqG96rIVA_9_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-3292000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_Vj7Yj0SgMUGc3MAdgU3kFw_9_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2131000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_fMW-p8HONEieRswA52OVBw_9_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3991000</us-gaap:OperatingIncomeLoss>
    <plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_1mg3Zuo8d0moanV8oukP3A_10_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">808000</plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax>
    <plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_SabyQaMCFkiAV5OrCFkp3g_10_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1056000</plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax>
    <plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_hZCV2cbHfkWGZYHF2-HaEg_10_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">180000</plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax>
    <plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_ZIaFkU4rTUGLOHC83pfEFg_10_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">299000</plx:OtherNonoperatingExpenseNetOfgainLossForeignCurrencyTransactionBeforeTax>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc__QE9bKlha0qt15MX55jQtg_11_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">818000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_EpPJfe39DkOWUd9GTcQXsg_11_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1186000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_QpvNzryal0CDUqGAZiJLDQ_11_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">288000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:OtherNonoperatingIncome
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_CLF567JEtEegxFd_APrB4w_11_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">151000</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_NQm7X_bVn0Wnu8Ntwzl_AA_12_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">10000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_Gj9g5wQNeUiranCHm88Qbg_12_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">130000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_tzzC8N27o0qnMpdbpMunEQ_12_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">108000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_r9rxSD-Fb0mz2kK3YUo_CA_12_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-148000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_w5Yb65vmTUqaef85SIr11Q_13_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-832000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_ERXc2yi_f0-ow400pSltRA_13_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-3162000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_seJrCUZzWUyj2iqWms0KTQ_13_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2239000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_-45Sn-CbSkW_xhTQSltvhw_13_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3843000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_wBjn4eCB6UGrd67harpmOg_14_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">268000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_nX3VDjDuu068KMNrtA6pFA_14_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_lAUhp-L0wUqFiIrfx0rRjA_14_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-116000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_CCDHfQZeMUCXLzvpwvofvw_14_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">607000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_Tup6S6nEi0SBTOvTFtctEA_15_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-1100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_wT0w-xl_TkioOe1P1oPlwA_15_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-3562000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_N73aFzg1ikWdl0ZLarSR2w_15_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2355000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_JO7eW8OKlUyhpMHXNXiXfQ_15_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3236000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="2"
      id="Tc_vY7Zz8V2JE6pma9q8qXowQ_17_3"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">-0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="2"
      id="Tc_76A4yhud8EmT_1KVRC-pXA_17_6"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">-0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="2"
      id="Tc_qa57J30H7EOeCmH1vWjooA_17_9"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="2"
      id="Tc__2jE-YNCtkq0MHti7WxYwA_17_12"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">0.04</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="2"
      id="Tc_kdu9UUep7ESz3Q7HSiy_-g_18_3"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">-0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="2"
      id="Tc_LgnDWwxmeE66ouLtJXalfg_18_6"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">-0.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="2"
      id="Tc_soN1DngY4UCaBVDFCcCS6Q_18_9"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="2"
      id="Tc_HEYGItwv4EKjA41yFgw7pA_18_12"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="0"
      id="Tc_WMsV2aBnN0iLZLK02QJt4Q_21_3"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">78225112</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="0"
      id="Tc_noORtC1jaE2gBJ20c2e_Jw_21_6"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">73301091</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="0"
      id="Tc_5GAsIUm3v0S45x97ylroeQ_21_9"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">79281685</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="0"
      id="Tc_4iDWed2OYUqKSmcF-ANvMw_21_12"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">73549745</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="0"
      id="Tc_U8QfkxLAi0qRfeyOcOWX8w_22_3"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">78225112</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="0"
      id="Tc_9UrxHKzcdUelLy3uHarROQ_22_6"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">73301091</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="0"
      id="Tc_GGMzZdDCZ0SB2dUb2qGtBg_22_9"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">80814564</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="0"
      id="Tc_vwa-7G9HXU-DpzuBqCQ8OA_22_12"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">81217068</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_761cvv_HXU2xI_U7AsL1AA"
      decimals="INF"
      id="Tc_9UAB6ZalEka19hY4YhOg5A_6_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">72952124</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_761cvv_HXU2xI_U7AsL1AA"
      decimals="-3"
      id="Tc_qFLKm1oDkUO3ysbHZ2tqwQ_6_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_7BvwDWTQK0ShOuP9uKsL_w"
      decimals="-3"
      id="Tc_UrjVywT_w0uf55LtJeQfZg_6_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">415045000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_UNTa3I5u9kqeTv9FgW1_Ag"
      decimals="-3"
      id="Tc_MD7h0mHadUuvLqhOYUH6Fw_6_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-381549000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_ikcM5x4J7Ua7ndrvsMT4WQ"
      decimals="-3"
      id="Tc_O1sdQozggU--sz8MJFDsGg_6_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">33569000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3QCYXsKzjkqrL_Tqx7sWEg"
      decimals="-3"
      id="Tc_rsVV4AYt40ekY27Zn2ov-A_8_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_rwMgEGPVD0SY1Y-KA3qD6Q"
      decimals="-3"
      id="Tc_k-IAnEWvwUGv92jnDVFljw_8_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">224000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2023_srt_CumulativeEffectPeriodOfAdoptionAxis_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate202006Member_upHYMK9ggEy3QQ-m5XNdoQ"
      decimals="-3"
      id="Tc_xcbqDkbPnU-1FH0PInO9LA_8_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-169000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-_wFays9-UWPOynoqeE24A"
      decimals="-3"
      id="Tc_Dw58Fz0DRUyRr4yoK6nDOA_9_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1191000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_blh0E11oy0qWoa7QlepKuw_9_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1191000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5Le7HqH0wEynn7U0eLUwpw"
      decimals="INF"
      id="Tc_vhpegQ9XAU-O7ZTk8mEm5A_10_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">681459</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_5Le7HqH0wEynn7U0eLUwpw"
      decimals="-3"
      id="Tc_2IvoTeJgzk2u9pbUxgDYUg_10_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-_wFays9-UWPOynoqeE24A"
      decimals="-3"
      id="Tc_qGQs6P8KYkeUJ5kkuVzuWQ_10_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1407000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_K0uEfz_RJUelY0ZE9ye3Sg_10_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1408000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_wFcKmiOLbke6KQ0TZk5Zsg"
      decimals="-3"
      id="Tc_ySl0Ha4tWU-rl4q9Ib_1TA_11_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-3562000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_YeAGhN0jNEKDwrARqJQ1vQ_11_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-3562000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6l0NaCT1sEOnj3WEXVnpEA"
      decimals="INF"
      id="Tc_HhK-UvHh-ECa7iCf80nPyA_12_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">73633583</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6l0NaCT1sEOnj3WEXVnpEA"
      decimals="-3"
      id="Tc_f4vIXjnutEmP-Vfh9wbHew_12_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">74000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ci3mkA8inEugSxpG-FuQrQ"
      decimals="-3"
      id="Tc_2CHGE2frnU-LYYdAgeM0HA_12_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">417250000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1Uwm5-nSiEe1UtufcBH-0Q"
      decimals="-3"
      id="Tc_ulP1wIBizkyd1kb1zOANHw_12_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-384887000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA"
      decimals="-3"
      id="Tc_1vNk_DVvWEexBHGhB0VnHQ_12_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">32437000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1BJ44ASqyEukCpWkJ6dVGA"
      decimals="INF"
      id="Tc_o-soIjnwX0mno9iveiTtnQ_13_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">75850275</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1BJ44ASqyEukCpWkJ6dVGA"
      decimals="-3"
      id="Tc_E5H3xW4MvUmri7DDp7SFHA_13_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">76000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JLAmLejgKEWYC493nuhe1Q"
      decimals="-3"
      id="Tc_MJBe5UmF3kK0qulZ-zTocA_13_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">421528000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_USxfrXz1rkCYTcNzIVQZ0A"
      decimals="-3"
      id="Tc_zSapq1JMnkqZmiNarkaXcQ_13_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-378393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_ZzR-QtJYgU6slpvQlNO7dA_13_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">43211000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_evPySq6pWUGtY591BlkL7g"
      decimals="INF"
      id="Tc_l6ZF-GSBfk-JXLKuKWOyaQ_15_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">2775215</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_evPySq6pWUGtY591BlkL7g"
      decimals="-3"
      id="Tc_aUJLH1s_AkSqR_TWkKM9Xg_15_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uHaruiJLYEGlS_yAuGkvlw"
      decimals="-3"
      id="Tc_9hMeFSUU8UGZb5nlZyglYw_15_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">6809000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_ZtnESanZg0GS8nrX2afqPw_15_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">6812000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uHaruiJLYEGlS_yAuGkvlw"
      decimals="-3"
      id="Tc_Wjg0TXeSj0WZ6H56EJIDGQ_16_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1004000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_BH_RyJm3AEC088OY_nOA6Q_16_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1004000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_evPySq6pWUGtY591BlkL7g"
      decimals="INF"
      id="Tc_ScyVFUPI80q6wHfbEkNl1w_17_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">559210</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uHaruiJLYEGlS_yAuGkvlw"
      decimals="-3"
      id="Tc_Ot5i5j0vBk2dtzXFcNl-uQ_17_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">561000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_VbBR7Rzwa06toW6kEwMeVA_17_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">561000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_evPySq6pWUGtY591BlkL7g"
      decimals="INF"
      id="Tc_eGd5M6r8mEq-ic6FBd_Iuw_18_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">1156625</plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_evPySq6pWUGtY591BlkL7g"
      decimals="-3"
      id="Tc_5B7GF19NLEioHWoahxic5Q_18_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1000</plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_uHaruiJLYEGlS_yAuGkvlw"
      decimals="-3"
      id="Tc_JAif2Tmk7UysPKEtp6D1hA_18_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2419000</plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_bgIWY-wskEqcI4IknLqxYQ_18_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2420000</plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TAwwe5x3akmfidt8z-84Zw"
      decimals="-3"
      id="Tc_2GnCXj9Mikqtqox3tW42wA_19_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-1100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_5DLxOpSj_UKPArJCtTAEOQ_19_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-1100000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MoWXQGG3_ka4yi-5e8DRWQ"
      decimals="INF"
      id="Tc_d1wvEIx0gEO3V9yDgYRFbg_20_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">80341325</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MoWXQGG3_ka4yi-5e8DRWQ"
      decimals="-3"
      id="Tc_Aimk5I0s2UOxD4Pxmo7Vkg_20_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">80000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_x2V2OwuyRkGovAC9kMzO1w"
      decimals="-3"
      id="Tc_qkqhcATeD0So8Iew1vc9kA_20_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">432321000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gx6X1c0dg0-aboMNBFKFGg"
      decimals="-3"
      id="Tc_tLmwbzS1D0aFqp1uhHXXnA_20_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-379493000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_gt9OFz-50E6p3OUiPhhnTQ_20_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">52908000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YfnvTfvAE0KtNUtZkwS5AA"
      decimals="INF"
      id="Tc_e3m2lejV3E6_xHTX2KUqPA_21_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">73292674</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_YfnvTfvAE0KtNUtZkwS5AA"
      decimals="-3"
      id="Tc_00WLczCPwUmdXayC2QsyPg_21_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">73000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_h9xaPufFAUWhI__zK0WDdQ"
      decimals="-3"
      id="Tc_OFrx7KOgkUCv9sqlrUIX7g_21_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">416631000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yU7hKhH3lEmO2pb_PDOgwA"
      decimals="-3"
      id="Tc_ZDt3cYP_VUWMfQygpEyNKA_21_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-388123000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2024_hFoy38nssE-_Imrl9korwA"
      decimals="-3"
      id="Tc_vuvGTmjto0yeu1TVngD8Bw_21_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">28581000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T9xFatVQiU6cxnwo_7JjZA"
      decimals="-3"
      id="Tc_viqePOY8zkWba2fYuwOivg_23_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">358000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_9KRZg0GZpE6l3hsFOSWDDA_23_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">358000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-x0_bEphIU2K4orXSd874w"
      decimals="INF"
      id="Tc_oUNW5FB3IUaHwHEkz3jDQg_24_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">340909</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_-x0_bEphIU2K4orXSd874w"
      decimals="-3"
      id="Tc_-PUNZgHMQkyTkTWCcJj9_w_24_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_T9xFatVQiU6cxnwo_7JjZA"
      decimals="-3"
      id="Tc_pOzZ1l6pCkO6LMwZNUedvA_24_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">261000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_QGZh_j8pJkyTbtcAtL_l2Q_24_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">262000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_WUrqKarnvUy3SRJfTqmqnA"
      decimals="-3"
      id="Tc_8GQ2wD8MOU-31bqN9n4xrA_25_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3236000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_JFLGBJFvrkS4YzZzxG8-Lw_25_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3236000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6l0NaCT1sEOnj3WEXVnpEA"
      decimals="INF"
      id="Tc_Le8enGNn-U2_sRTg_vxE8A_26_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">73633583</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6l0NaCT1sEOnj3WEXVnpEA"
      decimals="-3"
      id="Tc_bdJtiJ58nEOjhGpCtMB9Og_26_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">74000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_ci3mkA8inEugSxpG-FuQrQ"
      decimals="-3"
      id="Tc_h1eSdIfHXESjQPBjNBFpGw_26_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">417250000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_1Uwm5-nSiEe1UtufcBH-0Q"
      decimals="-3"
      id="Tc_MVZcAPRX3EOvBE58Mf97Nw_26_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-384887000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA"
      decimals="-3"
      id="Tc_5M9xxZwU3UmF_cblZhhGZQ_26_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">32437000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gT-aDshKVkGrJq9_mtpt4w"
      decimals="INF"
      id="Tc_Eto7e-Xr2Em4IMXw0lGBpQ_27_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">79732115</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_gT-aDshKVkGrJq9_mtpt4w"
      decimals="-3"
      id="Tc_9QcC-lAKFECnxia1z9k-dQ_27_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">80000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_kp0yapnm40GB10yQ_ydGnA"
      decimals="-3"
      id="Tc_0W4geiAqpkaspCfcc4_F_A_27_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">431671000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gQDsVSQOBESn2aton7MkCQ"
      decimals="-3"
      id="Tc_VgwMD-k0gUyvUkmvJb8Dew_27_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-381848000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2025_82uuoTEUkkeqvb5YouDXFQ"
      decimals="-3"
      id="Tc_k1IeEsFAj0ecvTkAX0hXIA_27_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">49903000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OnEzSTerJUmlL5WGD4HZ3Q"
      decimals="-3"
      id="Tc_4brF_PJvBUG7Q75r0y-IZA_29_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">405000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_eS6E1dCzw0-H4zM_NcDNcA_29_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">405000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SwvQijHg2UmvkpniQH3hSQ"
      decimals="INF"
      id="Tc_rxQDkKYEFEiJ2WmgJtETYw_30_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">559210</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeituresShares>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OnEzSTerJUmlL5WGD4HZ3Q"
      decimals="-3"
      id="Tc_WipQVR98XkK9EfOJmc-sUA_30_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">193000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_FTn3EpyUwUC6kizPPRvgsA_30_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">193000</plx:ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures>
    <plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_SwvQijHg2UmvkpniQH3hSQ"
      decimals="INF"
      id="Tc_XLZq7il8QE2LEjRtLdk9Jw_31_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">50000</plx:StockIssuedDuringPeriodSharesWarrantsAndStockOptionsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OnEzSTerJUmlL5WGD4HZ3Q"
      decimals="-3"
      id="Tc_jf7IfLxhb0O2W9k3FZkcMw_31_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">52000</plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised>
    <plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_C4QHKDtlt0yWjusF7kQlPQ_31_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">52000</plx:StockIssuedDuringPeriodValueWarrantsAndStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TcJrtT61UU-RVxesnAWVRg"
      decimals="-3"
      id="Tc_lTHmg6ELbE-NNIZDR4WIMQ_32_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2355000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_ObIzKEgO7UacufW59txhuw_32_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2355000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MoWXQGG3_ka4yi-5e8DRWQ"
      decimals="INF"
      id="Tc_DIQSy69MjE6Hx7Lvt9M1dA_33_2"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">80341325</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_MoWXQGG3_ka4yi-5e8DRWQ"
      decimals="-3"
      id="Tc_bFmcmbsqUEiTiw2HcVzy5g_33_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">80000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_x2V2OwuyRkGovAC9kMzO1w"
      decimals="-3"
      id="Tc_7KM4LKxbEEO3dwEZjdauYw_33_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">432321000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2025_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gx6X1c0dg0-aboMNBFKFGg"
      decimals="-3"
      id="Tc_BtsjFvxv0EmoN_e2CkNW1A_33_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-379493000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_YHNHZn5JY0mkMVwE3b3Myg_33_14"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">52908000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="INF"
      id="Narr__gpeNqqRWEySSfwcmaaObA"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="INF"
      id="Narr_5Sr6M1ia2UuLn9aa0knvNQ"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="INF"
      id="Narr_bERza9spgUmuCuM1wJBTjQ"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="INF"
      id="Narr_Y84_Je8qFU2a0vMn869iKg"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">185000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_SiqsywtSBUiYOqibDdKb-g_4_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-1100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_doZeP18yKkiurKeN1-PdHA_4_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-3562000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_Qob-UEAF9EmExlPxBFFMJg_6_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1565000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_YHW07GBjtkikgiFyNJGnRw_6_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2599000</us-gaap:ShareBasedCompensation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_tlOKQwU-yEewFmB_pNaPeQ_7_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1078000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_z3RHjoqcK0SzNApUCiecGg_7_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">970000</us-gaap:Depreciation>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_1sTJysWqRk2T47Wdt3_c2g_8_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-136000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:ForeignCurrencyTransactionGainLossUnrealized
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_EPaS4WdCykW4HV19tK9qTQ_8_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-173000</us-gaap:ForeignCurrencyTransactionGainLossUnrealized>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_-JrUSDkMVEehpp2Mllbmog_9_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">14000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_QGaQh44OAEeUGTou_hYuKg_9_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">32000</us-gaap:PensionAndOtherPostretirementBenefitExpense>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_kKC16ba09E6i3GxgxGgY1w_10_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">177000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_IadXkWq-jU2JZ5z47BKT9A_10_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">236000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_5o_rcLXpdE6exHB3cTUxfA_11_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">18000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_FI4qYg6Fsk6uafli2RCYlQ_11_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">20000</plx:GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_p3-fuz4xOEuH2Pa99618gg_12_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_jUgk4hGsf0airUQq2C3a2Q_14_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">11768000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_T5eXMifMH0atEdQLNMAg3A_14_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-3069000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_83s5f-GC0EeV0d1EGv35Aw_15_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">62000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <plx:ChangeInOperatingLeaseRightOfUseAssets
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_VvBgo0Gk7EaehGsBo-Ffjg_15_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-13000</plx:ChangeInOperatingLeaseRightOfUseAssets>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_uY6huhE6DE-BLIB28NazbQ_16_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">12000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_qr0Xn5XT1UmhNkfKZ42fKg_16_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-1846000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_yC4El8sftkGrlBt4EsaxHQ_17_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-4033000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_E9pp2EZ_aEaHf7UeZSueTg_17_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-670000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_EddYIByaA06fdkPP5aJMrg_18_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-14023000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_OHS4m6kLk0SzjIoVeQf0kw_18_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">4683000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <plx:ProceedsFromWithdrawalOfShortTermDeposits
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_1bzvrZ1H-UO9nhyEO02FLA_21_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">20420000</plx:ProceedsFromWithdrawalOfShortTermDeposits>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_wbIzxtNScESnqVhl2cOKYQ_22_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1235000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_0CLl_Cahi0ulqVLXTn2ayA_22_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">857000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_bAJNTrjeX0e3mgniYITTuQ_23_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_QQ-8aVzoQkeqsCB136wL2A_24_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">19000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_Sh391ma6_Eu6dLIETD6Jpg_24_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">25000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_Zkv3G4cMfUWQLGgRK8YQpQ_25_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-1254000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_4s7nxJY9RE-vQtk-w_qj1w_25_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">19541000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_-V2Td1reckKHuoGGCLhipQ_28_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">20420000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_LW5l86ntVEySJnz31Snk6A_29_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">6812000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <plx:ProceedsFromWarrantsAndStockOptionExercises
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_KErlkJoeoEOdE7j7bPDgzQ_30_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2368000</plx:ProceedsFromWarrantsAndStockOptionExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_PjGg5_F6dUaotW5waJhc2Q_31_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">9180000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_FUBVQ2ZL0UChgAmQT7kd1A_31_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-20420000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_k8g5Ma70oE61_ehhYdXTnA_32_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-16000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_JsLhKMNkiUChX8rIfNH7Qw_32_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-29000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_zVGZZTW3zkqO6eUvHqs9zw_33_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-6113000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_9B8BYJvsA0yAqfXWjt81YA_33_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3775000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_tmFNX1BKZECIv_LmXQyfIQ_34_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">19760000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2023_ikcM5x4J7Ua7ndrvsMT4WQ"
      decimals="-3"
      id="Tc_Hu2rDi_HX0WScH0BeoWSEA_34_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">23634000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_exnBfk_OJU-Go0IEcFzLWA_35_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">13647000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA"
      decimals="-3"
      id="Tc_ZX5TME-l0EmZk_7ut3lgeQ_35_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">27409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_AihvGYzZw0m4B0XYCBzhXw_4_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">230000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_i3U-7R1XJUyVfSs5eq-cJQ_4_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">402000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <plx:OptionsExercised
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_Q1lBu59WMk-7vanrC7A2SA_5_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">52000</plx:OptionsExercised>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_6aAPLUtkl0Ov9EV3w80GMA_6_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3104000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_q3gcZFqXskaO8wFaLxbFVg_6_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">376000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_UhC6Qy_QPkyXYwF8pTQFWQ_9_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1182000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_3yIdIarT20y9X544JCltPg_10_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1532000</us-gaap:InterestPaidNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_sEjtkiM2-0q_3cmDtT0W1A_11_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">258000</plx:InterestReceivedNet>
    <plx:InterestReceivedNet
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_L8boP15fgEWIea96KWGGBA_11_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1481000</plx:InterestReceivedNet>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_F5exF5Y-8E6faVSC5m3EVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;1&#160;- SIGNIFICANT ACCOUNTING POLICIES&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#x201c;Company&#x201d;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (taliglucerase alfa) for the treatment of adult patients and children four years of age and greater with Gaucher disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Elelyso was first approved by the U.S.&#160;Food and Drug Administration (&#x201c;FDA&#x201d;) in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others. In May 2023, both the European Commission (&#x201c;EC&#x201d;) and the FDA announced the approval of Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia, Singapore, Australia and Taiwan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is committed to leveraging its record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat uncontrolled gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases (neutrophil extracellular traps).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company, through its wholly-owned subsidiary, Protalix Ltd., has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;) for the development and commercialization of Elfabrio through two exclusive global licensing and supply agreements. On October&#160;19, 2017, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;), with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;2015, Protalix Ltd. and Pfizer entered into an amended and restated exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). After giving effect to the sales under the Sales Agreement in January 2025, no shares of common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $20.0&#160;million. As of September&#160;30, 2025, approximately $15.7&#160;million in shares of Common Stock remain available to be sold under the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;"&gt;Because the Company&#x2019;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel. Since October 2023, following an infiltration by Hamas terrorists of Israel&#x2019;s southern border from the Gaza Strip and attacks on civilian and military targets, Israel has been engaged in military activity on a number of fronts, including with the Hamas in the Gaza Strip, Hezbollah in Lebanon, Iran, the Houthis terrorist group that controls parts of Yemen, and others. Such clashes may escalate in the future into a greater regional conflict. On October&#160;9, 2025, Israel and Hamas entered into a ceasefire agreement intended to permanently end the war between Israel and Hamas. However, there are no assurances regarding continued compliance with such agreement. While the conflict created and continues to create heightened security concerns, disruptions to business operations, and economic instability within Israel, the ceasefire may contribute to improved regional stability. However, the security situation remains fluid and any renewed military actions, restrictions, or government-imposed measures could adversely affect the Company&#x2019;s business, operations and financial condition. The Company&#x2019;s facilities are deemed an &#x201c;essential enterprise&#x201d; which means it operates or can be operated for the purposes of state defense or public security or for the maintenance of essential supplies or services, allowing the Company to maintain operations during emergencies. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss. As of the issuance of these financial statements, the impact of the military action has not had an adverse effect on the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of September&#160;30, 2025, are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;) on March&#160;17, 2025. The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Net earnings (loss) per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of Common Stock outstanding for each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#x201c;if-converted&#x201d; method.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;d.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#x201c;2024 Notes&#x201d;). The repayment of the convertible notes at maturity was financed entirely with available cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Prior to January&#160;1, 2024, the Company&#x2019;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the Company had the option to settle such notes may be settled wholly or partly in cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.&lt;/p&gt;&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;e.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company expects the adoption of this standard to result in expanded disclosures in its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In November 2024, the FASB issued ASU&#160;2024-03 &#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#x201d; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures&lt;span style="font-family:'Palatino Linotype';background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;In July 2025, the FASB issued ASU 2025-05,&#160;Financial Instruments - Credit Losses&#160;(Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This amendment introduces a practical expedient for the application of the current expected credit loss (CECL) model to current accounts receivable and contract assets.&#160;The &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;amendments will be effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods, on a prospective basis, with early adoption permitted. Based on the Company&#x2019;s evaluation of this guidance, no material impact is expected on its consolidated financial statement disclosures.&lt;/p&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <plx:NatureOfOperationsPolicyTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_UBrlwoupxUCubhwOjK9Szw">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;a.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;General&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Protalix BioTherapeutics, Inc. (collectively with its subsidiary, the &#x201c;Company&#x201d;) and its wholly-owned subsidiary, Protalix Ltd., are biopharmaceutical companies focused on the development and commercialization of recombinant therapeutic proteins based on the Company&#x2019;s proprietary ProCellEx&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; protein expression system (&#x201c;ProCellEx&#x201d;). To date, the Company has successfully developed two enzyme replacement therapies (ERTs); Elfabrio&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;&#xae;&lt;/sup&gt; (taliglucerase alfa) for the treatment of adult patients and children four years of age and greater with Gaucher disease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Elelyso was first approved by the U.S.&#160;Food and Drug Administration (&#x201c;FDA&#x201d;) in May 2012 and is now approved for marketing in 23 markets including Brazil, Israel and others. In May 2023, both the European Commission (&#x201c;EC&#x201d;) and the FDA announced the approval of Elfabrio, each for adult patients with a confirmed diagnosis of Fabry disease. Both approvals cover the 1&#160;mg/kg every two weeks dosage. Elfabrio, which the Company referred to as PRX-102 during its development stage, has been approved for marketing in the United States, the European Union, Great Britain, Switzerland, Peru, Israel, Russia, Singapore, Australia and Taiwan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company is committed to leveraging its record of success as the Company progresses with the development of treatments for rare and orphan diseases. In addition, the Company continuously works on the further development and enhancement of its ProCellEx technology. Accordingly, the Company is turning its focus to new, early-stage product candidates that treat indications for which there are high unmet needs in terms of efficacy and safety, including renal diseases. Treatments of interest will address both genetic and non-genetic diseases. The Company intends to use its ProCellEx platform and PEGylation capabilities, as well as other modalities such as small molecules and antibodies, to take advantage of highly innovative opportunities. The Company is also exploring novel platform technologies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company continuously evaluates potential strategic marketing partnerships as well as collaboration programs with biotechnology and pharmaceutical companies and academic research institutions. Except with respect to Elfabrio and Elelyso, the Company holds the worldwide commercialization rights to its other proprietary development candidates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company&#x2019;s product pipeline currently includes, among other candidates:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-115, the Company&#x2019;s plant cell-expressed recombinant PEGylated uricase (urate oxidase) &#x2013; a chemically modified enzyme to treat uncontrolled gout; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;"&gt;(2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;PRX-119, the Company&#x2019;s plant cell-expressed PEGylated recombinant human DNase&#160;I product candidate for long and customized systemic circulation in the bloodstream for NETs-related diseases (neutrophil extracellular traps).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Obtaining marketing approval with respect to any product candidate in any country is dependent on the Company&#x2019;s ability to implement the necessary regulatory steps required to obtain such approvals, and demonstrate the safety and efficacy of its product candidates. The Company cannot reasonably predict the outcome of these activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;The Company, through its wholly-owned subsidiary, Protalix Ltd., has licensed the rights to commercialize Elelyso worldwide (other than Brazil) to Pfizer Inc. (&#x201c;Pfizer&#x201d;), and in Brazil to Funda&#xe7;&#xe3;o Oswaldo Cruz (&#x201c;Fiocruz&#x201d;), an arm of the Brazilian Ministry of Health (the &#x201c;Brazilian MoH&#x201d;). Elelyso is marketed as BioManguinhos alfataliglicerase in Brazil. The Company has partnered with Chiesi Farmaceutici S.p.A. (&#x201c;Chiesi&#x201d;) for the development and commercialization of Elfabrio through two exclusive global licensing and supply agreements. On October&#160;19, 2017, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi Ex-US Agreement&#x201d;) pursuant to which Chiesi was granted an exclusive license for all markets outside of the United States to commercialize Elfabrio. On July&#160;23, 2018, Protalix Ltd. entered into an Exclusive License and Supply Agreement with Chiesi (the &#x201c;Chiesi US Agreement&#x201d;), with respect to the commercialization of Elfabrio in the United States.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;Since its approval by the FDA, Elelyso has been marketed by Pfizer in accordance with the exclusive license and supply agreement entered into between Protalix Ltd. and Pfizer, which is referred to herein as the Pfizer Agreement. In October &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;2015, Protalix Ltd. and Pfizer entered into an amended and restated exclusive license and supply agreement, which is referred to herein as the Amended Pfizer Agreement, pursuant to which the Company sold to Pfizer its share in the collaboration created under the Pfizer Agreement for the commercialization of Elelyso. As part of the sale, the Company agreed to transfer its rights to Elelyso in Israel to Pfizer while gaining full rights to it in Brazil. Under the Amended Pfizer Agreement, Pfizer is entitled to all of the revenues, and is responsible for 100% of expenses globally for Elelyso, excluding Brazil where the Company is responsible for all expenses and retains all revenues.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:8pt;margin:0pt 0pt 0pt 54pt;"&gt;On June&#160;18, 2013, the Company entered into a Supply and Technology Transfer Agreement (the &#x201c;Brazil Agreement&#x201d;) with Fiocruz for BioManguinhos alfataliglicerase. Fiocruz&#x2019;s purchases of BioManguinhos alfataliglicerase to date have been significantly below certain agreed-upon purchase milestones and, accordingly, the Company has the right to terminate the Brazil Agreement. Notwithstanding the termination right, the Company is, at this time, continuing to supply BioManguinhos alfataliglicerase to Fiocruz and patients continue to be treated with BioManguinhos alfataliglicerase in Brazil.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;background:#ffffff;margin:0pt 0pt 0pt 54pt;"&gt;On February&#160;27, 2023, the Company entered into that certain At The Market Offering Agreement (as may be amended from time to time, the &#x201c;Sales Agreement&#x201d;) with H.C.&#160;Wainwright &amp;amp; Co., LLC, as the Company&#x2019;s sales agent (the &#x201c;Agent&#x201d;). After giving effect to the sales under the Sales Agreement in January 2025, no shares of common stock, par value $0.001 per share (the &#x201c;Common Stock&#x201d;), remained available for offer and sale&#160;under the Sales Agreement. On March&#160;17, 2025, the Company entered into an amendment to the Sales Agreement pursuant to which the Company increased the aggregate gross sales price of shares of Common Stock available for offer and sale under the Sales Agreement by $20.0&#160;million. As of September&#160;30, 2025, approximately $15.7&#160;million in shares of Common Stock remain available to be sold under the Sales Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 54pt;"&gt;Because the Company&#x2019;s operations are conducted in the State of Israel, the business and operations may be directly affected by economic, political, geopolitical and military conditions in Israel. Since October 2023, following an infiltration by Hamas terrorists of Israel&#x2019;s southern border from the Gaza Strip and attacks on civilian and military targets, Israel has been engaged in military activity on a number of fronts, including with the Hamas in the Gaza Strip, Hezbollah in Lebanon, Iran, the Houthis terrorist group that controls parts of Yemen, and others. Such clashes may escalate in the future into a greater regional conflict. On October&#160;9, 2025, Israel and Hamas entered into a ceasefire agreement intended to permanently end the war between Israel and Hamas. However, there are no assurances regarding continued compliance with such agreement. While the conflict created and continues to create heightened security concerns, disruptions to business operations, and economic instability within Israel, the ceasefire may contribute to improved regional stability. However, the security situation remains fluid and any renewed military actions, restrictions, or government-imposed measures could adversely affect the Company&#x2019;s business, operations and financial condition. The Company&#x2019;s facilities are deemed an &#x201c;essential enterprise&#x201d; which means it operates or can be operated for the purposes of state defense or public security or for the maintenance of essential supplies or services, allowing the Company to maintain operations during emergencies. The Company has elected to store manufactured drug substance in multiple locations, both within and outside of Israel, to mitigate the risk of loss. As of the issuance of these financial statements, the impact of the military action has not had an adverse effect on the Company&#x2019;s operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 54pt;"&gt;The Company expects to continue to incur significant expenditures in the near future due to research and developments efforts with respect to its product candidates. The Company believes that its cash and cash equivalents and short-term bank deposits as of September&#160;30, 2025, are sufficient to satisfy the Company&#x2019;s capital needs for at least 12&#160;months from the date that these financial statements are issued.&lt;/p&gt;</plx:NatureOfOperationsPolicyTextBlock>
    <plx:NumberOfGlobalLicensingAndSupplyAgreements
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="INF"
      id="Narr_KwlsgX3n80-nUy7hnzTMgw"
      unitRef="Unit_Standard_agreement_FXubWDLurk-D3rwvgsKCMg">2</plx:NumberOfGlobalLicensingAndSupplyAgreements>
    <plx:CollaborativeArrangementRevenuesExpensesSharingPercentage
      contextRef="Duration_10_1_2015_To_10_31_2015_dei_LegalEntityAxis_plx_ProtalixBioTherapeuticsIncorporationMember_srt_StatementGeographicalAxis_country_BR_us-gaap_TypeOfArrangementAxis_plx_AmendedPfizerAgreementMember_crdEnIEuZ0uz2yhEN1tslA"
      decimals="2"
      id="Narr_54Hu-sDFaEWkOKIMGvP0lA"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">1</plx:CollaborativeArrangementRevenuesExpensesSharingPercentage>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_dH_SIULHC0imY02WiFQo7g"
      decimals="INF"
      id="Narr_NHAj3FXx70ehD5JRn-D_eQ"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_1_31_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_dH_SIULHC0imY02WiFQo7g"
      decimals="INF"
      id="Narr_UIgfiFbNxkuqSzOaOwCksA"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <plx:CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance
      contextRef="As_Of_3_17_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_CFDzr7g43kS7D8I0mFf4kw"
      decimals="-5"
      id="Narr_gc_jPC8l0UygaieXDny7MQ"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">20000000</plx:CommonStockIncreaseInGrossSalesPriceOfSharesReservedForFutureIssuance>
    <plx:CommonStockValueOfCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_OgxzvfhlIUigqCIom_Fjpw"
      decimals="-5"
      id="Narr_yxXFxYwiXkmF29TMX3PQhg"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">15700000</plx:CommonStockValueOfCapitalSharesReservedForFutureIssuance>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_8Ie7WZ0F00qNeo5XvfHyyA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;b.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:8pt;margin-top:0pt;"&gt;Basis of presentation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 54pt;"&gt;These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements in the Annual Report on Form&#160;10-K for the year ended December&#160;31, 2024, filed by the Company with the U.S.&#160;Securities and Exchange Commission (the &#x201c;Commission&#x201d;) on March&#160;17, 2025. The comparative balance sheet at December&#160;31, 2024 has been derived from the audited financial statements at that date. There have been no material changes in our significant accounting policies as described in our consolidated financial statements for the year ended December&#160;31, 2024.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_4ouvBEQjqU24YXMG4MA9gA">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;c.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:12pt;margin-top:0pt;"&gt;Net earnings (loss) per share&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of Common Stock outstanding for each period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Diluted earnings per share is calculated by dividing the net income by the weighted-average number of shares of Common Stock outstanding during each period increased to include the number of additional shares of Common Stock that would have been outstanding if the potentially dilutive shares had been issued.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In computing diluted earnings per share, basic earnings per share are adjusted to take into account the potential dilution that could occur upon: (i)&#160;the exercise of options granted under employee stock compensation plans using the treasury stock method; (ii)&#160;the exercise of warrants using the treasury stock method; and (iii)&#160;the conversion of the convertible notes using the &#x201c;if-converted&#x201d; method.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_7UA5GvRh9E2E4DGvXvGm0w">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;d.&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin-bottom:10pt;margin-top:0pt;"&gt;Convertible notes&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In September 2024, the Company repaid in full all of the outstanding principal and interest payable under its 7.50%&#160;Senior Secured Convertible Promissory Notes due 2024 (the &#x201c;2024 Notes&#x201d;). The repayment of the convertible notes at maturity was financed entirely with available cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Prior to January&#160;1, 2024, the Company&#x2019;s outstanding 2024 Notes were accounted for as a liability (debt) and equity component (conversion option) as the Company had the option to settle such notes may be settled wholly or partly in cash.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;Starting from January&#160;1, 2024, the convertible debt instruments were accounted for as a single liability measured at amortized cost.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_plx_SevenPointFivePercentageSeniorSecuredConvertibleNotesDue2024Member_GGLx0RMJkEWOCKabwh15XA"
      decimals="INF"
      id="Narr_pDK1kORZckioC-XL-WvHmg"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">0.075</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_qRgd_aNCkkq_AZ6_qHYX_Q">&lt;table style="border-collapse:collapse;border:0;"&gt;&lt;tr&gt;&lt;td style="width:36pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;e.&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Recently issued accounting pronouncements, not yet adopted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-09 &#x201c;Income Taxes (Topic 740): Improvements to Income Tax Disclosures.&#x201d; This guidance is intended to enhance the transparency and decision-usefulness of income tax disclosures. The amendments in ASU 2023-09 address investor requests for enhanced income tax information primarily through changes to disclosure regarding rate reconciliation and income taxes paid both in the U.S. and in foreign jurisdictions. ASU 2023-09 is effective for fiscal years beginning after December&#160;15, 2024 on a prospective basis with the option to apply the standard retrospectively. The Company expects the adoption of this standard to result in expanded disclosures in its consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;In November 2024, the FASB issued ASU&#160;2024-03 &#x201c;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,&#x201d; which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. ASU 2024-03 is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures&lt;span style="font-family:'Palatino Linotype';background:#ffffff;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;In July 2025, the FASB issued ASU 2025-05,&#160;Financial Instruments - Credit Losses&#160;(Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This amendment introduces a practical expedient for the application of the current expected credit loss (CECL) model to current accounts receivable and contract assets.&#160;The &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 54pt;"&gt;amendments will be effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods, on a prospective basis, with early adoption permitted. Based on the Company&#x2019;s evaluation of this guidance, no material impact is expected on its consolidated financial statement disclosures.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_jzZmTInS7Ey9HzkNJaELGg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;2&#160;- INVENTORIES&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at September&#160;30, 2025 and December&#160;31, 2024 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,983&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,243&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Group_bI6GT31Xv0C34MZjDKrp2Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Inventories at September&#160;30, 2025 and December&#160;31, 2024 consisted of the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Raw materials&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,983&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,549&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Work in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,245&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finished goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:72.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total inventory&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,255&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21,243&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_o4cVtA746U6-b3qD0SGAKw_3_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">4983000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_fKuXWC6sg0aEdNdw7wIPYw_3_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">4549000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_5-oVeSGVb0eWmLLA4oWwgQ_4_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">5355000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_5Wqsfz0jCkGN-R56SWKCeg_4_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">11245000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_YA71NgIUdECEQTnLfzAGaQ_5_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">10917000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_wmqjUOkvykalNe2Uoyz9qQ_5_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">5449000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_3-8tZMd64Eyz1jQZvknVxg_6_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">21255000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_obJ2UUni3UWl62-jdk87Sw_6_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">21243000</us-gaap:InventoryNet>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_z5o9Aq5gIUKurNhDSxXhSA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;NOTE&#160;3&#160;&#x2013; FAIR VALUE MEASUREMENT&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received from the sale of an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The accounting standard establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level&#160;1 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Level&#160;3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level&#160;3 inputs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The fair value of the financial instruments included in the working capital of the Company is identical or close to their carrying value.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_YrnblJbP5UG0a-yds5pW3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 4 &#x2013; OPERATING LEASES&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company is a party to several lease agreements for its facilities that included varying lease periods and options for extensions. The Company is currently in the second option period for each of the three leases, which periods are not uniform. In the three months ended September&#160;30, 2025, the Company amended all of the facility leases, collectively, to provide that the third option period for each lease will end on December&#160;31, 2031 and will be associated with a unform rent increase equal to 7.5%. Thereafter, each lease will extend automatically, on an individual basis, for up to four additional five-year periods unless the Company provides the lessor with six months&#x2019; advance notice that it does not intend that any individual option extension become effective. Each option to renew a lease in each of the four option periods shall include a rent increase equal to 5% of the rent payable for the applicable previous option period. Prior to the amendment, the options to extend the leases were associated with increases of either 7.5% or 10%. The Company expects to exercise the options in future periods. As of September&#160;30, 2025, the Company provided bank guarantees of approximately $0.6&#160;million, in the aggregate, to secure the fulfillment of its obligations under the lease agreements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company adjusted the operating lease right of use assets by $3.1&#160;million reflecting the amount of remeasurement of the lease liability using a new discount rate at the amendment date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company is a party to several three-year leases for vehicles which are regularly amended as new vehicles are leased.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The following table sets forth data regarding the Company&#x2019;s operating leases for the three and nine months ended September&#160;30, 2024 and 2025:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:28.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:29.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,195&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,207&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The following table sets forth a maturity analysis of the Company&#x2019;s operating lease liabilities as of September&#160;30, 2025:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#009999;font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;First year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Second year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Third year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fourth year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,040&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fifth year and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,273&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,925&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_ANkVj9Dl3UG6vp8ROgt80w">true</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <plx:NumberOfFacilitiesLeased
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="INF"
      id="Narr_lDK2m7hx8k2IC7udZKUm4w"
      unitRef="Unit_Standard_facility_0Iv5bNDqPUmCp-a8ET1QPQ">3</plx:NumberOfFacilitiesLeased>
    <plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="INF"
      id="Narr_yYvJc90w0UK5ej__0ZWnLQ"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">0.075</plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments>
    <plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions
      contextRef="Duration_1_1_2025_To_9_30_2025_srt_RangeAxis_srt_MaximumMember_3zb9vtsmPUO-q5fMEz9RUA"
      decimals="INF"
      id="Narr_vt9bB3u7s0iSlrV3E4ja1Q"
      unitRef="Unit_Standard_item_D0AldO7cf0SCjEYMUWnWVg">4</plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      id="Narr_qzJLiSFhmESlZ7vfxuABgg">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <plx:LesseeOperatingLeaseTerminationAdvancedNoticeTerm
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_Z8XIdSugnk2qgIAzpx5urQ">P6M</plx:LesseeOperatingLeaseTerminationAdvancedNoticeTerm>
    <plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions
      contextRef="Duration_1_1_2025_To_9_30_2025_srt_RangeAxis_srt_MaximumMember_3zb9vtsmPUO-q5fMEz9RUA"
      decimals="INF"
      id="Narr_Q1HIUEeqCUufOjOqVJB2nw"
      unitRef="Unit_Standard_item_D0AldO7cf0SCjEYMUWnWVg">4</plx:LesseeOperatingLeaseNumberOfRenewalTermExtensions>
    <plx:LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="INF"
      id="Narr_r1a2g49H00SkR5KcxZdZmg"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">0.05</plx:LesseeOperatingLeaseRentIncreaseRateForRenewalPeriod>
    <plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments
      contextRef="As_Of_6_30_2025_srt_RangeAxis_srt_MinimumMember_C7QvDhrMDUq4S3iRN9FCdA"
      decimals="INF"
      id="Narr_QBlTOJJaE0CdAXs40eNolg"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">0.075</plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments>
    <plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments
      contextRef="As_Of_6_30_2025_srt_RangeAxis_srt_MaximumMember_lTg-LzfNR0mwdU1OEzj4aQ"
      decimals="INF"
      id="Narr_FcpTR_s7-0mpL-3fl6jEeQ"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">0.10</plx:PercentageOfChangeInOperatingLeaseMonthlyRentalPayments>
    <plx:BankGuarantee
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-5"
      id="Narr_BON_kzVir0CmMizOKl9ZAA"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">600000</plx:BankGuarantee>
    <plx:LesseeOperatingLeaseLiabilityAdjustment
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-5"
      id="Narr_CuohFdnnNUib4OWuofkaLA"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3100000</plx:LesseeOperatingLeaseLiabilityAdjustment>
    <plx:LesseeOperatingLeaseRightOfUseAssetAdjustment
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-5"
      id="Narr_LlkIgIVQxE2l6A-t46WFew"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3100000</plx:LesseeOperatingLeaseRightOfUseAssetAdjustment>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_9_30_2025_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_VehiclesMember_r-Ghqyl9T0iF4Ti21qRoSQ"
      id="Narr_U34mrtHUFESyu2ldj3vBow">P3Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_q9fl2KnODEG8iGWPwAiPdw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The following table sets forth data regarding the Company&#x2019;s operating leases for the three and nine months ended September&#160;30, 2024 and 2025:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:28.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:29.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:42.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating lease costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,195&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 476&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 420&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,338&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,207&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 457&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 22.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.26%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.81%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12.8&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:11pt;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc__69OLY4QXEWGUquUnED3Xg_3_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1395000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_ohLrsAujokq_0V6xAxIW9w_3_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1195000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_kAlBcwjyfEChG0zcNfOVnA_3_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">476000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_LoVtPuXaNUqnGG5VzX-8aA_3_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">420000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_3BFv4FrBF0uVB3DiMtxKfg_4_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1338000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_2AEOc2y3wE-_QAW4wu_Mnw_4_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1207000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_sP8AoU-LY0mqKUDqxJSHTw_4_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">457000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_SFkrJFjuX0SD4nxR71x-VA_4_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">413000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      id="Tc_UG57LpEyb0-8W5C7dGWq7w_5_3">P22Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA"
      id="Tc_hmU3upGtLE6vBOHOnfZjnA_5_6">P6Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      id="Tc_dYjs26OI60iQQglavRFJXA_5_9">P22Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA"
      id="Tc_FfdgD_37vkuOqHLuplMM3g_5_12">P6Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="3"
      id="Tc_mlmd-wk0O02VFQB3E7fNLw_6_3"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">0.134</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA"
      decimals="3"
      id="Tc_nxaUS1X8Ckikow4du94sWQ_6_6"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">0.128</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="3"
      id="Tc_sFhcDwTuZ0aMJ4u-0JK3vw_6_9"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">0.134</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2024_fOit7o5wP0itixLXuhWgSA"
      decimals="3"
      id="Tc_eKCev_z4i0iTavTggB39Yg_6_12"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">0.128</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_6lzWnNoFwEiWB-Bx9-bGog">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The following table sets forth a maturity analysis of the Company&#x2019;s operating lease liabilities as of September&#160;30, 2025:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;(&lt;i style="font-style:italic;"&gt;U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="color:#009999;font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;First year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,397&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Second year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Third year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,074&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fourth year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,040&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fifth year and thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 22,273&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total undiscounted cash flows&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 26,925&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: imputed interest&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,748&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:82.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Present value of operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="color:#009999;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,177&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_Df5DLAF8qkK4-Siuoin80A_2_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1397000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_Oms0vPSbS0y9Zg_6yXRgIA_3_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1141000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_yBrsLGklGE6brQJD0sw7dw_4_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1074000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_syXvLDfAAke7A0dx9ssPng_5_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1040000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <plx:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_xOqkO2Egx0-B_XDJjPCP1w_6_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">22273000</plx:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndThereafter>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_-Cn7peqQokCOsRvC6YAiFw_7_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">26925000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_aTO29UQNukyQKF4s__Ltmw_8_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">18748000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_3mRarL_tOkSlr9Y_FA-XpA_9_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">8177000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_hMiNjYWkKUC2b_PVsYnWyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 5 &#x2013; STOCK TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;During the nine months ended September&#160;30, 2025, the Company issued &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;908,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock in connection with the exercise of warrants issued in 2020 generating proceeds equal to approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$2.1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million from such exercises. All such exercises were effected during the first quarter of 2025 and all unexercised warrants expired on March&#160;11, 2025. Accordingly, &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;as of March&#160;12, 2025, &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;no&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; warrants remained outstanding&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;During the nine months ended September&#160;30, 2025, the Company sold, in the aggregate, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2,775,215&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock under the Sales Agreement. &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company generated &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;gross proceeds equal to approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$7.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million in connection with such sales (issuance costs were &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.2&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million). All such sales were effected during the first and second quarters of 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;During the nine months ended September&#160;30, 2025, the Company issued, in the aggregate, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;248,625&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock in connection with the exercise of options to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;248,625&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock by certain current and former employees of the Company. The Company received cash proceeds equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.2&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million in connection with such exercises. All such exercises were effected during the third quarter of 2025.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;d.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;During the three months ended September&#160;30, 2025, the Company granted, with the approval of the Company&#x2019;s compensation committee, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; options to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1,448,990&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock, in the aggregate, to certain of the Company&#x2019;s officers, directors, other employees and a consultant under the Company&#x2019;s Amended and Restated 2006 Employee Stock Incentive Plan, as amended (the &#x201c;Plan&#x201d;). The options generally vest over a &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; period in &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;12&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;equal quarterly increments. Vesting of the options granted to executive officers is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the options on the applicable dates of grant &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;using the Black-Scholes option-pricing model to be approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.5&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million using the following assumptions (weighted average): stock price equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.56&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, exercise price equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.56&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, dividend yield of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, expected volatility of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;73.64%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, risk-free interest rate of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3.9%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; and expected life in years, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;5.75&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;e.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;During the three months ended September&#160;30, 2025, the Company granted, with the approval of the Company&#x2019;s compensation committee, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;559,210&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of restricted Common Stock, in the aggregate, to certain of the Company&#x2019;s officers, directors, other employees and a consultant under the Plan. The shares of restricted Common Stock generally vest over a &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three-year&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; period in &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;12&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;equal quarterly increments, with &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;52,910&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; of such shares of restricted Common Stock fully vested upon grant (September&#160;22, 2025). Vesting of restricted Common Stock granted to executive officers is subject to automatic acceleration in full upon a Corporate Transaction or a Change in Control, as those terms are defined in the Plan, and are subject to certain other terms and conditions. The Company estimated the aggregate fair value of the restricted stock on the applicable dates of grant to be approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.9&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million using stock prices equal to &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.64&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.89&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zYmBSshLM0q2nl3i43mcsA"
      decimals="INF"
      id="Narr_HwwwFz8mMUKDmLq-En6_Xw"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">908000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_zYmBSshLM0q2nl3i43mcsA"
      decimals="-5"
      id="Narr_QWsY8j-JT0-smMydl5nphA"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2100000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="As_Of_3_12_2025_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_1UAWM1totEqWlXUe3rPvGw"
      decimals="INF"
      id="Narr_Q-KASU-VR0qBI18zWVC5WA"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_O5qbhcAkvUyU14-GI5Itpw"
      decimals="INF"
      id="Narr_cpQytt07TUqVoG9cCzEJ8Q"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">2775215</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <plx:GrossProceedsFromIssuanceOfCommonStock
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_O5qbhcAkvUyU14-GI5Itpw"
      decimals="-5"
      id="Narr_agIEseXqmk2uEjsry0Y1Aw"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">7000000</plx:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_SubsidiarySaleOfStockAxis_plx_SalesAgreementMember_O5qbhcAkvUyU14-GI5Itpw"
      decimals="-5"
      id="Narr_J5DTofHxaUeCtSjOPx3jfw"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">200000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CrvjSyzu0kePIviFTWVKvA"
      decimals="INF"
      id="Narr_ISQUd6JPI0Cg0T6rN5gHvA"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">248625</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CrvjSyzu0kePIviFTWVKvA"
      decimals="INF"
      id="Narr_ct3LS5W_0Uu4ktp2tDdTjA"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">248625</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_CrvjSyzu0kePIviFTWVKvA"
      decimals="-5"
      id="Narr_3ux5FgwliUuoc67ZDJgKpQ"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      id="Narr_dPfL0rGwAUWXe05U59zdOw">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="INF"
      id="Narr_c7LKr6edEEi86W4WsgDXlA"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">1448990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      id="Narr_ZcGVkO-1-E6VMspZq6CnSA">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="INF"
      id="Narr_YFPkQ9iD2060zc4eZD9u1g"
      unitRef="Unit_Standard_installment_La8zkqC6pUaqrn9vr4M5jA">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-5"
      id="Narr_zzaekX2XykG-KJp2GnwWkw"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1500000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue>
    <us-gaap:SharePrice
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="2"
      id="Narr_IBG1TvYEYU2NjwyuqT6FeA"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">1.56</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="2"
      id="Narr_l7ZQmEiZREaHJBNXeeW04Q"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="2"
      id="Narr_iNKE7M0t7E6liOXhcWP8Sg"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="4"
      id="Narr_m4WoUBuz-0et0c973EH-Sg"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">0.7364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="3"
      id="Narr_7YfPa9NnNkqbCZtW0qNBHQ"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      id="Narr_xmM8BEYZ80OvJlYa0T90eA">P5Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_tPyaORiFkkOM-rUgWSubEA"
      decimals="INF"
      id="Narr_3KI3MphbbUSZiLFIQcDorw"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">559210</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_tPyaORiFkkOM-rUgWSubEA"
      id="Narr_muPYxeY0KkeNDUgiom_gIQ">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments
      contextRef="As_Of_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_D4u9NxlfVEGwyeTxPj6T4w"
      decimals="INF"
      id="Narr_yd6gTAUk4kWfb0BjWRS8Aw"
      unitRef="Unit_Standard_installment_La8zkqC6pUaqrn9vr4M5jA">12</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_tPyaORiFkkOM-rUgWSubEA"
      decimals="INF"
      id="Narr_zbp-GgD5G0WwBC-Tp9O5Tg"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">52910</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_tPyaORiFkkOM-rUgWSubEA"
      decimals="-5"
      id="Narr_1Bo3JRkVzkiKtyXLIS-tBQ"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">900000</plx:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodFairValue>
    <us-gaap:SharePrice
      contextRef="As_Of_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_Ji-guYoHVUu8eVJ9spIzyQ"
      decimals="2"
      id="Narr_6lIw1dJBbEGepX8_XjHNIg"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">1.64</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="As_Of_9_30_2025_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_JrP2MNklRUaZCBhVdKEU3Q"
      decimals="2"
      id="Narr_hX2b4Ec6TUKCfTC73zKqvg"
      unitRef="Unit_Divide_USD_shares_kIdV1ewPKkmf4x6uEdmhBQ">1.89</us-gaap:SharePrice>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_1CtZPikh1EedwbITHotbbg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 6 &#x2013; EARNINGS (LOSS) PER SHARE&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Basic and diluted earnings (loss) per share attributable to common stockholders were calculated as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(In&#160;thousands,&#160;except&#160;share&#160;data)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income (loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,562)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Add:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financial expenses of 2024 Notes*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (503)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income (loss) for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,562)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for basic calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,225,112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,301,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,281,685&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,549,745&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average dilutive effect of 2024 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,667,323&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average dilutive effect of stock options and restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,532,879&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,225,112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,301,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80,814,564&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,217,068&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3pt 0pt 10pt 36pt;"&gt;* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:10pt 0pt 10pt 36pt;"&gt;Diluted earnings (loss) per share do not include 11,288,007 shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock and warrants for the nine months ended September&#160;30, 2025 because the effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Diluted earnings (loss) per share do not include 3,745,682 shares of Common Stock underlying outstanding stock options and unvested shares of restricted stock for the three months ended September&#160;30, 2025 because the effect would be anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Diluted earnings (loss) per share do not include 30,515,287 shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock, warrants and the 2024 Notes for the nine months ended September&#160;30, 2024, and 20,173,438 shares of Common Stock underlying outstanding stock options, unvested shares of restricted stock and warrants for the three months ended September&#160;30, 2024, because the effect would be anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_2_vJLHtgZkCxHpBblF9tWg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;Basic and diluted earnings (loss) per share attributable to common stockholders were calculated as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(In&#160;thousands,&#160;except&#160;share&#160;data)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;span style="font-family:'Aptos Narrow';"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income (loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,562)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Add:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Financial expenses of 2024 Notes*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (503)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net income (loss) for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,562)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,733&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for basic calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,225,112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,301,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79,281,685&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,549,745&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average dilutive effect of 2024 Notes&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,667,323&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average dilutive effect of stock options and restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,532,879&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:36.81%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average shares of Common Stock outstanding for diluted calculation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 78,225,112&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 73,301,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 80,814,564&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,217,068&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:3pt 0pt 10pt 36pt;"&gt;* Financial expenses on 2024 Notes consists of add back of financial expense incurred during the period and inclusion of make-whole interest payments that will be incurred upon conversion.&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_wEtrT2b2b066qBOcA66d1A_4_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-1100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_VAZv86JHOk6utTrZFCmXTQ_4_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-3562000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_WBX8Q-NI70W1A8idDfXkUw_4_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2355000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_THx7AiuUmESQyphVXQdKJw_4_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3236000</us-gaap:NetIncomeLoss>
    <us-gaap:DilutiveSecurities
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_Snv6ssdxF02YdxlKntDHfQ_6_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-503000</us-gaap:DilutiveSecurities>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc__3wquKP_pEeCu6Zo1ygVgQ_7_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-1100000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_6sEXbnfzU0WdBGF4PYfoqA_7_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-3562000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_F3ssW5Nt3kOBfFj6AdzQZA_7_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2355000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_NWWyd7bsu0iEikkKbyaWIQ_7_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2733000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="0"
      id="Tc_2YzGkjYE0UKf11cPy7_kLQ_9_3"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">78225112</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="0"
      id="Tc_LnOUfT9ec0q8TuI3v1ePMQ_9_6"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">73301091</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="0"
      id="Tc_RcWyLmI4SEmPN0Vd6n2tyw_9_9"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">79281685</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="0"
      id="Tc_FdMvpT0rBEadP0pAB9X_bw_9_12"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">73549745</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="0"
      id="Tc_S8PqYG3sIUWFEIuDq0eQeQ_10_12"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">7667323</us-gaap:IncrementalCommonSharesAttributableToConversionOfDebtSecurities>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="0"
      id="Tc_664q6GYyc0OXpcMpeCFATA_11_9"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">1532879</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="0"
      id="Tc_B6sqqr4QyUGtYAkmr_O-TQ_12_3"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">78225112</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="0"
      id="Tc_EunwWHD8cEW21BP4bRSFGQ_12_6"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">73301091</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="0"
      id="Tc_VrErwCaAdkqT4StOXLTY_w_12_9"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">80814564</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="0"
      id="Tc_IeppVqtH1k-G4rT9912Dwg_12_12"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">81217068</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_xH2ut0yotUKC0HIos63e3g"
      decimals="INF"
      id="Narr_p8xtW39IgkW8FbzTU-HADQ"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">11288007</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsAndUnvestedRestrictedStockMember_-2H5wzF6b02WyHEkdfnNXQ"
      decimals="INF"
      id="Narr_l5jgI6vybUe_zd2lO-AnMw"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">3745682</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockWarrantsAndConvertibleNotesMember_xVbKyWax_0uHtrglZoisTQ"
      decimals="INF"
      id="Narr_ewHjhJWpt0iBl5XByV7ywA"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">30515287</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_plx_OutstandingStockOptionsUnvestedRestrictedStockAndWarrantsMember_gq56zarwQUuh08Mxtq1EHg"
      decimals="INF"
      id="Narr_2JW_ecEDlEqtRaTTi6v3Uw"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">20173438</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_I5qno-5Y3kuXLbt4DcOeNw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 7 &#x2013; TAXES ON INCOME (TAX BENEFIT)&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s taxes on income:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (175)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 443&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income (tax benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 268&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (116)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;The Company had an effective tax rate of (32)% for the nine months ended September&#160;30, 2025 compared to an effective tax rate of (13)% for the nine months ended September&#160;30, 2024. For the nine months ended September&#160;30, 2025, the difference between the Company&#x2019;s effective tax rate and the U.S.&#160;federal statutory rate of 21% was the result of forecasted profits derived primarily from U.S.&#160;taxable GILTI income mainly due to Section&#160;174 of the U.S.&#160;Tax Cuts and Jobs Act of 2017 (the &#x201c;TCJA&#x201d;), which was enacted in December 2017.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;On July&#160;4, 2025, tax reform legislation was enacted in the United States through the passage of H.R.1, One Big Beautiful Bill Act (&#x201c;HR1&#x201d;), which includes significant corporate tax changes, including a restoration of the current deductibility for domestic research expenditures beginning in 2025, with transition options for previously capitalized amounts.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Group_t5JAA8mmWUKnrW9W8ZSK2g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;span style="background:#ffffff;"&gt;The following table summarizes the Company&#x2019;s taxes on income:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:27.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="color:#009999;font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Current taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 91&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (175)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 177&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 236&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 59&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 443&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total taxes on income (tax benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.1%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 268&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (116)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_iu0qiUW_7kyJnOwlh_38wg_3_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">91000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_dVJ3VdtoX0uGtx0ZB6ZdkA_3_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">164000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_ja5PXXhq80-C9jRHkuNHkg_3_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-175000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_lLroaUihSEm4P1vpYbQwHg_3_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">164000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_jD5QpM8W_kOpxJ9OfMBeDA_4_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">177000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_bLD6VXwD20-rlnUiTEBFLQ_4_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">236000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_4CAu52z-pkCXIaXpBcNEwQ_4_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">59000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_SZhQIT_HXEmwARVQ9LCi_g_4_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">443000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="-3"
      id="Tc_pcSD99HvpE-1rWmaOVg61A_5_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">268000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="-3"
      id="Tc_LLOj48pw2kKr27cnRCdniA_5_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      decimals="-3"
      id="Tc_vlcyRNXOME2hH0oSoUPkeQ_5_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-116000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      decimals="-3"
      id="Tc_9KY41QfH3k-vIXQKMRm_rw_5_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">607000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="2"
      id="Narr_YKGvomTET0iKMDdaof8Ugg"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">-0.32</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      decimals="2"
      id="Narr_tcOm_mxWN0yeJ2wZ4EWiTA"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">-0.13</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      decimals="2"
      id="Narr_Fcaq6NdS6UyIbyo3md9Pkg"
      unitRef="Unit_Standard_pure_uAvc0UJJokGjg1mKEvvY4A">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_5MDvr-2ePkm2tTxJ_fCzUw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 8 &#x2013; &lt;/b&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;SEGMENT INFORMATION&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company operates in Israel as a &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_QJxRIWVBeUCE75e_V0YVVg;"&gt;&lt;span style="-sec-ix-hidden:Hidden_bTovpeYB_EG_cx9KDkApfQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;single&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; operating segment. The Company&#x2019;s President and Chief Executive Officer is the CODM. The CODM makes decisions on resource allocation, assesses performance of the business and monitors budget versus actual results on a consolidated basis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Segment information:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from customers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,851&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee salaries and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,502&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,853&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,734&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sub-contractors expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,649&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 260&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (817)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (970)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (289)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (212)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 970&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 372&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 329&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment expenses*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,818&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,790&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,356&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income (loss) before taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (832)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,162)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,843&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:42.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Taxes on income (tax benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 268&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (116)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net income (loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,562)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;"&gt;* Other expenses included in net income includes raw materials, rent and utilities and others.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Gaucher disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer (Ireland)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;15,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;11,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fiocruz (Brazil)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9,314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6,105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2,048&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fabry disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi (Italy)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,763&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,361&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;43,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;34,820&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;17,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;17,839&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;514&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;120&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"&gt;&lt;span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;d.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Long lived assets are located in Israel.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Group_LFc4KfJtWUuGJakM82E22Q">&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Segment information:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:42.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from customers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43,622&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 35,181&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,851&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 17,959&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:12.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Employee salaries and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,502&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,091&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,853&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,734&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Sub-contractors expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,348&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,413&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,886&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,649&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 260&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Interest income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (817)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (970)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (289)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (212)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,078&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 970&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 372&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 329&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other segment expenses*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,343&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,818&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,790&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,356&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income (loss) before taxes on income&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (832)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,162)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,239&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,843&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:42.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Taxes on income (tax benefit)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 268&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (116)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 607&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:42.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Segment net income (loss)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.38%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1,100)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.09%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (3,562)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.36%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,236&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 49.5pt;"&gt;* Other expenses included in net income includes raw materials, rent and utilities and others.&lt;/p&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg"
      decimals="-3"
      id="Tc_L2Zbk4Vnk0-8ysvFzjIeEg_3_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">43622000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w"
      decimals="-3"
      id="Tc_ilx_lxTgSU-c55vVaIbaTg_3_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">35181000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ"
      decimals="-3"
      id="Tc_Y2XUml5_dk6AmX2WeVL8rg_3_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">17851000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA"
      decimals="-3"
      id="Tc_kMgE_zmQq0CsAchnzGYhew_3_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">17959000</us-gaap:Revenues>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg"
      decimals="-3"
      id="Tc_93yvnpHx70eEiAuG48zI9w_5_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">16502000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w"
      decimals="-3"
      id="Tc_kZ4kzV3jL0qEYWy2t8yjxQ_5_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">15091000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ"
      decimals="-3"
      id="Tc_JjUxxQg88U2XuMGXU4imqw_5_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">5853000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA"
      decimals="-3"
      id="Tc_hlVslgHha0W7W5tJFvLO1w_5_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">4734000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg"
      decimals="-3"
      id="Tc_rOnA0fKaY0iAcLrX8csmQA_6_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">9348000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w"
      decimals="-3"
      id="Tc_ASEYtI-DxkKG-GQJCpcOgQ_6_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">6413000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ"
      decimals="-3"
      id="Tc_AR2ll7EiuEqJMt1nV1NUEw_6_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1886000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:ProfessionalAndContractServicesExpense
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA"
      decimals="-3"
      id="Tc_DFAv0yT7OUy_cKhq9n8M3A_6_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1649000</us-gaap:ProfessionalAndContractServicesExpense>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w"
      decimals="-3"
      id="Tc_3NRDE9nc5k202hAViWlBvA_7_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1021000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA"
      decimals="-3"
      id="Tc_d_5rjolQcESf-cpKyVlX7w_7_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">260000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg"
      decimals="-3"
      id="Tc_sx1CbWkWDUePXBinjlhEUA_8_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">817000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w"
      decimals="-3"
      id="Tc_zsLjCkB1aUekcPSB0UyUow_8_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">970000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ"
      decimals="-3"
      id="Tc_UK_We3TaskSYZkeSmPdaNQ_8_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">289000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA"
      decimals="-3"
      id="Tc_u4RvjnkkOUWl05VwZMJYEQ_8_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">212000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg"
      decimals="-3"
      id="Tc_lUPZ90wYHkKrJvagmhjOgQ_9_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1078000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w"
      decimals="-3"
      id="Tc_-DUqfoI9d0aJKNhQU9Z3aQ_9_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">970000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ"
      decimals="-3"
      id="Tc_m5On53T_Lku2CS4Ztb4vUw_9_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">372000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA"
      decimals="-3"
      id="Tc_fqLtCRylwkODtNY2x6fQ_Q_9_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">329000</us-gaap:Depreciation>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg"
      decimals="-3"
      id="Tc_an9HFOvlSkWAln62f8W58A_10_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">18343000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w"
      decimals="-3"
      id="Tc_QaQoUrN97Eew80TM_B5mXQ_10_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">15818000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ"
      decimals="-3"
      id="Tc_SVPA_2L8nEOVffQtAtglSA_10_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">7790000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA"
      decimals="-3"
      id="Tc_X_jpynl-JUeZwsMopA9pEA_10_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">7356000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg"
      decimals="-3"
      id="Tc_QsxeoMcTWkqZq18Z_3csfg_11_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-832000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w"
      decimals="-3"
      id="Tc_bAQXHHOKlkyU_wYHsWQUmA_11_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-3162000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ"
      decimals="-3"
      id="Tc_o9GXV6I6aEO1zVuR4LVKJA_11_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2239000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA"
      decimals="-3"
      id="Tc_wYSWXHePzUiiUliBuhVO0g_11_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3843000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg"
      decimals="-3"
      id="Tc_59oBr9yMS0q66Da29jeIHQ_12_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">268000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w"
      decimals="-3"
      id="Tc_VO7VZaKCS0Ce3aQC6PsWOg_12_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ"
      decimals="-3"
      id="Tc_kJt0eIxatEaqyNia7AE4ZQ_12_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-116000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA"
      decimals="-3"
      id="Tc_ImA2bnB1ZEaUX57UhlnhaQ_12_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">607000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_452eh9XOmkSLIwOzTgjLSg"
      decimals="-3"
      id="Tc_iiEU-6gG5kefQW0gdgOTww_13_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-1100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_rHoHIBI_Zk-tGGpKXqGW5w"
      decimals="-3"
      id="Tc_Vv6C2zLeXkKc_sGXOoEs9w_13_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">-3562000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2025_To_9_30_2025_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_amIAmDKht0StcIARlpPvlQ"
      decimals="-3"
      id="Tc_F__DsLllNEa4EyF1_awpfQ_13_9"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2355000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_7_1_2024_To_9_30_2024_us-gaap_StatementBusinessSegmentsAxis_plx_SingleReportableSegmentMember_KzrEexbDW0OfwnJymxjYyA"
      decimals="-3"
      id="Tc_-DGDSoqzSEa_B7As01iwCg_13_12"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3236000</us-gaap:NetIncomeLoss>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_1_1_2024_To_9_30_2024_Ce46L9XWiEStHgbIF6uDOQ"
      id="Narr_vvl5T-0_rkKGHFeoIxIo8w">Other expenses included in net income includes raw materials, rent and utilities and others.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_7_1_2024_To_9_30_2024_kWwoX2BUxUeuaFfIhUvtkQ"
      id="Narr_mvOR0EI-x0Oz6WUDG46PJw">Other expenses included in net income includes raw materials, rent and utilities and others.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Narr_gYf1pCgN8kq8n8_Ip6cuWw">Other expenses included in net income includes raw materials, rent and utilities and others.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:SegmentReportingOtherItemCompositionDescription
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      id="Narr_2jeQHPH_FUuPhqQVS0q4HQ">Other expenses included in net income includes raw materials, rent and utilities and others.</us-gaap:SegmentReportingOtherItemCompositionDescription>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_Yx6WLEpnaUiBszqtkFGilA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The following table summarizes the Company&#x2019;s disaggregation of revenues:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Nine Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:40.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Gaucher disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Pfizer (Ireland)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;15,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;11,431&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2,805&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;3,430&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Fiocruz (Brazil)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9,121&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;9,314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;6,105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;2,048&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Fabry disease:&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.16%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Chiesi (Italy)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,556&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14,075&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,763&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12,361&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:40.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total revenues from selling goods&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;43,108&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;34,820&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;17,673&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;17,839&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:40.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues from license and R&amp;amp;D services&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;514&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.8%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:10.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;361&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;178&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:1.33%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:12.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;120&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_J35jXCLpZEemlLCh3xmZDw"
      decimals="-3"
      id="Tc_KxKYJHQL2UC1IpjVrhR_TQ_4_2"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">15431000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_xIDPNJ0kwU6c6DEVa4EIhA"
      decimals="-3"
      id="Tc_NNp69tEQ20mXoXY5o6SpyA_4_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">11431000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_tGVlUvMwNESS1QuVEsIxCg"
      decimals="-3"
      id="Tc_j8hzN3IjbUOMzwX8Uj96iQ_4_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2805000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_PfizerMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_zd9vtIegUUmVwTycldKD6w"
      decimals="-3"
      id="Tc_yxJtmisw4EqOvKTMKFJCpQ_4_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3430000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_TC6cWr1PVEmqOYnE9WVTEw"
      decimals="-3"
      id="Tc_C-9JKZPv_k2ILkvfKNGOcA_5_2"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">9121000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_82eWapBWXEC0gB4NcExxIA"
      decimals="-3"
      id="Tc_kYsBtJiPz0S0iiBhr5vKGg_5_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">9314000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_LjReUd2e3ECAW3t58uSqwQ"
      decimals="-3"
      id="Tc_5O2SCcrNX0KxAbinX1DoeA_5_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">6105000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_FiocruzMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_-58If4GE2UOATvhmgfPXFw"
      decimals="-3"
      id="Tc_vigUpx6DtUaEGqZCQ5VFxA_5_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2048000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_gQv-s1-zbEiYrnnAYvRtQQ"
      decimals="-3"
      id="Tc_E46hscydGEWfbKqTBCc5sg_7_2"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">18556000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_aZcDMzIGjE-AMBlyb0cM3w"
      decimals="-3"
      id="Tc_NuS42PjD2EaiKVuNE5n9pg_7_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">14075000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2025_To_9_30_2025_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_U3vsnozyEUyKSmL6qLgZuw"
      decimals="-3"
      id="Tc_ci_mMM0QuEKrbz2zK2C6Vw_7_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">8763000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_MajorCustomersAxis_plx_ChiesiMember_srt_ProductOrServiceAxis_us-gaap_ProductMember_8K2eAUmCmkWnafp6nTCcww"
      decimals="-3"
      id="Tc_-LbKKqrGHU6PUFVqEkxyKw_7_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">12361000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_B_RDBf3UakmFxKgLCE1u4Q"
      decimals="-3"
      id="Tc_0M681MZ84kCVG2iyh0dK8w_8_2"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">43108000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_DfUDjS8huEe8YHRZP_FF_g"
      decimals="-3"
      id="Tc_G7P6NK1X10C1vlPiGymK0A_8_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">34820000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_ProductMember_EM-2D042mUKZtARE4xNQQQ"
      decimals="-3"
      id="Tc_YslMopAImEW_8GbrpXIx6w_8_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">17673000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_ProductMember_-nchaslNr0uweGPjWu-YUQ"
      decimals="-3"
      id="Tc_-ND6Nd5AjEOikh1Vxm3u5w_8_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">17839000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__u5aEet9ik6m5qJP9wbdkQ"
      decimals="-3"
      id="Tc_K3dbX9F7X0eI0-f3JV4swQ_9_2"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">514000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_1_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_5TVhAsNFQE213aFWrjtG8g"
      decimals="-3"
      id="Tc_8KSaprCqY06JKW01TTVokA_9_5"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">361000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2025_To_9_30_2025_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember__wSFk5nFpUKVmADVapX-hA"
      decimals="-3"
      id="Tc_99jMlGgXU0CXwcm9Io1DFQ_9_8"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">178000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2024_To_9_30_2024_srt_ProductOrServiceAxis_us-gaap_LicenseAndServiceMember_QMoe7jUDBUORp5O-RNIp8Q"
      decimals="-3"
      id="Tc_-a1qZfsYa0asNn0ewPq3VQ_9_11"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">120000</us-gaap:Revenues>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_TACYuMaUoEScf365cFKxsA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 9 &#x2013; &lt;/b&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;SUPPLEMENTARY FINANCIAL STATEMENT INFORMATION&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 36pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance sheets:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,209&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,811&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,568&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 558&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,080&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payable to customer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,056&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <plx:SupplementaryBalanceSheetsInformationTableTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_k6xHrvZZn0m4b8oMNtitVw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;(U.S. dollars in thousands)&lt;/i&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2025&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Accounts payable and accruals &#x2013; other:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Arial','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payroll and related expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 745&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,343&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Provision for vacation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,209&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,811&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accrued expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,126&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 9,568&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Royalties payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 558&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,080&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Income tax payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,385&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,476&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Payable to customer&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 920&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,056&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Property and equipment suppliers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 230&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.25%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 15,173&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 19,588&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</plx:SupplementaryBalanceSheetsInformationTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_-FEXbTpUSkGxCcmTsTIBSg_4_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">745000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_ZF6QFY62nEuxCvjyzCCSiQ_4_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1343000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_d43XXnP1v0W0SmvrbVXk6w_5_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2209000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_9K53Ha-HWkG5v5thno5sug_5_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1811000</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_aWFk_nj22Eym5wFQpHxfkg_6_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">8126000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_qmr1js1vp0OnsJGo3Ohk-A_6_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">9568000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_BPYPdCC-_EKEHsyMLrtvlw_7_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">558000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_c5Hsh19fFE2QMalgs6Rzkw_7_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1080000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_R4KxftU3VkKUUCCYEaejUA_8_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2385000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_J_ps75kYPUmbRhvpK8iEmg_8_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3476000</us-gaap:TaxesPayableCurrent>
    <plx:PayableToCustomerCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_s3zG2-INYESuPWGjbM3YVQ_9_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">920000</plx:PayableToCustomerCurrent>
    <plx:PayableToCustomerCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_CPCBVwXmj0yowPNgD0meVA_9_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">2056000</plx:PayableToCustomerCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_DfzMScZwkU2TesTYfTelmQ_10_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">230000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_Gcpij7Ee0E6H09udVNRx_A_10_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">254000</plx:AccountsPayablePropertyAndEquipmentSuppliersCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_9_30_2025_XeBalASeBU-07bY7FmcJbA"
      decimals="-3"
      id="Tc_fH_qMpt-pke00mLdGHvJxw_11_3"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">15173000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent
      contextRef="As_Of_12_31_2024_CB36K1r5ZU-0Bf75pt5hVQ"
      decimals="-3"
      id="Tc_QvEVHtQyXkaAyR9eRRUegA_11_6"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">19588000</plx:AccountsPayableAndAccruedLiabilitiesOtherCurrent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_1_1_2025_To_9_30_2025_pSLZLD5rY0qJoRwF0-rkcw"
      id="Tb_R6-AOICe3E6O1ozt9YR7_Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 10 &#x2013; SUBSEQUENT EVENTS&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Since the end of the quarter ended September&#160;30, 2025 and through the issuance of these financial statements, the Company collected approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$3.0&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million from sales to Fiocruz (Brazil), approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$9.9&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million from sales to Chiesi and &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.4&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;&#160;million from sales to Pfizer.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:36pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Since the end of the quarter ended September&#160;30, 2025, the Company issued, in the aggregate, &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;79,856&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock in connection with the exercise of options to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;79,856&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; shares of Common Stock by a former employee and a current employee of the Company. The Company received cash proceeds equal to approximately $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;94,200&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; in connection with such exercise.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ProceedsFromCustomers
      contextRef="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_SupplyAndTechnologyTransferAgreementWithFiocruzMember_V8A_9r0xvk696ZxvjJRa8A"
      decimals="-5"
      id="Narr_mBbwb7j8l0OLPGwaHUOrBg"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">3000000</us-gaap:ProceedsFromCustomers>
    <us-gaap:ProceedsFromCustomers
      contextRef="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_ChiesiAgreementsMember_f2rN9XEbVUelOX_cn66r4w"
      decimals="-5"
      id="Narr_xQxetgUS70eyf3jT0rDSsg"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">9900000</us-gaap:ProceedsFromCustomers>
    <us-gaap:ProceedsFromCustomers
      contextRef="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_TypeOfArrangementAxis_plx_PfizerAgreementMember_9plBbFjl-0GfbTD6J4eCZQ"
      decimals="-5"
      id="Narr_P0nn3Xk0CE2BaSdT43LFeA"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">1400000</us-gaap:ProceedsFromCustomers>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_71PZO8VDYEeOr9oCkh_Hog"
      decimals="INF"
      id="Narr_C9y7FJN4BECUWZ_dvasqiA"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">79856</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_71PZO8VDYEeOr9oCkh_Hog"
      decimals="INF"
      id="Narr_RYLWg1_1N0W1h1b6K36GVg"
      unitRef="Unit_Standard_shares_T5cC0Y-4Rk6EDulo5SozBQ">79856</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_10_1_2025_To_11_13_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_71PZO8VDYEeOr9oCkh_Hog"
      decimals="0"
      id="Narr_GG8pP4Tan0yoYmEjsXTM8Q"
      unitRef="Unit_Standard_USD__ZnT9pJrnkSKE5wy3-sNyg">94200</us-gaap:ProceedsFromStockOptionsExercised>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      id="Narr_AyYZIyWzhU2sV1Iuoh_iSg">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      id="Narr_wMrRpYHaHESprHskGDFT5g">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      id="Narr_FLgggVPY7Em1GFvLA8wadw">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="Duration_7_1_2025_To_9_30_2025_XvPhM3Ez30O8gB88GmvEsg"
      id="Narr_Cvipb9xXekSyxS9qmfmHXg">false</ecd:Rule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Tc_vhpegQ9XAU-O7ZTk8mEm5A_10_2"
          xlink:label="Tc_vhpegQ9XAU-O7ZTk8mEm5A_10_2"
          xlink:type="locator"/>
        <link:footnote id="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:label="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; Authorized &#x2013; as of September&#160;30, 2025 and December&#160;31, 2024 &#x2013; 185,000,000 shares.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_vhpegQ9XAU-O7ZTk8mEm5A_10_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_oUNW5FB3IUaHwHEkz3jDQg_24_2"
          xlink:label="Tc_oUNW5FB3IUaHwHEkz3jDQg_24_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_oUNW5FB3IUaHwHEkz3jDQg_24_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_ScyVFUPI80q6wHfbEkNl1w_17_2"
          xlink:label="Tc_ScyVFUPI80q6wHfbEkNl1w_17_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_ScyVFUPI80q6wHfbEkNl1w_17_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_rxQDkKYEFEiJ2WmgJtETYw_30_2"
          xlink:label="Tc_rxQDkKYEFEiJ2WmgJtETYw_30_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_rxQDkKYEFEiJ2WmgJtETYw_30_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_eGd5M6r8mEq-ic6FBd_Iuw_18_2"
          xlink:label="Tc_eGd5M6r8mEq-ic6FBd_Iuw_18_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_eGd5M6r8mEq-ic6FBd_Iuw_18_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_XLZq7il8QE2LEjRtLdk9Jw_31_2"
          xlink:label="Tc_XLZq7il8QE2LEjRtLdk9Jw_31_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_XLZq7il8QE2LEjRtLdk9Jw_31_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_9UAB6ZalEka19hY4YhOg5A_6_2"
          xlink:label="Tc_9UAB6ZalEka19hY4YhOg5A_6_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_9UAB6ZalEka19hY4YhOg5A_6_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_e3m2lejV3E6_xHTX2KUqPA_21_2"
          xlink:label="Tc_e3m2lejV3E6_xHTX2KUqPA_21_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_e3m2lejV3E6_xHTX2KUqPA_21_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Le8enGNn-U2_sRTg_vxE8A_26_2"
          xlink:label="Tc_Le8enGNn-U2_sRTg_vxE8A_26_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Le8enGNn-U2_sRTg_vxE8A_26_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_HhK-UvHh-ECa7iCf80nPyA_12_2"
          xlink:label="Tc_HhK-UvHh-ECa7iCf80nPyA_12_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_HhK-UvHh-ECa7iCf80nPyA_12_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_o-soIjnwX0mno9iveiTtnQ_13_2"
          xlink:label="Tc_o-soIjnwX0mno9iveiTtnQ_13_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_o-soIjnwX0mno9iveiTtnQ_13_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_Eto7e-Xr2Em4IMXw0lGBpQ_27_2"
          xlink:label="Tc_Eto7e-Xr2Em4IMXw0lGBpQ_27_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_Eto7e-Xr2Em4IMXw0lGBpQ_27_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_DIQSy69MjE6Hx7Lvt9M1dA_33_2"
          xlink:label="Tc_DIQSy69MjE6Hx7Lvt9M1dA_33_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_DIQSy69MjE6Hx7Lvt9M1dA_33_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_d1wvEIx0gEO3V9yDgYRFbg_20_2"
          xlink:label="Tc_d1wvEIx0gEO3V9yDgYRFbg_20_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_d1wvEIx0gEO3V9yDgYRFbg_20_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Tc_l6ZF-GSBfk-JXLKuKWOyaQ_15_2"
          xlink:label="Tc_l6ZF-GSBfk-JXLKuKWOyaQ_15_2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Tc_l6ZF-GSBfk-JXLKuKWOyaQ_15_2"
          xlink:to="_60036d7d_775b_4356_a3df_fbe2a6cb8bf7"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
